PT J
AU Chang, XU
   Na, LI
   Xiaoling, WU
   Xingye, D
   Zhiwen, Y
   Qianhui, S
   Tianyu, S
   Yemao, C
   Dandan, P
   Kai, C
AF Chang, X U
   Na, L I
   Xiaoling, W U
   Xingye, Dai
   Zhiwen, Yang
   Qianhui, Sun
   Tianyu, Shi
   Yemao, Chai
   Dandan, Pang
   Kai, Cheng
TI Effect of electroacupuncture on inflammatory signal expression in local tissues
SO Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
LA English
DT Journal Article
DE NLR family, pyrin domain-containing 3 protein; chronic pelvic pain syndrome; cytokines; electroacupuncture; inflammatory; receptors, purinergic P2X7; signal transduction
AB OBJECTIVES: To study the expression of inflammatory signal in local prostate  tissue of chronic pelvic pain syndrome (CPPS) rats by electroacupuncture (EA) of  Guanyuan (CV4), Zhongji (CV3), Huiyang (BL35) and Sanyinjiao (SP6), and to  explore the possible mechanism of anti-inflammatory and analgesic effects of EA.  METHODS：A total of 36 Sprague-Dawley male rats were randomly divided into three  groups: control, model and EA (n=12 rats/group). The CPPS model was made by  injection of CFA into ventral lobes of the prostate (0.1 mL). Electric  acupuncture apparatus was applied to stimulate Guanyuan (CV4), Zhongji (CV3),  bilateral Huiyang (BL35) and Sanyinjiao (SP6) acupoints in EA group. The general  condition of rats was observed and the prostate index (PI) was calculated. The  thermal pain threshold was collected after each therapeutic course.  Histopathological changes of the prostate tissue were examined by  hematoxylin-eosin staining method. The expression levels of tumor necrosis factor  α (TNF-α), interleukin-1β (IL-1β) and prostaglandin E2 (PGE2) in prostatic  homogenates were measured by enzyme linked immunosorbent assay (ELISA). Moreover,  the expression levels of purinergic 2X7 receptor (P2X7R), NOD-like receptor pyrin  domain-containing 3 (NLRP3), caspase-1 and interleukin-18 (IL-18) mRNA were  quantified by quantitative real-time polymerase chain reaction. RESULTS: Compared  with control group, the PI of rats increased, and the thermal pain threshold  decreased significantly in model group. The morphological structure of prostate  tissues of rats in model group was severely damaged with a large number of  inflammatory cells infiltration. Additionally, the levels of TNF-α, IL-1β and  PGE2 were higher, and the expressions of P2X7R, NLRP3, caspase-1 and IL-18 mRNA  were higher than those in control group. After EA treatment, the PI was  significantly decreased, the thermal pain threshold was significantly increased,  and the tissue damage was significantly improved. The expressions of inflammatory  cytokines were lower in EA group, and expression of P2X7R/NLRP3 pathway was  down-regulated. CONCLUSION: The effect of EA at Guanyuan (CV4), Zhongji (CV3),  Huiyang (BL35) and Sanyinjiao (SP6) can improve inflammation and pain symptoms of  CPPS rats induced by Complete Freund's adjuvant (CFA). This suggests that EA at  Guanyuan (CV4), Zhongji (CV3), Huiyang (BL35) and Sanyinjiao (SP6) can produce  anti-inflammatory analgesia effect by preventing the activation of P2X7R/NLRP3  signal pathway, inhibit the release of inflammatory cytokines in CPPS rats, which  may provide a putative novel target for the treatment of CPPS.
C1 Major in Acupuncture and Tuina, school of Acupuncture and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.
   Experimental science of acupuncture and moxibustion teaching and research section, school of Acupuncture and Tuina, Beijing University of Chinese Medicine,Beijing 100029, China.
   Major in Acupuncture and Tuina, school of Acupuncture and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.
   Major in Acupuncture and Tuina, school of Acupuncture and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.
   Major in Acupuncture and Tuina, school of Acupuncture and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.
   Major in Acupuncture and Tuina, school of Acupuncture and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.
   Major in Acupuncture and Tuina, school of Acupuncture and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.
   Complex laboratory, school of Acupuncture and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.
   Academy of Chinese Medical Sciences, Beijing 100700, China.
   Meridians and acupoints teaching and research section, school of Acupuncture and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.
NR 0
TC 0
SN 2589-451
EI 0255-292
J9 J Tradit Chin Med
PD NOV 16
PY 2022
VL 42
IS 6
BP 965
EP 971
DI 10.19852/j.cnki.jtcm.20220928.003
PG 6
WC Rats; Male; Animals; Electroacupuncture; Interleukin-18; NLR Family, Pyrin Domain-Containing 3 Protein; genetics; Pyrin Domain; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; genetics; Dinoprostone; Pelvic Pain; genetics; Chronic Pain; Freund's Adjuvant; Signal Transduction; Cytokines; RNA, Messenger; Caspases
UT PubMed:36378055
PM 36378055
DA 2022-11-16
ER

PT J
AU Liang, D
   Ren, Y
   Huang, L
   Jin, S
AF Liang, Dongdong
   Ren, Yelong
   Huang, Ledan
   Jin, Shenhui
TI A Study on THE Mechanism of Electroacupuncture to Alleviate Visceral Pain and NGF
SO Computational intelligence and neuroscience
LA English
DT Journal Article
AB Visceral pain is unbearable, and natural methods are needed to relieve it.  Electroacupuncture is a relatively new technique that helps relieve visceral pain  by improving blood circulation and providing energy to clogged parts of the body.  However, its analgesic effect and mechanism in colorectal pain are still unknown.  In this study, the visceral pain models of electroacupuncture in rats were  compared and discussed, using nanocomponents to stimulate the expression and  mechanism of the nerve growth factor in colorectal pain and electroacupuncture  and to observe the expression and mechanism of nerve growth factor in visceral  pain relief rats induced by nanocomponents and electroacupuncture. The results  show that nanocomponents can effectively relieve visceral pain under the action  of electroacupuncture. NGF can activate endogenous proliferation, migration,  differentiation, and integration. NSC can promote nerve regeneration and recovery  after injury.
C1 Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China.
   Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China.
   Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China.
   Department of Anesthesiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China.
NR 0
TC 0
SN 1687-527
EI 1687-526
J9 Comput Intell Neurosci
PD OCT 25
PY 2022
VL 2022
IS 
BP 3755439
EP 3755439
DI 10.1155/2022/3755439
PG 0
WC Rats; Animals; Electroacupuncture; Visceral Pain; therapy; Nerve Growth Factor; metabolism; Rats, Sprague-Dawley; Analgesics; Colorectal Neoplasms
UT PubMed:36275969
PM 36275969
DA 2022-10-25
ER

PT J
AU Chen, W
   Li, HC
   Wan, HY
   Liu, YH
   Jing, XH
   Zhang, XN
   He, W
AF Chen, Wei
   Li, Heng-Cong
   Wan, Hong-Ye
   Liu, Yi-Han
   Jing, Xiang-Hong
   Zhang, Xiao-Ning
   He, Wei
TI [Effect of electroacupuncture on spontaneous pain during the synovial
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE electroacupuncture; interleukin-6 (IL-6); knee osteoarthritis; saphenous nerve; synovitis; tumor necrosis factor-α (TNF-α)
AB OBJECTIVE: To observe the effect of electroacupuncture (EA) on pain behavior,  synovial inflammatory response and demyelination of saphenous nerve in the rats  modeled with knee osteoarthritis (KOA) and explore the effect mechanism of EA for  reliving allodynia. METHODS: Eighty-four male SD rats were randomly divided into  a control group, a model group and an EA group, 28 rats in each one.  Intra-articular injection of sodium monoiodoacetate (MIA) was administered in  right knee joint of each rat in the model group and the EA group to establish the  KOA model. In the EA group, separately, on day 5, 7 and 9 after modeling, EA was  applied at "Zusanli" (ST 36) and "Yanglingquan" (GB 34) on the right side, with  disperse-dense wave (2 Hz/15 Hz), 1 mA in current intensity, for 30 min in one  intervention, once a day, and 3 interventions were required. On the 9th day after  modeling, the weight-bearing rate was calculated for the affected limbs of the  rats in each group, the synovial morphological changes were observed using HE and  Masson staining, flow cytometry was adopted to detect the synovial immunocyte  counts, and MSD multi-spot assay was used to detected the synovial inflammatory  cytokine content. On the 14th day after modeling, the hind-paw mechanical  withdrawal threshold was observed in each group and the ultrastructure of the  saphenous nerve was observed under transmission electron microscopy. RESULTS: On  the 9th day after modeling, compared with the control group, the weight-bearing  rate of the affected limb was reduced (P<0.01), the synovial hyperplasia,  inflammatory cell infiltration and synovial fibrosis occurred in the affected  limb; the counts of synovial CD11b(+) cells and M1 macrophages (CD11b(+)CD86(+))  were increased (P<0.01), the contents of tumor necrosis factor-α (TNF-α),  interleukin (IL)-6, IL-1β, IL-10 and IL-13 in the synovial tissue were elevated  (P<0.01, P<0.05) for the rats of the model group. Compared with the model group,  the weight-bearing rate of the affected limb was increased (P<0.05), the synovial  hyperplasia, inflammatory cell infiltration and synovial fibrosis were mitigated,  the counts of CD11b(+) cells and M1 macrophages (CD11b(+)CD86(+)) in the synovial  tissue, and the contents of TNF-α and IL-6 were reduced (P<0.01, P<0.05) in the  EA group. On the 14th day after modeling, the hind-paw mechanical withdrawal  threshold was reduced in the model group when compared with the control group  (P<0.01), and it was increased in the EA group when compared with the model group  (P<0.05). Besides, in the model group, obviously, the myelin sheath structure was  destroyed, the myelin layer was disintegrated and loosened, the axon was extruded  or the layer thicken and cracked. Compared with the model group, the injury of  saphenous nerve was alleviated remarkably in the EA group. CONCLUSION: The  intervention with EA may attenuate the synovial inflammatory response and the  injury of saphenous nerve in the affected limb of the rat with KOA, so that the  spontaneous pain during the synovial inflammatory response stage and allodynia at  the later stage are relieved.
C1 Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD DEC 10
PY 2022
VL 42
IS 12
BP 1385
EP 93
DI 10.13703/j.0255-2930.20220526-k0006
PG -1292
WC Male; Rats; Animals; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Hyperplasia; Cytokines; Pain; etiology
UT PubMed:36484192
PM 36484192
DA 2022-12-10
ER

PT J
AU Xing, RY
   Yang, Y
   Zhang, M
   Wang, HY
   Tan, MY
   Gao, C
   Yang, C
   Zhai, MY
   Xie, YH
AF Xing, Ruyi
   Yang, Yang
   Zhang, Min
   Wang, Hanyu
   Tan, Mengyuan
   Gao, Chen
   Yang, Chao
   Zhai, Mingyu
   Xie, Yanhu
TI Effect of Transcutaneous Electrical Acupoint Stimulation Combined with Transversus Abdominis Plane Block on Postoperative Recovery in Elderly Patients Undergoing Laparoscopic Gastric Cancer Surgery: A Randomized Controlled Trial
SO PAIN AND THERAPY
LA English
DT Article
DE Transcutaneous electrical acupoint stimulation; Laparoscopic surgery; Postoperative pain; Transversus abdominis plane block; Recovery
ID measuring quality; double-blind; acupuncture; responses; morphine; score; pain
AB Introduction This study assessed the influence of transcutaneous electrical acupoint stimulation (TEAS) combined with transversus abdominis plane block (TAPB) on the recovery of elderly patients undergoing laparoscopic gastric cancer surgery. Methods Ninety patients (age >= 60 years) undergoing laparoscopic gastric cancer surgery were randomly divided into general anesthesia group (group G), TAPB group (group NG), and TEAS combined with TAPB group (group NTG). Patients in the NTG group received TEAS at PC6, LI4, and ST36 acupoints and TAPB. Patients in the NG group received TAPB. The quality of recovery (QoR) was assessed using the QoR-15 questionnaire. The percentages of T lymphocyte subsets were determined. Consumption of anesthetics, extubation time, visual analog scale (VAS) scores, time of first postoperative ambulation and flatus, and postoperative adverse events were also recorded. Results QoR-15 scores on postoperative day (POD) 3 and POD 7 were higher in the NTG group than in the G and NG groups (P < 0.05). On POD 1 and POD 3, the percentages of CD3(+) and CD4(+) T cells and the CD4(+)/CD8(+) ratio were higher and the percentage of CD8(+) T cells was lower in the NTG group than in the G and NG groups (P < 0.05). Remifentanil consumption, and the incidence of postoperative nausea and vomiting (PONV) were lower and extubation time and time of first postoperative flatus were shorter in the NTG group than in the G and NG groups (P < 0.05). Compared with the G group, the VAS scores on POD 1 were lower in the NG group and those on POD 2 were lower in the NTG group (P < 0.05). Conclusion The combination of TEAS and TAPB ameliorated postoperative pain, improved immune and gastrointestinal function, reduced the incidence of PONV, and effectively promoted postoperative recovery in elderly patients undergoing laparoscopic gastric cancer surgery.
C1 [Xing, Ruyi; Yang, Yang; Zhang, Min; Wang, Hanyu; Tan, Mengyuan; Gao, Chen; Yang, Chao; Zhai, Mingyu; Xie, Yanhu] Univ Sci & Technol China, Div Life Sci & Med, USTC, Affiliated Hosp 1,Dept Anaesthesiol, Hefei 230001, Anhui, Peoples R China.
C3 Chinese Academy of Sciences; University of Science & Technology of China, CAS
RP Zhai, MY; Xie, YH (corresponding author), Univ Sci & Technol China, Div Life Sci & Med, USTC, Affiliated Hosp 1,Dept Anaesthesiol, Hefei 230001, Anhui, Peoples R China.
EM zmynj1@126.com; xyh200701@sina.cn
CR Benyamin R, 2008, PAIN PHYSICIAN, V11, P0
   Cabioglu MT, 2008, AM J CHINESE MED, V36, P25, DOI 10.1142/S0192415X08005552
   Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9
   Chazapis M, 2016, BRIT J ANAESTH, V116, P241, DOI 10.1093/bja/aev413
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Chen YQ, 2016, J CLIN ANESTH, V32, P255, DOI 10.1016/j.jclinane.2016.03.019
   Chi YL, 2019, AM J CHINESE MED, V47, P1445, DOI 10.1142/S0192415X19500745
   Francis NK, 2015, COLORECTAL DIS, V17, PO148, DOI 10.1111/codi.13002
   Frey UH, 2009, BRIT J ANAESTH, V102, P620, DOI 10.1093/bja/aep014
   Ghai B, 2022, J ANAESTH CLIN PHARM, V38, P3, DOI 10.4103/joacp.JOACP_362_19
   Hamid HKS, 2021, LANGENBECK ARCH SURG, V406, P273, DOI 10.1007/s00423-020-01995-9
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Houghtling RA, 2000, ANN NY ACAD SCI, V917, P771
   Hu SX, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0105219
   Jarrar A, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2018-025818
   Kleif J, 2018, BRIT J ANAESTH, V120, P28, DOI 10.1016/j.bja.2017.11.013
   Lai Min, 2008, ZHEN CI YAN JIU, V33, P245
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Li H, 2015, WORLD J GASTROENTERO, V21, P8304, DOI 10.3748/wjg.v21.i27.8304
   Lv Y, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000010969
   Meng D, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/9922879
   Myles PS, 2018, BRIT J ANAESTH, V120, P705, DOI 10.1016/j.bja.2017.12.037
   Myles PS, 2016, ANESTHESIOLOGY, V125, P39, DOI 10.1097/ALN.0000000000001158
   Nieboer TE, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003677.pub4
   Qu Li Zhe, 2020, ZHEN CI YAN JIU, V45, P136, DOI 10.13702/j.1000-0607.1904016
   Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028
   Song BJ, 2020, NAT SCI SLEEP, V12, P809, DOI 10.2147/NSS.S270739
   Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b
   Tan SJ, 2016, INT J SURG, V33, P124, DOI 10.1016/j.ijsu.2016.07.077
   Tian CT, 2015, CHINESE MED J-PEKING, V128, P105, DOI 10.4103/0366-6999.147828
   Tran D, 2019, ANESTHESIOLOGY, V131, P1166, DOI 10.1097/ALN.0000000000002842
   Tu Q, 2018, TECHNOL CANCER RES T, V17, P0, DOI 10.1177/1533033818806477
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wu HX, 2016, EXP THER MED, V11, P495, DOI 10.3892/etm.2015.2913
   Yu XD, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-3892-4
   Zhang W, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5650413
   Zhao Y, 2021, BMC ANESTHESIOL, V21, P0, DOI 10.1186/s12871-021-01317-6
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
NR 41
TC 21
Z9 26
U1 3
U2 20
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8237
EI 2193-651X
J9 PAIN THER
JI PAIN THER.
PD DEC 15
PY 2022
VL 11
IS 4
BP 1327
EP 1339
DI 10.1007/s40122-022-00429-2
EA SEP 2022
PG 13
WC Clinical Neurology
SC Neurosciences & Neurology
GA 5X6DI
UT WOS:000853452700001
PM 36098938
DA 2026-01-16
ER

PT J
AU D'Alessandro, EG
   Nagy, DRN
   de Brito, CMM
   Almeida, EPM
   Battistella, LR
   Cecatto, RB
AF D'Alessandro, Eduardo Guilherme
   Nebuloni Nagy, Daniela Ribeiro
   Moran de Brito, Christina May
   Marinho Almeida, Elisangela Pinto
   Battistella, Linamara Rizzo
   Cecatto, Rebeca Boltes
TI Acupuncture for chemotherapy-induced peripheral neuropathy: a randomised controlled pilot study
SO BMJ SUPPORTIVE & PALLIATIVE CARE
LA English
DT Article
DE neuropathy; chemotherapy; quality of life; acupuncture; rehabilitation
ID management; cancer; neurotoxicity; cipn
AB Chemotherapy-induced peripheral neuropathy (CIPN) can cause loss of independence and poor quality of life (QoL) due to severe disabilities, but in spite of its importance there is still a lack of data for the management of CIPN. Acupuncture has showed promising results and may be a cost-effective option for the treatment. Objectives To evaluate the effect of acupuncture treatment on neurological symptoms of CIPN and QoL of oncological patients. Methods We performed a clinical, single-centre, randomised and controlled pilot study that involved 33 adult patients with cancer and CIPN randomised into two groups (control and acupuncture treated with 10 sessions, two times per week). Both groups were subjected to a complete physical examination and clinical assessment with National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Scale V.2.0, FIM Scale, European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Scale and Visual Analogue Scale for pain before and 5 weeks after treatment. Results There were no adverse events, and we found statistical differences in groups in physical (p=0.03) and function (p=0.04) domains of EORTC QLQ-C30 when comparing control and acupuncture groups. About NCI CTCAE Scale and neuropathy sensory symptoms, we found better results in acupuncture group, comparing pretreatment and post-treatment analyses (p=0.01). In control group, we have no differences after 5 weeks (p=0.11). Conclusion Although these results suggest an interesting effect of acupuncture on this patient population, the clinical significance has remained unclear. Given the tendency towards benefit and the lack of adverse effects, the authors recommend a follow-up acupuncture trial using higher follow-up time and better sample size.
C1 [D'Alessandro, Eduardo Guilherme; Nebuloni Nagy, Daniela Ribeiro] Univ Sao Paulo, Inst Canc, Hosp Clin, Fac Med, Sao Paulo, Brazil.
   [Moran de Brito, Christina May; Marinho Almeida, Elisangela Pinto; Cecatto, Rebeca Boltes] Univ Sao Paulo, Inst Canc, Rehabil Dept, Hosp Clin,Fac Med, Sao Paulo, Brazil.
   [Moran de Brito, Christina May] Hosp Sirio Libanes, Rehabil Serv, Sao Paulo, Brazil.
   [Battistella, Linamara Rizzo] Univ Sao Paulo, Fac Med, Dept Legal Med Med Eth Social & Work Med, Sao Paulo, Brazil.
   [Battistella, Linamara Rizzo] Univ Sao Paulo, Inst Med Fis & Reabilitacao, Fac Med, Hosp Clin IMREA HCFMUSP, Sao Paulo, Brazil.
   [Cecatto, Rebeca Boltes] Univ Nove Julho, Sch Med, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Hospital Sirio Libanes; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Nove de Julho
RP Cecatto, RB (corresponding author), Inst Canc Estado Sao Paulo Octavio Frias de Olive, BR-05020000 Sao Paulo, Brazil.
EM rebeca.boltes@gmail.com
FU CNPQ/Brazil [401459/2013-6]
CR Ambrósio EMM, 2012, COMPLEMENT THER MED, V20, P364, DOI 10.1016/j.ctim.2012.05.002
   Argyriou AA, 2012, CRIT REV ONCOL HEMAT, V82, P51, DOI 10.1016/j.critrevonc.2011.04.012
   Australian Acupuncture and Chinese Medicine Association LTD, 2017, AC EV PROJ PLAIN ENG, V0, P0
   Behrend Susan Weiss, 2014, ONCOL NURS FORUM, V41, P559, DOI 10.1188/14.ONF.559-560
   Center for health information and analysis, 2015, MAND BEN REV H B 397, V0, P0
   Deadman P, 1998, A MANUAL OF ACUPUNCTURE, V0, P0
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dropcho EJ, 2010, SEMIN NEUROL, V30, P273, DOI 10.1055/s-0030-1255217
   Fayers P, 2002, EUR J CANCER, V38, P0
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   Hammack JE, 2002, PAIN, V98, P195, DOI 10.1016/S0304-3959(02)00047-7
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hausheer FH, 2006, SEMIN ONCOL, V33, P15, DOI 10.1053/j.seminoncol.2005.12.010
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Kim JH, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-254
   LANGOHR HD, 1982, EUR NEUROL, V21, P309, DOI 10.1159/000115497
   Lao Lixing, 2006, J SOC INTEGR ONCOL, V4, P13
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Majithia N, 2016, SUPPORT CARE CANCER, V24, P1439, DOI 10.1007/s00520-015-3063-4
   Molassiotis A, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5302-4
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Riberto M, 2013, DISABIL REHABIL, V35, P367, DOI 10.3109/09638288.2012.694573
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Smith EML, 2013, QUAL LIFE RES, V22, P2787, DOI 10.1007/s11136-013-0379-8
   Stubblefield MD, 2009, J NATL COMPR CANC NE, V7, PS1, DOI 10.6004/jnccn.2009.0078
   Tofthagen C, 2012, ONCOL NURS FORUM, V39, PE416, DOI 10.1188/12.ONF.E416-E424
NR 28
TC 36
Z9 41
U1 9
U2 56
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2045-435X
EI 2045-4368
J9 BMJ SUPPORT PALLIAT
JI BMJ Support. Palliat. Care
PD MAR 15
PY 2022
VL 12
IS 1
BP 64
EP 72
DI 10.1136/bmjspcare-2018-001542
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA ZF7IB
UT WOS:000759737800013
PM 31256014
DA 2026-01-16
ER

PT J
AU Bettini, E
   Idiokitas, R
   Mahmood, L
   Jacobs, S
   Steinhorn, D
AF Bettini, Elizabeth
   Idiokitas, Risi
   Mahmood, Laila
   Jacobs, Shana
   Steinhorn, David
TI Safety and Acceptance of Acupuncture and Acupressure in Children, Adolescents,
SO Cancer nursing
LA English
DT Journal Article
AB BACKGROUND: Hematopoietic stem cell transplant (HSCT) is associated with  significant morbidity and high symptom burden including mucositis pain, nausea,  and vomiting. There is little documentation in the literature regarding  acupuncture or acupressure for children undergoing HSCT. OBJECTIVE: The purpose  of this study was to determine the safety and acceptance of acupuncture and  acupressure in children undergoing HSCT in a large tertiary care children's  hospital. METHODS: This is a descriptive retrospective study that evaluated 80  admissions to the HSCT unit over a 24-month period. Every child admitted for HSCT  was offered acupuncture or acupressure as part of their care. RESULTS: Of 80  patients, 46 were male patients (ages range, 0-32 years; mean, 8 years).  Diagnoses include leukemia/lymphoma, sickle cell disease, aplastic anemia,  neuroblastoma, and other metabolic, other solid tumor, or other hematologic  disorders. Both allogenic and autologous were represented. Sixty-six patients  (82.5%) agreed to treatment with acupuncture, acupressure, or both. There were no  adverse effects or safety concerns noted. Symptoms addressed by acupuncture or  acupressure included pain from mucositis, nausea, constipation, diarrhea,  anxiety, insomnia, and general wellness or healing. CONCLUSION: This study  demonstrates that acupuncture and acupressure are well accepted by children and  their families admitted for HSCT and are safe even when performed in the first 4  weeks following transplant when the patient is likely to have thrombocytopenia.  IMPLICATIONS FOR PRACTICE: These findings suggest that there may be more  therapies for patients undergoing HSCT to help with symptom control.
C1 Author Affiliations: Palliative Care, Children's National Hospital, Washington, DC (Drs Bettini, Idiokitas, Mahmood, and Jacobs)
   and Capital Caring Hospice,Falls Church, Virginia (Dr Steinhorn).
NR 0
TC 0
SN 1538-980
EI 
J9 Cancer Nurs
PD JUN 10
PY 2022
VL 46
IS 3
BP E204
EP E207
DI 10.1097/NCC.0000000000001135
PG 1
WC Humans; Child; Male; Adolescent; Young Adult; Infant, Newborn; Infant; Child, Preschool; Adult; Female; Acupressure; Mucositis; etiology; Retrospective Studies; Acupuncture Therapy; adverse effects; Nausea; etiology; Pain; etiology; Hematopoietic Stem Cell Transplantation; adverse effects
UT PubMed:35679148
PM 35679148
DA 2022-06-10
ER

PT J
AU Mao, JJ
   Ismaila, N
   Bao, T
   Barton, D
   Ben-Arye, E
   Garland, EL
   Greenlee, H
   Leblanc, T
   Lee, RT
   Lopez, AM
   Loprinzi, C
   Lyman, GH
   MacLeod, J
   Master, VA
   Ramchandran, K
   Wagner, LI
   Walker, EM
   Bruner, DW
   Witt, CM
   Bruera, E
AF Mao, Jun J.
   Ismaila, Nofisat
   Bao, Ting
   Barton, Debra
   Ben-Arye, Eran
   Garland, Eric L.
   Greenlee, Heather
   Leblanc, Thomas
   Lee, Richard T.
   Lopez, Ana Maria
   Loprinzi, Charles
   Lyman, Gary H.
   MacLeod, Jodi
   Master, Viraj A.
   Ramchandran, Kavitha
   Wagner, Lynne I.
   Walker, Eleanor M.
   Bruner, Deborah Watkins
   Witt, Claudia M.
   Bruera, Eduardo
TI Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID induced oral mucositis; placebo-controlled trial; induced peripheral neuropathy; randomized controlled-trial; breast-cancer patients; quality-of-life; inhibitor-induced arthralgia; brief hypnosis intervention; stem-cell transplantation; controlled clinical-trial
AB PURPOSE The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other health care providers on integrative approaches to managing pain in patients with cancer.METHODS The Society for Integrative Oncology and ASCO convened an expert panel of integrative oncology, medical oncology, radiation oncology, surgical oncology, palliative oncology, social sciences, mind-body medicine, nursing, and patient advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2021. Outcomes of interest included pain intensity, symptom relief, and adverse events. Expert panel members used this evidence and informal consensus to develop evidence-based guideline recommendations.RESULTS The literature search identified 227 relevant studies to inform the evidence base for this guideline.RECOMMENDATIONS Among adult patients, acupuncture should be recommended for aromatase inhibitor-related joint pain. Acupuncture or reflexology or acupressure may be recommended for general cancer pain or musculoskeletal pain. Hypnosis may be recommended to patients who experience procedural pain. Massage may be recommended to patients experiencing pain during palliative or hospice care. These recommendations are based on an intermediate level of evidence, benefit outweighing risk, and with moderate strength of recommendation. The quality of evidence for other mind-body interventions or natural products for pain is either low or inconclusive. There is insufficient or inconclusive evidence to make recommendations for pediatric patients. More research is needed to better characterize the role of integrative medicine interventions in the care of patients with cancer.
C1 [Mao, Jun J.; Bao, Ting] Mem Sloan Kettering Canc Ctr, New York, NY USA.
   [Ismaila, Nofisat] Amer Soc Clin Oncol, Alexandria, VA USA.
   [Barton, Debra] Univ Michigan, Sch Nursing, Ann Arbor, MI USA.
   [Ben-Arye, Eran] Clalit Hlth Serv, Lin Med Ctr, Haifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Carmel Med Ctr, Haifa, Israel.
   [Ben-Arye, Eran] Technion Fac Med, Haifa, Israel.
   [Garland, Eric L.] Univ Utah, Coll Social Work, Salt Lake City, UT USA.
   [Greenlee, Heather; Lyman, Gary H.] Fred Hutchinson Canc Res Ctr, Seattle, WA USA.
   [Leblanc, Thomas] Duke Univ, Sch Med, Durham, NC USA.
   [Lee, Richard T.] City Hope Comprehens Canc Ctr, Duarte, CA USA.
   [Lopez, Ana Maria] Thomas Jefferson Sidney Kimmel Canc Ctr, Philadelphia, PA USA.
   [Loprinzi, Charles] Mayo Clin, Rochester, MN USA.
   [MacLeod, Jodi] Mem Sloan Kettering Integrat Med Serv, New York, NY USA.
   [Master, Viraj A.; Bruner, Deborah Watkins] Emory Univ, Winship Canc Inst, Atlanta, GA USA.
   [Ramchandran, Kavitha] Stanford Univ, Palo Alto, CA USA.
   [Wagner, Lynne I.] Wake Forest Sch Med, Winston Salem, NC USA.
   [Walker, Eleanor M.] Henry Ford Hosp, Detroit, MI USA.
   [Witt, Claudia M.] Univ Hosp Zurich, Zurich, Switzerland.
   [Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
C3 Memorial Sloan Kettering Cancer Center; American Society of Clinical Oncology; University of Michigan System; University of Michigan; Clalit Health Services; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Utah System of Higher Education; University of Utah; Fred Hutchinson Cancer Center; Duke University; City of Hope; Mayo Clinic; Emory University; Stanford University; Wake Forest University; Henry Ford Health System; Henry Ford Hospital; University of Zurich; University Zurich Hospital; University of Texas System; UTMD Anderson Cancer Center
RP Mao, JJ (corresponding author), Soc Integrat Oncol, 4301 50th St NW,Suite 300 PMB 1032, Washington, DC 20016 USA.
EM guidelines@integrativeonc.org
FU Samueli Foundation
CR Abdulrhman M, 2012, PEDIATR HEMAT ONCOL, V29, P285, DOI 10.3109/08880018.2012.669026
   Adair M, 2018, INTEGR CANCER THER, V17, P774, DOI 10.1177/1534735417753540
   Aghamohammadi A, 2018, CLIN ORAL INVEST, V22, P2263, DOI 10.1007/s00784-017-2324-7
   Al Jaouni SK, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/5861024
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Alvi ZA, 2013, PAK. ARMED FORCES MED J., V63, P379
   Amanat A, 2017, INDIAN J PALLIAT CAR, V23, P317, DOI 10.4103/IJPC.IJPC_146_16
   Ameri A, 2021, J ALTERN COMPLEM MED, V27, P255, DOI 10.1089/acm.2020.0468
   Amraoui J, 2018, JAMA NETW OPEN, V1, P0, DOI 10.1001/jamanetworkopen.2018.1164
   An W, 2021, FOOD FUNCT, V12, P3352, DOI 10.1039/D0FO02808H
   Unknown -, 2020, CANC FACTS FIGURES 2, V0, P0
   Ardakani MT, 2016, COMPLEMENT THER MED, V29, P29, DOI 10.1016/j.ctim.2016.08.001
   Argyriou AA, 2006, J PAIN SYMPTOM MANAG, V32, P237, DOI 10.1016/j.jpainsymman.2006.03.013
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bao T, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkaa048
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2018, INTEGR CANCER THER, V17, P854, DOI 10.1177/1534735418754309
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bao T, 2011, J PAIN SYMPTOM MANAG, V41, P995, DOI 10.1016/j.jpainsymman.2010.08.012
   Bao YJ, 2010, CHIN J INTEGR MED, V16, P309, DOI 10.1007/s11655-010-0501-5
   Bardy J, 2012, BRIT J ORAL MAX SURG, V50, P221, DOI 10.1016/j.bjoms.2011.03.005
   Bates D, 2017, BIOL BLOOD MARROW TR, V23, P1567, DOI 10.1016/j.bbmt.2017.05.015
   Bauml J, 2014, SUPPORT CARE CANCER, V22, P2465, DOI 10.1007/s00520-014-2220-5
   Bauml JM, 2015, CANCER-AM CANCER SOC, V121, P2431, DOI 10.1002/cncr.29173
   Ben-Arye E, 2021, J CANCER RES CLIN, V147, P2361, DOI 10.1007/s00432-020-03506-1
   Binns-Turner Pamela G, 2011, AANA J, V79, P0
   Biswal BM, 2003, SUPPORT CARE CANCER, V11, P242, DOI 10.1007/s00520-003-0443-y
   Bolouri AJ, 2015, IRAN J CANCER PREV, V8, P0, DOI 10.17795/ijcp-4019
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Brier MJ, 2017, CANCER-AM CANCER SOC, V123, P169, DOI 10.1002/cncr.30318
   Bruera E, 2003, JAMA-J AM MED ASSOC, V290, P2476, DOI 10.1001/jama.290.18.2476
   Burrai F, 2014, HOLIST NURS PRACT, V28, P301, DOI 10.1097/HNP.0000000000000041
   Butler LD, 2009, HEALTH PSYCHOL, V28, P579, DOI 10.1037/a0016124
   Cabrera-Jaime S, 2018, EUR J ONCOL NURS, V32, P40, DOI 10.1016/j.ejon.2017.11.006
   Calcagni N, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0223564
   Cerchietti LCA, 2006, INT J RADIAT ONCOL, V65, P1330, DOI 10.1016/j.ijrobp.2006.03.042
   Chaitanya N, 2020, J NUTR SCI VITAMINOL, V66, P93, DOI 10.3177/jnsv.66.93
   Chan A, 2017, SUPPORT CARE CANCER, V25, P3785, DOI 10.1007/s00520-017-3810-9
   Charalambous A, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0156911
   Charalambous M, 2018, EUR J ONCOL NURS, V34, P89, DOI 10.1016/j.ejon.2018.04.003
   Chattopadhyay S, 2014, SOUTH ASIAN J CANCER, V3, P8, DOI 10.4103/2278-330X.126501
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chim K, 2013, BMC CANCER, V13, P0, DOI 10.1186/1471-2407-13-401
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Cong Y, 2015, MEDIAT INFLAMM, V2015, P0, DOI 10.1155/2015/961635
   Cramer H, 2015, INTEGR CANCER THER, V14, P5, DOI 10.1177/1534735414550035
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   da Silva FP, 2019, J MANIP PHYSIOL THER, V42, P503, DOI 10.1016/j.jmpt.2018.12.007
   Danhauer Suzanne C, 2010, J SOC INTEGR ONCOL, V8, P140
   De Groef A, 2018, CLIN REHABIL, V32, P451, DOI 10.1177/0269215517730863
   De Paolis G, 2019, COMPLEMENT THER CLIN, V34, P280, DOI 10.1016/j.ctcp.2018.12.014
   Decker-Baumann C, 1999, EUR J CANCER, V35, P202, DOI 10.1016/S0959-8049(98)00389-X
   Delavarian Z, 2019, SPEC CARE DENT, V39, P166, DOI 10.1111/scd.12358
   Deng G, 2020, PAIN MED, V21, P636, DOI 10.1093/pm/pnz190
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Deng Gary E, 2009, J SOC INTEGR ONCOL, V7, P85
   Desai K, 2021, J ALTERN COMPLEM MED, V27, P1011, DOI 10.1089/acm.2021.0102
   Dikmen HA, 2019, PAIN MANAG NURS, V20, P47, DOI 10.1016/j.pmn.2018.03.001
   Dilaveri CA, 2020, J ALTERN COMPLEM MED, V26, P602, DOI 10.1089/acm.2019.0479
   dos Reis PED, 2016, SUPPORT CARE CANCER, V24, P4393, DOI 10.1007/s00520-016-3279-y
   Dion LJ, 2016, COMPLEMENT THER CLIN, V23, P82, DOI 10.1016/j.ctcp.2015.04.005
   Diwan AK, 2018, ANN INT MED DENTAL RES, V4, P0
   Dogan MD, 2017, J ALTERN COMPLEM MED, V23, P971, DOI 10.1089/acm.2016.0425
   Dowell Deborah, 2016, JAMA, V315, P1624, DOI 10.15585/mmwr.rr6501e1
   Ebert N, 2021, STRAHLENTHER ONKOL, V197, P63, DOI 10.1007/s00066-020-01684-y
   Erdem Ö, 2014, HOLIST NURS PRACT, V28, P242, DOI 10.1097/HNP.0000000000000033
   Ernst E, 2009, SUPPORT CARE CANCER, V17, P333, DOI 10.1007/s00520-008-0569-z
   Eyigor S, 2018, COMPLEMENT THER CLIN, V32, P40, DOI 10.1016/j.ctcp.2018.04.010
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Feyzioglu O, 2020, SUPPORT CARE CANCER, V28, P4295, DOI 10.1007/s00520-019-05287-x
   Fidler P, 1996, CANCER, V77, P522, DOI 10.1002/(SICI)1097-0142(19960201)77:3<522::AID-CNCR14>3.0.CO;2-6
   Fogh SE, 2017, INT J RADIAT ONCOL, V97, P786, DOI 10.1016/j.ijrobp.2016.11.022
   Forchuk C, 2004, CANCER NURS, V27, P25, DOI 10.1097/00002820-200401000-00004
   Fredenburg HA, 2014, ART PSYCHOTHER, V41, P174, DOI 10.1016/j.aip.2014.01.007
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Ge J, 2013, INT J RADIAT ONCOL, V85, PE1, DOI 10.1016/j.ijrobp.2012.08.018
   Gerçeker GÖ, 2021, EUR J ONCOL NURS, V50, P0, DOI 10.1016/j.ejon.2020.101886
   Gershon J, 2004, J AM ACAD CHILD PSY, V43, P1243, DOI 10.1097/01.chi.0000135621.23145.05
   Ghalayani P, 2017, ASIA-PAC J CLIN ONCO, V13, PE48, DOI 10.1111/ajco.12295
   Ghoreishi Z, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-355
   Gilligan T, 2017, J CLIN ONCOL, V35, P3618, DOI 10.1200/JCO.2017.75.2311
   Giron PS, 2016, SUPPORT CARE CANCER, V24, P2491, DOI 10.1007/s00520-015-3054-5
   Glare PA, 2014, J CLIN ONCOL, V32, P1739, DOI 10.1200/JCO.2013.52.4629
   Gordon LG, 2017, PATIENT, V10, P295, DOI 10.1007/s40271-016-0204-x
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Gupta A, 2020, JCO ONCOL PRACT, V16, P733, DOI 10.1200/OP.20.00113
   Haase O, 2005, DIS COLON RECTUM, V48, P1955, DOI 10.1007/s10350-005-0114-9
   Halm MA, 2014, J HOLIST NURS, V32, P290, DOI 10.1177/0898010114527184
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hawkins PJ, 1998, CONT HYPNOSIS, V15, P199, DOI 10.1002/CH.135
   Hawley P, 2014, SUPPORT CARE CANCER, V22, P751, DOI 10.1007/s00520-013-2031-0
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Heydarirad G, 2020, J ALTERN COMPLEM MED, V26, P807, DOI 10.1089/acm.2020.0012
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Hizli F, 2015, INT UROL NEPHROL, V47, P1773, DOI 10.1007/s11255-015-1111-0
   Hsieh FC, 2019, EUR J CANCER CARE, V28, P0, DOI 10.1111/ecc.13064
   Hsiung WT, 2015, COMPLEMENT THER MED, V23, P339, DOI 10.1016/j.ctim.2015.03.010
   Huang CJ, 2019, AM J CLIN NUTR, V109, P606, DOI 10.1093/ajcn/nqy329
   Huang ST, 2010, INT J NURS STUD, V47, P1354, DOI 10.1016/j.ijnurstu.2010.03.008
   Huberty J, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2530-8
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Izgu N, 2019, CANCER NURS, V42, P139, DOI 10.1097/NCC.0000000000000577
   Jane SW, 2011, PAIN, V152, P2432, DOI 10.1016/j.pain.2011.06.021
   Jayachandran Sadaksharam, 2012, INDIAN J PALLIAT CARE, V18, P190, DOI 10.4103/0973-1075.105689
   Johannsen M, 2016, J CLIN ONCOL, V34, P3390, DOI 10.1200/JCO.2015.65.0770
   John GM, 2016, J CANCER SURVIV, V10, P850, DOI 10.1007/s11764-016-0530-y
   Khanal B, 2010, INT J ORAL MAX SURG, V39, P1181, DOI 10.1016/j.ijom.2010.05.014
   Khurana H, 2013, ORAL DIS, V19, P456, DOI 10.1111/odi.12024
   Kim ES, 2017, J CLIN ONCOL, V35, P0, DOI 10.1200/JCO.2017.73.7916
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Kono T, 2013, CANCER CHEMOTH PHARM, V72, P1283, DOI 10.1007/s00280-013-2306-7
   Kurt S, 2018, EUR J ONCOL NURS, V32, P12, DOI 10.1016/j.ejon.2017.11.001
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Kwekkeboom Kristine L, 2003, ONCOL NURS FORUM, V30, P433, DOI 10.1188/03.ONF.433-440
   Lam TY, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1838-5
   Lang EV, 2008, J VASC INTERV RADIOL, V19, P897, DOI 10.1016/j.jvir.2008.01.027
   Lang EV, 2006, PAIN, V126, P155, DOI 10.1016/j.pain.2006.06.035
   Latte-Naor S, 2019, J ONCOL PRACT, V15, P7, DOI 10.1200/JOP.18.00554
   Latte-Naor S, 2018, SUPPORT CARE CANCER, V26, P2063, DOI 10.1007/s00520-018-4053-0
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee RT, 2014, J CLIN ONCOL, V32, P4095, DOI 10.1200/JCO.2014.55.8676
   Lengacher CA, 2016, J CLIN ONCOL, V34, P2827, DOI 10.1200/JCO.2015.65.7874
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Li XM, 2011, BREAST CANCER RES TR, V128, P411, DOI 10.1007/s10549-011-1533-z
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Arruda MALB, 2016, J PALLIAT MED, V19, P943, DOI 10.1089/jpm.2015.0528
   Lima ICGD, 2021, CLIN ORAL INVEST, V25, P4115, DOI 10.1007/s00784-020-03743-1
   Liossi C, 1999, INT J CLIN EXP HYP, V47, P104, DOI 10.1080/00207149908410025
   Liossi C, 2003, INT J CLIN EXP HYP, V51, P4, DOI 10.1076/iceh.51.1.4.14064
   Liou KT, 2019, PAIN MED, V20, P2060, DOI 10.1093/pm/pnz087
   Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508
   Liu HZ, 2019, BRAZ J PSYCHIAT, V41, P540, DOI 10.1590/1516-4446-2018-0346
   Lopes LC Jr, 2020, REV LAT-AM ENFERM, V28, P0, DOI 10.1590/1518-8345.4213.3377
   Lopez-Vaquero D, 2017, MOL CLIN ONCOL, V6, P931, DOI 10.3892/mco.2017.1238
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Loven D, 2009, EUR J CANCER CARE, V18, P78, DOI 10.1111/j.1365-2354.2008.00996.x
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Luo YK, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/8692343
   Lustberg MB, 2018, BREAST CANCER RES TR, V167, P709, DOI 10.1007/s10549-017-4559-z
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mansourian A, 2015, INT J RADIAT RES, V13, P269, DOI 10.7508/ijrr.2015.03.011
   Mao JJ, 2007, J AM BOARD FAM MED, V20, P434, DOI 10.3122/jabfm.2007.05.060225
   Mao JJ, 2007, COMPLEMENT THER MED, V15, P21, DOI 10.1016/j.ctim.2006.07.006
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao Jun J, 2008, J CANCER SURVIV, V2, P116, DOI 10.1007/s11764-008-0052-3
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Martínez N, 2019, CLIN TRANSL ONCOL, V21, P489, DOI 10.1007/s12094-018-1950-0
   Massingill Jeanne, 2018, INT J THER MASSAGE BODYWORK, V11, P4
   Matsuda C, 2015, CANCER CHEMOTH PHARM, V76, P97, DOI 10.1007/s00280-015-2767-y
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Mendoza ME, 2017, PSYCHO-ONCOLOGY, V26, P1832, DOI 10.1002/pon.4232
   Miranzadeh S, 2015, EUR J ONCOL NURS, V19, P207, DOI 10.1016/j.ejon.2014.10.019
   Mishra L, 2017, INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES: REVIEW AND RESEARCH, V43, P25
   Mohammad EB, 2019, PALLIAT SUPPORT CARE, V17, P29, DOI 10.1017/S1478951518000639
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Montgomery GH, 2002, INT J CLIN EXP HYP, V50, P17, DOI 10.1080/00207140208410088
   Montgomery GH, 2007, JNCI-J NATL CANCER I, V99, P1304, DOI 10.1093/jnci/djm106
   Montgomery GH, 2010, J CONSULT CLIN PSYCH, V78, P80, DOI 10.1037/a0017392
   Moriyama S, 2018, J MED INVESTIG, V65, P184, DOI 10.2152/jmi.65.184
   Motallebnejad M, 2008, J CONT DENT PRACT, V9, P40, DOI 10.5005/jcdp-9-3-40
   Motoo Y, 2020, INT J CLIN ONCOL, V25, P1123, DOI 10.1007/s10147-020-01648-3
   Nahin Richard L, 2016, NCHS DATA BRIEF, V0, P1
   Naidu M U R, 2005, DRUGS R D, V6, P291, DOI 10.2165/00126839-200506050-00005
   Nekuzad N, 2012, IRAN J PHARM RES, V11, P1065
   Nia HS, 2017, INT J NURS PRACT, V23, P0, DOI 10.1111/ijn.12513
   Nihei S, 2018, J PHARM HEALTH CARE, V4, P0, DOI 10.1186/s40780-018-0114-2
   Niravath P, 2019, BREAST CANCER RES TR, V177, P427, DOI 10.1007/s10549-019-05319-4
   Nishioka M, 2011, INT J CLIN ONCOL, V16, P322, DOI 10.1007/s10147-010-0183-1
   Noh GO, 2019, EUR J ONCOL NURS, V42, P82, DOI 10.1016/j.ejon.2019.08.007
   Oberbaum M, 2001, CANCER, V92, P684, DOI 10.1002/1097-0142(20010801)92:3<684::AID-CNCR1371>3.0.CO;2-#
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Okuno SH, 1999, AM J CLIN ONCOL-CANC, V22, P258, DOI 10.1097/00000421-199906000-00009
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Paice JA, 2011, CA-CANCER J CLIN, V61, P157, DOI 10.3322/caac.20112
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pan YQ, 2018, INTEGR CANCER THER, V17, P602, DOI 10.1177/1534735418786801
   Patel MI, 2020, J CLIN ONCOL, V38, P3439, DOI 10.1200/JCO.20.00642
   Pathak S, 2019, CUREUS J MED SCIENCE, V11, P0, DOI 10.7759/cureus.4855
   Pattanayak Lucy, 2016, J GLOB ONCOL, V2, P200, DOI 10.1200/jgo.2015.000786
   Peng N, 2018, BREAST, V37, P18, DOI 10.1016/j.breast.2017.08.003
   Peppone LJ, 2015, BREAST CANCER RES TR, V150, P597, DOI 10.1007/s10549-015-3351-1
   Peterson DE, 2007, CANCER, V109, P322, DOI 10.1002/cncr.22384
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Piredda M, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12757
   Porter LS, 2019, SUPPORT CARE CANCER, V27, P4307, DOI 10.1007/s00520-019-04710-7
   Post-White Janice, 2003, INTEGR CANCER THER, V2, P332, DOI 10.1177/1534735403259064
   Pour-fard-pachekenari AK, 2019, CLIN ORAL INVEST, V23, P1811, DOI 10.1007/s00784-018-2621-9
   Pourdeghatkar F, 2017, IRANIAN JOURNAL OF BLOOD AND CANCER, V9, P84
   Pourmovahed Z, 2013, IRAN J PEDIATR, V23, P564
   Putwatana P, 2009, CANCER NURS, V32, P82, DOI 10.1097/01.NCC.0000343362.68129.ed
   Quinlan-Woodward J, 2016, ONCOL NURS FORUM, V43, P725, DOI 10.1188/16.ONF.725-732
   Raeessi MA, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-293
   Rambod M, 2019, EUR J ONCOL NURS, V43, P0, DOI 10.1016/j.ejon.2019.101678
   Rao S, 2017, FOODS, V6, P0, DOI 10.3390/foods6090077
   Rao S, 2014, INTEGR CANCER THER, V13, P201, DOI 10.1177/1534735413503549
   Rashad UM, 2009, J LARYNGOL OTOL, V123, P223, DOI 10.1017/S0022215108002478
   Rastelli AL, 2011, BREAST CANCER RES TR, V129, P107, DOI 10.1007/s10549-011-1644-6
   Ratcliff CG, 2019, J AM COLL RADIOL, V16, P691, DOI 10.1016/j.jacr.2018.09.009
   Rezaeipour N, 2017, INT J CANCER MANAG, V10, P0, DOI 10.5812/ijcm.8642
   Richardson J, 2006, J PAIN SYMPTOM MANAG, V31, P70, DOI 10.1016/j.jpainsymman.2005.06.010
   Rizi MS, 2017, COMPLEMENT THER CLIN, V29, P136, DOI 10.1016/j.ctcp.2017.09.002
   Rosen Jennifer, 2013, ADV MIND BODY MED, V27, P12
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Sahebjamee M, 2015, ORAL HLTH PREV DENT, V13, P309, DOI 10.3290/j.ohpd.a33091
   Salehi M, 2018, GAZI MED J, V29, P196, DOI 10.12996/gmj.2018.55
   Samdariya S, 2015, INDIAN J PALLIAT CAR, V21, P268, DOI 10.4103/0973-1075.164892
   Sarumathy S, 2012, ASIAN J PHARM CLIN R, V5, P138
   Sattari A, 2019, JUNDISHAPUR J CHRONI, V8, P0
   Shah Swikant, 2020, INDIAN J DENT RES, V31, P718, DOI 10.4103/ijdr.ijdr_822_18
   Shamloo MBB, 2019, COMPLEMENT THER CLIN, V35, P78, DOI 10.1016/j.ctcp.2019.01.016
   Shapiro AC, 2016, BREAST CANCER RES TR, V155, P501, DOI 10.1007/s10549-016-3710-6
   Shea BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j4008
   Shiffman RN, 2012, J AM MED INFORM ASSN, V19, P94, DOI 10.1136/amiajnl-2011-000172
   Shin ES, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009873.pub3
   Shuai T, 2020, FRONT NUTR, V7, P0, DOI 10.3389/fnut.2020.00049
   Sikorskii A, 2020, SUPPORT CARE CANCER, V28, P1395, DOI 10.1007/s00520-019-04959-y
   Sloman R, 1994, CONTEMP NURSE, V3, P6
   Smith JT, 1996, J COUNS PSYCHOL, V43, P187, DOI 10.1037/0022-0167.43.2.187
   Snow A, 2012, J PSYCHOSOC ONCOL, V30, P281, DOI 10.1080/07347332.2012.664261
   Soares AD, 2021, J ETHNOPHARMACOL, V264, P0, DOI 10.1016/j.jep.2020.113365
   Soden K, 2004, PALLIATIVE MED, V18, P87, DOI 10.1191/0269216304pm874oa
   Soo MS, 2016, J AM COLL RADIOL, V13, P526, DOI 10.1016/j.jacr.2015.12.004
   Stephenson NLN, 2007, ONCOL NURS FORUM, V34, P127, DOI 10.1188/07.ONF.127-132
   Sun DZ, 2015, CHIN J INTEGR MED, V21, P579, DOI 10.1007/s11655-014-1950-z
   SYRJALA KL, 1992, PAIN, V48, P137, DOI 10.1016/0304-3959(92)90049-H
   Tanaka Y, 2016, SUPPORT CARE CANCER, V24, P933, DOI 10.1007/s00520-015-2864-9
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Taylor AG, 2003, J ALTERN COMPLEM MED, V9, P77, DOI 10.1089/107555303321222964
   Thanh NN, 2010, J PEDIATR ONCOL NURS, V27, P146, DOI 10.1177/1043454209355983
   Thuma Kanitta, 2016, JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND, V99, P0
   Tian X, 2020, ANN PALLIAT MED, V9, P1431, DOI 10.21037/apm-20-44
   Tomazevic T, 2013, COMPLEMENT THER MED, V21, P306, DOI 10.1016/j.ctim.2013.04.002
   Toth M, 2013, J ALTERN COMPLEM MED, V19, P650, DOI 10.1089/acm.2012.0466
   Tsay SL, 2008, CANCER NURS, V31, P109, DOI 10.1097/01.NCC.0000305694.74754.7b
   Tsujimoto T, 2015, ONCOL REP, V33, P33, DOI 10.3892/or.2014.3564
   Uysal N, 2017, INT J NURS PRACT, V23, P0, DOI 10.1111/ijn.12532
   Vitale MG, 2020, MOLECULES, V25, P0, DOI 10.3390/molecules25102297
   Wang C, 2018, INTEGR CANCER THER, V17, P444, DOI 10.1177/1534735417725578
   Wang WS, 2007, ONCOLOGIST, V12, P312, DOI 10.1634/theoncologist.12-3-312
   Wang YC, 2015, J ALTERN COMPLEM MED, V21, P667, DOI 10.1089/acm.2014.0310
   Warth M, 2015, DTSCH ARZTEBL INT, V112, P788, DOI 10.3238/arztebl.2015.0788
   Weinrich S P, 1990, APPL NURS RES, V3, P140, DOI 10.1016/S0897-1897(05)80135-1
   Wilkie D J, 2000, HOSP J, V15, P31
   Witt CM, 2022, J CANCER EDUC, V37, P499, DOI 10.1007/s13187-020-01829-8
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Wren AA, 2019, SUPPORT CARE CANCER, V27, P3583, DOI 10.1007/s00520-019-4657-z
   Wyatt G, 2017, J PAIN SYMPTOM MANAG, V54, P670, DOI 10.1016/j.jpainsymman.2017.07.037
   Wyatt G, 2012, ONCOL NURS FORUM, V39, P568, DOI 10.1188/12.ONF.568-577
   Xu LP, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101170
   Yayla EM, 2019, CANCER NURS, V42, P35, DOI 10.1097/NCC.0000000000000551
   Yayla EM, 2016, COMPLEMENT THER MED, V27, P58, DOI 10.1016/j.ctim.2016.05.010
   Ye XW, 2016, J PAIN SYMPTOM MANAG, V51, P979, DOI 10.1016/j.jpainsymman.2015.12.330
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   You WC, 2009, J ALTERN COMPLEM MED, V15, P771, DOI 10.1089/acm.2008.0322
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zengin S, 2013, COMPLEMENT THER MED, V21, P689, DOI 10.1016/j.ctim.2013.08.017
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
   Zhao CL, 2014, J TRADIT CHIN MED, V34, P10
   Zheng BM, 2018, INT J RADIAT ONCOL, V100, P418, DOI 10.1016/j.ijrobp.2017.10.013
   Zhi WI, 2021, ONCOLOGY-NY, V35, P35, DOI 10.46883/ONC.2021.3501.0035
NR 276
TC 194
Z9 226
U1 13
U2 113
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 1
PY 2022
VL 40
IS 34
BP 3998
EP +
DI 10.1200/JCO.22.01357
PG 30
WC Oncology
SC Oncology
GA 6R3KD
UT WOS:000892205500012
PM 36122322
DA 2026-01-16
ER

PT J
AU Kristoffersen, AE
   Wider, B
   Nilsen, JV
   Bjelland, M
   Mora, DC
   Nordberg, JH
   Broderstad, AR
   Nakandi, K
   Stub, T
AF Kristoffersen, Agnete E
   Wider, Barbara
   Nilsen, Jorunn V
   Bjelland, Mona
   Mora, Dana C
   Nordberg, Johanna Hök
   Broderstad, Ann Ragnhild
   Nakandi, Kiwumulo
   Stub, Trine
TI Prevalence of late and long-term effects of cancer (treatment) and use of
SO BMC complementary medicine and therapies
LA English
DT Journal Article
DE CAM; Cancer; Complementary therapies; Late effects; Long-term effects; Supportive care
AB BACKGROUND: The increasing number of patients surviving cancer leads to more  people experiencing late and long term-effects from the disease and its  treatment. Fatigue, sleep disorders, early menopause, pain, and nerve damage are  commonly reported. Methods helping people to recover after cancer treatment are  therefore essential. The aims of this study were threefold; (1) to determine the  level of cancer patients suffering from late and long-term effects of cancer  diagnosis and treatment in Norway, (2) explore complementary and alternative  medicine (CAM) modalities used for managing these adversities, and (3) describe  self-perceived benefits and harms of the CAM interventions. METHODS: The study  was conducted in cooperation with the Norwegian Cancer Society (NCS) and  consisted of an online cross-sectional study among members of the NCS user panel  with present or previous cancer (n = 706). The study was carried out in  September/October 2021 using a modified cancer-specific version of the  International Questionnaire to Measure Use of Complementary and Alternative  Medicine (I-CAM-Q). A total of 315 women and 153 men agreed to participate,  resulting in a response rate of 67%. RESULTS: Most of the participants (83%)  suffered from late and long-term effects of cancer treatment; mostly fatigue  (59.2%), sleep disorder (41.5%), hot flashes (39.2%), nerve damage  (polyneuropathy, 38.0%), and pain (36.6%) with a mean number of 5.1 different  late and long-term effects. Late and long-term effects were positively associated  with younger age and college/university education. Nearly half of the  participants experiencing late and long-term effects (43%) reported having used  CAM to treat these complaints. Most frequently used were self-help practices  (26%) such as relaxation therapy (19%), yoga (14%) and meditation (13%), but also  visits to CAM providers were reported by 22%. Herbal- and other natural remedies  to treat late and long-term effects were used by 13%. A high percentage of CAM  users reported self-perceived improvements of their symptoms (86% for self-help  practices, 90% for visits to CAM providers). Few experienced adverse effects of  the CAM treatment. CONCLUSION: A large proportion of cancer patients suffered  from a wide range of late and long-term effects of cancer diagnosis and  treatment, and they use CAM to treat these complaints to a rather high degree.  Relaxation therapy, yoga, meditation, massage, and acupuncture were the most  frequently used therapies regardless of complaint. The therapies used are  generally considered to be both safe and beneficial for the respective complaint,  indicating that the participants seem to be well informed about the choices they  make.
C1 National Research Center in Complementary and Alternative Medicine (NAFKAM), Department of Community Medicine, UiT The Arctic University of Norway, Tromsø,Norway. agnete.kristoffersen@uit.no.
   National Research Center in Complementary and Alternative Medicine (NAFKAM), Department of Community Medicine, UiT The Arctic University of Norway, Tromsø,Norway.
   The Norwegian Cancer Society, Oslo, Norway.
   The Norwegian Cancer Society, Oslo, Norway.
   National Research Center in Complementary and Alternative Medicine (NAFKAM), Department of Community Medicine, UiT The Arctic University of Norway, Tromsø,Norway.
   Regional Cancer Center Stockholm Gotland, Stockholm, Sweden.
   Karolinska Institutet, Department of Neurobiology, Care Sciences & Society, 
   Centre for Sami Health Research, Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
   National Research Center in Complementary and Alternative Medicine (NAFKAM), Department of Community Medicine, UiT The Arctic University of Norway, Tromsø,Norway.
   National Research Center in Complementary and Alternative Medicine (NAFKAM), Department of Community Medicine, UiT The Arctic University of Norway, Tromsø,Norway.
NR 0
TC 0
SN 2662-767
EI 
J9 BMC Complement Med Ther
PD DEC 6
PY 2022
VL 22
IS 1
BP 322
EP 322
DI 10.1186/s12906-022-03790-z
PG 0
WC Male; Humans; Female; Prevalence; Cross-Sectional Studies; Complementary Therapies; Neoplasms; therapy; Pain; Fatigue; therapy
UT PubMed:36471296
PM 36471296
DA 2022-12-06
ER

PT J
AU Zhang, XW
   Hou, WB
   Pu, FL
   Wang, XF
   Wang, YR
   Yang, M
   Cheng, K
   Wang, YY
   Robinson, N
   Liu, JP
AF Zhang, Xiao-wen
   Hou, Wen-bin
   Pu, Feng-lan
   Wang, Xue-feng
   Wang, Yi-ran
   Yang, Ming
   Cheng, Ke
   Wang, Yuyi
   Robinson, Nicola
   Liu, Jian-ping
TI Acupuncture for cancer-related conditions: An overview of systematic reviews
SO PHYTOMEDICINE
LA English
DT Review
DE Acupuncture; Cancer -related conditions; Overview; Systematic reviews; Randomized controlled trials
ID inhibitor-induced arthralgia; breast-cancer; palliative care; hot flashes; placebo; fatigue; safety; burden; pain
AB Background: Acupuncture is commonly used for cancer-related conditions worldwide, and evidence is increasing year on year. There is a need to summarize the evidence of acupuncture for cancer-related conditions comprehensively and critically. Objective: To evaluate and summarize the systematic reviews (SRs) that assess the effects and safety of acupuncture for cancer-related conditions, and to inform clinical practice and future studies. Methods: A comprehensive search was conducted on Pubmed, Embase, the Cochrane Library, Web of Science, CNKI, VIP, Sinomed, and Wanfang from their inception to October 16, 2021. SRs of randomized controlled trials (RCTs) on acupuncture for cancer-related conditions were to be included. Two reviewers screened the eligible articles, and four reviewers in pair extracted data and assessed the methodological quality/risk of bias of all included reviews by AMSTAR 2 and ROBIS tools. The overlap of primary studies was measured by calculating corrected covered areas. Data from the included reviews were synthesized with a summary of meta-analysis or narrative description. Results: Fifty-one SRs of RCTs on acupuncture for cancer-related conditions were included and synthesized. The methodological quality of SRs included 1 "high", 5 "low" and 45 "very low" by AMSTAR 2. Sixteen SRs assessed as low risk of bias (31.37%), and 35 SRs had high risk of bias (68.63%) by ROBIS. Acupuncture showed effective on systemic conditions in relation to different cancers, including cancer-related pain (17 SRs, 80 RCTs), fatigue (7 SRs, 18 RCTs), insomnia (4 SRs, 10 RCTs), quality of life (2 SRs, 15 RCTs); conditions in relation to chemoradiotherapy, including nausea and vomiting (3 SRs, 36 RCTs) and bone marrow suppression (2 SRs, 21 RCTs); and conditions in relation to specific cancers, including breast cancer-related menopause (3 SRs, 6 RCTs), hot flashes (12 SRs, 13 RCTs), arthralgia (5 SRs, 10 RCTs), and nasopharyngeal cancer-related dysphagia (1 SRs, 7 RCTs). Acupuncture appeared to have benefit for patients with lymphoedema (3 SRs, 3 RCTs), gastrointestinal function (5 SRs, 27 RCTs), and xerostomia (4 SRs, 7 RCTs). Limited evidence showed inconsistent results on acupuncture for chemotherapy-induced peripheral neuropathy (3 SRs, 6 RCTs), depression and anxiety (3 SRs, 9 RCTs). Acupuncture was regarded as a safe therapy for cancer patients as no severe adverse events related were reported. Conclusion: Evidence from SRs showed that acupuncture is beneficial to cancer survivors with cancer-related pain, fatigue, insomnia, improved quality of life, nausea and vomiting, bone marrow suppression, menopausal symptoms, arthralgia, and dysphagia, and may also be potential for lymphoedema, gastrointestinal function, and xerostomia. For neuropathy, depression and anxiety, acupuncture should be used as an option based on individual conditions. Acupuncture is relatively safe without serious adverse events. More well-designed clinical trials of acupuncture are recommended on cancer-related depression and anxiety, arthralgia, xerostomia, gastrointestinal dysfunction and dysphagia.
C1 [Zhang, Xiao-wen; Pu, Feng-lan; Robinson, Nicola; Liu, Jian-ping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing 100029, Peoples R China.
   [Wang, Xue-feng; Wang, Yi-ran] Beijing Univ Chinese Med, Sch Humanities, Beijing 100029, Peoples R China.
   [Yang, Ming] Beijing Univ Chinese Med, Affiliated Hosp 3, Beijing 100029, Peoples R China.
   [Cheng, Ke] Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Shanghai 201203, Peoples R China.
   [Wang, Yuyi] Chongqing Hosp Tradit Chinese Med, Chongqing 400011, Peoples R China.
   [Robinson, Nicola] London South Bank Univ, Inst Hlth & Social Care, London, England.
   [Liu, Jian-ping] UiT Arctic Univ Tromso, Fac Hlth Sci, Natl Res Ctr Complementary & Alternat Med NAFKAM, Dept Community Med, N-9037 Tromso, Norway.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Shanghai University of Traditional Chinese Medicine; London South Bank University; UiT The Arctic University of Tromso
RP Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing 100029, Peoples R China.
EM Liujp@bucm.edu.cn
FU key project of the National Natural Science Foundation of China [81830115]; NCCIH [AT001293, 020468C]; International development and capacity enhancement of evidence -based Chinese medicine Project, Ministry of Science and Technology of the People's Republic of China [G20200001187]
CR Anshasi H, 2021, PALLIAT SUPPORT CARE, V19, P361, DOI 10.1017/S1478951520001194
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Benedetti F, 2013, PHYSIOL REV, V93, P1207, DOI 10.1152/physrev.00043.2012
   Bhakta N, 2019, LANCET ONCOL, V20, PE42, DOI 10.1016/S1470-2045(18)30761-7
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chen YP, 2016, J CANCER RES THER, V12, P535, DOI 10.4103/0973-1482.172716
   Chien TJ, 2020, CLIMACTERIC, V23, P130, DOI 10.1080/13697137.2019.1664460
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Chien TJ, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180918
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Chiu HY, 2016, CANCER NURS, V39, P228, DOI 10.1097/NCC.0000000000000278
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   Choi TY, 2012, COMPLEMENT THER MED, V20, P447, DOI 10.1016/j.ctim.2012.07.007
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Craig Wm, 1869, EDINB MED J, V14, P617
   Dans M, 2021, J NATL COMPR CANC NE, V19, P780, DOI 10.6004/jnccn.2021.0033
   Dong B, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-020-03193-y
   Garcia MK, 2015, MED ACUPUNCT, V27, P158, DOI 10.1089/acu.2015.1104
   Garcia MK, 2015, CANCER-AM CANCER SOC, V121, P3948, DOI 10.1002/cncr.29630
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Guo J, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420959442
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   [黄厚强 Huang Houqiang], 2016, 护理学杂志 JOURNAL OF NURSING SCIENCE, V31, P90
   Huang Rui, 2021, ZHONGGUO ZHEN JIU, V41, P557, DOI 10.13703/j.0255-2930.20200618-k0005
   Hughes JG, 2019, ACUPUNCT MED, V37, P223, DOI 10.1136/acupmed-2017-011592
   Kim KH, 2016, ACUPUNCT MED, V34, P248, DOI 10.1136/acupmed-2015-010941
   Kim TH, 2022, EUR J INTEGR MED, V49, P0, DOI 10.1016/j.eujim.2021.101605
   Lee MS, 2009, BREAST CANCER RES TR, V115, P497, DOI 10.1007/s10549-008-0230-z
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Li H, 2016, SYSTEMATIC REV RANDO, V0, P0
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Liu MT, 2020, MED INNOV CHINA, V17, P159, DOI 10.3969/j.issn.1674- 4985.2020.34.042
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   Liu YH, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/2504021
   Lopes LC, 2016, REV LAT-AM ENFERM, V24, P0, DOI 10.1590/1518-8345.0647.2762
   [卢静 Lu Jing], 2018, 南京医科大学学报. 自然科学版 JOURNAL OF NANJING MEDICAL UNIVERSITY. NATURAL SCIENCES EDITION, V38, P1533
   Lu Weidong, 2007, J SOC INTEGR ONCOL, V5, P1, DOI 10.2310/7200.2006.035
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao HJ, 2016, CANCER-AM CANCER SOC, V122, P3667, DOI 10.1002/cncr.30189
   McGuinness LA, 2021, BMJ, V372, P0, DOI 10.1136/BMJ.N71
   Ni XX, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420980825
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Peng H, 2010, J CHIN INTEGR MED, V8, P501, DOI 10.3736/jcim20100601
   Piao HH, 2010, LISHIZHEN MED MAT ME, V21, P1476, DOI 10.3969/j.issn.1008-0805.2010.06.087
   Pieper D, 2014, J CLIN EPIDEMIOL, V67, P368, DOI 10.1016/j.jclinepi.2013.11.007
   Posadzki P, 2013, SUPPORT CARE CANCER, V21, P2067, DOI 10.1007/s00520-013-1765-z
   Rositch AF, 2020, LANCET GLOB HEALTH, V8, PE153, DOI 10.1016/S2214-109X(20)30001-2
   Shea BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j4008
   Shen H, 2015, P CHINESE MED ENG BR, V0, P845
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tao WW, 2019, CHIN J PRACT NURS, V0, PP1836, DOI 10.3760/cma.j.issn.1672-7088.2019.23.017
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Wang CCF, 2019, EUR J INTEGR MED, V27, P81, DOI 10.1016/j.eujim.2019.03.004
   Wang JF, 2020, J EMERG TRADIT CHIN -MED, V29, P1140, DOI 10.3969/j.issn.1004-745X.2020.07.005
   Wang S, 2020, META ANAL ACUPUNCTUR, V0, P0
   Wen YF, 2021, J HEMATOL ONCOL, V14, P0, DOI 10.1186/s13045-021-01093-3
   Whiting P, 2016, J CLIN EPIDEMIOL, V69, P225, DOI 10.1016/j.jclinepi.2015.06.005
   World Health Organization (WHO), 2022, CANC WHO NEWSR FACT, V0, P0
   Wu XY, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16776
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yang P, 2021, SHANGHAI J ACUPUNCT MOX, V40, P366, DOI 10.13460/j.issn.1005-0957.2021.03.0366
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   You L, 2021, ESMO OPEN, V6, P0, DOI 10.1016/j.esmoop.2021.100255
   Yu SB, 2020, EXPLORE-NY, V16, P97, DOI 10.1016/j.explore.2019.06.002
   Yuan C, 2020, J YUNNAN UNIV TRADIT CHIN MED, V43, P61, DOI 10.19288/j.cnki.issn.1000-2723.2020.04.011
   Zeng YW, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2021-049318
   Zhang FY, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2304-8
   Zhang HB, 2015, P WORLD FEDERATION C, V0, P141
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   Zhang YZ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.646315
   Zheng Y, 2014, J LIAONING UNIV TRADIT CHIN MED, V16, P152, DOI 10.13194/j.issn.1673-842x.2014.01.055
   Zhou HY, 2017, STUDY META ANAL ACUP, V0, P0
   Zhuang LP, 2013, INTEGR CANCER THER, V12, P197, DOI 10.1177/1534735412451321
NR 80
TC 50
Z9 65
U1 7
U2 87
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0944-7113
EI 1618-095X
J9 PHYTOMEDICINE
JI Phytomedicine
PD NOV 15
PY 2022
VL 106
IS 
BP 
EP 
DI 10.1016/j.phymed.2022.154430
EA SEP 2022
PG 20
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine
GA 5A9YC
UT WOS:000863233400003
PM 36099656
DA 2026-01-16
ER

PT J
AU Wang, M
   Pei, Z
   Molassiotis, A
AF Wang, Mian
   Pei, Ziwen
   Molassiotis, Alex
TI Recent advances in managing chemotherapy-induced peripheral neuropathy: A
SO European journal of oncology nursing : the official journal of European Oncology
LA English
DT Journal Article
DE Cancer; Chemotherapy-induced peripheral neuropathy; Pain; Symptom management; Systematic review
AB PURPOSE: The aim in this review was to explore recent advances in  chemotherapy-induced peripheral neuropathy (CIPN) management interventions and to  identify the implications for practice and future research. METHODS: A  comprehensive search through seven electronic databases (AMED, CINAHL, Cochrane  Library, EMBASE, PEDro, PubMed, and Web of Science) was conducted for studies  published between January 1, 2013 and August 3, 2019. An updated search for  subsequently published studies was made through PubMed on February 15, 2022.  Randomized controlled trials (RCTs) involving either pharmacological or  non-pharmacological interventions were considered eligible. The Cochrane Risk of  Bias tool version 2.0 (RoB 2.0) was used to appraise the methodological risk of  bias. Data extracted from the included RCTs were synthesized in a narrative  approach. RESULTS: Forty-two RCTs involving a total of 3393 participants were  included. Overall, a high risk of bias was found in most of the included RCTs.  The results further confirmed the analgesic effect of duloxetine on pain-related  to CIPN. Exercise-based interventions, acupuncture, and several non-invasive  neuromodulation techniques showed promise for managing CIPN. CONCLUSIONS: The  effects of most pharmacological and non-pharmacological interventions on CIPN are  inconclusive due to methodological issues. Duloxetine remains the only  pharmacological intervention recommended for managing pain related to CIPN.  Although definitive recommendations cannot be made based on current research  evidence, non-pharmacological interventions, especially non-invasive  neuromodulation techniques, warrant future research.
C1 School of Nursing, The Hong Kong Polytechnic University, Hong Kong SAR, China.
   Department of Rehabilitation Medicine, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, Hubei Province, China.
   School of Nursing, The Hong Kong Polytechnic University, Hong Kong SAR, China.
EM alex.molasiotis@polyu.edu.hk
NR 0
TC 0
SN 1532-212
EI 
J9 Eur J Oncol Nurs
PD APR 15
PY 2022
VL 58
IS 
BP 102134
EP 102134
DI 10.1016/j.ejon.2022.102134
PG 0
WC Antineoplastic Agents; adverse effects; Duloxetine Hydrochloride; therapeutic use; Humans; Pain; Pain Management; Peripheral Nervous System Diseases; chemically induced
UT PubMed:35421796
PM 35421796
DA 2022-04-15
ER

PT J
AU Efverman, A
AF Efverman, Anna
TI Implementation of Acupuncture in Routine Oncology Care: A Comparison of
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; attitudes; evidence-based care; expectations; integrative medicine; integrative oncology; nursing; physiotherapy
AB BACKGROUND: It is important to investigate beliefs in acupuncture in  professionals because professionals' expectations may affect treatment outcomes.  AIM: To document the type, number, and education of professionals practicing  acupuncture. Further, to compare beliefs about the effectiveness of acupuncture  for common cancer related symptoms in the different types of professionals.  METHODS: This cross-sectional study employed a questionnaire on practice and  beliefs regarding acupuncture effects for symptoms that commonly occur in  patients treated within oncology care settings. The respondents (n = 555)  consisted of oncology professionals that is, physicians (n = 133), nurses  (n = 172), and physiotherapists (n = 117). Additional respondents consisted of  acupuncturists (n = 133), working outside approved health care. RESULTS: Of the  respondents, acupuncture was practiced by 4% of the physicians, 6% of the nurses,  58% of the physiotherapists, and 90% of the acupuncturists. The professionals  believed acupuncture to be effective for pain (of the physicians, nurses,  physiotherapists, and acupuncturists, 94%, 98%, 89%, and 99% respectively  believed in the effectiveness), chemotherapy-induced nausea (corresponding  figures: 74%, 89%, 89%, and 93%), and vasomotor symptoms (corresponding figures:  71%, 81%, 80%, and 97%). The physicians believed acupuncture to be effective in a  mean of 5 symptoms, nurses in 6 symptoms, physiotherapists in 6 symptoms, and  acupuncturists in 10 symptoms (P < .001). CONCLUSIONS: Since the professionals  varied substantially regarding practice, education and beliefs in acupuncture,  oncology clinics may consider delivering patient preferred acupuncture according  to evidence-informed guidelines rather than on varying preferences among the  professionals, since professionals' treatment expectations may modify treatment  outcomes.
C1 University of Gävle, Gävle, Sweden.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD NOV 19
PY 2022
VL 21
IS 
BP 15347354221132834
EP 15347354221132834
DI 10.1177/15347354221132834
PG 1
WC Humans; Physical Therapists; Cross-Sectional Studies; Acupuncture Therapy; Physicians; Nurses
UT PubMed:36398874
PM 36398874
DA 2022-11-19
ER

PT J
AU Romero, SAD
   Emard, N
   Baser, RE
   Panageas, K
   MacLeod, J
   Walker, D
   Barton-Burke, M
   Liou, K
   Deng, G
   Farrar, J
   Xiao, H
   Mao, JJ
   Epstein, A
AF Romero, Sally A D
   Emard, Nicholas
   Baser, Raymond E
   Panageas, Katherine
   MacLeod, Jodi
   Walker, Desiree
   Barton-Burke, Margaret
   Liou, Kevin
   Deng, Gary
   Farrar, John
   Xiao, Han
   Mao, Jun J
   Epstein, Andrew
TI Acupuncture versus massage for pain in patients living with advanced cancer: a
SO BMJ open
LA English
DT Journal Article
DE cancer pain; complementary medicine; pain management
AB INTRODUCTION: Pain, comorbid fatigue and sleep disturbances are common and  distressing symptoms for patients with advanced cancer, negatively impacting  their quality of life. Clinical guidelines recommend non-pharmacological  interventions, including acupuncture and massage, for pain management in adult  patients with cancer in adjunct to conventional care. However, high-quality  evidence about the comparative effectiveness and long-term durability of these  therapies for symptom management is limited. METHODS AND ANALYSIS: We describe  the design of a two-arm, parallel group, multicentre randomised controlled trial  that investigates the use of acupuncture versus massage for musculoskeletal pain  among 300 patients with diverse types of advanced cancer. The primary aim is to  evaluate the long-term effectiveness (26 weeks from randomisation) of acupuncture  vs massage for pain (primary outcome) and comorbid symptoms (fatigue, sleep  disturbance and quality of life). The secondary aim is to identify patient-level  demographic characteristics (eg, sex, race, age), clinical factors (eg, insomnia,  pain severity) and psychological attributes that are associated with a greater  reduction in pain for either acupuncture or massage. Patients will receive weekly  acupuncture or massage treatments for 10 weeks, followed by monthly booster  sessions up to 26 weeks. The primary endpoint will be the change in worst pain  intensity score from baseline to 26 weeks. We will collect validated  patient-reported outcomes at multiple time points over 26 weeks. ETHICS AND  DISSEMINATION: The Institutional Review Board at Memorial Sloan Kettering Cancer  Center in New York approved this protocol. Results will be disseminated via  peer-reviewed scientific journals and conference presentations. Our findings will  help patients and healthcare providers make informed decisions about  incorporating non-pharmacological treatments to manage pain for patients with  advanced cancer. TRIAL REGISTRATION NUMBER: NCT04095234.
C1 Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, CA, USA.
   Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Office of Nursing Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA maoj@mskcc.org.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD DEC 30
PY 2022
VL 12
IS 9
BP e058281
EP e058281
DI 10.1136/bmjopen-2021-058281
PG 1
WC Adult; Humans; Quality of Life; Acupuncture Therapy; methods; Massage; Musculoskeletal Pain; complications; Neoplasms; complications; Fatigue; complications; Treatment Outcome; Randomized Controlled Trials as Topic; Multicenter Studies as Topic
UT PubMed:36581960
PM 36581960
DA 2022-12-30
ER

PT J
AU Jin, M
   Xie, LL
   Mao, N
   Wei, JZ
   Chen, JC
   Chen, XF
   Mao, HJ
AF Jin, Ming
   Xie, Lulu
   Mao, Ni
   Wei, Jianzi
   Chen, Junchao
   Chen, Xuefen
   Mao, Huijuan
TI The characteristics of registered acupuncture clinical trials enrolling cancer patients
SO SUPPORTIVE CARE IN CANCER
LA English
DT Review
DE Acupuncture; Clinical trial registration; Cancer; Cancer-related symptoms
ID international committee
AB Purpose This study sought to explore and summarize the global state of acupuncture clinical trials enrolling cancer patients included in international registries to date. Methods All relevant trials evaluating acupuncture-related interventions for the treatment of cancer that were registered in 16 trial registries from January 1, 2001, through December 31, 2020, were identified. Subsequent publications related to these trials were additionally retrieved from the PubMed, Cochrane Library, Embase, CNKI (China National Knowledge Infrastructure), VIP (China Science and Technology Journal Database), and Wanfang databases. We compared information included in these registries regarding completed trials with any associated publications, with a focus on study design, sample size, and selective reporting, based on the registered protocol. Results In total, 222 eligible trials across 19 countries were identified. These trials included 17 specific cancer types and 32 symptoms. The five most common cancer types were breast cancer, head and neck cancer, colorectal cancer, lung cancer, and gastric cancer, accounting for almost half of all registered trials (48.2%). The top five symptoms included in these trials were chemotherapy-induced peripheral neuropathy (CIPN), cancer-related pain, cancer-related fatigue, chemotherapy-induced nausea and vomiting (CINV), and gastrointestinal dysfunction. The overall rate of article publication was low, with publications being associated with just 33.3% of these registered trials. Conclusions This review is the first snapshot of the landscape of acupuncture clinical trials registered in international trial registries, providing a methodological basis for the management of common treatment- and disease-related side effects among cancer patients undergoing acupuncture and offering useful information that will guide future acupuncture-focused research.
C1 [Jin, Ming] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai 200437, Peoples R China.
   [Xie, Lulu; Mao, Ni; Wei, Jianzi; Mao, Huijuan] Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Shanghai 201203, Peoples R China.
   [Chen, Junchao] Shanghai Univ Tradit Chinese Med, Inst Disciplinary Sci, Shanghai 201203, Peoples R China.
   [Chen, Xuefen] Shanghai Univ Tradit Chinese Med, Sch Publ Hlth, Shanghai 201203, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Mao, HJ (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Shanghai 201203, Peoples R China.; Chen, XF (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Publ Hlth, Shanghai 201203, Peoples R China.
EM jinming80266@163.com; xielulu920@163.com; mn13887454832@163.com; weijz2000@126.com; junchaochen@live.cn; chenxf915@163.com; maohuijuan1977@hotmail.com
FU National Natural Science Foundation of Shanghai [21ZR1463300]
CR Bian ZX, 2010, TRIALS, V11, P0, DOI 10.1186/1745-6215-11-64
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Chen JC, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/9461415
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   De Angelis CD, 2005, NEW ENGL J MED, V352, P2436, DOI 10.1056/NEJMe058127
   Fanaroff AC, 2019, LANCET, V394, P633, DOI 10.1016/S0140-6736(19)31256-5
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hou WZ, 2019, J OBSTET GYNAECOL RE, V45, P2307, DOI 10.1111/jog.14122
   Huser V, 2013, J AM MED INFORM ASSN, V20, PE169, DOI 10.1136/amiajnl-2012-001501
   Jang A, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420949679
   Kunath F, 2011, BMJ OPEN, V1, P0, DOI 10.1136/bmjopen-2011-000430
   Lin XF, 2016, J BONE JOINT SURG AM, V98, P1578, DOI 10.2106/JBJS.15.00620
   Liu JP, 2013, BMJ OPEN, V3, P0, DOI 10.1136/bmjopen-2013-002968
   Schulz KF, 2010, EPIDEMIOL BIOSTAT PU, V7, P325
   SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Viergever RF, 2015, BMJ OPEN, V5, P0, DOI 10.1136/bmjopen-2015-008932
   Yu He, 2007, ZHONG XI YI JIE HE XUE BAO, V5, P234
   Zarin DA, 2015, NEW ENGL J MED, V372, P174, DOI 10.1056/NEJMsr1414226
   Zhang YQ, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067476
   Zhao Jingsheng, 2017, ZHONGGUO ZHEN JIU, V37, P1115, DOI 10.13703/j.0255-2930.2017.10.024
NR 24
TC 6
Z9 6
U1 1
U2 13
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD DEC 15
PY 2022
VL 30
IS 12
BP 10461
EP 10470
DI 10.1007/s00520-022-07331-9
EA SEP 2022
PG 10
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 8M5WY
UT WOS:000849310000002
PM 36048280
DA 2026-01-16
ER

PT J
AU Han, G
   Lee, YS
   Jang, HJ
   Kim, SY
   Lee, YJ
   Ha, IH
AF Han, Gajin
   Lee, Ye-Seul
   Jang, Hee Jae
   Kim, Song-Yi
   Lee, Yoon Jae
   Ha, In-Hyuk
TI Symptom Management and Quality of Life of Breast Cancer Patients Using Acupuncture-Related Therapies and Herbal Medicine: A Scoping Review
SO CANCERS
LA English
DT Review
DE breast cancer; anticancer treatment; side effects; acupuncture; herbal medicine; scoping review
ID induced peripheral neuropathy; postmastectomy pain syndrome; controlled-trial; follow-up; women; fatigue; electroacupuncture; complementary; arthralgia; lymphedema
AB Simple Summary This is a scoping review of published literature on the usefulness of acupuncture-related therapies and herbal medicine in alleviating the side effects associated with breast cancer treatments. It is an important study given that the various treatment interventions for breast cancer, such as surgery, chemotherapy, radiotherapy, and hormone therapy, have unpleasant side effects that compromise the patient's quality of life. The study revealed positive impact of some acupuncture-related therapies and herbal medicines in improving the symptoms and quality of life of patients with breast cancer. These findings will inform further studies on the economic impact of acupuncture and herbal medicines in the management of adverse events in patients on breast cancer treatment. The side effects associated with breast cancer treatments often reduce the patients' quality of life. The effectiveness of acupuncture-related therapies and herbal medicine in managing the side effect is not fully understood. The study included clinical studies published in the 10 years since 2011 and analyzed the effectiveness of the therapies for managing side effects of anticancer treatment. The databases of MEDLINE via PubMed, CENTRAL, EMBASE, OASIS, and NSDL were searched. Thirty studies, including 13 (43.3%) randomized controlled trials (RCTs), 12 (40.0%) before-and-after studies, three (10.0%) case series, one (3.3%) case report, and one (3.3%) non-RCT, were included in this review. The main symptoms identified were aromatase inhibitors-induced arthralgia (AIA), lymphedema, and chemotherapy-induced peripheral neuropathy (CIPN). The types of acupuncture-related therapies applied included manual acupuncture, electro-acupuncture, moxibustion, and electro-moxibustion. In ten studies, eight herbal medications were administered. The Brief Pain Inventory-Short Form (BPI-SF) and Functional Assessment of Cancer Therapy-General (FACT-G) and -Breast (FACT-B) were frequently used to evaluate pain and QoL, respectively. Most studies suggested beneficial effects of acupuncture and herbal medicine on managing pain, daily function, and quality of life in patients going through AIA, CIPN, and/or lymphedema, with mild side effects. The scoping review implies the potential of CAM therapies as promising interventions for managing symptoms which otherwise lack alternative management options, and for improving the quality of life of breast cancer patients.
C1 [Han, Gajin] JINRESEARCH, Namyangju 12113, South Korea.
   [Han, Gajin] Kyung Hee Sweet & Sunny Korean Med Clin, Namyangju 12113, South Korea.
   [Lee, Ye-Seul; Lee, Yoon Jae; Ha, In-Hyuk] Jaseng Med Fdn, Jaseng Spine & Joint Res Inst, Seoul 06110, South Korea.
   [Jang, Hee Jae] Kyung Hee Yakson Korean Med Clin, Suwon 16393, South Korea.
   [Kim, Song-Yi] Gachon Univ, Coll Korean Med, Dept Anat & Acupoint, Seongnam 13120, South Korea.
C3 Gachon University
RP Lee, YS (corresponding author), Jaseng Med Fdn, Jaseng Spine & Joint Res Inst, Seoul 06110, South Korea.
EM yeseul.j.lee@gmail.com
FU Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HF20C0222]
CR Abbasi B, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0190231
   Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI 10.1080/1364557032000119616
   Azamjah Nasrindokht, 2019, ASIAN PAC J CANCER PREV, V20, P2015, DOI 10.31557/apjcp.2019.20.7.2015
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Bauml J, 2014, ACUPUNCT MED, V32, P183, DOI 10.1136/acupmed-2013-010459
   Ben-Arye E, 2014, PATIENT EDUC COUNS, V97, P135, DOI 10.1016/j.pec.2014.06.006
   Beuth J, 2013, IN VIVO, V27, P869
   Buckner CA, 2018, CURR ONCOL, V25, PE275, DOI 10.3747/co.25.3884
   Cameron D, 2017, LANCET, V389, P1195, DOI 10.1016/S0140-6736(16)32616-2
   Campagna M, 2020, CANCERS, V12, P0, DOI 10.3390/cancers12020355
   Cassileth BR, 2013, CANCER-AM CANCER SOC, V119, P2455, DOI 10.1002/cncr.28093
   Chappell AG, 2020, WORLD J PLAST SURG, V9, P247, DOI 10.29252/wjps.9.3.247
   Chino A, 2011, J ALTERN COMPLEM MED, V17, P1075, DOI 10.1089/acm.2010.0536
   Collins Kimberly B, 2004, J AM ACAD NURSE PRACT, V16, P76
   Colquhoun HL, 2014, J CLIN EPIDEMIOL, V67, P1291, DOI 10.1016/j.jclinepi.2014.03.013
   De Groef A, 2017, CLIN REHABIL, V31, P1625, DOI 10.1177/0269215517708605
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Giron PS, 2016, SUPPORT CARE CANCER, V24, P2491, DOI 10.1007/s00520-015-3054-5
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   ha choi hyang, 2020, JOURNAL OF RADIOLOGICAL SCIENCE AND TECHNOLOGY 방사선기술과학, V43, P23, DOI 10.17946/jrst.2020.43.1.23
   Han K, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420962854
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Ho PJ, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2017-020512
   Jeong YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5367014
   Jeong YJ, 2015, MED ACUPUNCT, V27, P206, DOI 10.1089/acu.2014.1071
   Kang SY, 2020, J BREAST CANCER, V23, P115
   Kiecolt-Glaser JK, 2014, J CLIN ONCOL, V32, P1040, DOI 10.1200/JCO.2013.51.8860
   Kim TH, 2019, ACUPUNCT MED, V37, P164, DOI 10.1177/0964528419832610
   Korea Central Cancer Registry National Cancer Center, 2020, CPI BY ITEM (EXPENDITURE CATEGORY: 2020=100), V0, P0
   Kwekkeboom KL, 2016, SEMIN ONCOL NURS, V32, P373, DOI 10.1016/j.soncn.2016.08.004
   Li YF, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/2478565
   Lin YH, 2016, INTEGR CANCER THER, V15, P343, DOI 10.1177/1534735415607630
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Mallory MJ, 2015, AM J CHINESE MED, V43, P45, DOI 10.1142/S0192415X15500032
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Molassiotis A, 2006, SUPPORT CARE CANCER, V14, P260, DOI 10.1007/s00520-005-0883-7
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Northern Cancer Alliance National Health Service, 2020, BREAST CANC CLIN GUI, V0, P0
   Ogawa K, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/928129
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Peng N, 2018, BREAST, V37, P18, DOI 10.1016/j.breast.2017.08.003
   Quinlan-Woodward J, 2016, ONCOL NURS FORUM, V43, P725, DOI 10.1188/16.ONF.725-732
   Rosenberg SM, 2015, ONCOLOGIST, V20, P598, DOI 10.1634/theoncologist.2015-0007
   Rostock M, 2011, GYNECOL ENDOCRINOL, V27, P844, DOI 10.3109/09513590.2010.538097
   Saghatelyan T, 2020, PHYTOMEDICINE, V70, P0, DOI 10.1016/j.phymed.2020.153218
   Santen RJ, 2017, J CLIN ENDOCR METAB, V102, P3647, DOI 10.1210/jc.2017-01138
   Taso CJ, 2014, J NURS RES, V22, P155, DOI 10.1097/jnr.0000000000000044
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   Wang CH, 2018, JOURNAL OF TRADITIONAL CHINESE MEDICAL SCIENCES, V5, P255, DOI 10.1016/j.jtcms.2018.06.002
   Wang CH, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866919
   Yang Yan, 2009, ZHONGGUO ZHEN JIU, V29, P955
   Zhang XC, 2020, CURR BREAST CANCER R, V12, P244, DOI 10.1007/s12609-020-00381-0
   Zhang X, 2018, CHIN J INTEGR MED, V24, P867, DOI 10.1007/s11655-017-2928-4
   [祝利民 Zhu Limin], 2014, 上海交通大学学报. 医学版 JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY .MEDICAL SCIENCE, V34, P126
NR 62
TC 13
Z9 16
U1 2
U2 33
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6694
J9 CANCERS
JI Cancers
PD OCT 15
PY 2022
VL 14
IS 19
BP 
EP 
DI 10.3390/cancers14194683
PG 29
WC Oncology
SC Oncology
GA 5G3PJ
UT WOS:000866914000001
PM 36230606
DA 2026-01-16
ER

PT J
AU Romero, SAD
   Emard, N
   Baser, RE
   Panageas, K
   MacLeod, J
   Walker, D
   Barton-Burke, M
   Liou, K
   Deng, G
   Farrar, J
   Xiao, H
   Mao, JJ
   Epstein, A
AF Romero, Sally A. D.
   Emard, Nicholas
   Baser, Raymond E.
   Panageas, Katherine
   MacLeod, Jodi
   Walker, Desiree
   Barton-Burke, Margaret
   Liou, Kevin
   Deng, Gary
   Farrar, John
   Xiao, Han
   Mao, Jun J.
   Epstein, Andrew
TI Acupuncture versus massage for pain in patients living with advanced cancer: a protocol for the IMPACT randomised clinical trial
SO BMJ OPEN
LA English
DT Article
ID insomnia severity index; inhibitor-related arthralgia; false discovery rate; breast-cancer; hospital anxiety; oncology massage; depression scale; united-states; outcm; therapy
AB Introduction Pain, comorbid fatigue and sleep disturbances are common and distressing symptoms for patients with advanced cancer, negatively impacting their quality of life. Clinical guidelines recommend non-pharmacological interventions, including acupuncture and massage, for pain management in adult patients with cancer in adjunct to conventional care. However, high-quality evidence about the comparative effectiveness and long-term durability of these therapies for symptom management is limited. Methods and analysis We describe the design of a two-arm, parallel group, multicentre randomised controlled trial that investigates the use of acupuncture versus massage for musculoskeletal pain among 300 patients with diverse types of advanced cancer. The primary aim is to evaluate the long-term effectiveness (26 weeks from randomisation) of acupuncture vs massage for pain (primary outcome) and comorbid symptoms (fatigue, sleep disturbance and quality of life). The secondary aim is to identify patient-level demographic characteristics (eg, sex, race, age), clinical factors (eg, insomnia, pain severity) and psychological attributes that are associated with a greater reduction in pain for either acupuncture or massage. Patients will receive weekly acupuncture or massage treatments for 10 weeks, followed by monthly booster sessions up to 26 weeks. The primary endpoint will be the change in worst pain intensity score from baseline to 26 weeks. We will collect validated patient-reported outcomes at multiple time points over 26 weeks. Ethics and dissemination The Institutional Review Board at Memorial Sloan Kettering Cancer Center in New York approved this protocol. Results will be disseminated via peer-reviewed scientific journals and conference presentations. Our findings will help patients and healthcare providers make informed decisions about incorporating non-pharmacological treatments to manage pain for patients with advanced cancer.
C1 [Romero, Sally A. D.] Univ Calif San Diego, Dept Obstet Gynecol & Reprod Sci, San Diego, CA 92103 USA.
   [Emard, Nicholas; Panageas, Katherine] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 1275 York Ave, New York, NY 10021 USA.
   [Baser, Raymond E.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
   [MacLeod, Jodi; Walker, Desiree; Liou, Kevin; Deng, Gary; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.
   [Barton-Burke, Margaret] Mem Sloan Kettering Canc Ctr, Off Nursing Res, 1275 York Ave, New York, NY 10021 USA.
   [Farrar, John] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Xiao, Han; Epstein, Andrew] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.
C3 University of California System; University of California San Diego; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Memorial Sloan Kettering Cancer Center
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.
EM maoj@mskcc.org
FU Patient-Centered Outcomes Research Institute (PCORI) [SMPAI-2018C2-12883]; National Institutes of Health/National Cancer Institute Cancer Center [P30 CA008748]; Translational and Integrative Medicine Research Fund at Memorial Sloan Kettering Cancer Center; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Unknown -, 2014, MEDICINE HANDS: MASSAGE THERAPY FOR PEOPLE WITH CANCER, V0, P0
   Unknown -, 2017, CANCER FACTS AND STATISTICS, V0, P0
   Barile JP, 2013, QUAL LIFE RES, V22, P1201, DOI 10.1007/s11136-012-0246-z
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Benjamini Y, 2001, ANN STAT, V29, P1165
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Buckenmaier C, 2016, PAIN MED, V17, P1211, DOI 10.1093/pm/pnw092
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Chen LX, 2013, JCR-J CLIN RHEUMATOL, V19, P308, DOI 10.1097/RHU.0b013e3182a21848
   Chen PY, 2008, INT J BIOSTAT, V0, PP4, DOI 10.2202/1557-4679.1098
   Cheng Xin-Nong, 1987, CHINESE ACUPUNCTURE AND MOXIBUSTION, V0, P0
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Cleeland CS, 2013, CANCER-AM CANCER SOC, V119, P4333, DOI 10.1002/cncr.28376
   Colagiuri B, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/857804
   Commission TJ, 2018, R3 REP ISS 11 PAIN A, V0, P0
   Delgado-Guay MO, 2018, J PALLIAT MED, V21, P678, DOI 10.1089/jpm.2017.0236
   Dodd M J, 2001, ONCOL NURS FORUM, V28, P465
   Dodd MJ, 2010, EUR J ONCOL NURS, V14, P101, DOI 10.1016/j.ejon.2009.09.005
   Dong ST, 2016, SUPPORT CARE CANCER, V24, P1373, DOI 10.1007/s00520-015-2913-4
   Dong ST, 2014, J PAIN SYMPTOM MANAG, V48, P411, DOI 10.1016/j.jpainsymman.2013.10.027
   Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464
   Farrar JT, 2010, J PAIN, V11, P109, DOI 10.1016/j.jpain.2009.06.007
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0
   Garland SN, 2016, CONTEMP CLIN TRIALS, V47, P349, DOI 10.1016/j.cct.2016.02.010
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   Henderson NC, 2016, HEALTH SERV OUTCOME, V16, P213, DOI 10.1007/s10742-016-0159-3
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hurst H, 2004, J MANIP PHYSIOL THER, V27, P26, DOI 10.1016/j.jmpt.2003.11.003
   Imai K, 2013, ANN APPL STAT, V7, P443, DOI 10.1214/12-AOAS593
   Johnsen AT, 2009, PALLIATIVE MED, V23, P491, DOI 10.1177/0269216309105400
   Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005
   Keefe JR, 2017, J PSYCHIATR RES, V84, P90, DOI 10.1016/j.jpsychires.2016.09.029
   Kent DM, 2010, TRIALS, V11, P0, DOI 10.1186/1745-6215-11-85
   Kirkova J, 2011, AM J HOSP PALLIAT ME, V28, P350, DOI 10.1177/1049909110391464
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Lin CC, 2006, J PAIN SYMPTOM MANAG, V32, P52, DOI 10.1016/j.jpainsymman.2005.12.019
   Liou KT, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020085
   Lopez G, 2017, SUPPORT CARE CANCER, V25, P3645, DOI 10.1007/s00520-017-3784-7
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2017, J ONCOL PRACT, V13, PE207, DOI 10.1200/JOP.2016.015081
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2010, PRIMARY CARE, V37, P105, DOI 10.1016/j.pop.2009.09.010
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Miaskowski Christine, 2006, ONCOL NURS FORUM, V33, PE79, DOI 10.1188/06.ONF.E79-E89
   MOOREY S, 1991, BRIT J PSYCHIAT, V158, P255, DOI 10.1192/bjp.158.2.255
   Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601
   Network NCC, 2018, NCCN CLIN PRACTICE G, V0, P0
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Porta-Sales J, 2015, J PALLIAT MED, V18, P923, DOI 10.1089/jpm.2015.29002.jps
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Revicki DA, 2009, QUAL LIFE RES, V18, P783, DOI 10.1007/s11136-009-9489-8
   Robinson-Papp J, 2015, J PAIN SYMPTOM MANAG, V50, P381, DOI 10.1016/j.jpainsymman.2015.03.013
   Rothrock NE, 2010, J CLIN EPIDEMIOL, V63, P1195, DOI 10.1016/j.jclinepi.2010.04.012
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Schulz KF, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/bmj.c869
   Smith AB, 2002, PSYCHOL PSYCHOTHER-T, V75, P165, DOI 10.1348/147608302169625
   Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119
   Tango T, 2017, J BIOPHARM STAT, V27, P963, DOI 10.1080/10543406.2017.1293083
   Tick H, 2018, EXPLORE-NY, V14, P177, DOI 10.1016/j.explore.2018.02.001
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wager S, 2018, J AM STAT ASSOC, V113, P1228, DOI 10.1080/01621459.2017.1319839
   Walsh D, 2000, SUPPORT CARE CANCER, V8, P175, DOI 10.1007/s005200050281
   Walsh D, 2006, SUPPORT CARE CANCER, V14, P831, DOI 10.1007/s00520-005-0899-z
   Walton T, 2010, MEDICAL CONDITIONS AND MASSAGE THERAPY: A DECISION TREE APPROACH, V0, P0
   Wang CG, 2018, J STAT SOFTW, V85, P1, DOI 10.18637/jss.v085.i07
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 76
TC 5
Z9 5
U1 5
U2 30
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD SEP 15
PY 2022
VL 12
IS 9
BP 
EP 
DI 10.1136/bmjopen-2021-058281
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 4M6LJ
UT WOS:000853434200053
PM 36581960
DA 2026-01-16
ER

PT J
AU Li, SK
   Fan, YX
   Cao, XW
   Zhao, J
   Zhu, S
   Liu, ZQ
AF Li, Shao-Kang
   Fan, Yuan-Xiao
   Cao, Xiao-Wen
   Zhao, Jie
   Zhu, Sen
   Liu, Zhi-Qing
TI [Effect of administration of acupuncture stimulation combined with Gushen Zhuyu
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupuncture; Apoptosis; Lumbar disc herniation; Traditional Chinese medicine
AB OBJECTIVE: To investigate the therapeutic effect of acupuncture stimulation  combined with administration of"Gushen Zhuyu Tang"(decoction for consolidating  kidney to eliminate blood stasis, DCKEBS) in the treatment of lumbar disc  herniation (LDH) patients. METHODS: A total of 147 patients with LDH were  randomly divided into DCKEBS, acupuncture and DCKEBS+acupuncture groups (n= 49  cases in each group). The patients of the acupuncture group received a)  acupuncture stimulation of Dazhui (GV14), Ganshu (BL18), Shenshu (BL23), Tianshu  (ST25), Yanglingquan (GB34), etc., b) fire needle pricking of the topical  tendons, cord-like points, tender-points, c) row-needles stimulation of the  attachment sites of muscles of the sacroiliac joint or crista iliaca, and d)  acupotomy-debonding of the topical high-tension muscles, twice a week for 4  weeks. Those patients of the DCKEBS group were ordered to take DCKEBS [containing  fried Yiyiren (Semen Coicis), Shanzhuyu (Fructus Corni), fried Baizhu (Rhizoma  Astractylodis), Sangjisheng (Ramulus Loranthi), Duzhong (Cortex Eucommiae),  Buguzhi (Fructus Psoraieae), etc.] 150 mL, twice daily, continuously for 4 weeks,  and those of the DCKEBS+acupuncture group received the combined treatment  mentioned above in the acupuncture and DCKEBS groups. The pain severity was  assessed by using visual ana-logue scale (VAS, 0-10 points) and the modified  Japan Orthopaedic Association questionnaire (M-JOA) score (0-30 points),  separately, and the lumbar range of motion (ROM) and lumbar muscle strength were  tested to evaluate the lumbar motor function. The levels of serum tumor necrosis  factor α(TNF-α), matrix metalloproteinase-2 (MMP-2), and apoptosis related  factors Caspase-3 and Caspase-9 were assayed using ELISA. The total effective  rates of the three groups were compared. RESULTS: After the treatment, the VAS  and M-JOA scores, contents of serum TNF-α, MMP-2, Caspase-3 and Caspase-9 were  significantly decreased (P<0.01), and the myodynamia of lumbar muscular flexor  and extensor was considerably increased (P<0.01) in the three groups, and the ROM  angles of lumbar extending and buckling were increased (P<0.01) in the  DCKEBS+acupuncture group compared with pretreatment. Comparison among the 3  groups showed that the VAS and M-JOA scores, and serum TNF-α, MMP-2, Caspase-3  and Caspase-9 contents of the DCKEBS+acupuncture group were significantly lower  than those of both DCKEBS and acupuncture groups (P<0.01), while the ROM angles  of lumbar extending and buckling, and the myodynamia of lumbar muscular flexor  and extensor were obviously higher in the DCKEBS+acupuncture group than those of  the DCKEBS and acupuncture groups (P<0.01). The total effective rate was  93.88%(46/49) in the DCKEBS+acupuncture group, higher than 75.51%(37/49) in the  DCKEBS group and 71.43%(35/49) in the acupuncture group (P<0.05). CONCLUSION:  Acupuncture combined with DCKEBS can relieve pain, improve lumbar muscle strength  and lumbar movement function, and reduce serum TNF-α, MMP-2, Caspase-3 and  Caspase-9 levels in LDH patients.
C1 Department of Acupuncture and Moxibustion, Gongli Hospital, Pudong New Area, Shanghai 200135, China.
   Department of Acupuncture and Moxibustion, Gongli Hospital, Pudong New Area, Shanghai 200135, China.
   Department of Acupuncture and Moxibustion, Gongli Hospital, Pudong New Area, Shanghai 200135, China.
   Department of Acupuncture and Moxibustion, Gongli Hospital, Pudong New Area, Shanghai 200135, China.
   Department of Acupuncture and Moxibustion, Gongli Hospital, Pudong New Area, Shanghai 200135, China.
   Department of Acupuncture and Moxibustion, Gongli Hospital, Pudong New Area, Shanghai 200135, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD OCT 28
PY 2022
VL 47
IS 10
BP 907
EP 13
DI 10.13702/j.1000-0607.20210951
PG -894
WC Humans; Intervertebral Disc Displacement; therapy; Matrix Metalloproteinase 2; Caspase 9; Caspase 3; Tumor Necrosis Factor-alpha; Treatment Outcome; Acupuncture Therapy; Acupuncture Points
UT PubMed:36301169
PM 36301169
DA 2022-10-28
ER

PT J
AU Avery, EC
   Augustine, H
   Sade, S
   Dengler, J
AF Avery, Emma Claire
   Augustine, Haley
   Sade, Shachar
   Dengler, Jana
TI Extradigital glomus tumour of the thigh causing 8 years of undiagnosed
SO BMJ case reports
LA English
DT Journal Article
DE Pain; Plastic and reconstructive surgery; Radiology
AB A woman in her mid-50s was referred to a plastic surgeon with an 8-year history  of undiagnosed, localised severe, reproducible pain of the right thigh. Treatment  with oral and topical analgesics, corticosteroids, acupuncture and physiotherapy  did not provide symptom relief. She was referred to multiple specialists over the  preceding 8 years including chronic pain physicians, physiatry, orthopaedic  surgery and plastic surgery. Investigations including sonographic and MRI  eventually revealed a non-specific soft tissue abnormality in the area of  tenderness, which was excised en bloc. Histopathology revealed an extradigital  glomus tumour. The patient's symptoms immediately and permanently resolved  postexcision.Physicians seeing patients suffering from undiagnosed focal,  reproducible pain should consider extradigital glomus tumours in their  differential diagnosis. Workup for extradigital glomus tumour includes focused  sonographic or MRI over the area of pain. Additionally, local injection of an  anaesthetic agent can be used to assist with diagnosis.
C1 Plastic, Reconstructive and Aesthetic Surgery, University of Toronto, Toronto, Ontario, Canada.
   Plastic, Reconstructive and Aesthetic Surgery, University of Toronto, Toronto, Ontario, Canada.
   Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
   Plastic, Reconstructive and Aesthetic Surgery, University of Toronto, Toronto, Ontario, Canada jana.dengler@mail.utoronto.ca.
   Division of Plastic and Reconstructive Surgery, Tory Trauma Program, Sunnybrook
NR 0
TC 0
SN 1757-790
EI 
J9 BMJ Case Rep
PD DEC 20
PY 2022
VL 15
IS 12
BP 
EP 
DI 10.1136/bcr-2022-249869
PG 0
WC Female; Humans; Glomus Tumor; surgery; Thigh; pathology; Ultrasonography; Magnetic Resonance Imaging; Chronic Pain
UT PubMed:36535730
PM 36535730
DA 2022-12-20
ER

PT J
AU Xu, ZH
   Wang, XB
   Wu, YY
   Wang, CB
   Fang, XD
AF Xu, Zhonghang
   Wang, Xingbo
   Wu, Yuanyu
   Wang, Chengbing
   Fang, Xuedong
TI The effectiveness and safety of acupuncture for chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE chemotherapy-induced peripheral neuropathy; acupuncture; systematic review; meta-analysis; physiotherapy
ID quality-of-life; grading quality; cancer; pain; electroacupuncture; breast; recommendations; strength; qlq-c30
AB Objectives: This systematic review and meta-analysis aimed to evaluate the effectiveness and safety of acupuncture on chemotherapy-induced peripheral neuropathy (CIPN). Methods: We searched for relevant randomized controlled trials (RCTs) in PubMed, Cochrane Library, and Embase databases from their inception to 1 April 2022. The Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx), Brief Pain Inventory-Short Form (BPI-SF), the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC QLQ-C30), Numerical Rating Scale (NRS), and adverse events were the outcome measures. All studies had at least one of these outcome measures. Mean differences (MDs) with 95% confidence intervals (CIs) were assessed in the meta-analysis using the RevMan 5.3 software. Results: Five studies were included in the analysis. The results showed that acupuncture and placebo acupuncture were not significantly different in reducing chemotherapy-induced neurotoxicity and functional disability (random-effects estimates; MD: 4.30; 95% CI: -0.85 similar to 9.45; P = 0.10; I-2 = 74%). Acupuncture was better than placebo acupuncture in reducing pain severity and pain interference with patients' daily function (fixed-effect estimates; MD: -1.14; 95% CI: 1.87 to -0.42; P = 0.002; I-2 = 13%). Acupuncture was not significantly different from placebo acupuncture in relieving CIPN symptoms (MD: -0.81; 95% CI: -2.02 to 0.40, P = 0.19). Acupuncture improved quality of life better than placebo acupuncture (MD: 10.10; 95% CI: 12.34 to 17.86, P = 0.01). No severe adverse events were recorded in all five studies. Conclusion: This meta-analysis suggests that acupuncture may be more effective and safer in reducing pain severity and pain interference with patients' daily function than placebo acupuncture. Additionally, acupuncture may improve the quality of life of patients with CIPN. However, large sample size studies are needed to confirm this conclusion.
C1 [Xu, Zhonghang; Wang, Xingbo; Wu, Yuanyu; Wang, Chengbing; Fang, Xuedong] Jilin Univ, China Japan Union Hosp, Changchun, Peoples R China.
C3 Jilin University
RP Fang, XD (corresponding author), Jilin Univ, China Japan Union Hosp, Changchun, Peoples R China.
EM fangxd@jlu.edu.cn
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bonhof CS, 2018, GYNECOL ONCOL, V149, P455, DOI 10.1016/j.ygyno.2018.03.052
   Brozek JL, 2009, ALLERGY, V64, P669, DOI 10.1111/j.1398-9995.2009.01973.x
   Chernyak GV, 2005, ANESTHESIOLOGY, V102, P1031, DOI 10.1097/00000542-200505000-00024
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Comachio J, 2020, J ACUPUNCT MERIDIAN, V13, P87
   Cumpston M, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000142
   De Iullis F, 2015, CRIT REV ONCOL HEMAT, V96, P34, DOI 10.1016/j.critrevonc.2015.04.011
   Dubrovsky G, 2020, MED ACUPUNCT, V32, P16, DOI 10.1089/acu.2019.1381
   Ewertz M, 2015, ACTA ONCOL, V54, P587, DOI 10.3109/0284186X.2014.995775
   Faivre S, 2003, BIOCHEM PHARMACOL, V66, P225, DOI 10.1016/S0006-2952(03)00260-0
   Fukuda Y, 2017, FRONT NEUROSCI-SWITZ, V11, P0, DOI 10.3389/fnins.2017.00481
   Giorgi F, 1996, AM J CLIN ONCOL-CANC, V19, P394, DOI 10.1097/00000421-199608000-00016
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ho CY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/514610
   Hu SY, 2019, CLIN CANCER RES, V25, P6295, DOI 10.1158/1078-0432.CCR-18-2152
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Hwang MS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019837
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Kawakita K, 2014, BIOPSYCHOSOC MED, V8, P0, DOI 10.1186/1751-0759-8-4
   Kumar SP, 2011, INDIAN J PALLIAT CAR, V17, P108, DOI 10.4103/0973-1075.84531
   Litscher G, 2002, LASER MED SCI, V17, P19, DOI 10.1007/s10103-002-8262-9
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Ma SX, 2004, EVID-BASED COMPL ALT, V1, P41, DOI 10.1093/ecam/neh017
   Mezzanotte JN, 2022, CURR TREAT OPTION ON, V23, P29, DOI 10.1007/s11864-021-00926-0
   OSOBA D, 1994, QUAL LIFE RES, V3, P353, DOI 10.1007/BF00451727
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Schünemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   She L, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.687564
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Todd RC, 2009, METALLOMICS, V1, P280, DOI 10.1039/b907567d
   Tsai CH, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22179257
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 40
TC 17
Z9 21
U1 1
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD OCT 3
PY 2022
VL 13
IS 
BP 
EP 
DI 10.3389/fneur.2022.963358
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 5N9NW
UT WOS:000872113700001
PM 36262831
DA 2026-01-16
ER

PT J
AU Stussman, BJ
   Nahin, RL
   Barnes, PM
   Scott, R
   Feinburg, T
   Ward, BW
AF Stussman, Barbara J.
   Nahin, Richard L.
   Barnes, Patricia M.
   Scott, Remle
   Feinburg, Termeh
   Ward, Brian W.
TI Reasons Office-Based Physicians in the United States Recommend Common Complementary Health Approaches to Patients: An Exploratory Study Using a National Survey
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE U; S; physicians; National Ambulatory Medical Care Survey; chiropractic; acupuncture; dietary supplements; mind and body
ID alternative medicine use; breast-cancer; care; pain; attitudes; communication; experience; clinician; patterns; women
AB Objective: To examine the reasons why office-based physicians do or do not recommend four selected complementary health approaches to their patients in the context of the Andersen Behavioral Model.Design: Descriptive estimates of physician-level data from the 2012 National Ambulatory Medical Care Survey (NAMCS) Physician Induction Interview, a nationally representative survey of office-based physicians (N = 5622, weighted response rate = 59.7%).Setting/Location: The United States.Outcome measures: Reasons for the recommendation or lack thereof to patients for: herbs and other non-vitamin supplements, chiropractic/osteopathic manipulation, acupuncture, and mind-body therapies (including meditation, guided imagery, and progressive relaxation). Differences by physician sex and medical specialty were described.Results: For each of the four complementary health approaches, more than half of the physicians who made recommendations indicated that they were influenced by scientific evidence in peer-reviewed journals (ranging from 52.0% for chiropractic/osteopathic manipulation [95% confidence interval, CI = 47.6-56.3] to 71.3% for herbs and other non-vitamin supplements [95% CI = 66.9-75.4]). More than 60% of all physicians recommended each of the four complementary health approaches because of patient requests. A higher percentage of female physicians reported evidence in peer-reviewed journals as a rationale for recommending herbs and non-vitamin supplements or chiropractic/osteopathic manipulation when compared with male physicians (herbs and non-vitamin supplements: 78.8% [95% CI = 72.4-84.3] vs. 66.6% [95% CI = 60.8-72.2]; chiropractic/osteopathic manipulation: 62.3% [95% CI = 54.7-69.4] vs. 47.5% [95% CI = 42.3-52.7]). For each of the four complementary health approaches, a lack of perceived benefit was the most frequently reported reason by both sexes for not recommending. Lack of information sources was reported more often by female versus male physicians as a reason to not recommend herbs and non-vitamin supplements (31.4% [95% CI = 26.8-36.3] vs. 23.4% [95% CI = 21.0-25.9]).Conclusions: There are limited nationally representative data on the reasons as to why office-based physicians decide to recommend complementary health approaches to patients. Developing a more nuanced understanding of influencing factors in physicians' decision making regarding complementary health approaches may better inform researchers and educators, and aid physicians in making evidence-based recommendations for patients.
C1 [Stussman, Barbara J.; Nahin, Richard L.] NCCIH, NIH, Bethesda, MD USA.
   [Barnes, Patricia M.; Ward, Brian W.] Natl Ctr Hlth Stat, Hyattsville, MD USA.
   [Scott, Remle] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Prevent Med & Biostat, Bethesda, MD USA.
   [Feinburg, Termeh] Kelly Govt Solut, Rockville, MD USA.
   [Stussman, Barbara J.] NCCIH, NIH, 6707 Democracy Blvd,Suite 401, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA
RP Stussman, BJ (corresponding author), NCCIH, NIH, Bethesda, MD USA.; Stussman, BJ (corresponding author), NCCIH, NIH, 6707 Democracy Blvd,Suite 401, Bethesda, MD 20892 USA.
EM stussmanbj@mail.nih.gov
CR ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284
   Unknown -, 2012, VITAL HLTH STAT, V0, P0
   Unknown -, 2019, PAIN MANAGEMENT BEST PRACTICES INTER-AGENCY TASK FORCE REPORT: UPDATES, V0, P0
   Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
   Aveni E, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0184979
   Barnes PM, 2002, ADV DATA, V2004, P1, DOI 10.1016/J.SIGM.2004.07.003
   Barnes PM, 2008, NATL HLTH STAT REPOR, V0, P0, DOI DOI 10.1037/E623942009-001
   Berman BM, 2002, ARCH INTERN MED, V162, P766, DOI 10.1001/archinte.162.7.766
   Bethell C, 2011, UNPUB, V0, P0
   Bonnie RJ, 2017, PAIN MANAGEMENT AND THE OPIOID EPIDEMIC: BALANCING SOCIETAL AND INDIVIDUAL BENEFITS AND RISKS OF PRESCRIPTION OPIOID USE, V0, PP1, DOI 10.17226/24781
   Brown C, 2009, J ALTERN COMPLEM MED, V15, P911, DOI 10.1089/acm.2008.0561
   Casbarro N, 2021, COMPLEMENT THER MED, V58, P0, DOI 10.1016/j.ctim.2021.102693
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Cowan AE, 2018, NUTRIENTS, V10, P11
   Curlin FA, 2009, J ALTERN COMPLEM MED, V15, P987, DOI 10.1089/acm.2008.0512
   Davis MA, 2013, HEALTH AFFAIR, V32, P45, DOI 10.1377/hlthaff.2011.0321
   Dennis JA, 2020, J ALTERN COMPLEM MED, V26, P1080, DOI 10.1089/acm.2020.0237
   Doyle C, 2013, BMJ OPEN, V3, P0, DOI 10.1136/bmjopen-2012-001570
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Foley H, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-018-38279-8
   Furlow ML, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-35
   Grainger R, 2014, CLIN RHEUMATOL, V33, P3, DOI 10.1007/s10067-013-2379-z
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P527, DOI 10.1007/s10549-016-3740-0
   Groden SR, 2017, AM J GERIAT PSYCHIAT, V25, P1393, DOI 10.1016/j.jagp.2017.08.001
   Groenewald CB, 2017, ACAD PEDIATR, V17, P785, DOI 10.1016/j.acap.2017.02.008
   Guzman Jennifer R, 2019, J FAM MED DIS PREV, V5, P0, DOI 10.23937/2469-5793/1510109
   Hirschkorn KA, 2005, SOC SCI MED, V61, P157, DOI 10.1016/j.socscimed.2004.11.048
   Huston P, 2021, J ALTERN COMPLEM MED, V27, P434, DOI 10.1089/acm.2020.0418
   Jain N, 2001, J ALTERN COMPLEM MED, V7, P689, DOI 10.1089/10755530152755243
   Kennedy J, 2005, CLIN THER, V27, P1847, DOI 10.1016/j.clinthera.2005.11.004
   Koenig CJ, 2012, PATIENT EDUC COUNS, V89, P368, DOI 10.1016/j.pec.2012.02.020
   Lambe CE, 2013, J CHRIST NURS, V30, P218
   Lee YS, 2015, ACUPUNCT MED, V33, P129, DOI 10.1136/acupmed-2014-010661
   Levine SM, 2003, J AM BOARD FAM PRACT, V16, P318, DOI 10.3122/jabfm.16.4.318
   Macinko J, 2019, J ALTERN COMPLEM MED, V25, P920, DOI 10.1089/acm.2019.0206
   Manek NJ, 2010, BMC COMPLEM ALTERN M, V10, P0, DOI 10.1186/1472-6882-10-5
   Mbizo J, 2018, BMC COMPLEM ALTERN M, V18, P281
   Milden SP, 2004, BEHAV MED, V30, P73, DOI 10.3200/BMED.30.2.73-84
   Nahin RL, 2012, NATL. HEALTH STAT. REP, V95, P1
   Nahin RL, 2016, MAYO CLIN PROC, V91, P1292, DOI 10.1016/j.mayocp.2016.06.007
   Nahin RL, 2015, J PAIN, V16, P1147, DOI 10.1016/j.jpain.2015.07.013
   National Center for Complementary and Integrative Health (NCCIH), 2021, PIL STUD COMM US MIS, V0, P0
   National Center for Health Statistics, 2015, 2012 NAMCS MIRC FIL, V0, P0
   Ndao-Brumblay SK, 2010, PAIN MED, V11, P16, DOI 10.1111/j.1526-4637.2009.00767.x
   Oskoui M, 2020, CAN J NEUROL SCI, V28, P1
   Parker Jennifer D, 2017, VITAL HEALTH STAT 2, V0, P1
   Qaseem Amir, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Research Triangle Institute, 2018, SUDAAN REL 11 0 COMP, V0, P0
   Sawni Anju, 2007, BMC COMPLEMENT ALTERN MED, V7, P18, DOI 10.1186/1472-6882-7-18
   Shelley BM, 2009, ANN FAM MED, V7, P139, DOI 10.1370/afm.947
   Siedlecki SL, 2021, COMPLEMENT THER CLIN, V43, P0, DOI 10.1016/j.ctcp.2021.101327
   Sikand A, 1998, ARCH PEDIAT ADOL MED, V152, P1059
   Smith SR, 1999, ANN PHARMACOTHER, V33, P294, DOI 10.1345/aph.18320
   Spencer CN, 2016, CANCER-AM CANCER SOC, V122, P1552, DOI 10.1002/cncr.29819
   Stussman BJ, 2020, J ALTERN COMPLEM MED, V26, P25, DOI 10.1089/acm.2019.0303
   Tick H, 2018, EXPLORE-NY, V14, P177, DOI 10.1016/j.explore.2018.02.001
   Tilburt JC, 2010, MED CARE, V48, P341, DOI 10.1097/MLR.0b013e3181ca3ee2
   Tovey Philip, 2002, COMPLEMENT THER NURS MIDWIFERY, V8, P12
   Upchurch DM, 2013, J EVIDENCE BASED COM, V18, P100
   Upchurch DM, 2007, J WOMENS HEALTH, V16, P102, DOI 10.1089/jwh.2006.M074
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   Whedon JM, 2020, J ALTERN COMPLEM MED, V26, P966, DOI 10.1089/acm.2020.0078
   Winslow LC, 2002, ARCH INTERN MED, V162, P1176
   Zhang Y, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/413173
NR 66
TC 2
Z9 3
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD AUG 15
PY 2022
VL 28
IS 8
BP 651
EP 663
DI 10.1089/jicm.2022.0493
EA MAY 2022
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA S6JB5
UT WOS:000794032700001
PM 35549394
DA 2026-01-16
ER

PT J
AU Wan, Q
   Chen, H
   Wang, X
   Xi, H
   Zheng, S
   Luo, S
   Wu, W
   Pan, R
AF Wan, Qingyun
   Chen, Hao
   Wang, Xiaoqiu
   Xi, Hanqing
   Zheng, Shiyu
   Luo, Shuting
   Wu, Wenzhong
   Pan, Rui
TI Effectiveness of different acupuncture therapies for chronic cancer pain: A
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Pain is a common and distressing symptom experienced by cancer  patients. Previous research found acupuncture was associated with significant  reductions in pain intensity and opioid use. Acupuncture therapies are various,  and the difference in efficacy and safety has never been assessed. This paper  aims to assess and rank the effectiveness of the different acupuncture methods  and provide an acupuncture treatment guideline for relieving chronic pain in  cancer survivors. METHODS: Four English databases (PubMed, Embase, Cochrane  library, and Web of Science) and 4 Chinese databases (China National Knowledge  Infrastructure, Wanfang Data, and Chinese Biomedical Literature Database) will be  searched for randomized controlled trials (RCTs) published from the database  inception to November 30, 2021. The primary outcomes will be patient-reported  pain intensity measured by the Brief Pain Inventory, Visual Analog Scale, Verbal  Rating Scale, Numerical Rating Scale, and other valid outcome measures. The  Grading of Recommendations Assessment, and Development and Evaluation System will  evaluate the quality of evidence. Bayesian network meta-analysis will be  performed in WinBUGS V.1.4.3 to determine the comparative effectiveness of the  acupuncture therapies. RESULTS: This study will quantify the effectiveness of  each acupuncture intervention for chronic cancer pain with pain scores and the  use of analgesics. The adverse events of acupuncture treatment for cancer pain  will also be reported. CONCLUSION: The conclusion of our study will help  physicians and patients choose suitable acupuncture methods to manage cancer  pain.
C1 Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Nanjing University of Chinese Medicine, Nanjing, China.
   Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
   Jiangsu Cancer Hospital, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD JAN 29
PY 2022
VL 101
IS 4
BP e27965
EP e27965
DI 10.1097/MD.0000000000027965
PG 1
WC Acupuncture Therapy; Cancer Pain; therapy; Chronic Pain; etiology; Humans; Neoplasms; complications; Pain Measurement; Research Design; Network Meta-Analysis as Topic
UT PubMed:35089187
PM 35089187
DA 2022-01-29
ER

PT J
AU Wanqing, DU
   Liuding, W
   Min, J
   Xiao, L
   Bo, LI
   Yunling, Z
   Xing, L
AF Wanqing, D U
   Liuding, Wang
   Min, Jia
   Xiao, Liang
   Bo, L I
   Yunling, Zhang
   Xing, Liao
TI Mixed methods research in complementary and alternative medicine: a scoping
SO Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
LA English
DT Journal Article
DE biomedical research; complementary therapies; mixed methods; pilot projects; review
AB OBJECTIVE: To update the current characteristics about the scope and quality of  mixed methods research (MMR) in complementary and alternative medicine (CAM)  after nearly 10 years. METHODS: A 5-stage approach for conducting a scoping  review was adopted. Articles published on the top 10 journals in CAM with the  highest impact factor in 2020 were screened for MMR. Information of included  articles were extracted, and then synthesized to illustrate the current state.  Methodological quality was evaluated according to the Mixed Method Appraisal Tool  (MMAT) 2018 version. RESULTS: A total of 55 (55/2991, 2%) articles using mixed  methods were retrieved, including 17 medical studies and 38 ethnobotanical  studies. We performed an in-depth analysis on the 17 medical studies, which  studied cancer, stress, pain, fatigue, exercises, mindfulness intervention,  herbal medicine use, art and acupuncture. Thirteen pilot studies applied MMR to  evaluate the feasibility of interventions or programs (13/17, 76%); phenomenology  was inferred as the most common philosophical assumptions (13/17, 76%); the most  applied type of MMR was convergent design (16/17, 94%); integration often took  place at integration (12/17, 71%). Among the 16 eligible studies for quality  appraisal, majority were rated as good (14/16, 88%), whereas two studies were  rated as poorly described. Primarily, a poor rating was due to incomplete  reporting of data analysis and citations in qualitative components; lack of  confounder controlling and the sampling strategy in quantitative components; poor  description of integration and justification for mixed methods. Comparing with  the previous review, fewer MMR were published in 2020 in CAM, but the proportion  of studies that clearly reported MMR has increased by 4 times (4%→15%).  CONCLUSION: CAM researchers need to realize the benefits that MMR can have on  conducting further health care research. Our findings highlight that applying MMR  will be helpful to understand the complex dynamics and interdisciplinary nature  of complex intervention. In addition, addressing a standardized reporting  criteria for MMR is recommended.
C1 Department of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
   2 Center for Evidence-based Chinese Medicine, Institute of Basic Research in 
   3 Xiyuan School of Clinical Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
   Department of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
   Department of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
   Department of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
   Department of Clinical Epidemiology, Beijing Traditional Chinese Medicine Hospital, Capital Medical University, Beijing Institute of Traditional ChineseMedicine, Beijing 100010, China.
   Department of Neurology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
   Center for Evidence-based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700,China.
NR 0
TC 0
SN 2589-451
EI 0255-292
J9 J Tradit Chin Med
PD JUL 19
PY 2022
VL 42
IS 4
BP 652
EP 666
DI 10.19852/j.cnki.jtcm.20220602.002
PG 14
WC Acupuncture; Acupuncture Therapy; Complementary Therapies; Humans; Phytotherapy; Publications
UT PubMed:35848983
PM 35848983
DA 2022-07-19
ER

PT J
AU Dyer, NL
   Surdam, J
   Srinivasan, R
   Agarwal, A
   Dusek, JA
AF Dyer, Natalie L
   Surdam, Jessica
   Srinivasan, Roshini
   Agarwal, Ankita
   Dusek, Jeffery A
TI The Impact of Individualized Complementary and Integrative Health Interventions
SO Journal of integrative and complementary medicine
LA English
DT Journal Article
DE cancer; complementary and integrative health; integrative medicine; pain; practice-based research; quality of life; systematic review; well-being
AB Background: The goal of this systematic review was to evaluate the impact of  individualized complementary and integrative health (CIH) interventions on  quality-of-life outcomes as collected in CIH outpatient clinics. Methods: A  systematic review was conducted using PubMed, OVID, Cochrane, Web of Science,  Scopus, and Embase through December 2020. Inclusion criteria were as follows:  individualized CIH treatment, longitudinal effectiveness design, patient-reported  outcomes, outpatient CIH clinic setting, participants aged ≥18 years, sample size  of ≥25, and English full text. The study was listed in the PROSPERO database  (CRD42020159193), and PRISMA guidelines were used. The variables extracted from  articles focused on study details/demographics, CIH intervention characteristics,  and outcome characteristics. Results: The literature search yielded 3316 records  with 264 assessed for full-text review. Of these, 19 studies (including ∼14,002  patients) were specific to quality of life (or well-being) as a main outcome.  Most studies included were multidisciplinary studies (n = 12), followed by  acupuncture (n = 4), chiropractic (n = 3), and massage or reflexology (n = 1).  The short-form group of questionnaires (SF-12, SF-36, SF-8) were the most used  quality-of-life/well-being questionnaire, comprising 37% of studies (n = 7), and  the Patient Reported Outcomes Measurement Information System (PROMIS) measures  comprised 21% (n = 4). Both questionnaires are normed to U.S. population,  allowing for comparison. The average improvement across the comparable SF and  PROMIS measures for Physical Health was 6% (range 2%-20%) and for Mental Health  was 5% (range 1%-11%), demonstrating clinical significance. Improvements in the  observational studies are comparable to improvements reported from randomized  controlled trials. Conclusions: Results from this systematic review indicate that  CIH therapies largely have positive effects on health-related quality of life and  well-being for various patient populations seen in CIH clinical settings. Direct  comparisons across studies were limited due to the variability in study design  and incomplete reporting in some of the publications. Suggestions for improving  the design and reporting for future practice-based research are provided.
C1 Connor Whole Health, University Hospitals, Cleveland, OH, USA.
   Connor Whole Health, University Hospitals, Cleveland, OH, USA.
   Duke University School of Medicine, Durham, NC, USA.
   Department of Nutrition, Case Western Reserve University, Cleveland, OH, USA.
   Connor Whole Health, University Hospitals, Cleveland, OH, USA.
   Department of Family Medicine and Community Health, Case Western Reserve
NR 0
TC 0
SN 2768-361
EI 2768-360
J9 J Integr Complement Med
PD JUL 15
PY 2022
VL 28
IS 8
BP 618
EP 640
DI 10.1089/jicm.2021.0413
PG 22
WC Adolescent; Adult; Complementary Therapies; Humans; Massage; Mental Health; Patient Reported Outcome Measures; Quality of Life
UT PubMed:35834609
PM 35834609
DA 2022-07-15
ER

PT J
AU Huong, HTX
   Alex, M
   Wan, CC
   Anh, VH
   Phuc, BT
AF Huong, Hoang Thi Xuan
   Alex, Molassiotis
   Wan, Chan Choi
   Anh, Vu Hoang
   Phuc, Bui Thanh
TI Pilot randomized sham-controlled trial of self-acupressure to manage the symptom cluster of insomnia, depression, and anxiety in cancer patients undergoing chemotherapy
SO SLEEP AND BREATHING
LA English
DT Article
DE Symptom cluster; Insomnia; Cancer; Trial; Acupressure; Anxiety; Depression; Sleep
ID auricular point acupressure; sleep disturbances; hospital anxiety; severity index; fatigue; acupuncture; quality; scale; pain
AB Purpose Current evidence for using self-acupressure to manage the cancer-related symptom cluster of insomnia, depression, and anxiety, while promising, is unknown. This study evaluated the feasibility of self-acupressure to manage this symptom cluster and to explore its potential effectiveness. Methods Participants were assigned randomly to three study groups, namely the true acupressure (TAP), the sham acupressure (SAP), and the enhanced standard care group (ESC). Participants in the TAP and SAP groups received a training session on acupressure and were required to practice self-acupressure at home once per day for 28 days. The duration of participant involvement was 8 weeks. Patients completed a Numerical Rating Scale (NRS) for each symptom, the Insomnia Severity Index, the Hospital Anxiety and Depression Scale, and the Functional Assessment of Cancer Therapy-General at baseline (T1), post-intervention (T2, week 4), and post follow-up (T3, week 8). Results The results indicated that the intervention had clinical significance in improving the targeted symptoms and quality of life. In the TAP group, the symptom cluster severity was significantly lower than in the other groups at T2 (p < 0.05). The insomnia severity and anxiety scores in the TAP and SAP groups were significantly lower than those in ESC at T2 and T3 (p < 0.05). Conclusion The trial was feasible. The promising results of the study suggest that further testing of self-acupressure is warranted to inform its effectiveness on the targeted symptom cluster in patients with cancer. A placebo effect was evident alongside therapeutic effects.
C1 [Huong, Hoang Thi Xuan; Alex, Molassiotis; Wan, Chan Choi] Hong Kong Polytech Univ, Sch Nursing, Hung Hom, Kowloon, 11 Yuk Choi Rd, Hong Kong, Peoples R China.
   [Huong, Hoang Thi Xuan; Anh, Vu Hoang] Phenikaa Univ, Fac Nursing, Hanoi, Vietnam.
   [Phuc, Bui Thanh] Vietnam Germany Univ Hosp, Hanoi, Vietnam.
   Vietnam Natl Canc Hosp, 43 Quan St, Hanoi, Vietnam.
   Hanoi Oncol Hosp, 42A Thanh Nhan, Hanoi, Vietnam.
C3 Hong Kong Polytechnic University; Vietnamese-German University
RP Huong, HTX (corresponding author), Hong Kong Polytech Univ, Sch Nursing, Hung Hom, Kowloon, 11 Yuk Choi Rd, Hong Kong, Peoples R China.; Huong, HTX (corresponding author), Phenikaa Univ, Fac Nursing, Hanoi, Vietnam.
EM xuan-huong.hoangthi@connect.polyu.hk
FU Hong Kong Polytechnic University, Hong Kong SAR; Phenikaa University, Hanoi, Vietnam [07-2019.03]
CR Alvaro PK, 2013, SLEEP, V36, P1059, DOI 10.5665/sleep.2810
   Arvidsdotter T, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-308
   Bjelland I, 2002, JOURNAL OF PSYCHOSOMATIC RESEARCH, V52, P69, DOI 10.1016/s0022-3999(01)00296-3
   Carter SL, 2010, SOCIAL VALIDITY MANUAL: A GUIDE TO SUBJECTIVE EVALUATION OF BEHAVIOR INTERVENTIONS IN APPLIED BEHAVIOR ANALYSIS, V0, PP37, DOI 10.1016/B978-0-12-374897-3.00003-9
   Cerrone R, 2008, MINERVA MED, V99, P535
   Cheng KKF, 2013, EUR J CANCER CARE, V22, P70, DOI 10.1111/j.1365-2354.2012.01372.x
   Davidson JR, 2002, SOC SCI MED, V54, P1309, DOI 10.1016/S0277-9536(01)00043-0
   Desai K, 2013, SUPPORT CARE CANCER, V21, P43, DOI 10.1007/s00520-012-1490-z
   Dowrick Adam S, 2012, J BONE JOINT SURG AM, V94 Suppl 1, P7, DOI 10.2106/JBJS.L.00298
   Ellis J, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12538
   Friedmen LM, 2010, FUNDAMENTALS OF CLINICAL TRIALS, V0, P1
   Hertzog MA, 2008, RES NURS HEALTH, V31, P180, DOI 10.1002/nur.20247
   Hmwe NTT, 2016, HOLIST NURS PRACT, V30, P283, DOI 10.1097/HNP.0000000000000165
   Hughes JG, 2015, EUR J INTEGR MED, V7, P623, DOI 10.1016/j.eujim.2015.08.003
   Hoang HTX, 2020, SLEEP BREATH, V24, P241, DOI 10.1007/s11325-019-01839-x
   King MT, 2010, PATIENT-RELAT OUTCOM, V1, P119, DOI 10.2147/PROM.S10621
   Kumar JVR, 2015, ASIAN JOURNAL OF NURSING EDUCATION AND RESEARCH, V5, P513, DOI 10.5958/2349-2996.2015.00105.6
   Kuo HC, 2018, RES NURS HEALTH, V41, P469, DOI 10.1002/nur.21885
   Liou KT, 2019, JNCI CANCER SPECT, V3, P0, DOI 10.1093/jncics/pkz041
   Nguyen LT, 2018, J PAIN SYMPTOM MANAG, V55, P1459, DOI 10.1016/j.jpainsymman.2018.02.019
   Molassiotis A, 2010, J PAIN SYMPTOM MANAG, V39, P847, DOI 10.1016/j.jpainsymman.2009.09.012
   Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601
   Nguyen Ly Thuy, 2016, JBI DATABASE SYSTEM REV IMPLEMENT REP, V14, P49, DOI 10.11124/jbisrir-2016-2476
   Pilkington K, 2010, AUTON NEUROSCI-BASIC, V157, P91, DOI 10.1016/j.autneu.2010.04.002
   Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, P0, DOI 10.1186/1477-7525-6-46
   Purcell A, 2011, SUPPORT CARE CANCER, V19, P1429, DOI 10.1007/s00520-010-0970-2
   Romito F, 2014, EUR J CANCER CARE, V23, P385, DOI 10.1111/ecc.12106
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Song HJ, 2015, COMPLEMENT THER MED, V23, P68, DOI 10.1016/j.ctim.2014.11.002
   Tan JY, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0132989
   Tang WR, 2014, COMPLEMENT THER MED, V22, P581, DOI 10.1016/j.ctim.2014.05.006
   Tough EA, 2009, ACUPUNCT MED, V27, P118, DOI 10.1136/aim.2009.000737
   Tsay SL, 2003, INT J NURS STUD, V40, P1, DOI 10.1016/S0020-7489(02)00019-6
   Vu Van D, 2019, EFFECTS QIGONG SYMPT, V0, P0
   Waits A, 2018, SLEEP MED REV, V37, P24, DOI 10.1016/j.smrv.2016.12.004
   Weinfurt K, 1995, READING UNDERSTANDIN, V0, P245
   Yang M, 2009, CURR MED RES OPIN, V25, P2487, DOI 10.1185/03007990903167415
   Yeh CH, 2019, PAIN MANAG NURS, V20, P614, DOI 10.1016/j.pmn.2019.04.005
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeung WF, 2012, SLEEP MED, V13, P971, DOI 10.1016/j.sleep.2012.06.003
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
NR 43
TC 22
Z9 24
U1 4
U2 26
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1520-9512
EI 1522-1709
J9 SLEEP BREATH
JI Sleep Breath.
PD MAR 15
PY 2022
VL 26
IS 1
BP 445
EP 456
DI 10.1007/s11325-021-02370-8
EA APR 2021
PG 12
WC Clinical Neurology; Respiratory System
SC Neurosciences & Neurology; Respiratory System
GA ZC9SF
UT WOS:000640153700002
PM 33855642
DA 2026-01-16
ER

PT J
AU Chen, ZH
   Zheng, QK
   Chen, SJ
   Li, X
   Lian, XW
AF Chen, Zhen-Hua
   Zheng, Qi-Kai
   Chen, Shui-Jin
   Li, Xiang
   Lian, Xiao-Wen
TI [Warming acupuncture combined with "three steps and seven methods" of tuina for
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE chronic nonspecific low back pain; three steps and seven methods; tuina; warming acupuncture; yang deficiency and cold-dampness blockage
AB OBJECTIVE: To compare the clinical efficacy and possible mechanism of warming  acupuncture combined with "three steps and seven methods" of tuina and simple  "three steps and seven methods" of tuina in treatment of chronic nonspecific low  back pain (NLBP) of yang deficiency and cold-dampness blockage. METHODS: A total  of 138 patients were randomized into an observation group (69 cases, 5 cases  dropped off) and a control group (69 cases, 7 cases dropped off). In the control  group, "three steps and seven methods" of tuina was applied. On the basis of the  treatment in the control group, warming acupuncture was applied at Shenshu (BL  23), Yaoyangguan (GV 3), Mingmen (GV 4), Weizhong (BL 40) and ashi points. The  treatment was given once a day, 6 times a week for 3 weeks in both groups. Before  and after treatment, the short form of McGill pain questionnaire (SF-MPQ) score,  Oswestry disability index (ODI) score, finger-to-floor distance (FFD), Schober  test distance, fear-avoidance beliefs questionnaire (FABQ) score and yang  deficiency and cold-dampness blockage score were observed, the serum levels of  tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 and thromboxane B(2)  (TXB(2)) were detected in both groups. The recurrence rate was evaluated in  follow-up of 6 months after treatment. RESULTS: After treatment, the scores of  PRI, PPI, VAS, ODI, FABQ and FFD, yang deficiency and cold-dampness blockage  scores were decreased compared before treatment in both groups (P<0.01), and  those in the observation group were lower than the control group (P<0.01); the  Schober test distances were increased compared before treatment in both groups  (P<0.01), and that in the observation group was larger than the control group  (P<0.01). After treatment, the serum levels of TNF-α, IL-1β, IL-6 and TXB(2) were  decreased compared before treatment in both groups (P<0.01), and those in the  observation group were lower than the control group (P<0.01). In follow-up, the  recurrence rate was 12.8% (6/47) in the observation group, which was lower than  34.3% (12/35) in the control group (P<0.05). CONCLUSION: Warming acupuncture  combined with "three steps and seven methods" of tuina can effectively alleviate  pain in patients with chronic NLBP of yang deficiency and cold-dampness blockage,  improve activity and dysfunction of waist, the clinical efficacy is superior to  simple "three steps and seven methods" of tuina, its mechanism may be relate to  the inhibition of inflammatory reaction.
C1 Department of Tuina, Rehabilitation Hospital Affiliated to Fujian University of TCM, Fuzhou 350003, China
   Fujian Provincial Key Laboratory of RehabilitationTechnology, Fuzhou 350003.
   Department of Tuina, Rehabilitation Hospital Affiliated to Fujian University of TCM, Fuzhou 350003, China
   Fujian Provincial Key Laboratory of RehabilitationTechnology, Fuzhou 350003.
   Department of Tuina, Rehabilitation Hospital Affiliated to Fujian University of TCM, Fuzhou 350003, China
   Fujian Provincial Key Laboratory of RehabilitationTechnology, Fuzhou 350003.
   College of Rehabilitation Medicine, Fujian University of TCM.
   Department of Tuina, Rehabilitation Hospital Affiliated to Fujian University of TCM, Fuzhou 350003, China
   Fujian Provincial Key Laboratory of RehabilitationTechnology, Fuzhou 350003.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAY 12
PY 2022
VL 42
IS 5
BP 505
EP 10
DI 10.13703/j.0255-2930.20210622-k0001
PG -495
WC Acupuncture Points; Acupuncture Therapy; Humans; Interleukin-6; Low Back Pain; therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Yang Deficiency; therapy
UT PubMed:35543940
PM 35543940
DA 2022-05-12
ER

PT J
AU Qi, QL
   Han, X
   Tang, C
AF Qi, Qing-ling
   Han, Xue
   Tang, Cheng
TI Effects of Acupuncture on Breast Cancer Patients Taking Aromatase Inhibitors
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID induced arthralgia; controlled-trial; joint symptoms; double-blind; dual-center; women; electroacupuncture; management; fatigue
AB Although acupuncture has been used in clinical practice for thousands of years, it remains a controversial treatment option to help alleviate pain in cancer patients. In this study, we analyzed published material on randomized trials of acupuncture from MEDLINE published up until July 31, 2018, to assess its effects on pain experienced by cancer patients. Revman 5.0 software was used to conduct meta-analysis with pain score as the index. The results of nine randomized controlled trials involving 592 patients were analyzed and showed that acupuncture can relieve the pain caused by aromatase inhibitors. Weighted mean difference of worst pain and pain severity was-3.03, 95% CI (-3.90,-2.16) and-2.69, 95% CI (-4.08,-1.30), respectively (P < 0:01). This led us to conclude that acupuncture has pain relieving effects against pain caused by aromatase inhibitors.
C1 [Qi, Qing-ling; Han, Xue] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Tianjin 300381, Peoples R China.
   [Tang, Cheng] Tianjin Med Univ, Sch Pharm, Tianjin 300070, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin Medical University
RP Qi, QL (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Tianjin 300381, Peoples R China.
EM qiqinglingdr@163.com; hhhhhxue163@163.com; tangcheng@tmu.edu.cn
FU Natural Science Foundation of First Teaching Hospital of Tianjin University of Traditional Chinese Medicine;  [201920]
CR Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bauml Joshua, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP302, DOI 10.1093/jncimonographs/lgu029
   Bower JE, 2013, J CLIN ONCOL, V31, P1656, DOI 10.1200/JCO.2012.46.2143
   Burstein HJ, 2007, J CLIN ONCOL, V25, P0, DOI 10.1200/JCO.2007.11.9529
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dai L, 2019, CHIN J INTEGR MED, V25, P71, DOI 10.1007/s11655-018-2999-x
   Deng G, 2018, ONCOLOGY-NY, V32, P310
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Halsey EJ, 2015, ACUPUNCT MED, V33, P188, DOI 10.1136/acupmed-2014-010735
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
NR 20
TC 4
Z9 5
U1 1
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD SEP 12
PY 2022
VL 2022
IS 
BP 
EP 
DI 10.1155/2022/1164355
PG 4
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 5C8BX
UT WOS:000864480200007
PM 36132087
DA 2026-01-16
ER

PT J
AU Jones, KF
   Wechsler, S
   Zulewski, D
   Wood, L
AF Jones, Katie Fitzgerald
   Wechsler, Stephen
   Zulewski, David
   Wood, Lisa
TI Pharmacological and Nonpharmacological Management of Chemotherapy-Induced Peripheral Neuropathy: A Scoping Review of Randomized Controlled Trials
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Review
DE chemotherapy-induced neuropathy; chronic pain; neuropathic pain; peripheral neuropathy
ID cancer-related lymphedema; level laser therapy; quality-of-life; induced polyneuropathy; survivors; balance; impact; symptoms; exercise; falls
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of cancer treatment with no effective preventative strategy or definitive treatment.Purpose: To synthesize empiric literature from randomized controlled trials (RCTs) of pharmacological and nonpharmacological management of CIPN.Data Sources: Articles published between January 1, 2010, and February 28, 2021, were identified using keywords searching Medline, PubMed, CINAHL, Web of Science, Cochrane Library, and Embase.Study Selection: RCTs that recruited individuals who were post-chemotherapy and experienced persistent CIPN symptoms.Data Extraction and Synthesis: Three independent reviewers screened a total of 2023 abstracts. After screening, full-text review, and quality appraisal, 22 articles were included in this review. Data related to study design, participant characteristics, interventions, controls, outcome measures, and relevant findings were extracted from full texts. Descriptive quantitative summaries were calculated and narrative analysis was performed.Results: Of the 22 studies, 4 investigated pharmacologic treatments, 2 compared acupuncture to pharmacologic treatments, and 16 studies examined nonpharmacologic treatments. Pharmacologic studies reported mixed results with evidence of participant response varying by history of chemotherapeutic agent. Acupuncture, exercise/physical therapy, and neurofeedback appear to be effective treatments for CIPN. Evidence regarding biophysical agents and cognitive-behavioral therapy is equivocal. Scrambler therapy is not supported.Limitations: Studies included in this review share several limitations, including widely variable outcome measures, small and demographically homogenous samples, and nonstandardized treatment protocols.Conclusion: This scoping review summarized the current body of high-quality RCTs investigating treatment for CIPN. The majority of studies in this review reports benefits of pharmacologic and nonpharmacologic interventions, although management may require a multipronged approach and should be tailored to the individual. Clinical implications are proposed and suggestions made for future research include implementation of standardized intervention protocols, use of outcome measures representative of the spectrum of CIPN symptoms, and stratification by the chemotherapeutic agent.
C1 [Jones, Katie Fitzgerald; Zulewski, David; Wood, Lisa] Boston Coll, William F Connell Sch Nursing, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.
   [Wechsler, Stephen] Massachusetts Gen Hosp, Inst Hlth Professionals, Sch Rehabil Sci, Boston, MA 02114 USA.
C3 Boston College; Harvard University; Harvard University Medical Affiliates; Massachusetts General Hospital
RP Jones, KF (corresponding author), Boston Coll, William F Connell Sch Nursing, 140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.
EM jonesafq@bc.edu
FU National Institute of Nursing Research [F31NR019929] Funding Source: NIH RePORTER; NINR NIH HHS [F31 NR019929] Funding Source: Medline
CR Argenta PA, 2017, GYNECOL ONCOL, V144, P159, DOI 10.1016/j.ygyno.2016.11.013
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI 10.1080/1364557032000119616
   Avan R, 2018, J RES MED SCI, V23, P0, DOI 10.4103/jrms.JRMS_1068_17
   Bao T, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkaa048
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Beijers AJM, 2020, ANN ONCOL, V31, P131, DOI 10.1016/j.annonc.2019.09.006
   Bulls HW, 2021, ANN BEHAV MED, V55, P844, DOI 10.1093/abm/kaaa101
   Cammisuli S, 2016, EUR J PHYS REHAB MED, V52, P479
   CancerNet, 2011, CANC SURV GUID, V0, P0
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Childs DS, 2021, J PAIN SYMPTOM MANAG, V61, P1247, DOI 10.1016/j.jpainsymman.2020.11.025
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Dimitrova A, 2017, MED ACUPUNCT, V29, P352, DOI 10.1089/acu.2017.1242
   Eckhoff L, 2015, EUR J CANCER, V51, P292, DOI 10.1016/j.ejca.2014.11.024
   Finlayson CS, 2015, J PALLIAT MED, V18, P176, DOI 10.1089/jpm.2014.0222
   Fu MR, 2014, CLIN J ONCOL NURS, V18, P68, DOI 10.1188/14.CJON.S3.68-79
   Fu MR, 2013, PSYCHO-ONCOLOGY, V22, P1466, DOI 10.1002/pon.3201
   Galantino ML, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419850627
   Galantino ML, 2019, INT J YOGA THER, V30, P49
   Geiger G, 2015, BIOELECTROMAGNETICS, V36, P251, DOI 10.1002/bem.21897
   Gewandter JS, 2013, SUPPORT CARE CANCER, V21, P2059, DOI 10.1007/s00520-013-1766-y
   Gewandter JS, 2017, NEUROLOGY, V89, P859, DOI 10.1212/WNL.0000000000004272
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Goto Y, 2020, J CLIN NEUROSCI, V73, P101, DOI 10.1016/j.jocn.2020.01.020
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hile ES, 2010, PHYS THER, V90, P1649, DOI 10.2522/ptj.20090405
   Hincker A, 2019, PAIN, V160, P1835, DOI 10.1097/j.pain.0000000000001577
   Hou S, 2018, PAIN PHYSICIAN, V21, P571, DOI 10.36076/ppj.2018.6.571
   Hsieh YL, 2016, SUPPORT CARE CANCER, V24, P233, DOI 10.1007/s00520-015-2773-y
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Huang MH, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0208573
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Kandula T, 2018, JAMA NEUROL, V75, P980, DOI 10.1001/jamaneurol.2018.0963
   Kerckhove N, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00086
   Kleckner IR, 2018, SUPPORT CARE CANCER, V26, P1019, DOI 10.1007/s00520-017-4013-0
   Kneis S, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5522-7
   Knoerl R, 2018, J PAIN, V19, P382, DOI 10.1016/j.jpain.2017.11.009
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Lindblad K, 2016, SUPPORT CARE CANCER, V24, P2523, DOI 10.1007/s00520-015-3060-7
   Liou KT, 2019, PAIN MED, V20, P2060, DOI 10.1093/pm/pnz087
   Lopes-Souza P, 2018, DRUG DISCOV THER, V12, P239, DOI 10.5582/ddt.2018.01039
   Loprinzi C, 2020, SUPPORT CARE CANCER, V28, P1183, DOI 10.1007/s00520-019-04881-3
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Ludwick A, 2020, PAIN MANAG NURS, V21, P142, DOI 10.1016/j.pmn.2019.08.005
   Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018
   McCrary JM, 2019, SUPPORT CARE CANCER, V27, P3849, DOI 10.1007/s00520-019-04680-w
   Monfort SM, 2017, BREAST CANCER RES TR, V164, P69, DOI 10.1007/s10549-017-4230-8
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Prinsloo S, 2018, J PAIN SYMPTOM MANAG, V55, P1276, DOI 10.1016/j.jpainsymman.2018.01.010
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Rick O, 2017, BIOELECTROMAGNETICS, V38, P85, DOI 10.1002/bem.22005
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Schönsteiner SS, 2017, EXP HEMATOL ONCOL, V5, P0, DOI 10.1186/s40164-017-0065-6
   Schwenk M, 2016, GERONTOLOGY, V62, P553, DOI 10.1159/000442253
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Smoot B, 2015, J CANCER SURVIV, V9, P287, DOI 10.1007/s11764-014-0411-1
   Song SY, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420925519
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Streckmann F, 2019, SUPPORT CARE CANCER, V27, P2471, DOI 10.1007/s00520-018-4531-4
   Sun YJ, 2016, EXP THER MED, V12, P4017, DOI 10.3892/etm.2016.3871
   Tanay MA, 2019, EUR J CANCER CARE, V28, P0, DOI 10.1111/ecc.13011
   Tofthagen C, 2012, SUPPORT CARE CANCER, V20, P583, DOI 10.1007/s00520-011-1127-7
   Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850
   van den Beuken-van Everdingen MH, 2016, J PAIN SYMPTOM MANAG, V51, P0
   Verhulst ALJ, 2015, ONCOL REV, V9, P0, DOI 10.4081/oncol.2015.263
   Wechsler S, 2021, REHABIL ONCOL, V39, P6, DOI 10.1097/01.REO.0000000000000238
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Zanville NR, 2016, SUPPORT CARE CANCER, V24, P4779, DOI 10.1007/s00520-016-3329-5
   Zimmer P, 2018, SUPPORT CARE CANCER, V26, P615, DOI 10.1007/s00520-017-3875-5
NR 75
TC 16
Z9 22
U1 2
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUN 15
PY 2022
VL 25
IS 6
BP 964
EP 995
DI 10.1089/jpm.2021.0512
EA FEB 2022
PG 32
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 3S9TI
UT WOS:000751990300001
PM 35128938
DA 2026-01-16
ER

PT J
AU Shi, H
   Huang, Q
   Yao, WP
   He, L
   Zhang, CD
   Yang, ZM
AF Shi, Hao
   Huang, Qian
   Yao, Wen-Ping
   He, Lei
   Zhang, Chuan-Dong
   Yang, Zheng-Ming
TI [Randomized controlled trial on cervical spondylotic radiculopathy of
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupuncture; Cervical spondylotic radiculopathy; Thunder-fire moxibustion; Wind-cold-damp type
AB OBJECTIVE: To explore the therapeutic effect of acupuncture combined with  thunder-fire moxibustion on cervical spondylotic radiculopathy of wind-cold-damp  type and its impacts on the conduction velocity of F wave of median nerve and  ulnar nerve, as well as hypersensitive C-responsive protein (hs-CRP), interleukin  6 (IL-6), IL-1β and tumor necrosis factor α (TNF-α) in serum. METHODS: A total of  94 patients with cervical spondylotic radiculopathy of wind-cold-damp type were  randomly divided into a control group and a combined therapy group, 47 cases in  each group. In the control group, acupuncture was applied to Fengchi (GV20),  Tianzhu (BL10), Neck-Jiaji (EX-B5), Dazhui (GV14) and others, 30 min each time,  once daily, 5 times a week, totally for 4 weeks. In the combined therapy group,  on the base of the treatment as the control group, the thunder-fire moxibustion  was adopted over GV20, EX-B5, GV14, Jianjing (ST21) and Tianzong (SI11), 20 min  each time, once every other day, for 4 weeks in total. After the treatment, the  curative effect was compared in the patients between two groups. The short-form  McGill pain questionnaire (SF-MPQ), the neck specificity scale and the MOS  36-item short form health survey (SF-36) were scored. The conduction velocity of  F wave in median nerve and ulnar nerve was detected by electromyography. The  expression of hs-CRP was measured by immunoturbidimetry. IL-6, IL-1β and TNF-α in  serum were determined by enzyme linked immunosorbent assay. RESULTS: The total  effective rate in the combined therapy group was 95.7% (45/47), which was higher  than 80.9% (38/47) in the control group (P<0.05). Compared with their own  pretreatment, the scores of SF-MPQ, neck specificity scale and SF-36 were all  obviously improved after treatment in the patients of either group (P<0.05),  while the conduction velocity of F wave in median nerve and ulnar nerve was  accelerated and hs-CRP, IL-6, IL-1β and TNF-α in serum were decreased (P<0.05).  Compared with the control group, the improvements in the scores of SF-MPQ, neck  specificity scale and SF-36 were more obvious (P<0.05), the increase of the  conduction velocity of F wave in median nerve and ulnar nerve and the decrease of  hs-CRP, IL-6, IL-1β and TNF-α in serum were more remarkable (P<0.05) in the  combined therapy group. CONCLUSION: Acupuncture combined with thunder-fire  moxibustion relieves the clinical symptoms of cervical spondylotic radiculopathy  of wind-cold-damp type.
C1 Department of Acupuncture and Moxibustion, Lianyungang Hospital of Traditional Chinese Medicine Affi-liated to Kangda College of Nanjing Medical University,Lianyungang 222000, Jiangsu Province, China
   Clinical Medicine Department ofKangda College of Nanjing Medical University, Lianyungang 222000, JiangsuProvince.
   Department of Acupuncture and Moxibustion, Lianyungang Hospital of Traditional Chinese Medicine Affi-liated to Kangda College of Nanjing Medical University,Lianyungang 222000, Jiangsu Province, China.
   Department of Acupuncture and Moxibustion, Lianyungang Hospital of Traditional Chinese Medicine Affi-liated to Kangda College of Nanjing Medical University,Lianyungang 222000, Jiangsu Province, China.
   Department of Acupuncture and Moxibustion, Lianyungang Hospital of Traditional Chinese Medicine Affi-liated to Kangda College of Nanjing Medical University,Lianyungang 222000, Jiangsu Province, China.
   Department of Preventive Treatment, Lianyungang Hospital of Traditional Chinese Medicine Affi-liated to Kangda College of Nanjing Medical University, Lianyungang222000, Jiangsu Province, China.
   Department of Acupuncture and Moxibustion, Lianyungang Hospital of Traditional Chinese Medicine Affi-liated to Kangda College of Nanjing Medical University,Lianyungang 222000, Jiangsu Province, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JAN 1
PY 2022
VL 46
IS 12
BP 1036
EP 42
DI 10.13702/j.1000-0607.20210006
PG -994
WC Acupuncture Points; Acupuncture Therapy; Humans; Moxibustion; Radiculopathy; therapy; Wind
UT PubMed:34970881
PM 34970881
DA 2022-01-01
ER

PT J
AU Li, J
   Xu, D
   Liu, Y
   Cao, Y
   He, J
   Liao, M
AF Li, Jialing
   Xu, Danghan
   Liu, Yingyu
   Cao, Yang
   He, Jun
   Liao, Muxi
TI Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint
SO Frontiers in neurology
LA English
DT Journal Article
DE Guillain–Barré syndrome; acupuncture; case report; immune checkpoint inhibitors; immune-related adverse events; limb weakness; numbness
AB Guillain-Barré syndrome(GBS) is an autoimmune-mediated peripheral neuropathy.  Immune checkpoint inhibitors (ICIs) are the standard treatment for cancer and may  lead to immune-related adverse events (irAEs) such as GBS. Corticosteroids,  plasma exchange (PE), and intravenous immunoglobulin (IVIG) are currently  accepted treatments for ICI-induced GBS. However, there are still adverse  reactions, and the effect of relieving symptoms is not as good as expected. Safe  and effective complementary replacement therapy to alleviate GBS symptoms and  ameliorate the quality of life is urgently required. In this case, a 63-year-old  man received ICI therapy and antitumor chemotherapy for lung malignancy. After  two courses of treatment, the patient gradually developed limb weakness,  numbness, and pain at the ends of the limbs, with cerebrospinal fluid (CSF)  albuminocytological dissociation, and electromyography (EMG) suggested  demyelinating changes and was diagnosed as GBS. Although the patient received  high doses of intravenous gamma globulin and limb weakness symptoms were  alleviated, there was still significant numbness and pain in the extremities.  After four times of acupuncture treatments, the patient complained that the  symptoms of limb numbness and fatigue were significantly alleviated without any  discomfort. This case report may provide a new alternative and complementary  therapy for immune checkpoint inhibitor-induced GBS, but more definitive and  robust evidence is needed to support its efficacy.
C1 The First Clinical School of Medicine, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine,Guangzhou, China.
   The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
   Guangdong Provincial Key Laboratory of Traditional Chinese Medicine and 
   Acupuncture and Rehabilitation Clinical School of Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
   The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
   The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
   The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
NR 0
TC 0
SN 1664-229
EI 1664-229
J9 Front Neurol
PD JUN 21
PY 2022
VL 13
IS 
BP 908282
EP 908282
DI 10.3389/fneur.2022.908282
PG 0
UT PubMed:35720101
PM 35720101
DA 2022-06-21
ER

PT J
AU Wang, W
   Wang, X
   Liu, Y
   Sun, Y
   Liu, X
   Yan, Y
   Liu, Z
AF Wang, Weiming
   Wang, Xinlu
   Liu, Yan
   Sun, Yuanjie
   Liu, Xiaoxu
   Yan, Yan
   Liu, Zhishun
TI Effects of Electroacupuncture on Opioid-Induced Constipation in Patients With
SO Frontiers in medicine
LA English
DT Journal Article
DE acupuncture; cancer patients; opioid-induced constipation; randomized controlled trial; spontaneous bowel movements
AB BACKGROUND: Opioid-induced constipation (OIC) is one of the most prevalent  adverse events associated with cancer patients who receive opioid analgesics for  moderate to severe pain. Acupuncture may be an effective treatment for OIC. We  designed this trial to assess the efficacy and safety of electroacupuncture for  OIC in cancer patients. METHODS: This is a multicenter, sham-controlled,  parallel-group, subject- and assessor-blinded randomized trial. A total of 100  cancer patients with OIC will be randomly assigned to either the  electroacupuncture group or the sham electroacupuncture group at a ratio of 1:1.  Patients in each group will receive a total of 24-session treatment over 8 weeks,  three sessions a week and 30 min each session. Thereafter, patients will be  followed up for another 8 weeks. The primary outcome will be the proportion of  responders, defined as a patient who has ≥3 spontaneous bowel movements (SBMs)/wk  and ≥ increase of 1 SBM from baseline simultaneously for at least 6 out of 8  weeks of the treatment period. The secondary outcomes will include the mean  weekly SBMs and complete spontaneous bowel movements, the mean Bristol Stool Form  Scale score for stool consistency, the mean score for straining of SBM, the total  and subscale scores of Patient Assessment of Constipation-Symptom questionnaires,  and the total and subscale scores of Patient Assessment of Constipation-Quality  of Life questionnaire. Patients' global assessment of treatment effectiveness,  patients' expectation toward the effectiveness of acupuncture and safety of  acupuncture will also be assessed. All efficacy analyses will be performed in the  intention-to-treat population. DISCUSSION: To improve the adherence to  intervention protocols, the majority of the participants will be recruited from  an inpatient setting. The results will help to determine the clinical effects and  safety of electroacupuncture for the treatment of OIC among patients with cancer.  CLINICAL TRIAL REGISTRATION: www.ClinicalTrials.gov, identifier: NCT03797586,  registered on 4 January 2019, https://clinicaltrials.gov/ct2/show/NCT03797586.
C1 Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Department of Acupuncture and Moxibustion, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
NR 0
TC 0
SN 2296-858
EI 2296-858
J9 Front Med (Lausanne)
PD MAY 3
PY 2022
VL 9
IS 
BP 818258
EP 818258
DI 10.3389/fmed.2022.818258
PG 0
UT PubMed:35492306
PM 35492306
DA 2022-05-03
ER

PT J
AU Kwon, CY
   Yeh, CH
AF Kwon, Chan-Young
   Yeh, Chao Hsing
TI Use of Information and Communication Technologies to Enhance Self-Acupressure: a
SO Journal of acupuncture and meridian studies
LA English
DT Review
DE Acupressure; East Asian traditional medicine; Information and communication technologies; Review; Telecommunications
AB Currently, acupressure is widely accepted as a non-pharmacological therapy for  managing pain, nausea and vomiting, and mental health conditions. Since  acupressure can be self-administered, clinicians and researchers' interest in  information and communication technologies (ICTs) for disseminating acupressure  to manage symptoms has increased. This mini review was conducted to examine  clinical studies of acupressure using ICTs, with a particular focus on  self-acupressure. Through a search of MEDLINE, EMBASE, and CENTRAL, all studies  of self-acupressure using ICTs published before December 31, 2021 were collected.  Twelve studies met the inclusion criteria. More than half of the studies  published since 2020 (4/7, 54.14%) were described as being related to COVID-19.  As target conditions, musculoskeletal injuries or pain, cancer-related symptoms,  dysmenorrhea, mental health issues, and obesity were considered. The most  frequently used acupoints were LI4, LR3, and Shenmen. Moreover, smartphone  applications were the most commonly used ICT method to support self-acupressure.  In addition to the basic information of self-acupressure, other tools such as  timers, reminders, and schedule checkers to facilitate its implementations have  been incorporated into the smartphone applications. Recently, there have been  some attempts to combine acupressure and ICTs. Although these studies mainly  focus on musculoskeletal pain or injuries, recent studies related to mental  health have emerged in relation to COVID-19. However, few studies have been  conducted to date, making it difficult to fully grasp the trends in this field.  Therefore, more studies are needed to evaluate the feasibility and efficacy of  combining self-acupressure and ICTs in more diverse clinical areas.
C1 Department of Oriental Neuropsychiatry, Dong-Eui University College of Korean Medicine, Busan, Korea.
   Cizik School of Nursing, University of Texas Health Science Center at Houston, Houston, TX, USA.
NR 0
TC 0
SN 2093-815
EI 
J9 J Acupunct Meridian Stud
PD DEC 16
PY 2022
VL 15
IS 4
BP 214
EP 226
DI 10.51507/j.jams.2022.15.4.214
PG 12
WC Female; Humans; Acupressure; methods; COVID-19; therapy; Nausea; therapy; Vomiting; therapy; Communication
UT PubMed:36521770
PM 36521770
DA 2022-12-16
ER

PT J
AU Stringer, J
   Ryder, WD
   Mackereth, PA
   Misra, V
   Wardley, AM
AF Stringer, Jacqui
   Ryder, W David
   Mackereth, Peter A
   Misra, Vivek
   Wardley, Andrew M
TI A randomised, pragmatic clinical trial of ACUpuncture plus standard care versus
SO European journal of oncology nursing : the official journal of European Oncology
LA English
DT Journal Article
DE Acupuncture; Chemotherapy induced peripheral neuropathy; Controlled trial
AB PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose limiting  toxicity posing a major clinical challenge for managing patients receiving  specific chemotherapy regimens (e.g., Taxanes). There is a growing body of  literature suggesting acupuncture can improve CIPN symptoms. The purpose of the  ACUFOCIN trial was to collect preliminary data on the safety, feasibility,  acceptability and initial effectiveness of acupuncture as a treatment for CIPN,  comparing use of acupuncture plus standard care (Acupuncture) against standard  care alone (Control). METHOD: At a tertiary cancer centre, a pragmatic,  randomised, parallel group design study was used to investigate the effectiveness  of a 10-week course of acupuncture. Participants experiencing CIPN of ≥ Grade II,  recording a 'Most Troublesome' CIPN symptom score of ≥3 using the "Measure  Yourself Medical Outcome Profile" (MYMOP 2), were randomised to 'Acupuncture' or  'Control' arms. Clinicians were blinded to allocated groups, however as it was  not possible to blind participants, it cannot be guaranteed they did not disclose  study allocation within their clinic assessments. The primary outcome measure was  the number of patients reporting a ≥ 2-point improvement (success) in their  MYMOP2 score at week 10. 100 participants (120 to allow for attrition) were  required for a hypothesised improvement in success proportions from 30% to 55%  using a primary analysis model with logistic regression adjusted for  stratification factors and baseline MYMOP2 scores. Feasibility and acceptability  of study design was addressed through percentage return of primary outcome,  retention rate and a nested qualitative study. RESULTS: Primary MYMOP2 outcome  data at week 10 was available for 108/120 randomised participants; this is  greater than the 100 participants required to adequately power the study. There  were 36/53 (68%) successes in 'Acupuncture' compared to 18/55 (33%) in 'Control'.  Beneficial effects were seen in the secondary outcome data, including clinicians'  grading of neuropathy, EORTC, QLQ-CIPN20, QLQ-C30 summary scores and patient  reported pain scores. There were no serious adverse events reported within the  study and only 16 acupuncture associated events, none of which required  intervention. CONCLUSION: A 10-week course of acupuncture resulted in measurable  improvement in participants symptoms of CIPN. The results warrant further  investigation.
C1 The Christie NHS Foundation Trust, Wilmslow Rd, Manchester, M20 4BX, UK
   School of Medical Sciences, Faculty of Biology, Medicine and Health, The University ofManchester, Oxford Road, Manchester, M13 9PL, UK. 
   Manchester Clinical Trials Unit, Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK. Electronicaddress: david.ryder@manchester.ac.uk.
   The Christie NHS Foundation Trust, Wilmslow Rd, Manchester, M20 4BX, UK. 
   The Christie NHS Foundation Trust, Wilmslow Rd, Manchester, M20 4BX, UK. 
   School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester, M13 9PL, UK
   Outreach Research& Innovation Group, Adamson House, Ground Floor, Towers Business Park, WilmslowRoad, Didsbury, M20 2YY, UK.
EM ndrew.Wardley@Outreach-Research-Innovation.com
NR 0
TC 0
SN 1532-212
EI 1462-388
J9 Eur J Oncol Nurs
PD AUG 12
PY 2022
VL 60
IS 
BP 102171
EP 102171
DI 10.1016/j.ejon.2022.102171
PG 0
WC Acupuncture Therapy; adverse effects; Antineoplastic Agents; adverse effects; Humans; Peripheral Nervous System Diseases; chemically induced; Quality of Life; Research Design; Taxoids; adverse effects
UT PubMed:35952460
PM 35952460
DA 2022-08-12
ER

PT J
AU Cui, LL
   Bai, ZL
AF Cui, Leilei
   Bai, Zhaoliang
TI RETRACTED: Effect of Moxibustion Instrument Combined with Intermediate Frequency Electrostatic Therapy on Pain and Joint Function in Elderly Patients with Cold-Dampness Knee Arthritis (Retracted Article)
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article; Retracted Publication
ID osteoarthritis
AB Objective. To explore the effect of a moxibustion instrument combined with intermediate frequency electrostatic therapy on pain and joint function in elderly patients with cold-dampness arthritis (KOA). Method. 200 patients with cold-dampness KOA treated in our hospital from May 2019 to September 2021 were selected. According to the random number table method, they were divided into the observation group (n=100) and control group (n=100). The observation group was treated with moxibustion combined with medium-frequency treatment, and the control group was treated with medium-frequency treatment. The clinical effects of the two groups were compared. The joint functions of the two groups were evaluated by the visualization scale of the osteoarthritis index (WOMAC index) of McMaster University in Western Ontario. The TCM symptom scores of the two groups were evaluated according to the guiding principles for clinical research of new traditional Chinese medicine. The visual analogue scale (VAS) was used to evaluate the pain degree of the two groups, and the microcirculatory blood perfusion (MBPU) and interleukin-1 were compared between the two groups, beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha). The levels of matrix metalloproteinase-1 (MMP-1), serum bone morphogenetic protein-2 (BMP-2), cartilage oligomeric matrix protein (COMP), and serum type II collagen C-terminal peptide (CTX-II) were assessed by the comprehensive quality of life questionnaire-74. Result. The total effective rate of the observation group (92.00%) was higher than that of the control group (76.00%), and the difference was statistically significant (P < 0.05) in beta and TNF-alpha. The levels of MMP-3, BMP-2, comp, and CTX-II and the improvement of quality of life score in the control group were better than those in the control group (P < 0.05). Conclusion. Moxibustion instrument combined with intermediate frequency electrostatic therapy can effectively improve the knee joint function, pain, blood perfusion, inflammatory reaction, and cartilage damage of the elderly patients with cold-dampness-type knee arthritis, and the therapeutic effect is good.
C1 [Cui, Leilei] 971st Navy Hosp Chinese Peoples Liberat Army, Outpatients 1, Qingdao 266071, Shandong, Peoples R China.
   [Bai, Zhaoliang] 971st Hosp, Outpatient Dept, Peoples Liberat Army Navy, Qingdao 266071, Shandong, Peoples R China.
RP Bai, ZL (corresponding author), 971st Hosp, Outpatient Dept, Peoples Liberat Army Navy, Qingdao 266071, Shandong, Peoples R China.
EM 541846434@qq.com; bai19842021@163.com
CR Unknown -, 2002, GUIDELINES FOR CLINICAL RESEARCH ON CHINESE NEW HERBAL MEDICINES, V0, P0
   Association, 2018, CHIN J ORTHOP, V38, P11
   Attur M, 2020, ARTHRITIS RES THER, V22, P0, DOI 10.1186/s13075-020-02298-6
   BELLAMY N, 1989, SEMIN ARTHRITIS RHEU, V18, P14, DOI 10.1016/0049-0172(89)90010-3
   Benner RW, 2019, ORTHOP CLIN N AM, V50, P425, DOI 10.1016/j.ocl.2019.05.001
   Bing S, 2012, J NEUROSURG, V28, P645
   Chen JX, 2021, INT J GEN MED, V14, P8481, DOI 10.2147/IJGM.S342435
   Cheng HB, 2020, CARTILAGE, V11, P512, DOI 10.1177/1947603518798884
   Ho KD, 2022, AM J PHYS MED REHAB, V101, P11, DOI 10.1097/PHM.0000000000001730
   Jian-Hui Sun, 2020, ZHONGGUO ZHONG YAO ZA ZHI, V45, P4065, DOI 10.19540/j.cnki.cjcmm.20200608.203
   Kan HS, 2019, HONG KONG MED J, V25, P0, DOI 10.12809/hkmj187600
   Lacko M, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10245801
   Li J, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000016301
   Li PN, 2020, DRUG DELIV, V27, P1034, DOI 10.1080/10717544.2020.1787555
   Lin L, 2020, LASER MED SCI, V35, P823, DOI 10.1007/s10103-019-02863-9
   Lingjiang L, 2009, CLIN METADATA, V24, P763
   Mishra A, 2019, J ORTHOP SURG RES, V14, P0, DOI 10.1186/s13018-019-1391-7
   Primorac D, 2020, GENES-BASEL, V11, P0, DOI 10.3390/genes11080854
   Schell J, 2017, NUTRIENTS, V9, P0, DOI 10.3390/nu9090949
   Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768
   Song XY, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000024115
   The State Administration of Traditional Chinese Medicine, 1994, STAND DIAGN EFF TCM, V0, P0
   Wang Mi-Na, 2020, ZHONGGUO GU SHANG, V33, P388, DOI 10.12200/j.issn.1003-0034.2020.04.020
   Wang X, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019974
   Weili C, 2019, GUANGDONG MED, V40, P2399
   Wu SY, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019541
NR 26
TC 1
Z9 2
U1 0
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD MAY 5
PY 2022
VL 2022
IS 
BP 
EP 
DI 10.1155/2022/2613901
PG 8
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 1J1FW
UT WOS:000797671100004
PM 35572837
DA 2026-01-16
ER

PT J
AU Stringer, J
   Ryder, WD
   Mackereth, PA
   Misra, V
   Wardley, AM
AF Stringer, Jacqui
   Ryder, W. David
   Mackereth, Peter A.
   Misra, Vivek
   Wardley, Andrew M.
TI A randomised, pragmatic clinical trial of ACUpuncture plus standard care versus standard care alone FOr Chemotherapy Induced peripheral Neuropathy (ACUFOCIN)
SO EUROPEAN JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
DE Acupuncture; Chemotherapy induced peripheral neuropathy; Controlled trial
ID symptoms
AB Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose limiting toxicity posing a major clinical challenge for managing patients receiving specific chemotherapy regimens (e.g., Taxanes). There is a growing body of literature suggesting acupuncture can improve CIPN symptoms. The purpose of the ACUFOCIN trial was to collect preliminary data on the safety, feasibility, acceptability and initial effectiveness of acupuncture as a treatment for CIPN, comparing use of acupuncture plus standard care (Acupuncture) against standard care alone (Control). Method: At a tertiary cancer centre, a pragmatic, randomised, parallel group design study was used to investigate the effectiveness of a 10-week course of acupuncture. Participants experiencing CIPN of >= Grade II, recording a "Most Troublesome' CIPN symptom score of >= 3 using the "Measure Yourself Medical Outcome Profile " (MYMOP 2), were randomised to "Acupuncture' or "Control' arms. Clinicians were blinded to allocated groups, however as it was not possible to blind participants, it cannot be guaranteed they did not disclose study allocation within their clinic assessments. The primary outcome measure was the number of patients reporting a >= 2-point improvement (success) in their MYMOP2 score at week 10. 100 participants (120 to allow for attrition) were required for a hypothesised improvement in success proportions from 30% to 55% using a primary analysis model with logistic regression adjusted for stratification factors and baseline MYMOP2 scores. Feasibility and acceptability of study design was addressed through percentage return of primary outcome, retention rate and a nested qualitative study. Results: Primary MYMOP2 outcome data at week 10 was available for 108/120 randomised participants; this is greater than the 100 participants required to adequately power the study. There were 36/53 (68%) successes in "Acupuncture' compared to 18/55 (33%) in "Control'. Beneficial effects were seen in the secondary outcome data, including clinicians' grading of neuropathy, EORTC, QLQ-CIPN20, QLQ-C30 summary scores and patient reported pain scores. There were no serious adverse events reported within the study and only 16 acupuncture associated events, none of which required intervention. Conclusion: A 10-week course of acupuncture resulted in measurable improvement in participants symptoms of CIPN. The results warrant further investigation.
C1 [Stringer, Jacqui; Mackereth, Peter A.; Misra, Vivek] Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England.
   [Stringer, Jacqui; Wardley, Andrew M.] Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Oxford Rd, Manchester M13 9PL, Lancs, England.
   [Ryder, W. David] Univ Manchester, Fac Biol Med & Hlth, Manchester Clin Trials Unit, Oxford Rd, Manchester M13 9PL, Lancs, England.
   [Wardley, Andrew M.] Outreach Res & Innovat Grp, Adamson House,Ground Floor,Towers Business Pk, Didsbury M20 2YY, England.
C3 Christie NHS Foundation Trust; University of Manchester; University of Manchester
RP Stringer, J (corresponding author), Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England.
EM jacqui.stringer3@nhs.net; david.ryder@manchester.ac.uk; petermackereth@icloud.com; vivek.misra@nhs.net; Andrew.Wardley@Outreach-Research-Innovation.com
FU National Institute for Health Research (NIHR) [PB-PG-0213-30129]; Pink Ribbon Foundation; National Institutes of Health Research (NIHR) [PB-PG-0213-30129] Funding Source: National Institutes of Health Research (NIHR)
CR Armstrong K, 2020, J ALTERN COMPLEM MED, V26, P928, DOI 10.1089/acm.2019.0267
   Banach M, 2017, BRAIN BEHAV, V7, P0, DOI 10.1002/brb3.558
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2012, MED ACUPUNCT, V24, P181, DOI 10.1089/acu.2011.0868
   Blossfeldt Patrick, 2004, ACUPUNCT MED, V22, P146
   Bonhof CS, 2020, SUPPORT CARE CANCER, V28, P5933, DOI 10.1007/s00520-020-05438-5
   Brami C, 2016, CRIT REV ONCOL HEMAT, V98, P325, DOI 10.1016/j.critrevonc.2015.11.014
   British Acupuncture Council, 2021, US, V0, P0
   Cai RL, 2018, J INTEGR MED-JIM, V16, P26, DOI 10.1016/j.joim.2017.12.002
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Desforges AD, 2022, BIOMED PHARMACOTHER, V147, P0, DOI 10.1016/j.biopha.2022.112671
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   European Medicines Agency, 2016, APPENDIX 2 TO THE GUIDELINE ON THE EVALUATION OF ANTICANCER MEDICINAL PRODUCTS IN MAN: THE USE OF PATIENT-REPORTED OUTCOME (PRO) MEASURES IN ONCOLOGY STUDIES, V0, P0
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Freed B, 2021, CLIN TRIALS, V18, P361, DOI 10.1177/1740774520984870
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jeong YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5367014
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Lai HC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6173412
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Li QQ, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/267959
   Linde K, 2016, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007587.pub2
   Liu LZ, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/328196
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Molassiotis A, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5302-4
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Paterson C, 1996, BRIT MED J, V312, P1016
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Seo Hyun-sik, 2020, JOURNAL OF KOREAN MEDICINE 대한한의학회지, V41, P88, DOI 10.13048/jkm.20047
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Zhang C, 2010, J TRADIT CHIN MED, V30, P13, DOI 10.1016/S0254-6272(10)60003-9
   Zhou W, 2014, J ACUPUNCT MERIDIAN, V7, P186
NR 36
TC 19
Z9 23
U1 3
U2 12
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1462-3889
EI 1532-2122
J9 EUR J ONCOL NURS
JI Eur. J. Oncol. Nurs.
PD OCT 15
PY 2022
VL 60
IS 
BP 
EP 
DI 10.1016/j.ejon.2022.102171
EA AUG 2022
PG 10
WC Oncology; Nursing
SC Oncology; Nursing
GA 4S1ZI
UT WOS:000857247400001
PM 35952460
DA 2026-01-16
ER

PT J
AU Han, KH
   Cho, KH
   Han, C
   Cui, S
   Lin, L
   Baek, HY
   Kim, J
AF Han, Kyou-Hwan
   Cho, Ki Haeng
   Han, Caroline
   Cui, Shanqin
   Lin, Lily
   Baek, Ho-Yu
   Kim, Jaejong
TI The effectiveness and safety of acupuncture treatment on sciatica: A systematic
SO Complementary therapies in medicine
LA English
DT Journal Article
DE A systematic review and meta-analysis; Acupuncture treatment; Analgesic; Randomized controlled trial; Sciatica
AB BACKGROUND: Sciatica results from primary or secondary damage to the sciatic  nerve in the lumbar or gluteal region. The first option for sciatica is  analgesics, but their therapeutic effect and safety in long-term use are  questionable. On the other hand, acupuncture has recently been recognized as a  complementary and alternative medicine (CAM) to conventional medicine, and  studies on its effectiveness and safety have been actively conducted. OBJECTIVE:  To systematically compare acupuncture with analgesics in terms of effect, safety,  and durability in the treatment of sciatica METHODS: This review was performed in  accordance with Cochrane Handbook for Systematic Reviews of Interventions Version  6.2. Four databases were searched for this review: Wangfang, the Korean  Traditional Knowledge Portal (KTKP), PubMed, and EBSCOhost. The primary outcome  measures in the review were total effective rate (TER), visual analog scale (VAS)  score and pain threshold, and the secondary ones were adverse effects (AEs) and  relapse rates. Risk ratio (RR) for TER and mean difference (MD) for VAS score and  pain threshold were used as statistics for the meta-analysis of effectiveness,  along with associated 95 % confidence intervals (CIs) and P-values. AEs and  relapse rates were used for the safety and durability of the interventions.  Version 2 of the Cochrane risk-of-bias assessment tool for randomized trials (RoB  2) was used for the methodological quality of randomized controlled trials (RCTs)  included in the review. RESULTS: The synthesized TER of 28 RCTs involving 2707  participants was significantly higher in the acupuncture group compared to the  analgesic group (RR [95 % CI] = 1.20 [1.16, 1.24], P < 0.001). The synthesized  VAS score of 7 RCTs involving 589 participants was significantly reduced in the  acupuncture group compared to the analgesic group (MD [95 % CI] = - 1.78 [- 2.44,  - 1.12], P < 0.001). In 5 RCTs involving 311 participants, the synthesized pain  threshold was significantly elevated in the acupuncture group compared to the  analgesic group (MD [95 % CI] = 0.93 [0.64, 1.22], P < 0.001). Additionally,  adverse effects (AEs) and relapse rates of RCTs in the review were lower in the  acupuncture group compared to the analgesic group. CONCLUSION: In this systematic  review, acupuncture treatment was significantly effective and safe compared to  analgesics in sciatica. In the future, studies with a rigorous study design are  required to increase the validity of the effectiveness and safety of acupuncture  treatment for sciatica.
C1 SBU Research Institute of Integrative Medicine, South Baylo University, 2727 West 6th Street, Los Angeles, CA 90057, USA. 
   SBU Research Institute of Integrative Medicine, South Baylo University, 2727 West 6th Street, Los Angeles, CA 90057, USA.
   SBU Research Institute of Integrative Medicine, South Baylo University, 2727 West 6th Street, Los Angeles, CA 90057, USA.
   SBU Research Institute of Integrative Medicine, South Baylo University, 2727 West 6th Street, Los Angeles, CA 90057, USA.
   SBU Research Institute of Integrative Medicine, South Baylo University, 2727 West 6th Street, Los Angeles, CA 90057, USA.
   School of Big Data and Financial Statistics, Wonkwang University, 460 Iksandaero, Iksan, Jeonbuk 54538, the Republic of Korea.
   SBU Research Institute of Integrative Medicine, South Baylo University, 2727 West 6th Street, Los Angeles, CA 90057, USA.
EM youhwan2013@gmail.com
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD AUG 20
PY 2022
VL 71
IS 
BP 102872
EP 102872
DI 10.1016/j.ctim.2022.102872
PG 0
WC Humans; Neoplasm Recurrence, Local; drug therapy; Acupuncture Therapy; adverse effects; Analgesics; therapeutic use; Complementary Therapies; Sciatica; therapy
UT PubMed:35985442
PM 35985442
DA 2022-08-20
ER

PT J
AU Lu, C
   Bao, W
   Deng, D
   Li, R
   Li, G
   Zou, S
   Wang, Y
AF Lu, Chao
   Bao, Wenlong
   Deng, Dehou
   Li, Rongrong
   Li, Guangliang
   Zou, Shanlin
   Wang, Yan
TI Efficacy of electroacupuncture with different frequencies in the treatment of
SO Frontiers in neurology
LA English
DT Journal Article
DE Mecobalamin; chemotherapy-induced peripheral neuropathy; electroacupuncture; protocol; randomized controlled trial
AB INTRODUCTION: Chemotherapy-induced peripheral neuropathy (CIPN) is a common  complication in patients with cancer during chemotherapy. It mainly leads to  severe numbness of the hands and feet and causes great pain in patients.  Electroacupuncture (EA) is considered to be beneficial in improving peripheral  neuropathy and relieving numbness of the hands and feet. This trial aims to  evaluate the therapeutic effect of different frequencies of EA on CIPN in  patients with cancer. METHODS AND ANALYSIS: This study is a randomized controlled  trial. In total, 160 eligible CIPN patients are randomly assigned to the 2 Hz EA  group, 100 Hz EA group, 2/100 Hz EA group, and control group in the ratio of  1:1:1:1. All patients in the EA treatment groups receive treatment with EA three  times a week for 4 weeks and following up for 4 weeks. The patients in the  control group are given Mecobalamin (MeCbl) tablets orally, one tablet at a time,  three times a day, for 4 weeks, and following up for 4 weeks. The primary outcome  measures are the participant neurotoxicity questionnaire (PNQ) and the peripheral  neurotoxicity assessment rating (NCI CTCAE V5.0). Secondary outcomes are the  quality of life scale (EORTC QLQ-C30) and the measurement of peripheral nerve  conduction velocity (NCV). The results are evaluated at baseline, post-treatment  phase, and following up for 4 weeks. All major analyses are based on the  intention to treat principle. ETHICS/DISSEMINATION: This protocol was approved by  the Medical Ethics Committee of the Cancer Hospital of the University of Chinese  Academy of Sciences (Zhejiang Cancer Hospital) on 7 December 2021. The license  number is IRB-2021-458. This study provides clinical efficacy data of different  frequencies of EA in the treatment of CIPN. The results help to prove whether EA  is an effective therapy for CIPN and optimize the frequency of EA for CIPN. The  results of this study are shared with health care professionals, the public, and  relevant organizations through the publication of manuscripts and conference  reports. TRIAL REGISTRATION NUMBER: ChiCTR2100054458.
C1 The Traditional Chinese Medicine Department, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou,China.
   The Traditional Chinese Medicine Department, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou,China.
   The Traditional Chinese Medicine Department, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou,China.
   The Third Clinical Medical College, Zhejiang University of Traditional Chinese Medicine, Hangzhou, China.
   Breast Medical Oncology Department, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
   The Traditional Chinese Medicine Department, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou,China.
   The Traditional Chinese Medicine Department, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou,China.
NR 0
TC 0
SN 1664-229
EI 1664-229
J9 Front Neurol
PD AUG 16
PY 2022
VL 13
IS 
BP 843886
EP 843886
DI 10.3389/fneur.2022.843886
PG 0
UT PubMed:35968286
PM 35968286
DA 2022-08-16
ER

PT J
AU Jin, M
   Xie, L
   Mao, N
   Wei, J
   Chen, J
   Chen, X
   Mao, H
AF Jin, Ming
   Xie, Lulu
   Mao, Ni
   Wei, Jianzi
   Chen, Junchao
   Chen, Xuefen
   Mao, Huijuan
TI The characteristics of registered acupuncture clinical trials enrolling cancer
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Review
DE Acupuncture; Cancer; Cancer-related symptoms; Clinical trial registration
AB PURPOSE: This study sought to explore and summarize the global state of  acupuncture clinical trials enrolling cancer patients included in international  registries to date. METHODS: All relevant trials evaluating acupuncture-related  interventions for the treatment of cancer that were registered in 16 trial  registries from January 1, 2001, through December 31, 2020, were identified.  Subsequent publications related to these trials were additionally retrieved from  the PubMed, Cochrane Library, Embase, CNKI (China National Knowledge  Infrastructure), VIP (China Science and Technology Journal Database), and Wanfang  databases. We compared information included in these registries regarding  completed trials with any associated publications, with a focus on study design,  sample size, and selective reporting, based on the registered protocol. RESULTS:  In total, 222 eligible trials across 19 countries were identified. These trials  included 17 specific cancer types and 32 symptoms. The five most common cancer  types were breast cancer, head and neck cancer, colorectal cancer, lung cancer,  and gastric cancer, accounting for almost half of all registered trials (48.2%).  The top five symptoms included in these trials were chemotherapy-induced  peripheral neuropathy (CIPN), cancer-related pain, cancer-related fatigue,  chemotherapy-induced nausea and vomiting (CINV), and gastrointestinal  dysfunction. The overall rate of article publication was low, with publications  being associated with just 33.3% of these registered trials. CONCLUSIONS: This  review is the first snapshot of the landscape of acupuncture clinical trials  registered in international trial registries, providing a methodological basis  for the management of common treatment- and disease-related side effects among  cancer patients undergoing acupuncture and offering useful information that will  guide future acupuncture-focused research.
C1 Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
   Institute of Disciplinary Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
   School of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. chenxf915@163.com.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. maohuijuan1977@hotmail.com.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD SEP 2
PY 2022
VL 30
IS 12
BP 10461
EP 10470
DI 10.1007/s00520-022-07331-9
PG 9
WC Female; Humans; Acupuncture; Acupuncture Therapy; methods; Antineoplastic Agents; Breast Neoplasms; Nausea; therapy; Clinical Trials as Topic
UT PubMed:36048280
PM 36048280
DA 2022-09-02
ER

PT J
AU Mahasti, S
   Caroline, B
   Bernard, A
   Yunfen, LI
   Jianyun, N
   Dequan, L
   Dedian, C
   Chunxin, C
   Estevez, L
   Wenhui, LI
   Armand, JP
   Miansheng, Z
   Liya, JU
AF Mahasti, Saghachian
   Caroline, Barry
   Bernard, Asselain
   Yunfen, L I
   Jianyun, Nie
   Dequan, Liu
   Dedian, Chen
   Chunxin, Chen
   Estevez, Laura
   Wenhui, L I
   Armand, Jean-Pierre
   Miansheng, Zhu
   Liya, J U
TI An international multicentric phase Ⅲ randomized controlled trial of
SO Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
LA English
DT Journal Article
DE breast neoplasms; chemotherapy, adjuvant; clinical protocols; fatigue; immunity; time-acupoints-space acupuncture
AB OBJECTIVE: To determine the difference in prevention of chemotherapy-induced  fatigue between time-acupoints-space acupuncture (ATAS) administered weekly  compared to sham acupuncture and non-acupuncture in patients with early breast  cancer receiving adjuvant chemotherapy by epirubicine-cyclophosphamide (EC)  followed by paclitaxel, as measured by the multi-dimensional fatigue inventory  (MFI) over the previous week and Visual Analogue Scale measuring fatigue (VAS-F),  and to evaluate the effects of ATAS on self-reported neuropathy pain, sleep,  anxiety and depression. METHODS: In this multicenter clinical trial, we have  randomized patients into 3 groups: ATAS, Sham and non-acupuncture with an unequal  randomization of 2∶1∶1. A cloud related electronical clinical report form and  smartphone platform was established for data entry. Patients with a history of  stage Ⅰ-Ⅲ breast cancer scheduled to receive adjuvant chemotherapy. Acupuncture  will be delivered once a week during chemotherapy with VAS-F evaluation. In order  to qualify and quantify the mechanism of fatigue induced by chemotherapy with or  without acupuncture, an evaluation of immune profiling was incorporate in this  study. RESULTS: The presence and seriousness of chemotherapy-induced fatigue  should be considered in therapeutic programs for early breast cancer treatment.  Fatigue induced by adjuvant chemotherapy in patients with breast cancer remains a  major concern affecting the quality of life significantly. Unfortunately, we do  not have effective pharmacological interventions yet. And clinical trials of  acupuncture in preventing chemotherapy-induced fatigue in patients with early  breast cancer have not been reported. CONCLUSION: The findings of the trial will  allow us to determine the effects of acupuncture treatment approach. We will also  be able to confirm whether ATAS is better than sham acupuncture and  non-acupuncture treatments.
C1 Institute Gustave Roussy, Paris, France.
   Research Center of Epidemiology and public health, Paris, France.
   Institute Curie of Paris, Paris, France.
   Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming, China.
   Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming, China.
   Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming, China.
   Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming, China.
   MD Anderson Cancer Hospital, Madrid, Spain.
   MD Anderson Cancer Hospital, Madrid, Spain.
   Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming, China.
   Institute Gustave Roussy, Paris, France.
   ARIATAS Association pour la Recherche et l' Information de l' Acupuncture Time-Acupoints-Space, Paris, France.
   Yunnan Zhu's expert workstation, National famous traditional Chinese medicine 
   PreciMed Platform Europe, Paris, France.
NR 0
TC 0
SN 2589-451
EI 0255-292
J9 J Tradit Chin Med
PD APR 28
PY 2022
VL 42
IS 2
BP 289
EP 295
DI 10.19852/j.cnki.jtcm.2022.02.008
PG 6
WC Acupuncture Points; Acupuncture Therapy; methods; Antineoplastic Agents; adverse effects; Breast Neoplasms; drug therapy; Clinical Trials, Phase III as Topic; Female; Humans; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic
UT PubMed:35473351
PM 35473351
DA 2022-04-28
ER

PT J
AU Chou, YH
   Yeh, ML
   Huang, TS
   Hsu, H
AF Chou, Ya-Hui
   Yeh, Mei-Ling
   Huang, Tzu-Shin
   Hsu, Hedi
TI Acupoint stimulation improves pain and quality of life in head and neck cancer
SO Asia-Pacific journal of oncology nursing
LA English
DT Journal Article
DE Acupoint stimulation; Chemoradiotherapy; Head and neck cancer; Pain; Quality of life
AB OBJECTIVE: This study aimed to evaluate the effect of acupoint stimulation on  pain, negative moods, and quality of life for head and neck cancer (HNC) patients  who underwent concurrent chemoradiotherapy (CCRT). METHODS: This randomized  controlled trial recruited participants from a medical center and randomly  assigned using a permuted block randomization list with computer-generated random  serial numbers into the AcuCare group (n ​= ​46) receiving acupoint stimulation  with transcutaneous acupoint electrical stimulation (TAES) and auricular  acupressure (AA) or the control group (n ​= ​46) without any acupoint  stimulation. Outcomes were repeatedly assessed pain intensity using the visual  analogue scale, negative moods using the hospital anxiety and depression scale,  and quality of life (QoL) using the European Organization for Research and  Treatment of Cancer Quality of Life Questionnaire-Head and Neck 35. RESULTS:  After adjusting varying mucositis grades and time-dependent growth effects, the  generalized estimating equations showed a significantly increase in pain  intensity at weeks 1, 2, 3, and 6 (P ​< ​0.05), but not in negative moods  (P ​> ​0.05), compared to baseline and control group. Analysis of covariance  showed a significant group-difference in the senses problems of QoL (F ​= ​7.33,  P ​= ​0.01) at Week 6. CONCLUSIONS: This study supports that acupoint stimulation  could effectively reduce pain and improve senses problem of QoL for patients with  HNC. TRIAL REGISTRATION: This study was registered at  https://clinicaltrials.gov/NCT03640195.
C1 Department of Nursing, Taoyuan Chang Gung Memorial Hospital
   School of Nursing, National Taipei University of Nursing and Health Sciences, Taoyuan, Taiwan.
   School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
   Department of Nursing, Taoyuan Chang Gung Memorial Hospital, Taoyuan, Taiwan.
   School of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
NR 0
TC 0
SN 2349-667
EI 2347-562
J9 Asia Pac J Oncol Nurs
PD MAY 10
PY 2022
VL 9
IS 1
BP 61
EP 68
DI 10.1016/j.apjon.2021.11.002
PG 7
UT PubMed:35528798
PM 35528798
DA 2022-05-10
ER

PT J
AU Wang, XQ
   Xiao, L
   Duan, PB
   Xu, Q
   Yang, LH
   Wang, AQ
   Wang, Y
AF Wang, Xiao-Qing
   Xiao, Lei
   Duan, Pei-Bei
   Xu, Qian
   Yang, Li-Hua
   Wang, A-Qin
   Wang, Yan
TI The feasibility and efficacy of perioperative auricular acupuncture technique via intradermal needle buried for postoperative movement- evoked pain after open radical gastrectomy: A randomized controlled pilot trial
SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING
LA English
DT Article
DE Gastric cancer; Movement-evoked pain; Auricular acupuncture; Intradermal needle; Randomized controlled trial
AB Introduction: Auricular acupuncture is widely used in the treatment of pain. Recently, the most commonly used method of auricular acupuncture is to embed an intradermal needle into the skin to enhance analgesia through continuous stimulation. We aimed to explore the efficacy and feasibility of this form of auricular acupuncture in the treatment of postoperative movement-evoked pain. Methods: This single-blind randomized controlled pilot trial was conducted between 23/8/2019 and 10/1/ 2020. Forty patients were recruited and randomised to either the control group (n = 20) or the experimental group (n = 20). Patients in the control group received sham auricular acupuncture, while patients in the experimental group received auricular acupuncture. A standard routine analgesia was performed in both groups. The patients with NRS score>4 were given rescue analgesia. Postoperative pain, use of opioids and other analgesics, postoperative recovery and patient's satisfaction were recorded. Results: The credibility and feasibility of auricular acupuncture for postoperative pain were high in both groups. After auricular acupuncture, the scores of the postoperative movement-evoked pain had a tendency to decrease, but no significant difference was observed between two groups at any time point (P = 0.234-0.888). The data on postoperative pain at rest confirmed that no significant difference was observed between two groups within 48 h of surgery (P = 0.134-0.520), and the postoperative pain at rest scores decreased over time; however, from the third day, the pain at rest scores of the experimental group were decreased, and significant differences were observed between the two groups (P = 0.039-0.047). As for use of rescue analgesic, total opioid consumption and the incidence of postoperative nausea and vomiting, there were no significant differences between the two groups (P = 0.311, P = 0.101, P = 0.661) . In terms of patients' satisfaction, the score of the experimental group was higher than that of the control group, and a significant difference was observed between the two groups (P = 0.000). As for adverse events, two participants reported pain and one patient reported discomfort at the insertion sites during the process of auricular acupuncture intervention, but they both were minor and tolerable. Conclusion: Auricular acupuncture may have a relief effect on mild postoperative pain at rest with pain score below 3, suggesting that it may be a feasible adjuvant method to relieve mild pain at rest. However, more multi-centre and large-sample studies are needed to verify this result. (c) 2021 Elsevier Inc. All rights reserved.
C1 [Wang, Xiao-Qing] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Surg Oncol, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Xiao, Lei; Duan, Pei-Bei; Wang, Yan] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Nursing, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Yang, Li-Hua] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Oncol, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, A-Qin] Nanjing Univ Chinese Med, Sch Nursing, 138 Xianlin Rd, Nanjing 210046, Jiangsu, Peoples R China.
   [Xu, Qian] Nanjing Univ Chinese Med, Affiliated Hosp, Jiangsu Prov Hosp Chinese Med, Anesthesiol & Pain Med, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Duan, PB; Wang, Y (corresponding author), Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Nursing, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM wangxiaoqing319@126.com; xiaolei1971@163.com; dpb_58@163.com; xuqian36@126.com; yanglihua17@sina.com; 1078651915@qq.com; zyyssswy@sina.com
FU Affiliated Hospital of Nanjing University of Chinese Medicine [Y19074]; Priority Academic Program Development of Jiangsu Higher Education Institutions [2019YSHL089]
CR 20ShahAN MooreCB, 2019, LARYNGOSCOPE, V11, P0
   22UsichenkoTI LehmannC, 2008, ANAESTHESIA, V0, P0
   23AsherG JonasD, 2010, JALTERNCOMPLEMENTMED, V16, P1097
   25KhaliliG JanghorbaniM, 2013, JCLINANESTH, V25, P0
   29WangXQ DuanPB, 2020, EURJINTEGRMED, V33, P0
   3FerlayJ ColombetM, 2019, INTJCANCER, V144, P0
   41ScottDA McDonaldW, 2005, ACUTEPAINMANAGEMENTP, V0, P0
   黄琳, 1991, 控制理论与应用, V8, P11
   4BrayF FerlayJ, 2018, CANCERJCLIN, V0, P0
   51ClaudepierreP, 2004, JOINTBONESPINE, V71, P550
   53LourensA McCaulM, 2019, PAINRESMANAG, V16, P0
   61LiuSS WuCL, 2007, ANESTHANALG, V105, P0
   64TanJY MolassiotisA, 2014, EVIDBASEDCOMPLEMENTA, V2014, P0
   67MelchartD WeidenhammerW StrengA etal, 2004, PROSPECTIVEINVESTIGA, V0, P0
   68WittCM PachD, 2009, FORSCHKOMPLEMENTMED, V16, P91
   ABBATE D, 1980, LANCET, V2, P1309
   ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V
   Unknown -, 2015, CLINJPAIN, V31, P0
   Unknown -, 2008, MINERVAANESTESIOL, V74, P353
   Unknown -, 2010, JEVIDBASEDMED, V3, P140
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103
   Chan MTV, 2008, ANESTH ANALG, V107, P1189, DOI 10.1213/ane.0b013e318184b94e
   Chung KF, 2014, ACUPUNCT MED, V32, P455, DOI 10.1136/acupmed-2014-010635
   Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354
   Cumpston M, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000142
   Devin CJ, 2015, J CLIN NEUROSCI, V22, P930, DOI 10.1016/j.jocn.2015.01.003
   Emanuel EJ, 2013, LANCET, V381, P1532, DOI 10.1016/S0140-6736(13)60970-8
   Coura LEF, 2011, ACUPUNCT MED, V29, P16, DOI 10.1136/aim.2010.003251
   Fletcher D, 2008, PAIN, V137, P441, DOI 10.1016/j.pain.2008.02.026
   Gaffney CJ, 2017, ORTHOP CLIN N AM, V48, P407, DOI 10.1016/j.ocl.2017.05.001
   Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3
   He BJ, 2013, PAIN MED, V14, P1608, DOI 10.1111/pme.12197
   Herrera FJ, 2007, ANESTH ANALG, V105, P63, DOI 10.1213/01.ane.0000265534.73169.95
   Jung KW, 2012, CANCER RES TREAT, V44, P25, DOI 10.4143/crt.2012.44.1.25
   Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X
   Lai ECH, 2014, SURG-J R COLL SURG E, V12, P290, DOI 10.1016/j.surge.2014.02.004
   Lorenz KA, 2009, J AM BOARD FAM MED, V22, P291, DOI 10.3122/jabfm.2009.03.080162
   Meissner W, 2017, DTSCH ARZTEBL INT, V114, P161, DOI 10.3238/arztebl.2017.0161
   Miclescu A, 2017, SCAND J PAIN, V16, P204, DOI 10.1016/j.sjpain.2017.04.072
   Milne AN, 2009, HUM GENET, V126, P615, DOI 10.1007/s00439-009-0722-x
   Mitra S, 2018, CURR PAIN HEADACHE R, V22, P0, DOI 10.1007/s11916-018-0690-8
   Ndubisi C, 2019, CONTRACEPTION, V99, P143, DOI 10.1016/j.contraception.2018.11.016
   Nogier R, 2014, MED ACUPUNCT, V26, P76, DOI 10.1089/acu.2014.1035
   Plunkett A, 2018, PAIN MANAG, V8, P287, DOI 10.2217/pmt-2018-0007
   Romoli M, 2014, NEUROL SCI, V35, PS189, DOI 10.1007/s10072-014-1768-7
   Russo MW, 2017, ORTHOP CLIN N AM, V48, P401, DOI 10.1016/j.ocl.2017.06.006
   Schug SA, 2016, MED J AUSTRALIA, V204, P315, DOI 10.5694/mja16.00133
   沈孟育, 1998, 空气动力学学报, V16, P56
   Sovacool BK, 2017, SOC STUD SCI, V47, P703, DOI 10.1177/0306312717709363
   Srikandarajah S, 2011, PAIN, V152, P1734, DOI 10.1016/j.pain.2011.02.008
   StellenbergEL BruceJC, 2007, CHURCHILLLIVINGSTONE, V0, P0
   Todorov A, 2008, ANN NY ACAD SCI, V1124, P208, DOI 10.1196/annals.1440.012
   Xu SY, 2005, SMALL, V1, P1221, DOI 10.1002/smll.200500240
   Yang XY, 2015, BRIT J ANAESTH, V115, P883, DOI 10.1093/bja/aev352
   Yuan QL, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep30675
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
NR 66
TC 15
Z9 17
U1 1
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1550-8307
EI 1878-7541
J9 EXPLORE-NY
JI Explore-J Sci. Heal.
PD JAN-FEB 15
PY 2022
VL 18
IS 1
BP 36
EP 43
DI 10.1016/j.explore.2021.09.007
EA JAN 2022
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA YG3DB
UT WOS:000742371600008
PM 34642104
DA 2026-01-16
ER

PT J
AU Cao, X
   Wu, G
   Jiao, B
   Zhang, X
AF Cao, Xueqin
   Wu, Gang
   Jiao, Bo
   Zhang, Xianwei
TI Refractory postherpetic neuralgia in a multiple myeloma patient with lenalidomide
SO The Journal of international medical research
LA English
DT Journal Article
DE Postherpetic neuralgia; chemotherapy-induced periphery neuropathy; herpes zoster; lenalidomide; multiple myeloma; pain
AB Herpes zoster is not common in multiple myeloma (MM) patients treated with  lenalidomide-based regimens. We report an MM patient in his late 60s who received  lenalidomide as maintenance treatment and whose condition was complicated with  refractory postherpetic neuralgia. The patient received antiviral treatment and  analgesia immediately after the diagnosis of herpes zoster. Two months later, the  patient received acupuncture, radiofrequency treatment, and even spinal cord  stimulation, which failed to relieve the pain. Consequently, we performed  high-resolution magnetic resonance imaging of the cervical and thoracic nerves.  Then, stellate ganglion block, left C5/C6/C7/C8 nerve root block, and left  thoracic 1, 2 paravertebral nerve block were performed with the assistance of  real-time ultrasound. The pain was immediately relieved after treatment; however,  the symptoms reappeared 2 days later. At 5 months after treatment, the patient  still experienced severe pain. We suggest that MM patients complicated with  postherpetic neuralgia are refractory to treatment. Starting nerve block therapy,  pulsed radiofrequency, and other interventional therapies as early as possible  could be a more optimal treatment plan for these patients.
C1 Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
   Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
   Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
   Department of Anesthesiology and Pain Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
NR 0
TC 0
SN 1473-230
EI 0300-060
J9 J Int Med Res
PD SEP 30
PY 2022
VL 50
IS 9
BP 3000605221123882
EP 3000605221123882
DI 10.1177/03000605221123882
PG 1
WC Antiviral Agents; therapeutic use; Herpes Zoster; complications; Humans; Lenalidomide; therapeutic use; Multiple Myeloma; complications; Neuralgia, Postherpetic; complications
UT PubMed:36171724
PM 36171724
DA 2022-09-30
ER

PT J
AU Li, JL
   Xu, DH
   Liu, YY
   Cao, Y
   He, J
   Liao, MX
AF Li, Jialing
   Xu, Danghan
   Liu, Yingyu
   Cao, Yang
   He, Jun
   Liao, Muxi
TI Acupuncture Treatment of Guillain-Barre Syndrome After Using Immune Checkpoint Inhibitors: A Case Report
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE acupuncture; Guillain-Barre syndrome; immune checkpoint inhibitors; immune-related adverse events; case report; limb weakness; numbness
ID disease; pathogenesis; management; diagnosis; health; axis
AB Guillain-Barre syndrome(GBS) is an autoimmune-mediated peripheral neuropathy. Immune checkpoint inhibitors (ICIs) are the standard treatment for cancer and may lead to immune-related adverse events (irAEs) such as GBS. Corticosteroids, plasma exchange (PE), and intravenous immunoglobulin (IVIG) are currently accepted treatments for ICI-induced GBS. However, there are still adverse reactions, and the effect of relieving symptoms is not as good as expected. Safe and effective complementary replacement therapy to alleviate GBS symptoms and ameliorate the quality of life is urgently required. In this case, a 63-year-old man received ICI therapy and antitumor chemotherapy for lung malignancy. After two courses of treatment, the patient gradually developed limb weakness, numbness, and pain at the ends of the limbs, with cerebrospinal fluid (CSF) albuminocytological dissociation, and electromyography (EMG) suggested demyelinating changes and was diagnosed as GBS. Although the patient received high doses of intravenous gamma globulin and limb weakness symptoms were alleviated, there was still significant numbness and pain in the extremities. After four times of acupuncture treatments, the patient complained that the symptoms of limb numbness and fatigue were significantly alleviated without any discomfort. This case report may provide a new alternative and complementary therapy for immune checkpoint inhibitor-induced GBS, but more definitive and robust evidence is needed to support its efficacy.
C1 [Li, Jialing] Guangzhou Univ Chinese Med, Clin Sch Med 1, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Xu, Danghan; Cao, Yang; He, Jun; Liao, Muxi] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Xu, Danghan] Guangdong Prov Key Lab Tradit Chinese Med & Acupun, Guangzhou, Peoples R China.
   [Liu, Yingyu] Guangzhou Univ Chinese Med, Acupuncture & Rehabil Clin Sch Med, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Xu, DH; Liao, MX (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.; Xu, DH (corresponding author), Guangdong Prov Key Lab Tradit Chinese Med & Acupun, Guangzhou, Peoples R China.
EM xudanghan@126.com; 527938256@qq.com
FU Guangdong Provincial Key Laboratory of Traditional Chinese Medicine and Acupuncture [06]; Zhangjiawei National Famous and Old TCM Experts Inheritance Studio [149]; special fund Innovating and Strengthening the Hospital for preventive treatment of disease of the First Affiliated Hospital of Guangzhou University of Chinese Medicine [2019ZWB07]; Guangdong Province Rural Science and Technology Commissioner Project [KTPYJ2021026]
CR Baek JY, 2019, BIOMOLECULES, V9, P0, DOI 10.3390/biom9100624
   Bennedsgaard K, 2020, J PERIPHER NERV SYST, V25, P377, DOI 10.1111/jns.12413
   Brahmer JR, 2018, J CLIN ONCOL, V36, P1714, DOI 10.1200/JCO.2017.77.6385
   Cavaletti G, 2015, CURR OPIN NEUROL, V28, P500, DOI 10.1097/WCO.0000000000000234
   Chavez LM, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18112270
   Chen X, 2019, CLIN NEUROPHYSIOL, V130, P1440, DOI 10.1016/j.clinph.2019.03.035
   Chen Y, 2019, GASTROENT RES PRACT, V2019, P0, DOI 10.1155/2019/1759842
   Chon TY, 2013, MAYO CLIN PROC, V88, P1141, DOI 10.1016/j.mayocp.2013.06.009
   Cuzzubbo S, 2017, EUR J CANCER, V73, P1, DOI 10.1016/j.ejca.2016.12:001
   Darweesh SKL, 2014, J PERIPHER NERV SYST, V19, P24, DOI 10.1111/jns5.12051
   Doets AY, 2018, BRAIN, V141, P2866, DOI 10.1093/brain/awy232
   Donofrio Peter D, 2017, CONTINUUM (MINNEAP MINN), V23, P1295, DOI 10.1212/con.0000000000000513
   Elgert G, 1999, AM J ACUPUNCT, V27, P15
   Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030
   Fan Z, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000018619
   Flatters SJL, 2017, BRIT J ANAESTH, V119, P737, DOI 10.1093/bja/aex229
   Garcia CR, 2018, J CLIN ONCOL, V36, P0, DOI 10.1200/JCO.2018.36.5_suppl.37
   Ghaisas S, 2016, PHARMACOL THERAPEUT, V158, P52, DOI 10.1016/j.pharmthera.2015.11.012
   Haanen JBAG, 2017, ANN ONCOL, V28, P119, DOI 10.1093/annonc/mdx225
   Hausheer FH, 2006, SEMIN ONCOL, V33, P15, DOI 10.1053/j.seminoncol.2005.12.010
   Hughes RAC, 2005, LANCET, V366, P1653, DOI 10.1016/S0140-6736(05)67665-9
   ILLA I, 1995, ANN NEUROL, V38, P218, DOI 10.1002/ana.410380214
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Islam Z, 2010, NEUROLOGY, V74, P581, DOI 10.1212/WNL.0b013e3181cff735
   Jang JH, 2020, BRAIN BEHAV IMMUN, V89, P641, DOI 10.1016/j.bbi.2020.08.015
   Janssen JBE, 2021, J IMMUNOTHER, V44, P276, DOI 10.1097/CJI.0000000000000364
   Li HZ, 2019, CLIN INTERV AGING, V14, P1607, DOI 10.2147/CIA.S210751
   Li Y, 2021, BIOMED RES INT, V2021, P0, DOI 10.1155/2021/9800488
   Lu LM, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067475
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   McGrogan A, 2009, NEUROEPIDEMIOLOGY, V32, P150, DOI 10.1159/000184748
   Mulak A, 2015, WORLD J GASTROENTERO, V21, P10609, DOI 10.3748/wjg.v21.i37.10609
   Okada K, 2021, J NEUROL, V268, P680, DOI 10.1007/s00415-020-10213-x
   Ruts L, 2010, NEUROLOGY, V75, P1439, DOI 10.1212/WNL.0b013e3181f88345
   Ruts L, 2010, NEUROLOGY, V74, P1680, DOI 10.1212/WNL.0b013e3181e07d14
   SCARLATO G, 1991, LANCET, V338, P314, DOI 10.1016/0140-6736(91)90453-V
   Schessl J, 2006, EUR J PEDIATR, V165, P605, DOI 10.1007/s00431-006-0140-1
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710
   Shahrizaila N, 2021, LANCET, V397, P1214, DOI 10.1016/S0140-6736(21)00517-1
   Shang P, 2021, J NEUROL, V268, P2402, DOI 10.1007/s00415-020-09742-2
   Thompson JA, 2019, J NATL COMPR CANC NE, V17, P255, DOI 10.6004/jnccn.2019.0013
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121
   Walgaard C, 2011, NEUROLOGY, V76, P968, DOI 10.1212/WNL.0b013e3182104407
   Wang HP, 2020, THORAC CANCER, V11, P191, DOI 10.1111/1759-7714.13240
   Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1
   Willison HJ, 2013, TRENDS IMMUNOL, V34, P453, DOI 10.1016/j.it.2013.05.001
   Zhang XY, 2021, BIOSCI TRENDS, V15, P283, DOI 10.5582/bst.2021.01318
NR 49
TC 7
Z9 10
U1 1
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD JUN 2
PY 2022
VL 13
IS 
BP 
EP 
DI 10.3389/fneur.2022.908282
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 2E1JG
UT WOS:000811989200001
PM 35720101
DA 2026-01-16
ER

PT J
AU Hershman, DL
   Unger, JM
   Greenlee, H
   Capodice, J
   Lew, DL
   Darke, A
   Minasian, LM
   Fisch, MJ
   Henry, NL
   Crew, KD
AF Hershman, Dawn L.
   Unger, Joseph M.
   Greenlee, Heather
   Capodice, Jillian
   Lew, Danika L.
   Darke, Amy
   Minasian, Lori M.
   Fisch, Michael J.
   Henry, N. Lynn
   Crew, Katherine D.
TI Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain A Randomized Clinical Trial
SO JAMA NETWORK OPEN
LA English
DT Article
ID stage breast-cancer; peripheral neuropathy; women; arthralgia; electroacupuncture; duloxetine; management; symptoms; outcm; therapy
AB IMPORTANCE Aromatase inhibitors (Als) have proven efficacy for the treatment of hormone-sensitive breast cancer; however, arthralgias (pain and stiffness) contribute to nonadherence with therapy for more than 50% of patients. OBJECTIVE To examine the effect of acupuncture in reducing Al-related joint pain through 52 weeks. DESIGN, SETTING, AND PARTICIPANTS A randomized clinical trial was conducted at 11 sites in the US from May 1, 2012, to February 29, 2016, with a scheduled final date of follow-up of September 5, 2017, to compare true acupuncture (TA) with sham acupuncture (SA) or waiting list control (WC). Women with early-stage breast cancer were eligible if they were taking an Al and scored 3 or higher on the Brief Pain Inventory Worst Pain (BPI-WP) item (score range, 0-10; higher scores indicate greater pain). Analysis was conducted for data received through May 3, 2021. INTERVENTIONS Participants were randomized 2:1:1 to the TA (n = 110), SA (n = 59), or WC (n = 57) group. The TA and SA protocols were composed of 6 weeks of intervention at 2 sessions per week (12 sessions overall), followed by 6 additional weeks of intervention with 1 session per week. Participants randomized to WC received no intervention. All participants were offered 10 acupuncture sessions to be used between weeks 24 and 52. MAIN OUTCOMES AND MEASURES In this long-term evaluation, the primary end point was the 52-week BPI-WP score, compared by study group using linear regression, adjusted for baseline pain and stratification factors. RESULTS Among 226 randomized women (mean [SD] age, 60.7 [8.6] years; 87.7% White; mean [SD] baseline BPI-WP score, 6.7 [1.5]). 191(84.5%) completed the trial. In a linear regression, 52-week mean BPI-WP scores were 1.08 (95% CI, 0.24-1.91) points lower in the TA compared with the SA group (P = .01) and were 0.99 (95% CI, 0.12-1.86) points lower in the TA compared with the WC group (P = .03). In addition. 52-week BPI pain interference scores were statistically significantly lower in the TA compared with the SA group (difference, 0.58; 95% CI, 0.00-1.16; P = .05). Between 24 and 52 weeks, 12 (13.2%) of TA, 6 (11.3%) of SA, and 5 (10.6%) of WC patients reported receipt of acupuncture. CONCLUSIONS AND RELEVANCE In this randomized clinical trial, women with Al-related joint pain receiving 12 weeks of TA had reduced pain at 52 weeks compared with controls, suggesting long-term benefits of this therapy.
C1 [Hershman, Dawn L.; Crew, Katherine D.] Columbia Univ, Irving Med Ctr, 161 Ft Washington Ave,10th Floor,Room 1068, New York, NY 10032 USA.
   [Unger, Joseph M.; Greenlee, Heather; Lew, Danika L.; Darke, Amy] Fred Hutchinson Canc Ctr, Seattle, WA USA.
   [Unger, Joseph M.; Lew, Danika L.; Darke, Amy] SWOG Stat & Data Management Ctr, Washington, WA USA.
   [Capodice, Jillian] Mt Sinai Hosp, Dept Urol, New York, NY 10029 USA.
   [Minasian, Lori M.] NCI, Div Canc Prevent, Bethesda, MD 20892 USA.
   [Fisch, Michael J.] AIM Specialty Hlth, Chicago, IL USA.
   [Henry, N. Lynn] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA.
C3 Columbia University; Cornell University; Weill Cornell Medicine; NewYork-Presbyterian Hospital; Fred Hutchinson Cancer Center; Southwest Oncology Group; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan
RP Hershman, DL (corresponding author), Columbia Univ, Irving Med Ctr, 161 Ft Washington Ave,10th Floor,Room 1068, New York, NY 10032 USA.
EM dlh23@columbia.edu
FU National Center for Complementary and Integrative Health of the National Institutes of Health [R01AT006376, UG1CA189974, U10CA37429]; Office of Research onWomen's Health; National Cancer Institute [UG1CA189974] Funding Source: NIH RePORTER
CR Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Burstein HJ, 2016, J CLIN ONCOL, V34, P1689, DOI 10.1200/JCO.2015.65.9573
   Cathcart-Rake E, 2021, SUPPORT CARE CANCER, V29, P387, DOI 10.1007/s00520-020-05473-2
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Dworkin RH, 2010, PAIN, V149, P177, DOI 10.1016/j.pain.2010.02.018
   Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2
   Fraser A, 1999, RHEUMATOLOGY, V38, P521, DOI 10.1093/rheumatology/38.6.521
   Garcia SF, 2007, J CLIN ONCOL, V25, P5106, DOI 10.1200/JCO.2007.12.2341
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2010, J CLIN ONCOL, V28, P4120, DOI 10.1200/JCO.2009.25.9655
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Kroenke K, 2010, JAMA-J AM MED ASSOC, V304, P163, DOI 10.1001/jama.2010.944
   Liou KT, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020085
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   MATHIAS S, 1986, ARCH PHYS MED REHAB, V67, P387
   Niravath P, 2019, BREAST CANCER RES TR, V177, P427, DOI 10.1007/s10549-019-05319-4
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   SAS Institute Inc, 2016, SAS 9 4 SYST OPT, V5th, P0
   Shen S, 2018, BREAST CANCER RES TR, V172, P603, DOI 10.1007/s10549-018-4946-0
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
NR 30
TC 43
Z9 49
U1 0
U2 20
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
EI 
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD NOV 11
PY 2022
VL 5
IS 11
BP 
EP 
DI 10.1001/jamanetworkopen.2022.41720
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 7A3KS
UT WOS:000898360200011
PM 36367721
DA 2026-01-16
ER

PT J
AU Pritchard, KT
   Baillargeon, J
   Lee, WC
   Raji, MA
   Kuo, YF
AF Pritchard, Kevin T
   Baillargeon, Jacques
   Lee, Wei-Chen
   Raji, Mukaila A
   Kuo, Yong-Fang
TI Trends in the Use of Opioids vs Nonpharmacologic Treatments in Adults With Pain,
SO JAMA network open
LA English
DT Journal Article
AB IMPORTANCE: Chronic pain prevalence among US adults increased between 2010 and  2019. Yet little is known about trends in the use of prescription opioids and  nonpharmacologic alternatives in treating pain. OBJECTIVES: To compare annual  trends in the use of prescription opioids, nonpharmacologic alternatives, both  treatments, and neither treatment; compare estimates for the annual use of  acupuncture, chiropractic care, massage therapy, occupational therapy, and  physical therapy; and estimate the association between calendar year and pain  treatment based on the severity of pain interference. DESIGN, SETTING, AND  PARTICIPANTS: A serial cross-sectional analysis was conducted using the  nationally representative Medical Expenditure Panel Survey to estimate the use of  outpatient services by cancer-free adults with chronic or surgical pain between  calendar years 2011 and 2019. Data analysis was performed from December 29, 2021,  to August 5, 2022. EXPOSURES: Calendar year (2011-2019) was the primary exposure.  MAIN OUTCOMES AND MEASURES: The association between calendar year and mutually  exclusive pain treatments (opioid vs nonpharmacologic vs both vs neither  treatment) was examined. A secondary outcome was the prevalence of  nonpharmacologic treatments (acupuncture, chiropractic care, massage therapy,  occupational therapy, and physical therapy). All analyses were stratified by pain  type. RESULTS: Among the unweighted 46 420 respondents, 9643 (20.4% weighted)  received surgery and 36 777 (79.6% weighted) did not. Weighted percentages  indicated that 41.7% of the respondents were aged 45 to 64 years and 55.0% were  women. There were significant trends in the use of pain treatments after  adjusting for demographic factors, socioeconomic status, health conditions, and  pain severity. For example, exclusive use of nonpharmacologic treatments  increased in 2019 for both cohorts (chronic pain: adjusted odds ratio [aOR],  2.72; 95% CI, 2.30-3.21; surgical pain: aOR, 1.53; 95% CI, 1.13-2.08) compared  with 2011. The use of neither treatment decreased in 2019 for both cohorts  (chronic pain: aOR, 0.43; 95% CI, 0.37-0.49; surgical pain: aOR, 0.59; 95% CI,  0.46-0.75) compared with 2011. Among nonpharmacologic treatments, chiropractors  and physical therapists were the most common licensed healthcare professionals.  CONCLUSIONS AND RELEVANCE: Among cancer-free adults with pain, the annual  prevalence of nonpharmacologic pain treatments increased and the prevalent use of  neither opioids nor nonpharmacologic therapy decreased for both chronic and  surgical pain cohorts. These findings suggest that, although access to outpatient  nonpharmacologic treatments is increasing, more severe pain interference may  inhibit this access.
C1 Department of Nutrition, Metabolism, and Rehabilitation Sciences, School of Public and Population Health, University of Texas Medical Branch, Galveston.
   Department of Epidemiology, School of Public and Population Health, University of Texas Medical Branch, Galveston.
   Department of Internal Medicine, University of Texas Medical Branch, Galveston.
   Department of Internal Medicine, University of Texas Medical Branch, Galveston.
   Department of Biostatistics and Data Science, School of Public and Population Health, University of Texas Medical Branch, Galveston.
NR 0
TC 0
SN 2574-380
EI 
J9 JAMA Netw Open
PD NOV 8
PY 2022
VL 5
IS 11
BP e2240612
EP e2240612
DI 10.1001/jamanetworkopen.2022.40612
PG 1
WC Adult; Female; Humans; Male; Analgesics, Opioid; therapeutic use; Chronic Pain; drug therapy; Cross-Sectional Studies; Pain Management; Physical Therapy Modalities
UT PubMed:36342717
PM 36342717
DA 2022-11-08
ER

PT J
AU Cui, L
   Bai, Z
AF Cui, Leilei
   Bai, Zhaoliang
TI Effect of Moxibustion Instrument Combined with Intermediate Frequency
SO Computational and mathematical methods in medicine
LA English
DT Journal Article
AB OBJECTIVE: To explore the effect of a moxibustion instrument combined with  intermediate frequency electrostatic therapy on pain and joint function in  elderly patients with cold-dampness arthritis (KOA). METHOD: 200 patients with  cold-dampness KOA treated in our hospital from May 2019 to September 2021 were  selected. According to the random number table method, they were divided into the  observation group (n = 100) and control group (n = 100). The observation group  was treated with moxibustion combined with medium-frequency treatment, and the  control group was treated with medium-frequency treatment. The clinical effects  of the two groups were compared. The joint functions of the two groups were  evaluated by the visualization scale of the osteoarthritis index (WOMAC index) of  McMaster University in Western Ontario. The TCM symptom scores of the two groups  were evaluated according to the guiding principles for clinical research of new  traditional Chinese medicine. The visual analogue scale (VAS) was used to  evaluate the pain degree of the two groups, and the microcirculatory blood  perfusion (MBPU) and interleukin-1 were compared between the two groups, β  (IL-1β) and tumor necrosis factor-α (TNF-α). The levels of matrix  metalloproteinase-1 (MMP-1), serum bone morphogenetic protein-2 (BMP-2),  cartilage oligomeric matrix protein (COMP), and serum type II collagen C-terminal  peptide (CTX-II) were assessed by the comprehensive quality of life  questionnaire-74. RESULT: The total effective rate of the observation group  (92.00%) was higher than that of the control group (76.00%), and the difference  was statistically significant (P < 0.05) in β and TNF-α. The levels of MMP-3,  BMP-2, comp, and CTX-II and the improvement of quality of life score in the  control group were better than those in the control group (P < 0.05). CONCLUSION:  Moxibustion instrument combined with intermediate frequency electrostatic therapy  can effectively improve the knee joint function, pain, blood perfusion,  inflammatory reaction, and cartilage damage of the elderly patients with  cold-dampness-type knee arthritis, and the therapeutic effect is good.
C1 The 971st Navy Hospital of the Chinese People's Liberation Army, The First Outpatients, Qingdao, Shandong 266071, China.
   Outpatient Department, 971st Hospital, People's Liberation Army Navy, Qingdao, Shandong 266071, China.
NR 0
TC 0
SN 1748-671
EI 1748-670
J9 Comput Math Methods Med
PD MAY 17
PY 2022
VL 2022
IS 
BP 2613901
EP 2613901
DI 10.1155/2022/2613901
PG 0
WC Aged; Humans; Knee Joint; Microcirculation; Moxibustion; Osteoarthritis, Knee; therapy; Pain; etiology; Quality of Life; Static Electricity; Treatment Outcome; Tumor Necrosis Factor-alpha
UT PubMed:35572837
PM 35572837
DA 2022-05-17
ER

PT J
AU Mora, DC
   Kristoffersen, AE
   Overvåg, G
   Jong, MC
   Mentink, M
   Liu, JP
   Stub, T
AF Mora, Dana C.
   Kristoffersen, Agnete E.
   Overvag, Grete
   Jong, Miek C.
   Mentink, Marit
   Liu, Jianping
   Stub, Trine
TI Safety of Complementary and Alternative Medicine (CAM) treatment among children and young adults who suffer from adverse effects of conventional cancer treatment: A systematic review
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE systematic review; observational studies; qualitative studies; complementary and alternative medicine; risk; patient safety
ID quality-of-life; yoga intervention; pediatric cancer; art-therapy; music-therapy; acupuncture; risk; chemotherapy; metaanalysis; feasibility
AB Background: Complementary and Alternative Medicine (CAM) is widely used around the world to treat adverse effects derived from cancer treatment among children and young adults. Parents often seek CAM to restore and maintain the child's physical and emotional condition during and after cancer treatment. Objectives: The objectives of this review were (i) to identify literature that investigates CAM use for treating adverse effects of conventional cancer treatment, (ii) to investigate the safety of the included CAM modalities, and (iii) to evaluate the quality of included studies. Methods: Five scientific research databases were used to identify observational, quasi-experimental, and qualitative studies from January 1990 to May 2021. Included studies investigated the use of CAM to treat adverse effects of cancer treatment in childhood cancer. Results: Fifteen studies were included in this review. Ten quasi-experimental, 3 observational studies (longitudinal/prospective), 2 qualitative studies, and 1 study with a quasi-experimental and qualitative arm were identified. Less than half (n = 6; 40%) of the studies included reported adverse effects for the CAM modality being studied. Among the studies that reported adverse effects, they were mostly considered as direct risk, as 13% reported mainly bleeding and bruising upon acupuncture treatment, and dizziness with yoga treatment. All adverse effects were assessed as minor and transient. CAM modalities identified for treating adverse effects of cancer treatment were alternative medical systems, manipulative and body-based therapies, biologically-based therapies, and mind-body therapies. CAM modalities were used to alleviate anxiety, pain, toxicity, prevent trauma, and improve health-related quality of life, functional mobility, and physical activity levels. All studies assessed scored 70% or above according to the Joanna Briggs Institute critical appraisal for study quality checklists. Conclusion: Most of the studies (58.3%) included in this review did not report adverse effects from CAM modalities used to treat adverse effects of cancer treatment in children and young adults. This lack of safety information is of concern because parents need to know whether the modality represents an extra burden or harm to the child. To improve awareness about safety in the field, a universal and uniform reporting system for adverse effects in CAM research is needed.
C1 [Mora, Dana C.; Kristoffersen, Agnete E.; Overvag, Grete; Stub, Trine] UiT Arctic Univ Norway, Tromso, Norway.
   [Mentink, Marit] Netherlands Inst Hlth Serv Res, Utrecht, Netherlands.
   [Liu, Jianping] Beijing Univ Chinese Med & Pharmacol, Beijing, Peoples R China.
C3 UiT The Arctic University of Tromso; Netherlands Institute for Health Services Research; Beijing University of Chinese Medicine
RP Mora, DC (corresponding author), UiT Arctic Univ Norway, Natl Res Ctr Complementary & Alternat Med NAFKAM, Dept Community Med, Fac Hlth Sci, POB 6050, N-9037 Tromso, Norway.
EM dana.c.mora@uit.no
FU Ekhagastiftelsen [2020-76]; NAFKAM - UIT The Arctic University of Norway
CR Abdulah DM, 2018, COMPLEMENT THER MED, V41, P180, DOI 10.1016/j.ctim.2018.09.020
   Adams D, 2011, PEDIATRICS, V128, PE1575, DOI 10.1542/peds.2011-1091
   Aguilar BA, 2017, J PEDIATR NURS, V36, P173, DOI 10.1016/j.pedn.2017.06.015
   Unknown -, 2005, COMPL ALT MED US, V0, P0
   Barnekreftforeningen, 2021, CHILDH CANC, V0, P0
   Barrera ME, 2002, PSYCHO-ONCOL, V11, P379, DOI 10.1002/pon.589
   Bhakta N, 2019, LANCET ONCOL, V20, PE42, DOI 10.1016/S1470-2045(18)30761-7
   Birdee GS, 2009, ACAD PEDIATR, V9, P212, DOI 10.1016/j.acap.2009.04.002
   Bishop FL, 2010, PEDIATRICS, V125, P768, DOI 10.1542/peds.2009-1775
   Bond Mason C, 2006, PAEDIATR CHILD HEALTH, V11, P148
   Bottomley Sarah J, 2003, J PEDIATR NURS, V18, P126, DOI 10.1053/jpdn.2003.13
   Chokshi SK, 2017, PEDIATR BLOOD CANCER, V64, P0, DOI 10.1002/pbc.26424
   Chotsampancharoen T, 2018, ACTA HAEMATOL-BASEL, V140, P203, DOI 10.1159/000493417
   Clerici CA, 2021, TUMORI J, V107, P171, DOI 10.1177/0300891620967750
   Cohen L, 2004, CANCER-AM CANCER SOC, V100, P2253, DOI 10.1002/cncr.20236
   Concato John, 2004, NEURORX, V1, P341, DOI 10.1602/neurorx.1.3.341
   Deng Gary E, 2009, J SOC INTEGR ONCOL, V7, P85
   Diorio C, 2020, PEDIATR BLOOD CANCER, V67, P0, DOI 10.1002/pbc.28324
   Diorio C, 2017, J GLOB ONCOL, V3, P791, DOI 10.1200/JGO.2016.005587
   Diorio C, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0529-3
   Facchini M, 2021, COMPLEMENT THER CLIN, V42, P0, DOI 10.1016/j.ctcp.2020.101289
   Favara-Scacco C, 2001, MED PEDIATR ONCOL, V36, P474, DOI 10.1002/mpo.1112
   Flank J, 2016, PEDIATR BLOOD CANCER, V63, P1144, DOI 10.1002/pbc.25955
   Fonnebo V, 2007, BMC MED RES METHODOL, V7, P0, DOI 10.1186/1471-2288-7-7
   Gagnier JJ, 2006, ANN INTERN MED, V144, P364, DOI 10.7326/0003-4819-144-5-200603070-00013
   Galantino Mary Lou, 2008, PEDIATR PHYS THER, V20, P66, DOI 10.1097/PEP.0b013e31815f1208
   Geyer R, 2011, PEDIATR PHYS THER, V23, P375, DOI 10.1097/PEP.0b013e318235628c
   Govardhan H, 2019, ONCOL RADIOTHER, V1, P34
   Hedén L, 2013, J PAIN SYMPTOM MANAG, V46, P366, DOI 10.1016/j.jpainsymman.2012.09.012
   HelsedirektoratetThe Norwegian Directorate of Health, 2021, NATL GUIDELINES GYNA, V0, P0
   Higgins J, 2008, COCHRANE HDB SYSTEMA, V0, P0
   Hooke MC, 2016, J PEDIATR ONCOL NURS, V33, P64, DOI 10.1177/1043454214563936
   Hu H, 2019, GLOB ADV HLTH MED, V8, P0
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   Joseph PD, 2015, BRIT J CLIN PHARMACO, V79, P357, DOI 10.1111/bcp.12305
   Juangpanich U, 2012, J NURSESASSOC THAILA, V30, P46
   Kanitz JL, 2013, COMPLEMENT THER MED, V21, PS20, DOI 10.1016/j.ctim.2012.02.001
   Karkhaneh M, 2020, BMJ PAEDIATR OPEN, V4, P0, DOI 10.1136/bmjpo-2019-000584
   Kennedy DD, 2004, AM J CLIN NUTR, V79, P1029
   Kim HJ, 2005, CANCER NURS, V28, P270
   Kuttner Leora, 2006, PAIN RES MANAG, V11, P217
   Ladas EJ, 2004, J CLIN ONCOL, V22, P517, DOI 10.1200/JCO.2004.03.086
   Ladas EJ, 2018, J ALTERN COMPLEM MED, V24, P910, DOI 10.1089/acm.2018.0224
   Lewis RW, 2021, SUPPORT CARE CANCER, V29, P8077, DOI 10.1007/s00520-021-06332-4
   Lissauer TCGP, 2016, ENGLISH PEDRIATRICS, V0, P0
   Lopes LC, 2016, EUR J CANCER CARE, V25, P921, DOI 10.1111/ecc.12381
   Lopes LC Jr, 2020, CANCER NURS, V43, P290, DOI 10.1097/NCC.0000000000000690
   Lopes LC Jr, 2021, REV ESC ENFERM USP, V55, P0, DOI 10.1590/S1980-220X2020025103709
   Lowrance WW, 1976, ACCEPTABLE RISK SCI, V0, P0, DOI DOI 10.1149/1.2132690
   Lüthi E, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-021-03271-9
   MacLennan AH, 2006, MED J AUSTRALIA, V184, P27, DOI 10.5694/j.1326-5377.2006.tb00092.x
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mallen C, 2006, J CLIN EPIDEMIOL, V59, P765, DOI 10.1016/j.jclinepi.2005.12.010
   Mandanmohan, 2003, INDIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, V47, P387
   Medina Cordoba CA, 2019, INDEX ENFERMER A, V28, P46
   Michalsen A, 2005, MED SCI MONITOR, V11, P0
   Mora DC, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03537-w
   Mustian KM, 2010, J CLIN ONCOL, V28, P0, DOI 10.1200/jco.2010.28.15_suppl.9013
   Myers SP, 2004, MED J AUSTRALIA, V181, P222, DOI 10.5694/j.1326-5377.2004.tb06244.x
   National Center for Complementary and Integrative Health National Institutes of Health, 2021, COMPLEMENTARY ALTERN, V0, P0
   Nilsson S, 2009, EUR J ONCOL NURS, V13, P102, DOI 10.1016/j.ejon.2009.01.003
   ORegan D, 2010, AUTON NEUROSCI-BASIC, V157, P96, DOI 10.1016/j.autneu.2010.05.001
   Orsey AD, 2017, REHABIL ONCOL, V35, P15, DOI 10.1097/01.REO.0000000000000052
   Ouzzani M, 2016, SYST REV-LONDON, V5, P0, DOI 10.1186/s13643-016-0384-4
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Papanikolaou PN, 2006, CAN MED ASSOC J, V174, P635, DOI 10.1503/cmaj.050873
   Piper C, 2019, J MED LIBR ASSOC, V107, P0, DOI 10.5195/jmla.2019.790
   Rheingans JI, 2007, J PEDIATR ONCOL NURS, V24, P81, DOI 10.1177/1043454206298837
   Nunes MDR, 2018, J CHILD HEALTH CARE, V22, P186, DOI 10.1177/1367493517752498
   Shamliyan T, 2010, J CLIN EPIDEMIOL, V63, P1061, DOI 10.1016/j.jclinepi.2010.04.014
   Stub T, 2013, THESIS ARCTIC U NORW, V0, P0
   Stub T, 2022, EXPLORE-NY, V18, P114, DOI 10.1016/j.explore.2020.11.008
   Stub T, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-021-03253-x
   Stub T, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-02882-y
   Stub T, 2016, COMPLEMENT THER MED, V26, P146, DOI 10.1016/j.ctim.2016.03.013
   Stub T, 2015, FORSCH KOMPLEMENTMED, V22, P30, DOI 10.1159/000377644
   Thanh NN, 2010, J PEDIATR ONCOL NURS, V27, P146, DOI 10.1177/1043454209355983
   The Norwegian Cancer Society, 2021, SENSK ENGL LAT EFF N, V0, P0
   Thygeson MV, 2010, J PEDIATR ONCOL NURS, V27, P276, DOI 10.1177/1043454210363478
   Tsukinoki R, 2013, EUR J EPIDEMIOL, V28, P1
   Turner LA, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-67
   Vandenbroucke JP, 2004, LANCET, V363, P1728, DOI 10.1016/S0140-6736(04)16261-2
   Velez-Florez G, 2018, CURR PSYCHIAT REP, V20, P0, DOI 10.1007/s11920-018-0927-6
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.2471/BLT.07.045120
   Waddington H, 2017, J CLIN EPIDEMIOL, V89, P43, DOI 10.1016/j.jclinepi.2017.02.015
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Wurz A, 2014, PEDIATR BLOOD CANCER, V61, P1828, DOI 10.1002/pbc.25096
   Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054
   Zuzak TJ, 2013, COMPLEMENT THER MED, V21, PS34, DOI 10.1016/j.ctim.2012.01.001
NR 90
TC 17
Z9 21
U1 4
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2022
VL 21
IS 
BP 
EP 
DI 10.1177/15347354221105563
PG 22
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA 2H6ZI
UT WOS:000814440100001
PM 35726681
DA 2026-01-16
ER

PT J
AU Hershman, DL
   Unger, JM
   Greenlee, H
   Capodice, J
   Lew, DL
   Darke, A
   Minasian, LM
   Fisch, MJ
   Henry, NL
   Crew, KD
AF Hershman, Dawn L
   Unger, Joseph M
   Greenlee, Heather
   Capodice, Jillian
   Lew, Danika L
   Darke, Amy
   Minasian, Lori M
   Fisch, Michael J
   Henry, N Lynn
   Crew, Katherine D
TI Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the
SO JAMA network open
LA English
DT Journal Article
AB IMPORTANCE: Aromatase inhibitors (AIs) have proven efficacy for the treatment of  hormone-sensitive breast cancer; however, arthralgias (pain and stiffness)  contribute to nonadherence with therapy for more than 50% of patients. OBJECTIVE:  To examine the effect of acupuncture in reducing AI-related joint pain through 52  weeks. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial was  conducted at 11 sites in the US from May 1, 2012, to February 29, 2016, with a  scheduled final date of follow-up of September 5, 2017, to compare true  acupuncture (TA) with sham acupuncture (SA) or waiting list control (WC). Women  with early-stage breast cancer were eligible if they were taking an AI and scored  3 or higher on the Brief Pain Inventory Worst Pain (BPI-WP) item (score range,  0-10; higher scores indicate greater pain). Analysis was conducted for data  received through May 3, 2021. INTERVENTIONS: Participants were randomized 2:1:1  to the TA (n = 110), SA (n = 59), or WC (n = 57) group. The TA and SA protocols  were composed of 6 weeks of intervention at 2 sessions per week (12 sessions  overall), followed by 6 additional weeks of intervention with 1 session per week.  Participants randomized to WC received no intervention. All participants were  offered 10 acupuncture sessions to be used between weeks 24 and 52. MAIN OUTCOMES  AND MEASURES: In this long-term evaluation, the primary end point was the 52-week  BPI-WP score, compared by study group using linear regression, adjusted for  baseline pain and stratification factors. RESULTS: Among 226 randomized women  (mean [SD] age, 60.7 [8.6] years; 87.7% White; mean [SD] baseline BPI-WP score,  6.7 [1.5]), 191 (84.5%) completed the trial. In a linear regression, 52-week mean  BPI-WP scores were 1.08 (95% CI, 0.24-1.91) points lower in the TA compared with  the SA group (P = .01) and were 0.99 (95% CI, 0.12-1.86) points lower in the TA  compared with the WC group (P = .03). In addition, 52-week BPI pain interference  scores were statistically significantly lower in the TA compared with the SA  group (difference, 0.58; 95% CI, 0.00-1.16; P = .05). Between 24 and 52 weeks, 12  (13.2%) of TA, 6 (11.3%) of SA, and 5 (10.6%) of WC patients reported receipt of  acupuncture. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, women  with AI-related joint pain receiving 12 weeks of TA had reduced pain at 52 weeks  compared with controls, suggesting long-term benefits of this therapy. TRIAL  REGISTRATION: ClinicalTrials.gov Identifier: NCT01535066.
C1 Columbia University Irving Medical Center, New York, New York.
   Fred Hutchinson Cancer Center, Seattle, Washington.
   SWOG Statistics and Data Management Center, Seattle, Washington.
   Fred Hutchinson Cancer Center, Seattle, Washington.
   Department of Urology, Mount Sinai Hospital, New York, New York.
   Fred Hutchinson Cancer Center, Seattle, Washington.
   SWOG Statistics and Data Management Center, Seattle, Washington.
   Fred Hutchinson Cancer Center, Seattle, Washington.
   SWOG Statistics and Data Management Center, Seattle, Washington.
   Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.
   AIM Specialty Health, Chicago, Illinois.
   Department of Medicine, University of Michigan, Ann Arbor.
   Columbia University Irving Medical Center, New York, New York.
NR 0
TC 0
SN 2574-380
EI 
J9 JAMA Netw Open
PD NOV 12
PY 2022
VL 5
IS 11
BP e2241720
EP e2241720
DI 10.1001/jamanetworkopen.2022.41720
PG 1
WC Humans; Female; Middle Aged; Aromatase Inhibitors; adverse effects; Waiting Lists; Acupuncture Therapy; methods; Arthralgia; therapy; Breast Neoplasms; complications
UT PubMed:36367721
PM 36367721
DA 2022-11-12
ER

PT J
AU Bae, K
   Lamoury, G
   Carroll, S
   Morgia, M
   Lim, S
   Baron-Hay, S
   Shin, IS
   Park, SJ
   Oh, B
AF Bae, Kyeore
   Lamoury, Gillian
   Carroll, Susan
   Morgia, Marita
   Lim, Stephanie
   Baron-Hay, Sally
   Shin, In-Soo
   Park, So-Jung
   Oh, Byeongsang
TI Comparison of the clinical effectiveness of treatments for aromatase
SO Critical reviews in oncology/hematology
LA English
DT Journal Article
DE Aromatase inhibitor; Breast cancer; Network meta-analysis; Pain; Quality of life
AB Aromatase inhibitor-induced arthralgia (AIA) contributes to poor adherence of  aromatase inhibitor therapies in patients with breast cancer. A systematic review  using network meta-analysis (NMA) was conducted to examine the clinical  effectiveness of multiple therapies and rank probabilities for the management of  AIA. Randomized controlled trials (RCTs) assessing treatments for AIA in  postmenopausal women with stage 0-III hormone receptor-positive breast cancer  were searched from inception to October 2021. The main NMA involved 1516  participants from 17 RCTs. Acupuncture was the highest ranked intervention to  improve pain intensity followed by sham acupuncture, multicomponent herbal  medicine, exercise, duloxetine, vitamin D, omega-3 fatty acids, physical therapy,  testosterone, and inactive controls. Single natural products were inferior to  controls. The current review provides new insights into the management of AIA in  breast cancer survivors for increased survival and can be utilized to make  evidence-based decisions regarding treatment.
C1 Integrative Cancer Center, Doban Hospital, Seoul, 03170, Republic of Korea
   Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney,New South Wales, 2065, Australia. 
   Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia
   Faculty of Medicine and Health, University ofSydney, Sydney, New South Wales, 2006, Australia. 
   Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia
   Faculty of Medicine and Health, University ofSydney, Sydney, New South Wales, 2006, Australia. 
   Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia. 
   Medical Oncology Department, Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, 2560, Australia
   Western Sydney University, Campbelltown, New SouthWales, 2560, Australia. 
   Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia
   Faculty of Medicine and Health, University ofSydney, Sydney, New South Wales, 2006, Australia. 
   Department of Graduate School of Education, Dongguk University, Seoul, 04620, Republic of Korea. 
   Department of Internal Medicine, Korean Medicine Hospital of Pusan National University, Yangsan, Gyeongnam, 50612, Republic of Korea. 
   Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, 2065, Australia
   Faculty of Medicine and Health, University ofSydney, Sydney, New South Wales, 2006, Australia.
EM yeong.oh@sydney.edu.au
NR 0
TC 0
SN 1879-046
EI 
J9 Crit Rev Oncol Hematol
PD DEC 20
PY 2022
VL 181
IS 
BP 103898
EP 103898
DI 10.1016/j.critrevonc.2022.103898
PG 0
WC Female; Humans; Aromatase Inhibitors; adverse effects; Arthralgia; chemically induced; Treatment Outcome; Breast Neoplasms; complications
UT PubMed:36535489
PM 36535489
DA 2022-12-20
ER

PT J
AU Wang, JX
   Chen, YF
   Zhai, X
   Chu, YP
   Liu, XD
   Ma, XL
AF Wang, Junxin
   Chen, Yufeng
   Zhai, Xing
   Chu, Yupeng
   Liu, Xiangdi
   Ma, Xueling
TI Visualizing Research Trends and Identifying Hotspots of Traditional Chinese Medicine (TCM) Nursing Technology for Insomnia: A 18-Years Bibliometric Analysis of Web of Science Core Collection
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE insomnia; TCM; nursing; technique; visualization analysis; bibliometric
ID auricular point acupressure; randomized controlled-trial; sleep quality; breast-cancer; aromatherapy; depression; patterns; anxiety; risk; association
AB ObjectiveTo explore the research hotspot and frontier direction of TCM nursing of insomnia and provide reference for the follow-up study of the optimal scheme of TCM nursing of insomnia. BackgroundInsomnia is a common sleep-wake disorder, affects 6-10% of adults and was associated with independent higher risks of cardiovascular disease and diabetes. TCM Nursing Techniques of insomnia has a long history and has shown a definite impact. However, it's still lack of analysis in the field of the most commonly used and effective techniques, as well as the co-morbidities associated with insomnia. Therefore, the database was searched and analyzed to find effective TCM Nursing Techniques for insomnia and related diseases related to insomnia. MethodRandomized controlled trials on the intervention of TCM Nursing Techniques in insomnia were retrieved from Web of Science Core Collection and imported into CiteSpace 5.6.R5 visualization software. The works of literature were co-cited by keywords authors and institutions for visual analysis, and the co-morbidities associated with insomnia of TCM Nursing Techniques in literature was extracted manually. The symptoms of co-morbidities associated with insomnia were imported into Cytoscape 3.9.0 software and clustered by CytoHubba. ResultAs of October 20, 2021, the literature published in the last 20 years from Web of Science Core Collection was screened, and the publication period of the included literature was from 2004 to 2021. From 2016 to now, the total number of articles has been increasing. A total of 146 articles were included, and the highest production year was 2020. There is little cooperation between states, institutions, and authors. China (including Hong Kong and Taiwan) and Hong Kong Polytech University are leading countries and institutions in this area. MYUNGHAENG HUR is the most cited author, and J ALTERN COMPLEM MED is the most cited journal. According to cluster analysis and keyword frequency, auricular therapy, aromatherapy, and acupressure are the three most commonly used techniques. While the top five co-morbidities are fatigue, anxiety, depression, pain and hemodialysis. The three frontier topics and the main research directions are sleep quality, comorbid insomnia and clinical trial design. ConclusionWe found that acupressure, aromatherapy, and auricular acupoint therapy are the most commonly used nursing methods of TCM to intervene in insomnia. However, these studies have limitations such as small sample size, lack of objectivity in evaluating sleep quality, and high heterogeneity of intervention measures, which are not conducive to forming TCM clinical nursing guidelines. Therefore, it is necessary to adopt objectified sleep quality evaluation methods, select suitable acupoints according to TCM theories, and design multi-center large-sample clinical trials based on the safety principle of randomized blind control. This study provides an in-depth perspective for insomnia research on TCM Nursing Techniques and includes information for follow-up research on TCM Nursing Techniques of insomnia.
C1 [Wang, Junxin; Liu, Xiangdi; Ma, Xueling] Beijing Univ Chinese Med, Sch Nursing, Beijing, Peoples R China.
   [Chen, Yufeng] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing, Peoples R China.
   [Zhai, Xing; Chu, Yupeng] Beijing Univ Chinese Med, Sch Management, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Liu, XD; Ma, XL (corresponding author), Beijing Univ Chinese Med, Sch Nursing, Beijing, Peoples R China.
EM 13810693238@126.com; maxl@bucm.edu.cn
FU National Natural Science Foundation of China [81503382]; Key project of Beijing University of Chinese Medicine [2020-JYB-ZDGG-078]; Vertical Science Development Foundation of BUCM [2019-ZXFZJJ-039]
CR Afshar MK, 2015, IRAN RED CRESCENT ME, V17, P0, DOI 10.5812/ircmj.17(4)2015.25880
   Afshar M, 2018, COMPLEMENT THER MED, V40, P37, DOI 10.1016/j.ctim.2018.07.006
   Airagnes G, 2016, CURR PSYCHIAT REP, V18, P0, DOI 10.1007/s11920-016-0727-9
   Ancoli-Israel S, 2014, SUPPORT CARE CANCER, V22, P2535, DOI 10.1007/s00520-014-2204-5
   Arai YCP, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/945063
   Bergdahl L, 2017, COMPLEMENT THER CLIN, V28, P220, DOI 10.1016/j.ctcp.2017.06.006
   Bikmoradi A, 2015, COMPLEMENT THER MED, V23, P331, DOI 10.1016/j.ctim.2014.12.001
   Blackburn L, 2017, ONCOL NURS FORUM, V44, PE185, DOI 10.1188/17.ONF.E185-E193
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Carotenuto M, 2013, NEUROPSYCH DIS TREAT, V9, P157, DOI 10.2147/NDT.S41892
   Castelnovo A, 2019, SLEEP MED REV, V44, P70, DOI 10.1016/j.smrv.2018.12.007
   Celikkayalar E, 2021, PATIENT PREFER ADHER, V15, P141, DOI 10.2147/PPA.S280503
   Chen CM, 2006, J AM SOC INF SCI TEC, V57, P359, DOI 10.1002/asi.20317
   Chen HY, 2007, J ALTERN COMPLEM MED, V13, P669, DOI 10.1089/acm.2006.6400
   Chen IH, 2019, J AM MED DIR ASSOC, V20, P822, DOI 10.1016/j.jamda.2019.01.003
   Chen PJ, 2017, SLEEP MED, V38, P122, DOI 10.1016/j.sleep.2017.07.016
   Cheong MJ, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000024652
   Chien LW, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/740813
   Chinese Medicine Academy of Chinese Medicine Insomnia Clinical practice Guidelines research group, 2016, WORLD J SLEEP MED, V3, P8
   Chinese Society of Neurology, 2018, CHIN J NEUROL, V51, P324, DOI 10.3760/cma.j.issn.1006-7876.2018.05.002
   Cho EH, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/2856592
   Cho MY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/381381
   Choi H, 2020, PSYCHIAT INVEST, V17, P1048, DOI 10.30773/pi.2020.0146
   Dopheide JA, 2020, AM J MANAG CARE, V26, PS76, DOI 10.37765/ajmc.2020.42769
   Edinger JD, 2016, SLEEP MED, V26, P69, DOI 10.1016/j.sleep.2016.03.005
   Farmer AD, 2021, FRONT HUM NEUROSCI, V14, P0, DOI 10.3389/fnhum.2020.568051
   Guo FF, 1900, P1, V0, P0
   Huang JK, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6920902
   Insomnia cooperative group of state administration of traditional chinese medicine, 2015, WORLD J SLEEP MED, V2, P14
   Jiao Y, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6049891
   Jiao Y, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/578972
   Johnson EO, 2006, J PSYCHIATR RES, V40, P700, DOI 10.1016/j.jpsychires.2006.07.008
   Ju MS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/403251
   Kao CL, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/567639
   Karadag E, 2017, NURS CRIT CARE, V22, P105, DOI 10.1111/nicc.12198
   Kim ME, 2019, J KOREAN ACAD NURS, V49, P655, DOI 10.4040/jkan.2019.49.6.655
   Koffel E, 2018, J GEN INTERN MED, V33, P955, DOI 10.1007/s11606-018-4390-1
   Kuo HC, 2018, RES NURS HEALTH, V41, P469, DOI 10.1002/nur.21885
   Lai FC, 2017, J AM GERIATR SOC, V65, PE103, DOI 10.1111/jgs.14729
   Lan Y, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0606-7
   Lee MK, 2017, EUR J INTEGR MED, V12, P79, DOI 10.1016/j.eujim.2017.04.009
   Li Li-Chun, 2018, ZHEN CI YAN JIU, V43, P573, DOI 10.13702/j.1000-0607.170765
   Li X, 2021, J AM COLL CARDIOL, V78, P1197, DOI 10.1016/j.jacc.2021.07.023
   Li ZH, 2021, EUR J ENDOCRINOL, V185, P765, DOI 10.1530/EJE-21-0314
   Liang S, 2018, WORLD CLIN DRUGS, V39, P217
   Lillehei AS, 2014, J ALTERN COMPLEM MED, V20, P441, DOI 10.1089/acm.2013.0311
   Liu S, 2017, CHINESE J CONT NEURO, V17, P633, DOI 10.3969/J.ISSN.1672-6731.2017.09.002
   McArdle N, 2022, J CLIN SLEEP MED, V18, P1503, DOI 10.5664/jcsm.9886
   Meng Fang, 2018, ZHONGGUO ZHEN JIU, V38, P575, DOI 10.13703/j.0255-2930.2018.06.002
   Mirchandaney R, 2022, CURR PSYCHIAT REP, V24, P121, DOI 10.1007/s11920-022-01326-3
   Muz G, 2017, APPL NURS RES, V37, P28, DOI 10.1016/j.apnr.2017.07.004
   National Administration of Traditional Chinese Medicine, 2015, NOT PRINT DISTR TCM, V0, P0
   Ni J, 2018, J TRADIT CHIN MED, V38, P763
   Nielsen A, 2020, PAIN MED, V21, P1276, DOI 10.1093/pm/pnz379
   Pei M, 2021, FRONT PSYCHIATRY, V12, P0, DOI 10.3389/fpsyt.2021.576050
   Ree M, 2017, SLEEP MED, V36, PS43, DOI 10.1016/j.sleep.2017.03.017
   Riemann D, 2017, J SLEEP RES, V26, P675, DOI 10.1111/jsr.12594
   Rosenberg RP, 2021, J CLIN PSYCHIAT, V82, P0, DOI 10.4088/JCP.EI20008AH5C
   Samara MT, 2020, ACTA PSYCHIAT SCAND, V142, P6, DOI 10.1111/acps.13201
   Sentürk A, 2018, HOLIST NURS PRACT, V32, P324, DOI 10.1097/HNP.0000000000000292
   Tan JY, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/506758
   Tang YH, 2021, J AFFECT DISORDERS, V288, P1, DOI 10.1016/j.jad.2021.03.066
   Taylor DJ, 2005, SLEEP, V28, P1457, DOI 10.1093/sleep/28.11.1457
   Usichenko T, 2017, BRAIN STIMUL, V10, P1042, DOI 10.1016/j.brs.2017.07.013
   Usichenko TI, 2018, MED ACUPUNCT, V30, P308, DOI 10.1089/acu.2018.1314
   Vieira A, 2018, COMPLEMENT THER CLIN, V33, P61, DOI 10.1016/j.ctcp.2018.08.005
   Wang XT, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101151
   Wang ZJ, 2017, EUR J INTEGR MED, V15, P17, DOI 10.1016/j.eujim.2017.08.010
   Wu Y, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/7178711
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeh CH, 2016, BEHAV SLEEP MED, V14, P279, DOI 10.1080/15402002.2014.981820
   Yeung WF, 2018, J SLEEP RES, V27, P220, DOI 10.1111/jsr.12597
   Yeung WF, 2012, SLEEP MED, V13, P971, DOI 10.1016/j.sleep.2012.06.003
   Yufang H, 2020, FUNDAMENTALS TRADITI, V0, P0
   Zhao B, 2019, BRAIN STIMUL, V12, P824, DOI 10.1016/j.brs.2019.02.016
   Zhao ZH, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7279486
   Zou GY, 2021, HUM BRAIN MAPP, V42, P259, DOI 10.1002/hbm.25221
NR 77
TC 17
Z9 19
U1 14
U2 145
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD MAR 31
PY 2022
VL 13
IS 
BP 
EP 
DI 10.3389/fneur.2022.816031
PG 16
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 0U8SQ
UT WOS:000787918200001
PM 35432182
DA 2026-01-16
ER

PT J
AU Zhi, WI
   Mao, JJ
   Baser, RE
   Li, SQ
   Blinder, VS
   Norton, L
   Seidman, AD
   Robson, ME
   Bao, T
AF Zhi, Wanqing Iris
   Mao, Jun J.
   Baser, Raymond E.
   Li, Susan Q.
   Blinder, Vicotria S.
   Norton, Larry
   Seidman, Andrew D.
   Robson, Mark E.
   Bao, Ting
TI Effectiveness of electroacupuncture versus auricular acupuncture in breast cancer survivors with chronic musculoskeletal pain: The PEACE randomized clinical trial
SO CANCER RESEARCH
LA English
DT Meeting Abstract
NR 0
TC 0
Z9 0
U1 5
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD FEB 15
PY 2022
VL 82
IS 4
BP 
EP 
DI 10.1158/1538-7445.SABCS21-P4-08-01
PG 3
WC Oncology
SC Oncology
GA ZY5SY
UT WOS:000772647602144
DA 2026-01-16
ER

PT J
AU Bonucci, M
   Geraci, A
   Pero, D
   Villivà, C
   Cordella, D
   Condello, M
   Meschini, S
   Del, Campo L
   Tomassi, F
   Porcu, A
   De, Lorenzo F
   Lozupone, F
AF Bonucci, Massimo
   Geraci, Andrea
   Pero, Dina
   Villivà, Cristina
   Cordella, Daniele
   Condello, Maria
   Meschini, Stefania
   Del Campo, Laura
   Tomassi, Franco
   Porcu, Alessandro
   De Lorenzo, Francesco
   Lozupone, Francesco
TI Complementary and Integrative Approaches to Cancer: A Pilot Survey of Attitudes
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB BACKGROUND: Cancer patients are among the main consumers of traditional,  complementary, integrative, and alternative medicine (TCIM) such as natural  products (herbals, integrators, etc.) and mind and body practices (yoga,  acupuncture, etc.). METHODS: A questionnaire on TCIM was submitted to 415 Italian  cancer patients. The questionnaire consisted of three sections: (i) biographical  and clinical information; (ii) use of natural substances; and (iii) use of  mind-body practices. RESULTS: 406 patients completed the questionnaire. The  prevalence of TCIM use was 72.3%. Of them, 75.6% started to use TCIM after a  tumor diagnosis. The main reasons for using TCIM were to mitigate side effects  (65.0%), to regain physical and mental balance (35.9%), to relieve pain (18.3%),  and to improve the efficacy of cancer therapy (16.0%). 44.7% of patients taking  natural products used them during conventional therapies (chemotherapy,  radiotherapy, etc.), and in 67.5% of cases without consulting a doctor. As a  consequence, only about 50% of patients taking natural substances used these  compounds appropriately, and the most common errors were related with the purpose  of reducing the side effects of the therapy (52.3%) and for boosting immune  system (32.1%). CONCLUSIONS: There is an impelling need to provide patients with  scientifically validated information to raise awareness about the benefits and  risks of using TCIM.
C1 Association for Research on Integrative Oncological Therapies (ARTOI), Roma, Italy.
   Italian Center for Global Health, Istituto Superiore di Sanità, Roma, Italy.
   Italian Association for Cancer Patients, Relatives and Friends (AIMaC), Roma, Italy.
   Association for Research on Integrative Oncological Therapies (ARTOI), Roma, Italy.
   Directorate-General Information Technology Unit, Istituto Superiore di Sanità, Roma, Italy.
   National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Roma, Italy.
   National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Roma, Italy.
   Italian Association for Cancer Patients, Relatives and Friends (AIMaC), Roma, Italy.
   Association for Research on Integrative Oncological Therapies (ARTOI), Roma, Italy.
   Italian Association for Cancer Patients, Relatives and Friends (AIMaC), Roma, Italy.
   Italian Association for Cancer Patients, Relatives and Friends (AIMaC), Roma, Italy.
   Italian Center for Global Health, Istituto Superiore di Sanità, Roma, Italy.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD AUG 13
PY 2022
VL 2022
IS 
BP 2923967
EP 2923967
DI 10.1155/2022/2923967
PG 0
UT PubMed:35958921
PM 35958921
DA 2022-08-13
ER

PT J
AU Xu, C
   Li, N
   Wu, XL
   Dai, XY
   Yang, ZW
   Sun, QH
   Shi, TY
   Chai, YM
   Pang, DD
   Cheng, K
AF Xu, Chang
   Li, Na
   Wu, Xiaoling
   Dai, Xingye
   Yang, Zhiwen
   Sun, Qianhui
   Shi, Tianyu
   Chai, Yemao
   Pang, Dandan
   Cheng, Kai
TI Effect of electroacupuncture on inflammatory signal expression in local tissues of rats with chronic pelvic pain syndrome based on purinergic 2X7 receptor/NOD-like receptor pyrin domain- containing 3 signal pathway
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
ID chronic nonbacterial prostatitis; neuropathic pain; hyperalgesia; acupoints
AB OBJECTIVES: To study the expression of inflammatory signal in local prostate tissue of chronic pelvic pain syndrome (CPPS) rats by electroacupuncture (EA) of Guanyuan (CV4), Zhongji (CV3), Huiyang (BL35) and Sanyinjiao (SP6), and to explore the possible mechanism of anti-inflammatory and analgesic effects of EA. METHODS : A total of 36 Sprague-Dawley male rats were randomly divided into three groups: control, model and EA (n=12 rats/group). The CPPS model was made by injection of CFA into ventral lobes of the prostate (0.1 mL). Electric acupuncture apparatus was applied to stimulate Guanyuan (CV4), Zhongji (CV3), bilateral Huiyang (BL35) and Sanyinjiao (SP6) acupoints in EA group. The general condition of rats was observed and the prostate index (PI) was calculated. The thermal pain threshold was collected after each therapeutic course. Histopathological changes of the prostate tissue were examined by hematoxylin-eosin staining method. The expression levels of tumor necrosis factor alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and prostaglandin E2 (PGE2) in prostatic homogenates were measured by enzyme linked immunosorbent assay (ELISA). Moreover, the expression levels of purinergic 2X7 receptor (P2X7R), NOD-like receptor pyrin domain-containing 3 (NLRP3), caspase-1 and interleukin-18 (IL-18) mRNA were quantified by quantitative real-time polymerase chain reaction.RESULTS: Compared with control group, the PI of rats increased, and the thermal pain threshold decreased significantly in model group. The morphological structure of prostate tissues of rats in model group was severely damaged with a large number of inflammatory cells infiltration. Additionally, the levels of TNF-alpha, IL-1 beta and PGE2 were higher, and the expressions of P2X7R, NLRP3, caspase-1 and IL-18 mRNA were higher than those in control group. After EA treatment, the PI was significantly decreased, the thermal pain threshold was significantly increased, and the tissue damage was significantly improved. The expressions of inflammatory cytokines were lower in EA group, and expression of P2X7R/NLRP3 pathway was down-regulated.CONCLUSION: The effect of EA at Guanyuan (CV4), Zhongji (CV3), Huiyang (BL35) and Sanyinjiao (SP6) can improve inflammation and pain symptoms of CPPS rats induced by Complete Freund's adjuvant (CFA). This suggests that EA at Guanyuan (CV4), Zhongji (CV3), Huiyang (BL35) and Sanyinjiao (SP6) can produce anti-inflammatory analgesia effect by preventing the activation of P2X7R/NLRP3 signal pathway, inhibit the release of inflammatory cytokines in CPPS rats, which may provide a putative novel target for the treatment of CPPS.
C1 [Xu, Chang; Wu, Xiaoling; Dai, Xingye; Yang, Zhiwen; Sun, Qianhui; Shi, Tianyu] Beijing Univ Chinese Med, Univ Chinese Med, Acupuncture & Tuina, Beijing 100029, Peoples R China.
   [Li, Na] Beijing Univ Chinese Med, Sch Acupuncture & Tuina, Expt Sci acupuncture & moxibust teaching & Res Sec, Beijing 100029, Peoples R China.
   [Chai, Yemao] Beijing Univ Chinese Med, Sch Acupuncture & Tuina, Complex Lab, Beijing 100029, Peoples R China.
   [Cheng, Kai] Beijing Univ Chinese Med, Sch Acupuncture & Tuina, Meridians & acupoints teaching & Res Sect, Beijing 100029, Peoples R China.
   [Pang, Dandan] Acad Chinese Med Sci, Beijing 100700, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Cheng, K (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture & Tuina, Meridians & acupoints teaching & Res Sect, Beijing 100029, Peoples R China.; Pang, DD (corresponding author), Acad Chinese Med Sci, Beijing 100700, Peoples R China.
EM Pangdan000@126.com; kevin@chengs.cn
FU Fundamental Research Funds for the Central Universities Project: RNA Sequencing Technology Screening the Mechanism of Acupuncture on Pain in Chronic Pelvic Pain Syndrome Rats;  [2020-JYB-XJSJJ-018]
CR Carter GT, 2014, PHYS MED REH CLIN N, V25, P457, DOI 10.1016/j.pmr.2014.01.007
   Fang JQ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-285
   Feng YN, 2020, J FUNCT FOODS, V72, P0, DOI 10.1016/j.jff.2020.104066
   Friedle SA, 2011, GLIA, V59, P1, DOI 10.1002/glia.21071
   Fulgenzi A, 2008, INT J IMMUNOPATH PH, V21, P61, DOI 10.1177/039463200802100108
   Garré JM, 2020, NAT COMMUN, V11, P0, DOI 10.1038/s41467-020-15590-5
   He Qing-xin, 2011, ZHONGHUA NAN KE XUE, V17, P939
   Huang AC, 2020, CHINESE J PHYSIOL, V63, P163, DOI 10.4103/CJP.CJP_34_20
   Ismael S, 2021, NEURAL REGEN RES, V16, P49, DOI 10.4103/1673-5374.286951
   Lee Sang-Hun, 2011, CURR UROL REP, V12, P288, DOI 10.1007/s11934-011-0186-0
   Li T, 2021, JIANGSU ZHONG YI YAO, V53, P78
   Lin SS, 2021, GUANGMING ZHONG YI, V36, P3372
   Liu B, 2020, WORLD J TRAD CHINESE, V6, P448, DOI 10.4103/wjtcm.wjtcm_40_20
   Liu Y, 2013, NEURAL REGEN RES, V8, P1663, DOI 10.3969/j.issn.1673-5374.2013.18.004
   Radhakrishnan R, 2009, INFLAMMOPHARMACOLOGY, V17, P23, DOI 10.1007/s10787-008-8051-6
   Ruiz-Negrón N, 2019, PHARMACOECONOMICS, V37, P669, DOI 10.1007/s40273-018-00761-6
   Shojaei-Zarghani S, 2021, BIOMED PHARMACOTHER, V134, P0, DOI 10.1016/j.biopha.2020.111140
   Smothers A, 2020, J CHRIST NURS, V37, PE21, DOI 10.1097/CNJ.0000000000000745
   Sun WP, 2020, NEUROMOL MED, V22, P250, DOI 10.1007/s12017-019-08581-3
   Wagenlehner FME, 2013, EUR UROL, V63, P953, DOI 10.1016/j.eururo.2012.10.042
   Wan HJ, 2015, EXPRESSION SIGNIFICA, V0, P2
   Wang WL, 2018, BIOMED PHARMACOTHER, V108, P1894, DOI 10.1016/j.biopha.2018.10.010
   Watanabe S, 2017, J PHARMACOL SCI, V133, P49, DOI 10.1016/j.jphs.2016.10.008
   Wu YY, 2019, J PAIN RES, V12, P3067, DOI 10.2147/JPR.S211826
   Xu ZF, 2020, WORLD J TRAD CHINESE, V6, P384, DOI 10.4103/wjtcm.wjtcm_41_20
   Yang WY, 2016, CLIN OBSERVATION ELE, V0, P32
   Yuan Z, 2014, INT UROL NEPHROL, V46, P1871, DOI 10.1007/s11255-014-0743-9
   Zhang J, 2013, BURNS, V39, P610, DOI 10.1016/j.burns.2012.08.013
   Zhang KD, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-016-1553-7
   Zhang W, 2021, TRANSL ANDROL UROL, V10, P0, DOI 10.21037/tau-20-913
   Zhang Y, 2019, ROLE SIGNIFICANCE P2, V0, P28
   Zhang YQ, 2002, PAIN, V99, P525, DOI 10.1016/S0304-3959(02)00268-3
   Zhao YD, 2016, ZHONG HUA ZHONG YI Y, V34, P129
   Zheng HD, 2020, WORLD J TRAD CHINESE, V6, P239, DOI 10.4103/wjtcm.wjtcm_18_20
NR 34
TC 7
Z9 8
U1 1
U2 21
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD DEC 15
PY 2022
VL 42
IS 6
BP 965
EP 971
DI 10.19852/j.cnki.jtcm.20220928.003
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 6I3TM
UT WOS:000886050700001
PM 36378055
DA 2026-01-16
ER

PT J
AU Tang, J
   Sun, Z
   Wang, Y
   Liu, J
   Wang, S
   Wang, X
AF Tang, Jie
   Sun, Zhilu
   Wang, Yan
   Liu, Jing
   Wang, Shuai
   Wang, Xilian
TI Effect and Mechanism of Endothelin Receptor A Inhibitor BQ-123 Combined with
SO Disease markers
LA English
DT Journal Article
AB OBJECTIVE: To research the impact and mechanism of endothelin receptor A  inhibitor BQ-123 combined with electroacupuncture on tibia cancer pain in rats.  METHODS: Sprague-Dawley (SD) rats were randomly divided into sham group (SHAM  group) and bone cancer pain model group (BCP group). The behavior of SD rats was  measured. The histology of the right tibia was observed by hematoxylin-eosin (HE)  staining. The remaining rats were randomly divided into model, BQ-123,  electroacupuncture, and BQ-123+ electroacupuncture group. Behavioral tests were  performed, and mechanical pain threshold (MWT) and thermal pain threshold (TWL)  were measured. The expressions of α-smooth muscle actin (αSMA), ETAR (endothelin  A receptor), ETB (End of Transmission Block), P-Phosphatidylinositol 3-kinase  (PI3K), and P-Protein kinase B (Akt) were detected by real-time fluorescence  quantitative PCR and western blot. RESULTS: In the BCP group, bone structure was  severely damaged, local tissue swelling was obvious, bone trabecula was missing,  and bone cortex was discontinuous. The optical density of Glial fibrillary acidic  protein (GFAP) and CD11b immunoreactive signal in BCP group was significantly  increased, and most of the ETAR of endothelin receptor was comapped with NeuN,  and a small part of GFAP was comapped with CD11b, but no comapped with CD11b. The  AS score of BQ-123+ electroacupuncture group was significantly lower than that of  BQ-123 group and electroacupuncture group (P < 0.05), whereas the MWT and TWL  values were significantly higher than that of the BQ-123 group and  electroacupuncture group (P < 0.05). The mRNA expression of α-SMA and ETAR in  BQ-123+ electroacupuncture group was lower than that in BQ-123 and  electroacupuncture group, and the protein expression of P-PI3K and P-Akt in  BQ-123+ electroacupuncture group was lower as well. CONCLUSION: BQ-123 may  inhibit the activation of PI3K/Akt signal path combined with electroacupuncture  to alleviate the effects of tibia cancer pain in rats.
C1 The First Affiliated Hospital, Department of Pain, Hengyang Medical School, University of South China, 421001, China.
   The First Affiliated Hospital, Department of Emergency, Hengyang Medical School, University of South China, 421001, China.
   The First Affiliated Hospital, Department of Pathology, Hengyang Medical School, University of South China, 421001, China.
   The First Affiliated Hospital, Department of Rehabilitation, Hengyang Medical School, University of South China, 421001, China.
   The First Affiliated Hospital, Department of Hand Foot Surgery, Hengyang Medical School, University of South China, 421001, China.
   The First Affiliated Hospital, Department of Pain, Hengyang Medical School, University of South China, 421001, China.
NR 0
TC 0
SN 1875-863
EI 0278-024
J9 Dis Markers
PD MAY 28
PY 2022
VL 2022
IS 
BP 8563202
EP 8563202
DI 10.1155/2022/8563202
PG 0
WC Animals; Cancer Pain; Electroacupuncture; Humans; Neoplasms; Peptides, Cyclic; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; genetics; Tibia; metabolism
UT PubMed:35620269
PM 35620269
DA 2022-05-28
ER

PT J
AU Wang, D
   Shi, HS
   Yang, ZG
   Liu, WB
   Qi, L
   Dong, CD
   Si, GM
   Guo, Q
AF Wang, Dan
   Shi, Hongshuo
   Yang, Zhenguo
   Liu, Wenbin
   Qi, Lu
   Dong, Chengda
   Si, Guomin
   Guo, Qi
TI Efficacy and Safety of Transcutaneous Electrical Acupoint Stimulation for Postoperative Pain: A Meta-Analysis of Randomized Controlled Trials
SO PAIN RESEARCH & MANAGEMENT
LA English
DT Review
ID surgery; acupuncture; electroacupuncture; cancer; analgesics; anesthesia; management; recovery; quality
AB Objective. This meta-analysis aims to evaluate the effectiveness and safety of transcutaneous electrical acupoint stimulation (TEAS) in treating post-operative pain. Methods. This meta-analysis was registered in PROSPERO (CRD42021286753). We searched PubMed, Embase, and the Cochrane Library for relevant randomized controlled trials (RCTs) about TEAS in treating postoperative pain that were published before November 2021. The primary outcome was visual analogue scale (VAS) within 24 h after surgery. The secondary outcomes included postoperative opioid analgesic drug consumption and the occurrence of adverse reactions within the postoperative 24-72 h. Adverse reactions included dizziness, nausea, and vomiting. Continuous variables were analyzed using mean difference (MDs) or standardized mean difference (SMDs) and 95% CIs. Relative risk (RR) and 95% CI were used for dichotomous data. The data were pooled and analyzed by RevMan 5.4 and STATA15.0 software. Results. Seventeen trials with 1375 participants were included. The current results suggested that application of TEAS showed obvious superiority in reducing VAS scores (SMD = -1.51, 95% CI = -2.20 similar to-0.82, I2 = 96%). Subgroup analysis was performed according to open surgery and minimally invasive surgery. VAS scores were decreased after surgery at 24 h (SMD = -0.84, 95% CI = -1.07 similar to-0.6, I2 = 96%; SMD = -0.88, 95% CI = -1.02 similar to-0.75, I2 = 96%). The incidence of postoperative dizziness and nausea and vomiting was significantly lower in the TEAS group within postoperative 24-72 h (RR = 0.48, 95% CI = 0.34 similar to 0.68, I2 = 0%; RR = 0.66, 95% CI = 0.44 similar to 1.01, I2 = 69%; and RR = 0.49, 95% CI = 0.24 similar to 1.00, I2 = 51%). Postoperative opioid analgesics were also reduced in the TEAS group within 72 h after surgery (SMD = -2.10, 95% CI = -3.37 similar to-0.82, I2 = 96%). Conclusions. TEAS can reduce postoperative pain as well as the incidence of dizziness, nausea, and vomiting and the number of analgesics used after surgery. TEAS is a reasonable modality to incorporate into a multimodal management approach for postoperative pain.
C1 [Wang, Dan; Shi, Hongshuo] Shandong Univ Tradit Chinese Med, Coll Tradit Chinese Med, Jinan, Peoples R China.
   [Yang, Zhenguo; Liu, Wenbin; Qi, Lu] Shandong Univ Tradit Chinese Med, Affiliated Hosp 2, Jinan, Peoples R China.
   [Dong, Chengda] Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan, Peoples R China.
   [Si, Guomin] Shandong First Med Univ, Dept Tradit Chinese Med, Prov Hosp, Jinan, Peoples R China.
   [Guo, Qi] 960 Hosp PLA, Dept Aviat Dis, Jinan, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Shandong First Medical University & Shandong Academy of Medical Sciences
RP Guo, Q (corresponding author), 960 Hosp PLA, Dept Aviat Dis, Jinan, Peoples R China.
EM wd19961007@163.com; zc141319@yeah.net; yangzhenguo81@163.com; 7214933@qq.com; ql_fox@126.com; 15066132023@163.com; sgm977tc@163.com; nationalflag@qq.com
CR Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Becker Daniel E, 2012, ANESTH PROG, V59, P90, DOI 10.2344/0003-3006-59.2.90
   Bicket MC, 2017, JAMA SURG, V152, P1066, DOI 10.1001/jamasurg.2017.0831
   Cai M, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-019-1665-3
   Chang Peng-Yuan, 2016, NEUROSURGERY, V63 Suppl 1, P43, DOI 10.1227/neu.0000000000001296
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   de Souza RC, 2016, LASER MED SCI, V31, P1645, DOI 10.1007/s10103-016-2032-6
   Gong YN, 2020, J LEUKOCYTE BIOL, V108, P189, DOI 10.1002/JLB.3AB0420-361RR
   Hemmings HC, 2019, BRIT J ANAESTH, V122, P705, DOI 10.1016/j.bja.2019.04.003
   Juruena MF, 2020, ADV EXP MED BIOL, V1191, P141, DOI 10.1007/978-981-32-9705-0_9
   Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X
   Li MM, 2020, NEUROMODULATION, V23, P838, DOI 10.1111/ner.13178
   Lin YW, 2020, BRAIN BEHAV IMMUN, V89, P604, DOI 10.1016/j.bbi.2020.06.033
   Liu X, 2015, ACUPUNCT MED, V33, P270, DOI 10.1136/acupmed-2014-010749
   Lovich-Sapola J, 2015, SURG CLIN N AM, V95, P301, DOI 10.1016/j.suc.2014.10.002
   McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X
   Qu F, 2015, INT J CLIN EXP MED, V8, P7754
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Rawal N, 2016, EUR J ANAESTH, V33, P160, DOI 10.1097/EJA.0000000000000366
   Schjerning AM, 2020, NAT REV CARDIOL, V17, P574, DOI 10.1038/s41569-020-0366-z
   Sharififar S, 2018, ANN PHYS REHABIL MED, V61, P339, DOI 10.1016/j.rehab.2018.06.005
   Shinbara H, 2015, ACUPUNCT MED, V33, P65, DOI 10.1136/acupmed-2014-010634
   Song BJ, 2020, NAT SCI SLEEP, V12, P809, DOI 10.2147/NSS.S270739
   Sun K, 2017, CLIN J PAIN, V33, P340, DOI 10.1097/AJP.0000000000000400
   Szmit M, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10010146
   Tai JB, 2020, ANN PALLIAT MED, V9, P2538, DOI 10.21037/apm-19-434
   Tanaka M, 2021, BIOMEDICINES, V9, P0, DOI 10.3390/biomedicines9080897
   Tu Q, 2019, UROLITHIASIS, V47, P279, DOI 10.1007/s00240-018-1056-8
   Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang BG, 1997, ANESTH ANALG, V85, P406, DOI 10.1097/00000539-199708000-00029
   Wang LL, 2020, LIFE SCI, V261, P0, DOI 10.1016/j.lfs.2020.118473
   Wang Y, 2005, EXP NEUROL, V192, P156, DOI 10.1016/j.expneurol.2004.11.003
   Wick EC, 2017, JAMA SURG, V152, P691, DOI 10.1001/jamasurg.2017.0898
   Yao YS, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/324360
   Yeh ML, 2018, CLIN NURS RES, V27, P450, DOI 10.1177/1054773816685745
   Yeh ML, 2011, INT J NURS STUD, V48, P703, DOI 10.1016/j.ijnurstu.2010.10.009
   Yu XD, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-3892-4
   Zhan WF, 2020, EUR J INTEGR MED, V35, P0, DOI 10.1016/j.eujim.2020.101087
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
   Zhang Y, 2013, MAGN RESON IMAGING, V31, P1105, DOI 10.1016/j.mri.2013.01.006
   Zhao YX, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/627023
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
   Zhuang Y, 2013, INT REV NEUROBIOL, V111, P1, DOI 10.1016/B978-0-12-411545-3.00001-8
NR 46
TC 43
Z9 51
U1 0
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1203-6765
EI 1918-1523
J9 PAIN RES MANAG
JI Pain Res. Manag.
PD APR 14
PY 2022
VL 2022
IS 
BP 
EP 
DI 10.1155/2022/7570533
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 1V6FZ
UT WOS:000806184400003
PM 35463630
DA 2026-01-16
ER

PT J
AU Utli, H
   Dinç, M
   Utli, MDA
AF Utli, Hediye
   Dinç, Mahmut
   Utli, Medical Doctor Adil
TI The effect of acupressure or reiki interventions on the levels of pain and
SO Explore (New York, N.Y.)
LA English
DT Journal Article
DE Acupressure; Analgesic use; Cancer pain; Fatigue; Palliative care; Reiki
AB OBJECTIVE: Taking pain under control is important to calm the individual and  reduce complications. This research was conducted with the aim of determining the  effect of Acupressure or Reiki interventions on the levels of pain and fatigue of  stage III and IV cancer patients receiving palliative care. METHOD: The research  was a single-blind, repeated measures, randomized controlled study. Research data  were collected between February and November 2022. The research sample consisted  of Acupressure and Reiki intervention groups and a control group with 52 patients  in each group for a total of 156 patients. Acupressure or Reiki was applied to  their intervention groups for a total of eight sessions of 20 min each over four  weeks, once a day on two days a week. Data were collected by means of a patient  description form, an analgesic follow-up form, the Numeric Pain Rating Scale, and  the Brief Fatigue Inventory. RESULTS: In comparison with the control group, a  significant reduction was seen over time in the levels of pain (p < 0.001),  analgesic use (p < 0.001), and fatigue (p < 0.001) in the Acupressure or Reiki  intervention groups. CONCLUSION: Acupressure or Reiki interventions were found to  effective in reducing levels of pain, analgesic use, and fatigue. It was seen  that in addition to their use in routine nursing care, both treatments can be  accepted as effective nursing interventions that reduce pain and fatigue in stage  III and IV cancer patients receiving palliative care.
C1 Department of Elderly Care, Vocational School of Health Services, Mardin Artuklu University, Mardin, Turkey. 
   Faculty of Health Sciences, Department of Nursing, Batman University, Batman, Turkey.
   Department of Emergency Medicine, Eskişehir Osmangazi Faculty of Medicine, Eskişehir, Turkey.
EM hediyeutli@artuklu.edu.tr
NR 0
TC 0
SN 1878-754
EI 
J9 Explore (NY)
PD DEC 9
PY 2022
VL 19
IS 1
BP 91
EP 99
DI 10.1016/j.explore.2022.11.007
PG 8
WC Humans; Therapeutic Touch; Acupressure; Palliative Care; Single-Blind Method; Pain; etiology; Neoplasms; complications; Analgesics; Fatigue; therapy
UT PubMed:36476354
PM 36476354
DA 2022-12-09
ER

PT J
AU Dyer, NL
   Surdam, J
   Dusek, JA
AF Dyer, Natalie L.
   Surdam, Jessica
   Dusek, Jeffery A.
TI A Systematic Review of Practiced-Based Research of Complementary and Integrative Health Therapies as Provided for Pain Management in Clinical Settings: Recommendations for the Future and a Call to Action
SO PAIN MEDICINE
LA English
DT Review
DE Systematic Review; Complementary and Integrative Health; Integrative Medicine; Practice-Based Research; Chiropractic; Acupuncture
ID low-back-pain; patient-reported outcm; massage therapy; chiropractic management; cancer pain; case series; neck pain; acupuncture; veterans; care
AB Objective. The goal of this systematic review was to evaluate practice-based, real-world research of individualized complementary and integrative health (CIH) therapies for pain as provided in CIH outpatient clinics. Methods. A systematic review was conducted on articles in PubMed, Ovid, Cochrane, Web of Science, Scopus, and Embase published through December 2020. The study was listed in the PROSPERO database (CRD42020159193). Major categories of variables extracted included study details and demographics, interventions, and outcomes. Results. The literature search yielded 3,316 records, with 264 assessed for full-text review. Of those, 23 studies (including similar to 8,464 patients) were specific to pain conditions as a main outcome. Studies included chiropractic, acupuncture, multi-modal individualized intervention/programs, physiotherapy, and anthroposophic medicine therapy. Retention rates ranged from 53% to 91%, with studies offering monetary incentives showing the highest retention. The 0-10 numerical rating scale was the most common pain questionnaire (n = 10; 43% of studies), with an average percent improvement across all studies and time points of 32% (range: 18-60%). Conclusions. Findings from this systematic review of practice-based, real-word research indicate that CIH therapies exert positive effects on various pain outcomes. Although all studies reported beneficial impacts on one or more pain outcomes, the heterogeneous nature of the studies limits our overall understanding of CIH as provided in clinical settings. Accordingly, we present numerous recommendations to improve publication reporting and guide future research. Our call to action is that future practice-based CIH research is needed, but it should be more expansive and conducted in association with a CIH scientific society with academic and health care members.
C1 [Dyer, Natalie L.; Surdam, Jessica; Dusek, Jeffery A.] Univ Hosp, Connor Integrat Hlth Network, Cleveland, OH USA.
   [Dusek, Jeffery A.] Case Western Reserve Univ, Dept Family Med & Community Hlth, Cleveland, OH 44106 USA.
C3 University Hospitals of Cleveland; University System of Ohio; Case Western Reserve University
RP Dusek, JA (corresponding author), Univ Hosp, Cleveland Med Ctr, Connor Integrat Hlth Network, 11000 Euclid Ave, Cleveland, OH 44106 USA.
EM Jeffery.dusek@UHhospitals.org
FU Char and Chuck Fowler Family Foundation; National Center for Complementary and Integrative Health (NCCIH) of the National Institutes of Health (NIH) [AT010598]; National Center for Complementary and Integrative Health [R01AT010598] Funding Source: NIH RePORTER
CR Abrams DI, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-146
   Unknown -, 2011, REL PAIN AM BLUEPR T, V0, P0, DOI DOI 10.17226/13172
   Askew RL, 2016, J CLIN EPIDEMIOL, V73, P103, DOI 10.1016/j.jclinepi.2015.08.035
   Blanchette MA, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0160037
   Blumenthal DM, 2021, HEALTH AFFAIRS BLOG, V0, P0, DOI DOI 10.1377/hblog20170927.062176/full/
   Burke JR, 2014, J CHIROPR MED, V13, P168, DOI 10.1016/j.jcm.2014.07.007
   Chaibi A, 2014, J HEADACHE PAIN, V15, P0, DOI 10.1186/1129-2377-15-67
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459
   Clarke TC, 2018, J ALTERN COMPLEM MED, V24, P139, DOI 10.1089/acm.2016.0182
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Cohen AT, 2015, EUR HEART J SUPPL, V17, PD2, DOI 10.1093/eurheartj/suv035
   Corcoran KL, 2017, J MANIP PHYSIOL THER, V40, P573, DOI 10.1016/j.jmpt.2017.07.001
   Crawford C, 2016, PAIN MED, V17, P1353, DOI 10.1093/pm/pnw099
   Dowell Deborah, 2016, JAMA, V315, P1624, DOI 10.15585/mmwr.rr6501e1
   Dunn AS, 2011, J REHABIL RES DEV, V48, P927, DOI 10.1682/JRRD.2010.10.0202
   Dunn AS, 2011, J MANIP PHYSIOL THER, V34, P533, DOI 10.1016/j.jmpt.2011.08.009
   Dusek JA, 2018, COMPLEMENT THER MED, V37, P43, DOI 10.1016/j.ctim.2018.01.012
   Dusek JA, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1025-0
   Elwy AR, 2020, MED CARE, V58, PS125, DOI 10.1097/MLR.0000000000001357
   Elwy AR, 2014, MED CARE, V52, PS70, DOI 10.1097/MLR.0000000000000228
   Ernst E, 2003, J PAIN, V4, P417, DOI 10.1067/S1526-5900(03)00735-1
   Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808
   Garcia MK, 2018, INTEGR CANCER THER, V17, P148, DOI 10.1177/1534735416685403
   Gedin F, 2019, J BODYW MOV THER, V23, P241, DOI 10.1016/j.jbmt.2018.02.012
   Gentile D, 2018, J ALTERN COMPLEM MED, V24, P968, DOI 10.1089/acm.2018.0192
   Gibson CJ, 2020, PAIN MED, V21, P1977, DOI 10.1093/pm/pnaa003
   Goertz CM, 2013, SPINE, V38, P627, DOI 10.1097/BRS.0b013e31827733e7
   Goh MR, 2010, PROC SINGAP HEALTHC, V19, P175, DOI 10.1177/201010581001900302
   GREEN SB, 1991, MULTIVAR BEHAV RES, V26, P499, DOI 10.1207/s15327906mbr2603_7
   Haas M, 2005, J MANIP PHYSIOL THER, V28, P555, DOI 10.1016/j.jmpt.2005.08.006
   Hamre Harald J, 2009, J PAIN RES, V2, P75
   Hay SI, 2017, LANCET, V389, P0
   Hays RD, 2019, SPINE, V44, P647, DOI 10.1097/BRS.0000000000002902
   JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6
   Johnson JR, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-486
   Johnson Jill R, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP330, DOI 10.1093/jncimonographs/lgu030
   Kong LJ, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/613279
   Kopansky-Giles D, 2010, JOURNAL OF ALTERNATIVE MEDICINE RESEARCH, V2, P61
   Kumar S, 2013, INT J GEN MED, V6, P733, DOI 10.2147/IJGM.S50243
   Lakens D, 2013, FRONT PSYCHOL, V4, P863, DOI 10.3389/fpsyg.2013.00863
   Lee H, 2019, COMPLEMENT THER MED, V43, P7, DOI 10.1016/j.ctim.2018.12.023
   Lee MK, 2020, J PATIENT-REP OUTCOM, V4, P0, DOI 10.1186/s41687-020-00271-0
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Lisi AJ, 2010, J REHABIL RES DEV, V47, P1, DOI 10.1682/JRRD.2009.07.0095
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Maiers M, 2008, J ALTERN COMPLEM MED, V14, P1083, DOI 10.1089/acm.2008.0225
   McGlothlin AE, 2014, JAMA-J AM MED ASSOC, V312, P1342, DOI 10.1001/jama.2014.13128
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Murphy DR, 2009, J MANIP PHYSIOL THER, V32, P723, DOI 10.1016/j.jmpt.2009.10.007
   Murthy VH, 2016, NEW ENGL J MED, V375, P2413, DOI 10.1056/NEJMp1612578
   National Academies of Sciences Engineering and Medicine, 2017, PAIN MAN OP EP BAL S, V0, P0
   National Center for Complementary and Integrative Health, 2020, WHY STUD COMPL HLTH, V0, P0
   National Institutes of Health, 2019, NAT PAIN STRAT COMPR, V0, P0
   Nelson NL, 2017, AM J PHYS MED REHAB, V96, P665, DOI 10.1097/PHM.0000000000000712
   Newell D, 2007, CLIN CHIROPR, V10, P179, DOI 10.1016/J.CLCH.2007.10.003
   Niemtzow RC, 2008, MED ACUPUNCT, V20, P255, DOI 10.1089/acu.2008.0594
   Nyiendo J, 2000, J MANIP PHYSIOL THER, V23, P239
   Okuse K, 2007, INT J BIOCHEM CELL B, V39, P490, DOI 10.1016/j.biocel.2006.11.016
   Olsen MF, 2017, BMC MED, V15, P0, DOI 10.1186/s12916-016-0775-3
   Pina LTS, 2017, EXPERT OPIN THER PAT, V27, P787, DOI 10.1080/13543776.2017.1297425
   Posadzki P, 2012, COMPLEMENT THER MED, V20, P232, DOI 10.1016/j.ctim.2011.12.001
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Schliesser JS, 2003, JOURNAL OF MANIPULATIVE AND PHYSIOLOGICAL THERAPEUTICS, V26, P592
   Schoomaker E, 2014, PAIN MED, V15, PS4, DOI 10.1111/pme.12385
   Secor ER Jr, 2004, J ALTERN COMPLEM MED, V10, P506, DOI 10.1089/1075553041323704
   Thompson LMA, 2015, J ACUPUNCT MERIDIAN, V8, P127, DOI 10.1016/j.jams.2015.04.002
   Tick H, 2018, EXPLORE-NY, V14, P177, DOI 10.1016/j.explore.2018.02.001
   *US FDA, 2017, FDA ED BLUEPR HLTH C, V0, P0
   Veterans Affairs and Department of Defense, 2017, CLIN PRACTICE GUIDEL, V0, P0
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Walker BF, 2013, SPINE, V38, P2071, DOI 10.1097/01.brs.0000435032.73187.c7
   Wayne PM, 2018, J ALTERN COMPLEM MED, V24, P781, DOI 10.1089/acm.2018.0002
   Westfall JM, 2007, JAMA-J AM MED ASSOC, V297, P403, DOI 10.1001/jama.297.4.403
   Wirth B, 2019, CHIROPR MAN THER, V27, P0, DOI 10.1186/s12998-018-0225-8
   Yeganeh M, 2017, COMPLEMENT THER CLIN, V27, P11, DOI 10.1016/j.ctcp.2016.11.012
   Yuan QL, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep30675
NR 79
TC 16
Z9 17
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JAN 15
PY 2022
VL 23
IS 1
BP 189
EP 210
DI 10.1093/pm/pnab151
EA MAY 2021
PG 22
WC Anesthesiology; Medicine, General & Internal
SC Anesthesiology; General & Internal Medicine
GA YI1JM
UT WOS:000743612500017
PM 34009391
DA 2026-01-16
ER

PT J
AU Yang, EM
   Lu, WD
   Giobbie-Hurder, A
   Shin, IH
   Chen, WY
   Block, CC
   Partridge, A
   Jeselsohn, RM
   Tolaney, SM
   Freedman, RA
   Ligibel, JA
AF Yang, EunMee
   Lu, Weidong
   Giobbie-Hurder, Anita
   Shin, Im Hee
   Chen, Wendy Y.
   Block, Caroline C.
   Partridge, Ann
   Jeselsohn, Rinath M.
   Tolaney, Sara M.
   Freedman, Rachel A.
   Ligibel, Jennifer A.
TI Auricular Acupuncture During Chemotherapy Infusion in Breast Cancer Patients: A Feasibility Study
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE auricular acupuncture; breast cancer; chemotherapy; symptom management; feasibility study
ID symptom burden clusters; anxiety; care; trajectory; prevalence; validation; fatigue; women; state; pain
AB Introduction: Breast cancer patients undergoing chemotherapy experience multiple distressing symptoms. The authors investigated the feasibility and potential benefits of auricular acupuncture during chemotherapy infusion in this population.Materials and Methods: Women with stage I-III breast cancer undergoing chemotherapy were enrolled and followed for three chemotherapy cycles. During the first cycle of chemotherapy that participants received after study enrollment, they were provided with educational materials. During the second and third cycles of chemotherapy after enrollment, they received auricular acupuncture. The primary outcome was feasibility, assessed by recruitment, retention, and completion of assessments. Secondary outcomes included symptom burden (Edmonton Symptom Assessment System-Revised Version) and anxiety (State-Trait Anxiety Inventory-State), assessed at four timepoints for each cycle: day 1, pre-education/acupuncture (T1); day 1, post-education/acupuncture (T2); day 2 (T3); and day 5 (T4). Nausea and vomiting (Multinational Association of Supportive Care in Cancer [MASCC] Antiemesis Tool) were assessed on days 2 and 5. Paired t test was used to compare patient-reported outcomes during cycle 1 (education) versus an average of outcomes during cycles 2 and 3 (acupuncture).Results: Twenty-six patients were enrolled, of which 24 completed all acupuncture sessions and 22 completed all outcome assessments. In cycles 2 and 3 versus cycle 1, participants experienced significant reductions in symptom burden (change from T1 to T4: -7.9 +/- 13.6, p = 0.02), anxiety (change from T1 to T2: -3.3 +/- 6.5, p = 0.02), and nausea severity on day 2 (-1.3 +/- 2.6, p = 0.04).Conclusions: The delivery of auricular acupuncture during chemotherapy infusion was feasible and associated with reduction of symptom burden, anxiety, and nausea in breast cancer patients. Larger-scale clinical studies are needed to confirm these findings.Clinical Trial Registration number: NCT03170648.
C1 [Yang, EunMee; Lu, Weidong; Chen, Wendy Y.; Block, Caroline C.; Partridge, Ann; Jeselsohn, Rinath M.; Tolaney, Sara M.; Freedman, Rachel A.; Ligibel, Jennifer A.] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,SW121A, Boston, MA 02115 USA.
   [Giobbie-Hurder, Anita] Dana Farber Canc Inst, Dept Data Sci, Div Biostat, Boston, MA 02115 USA.
   [Shin, Im Hee] Daegu Catholic Univ, Sch Med, Dept Med Stat & Informat, Daegu, South Korea.
C3 Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Catholic University of Daegu
RP Lu, WD (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,SW121A, Boston, MA 02115 USA.
EM weidong_lu@dfci.harvard.edu
CR Aapro M, 2018, SUPPORT CARE CANCER, V26, PS5, DOI 10.1007/s00520-018-4131-3
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Ambroggi M, 2015, ONCOLOGIST, V20, P1378, DOI 10.1634/theoncologist.2015-0110
   Unknown -, 2011, J CANC SCI THER, V0, P0
   Arai YCP, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/945063
   Arai YCP, 2010, EVID-BASED COMPL ALT, V7, P383, DOI 10.1093/ecam/nep172
   Boltong A, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0103512
   Booth Christopher M, 2007, J SUPPORT ONCOL, V5, P374
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Browall M, 2017, SUPPORT CARE CANCER, V25, P1423, DOI 10.1007/s00520-016-3527-1
   Bruera E, 1991, J PALLIAT CARE, V7, P6
   Bubis LD, 2018, J CLIN ONCOL, V36, P1103, DOI 10.1200/JCO.2017.76.0876
   Byar KatherineL, 2006, ONCOL NURS FORUM, V33, PE18, DOI 10.1188/06.ONF.E18-E26
   Cakmak YO, 2019, FRONT HUM NEUROSCI, V13, P0, DOI 10.3389/fnhum.2019.00421
   Carter K, 2017, BEHAV SCI BASEL, V16, P7
   Chad-Friedman E, 2017, CANCER-AM CANCER SOC, V123, P3882, DOI 10.1002/cncr.30904
   Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5
   Charalambous A, 2017, SAGE OPEN MED, V5, P0, DOI 10.1177/2050312117717507
   Chen HY, 2007, J ALTERN COMPLEM MED, V13, P669, DOI 10.1089/acm.2006.6400
   Cheng Alex C, 2017, AMIA ANNU SYMP PROC, V2017, P555
   Cleeland Charles S, 2007, J NATL CANCER INST MONOGR, V0, P16
   de Ligt KM, 2019, BREAST CANCER RES TR, V178, P703, DOI 10.1007/s10549-019-05433-3
   Deadman P, 2007, A MANUAL OF ACUPUNCTURE, V0, P0
   Deshields T, 2014, SUPPORT CARE CANCER, V22, P1089, DOI 10.1007/s00520-013-2049-3
   Dibble Suzanne L, 2003, ONCOL NURS FORUM, V30, PE40, DOI 10.1188/03.ONF.E40-E47
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Hashemi SM, 2020, BREAST CANCER-TOKYO, V27, P166, DOI 10.1007/s12282-019-01031-9
   He W, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/786839
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hsu HT, 2017, J PAIN SYMPTOM MANAG, V53, P1017, DOI 10.1016/j.jpainsymman.2016.12.354
   Hui D, 2017, J PAIN SYMPTOM MANAG, V53, P630, DOI 10.1016/j.jpainsymman.2016.10.370
   Hui D, 2016, J PAIN SYMPTOM MANAG, V51, P262, DOI 10.1016/j.jpainsymman.2015.10.004
   Jagsi R, 2017, CANCER-AM CANCER SOC, V123, P4791, DOI 10.1002/cncr.30959
   Jim HSL, 2011, ANN BEHAV MED, V42, P321, DOI 10.1007/s12160-011-9294-9
   Julian LJ, 2011, ARTHRIT CARE RES, V63, PS467, DOI 10.1002/acr.20561
   Kawakita K, 2014, BIOPSYCHOSOC MED, V8, P0, DOI 10.1186/1751-0759-8-4
   Kelly C, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2016-013059
   Lee IS, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/1304152
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Mao JJ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-7
   Michalek-Sauberer A, 2012, CLIN ORAL INVEST, V16, P1517, DOI 10.1007/s00784-011-0662-4
   Molassiotis A, 2007, J PAIN SYMPTOM MANAG, V34, P148, DOI 10.1016/j.jpainsymman.2006.10.018
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   National Cancer Institute, 2016, CHEM YOU SUPP PEOPL, V0, P0
   Nersesyan H, 2007, THER CLIN RISK MANAG, V3, P381
   Reilly CM, 2013, SUPPORT CARE CANCER, V21, P1525, DOI 10.1007/s00520-012-1688-0
   Rocque GB, 2020, CANCER MED-US, V9, P8423, DOI 10.1002/cam4.3461
   Sarenmalm EK, 2014, J PAIN SYMPTOM MANAG, V47, P731, DOI 10.1016/j.jpainsymman.2013.05.012
   Schneider A, 2016, EUR J ONCOL NURS, V24, P1, DOI 10.1016/j.ejon.2016.07.001
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   TAN JY, 2014, EVID-BASED COMPL ALT, V2014, P0
   Wang T, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/5645632
   Wirz-Ridolfi A, 2019, MED ACUPUNCT, V31, P145, DOI 10.1089/acu.2019.1349
   Yuemei Li, 2006, J TRADIT CHIN MED, V26, P163
   Zia FZ, 2017, J NATL CANC I MONOGR, V2017, P0
NR 57
TC 2
Z9 4
U1 2
U2 14
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD MAY 1
PY 2022
VL 28
IS 5
BP 427
EP 435
DI 10.1089/jicm.2021.0256
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 1G6NL
UT WOS:000795963000008
PM 35238615
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Hausner, D
   Samuels, N
   Gamus, D
   Lavie, O
   Tadmor, T
   Gressel, O
   Agbarya, A
   Attias, S
   David, A
   Schiff, E
AF Ben-Arye, Eran
   Hausner, David
   Samuels, Noah
   Gamus, Dorit
   Lavie, Ofer
   Tadmor, Tamar
   Gressel, Orit
   Agbarya, Abed
   Attias, Samuel
   David, Adi
   Schiff, Elad
TI Impact of acupuncture and integrative therapies on chemotherapy-induced peripheral neuropathy: A multicentered, randomized controlled trial
SO CANCER
LA English
DT Article
DE acupuncture; chemotherapy-induced peripheral neuropathy; integrative medicine; integrative oncology; pain
ID quality-of-life; oncology; prevention; safety; pain
AB Background To explore the impact of acupuncture with other complementary and integrative medicine (CIM) modalities on chemotherapy-induced peripheral neuropathy (CIPN) and quality of life (QoL) in oncology patients. Methods In this prospective, pragmatic, and patient-preference study, patients with CIPN were treated with acupuncture and CIM therapies (intervention group) or standard care alone (controls) for 6 weeks. Patients in the intervention arm were randomized to twice-weekly acupuncture-only (group A) or acupuncture with additional manual-movement or mind-body CIM therapies (group B). Severity of CIPN was assessed at baseline and at 6 weeks using the Functional Assessment of Cancer Therapy-Taxane (FACT-Tax) tool. Other QoL-related outcomes were assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC); and the Measure Yourself Concerns and Well-being questionnaire. Von Frey measurements examined perception thresholds. Results Of 168 participants, 136 underwent the study intervention (group A, 69; group B, 67), with 32 controls. Baseline-to-6-week assessment scores improved significantly in the intervention arm (vs controls) on FACT-Tax (p = .038) and emotional well-being (p = .04) scores; FACT-TAX scores for hand numbness/tingling (p = .007) and discomfort (p < .0001); and EORTC physical functioning (p = .045). Intervention groups A and B showed improved FACT-Tax physical well-being (p < .001), FACT-TAX total score (p < .001), FACT-TAX feet discomfort (p = .003), and EORTC pain (p = .017) scores. Conclusions Acupuncture, with or without CIM modalities, can relieve CIPN-related symptoms during oncology treatment. This is most pronounced for hand numbness, tingling, pain, discomfort, and for physical functioning.
C1 [Ben-Arye, Eran; Gressel, Orit; Agbarya, Abed] Clalit Hlth Serv, Integrat Oncol Program, Lin Zebulun & Carmel Med Ctr, Oncol Serv, Haifa, Israel.
   [Ben-Arye, Eran; Lavie, Ofer; Tadmor, Tamar; Gressel, Orit; Schiff, Elad] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
   [Hausner, David; Gamus, Dorit] Chaim Sheba Med Ctr, Tal Ctr Integrat Med, Inst Oncol, Ramat Gan, Israel.
   [Hausner, David; David, Adi] Chaim Sheba Med Ctr, Palliat Care Serv, Ramat Gan, Israel.
   [Samuels, Noah] Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaarei Zedek Med Ctr, Jerusalem, Israel.
   [Gamus, Dorit] Sheba Med Ctr, Complementary & Integrat Med Serv, Ramat Gan, Israel.
   [Lavie, Ofer] Carmel Hosp, Dept Obstet & Gynecol, Haifa, Israel.
   [Tadmor, Tamar] Bnai Zion Med Ctr, Unit Hematol, Haifa, Israel.
   [Agbarya, Abed] Bnai Zion Med Ctr, Inst Oncol, Haifa, Israel.
   [Attias, Samuel; Schiff, Elad] Bnai Zion Med Ctr, Dept Internal Med, Haifa, Israel.
   [Attias, Samuel; Schiff, Elad] Bnai Zion Med Ctr, Integrat Med Serv, Haifa, Israel.
C3 Clalit Health Services; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Tel Aviv University; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Tel Aviv University; Chaim Sheba Medical Center; Clalit Health Services; Carmel Medical Center; Bnai Zion Medical Center; Bnai Zion Medical Center; Bnai Zion Medical Center; Bnai Zion Medical Center
RP Ben-Arye, E (corresponding author), Lin Med Ctr, Oncol Serv, 35 Rothschild St, Haifa, Israel.
EM eranben@netvision.net.il
FU Adelis Foundation
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Alberti P, 2021, NEUROLOGY, V97, PE660, DOI 10.1212/WNL.0000000000012300
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Ben-Arye E, 2022, PSYCHO-ONCOLOGY, V31, P207, DOI 10.1002/pon.5794
   Ben-Arye E, 2013, MED ONCOL, V30, P0, DOI 10.1007/s12032-013-0511-1
   Cardoso F, 2018, ANN ONCOL, V29, P1634, DOI 10.1093/annonc/mdy192
   Cavaletti G, 2010, EUR J CANCER, V46, P479, DOI 10.1016/j.ejca.2009.12.008
   Cella D, 2003, CANCER-AM CANCER SOC, V98, P822, DOI 10.1002/cncr.11578
   Cioroiu C, 2017, CURR NEUROL NEUROSCI, V17, P0, DOI 10.1007/s11910-017-0757-7
   Cybularz PA, 2015, MED ACUPUNCT, V27, P224, DOI 10.1089/acu.2015.1099
   Frenkel M, 2010, INTEGR CANCER THER, V9, P276, DOI 10.1177/1534735410378663
   Grant SJ, 2019, SUPPORT CARE CANCER, V27, P2069, DOI 10.1007/s00520-018-4460-2
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Kerner H, 2020, BMJ SUPPORT PALLIAT, V10, P0, DOI 10.1136/bmjspcare-2017-001351
   Keshet Y, 2015, PSYCHO-ONCOLOGY, V24, P169, DOI 10.1002/pon.3621
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Manni L, 2011, ARCH ITAL BIOL, V149, P247, DOI 10.4449/aib.v149i2.1365
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Rossi C, 2021, INTEGR CANCER THER, V20, P15347354211040826, DOI 10.1177/15347354211040826
   Schröder S, 2007, EUR J NEUROL, V14, P276, DOI 10.1111/j.1468-1331.2006.01632.x
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shalom-Sharabi I, 2017, J CANCER RES CLIN, V143, P2535, DOI 10.1007/s00432-017-2509-0
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Wang XM, 2012, CYTOKINE, V59, P3, DOI 10.1016/j.cyto.2012.03.027
   Zhao XM, 2019, PHYSIOL RES, V68, P501, DOI 10.33549/physiolres.934084
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhi WI, 2019, BREAST CANCER RES TR, V178, P587, DOI 10.1007/s10549-019-05416-4
NR 33
TC 37
Z9 40
U1 4
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2022
VL 128
IS 20
BP 3641
EP 3652
DI 10.1002/cncr.34422
EA AUG 2022
PG 12
WC Oncology
SC Oncology
GA 4W5ZY
UT WOS:000839602000001
PM 35960141
DA 2026-01-16
ER

PT J
AU Liu, CJ
   Chen, ZH
   Li, SJ
   Ren, H
   Hu, XY
   Ren, YL
AF Liu, Cai-Jiao
   Chen, Zhi-Han
   Li, Si-Jing
   Ren, Huan
   Hu, Xiao-Yu
   Ren, Yu-Lan
TI [Visual analysis of research hotspots and frontiers on randomized controlled
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture and moxibustion; research frontiers; research hotspots; visual analysis
AB Retrieved the literature on randomized controlled trials (RCT) of acupuncture and  moxibustion from 2011 to 2020 in the Web of Science (WOS) database, and explored  research hotspots and frontiers in the field of acupuncture and moxibustion by  visually analyze to countries, institutions, authors, keywords, cited literature,  etc. using CiteSpace V5.6.R2. A total of 1147 articles were included. China has  the largest number of publications, and the top 3 publications are Beijing  University of Chinese Medicine, Capital Medical University and Kyung Hee  University. The hot research interventions in acupuncture and moxibustion include  acupuncture, electroacupuncture, and bee acupuncture. The hot research topics  include nerve regeneration, spasms, nausea, pain, obesity, cancer, etc. The  research frontiers include acupuncture analgesia, diversification of acupuncture  and its clinical effects, brain effects of acupuncture and acupuncture clinical  mechanisms. It is believed that the cooperation between countries and  institutions should be strengthened in the future, and deeper research should be  carried out on the research content that is both hot spot and frontier.
C1 College of Acupuncture- Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture- Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture- Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture- Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture- Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
   College of Acupuncture- Moxibustion and Tuina, Chengdu University of TCM, Chengdu 610075, Sichuan Province, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD FEB 14
PY 2022
VL 42
IS 2
BP 221
EP 6
DI 10.13703/j.0255-2930.20201221-k0001
PG -215
WC Acupuncture; Acupuncture Therapy; Animals; Electroacupuncture; Moxibustion; Randomized Controlled Trials as Topic
UT PubMed:35152591
PM 35152591
DA 2022-02-14
ER

PT J
AU Lee, JH
   Kim, B
   Ko, SG
   Kim, W
AF Lee, Ji Hwan
   Kim, Bonglee
   Ko, Seong-Gyu
   Kim, Woojin
TI Analgesic Effect of SH003 and Trichosanthes kirilowii Maximowicz in Paclitaxel-Induced Neuropathic Pain in Mice
SO CURRENT ISSUES IN MOLECULAR BIOLOGY
LA English
DT Article
DE Allodynia; chemotherapy-induced neuropathic pain; Cucurbitacin D; Paclitaxel; Trichosanthes kirilowii Maximowicz
ID induced peripheral neuropathy; substantia-gelatinosa; spinal-cord; system; acupuncture; bevacizumab; involvement; inhibition; duloxetine; management
AB Pacliatxel is a taxol-based chemotherapeutic drug that is widely used to treat cancer. However, it can also induce peripheral neuropathy, which limits its use. Although several drugs are prescribed to attenuate neuropathies, no optimal treatment is available. Thus, in our study, we analyzed whether SH003 and its sub-components could alleviate paclitaxel-induced neuropathic pain. Multiple paclitaxel injections (cumulative dose 8 mg/kg, i.p.) induced cold and mechanical allodynia from day 10 to day 21 after the first injection in mice. Oral administration of SH003, an herbal mixture extract of Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii Maximowicz (Tk), dose-dependently attenuated both allodynia. However, when administered separately only Tk decreased both allodynia. The effect of Tk was shown to be mediated by the spinal noradrenergic system as intrathecal pretreatment with alpha(1)- and alpha(2)-adrenergic-receptor antagonists (prazosin and idazoxan), but not 5-HT1/2, and 5-HT3-receptor antagonists (methysergide and MDL-72222) blocked the effect of Tk. The spinal noradrenaline levels were also upregulated. Among the phytochemicals of Tk, cucurbitacin D was shown to play a major role, as 0.025 mg/kg (i.p.) of cucurbitacin D alleviated allodynia similar to 500 mg/kg of SH003. These results suggest that Tk should be considered when treating paclitaxel-induced neuropathic pain.
C1 [Lee, Ji Hwan; Kim, Woojin] Kyung Hee Univ, Dept Physiol, Coll Korean Med, Seoul 02447, South Korea.
   [Lee, Ji Hwan; Kim, Bonglee; Ko, Seong-Gyu; Kim, Woojin] Kyung Hee Univ, Coll Korean Med, Korean Med Based Drug Repositioning Canc Res Ctr, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Kim, W (corresponding author), Kyung Hee Univ, Dept Physiol, Coll Korean Med, Seoul 02447, South Korea.; Kim, W (corresponding author), Kyung Hee Univ, Coll Korean Med, Korean Med Based Drug Repositioning Canc Res Ctr, Seoul 02447, South Korea.
EM mibdna@khu.ac.kr; bongleekim@khu.ac.kr; epiko@khu.ac.kr; wjkim@khu.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government (MSIT) [2020R1A5A2019413, 2020R1F1A1070512]
CR Argyriou AA, 2008, CRIT REV ONCOL HEMAT, V66, P218, DOI 10.1016/j.critrevonc.2008.01.008
   Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985
   Baba H, 2000, ANESTHESIOLOGY, V92, P485, DOI 10.1097/00000542-200002000-00031
   Battaglini E, 2018, CONTEMP CLIN TRIALS, V70, P135, DOI 10.1016/j.cct.2018.04.011
   Caraceni A, 2004, J CLIN ONCOL, V22, P2909, DOI 10.1200/jco.2004.08.141
   Carozzi VA, 2015, NEUROSCI LETT, V596, P90, DOI 10.1016/j.neulet.2014.10.014
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Cheon C, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420911442
   Cheon C, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2017-019502
   Choi HS, 2017, MOL CELL BIOCHEM, V426, P1, DOI 10.1007/s11010-016-2875-y
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Choi S, 2017, J PHYSIOL SCI, V67, P431, DOI 10.1007/s12576-016-0505-9
   Choi YK, 2014, MEDIAT INFLAMM, V2014, P0, DOI 10.1155/2014/492173
   Choi YK, 2017, ONCOTARGET, V8, P88386, DOI 10.18632/oncotarget.11393
   Choi YJ, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1490-5
   Corbett A, 2014, BRIT MED BULL, V111, P139, DOI 10.1093/bmb/ldu023
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Dougherty PM, 2004, PAIN, V109, P132, DOI 10.1016/j.pain.2004.01.021
   Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025
   Efferth T, 2011, CURR DRUG TARGETS, V12, P122, DOI 10.2174/138945011793591626
   Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Ge WZ, 2018, MOLECULES, V23, P0, DOI 10.3390/molecules23123345
   Giovannini S, 2021, DIAGNOSTICS, V11, P0, DOI 10.3390/diagnostics11040613
   Golden JP, 2004, DRUG DISCOV TODAY, V1, P186, DOI 10.1016/j.ddmod.2004.09.005
   Hayashida K, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20040822
   Hickey L, 2014, J NEUROSCI, V34, P4148, DOI 10.1523/JNEUROSCI.4835-13.2014
   Hirayama Y, 2015, INT J CLIN ONCOL, V20, P866, DOI 10.1007/s10147-015-0810-y
   Huang Luqi, 1995, ZHONGGUO ZHONGYAO ZAZHI, V20, P195
   Iyengar S, 2004, J PHARMACOL EXP THER, V311, P576, DOI 10.1124/jpet.104.070656
   Jeong MS, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22168405
   Kilkenny C, 2010, PLOS BIOL, V8, P0, DOI 10.1371/journal.pbio.1000412
   Kim MJ, 2017, KOREAN J PHYSIOL PHA, V21, P657, DOI 10.4196/kjpp.2017.21.6.657
   Kim MS, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6571674
   Kim W, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18122626
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   KITAJIMA J, 1989, YAKUGAKU ZASSHI, V109, P250, DOI 10.1248/yakushi1947.109.4_250
   KUMAZAWA T, 1978, J COMP NEUROL, V177, P417, DOI 10.1002/cne.901770305
   Lee JH, 2021, PHARMACOL RES PERSPE, V9, P0, DOI 10.1002/prp2.819
   Lee JH, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22168811
   Lee JH, 2021, BIOMEDICINES, V9, P0, DOI 10.3390/biomedicines9080970
   Lee JH, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26030548
   Lee JH, 2016, KOREAN J PHYSIOL PHA, V20, P407, DOI 10.4196/kjpp.2016.20.4.407
   Lee K, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/4120334
   Lee YA, 2021, BEHAV BRAIN RES, V409, P0, DOI 10.1016/j.bbr.2021.113316
   Li DX, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12100620
   Li DX, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20071652
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Munro G, 2012, PHARMACOL BIOCHEM BE, V101, P465, DOI 10.1016/j.pbb.2012.02.008
   Obata H, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18112483
   Pachman DR, 2011, CLIN PHARMACOL THER, V90, P377, DOI 10.1038/clpt.2011.115
   Patel R, 2022, POSTGRAD MED, V134, P245, DOI 10.1080/00325481.2021.1985351
   Pertovaara A, 2013, EUR J PHARMACOL, V716, P2, DOI 10.1016/j.ejphar.2013.01.067
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Song SY, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000018653
   Staff NP, 2020, EXP NEUROL, V324, P0, DOI 10.1016/j.expneurol.2019.113121
   Suebsakwong P, 2019, ACS MED CHEM LETT, V10, P1400, DOI 10.1021/acsmedchemlett.9b00161
   TAKESHIGE C, 1992, BRAIN RES BULL, V29, P617, DOI 10.1016/0361-9230(92)90131-G
   VERWEIJ J, 1994, ANN ONCOL, V5, P495, DOI 10.1093/oxfordjournals.annonc.a058903
   Wang D, 2021, INVEST NEW DRUG, V39, P122, DOI 10.1007/s10637-020-00997-0
   WESTLUND KN, 1982, PROG BRAIN RES, V57, P219, DOI 10.1016/S0079-6123(08)64131-X
   White MC, 2014, AM J PREV MED, V46, PS7, DOI 10.1016/j.amepre.2013.10.029
   Woo SM, 2016, PHYTOTHER RES, V30, P1817, DOI 10.1002/ptr.5687
   Xie QF, 2012, J ETHNOPHARMACOL, V144, P567, DOI 10.1016/j.jep.2012.09.041
   Yu XK, 2018, J ETHNOPHARMACOL, V224, P177, DOI 10.1016/j.jep.2018.05.034
   Zhang HQ, 2019, J PHARMACEUT BIOMED, V167, P114, DOI 10.1016/j.jpba.2019.02.003
   Zhang SM, 2021, SEMIN ONCOL, V48, P193, DOI 10.1053/j.seminoncol.2021.09.004
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 69
TC 19
Z9 21
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1467-3037
EI 1467-3045
J9 CURR ISSUES MOL BIOL
JI Curr. Issues Mol. Biol.
PD FEB 15
PY 2022
VL 44
IS 2
BP 718
EP 730
DI 10.3390/cimb44020050
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA ZL1RY
UT WOS:000763459800001
PM 35723335
DA 2026-01-16
ER

PT J
AU Cheung, DST
   Yeung, WF
   Chau, PH
   Lam, TC
   Yang, MX
   Lai, K
   Ip, CY
   Lao, LX
   Lin, CC
AF Cheung, Denise Shuk Ting
   Yeung, Wing Fai
   Chau, Pui Hing
   Lam, Tai Chung
   Yang, Mingxiao
   Lai, Kithelia
   Ip, Chun Yat
   Lao, Lixing
   Lin, Chia-Chin
TI Patient-centred, self-administered acupressure for Chinese advanced cancer patients experiencing fatigue and co-occurring symptoms: A pilot randomised controlled trial
SO EUROPEAN JOURNAL OF CANCER CARE
LA English
DT Article
DE acupressure; advanced cancer; fatigue; insomnia; pain; traditional Chinese medicine
ID quality-of-life; version; sleep; anxiety; intervention; depression; management; survivors; exercise; insomnia
AB Objectives To evaluate the feasibility and potential effects of patient-centred self-administered acupressure for alleviating fatigue and co-occurring symptoms among Chinese advanced cancer patients receiving treatment. Methods Thirty advanced cancer patients who screened positive for moderate/severe fatigue with symptoms of insomnia and/or pain were recruited from a hospital in Hong Kong. They were randomly assigned (1:1) to receive a 4-week patient-centred self-administered acupressure intervention or health education. Fatigue (primary outcome) and secondary outcomes (sleep quality, pain, fatigue-sleep disturbance-pain symptom cluster severity, anxiety, depression and quality of life) were measured by questionnaires and actigraphy. Results Twenty-four participants (80%) completed the study. Adherence to self-administered acupressure practice was satisfactory, with all retained participants attending all sessions and 90.9% practising acupressure daily. All completers rated the class as very enjoyable or quite enjoyable. Fatigue, pain, symptom cluster severity, anxiety, depression and quality of life appeared to improve from baseline to post-intervention in the intervention group. Among these outcomes, only the between-group difference in anxiety post-intervention was significant. The group x time interaction effect was nonsignificant for all outcomes. Conclusions Patient-centred self-administered acupressure appears to be feasible and acceptable among advanced cancer patients. A fully powered trial is warranted to confirm the intervention effect.
C1 [Cheung, Denise Shuk Ting; Chau, Pui Hing; Lin, Chia-Chin] Univ Hong Kong, Sch Nursing, Li Ka Shing Fac Med, Hong Kong, Peoples R China.
   [Yeung, Wing Fai] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Peoples R China.
   [Lam, Tai Chung] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China.
   [Yang, Mingxiao; Lao, Lixing] Univ Hong Kong, Sch Chinese Med, Li Ka Shing Fac Med, Hong Kong, Peoples R China.
   [Lai, Kithelia; Ip, Chun Yat] Queen Mary Hosp, Dept Clin Oncol, Hong Kong, Peoples R China.
   [Lao, Lixing] Virginia Univ Integrat Med, Fairfax, VA USA.
   [Lin, Chia-Chin] Alice Ho Miu Ling Nethersole Char Fdn Prof Nursin, Hong Kong, Peoples R China.
   [Lin, Chia-Chin] Taipei Med Univ, Sch Nursing, Coll Nursing, Taipei, Taiwan.
C3 University of Hong Kong; Hong Kong Polytechnic University; University of Hong Kong; University of Hong Kong; University of Hong Kong; Alice Ho Miu Ling Nethersole Hospital; Taipei Medical University
RP Lin, CC (corresponding author), Univ Hong Kong, Sch Nursing, Li Ka Shing Fac Med, Pokfulam, 4-F William MW Mong Block Bldg,21 Sassoon Rd, Hong Kong, Peoples R China.
EM cclin@hku.hk
CR Berger AM, 2015, J NATL COMPR CANC NE, V13, P1012, DOI 10.6004/jnccn.2015.0122
   Blaney J, 2010, PHYS THER, V90, P1135, DOI 10.2522/ptj.20090278
   Bower JE, 2014, NAT REV CLIN ONCOL, V11, P597, DOI 10.1038/nrclinonc.2014.127
   Chakraborty H, 2009, A MIXED MODEL APPROACH FOR INTENT-TOTREAT ANALYSIS IN LONGITUDINAL CLINICAL TRIALS WITH MISSING VALUES, V0, P0, DOI DOI 10.3768/RTIPRESS.2009.MR.0009.0903
   Cheung DST, 2020, J AM GERIATR SOC, V68, P1193, DOI 10.1111/jgs.16357
   Cheung EO, 2017, PSYCHO-ONCOLOGY, V26, P2101, DOI 10.1002/pon.4312
   Clifford BK, 2018, SUPPORT CARE CANCER, V26, P685, DOI 10.1007/s00520-017-3964-5
   Conboy L, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0149161
   Dong ST, 2016, J PAIN SYMPTOM MANAG, V51, P88, DOI 10.1016/j.jpainsymman.2015.07.013
   Fergusson Dean, 2018, RES INVOLV ENGAGEM, V4, P17, DOI 10.1186/s40900-018-0099-x
   Greer JA, 2012, ONCOLOGIST, V17, P1337, DOI 10.1634/theoncologist.2012-0041
   He YH, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-025564
   Hilfiker R, 2018, BRIT J SPORT MED, V52, P651, DOI 10.1136/bjsports-2016-096422
   Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185
   Kwekkeboom KL, 2016, SEMIN ONCOL NURS, V32, P373, DOI 10.1016/j.soncn.2016.08.004
   Kwekkeboom KL, 2012, J PAIN SYMPTOM MANAG, V44, P810, DOI 10.1016/j.jpainsymman.2011.12.281
   Landgren K, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0850-x
   Lauver DR, 2002, RES NURS HEALTH, V25, P246, DOI 10.1002/nur.10044
   LeBlanc TW, 2013, J ONCOL PRACT, V9, P277, DOI 10.1200/JOP.2013.000996
   Lee EC, 2014, BMC MED RES METHODOL, V14, P0, DOI 10.1186/1471-2288-14-41
   Li QP, 2016, EUR J ONCOL NURS, V25, P16, DOI 10.1016/j.ejon.2016.09.004
   Lo C, 2019, BMJ SUPPORT PALLIAT, V9, P209, DOI 10.1136/bmjspcare-2015-000866
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Mosher CE, 2017, CANCER NURS, V40, P66, DOI 10.1097/NCC.0000000000000350
   Mücke M, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006788.pub3
   Mustian KM, 2017, JAMA ONCOL, V3, P961, DOI 10.1001/jamaoncol.2016.6914
   Oldervoll LM, 2011, ONCOLOGIST, V16, P1649, DOI 10.1634/theoncologist.2011-0133
   Rodrigues AR, 2016, AM J HOSP PALLIAT ME, V33, P942, DOI 10.1177/1049909115603055
   Teo I, 2019, PSYCHO-ONCOLOGY, V28, P1394, DOI 10.1002/pon.5103
   Treweek S, 2013, BMJ OPEN, V3, P0, DOI 10.1136/bmjopen-2012-002360
   Tsai JS, 2012, J PALLIAT MED, V15, P737, DOI 10.1089/jpm.2011.0525
   Tzeng JI, 2012, INT J NURS STUD, V49, P102, DOI 10.1016/j.ijnurstu.2011.08.004
   Wang XS, 1996, PAIN, V67, P407, DOI 10.1016/0304-3959(96)03147-8
   Wang XS, 2004, J PAIN SYMPTOM MANAG, V27, P322, DOI 10.1016/j.jpainsymman.2003.09.008
   Yennurajalingam S, 2016, J PALLIAT MED, V19, P849, DOI 10.1089/jpm.2015.0276
   Yeung WF, 2018, J SLEEP RES, V27, P220, DOI 10.1111/jsr.12597
   Yeung Wing-Fai, 2012, EVID BASED COMPLEMENT ALTERNAT MED, V2012, P902578, DOI 10.1155/2012/902578
   Yeung WF, 2012, SLEEP MED, V13, P971, DOI 10.1016/j.sleep.2012.06.003
   Yu CLM, 2000, CANCER, V88, P1715, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1715::AID-CNCR28>3.3.CO;2-B
   Zhang ZJ, 2010, J AFFECT DISORDERS, V124, P9, DOI 10.1016/j.jad.2009.07.005
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
NR 41
TC 34
Z9 37
U1 2
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0961-5423
EI 1365-2354
J9 EUR J CANCER CARE
JI Eur. J. Cancer Care
PD SEP 15
PY 2022
VL 31
IS 5
BP 
EP 
DI 10.1111/ecc.13314
EA SEP 2020
PG 17
WC Oncology; Health Care Sciences & Services; Nursing; Rehabilitation
SC Oncology; Health Care Sciences & Services; Nursing; Rehabilitation
GA 4L4TF
UT WOS:000566654900001
PM 32896014
DA 2026-01-16
ER

PT J
AU Stie, M
   Delmar, C
   Norgaard, B
   Jensen, LH
AF Stie, Mette
   Delmar, Charlotte
   Norgaard, Birgitte
   Jensen, Lars Henrik
TI Impact of Open Dialogue about Complementary Alternative Medicine-A Phase II Randomized Controlled Trial
SO CANCERS
LA English
DT Article
DE complementary alternative medicine; communication; integrative; oncology; patient safety; quality of life
ID cancer-patients; integrative medicine; discussing complementary; communication; care; breast; intervention; perceptions; predictors; depression
AB Simple Summary A large number of patients with cancer use complementary alternative medicine (CAM), such as diet supplements, massage and acupuncture, as an adjunct to conventional cancer treatment and care. Some types of CAM reduce nausea and vomiting, pain, fear, fatigue and depression, but CAM may also cause new symptoms and side effects. Therefore, it is crucial that cancer patients receive professional guidance on how to use CAM in a safe and healthy manner. Open dialogue about CAM between patients and health professionals is, however, not an integrated part of cancer treatment and care. Therefore, the aim of our study was to assess how open dialogue, including guidance about CAM, affected patients' safety and health when it was an integrated part of the cancer treatment and care. We found that open dialogue about CAM does not compromise patient safety and that it may improve patients' quality of life, self-care and survival. Complementary alternative medicine (CAM) may reduce the symptom burden of side effects to antineoplastic treatment but also cause new side effects and non-adherence to conventional treatment. The aim of this RCT was to investigate the impact of open dialogue about complementary alternative medicine (OD-CAM) on cancer patients' safety, health and quality of life (QoL). Patients undergoing antineoplastic treatment were randomly assigned to standard care (SC) plus OD-CAM or SC alone. The primary endpoint was frequency of grade 3-4 adverse events (AE) eight weeks after enrollment. Secondary endpoints were frequency of grade 1-4 AE, QoL, psychological distress, perceived information, attitude towards and use of CAM 12 and 24 weeks after enrollment. Survival was analyzed post hoc. Fifty-seven patients were randomized to the OD-CAM group and fifty-five to the SC group. No significant difference in frequency of grade 3-4 AEs was shown. The same applied to grade 1-4 AEs and QoL, psychological distress and perceived information. A tendency towards better QoL, improved survival and a lower level of anxiety was found in the OD-CAM group. OD-CAM is not superior to SC in reducing the frequency of AEs in patients undergoing antineoplastic treatment. OD-CAM does not compromise patient safety; it may reduce psychological stress and improve QoL and overall survival.
C1 [Stie, Mette; Jensen, Lars Henrik] Univ Hosp Southern Denmark, Dept Oncol, DK-7100 Vejle, Denmark.
   [Stie, Mette] Univ Hosp Southern Denmark, Fac Hlth Sci, Dept Reg Hlth Res, DK-5000 Odense, Denmark.
   [Delmar, Charlotte] Aarhus Univ, Dept Publ Hlth, Res Unit Nursing & Hlth Care, DK-8000 Aarhus, Denmark.
   [Norgaard, Birgitte] Univ Southern Denmark, Dept Publ Hlth, DK-5000 Odense, Denmark.
C3 University of Southern Denmark; Lillebaelt Hospital; University of Southern Denmark; Odense University Hospital; Aarhus University; University of Southern Denmark
RP Stie, M (corresponding author), Univ Hosp Southern Denmark, Dept Oncol, DK-7100 Vejle, Denmark.; Stie, M (corresponding author), Univ Hosp Southern Denmark, Fac Hlth Sci, Dept Reg Hlth Res, DK-5000 Odense, Denmark.
EM mette.stie@rsyd.dk; cd@ph.au.dk; binorgaard@health.sdu.dk; lars.henrik.jensen@rsyd.dk
FU Fondation Idella [N/A] Funding Source: Medline
CR Baarts C, 2009, SOCIOL HEALTH ILL, V31, P719, DOI 10.1111/j.1467-9566.2009.01163.x
   Bahall M, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1853-6
   Bar-Sela G, 2015, SUPPORT CARE CANCER, V23, P1979, DOI 10.1007/s00520-014-2560-1
   Basch E, 2014, JNCI-J NATL CANCER I, V106, P0, DOI 10.1093/jnci/dju244
   Ben-Arye E, 2013, MED ONCOL, V30, P0, DOI 10.1007/s12032-013-0511-1
   Bossi P, 2018, ANN ONCOL, V29, P126, DOI 10.1093/annonc/mdy145
   Broom A, 2009, HEALTH, V13, P317, DOI 10.1177/1363459308101806
   Chong Ooi-Thye, 2006, CLIN J ONCOL NURS, V10, P83, DOI 10.1188/06.CJON.83-88
   Cramer H, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010802.pub2
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   de Jong FA, 2008, EUR J CANCER, V44, P374, DOI 10.1016/j.ejca.2007.12.012
   Ebel MD, 2015, J CANCER RES CLIN, V141, P1449, DOI 10.1007/s00432-015-1940-3
   European Organisation for Research and Treatment of Cancer, 2001, EUR ORGAN RES TREAT CANCER, V3rd, P0
   Fremd C, 2017, ARCH GYNECOL OBSTET, V295, P1239, DOI 10.1007/s00404-017-4348-2
   Frenkel M, 2014, J ALTERN COMPLEM MED, V20, P12, DOI 10.1089/acm.2012.0533
   Frenkel M, 2010, INTEGR CANCER THER, V9, P276, DOI 10.1177/1534735410378663
   Frenkel M, 2010, INTEGR CANCER THER, V9, P177, DOI 10.1177/1534735410363706
   Greenlee H, 2016, JAMA ONCOL, V2, P1170, DOI 10.1001/jamaoncol.2016.0685
   Grossarth-Maticek R, 2007, ARZNEIMITTELFORSCH, V57, P665
   Horneber M, 2018, INTEGR CANCER THER, V17, P1172, DOI 10.1177/1534735418808597
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Arraras JI, 2010, EUR J CANCER, V46, P2726, DOI 10.1016/j.ejca.2010.06.118
   Johnson SB, 2018, JNCI-J NATL CANCER I, V110, P0, DOI 10.1093/jnci/djx145
   Juraskova I, 2010, INTEGR CANCER THER, V9, P168, DOI 10.1177/1534735410365712
   Keshet Y, 2015, PSYCHO-ONCOLOGY, V24, P169, DOI 10.1002/pon.3621
   Keyhanmehr AS, 2018, COMPLEMENT THER CLIN, V31, P175, DOI 10.1016/j.ctcp.2018.02.009
   Klafke N, 2019, CANCER MED-US, V8, P3666, DOI 10.1002/cam4.2196
   Klafke N, 2016, SUPPORT CARE CANCER, V24, P2341, DOI 10.1007/s00520-015-3038-5
   Koithan M, 2007, INTEGR CANCER THER, V6, P174, DOI 10.1177/1534735407301992
   Kust D, 2016, ACTA CLIN CROAT, V55, P585, DOI 10.20471/acc.2016.55.04.08
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Molassiotis A, 2017, SUPPORT CARE CANCER, V25, P267, DOI 10.1007/s00520-016-3324-x
   Münstedt K, 2014, BREAST CARE, V9, P416, DOI 10.1159/000368428
   Nissen N, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-388
   Radwin L, 2000, RES NURS HEALTH, V23, P179, DOI 10.1002/1098-240X(200006)23:3<179::AID-NUR2>3.3.CO;2-K
   Roter DL, 2016, PATIENT EDUC COUNS, V99, P1519, DOI 10.1016/j.pec.2016.06.002
   Rubinstein LV, 2005, J CLIN ONCOL, V23, P7199, DOI 10.1200/JCO.2005.01.149
   Schofield P, 2010, PATIENT EDUC COUNS, V79, P143, DOI 10.1016/j.pec.2009.07.038
   Schulz KF, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/bmj.c869
   Segev Y, 2021, SUPPORT CARE CANCER, V29, P4055, DOI 10.1007/s00520-020-05961-5
   Shalom-Sharabi I, 2017, MED ONCOL, V34, P0, DOI 10.1007/s12032-017-1016-0
   Stie M, 2020, PATIENT EDUC COUNS, V103, P2224, DOI 10.1016/j.pec.2020.06.003
   Toledano A, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211004730
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Wanchai A, 2010, CLIN J ONCOL NURS, V14, P431, DOI 10.1188/10.CJON.E45-E55
   Werthmann Paul G, 2018, PERM J, V23, P18, DOI 10.7812/tpp/18-025
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   Zwingmann J, 2017, CANCER-AM CANCER SOC, V123, P3167, DOI 10.1002/cncr.30694
NR 49
TC 7
Z9 7
U1 1
U2 14
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6694
J9 CANCERS
JI Cancers
PD FEB 15
PY 2022
VL 14
IS 4
BP 
EP 
DI 10.3390/cancers14040952
PG 17
WC Oncology
SC Oncology
GA ZH7YR
UT WOS:000761149900001
PM 35205698
DA 2026-01-16
ER

PT J
AU Pritchard, KT
   Baillargeon, J
   Lee, WC
   Raji, MA
   Kuo, YF
AF Pritchard, Kevin T.
   Baillargeon, Jacques
   Lee, Wei-Chen
   Raji, Mukaila A.
   Kuo, Yong-Fang
TI Trends in the Use of Opioids vs Nonpharmacologic Treatments in Adults With Pain, 2011-2019
SO JAMA NETWORK OPEN
LA English
DT Article
ID united-states; health-care; back-pain; prescription; complementary; association; improvement; population; prevalence; management
AB IMPORTANCE Chronic pain prevalence among US adults increased between 2010 and 2019. Yet little is known about trends in the use of prescription opioids and nonpharmacologic alternatives in treating pain. OBJECTIVES To compare annual trends in the use of prescription opioids, nonpharmacologic alternatives, both treatments, and neither treatment; compare estimates for the annual use of acupuncture, chiropractic care, massage therapy, occupational therapy, and physical therapy; and estimate the association between calendar year and pain treatment based on the severity of pain interference. DESIGN, SETTING, AND PARTICIPANTS A serial cross-sectional analysis was conducted using the nationally representative Medical Expenditure Panel Survey to estimate the use of outpatient services by cancer-free adults with chronic or surgical pain between calendar years 2011 and 2019. Data analysis was performed from December 29, 2021, to August 5, 2022. EXPOSURES Calendar year (2011-2019) was the primary exposure. MAIN OUTCOMES AND MEASURES The association between calendar year and mutually exclusive pain treatments (opioid vs nonpharmacologic vs both vs neither treatment) was examined. A secondary outcome was the prevalence of nonpharmacologic treatments (acupuncture, chiropractic care, massage therapy, occupational therapy, and physical therapy). All analyses were stratified by pain type. RESULTS Among the unweighted 46 420 respondents, 9643 (20.4% weighted) received surgery and 36 777 (79.6% weighted) did not. Weighted percentages indicated that 41.7% of the respondents were aged 45 to 64 years and 55.0% were women. There were significant trends in the use of pain treatments after adjusting for demographic factors, socioeconomic status, health conditions, and pain severity. For example, exclusive use of nonpharmacologic treatments increased in 2019 for both cohorts (chronic pain: adjusted odds ratio [aOR], 2.72; 95% CI, 2.30-3.21; surgical pain: a OR, 1.53; 95% CI, 1.13-2.08) compared with 2011. The use of neither treatment decreased in 2019 for both cohorts (chronic pain: aOR, 0.43; 95% CI, 0.37-0.49; surgical pain: aOR. 0.59; 95% CI, 0.46-0.75) compared with 2011. Among nonpharmacologic treatments, chiropractors and physical therapists were the most common licensed healthcare professionals. CONCLUSIONS AND RELEVANCE Among cancer-free adults with pain, the annual prevalence of nonpharmacologic pain treatments increased and the prevalent use of neither opioids nor nonpharmacologic therapy decreased for both chronic and surgical pain cohorts. These findings suggest that, although access to outpatient nonpharmacologic treatments is increasing, more severe pain interference may inhibit this access.
C1 [Pritchard, Kevin T.] Univ Texas Med Branch, Sch Publ & Populat Hlth, Dept Nutr Metab & Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.
   [Baillargeon, Jacques] Univ Texas Med Branch, Sch Publ & Populat Hlth, Dept Epidemiol, Galveston, TX 77555 USA.
   [Lee, Wei-Chen; Raji, Mukaila A.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA.
   [Kuo, Yong-Fang] Univ Texas Med Branch, Sch Publ & Populat Hlth, Dept Biostat & Data Sci, Galveston, TX 77555 USA.
C3 University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston
RP Pritchard, KT (corresponding author), Univ Texas Med Branch, Sch Publ & Populat Hlth, Dept Nutr Metab & Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.
EM ktpritch@utmb.edu
FU National Institute on Drug Abuse [R01DA039192]; National Institute on Aging [P30-AG024832]; Agency for Healthcare Research and Quality [T32HS026133]; National Center for Complementary and Integrative Health [F31AT011856]; Agency for Healthcare Research and Quality [T32HS026133] Funding Source: NIH RePORTER; National Center for Complementary and Integrative Health [F31AT011856] Funding Source: NIH RePORTER; National Institute on Aging [P30AG024832] Funding Source: NIH RePORTER; National Institute on Drug Abuse [R01DA039192] Funding Source: NIH RePORTER
CR Agency for Healthcare Research and Quality, 2021, MEPS HC 213A PRESCR, V0, P0
   Agency for Healthcare Research and Quality, 2021, AHRQ PUB. NO. 22-0010, V0, P0
   Agency for Healthcare Research and Quality, 2020, MEPS HC-209: 2018 FULL YEAR CONSOLIDATED DATA FILE, V0, P0
   Unknown -, 2005, EMPOWERING THE IT WORKFORCE, V0, P0
   Bausell RB, 2001, MED CARE, V39, P190, DOI 10.1097/00005650-200102000-00009
   Bednarczyk M, 2020, J ACUTE CARE PHYS TH, V11, P54, DOI 10.1097/JAT.0000000000000115
   Bernard Didem, 2019, RESEARCH FINDINGS NO. 43, V0, P0
   Caldwell JT, 2016, AM J PUBLIC HEALTH, V106, P1463, DOI 10.2105/AJPH.2016.303212
   Candon M, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2021.42509
   Centers for Disease Control and Prevention US Department of Health Human Services, 2018, CALC TOT DAIL DOS OP, V0, P0
   Centers for Medicare and Medicaid Services, 2020, DEC MEM AC CHR LOW B, V0, P0
   Chevan J, 2011, J ORTHOP SPORT PHYS, V41, P467, DOI 10.2519/jospt.2011.3637
   Chou RHartung, 2020, COMPARATIVE EFFECTIVENESS REVIEW, V229, P0
   Chowdhury SadeqR, 2013, A COMPARISON OF TAYLOR LINEARIZATION AND BALANCED REPEATED REPLICATION METHODS FOR VARIANCE ESTIMATION IN MEDICAL EXPENDITURE PANEL SURVEY, V0, P0
   Chowdhury SR, 2019, METHODOLOGY REPORT #33 INTERNET, V0, P0
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Dahlhamer JM, 2021, PRESCRIPTION OPIOID USE AMONG ADULTS WITH CHRONIC PAIN: UNITED STATES, V0, P0
   Dahlhamer J, 2018, MMWR-MORBID MORTAL W, V67, P1001, DOI 10.15585/mmwr.mm6736a2
   Davis MA, 2012, SPINE, V37, P1693, DOI 10.1097/BRS.0b013e3182541f45
   DeRigne L, 2016, HEALTH AFFAIR, V35, P520, DOI 10.1377/hlthaff.2015.0965
   Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464
   Drug Enforcement Administration Department of Justice, 2014, FED REGIST, V79, P49661
   Duca LM, 2022, J PAIN, V23, P1492, DOI 10.1016/j.jpain.2022.02.013
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Encinosa W, 2022, INT J HEALTH ECON MA, V22, P1, DOI 10.1007/s10754-021-09307-4
   Esechie A, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2021-053487
   Feldman DE, 2020, J PAIN, V21, P869, DOI 10.1016/j.jpain.2019.11.014
   Fulton-Kehoe D, 2020, J PUBLIC HEALTH MAN, V26, P206, DOI 10.1097/PHH.0000000000001067
   Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009
   Groenewald CB, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2021.46697
   Hawk C, 2012, PREV MED, V54, P18, DOI 10.1016/j.ypmed.2011.07.002
   Herman PM, 2012, BMJ OPEN, V2, P0, DOI 10.1136/bmjopen-2012-001046
   Heyward J, 2018, JAMA NETW OPEN, V1, P0, DOI 10.1001/jamanetworkopen.2018.3044
   Hill S, 2014, OUTPATIENT PRESCRIPT, V0, P0
   Iqbal SU, 2007, THE VETERANS RAND 12 ITEM HEALTH SURVEY (VR-12): WHAT IT IS AND HOW IT IS USED, V0, P1
   Karmali RN, 2021, HEALTH SERV RES, V56, P275, DOI 10.1111/1475-6773.13561
   Karmali RN, 2020, MED CARE, V58, P433, DOI 10.1097/MLR.0000000000001299
   Kennedy J, 2014, J PAIN, V15, P979, DOI 10.1016/j.jpain.2014.05.009
   Kuo YF, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.15638
   Lee B, 2021, JAMA NETW OPEN, V4, P0, DOI 10.1001/jamanetworkopen.2021.38453
   Lee Wei-Chen, 2020, TEX J HEALTH SYST PHARM, V19, P46
   Liaw V, 2020, PUBLIC HEALTH REP, V135, P114, DOI 10.1177/0033354919892638
   Medical Expenditure Panel Survey Medical Provider Component (MEPS-MPC), 2021, METH REP 2019 DAT CO, V0, P0
   Michigan Opioid Prescribing Engagement Network (OPEN), 2021, OP PRESCR REC, V0, P0
   Muench J, 2022, J AM BOARD FAM MED, V35, P352, DOI 10.3122/jabfm.2022.02.210306
   Nahin RL, 2019, J PAIN, V20, P796, DOI 10.1016/j.jpain.2019.01.003
   Nahin Richard L, 2016, NCHS DATA BRIEF, V0, P1
   Nahin RL, 2016, MAYO CLIN PROC, V91, P1292, DOI 10.1016/j.mayocp.2016.06.007
   National Academics of Sciences Enginering and Medicine Health and Medicine Division Board on Global Health Board on Health Sciences Policy Global Forum on Innovation in Health Professional Education Forum on Neuroscience and Nervous System Disorders, 2019, ROL NONPH APPR PAIN, V0, P0
   Navathe AS, 2017, JAMA INTERN MED, V177, P214, DOI 10.1001/jamainternmed.2016.8263
   Neuman MD, 2019, LANCET, V393, P1547, DOI 10.1016/S0140-6736(19)30428-3
   Olfson M, 2020, HEALTH AFFAIR, V39, P146, DOI 10.1377/hlthaff.2019.00783
   Pollack SW, 2020, THE HEALTH WORKFORCE DELIVERING EVIDENCE-BASED NON-PHARMACOLOGICAL PAIN MANAGEMENT, V0, P0
   Pritchard KT, 2021, ARCH PHYS MED REHAB, V102, P1257, DOI 10.1016/j.apmr.2021.01.086
   Quinlan TAG, 2021, HEALTH SERV RES, V56, P1233, DOI 10.1111/1475-6773.13875
   Salz T, 2019, J CLIN ONCOL, V37, P1001, DOI 10.1200/JCO.18.00938
   Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9
   Shah R, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2021-052057
   Sites BD, 2014, REGION ANESTH PAIN M, V39, P6, DOI 10.1097/AAP.0000000000000022
   Skelly AC, 2020, NONINVASIVE NONPHARMACOLOGICAL TREATMENT FOR CHRONIC PAIN: A SYSTEMATIC REVIEW UPDATE, V0, P0, DOI DOI 10.23970/ahrqepccer227
   Smith M, 2010, J MANIP PHYSIOL THER, V33, P562, DOI 10.1016/j.jmpt.2010.08.017
   Tedesco D, 2017, JAMA SURG, V152, P0, DOI 10.1001/jamasurg.2017.2872
   Tian TY, 2013, J AM MED INFORM ASSN, V20, PE275, DOI 10.1136/amiajnl-2013-001856
   US Department of Health and Human Services, 2022, RED PROP AD CHRON PA, V0, P0
   Waljee JF, 2017, ANN SURG, V265, P728, DOI 10.1097/SLA.0000000000001904
   Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4
   Zelaya Carla E, 2020, NCHS DATA BRIEF, V0, P1
NR 68
TC 37
Z9 42
U1 1
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
EI 
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD NOV 7
PY 2022
VL 5
IS 11
BP 
EP 
DI 10.1001/jamanetworkopen.2022.40612
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA 7A3KZ
UT WOS:000898360900003
PM 36342717
DA 2026-01-16
ER

PT J
AU Wang, YH
   Zhou, MF
   Chen, L
   Song, YF
   Sun, MZ
   Pei, LX
   Sun, JH
AF Wang, Yu-Hang
   Zhou, Ming-Fei
   Chen, Lu
   Song, Ya-Fang
   Sun, Meng-Zhu
   Pei, Li-Xia
   Sun, Jian-Hua
TI [Application of Tiaoshen Jianpi acupuncture and moxibustion in hospice care for
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Tiaoshen Jianpi; acupuncture and moxibustion; analgesia; cancer, terminal; hospice care
AB To analyze the application feasibility of Tiaoshen Jianpi acupuncture and  moxibustion in hospice care for terminal cancer patients. Tiaoshen Jianpi  acupuncture and moxibustion adjusts the spirit to regulate emotions and fortifies  the spleen to supplement and boost foundation of acquired (postnatal)  constitution. And it could relieve adverse reactions after radiotherapy and  chemotherapy, alleviate pain and regulate emotions in hospice care for terminal  cancer patients, so as to promote the progress of hospice care for terminal  cancer patients.
C1 School of Acupuncture-Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
   Department of Oncology, Nanjing Xiaohang Hospital.
   Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province.
   School of Acupuncture-Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
   School of Acupuncture-Moxibustion and Tuina, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.
   Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province.
   Department of Acupuncture-Moxibustion and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAR 11
PY 2022
VL 42
IS 3
BP 333
EP 6
DI 10.13703/j.0255-2930.20201210-k0002
PG -327
WC Acupuncture Therapy; Hospice Care; Humans; Moxibustion; Neoplasms; therapy; Spleen
UT PubMed:35272415
PM 35272415
DA 2022-03-11
ER

PT J
AU Liedtke, W
AF Liedtke, Wolfgang
TI Long March Toward Safe and Effective Analgesia by Enhancing Gene Expression of
SO Frontiers in molecular neuroscience
LA English
DT Review
DE GSK3; KCC2; Kaiso; Kcc2 gene expression enhancer; delta-catenin; pain; spinal cord dorsal horn
AB Low intraneuronal chloride in spinal cord dorsal horn pain relay neurons is  critical for physiologic transmission of primary pain afferents because low  intraneuronal chloride dictates whether GABA-ergic and glycin-ergic  neurotransmission is inhibitory. If the neuronal chloride elevates to pathologic  levels, then spinal cord primary pain relay becomes leaky and exhibits the  behavioral hallmarks of pathologic pain, namely hypersensitivity and allodynia.  Low chloride in spinal cord dorsal horn neurons is maintained by proper gene  expression of Kcc2 and sustained physiologic function of the KCC2 chloride  extruding electroneutral transporter. Peripheral nerve injury and other forms of  neural injury evoke greatly diminished Kcc2 gene expression and subsequent  corruption of inhibitory neurotransmission in the spinal cord dorsal horn, thus  causing derailment of the gate function for pain. Here I review key discoveries  that have helped us understand these fundamentals, and focus on recent insights  relating to the discovery of Kcc2 gene expression enhancing compounds via  compound screens in neurons. One such study characterized the kinase inhibitor,  kenpaullone, more in-depth, revealing its function as a robust and long-lasting  analgesic in preclinical models of nerve injury and cancer bone pain, also  elucidating its mechanism of action via GSK3β inhibition, diminishing  delta-catenin phosphorylation, and facilitating its nuclear transfer and  subsequent enhancement of Kcc2 gene expression by de-repressing Kaiso epigenetic  transcriptional regulator. Future directions re Kcc2 gene expression enhancement  are discussed, namely combination with other analgesics and analgesic methods,  such as spinal cord stimulation and electroacupuncture, gene therapy, and  leveraging Kcc2 gene expression-enhancing nanomaterials.
C1 Regeneron Pharmaceuticals, Global Development Scientific Council, Tarrytown, NY, United States.
NR 0
TC 0
SN 1662-509
EI 1662-509
J9 Front Mol Neurosci
PD JUN 2
PY 2022
VL 15
IS 
BP 865600
EP 865600
DI 10.3389/fnmol.2022.865600
PG 0
UT PubMed:35645734
PM 35645734
DA 2022-06-02
ER

PT J
AU Dyer, NL
   Surdam, J
   Srinivasan, R
   Agarwal, A
   Dusek, JA
AF Dyer, Natalie L.
   Surdam, Jessica
   Srinivasan, Roshini
   Agarwal, Ankita
   Dusek, Jeffery A.
TI The Impact of Individualized Complementary and Integrative Health Interventions Provided in Clinical Settings on Quality of Life: A Systematic Review of Practice-Based Research
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review
DE systematic review; complementary and integrative health; integrative medicine; practice-based research; quality of life; well-being; cancer; pain
ID patient-reported outcm; randomized controlled-trials; medical-center; cancer care; pain; acupuncture; recommendations; implementation; veterans; science
AB Background: The goal of this systematic review was to evaluate the impact of individualized complementary and integrative health (CIH) interventions on quality-of-life outcomes as collected in CIH outpatient clinics.Methods: A systematic review was conducted using PubMed, OVID, Cochrane, Web of Science, Scopus, and Embase through December 2020. Inclusion criteria were as follows: individualized CIH treatment, longitudinal effectiveness design, patient-reported outcomes, outpatient CIH clinic setting, participants aged >= 18 years, sample size of >= 25, and English full text. The study was listed in the PROSPERO database (CRD42020159193), and PRISMA guidelines were used. The variables extracted from articles focused on study details/demographics, CIH intervention characteristics, and outcome characteristics.Results: The literature search yielded 3316 records with 264 assessed for full-text review. Of these, 19 studies (including similar to 14,002 patients) were specific to quality of life (or well-being) as a main outcome. Most studies included were multidisciplinary studies (n = 12), followed by acupuncture (n = 4), chiropractic (n = 3), and massage or reflexology (n = 1). The short-form group of questionnaires (SF-12, SF-36, SF-8) were the most used quality-of-life/well-being questionnaire, comprising 37% of studies (n = 7), and the Patient Reported Outcomes Measurement Information System (PROMIS) measures comprised 21% (n = 4). Both questionnaires are normed to U.S. population, allowing for comparison. The average improvement across the comparable SF and PROMIS measures for Physical Health was 6% (range 2%-20%) and for Mental Health was 5% (range 1%-11%), demonstrating clinical significance. Improvements in the observational studies are comparable to improvements reported from randomized controlled trials.Conclusions: Results from this systematic review indicate that CIH therapies largely have positive effects on health-related quality of life and well-being for various patient populations seen in CIH clinical settings. Direct comparisons across studies were limited due to the variability in study design and incomplete reporting in some of the publications. Suggestions for improving the design and reporting for future practice-based research are provided.
C1 [Dyer, Natalie L.; Surdam, Jessica; Dusek, Jeffery A.] Univ Hosp Cleveland, Connor Whole Hlth, Cleveland, OH 44106 USA.
   [Srinivasan, Roshini] Duke Univ, Sch Med, Durham, NC USA.
   [Agarwal, Ankita] Case Western Reserve Univ, Dept Nutr, Cleveland, OH USA.
   [Dusek, Jeffery A.] Case Western Reserve Univ, Dept Family Med & Community Hlth, Cleveland, OH USA.
   [Dusek, Jeffery A.] Univ Hosp Cleveland, Connor Whole Hlth, 11000 Euclid Ave, Cleveland, OH 44106 USA.
C3 University Hospitals of Cleveland; Duke University; University System of Ohio; Case Western Reserve University; University System of Ohio; Case Western Reserve University; University Hospitals of Cleveland
RP Dusek, JA (corresponding author), Univ Hosp Cleveland, Connor Whole Hlth, 11000 Euclid Ave, Cleveland, OH 44106 USA.
EM jeffery.dusek@uhhospitals.org
CR Abrams DI, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-146
   Ananth S, 2010, COMPLEMENTARY ALTERN, V0, P0
   Askew RL, 2016, J CLIN EPIDEMIOL, V73, P103, DOI 10.1016/j.jclinepi.2015.08.035
   Barnes PM, 2008, NATL HLTH STAT REPOR, V0, P0, DOI DOI 10.1037/E623942009-001
   Basch E, 2016, J CLIN ONCOL, V34, P557, DOI 10.1200/JCO.2015.63.0830
   Bauereiss N, 2018, PSYCHO-ONCOLOGY, V27, P2531, DOI 10.1002/pon.4829
   Beidelschies M, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.14017
   Brazier A, 2008, INTEGR CANCER THER, V7, P5, DOI 10.1177/1534735407313395
   Clark D, 2021, J ALTERN COMPLEM MED, V27, PS7, DOI 10.1089/acm.2020.0446
   Clarke TC, 2018, J ALTERN COMPLEM MED, V24, P139, DOI 10.1089/acm.2016.0182
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Coens C, 2020, LANCET ONCOL, V21, PE83, DOI 10.1016/S1470-2045(19)30790-9
   Crocker RL, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8595409
   den Hollander D, 2020, ESMO OPEN, V5, P0, DOI 10.1136/esmoopen-2020-000914
   Dusek JA, 2018, COMPLEMENT THER MED, V37, P43, DOI 10.1016/j.ctim.2018.01.012
   Dyer NL, 2022, PAIN MED, V23, P189, DOI 10.1093/pm/pnab151
   Elwy AR, 2020, MED CARE, V58, PS125, DOI 10.1097/MLR.0000000000001357
   Elwy AR, 2014, MED CARE, V52, PS70, DOI 10.1097/MLR.0000000000000228
   Fayers PM, 2015, QUALITY LIFE ASSESSM, V0, P0
   Feng R, 2015, DIAGN PATHOL, V10, P0, DOI 10.1186/s13000-015-0382-1
   Ferguson CJ, 2009, PROF PSYCHOL-RES PR, V40, P532, DOI 10.1037/a0015808
   Frenkel M, 2010, INTEGR CANCER THER, V9, P276, DOI 10.1177/1534735410378663
   Furlan AD, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/953139
   Gedin F, 2019, J BODYW MOV THER, V23, P241, DOI 10.1016/j.jbmt.2018.02.012
   GREEN SB, 1991, MULTIVAR BEHAV RES, V26, P499, DOI 10.1207/s15327906mbr2603_7
   Greeson JM, 2008, J ALTERN COMPLEM MED, V14, P763, DOI 10.1089/acm.2008.0114
   Haraldstad K, 2019, QUAL LIFE RES, V28, P2641, DOI 10.1007/s11136-019-02214-9
   Harrington J E, 2012, COMPLEMENT THER CLIN PRACT, V18, P10, DOI 10.1016/j.ctcp.2011.05.002
   Harris Philip, 2010, COMPLEMENT THER CLIN PRACT, V16, P31, DOI 10.1016/j.ctcp.2009.06.005
   Haslam A, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0363
   Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089
   Hays RD, 2019, SPINE, V44, P647, DOI 10.1097/BRS.0000000000002902
   Herman PM, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-132
   Hopton A, 2010, PAIN PRACT, V10, P94, DOI 10.1111/j.1533-2500.2009.00337.x
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Kotronoulas G, 2014, J CLIN ONCOL, V32, P1480, DOI 10.1200/JCO.2013.53.5948
   Kroenke K, 2019, J CLIN EPIDEMIOL, V115, P116, DOI 10.1016/j.jclinepi.2019.06.018
   KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k
   Lakens D, 2013, FRONT PSYCHOL, V4, P0, DOI 10.3389/fpsyg.2013.00863
   Leather DA, 2020, ADV THER, V37, P977, DOI 10.1007/s12325-019-01192-1
   Lin WF, 2019, CANCER MANAG RES, V11, P6663, DOI 10.2147/CMAR.S195935
   Lopez G, 2017, J CANCER, V8, P395, DOI 10.7150/jca.17506
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Medvedev ON, 2018, PEERJ, V6, Pe4903, DOI 10.7717/peerj.4903
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Mulkins A, 2003, J ALTERN COMPLEM MED, V9, P585, DOI 10.1089/107555303322284893
   Myklebust M, 2008, J ALTERN COMPLEM MED, V14, P821, DOI 10.1089/acm.2008.0154
   National Center for Complementary and Integrative Health, 2020, WHY STUD COMPL HLTH, V0, P0
   Niemtzow RC, 2008, MED ACUPUNCT, V20, P255, DOI 10.1089/acu.2008.0594
   Secor ER Jr, 2004, J ALTERN COMPLEM MED, V10, P506, DOI 10.1089/1075553041323704
   Singer J, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-167
   Skevington SM, 2002, QUAL LIFE RES, V11, P135, DOI 10.1023/A:1015013312456
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Taylor SL, 2021, J ALTERN COMPLEM MED, V27, PS1, DOI 10.1089/acm.2021.0080
   Thompson LMA, 2015, J ACUPUNCT MERIDIAN, V8, P127, DOI 10.1016/j.jams.2015.04.002
   Tick H, 2018, EXPLORE-NY, V14, P177, DOI 10.1016/j.explore.2018.02.001
   Tsu JHL, 2020, HONG KONG MED J, V26, P88, DOI 10.12809/hkmj205095
   Vodicka E, 2015, CONTEMP CLIN TRIALS, V43, P1, DOI 10.1016/j.cct.2015.04.004
   Wayne PM, 2018, J CANCER SURVIV, V12, P256, DOI 10.1007/s11764-017-0665-5
   Weiss J, 2013, J ALTERN COMPLEM MED, V19, P935, DOI 10.1089/acm.2012.0338
   Westfall JM, 2007, JAMA-J AM MED ASSOC, V297, P403, DOI 10.1001/jama.297.4.403
   World Health Organization, 2019, WHOQOL MEAS QUAL LIF, V0, P0
   Yan B, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7479459
NR 63
TC 15
Z9 16
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD AUG 15
PY 2022
VL 28
IS 8
BP 618
EP 640
DI 10.1089/jicm.2021.0413
EA JUL 2022
PG 23
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA S6JB5
UT WOS:000826935600001
PM 35834609
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Hausner, D
   Samuels, N
   Gamus, D
   Lavie, O
   Tadmor, T
   Gressel, O
   Agbarya, A
   Attias, S
   David, A
   Schiff, E
AF Ben-Arye, Eran
   Hausner, David
   Samuels, Noah
   Gamus, Dorit
   Lavie, Ofer
   Tadmor, Tamar
   Gressel, Orit
   Agbarya, Abed
   Attias, Samuel
   David, Adi
   Schiff, Elad
TI Impact of acupuncture and integrative therapies on chemotherapy-induced
SO Cancer
LA English
DT Journal Article
DE acupuncture; chemotherapy-induced peripheral neuropathy; integrative medicine; integrative oncology; pain
AB BACKGROUND: To explore the impact of acupuncture with other complementary and  integrative medicine (CIM) modalities on chemotherapy-induced peripheral  neuropathy (CIPN) and quality of life (QoL) in oncology patients. METHODS: In  this prospective, pragmatic, and patient-preference study, patients with CIPN  were treated with acupuncture and CIM therapies (intervention group) or standard  care alone (controls) for 6 weeks. Patients in the intervention arm were  randomized to twice-weekly acupuncture-only (group A) or acupuncture with  additional manual-movement or mind-body CIM therapies (group B). Severity of CIPN  was assessed at baseline and at 6 weeks using the Functional Assessment of Cancer  Therapy-Taxane (FACT-Tax) tool. Other QoL-related outcomes were assessed with the  European Organization for Research and Treatment of Cancer Quality of Life  Questionnaire (EORTC); and the Measure Yourself Concerns and Well-being  questionnaire. Von Frey measurements examined perception thresholds. RESULTS: Of  168 participants, 136 underwent the study intervention (group A, 69; group B,  67), with 32 controls. Baseline-to-6-week assessment scores improved  significantly in the intervention arm (vs controls) on FACT-Tax (p = .038) and  emotional well-being (p = .04) scores; FACT-TAX scores for hand numbness/tingling  (p = .007) and discomfort (p < .0001); and EORTC physical functioning (p = .045).  Intervention groups A and B showed improved FACT-Tax physical well-being  (p < .001), FACT-TAX total score (p < .001), FACT-TAX feet discomfort (p = .003),  and EORTC pain (p = .017) scores. CONCLUSIONS: Acupuncture, with or without CIM  modalities, can relieve CIPN-related symptoms during oncology treatment. This is  most pronounced for hand numbness, tingling, pain, discomfort, and for physical  functioning.
C1 Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, 
   Tal Center for Integrative Medicine, Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel.
   Palliative Care Service, Chaim Sheba Medical Center, Ramat Gan, Israel.
   Center for Integrative Complementary Medicine, Shaarei Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
   Tal Center for Integrative Medicine, Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel.
   Complementary and Integrative Medicine Service, Sheba Medical Center, Ramat-Gan, 
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Unit of Hematology, Bnai Zion Medical Center, Haifa, Israel.
   Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, 
   Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, Haifa, Israel.
   Institute of Oncology, Bnai Zion Medical Center, Haifa, Israel.
   Department of Internal Medicine & Integrative Medicine Service, Bnai-Zion, Medical Center, Haifa, Israel.
   Palliative Care Service, Chaim Sheba Medical Center, Ramat Gan, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Internal Medicine & Integrative Medicine Service, Bnai-Zion,
NR 0
TC 0
SN 1097-014
EI 
J9 Cancer
PD AUG 13
PY 2022
VL 128
IS 20
BP 3641
EP 3652
DI 10.1002/cncr.34422
PG 11
WC Acupuncture Therapy; Antineoplastic Agents; adverse effects; Humans; Hypesthesia; chemically induced; Neoplasms; drug therapy; Pain; chemically induced; Peripheral Nervous System Diseases; chemically induced; Prospective Studies; Quality of Life; Taxoids; therapeutic use
UT PubMed:35960141
PM 35960141
DA 2022-08-13
ER

PT J
AU Lu, ZH
   Luo, AL
   Min, S
   Dong, HL
   Xiong, QJ
   Li, XH
   Deng, QZ
   Liu, TT
   Yang, X
   Li, C
   Zhao, QC
   Xiong, LZ
AF Lu, Zhihong
   Luo, Ailin
   Min, Su
   Dong, Hailong
   Xiong, Qiuju
   Li, Xinhua
   Deng, Qingzhu
   Liu, Tingting
   Yang, Xue
   Li, Chen
   Zhao, Qingchuan
   Xiong, Lize
TI Acupoint Stimulation for Enhanced Recovery After Colon Surgery: A Prospective Multicenter Randomized Controlled Trial
SO JOURNAL OF MULTIDISCIPLINARY HEALTHCARE
LA English
DT Article
DE transcutaneous electrical acupoint stimulation; colon surgery; laparoscopy; ERAS
ID improve postoperative recovery; colorectal surgery; cancer patients; gastric-cancer; electroacupuncture; acupuncture; quality; metaanalysis; pathway; ileus
AB Purpose: The aim of this study was to evaluate the efficacy of transcutaneous electrical acupoint stimulation (TEAS) in improving bowel function and thus shortening hospital stay after laparoscopic colon surgery within the ERAS pathway.Patients and Methods: From November 2016 to March 2018, 100 patients who underwent elective colon surgery were enrolled and 94 finished study (n = 47 for each) in three university hospitals. Patients in the TEAS group received TEAS 30 min before surgery and once a day for 3 days after surgery, while those in the Control Group received no stimulation. Primary outcome was the time to discharge. Results: Compared with standardized postoperative care, TEAS resulted in a shorter time to first flatus (P=0.03) and time to first defecation (P=0.03), as well as a reduction in the length of hospital stay (P=0.02). Median patient-controlled analgesia (PCA) deliveries and PCA attempts at 24h, 48h and 72h after surgery were less in the TEAS group (P<0.01). No evidence of significant advantages in postoperative pain intensity, nausea, vomiting, sleeping quality and expenses was found in the TEAS group.Conclusion: Perioperative TEAS further shortens the time to meet discharge criteria after laparoscopic colon surgery in patients under ERAS strategy.
C1 [Lu, Zhihong; Dong, Hailong; Liu, Tingting; Yang, Xue; Xiong, Lize] Fourth Mil Med Univ, Xijing Hosp, Dept Anaesthesiol & Perioperat Med, Xian, Peoples R China.
   [Luo, Ailin; Li, Xinhua; Deng, Qingzhu] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Anaesthesiol, Wuhan, Peoples R China.
   [Min, Su; Xiong, Qiuju] Chongqing Med Univ, Affiliated Hosp 5, Dept Anaesthesiol, Chongqing, Peoples R China.
   [Li, Chen] Fourth Mil Med Univ, Dept Med Stat, Xian, Peoples R China.
   [Zhao, Qingchuan] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Peoples R China.
   [Xiong, Lize] Tongji Univ Sch Med, Shanghai Peoples Hosp 4, Translat Res Inst Brain & Brain Like Intelligence, Dept Anesthesiol, Shanghai, Peoples R China.
   [Lu, Zhihong; Xiong, Lize] Fourth Mil Med Univ, Xijing Hosp, Dept Anesthesiol & Perioperat Med, Changle West Road127, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University; Huazhong University of Science & Technology; Chongqing Medical University; Air Force Medical University; Air Force Medical University; Tongji University; Air Force Medical University
RP Lu, ZH; Xiong, LZ (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Anesthesiol & Perioperat Med, Changle West Road127, Xian 710032, Shaanxi, Peoples R China.
EM deerlu23@163.com; xlzmzk@163.com
FU National Key Basic Research Program of China [2014CB543200]; National Natural Science Foundation of China [81871028]; National Cultivation and Development Program [2021ZY019]; Aeromedical Flow Principal Investigator Program of Air Force Medical University [2022HYPI02]
CR Ban KA, 2019, CLIN COLON RECT SURG, V32, P109, DOI 10.1055/s-0038-1676475
   De Giorgio R, 2021, ADV THER, V38, P3589, DOI 10.1007/s12325-021-01766-y
   Farmer AD, 2018, LANCET GASTROENTEROL, V3, P203, DOI 10.1016/S2468-1253(18)30008-6
   Feng F, 2014, J DIGEST DIS, V15, P306, DOI 10.1111/1751-2980.12142
   Feng F, 2013, WORLD J GASTROENTERO, V19, P3642, DOI 10.3748/wjg.v19.i23.3642
   Guillou PJ, 2005, LANCET, V365, P1718, DOI 10.1016/S0140-6736(05)66545-2
   Huang ZX, 2022, WORLD J SURG ONCOL, V20, P0, DOI 10.1186/s12957-022-02796-8
   Gül DK, 2021, J OBSTET GYNAECOL, V41, P573, DOI 10.1080/01443615.2020.1787363
   Lassen K, 2009, ARCH SURG-CHICAGO, V144, P961, DOI 10.1001/archsurg.2009.170
   Lee HY, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2243-4
   Li WJ, 2021, J INTEGR MED-JIM, V19, P211, DOI 10.1016/j.joim.2021.01.005
   Liu YH, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/2504021
   Lu Z, 2015, BRIT J ANAESTH, V115, P183, DOI 10.1093/bja/aev227
   Luo D, 2008, DIGEST DIS SCI, V53, P689, DOI 10.1007/s10620-007-9929-7
   Menear A, 2017, NURS CRIT CARE, V22, P348, DOI 10.1111/nicc.12315
   Meng ZQ, 2010, WORLD J GASTROENTERO, V16, P104, DOI 10.3748/wjg.v16.i1.104
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Ni XF, 2019, J GASTROINTEST SURG, V23, P1502, DOI 10.1007/s11605-019-04170-8
   Ota H, 2017, SURG TODAY, V47, P668, DOI 10.1007/s00595-016-1423-4
   Ripollés-Melchor J, 2019, JAMA SURG, V154, P725, DOI 10.1001/jamasurg.2019.0995
   Santucci NR, 2021, COMPLEMENT THER MED, V59, P0, DOI 10.1016/j.ctim.2021.102711
   Sheng RY, 2021, WORLD J TRAD CHINESE, V7, P397, DOI 10.4103/wjtcm.wjtcm_27_21
   Smith TW, 2020, AM J SURG, V219, P530, DOI 10.1016/j.amjsurg.2019.11.009
   Sommer NP, 2021, INT J COLORECTAL DIS, V36, P2017, DOI 10.1007/s00384-021-03939-1
   Soylu D, 2021, COMPLEMENT THER CLIN, V43, P0, DOI 10.1016/j.ctcp.2021.101304
   Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b
   Thillainadesan J, 2021, DIS COLON RECTUM, V64, P1020, DOI 10.1097/DCR.0000000000002128
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wang XY, 2021, J GASTROEN HEPATOL, V36, P3015, DOI 10.1111/jgh.15645
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Yang NN, 2021, THERANOSTICS, V11, P4078, DOI 10.7150/thno.52574
   Yang NN, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13808
   Zhang ZD, 2014, ACUPUNCT MED, V32, P223, DOI 10.1136/acupmed-2013-010490
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
   Zhu YJ, 2022, J PAIN SYMPTOM MANAG, V63, P210, DOI 10.1016/j.jpainsymman.2021.09.009
NR 35
TC 4
Z9 7
U1 3
U2 33
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2390
EI 
J9 J MULTIDISCIP HEALTH
JI J. Multidiscip. Healthc.
PD JUN 15
PY 2022
VL 15
IS 
BP 2871
EP 2879
DI 10.2147/JMDH.S391852
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 7F7QT
UT WOS:000902038100001
PM 36570812
DA 2026-01-16
ER

PT J
AU Tang, HY
   Chen, XQ
   Wang, H
   Chu, HR
   Zhu, CF
   Huang, S
   Zhang, MT
   Shen, GM
AF Tang, He-Yong
   Chen, Xi-Qiuyu
   Wang, Hao
   Chu, Hao-Ran
   Zhu, Cai-Feng
   Huang, Shun
   Zhang, Meng-Ting
   Shen, Guo-Ming
TI Acupuncture relieves the visceral pain of diarrhea-predominant irritable bowel syndrome rats by regulating P2X4 expression
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE acupuncture; visceral pain; IBS-D rat
ID p2x(7) receptor; up-regulation; model; gene; hypersensitivity; microglia; electroacupuncture; serotonin; agent; cells
AB Objectives: We researched the effect and mechanism of acupuncture treatment for visceral pain in rats with diarrhea-predominant irritable bowel syndrome (IBS-D). Methods: We set up a rat model of IBS-D with chemical and chronic-and acute-pressure stimulations. Then, the IBS-D rats were treated with acupuncture or 5-BDBD, and the therapeutic efficacy of acupuncture in IBS-D rats was assessed by means of the Bristol scale, diarrhea index, abdominal withdrawal reflex (AWR) score, mast cell count and histologic staining. Results: Acupuncture significantly decreased clinical symptoms in IBS-D rats after a 14 day-treatment. Furthermore, significant down-regulation of P2X4, OX42, BDNF (brain-derived neurotrophic factor) and IRF-5 (interferon regulatory factor 5) expressions were observed in the IBS-D rats, along with the decreased inflammatory factors [interleukin 1 beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6)], chemokines [monocyte chemoattractant protein-1 (MCP-1), regu-lated on activation, normal T cell expressed and secreted (RANTES), and C-X-C motif chemokine ligand 1 (CXCL1)], and neurotransmitters [substance P (SP), 5-hydroxytryptamine (5-HT), and calcitonin gene-related peptide (CGRP)]. 5-BDBD treatment had a similar effect on IBS-D rats. Conclusions: Acupuncture can effectively alleviate abdominal pain by decreasing visceral hypersensitivity and controlling the expression of P2X4 and spinal microglial inflamma-tion in IBS rats.
C1 [Tang, He-Yong; Chen, Xi-Qiuyu; Wang, Hao; Huang, Shun; Zhang, Meng-Ting; Shen, Guo-Ming] Anhui Univ Tradit Chinese Med, Sch Integrated Tradit Chinese & Western Med, Hefei 230012, Anhui, Peoples R China.
   [Chu, Hao-Ran; Zhu, Cai-Feng] Anhui Univ Tradit Chinese Med, Affiliated Hosp 2, Hefei 230012, Anhui, Peoples R China.
   [Shen, Guo-Ming] Anhui Univ Tradit Chinese Med, Sch Integrated Tradit Chinese & Western Med, 1 Qianjiang Rd, Hefei 230012, Anhui, Peoples R China.
C3 Anhui University of Chinese Medicine; Anhui University of Chinese Medicine; Anhui University of Chinese Medicine
RP Shen, GM (corresponding author), Anhui Univ Tradit Chinese Med, Sch Integrated Tradit Chinese & Western Med, 1 Qianjiang Rd, Hefei 230012, Anhui, Peoples R China.
EM shengm_66@163.com
FU Open fund project acupuncture and Moxibustion Clinical Medicine Research Center of Anhui [2021- zjzx07]; Major Research Project of Natural Sciences [81973936]; National Natural Science Foundation of China (Youth Program) [81904095]
CR Al-Chaer ED, 2000, GASTROENTEROLOGY, V119, P1276, DOI 10.1053/gast.2000.19576
   Amarenco G, 2014, PROG UROL, V24, P708, DOI 10.1016/j.purol.2014.06.008
   Asagarasu A, 2010, J MED CHEM, V53, P7549, DOI 10.1021/jm1002292
   Barshop K, 2016, CLIN TRANSL GASTROEN, V7, P0, DOI 10.1038/ctg.2016.12
   Beggs S, 2012, NAT NEUROSCI, V15, P1068, DOI 10.1038/nn.3155
   Berman BM, 2010, NEW ENGL J MED, V363, P454, DOI 10.1056/NEJMct0806114
   Burnstock G, 2008, NEUROGASTROENT MOTIL, V20, P8, DOI 10.1111/j.1365-2982.2008.01107.x
   Burnstock G, 2014, FRONT CELL NEUROSCI, V8, P0, DOI 10.3389/fncel.2014.00204
   Chao GQ, 2014, WORLD J GASTROENTERO, V20, P1871, DOI 10.3748/wjg.v20.i7.1871
   Chen XM, 2015, BRIT J ANAESTH, V114, P150, DOI 10.1093/bja/aeu199
   Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002
   Corbin AL, 2020, SCI IMMUNOL, V5, P0, DOI 10.1126/sciimmunol.aax6085
   DeLeo JA, 2004, NEUROSCIENTIST, V10, P40, DOI 10.1177/1073858403259950
   Fabié A, 2018, CELL REP, V24, P1163, DOI 10.1016/j.celrep.2018.06.107
   Ford AC, 2020, LANCET, V396, P1675, DOI 10.1016/S0140-6736(20)31548-8
   Grenham S, 2011, FRONT PHYSIOL, V2, P0, DOI 10.3389/fphys.2011.00094
   Habba SF, 2011, MED HYPOTHESES, V76, P97, DOI 10.1016/j.mehy.2010.08.040
   Hadjivasilis A, 2019, ANN GASTROENTEROL, V32, P554, DOI 10.20524/aog.2019.0428
   Hou QK, 2017, CELL PHYSIOL BIOCHEM, V44, P2256, DOI 10.1159/000486059
   Inoue K, 2019, CURR OPIN PHARMACOL, V47, P33, DOI 10.1016/j.coph.2019.02.001
   Kapeller J, 2008, HUM MOL GENET, V17, P2967, DOI 10.1093/hmg/ddn195
   Keating C, 2011, J IMMUNOL, V187, P1467, DOI 10.4049/jimmunol.1100423
   Keszthelyi D, 2012, AM J PHYSIOL-GASTR L, V303, PG141, DOI 10.1152/ajpgi.00060.2012
   Kim DY, 2000, AM J GASTROENTEROL, V95, P2698, DOI 10.1016/S0002-9270(00)01970-5
   Latorre R, 2016, NEUROGASTROENT MOTIL, V28, P620, DOI 10.1111/nmo.12754
   Liu SM, 2015, PURINERG SIGNAL, V11, P161, DOI 10.1007/s11302-014-9439-y
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long T, 2020, J HEADACHE PAIN, V21, P0, DOI 10.1186/s10194-019-1070-4
   Lovell RM, 2012, CLIN GASTROENTEROL H, V10, P712, DOI 10.1016/j.cgh.2012.02.029
   OMahony L, 2005, GASTROENTEROLOGY, V128, P541, DOI 10.1053/j.gastro.2004.11.050
   Oswiecimska J, 2017, ADV MED SCI-POLAND, V62, P17, DOI 10.1016/j.advms.2016.11.001
   Ouyang H, 2004, ALIMENT PHARM THER, V20, P831, DOI 10.1111/j.1365-2036.2004.02196.x
   Pei LX, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000010877
   Shao YY, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7830280
   Siegert Fritzi, 2010, MED MONATSSCHR PHARM, V33, P285
   Soares-Bezerra RJ, 2013, PHARMACEUTICALS, V6, P650, DOI 10.3390/ph6050650
   Srivastava P, 2020, EXP NEUROL, V329, P0, DOI 10.1016/j.expneurol.2020.113308
   Sun JH, 2011, CHIN J INTEGR MED, V17, P780, DOI 10.1007/s11655-011-0875-z
   Sun YN, 2004, WORLD J GASTROENTERO, V10, P1830
   Sweitzer SM, 2001, J PHARMACOL EXP THER, V297, P1210
   Tanaka Y, 2011, J NEUROGASTROENTEROL, V17, P131, DOI 10.5056/jnm.2011.17.2.131
   Tang HY, 2021, ANN TRANSL MED, V9, P0, DOI 10.21037/atm-21-2779
   TRAUB RJ, 1992, PAIN, V49, P393, DOI 10.1016/0304-3959(92)90247-9
   Tsuda Makoto, 2007, BRAIN AND NERVE (TOKYO), V59, P953
   Wang DM, 2014, EUR J PHARMACOL, V728, P59, DOI 10.1016/j.ejphar.2014.01.057
   Weng ZJ, 2015, PURINERG SIGNAL, V11, P321, DOI 10.1007/s11302-015-9447-6
   Wu Justin Cy, 2010, J NEUROGASTROENTEROL MOTIL, V16, P306, DOI 10.5056/jnm.2010.16.3.306
   Wu Tao, 2016, J CLIN MED LITERAT, V0, P0
   Xu GY, 2008, GUT, V57, P1230, DOI 10.1136/gut.2007.134221
   Zhang Z, 2008, NEUROSCIENCE, V152, P495, DOI 10.1016/j.neuroscience.2007.12.042
   Zhao Zhi-Ming, 2018, ZHEN CI YAN JIU, V43, P506, DOI 10.13702/j.1000-0607.180184
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zheng H, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003884
NR 53
TC 7
Z9 9
U1 1
U2 16
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2022
VL 14
IS 8
BP 5563
EP 5573
DI 
PG 11
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA 5A3ZX
UT WOS:000862829300012
PM 36105029
DA 2026-01-16
ER

PT J
AU Zhi, WI
   Baser, RE
   Talukder, D
   Mei, YZ
   Harte, SE
   Bao, T
AF Zhi, W Iris
   Baser, Raymond E
   Talukder, Dristi
   Mei, Ying Zi
   Harte, Steven E
   Bao, Ting
TI Mechanistic and thermal characterization of acupuncture for chemotherapy-induced
SO Breast cancer research and treatment
LA English
DT Journal Article
DE Acupuncture; Breast cancer; Chemotherapy; Neuropathy; Quantitative sensory testing; Sensory loss
AB PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and  debilitating side effect of chemotherapy. Acupuncture is a promising  non-pharmacological intervention for CIPN. However, the physiological effects of  acupuncture treatment remain poorly understood. We examined the effects of  acupuncture on CIPN using semi-objective quantitative sensory testing (QST).  METHODS: We conducted a randomized controlled trial of real acupuncture (RA) and  sham acupuncture (SA) compared to usual care (UC) in cancer survivors with  moderate-to-severe CIPN. Treatment response was assessed with QST measures of  tactile and vibration detection thresholds in hands and feet, thermal detection,  and pain thresholds at weeks 0, 8, and 12. Constrained linear mixed model (cLMM)  regression was used for statistical analysis. RESULTS: 63 patients completed QST  testing. At week 8, vibrational detection thresholds in feet were significantly  lower in RA and SA (p = 0.019 and p = 0.046) than in UC, with no difference  between RA and SA (p = 0.637). Both RA and SA also showed significantly higher  cool thermal detection than UC (p = 0.008 and p = 0.013, respectively), with no  difference between RA and SA (p = 0.790). No differences in tactile detection,  vibrational detection in hands, warm thermal detection, and thermal pain  thresholds were detected among the three arms at weeks 8 and 12. CONCLUSION: QST  demonstrated different patterns in RA, SA, and UC. After eight weeks of RA, we  observed significant improvements in the vibrational detection threshold in feet  and cool thermal detection threshold in hands compared to UC. No significant  differences were seen when compared to SA. TRIAL REGISTRATION: ClinicalTrials.gov  (NCT03183037); June 9, 2017.
C1 Breast Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Epidemiology and Biostatistics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Barnard College, Columbia University, New York, NY, USA.
   Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. baot@mskcc.org.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering
NR 0
TC 0
SN 1573-721
EI 0167-680
J9 Breast Cancer Res Treat
PD DEC 18
PY 2022
VL 197
IS 3
BP 535
EP 545
DI 10.1007/s10549-022-06846-3
PG 10
WC Humans; Female; Breast Neoplasms; drug therapy; Peripheral Nervous System Diseases; chemically induced; Acupuncture Therapy; adverse effects; Pain Threshold; Antineoplastic Agents; adverse effects
UT PubMed:36527520
PM 36527520
DA 2022-12-18
ER

PT J
AU Mao, JJ
   Pillai, GG
   Andrade, CJ
   Ligibel, JA
   Basu, P
   Cohen, L
   Khan, IA
   Mustian, KM
   Puthiyedath, R
   Dhiman, KS
   Lao, LX
   Ghelman, R
   Guido, PC
   Lopez, G
   Gallego-Perez, DF
   Salicrup, LA
AF Mao, Jun J.
   Pillai, Geetha Gopalakrishna
   Andrade, Carlos Jose
   Ligibel, Jennifer A.
   Basu, Partha
   Cohen, Lorenzo
   Khan, Ikhlas A.
   Mustian, Karen M.
   Puthiyedath, Rammanohar
   Dhiman, Kartar Singh
   Lao, Lixing
   Ghelman, Ricardo
   Caceres Guido, Paulo
   Lopez, Gabriel
   Gallego-Perez, Daniel F.
   Salicrup, Luis Alejandro
TI Integrative oncology: Addressing the global challenges of cancer prevention and treatment
SO CA-A CANCER JOURNAL FOR CLINICIANS
LA English
DT Article
DE cancer prevention; complementary; alternative; and integrative medicine; global health; health policy; survivorship
ID randomized controlled-trial; quality-of-life; alternative medicine use; stage breast-cancer; stress reduction; massage therapy; american society; clinical-trials; sham acupuncture; supplement use
AB The increase in cancer incidence and mortality is challenging current cancer care delivery globally, disproportionally affecting low- and middle-income countries (LMICs) when it comes to receiving evidence-based cancer prevention, treatment, and palliative and survivorship care. Patients in LMICs often rely on traditional, complementary, and integrative medicine (TCIM) that is more familiar, less costly, and widely available. However, spheres of influence and tensions between conventional medicine and TCIM can further disrupt efforts in evidence-based cancer care. Integrative oncology provides a framework to research and integrate safe, effective TCIM alongside conventional cancer treatment and can help bridge health care gaps in delivering evidence-informed, patient-centered care. This growing field uses lifestyle modifications, mind and body therapies (eg, acupuncture, massage, meditation, and yoga), and natural products to improve symptom management and quality of life among patients with cancer. On the basis of this review of the global challenges of cancer control and the current status of integrative oncology, the authors recommend: 1) educating and integrating TCIM providers into the cancer control workforce to promote risk reduction and culturally salient healthy life styles; 2) developing and testing TCIM interventions to address cancer symptoms or treatment-related adverse effects (eg, pain, insomnia, fatigue); and 3) disseminating and implementing evidence-based TCIM interventions as part of comprehensive palliative and survivorship care so patients from all cultures can live with or beyond cancer with respect, dignity, and vitality. With conventional medicine and TCIM united under a cohesive framework, integrative oncology may provide citizens of the world with access to safe, effective, evidence-informed, and culturally sensitive cancer care.
C1 [Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Pillai, Geetha Gopalakrishna] WHO, Tradit Complementary & Integrat Med Unit, Serv Delivery & Safety Dept, Geneva, Switzerland.
   [Andrade, Carlos Jose] Brazilian Natl Canc Inst, Rio De Janeiro, Brazil.
   [Ligibel, Jennifer A.] Dana Farber Canc Inst, Leonard P Zakim Ctr Integrat Therapies & Hlth Liv, Boston, MA 02115 USA.
   [Ligibel, Jennifer A.] Harvard Med Sch, Boston, MA 02115 USA.
   [Basu, Partha] WHO, Int Agcy Res Canc, Lyon, France.
   [Cohen, Lorenzo; Lopez, Gabriel] Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, Integrat Med Program, Houston, TX 77030 USA.
   [Khan, Ikhlas A.] Univ Mississippi, Natl Ctr Nat Prod Res, Jackson, MS 39216 USA.
   [Mustian, Karen M.] Univ Rochester, Med Ctr, Wilmot Canc Inst, Dept Surg, Rochester, NY 14642 USA.
   [Puthiyedath, Rammanohar] Amrita Vishwa Vidyapeetham Univ, Amritapuri, Kerala, India.
   [Dhiman, Kartar Singh] Cent Council Res Ayurved Sci, New Delhi, India.
   [Lao, Lixing] Virginia Univ Integrat Med, Fairfax, VA USA.
   [Ghelman, Ricardo] Univ Sao Paulo, Brazilian Acad Consortium Integrat Hlth, Sao Paulo, Brazil.
   [Caceres Guido, Paulo] Garrahan Pediat Hosp, Pharmacokinet & Res Clin Pharmacol & Integrat Med, Buenos Aires, DF, Argentina.
   [Caceres Guido, Paulo; Gallego-Perez, Daniel F.] Tradit Complementary & Integrat Med Network Amer, Sao Paulo, Brazil.
   [Gallego-Perez, Daniel F.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
   [Salicrup, Luis Alejandro] NCI, Ctr Global Hlth, NIH, Rockville, MD USA.
   [Salicrup, Luis Alejandro] NCI, Off Canc Complementary & Alternat Med, Div Canc Treatment & Diag, NIH, Rockville, MD USA.
C3 Memorial Sloan Kettering Cancer Center; World Health Organization; National Cancer Institute (Inca); Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; World Health Organization; International Agency for Research on Cancer (IARC); University of Texas System; UTMD Anderson Cancer Center; University of Mississippi; University of Rochester; Amrita Vishwa Vidyapeetham; Universidade de Sao Paulo; Hospital de Pediatria Doctor Juan Garrahan; Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH Division of Cancer Treatment & Diagnosis
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
EM maoj@mskcc.org
FU MSK National Institutes of Health/National Cancer Institute Cancer Center grant [P30 CA008748]; Herbal Education and Research in Oncology Program by the Laurance S. Rockefeller Foundation; Tibet Cheezheng Tibetan Medicine Company, Ltd.; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Afungchwi GM, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1719-y
   Aggarwal BB, 2006, EXPERT OPIN THER TAR, V10, P87, DOI 10.1517/14728222.10.1.87
   Alegbeleye BJ, 2020, INT J SCI ADV, V1, P49
   Aliyu UM, 2017, NIGER J CLIN PRACT, V20, P1576, DOI 10.4103/njcp.njcp_88_17
   American Association for the Advancement of Science, 2014, SCIENCE, V346, P1564
   Andersen SR, 2013, ACTA ONCOL, V52, P336, DOI 10.3109/0284186X.2012.745948
   Anderson JG, 2012, J ALTERN COMPLEM MED, V18, P235, DOI 10.1089/acm.2011.0022
   Unknown -, 1900, A/RES/70/1PARA.21, V0, P0
   Unknown -, 2018, CANCER FACTS AND FIGURES, V0, P0
   Unknown -, 1900, NUTRITION, V0, P0
   Armer JS, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkz098
   Asiimwe JB, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/9963038
   Asiki G, 2016, ACTA PAEDIATR, V105, P191, DOI 10.1111/apa.13252
   Ataguba JEO, 2012, HEALTH ECON POLICY L, V7, P309, DOI 10.1017/S1744133110000356
   Bae JY, 2020, PLANTA MED, V86, P144, DOI 10.1055/a-1037-4051
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Barni MV, 2012, ONCOL REP, V27, P1041, DOI 10.3892/or.2012.1630
   Ben-Arye E, 2013, MED ONCOL, V30, P0, DOI 10.1007/s12032-013-0511-1
   Bhoo-Pathy N, 2017, EUR J CANCER, V74, P26, DOI 10.1016/j.ejca.2016.12.014
   Bower Julienne E, 2005, CANCER CONTROL, V12, P165
   Bower JE, 2021, J CLIN ONCOL, V39, P3473, DOI 10.1200/JCO.21.00279
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Brahmi Sami Aziz, 2011, PAN AFR MED J, V10, P0
   Brenner DR, 2019, PREV MED, V122, P49, DOI 10.1016/j.ypmed.2019.03.014
   Broom Alex, 2009, OMAN MED J, V24, P99, DOI 10.5001/omj.2009.24
   Brown KF, 2018, BRIT J CANCER, V118, P1130, DOI 10.1038/s41416-018-0029-6
   Bruni L, 2021, PREV MED, V144, P0, DOI 10.1016/j.ypmed.2020.106399
   Guido PC, 2015, EUR J INTEGR MED, V7, P5, DOI 10.1016/j.eujim.2014.06.010
   Carlson LE, 2004, PSYCHONEUROENDOCRINO, V29, P448, DOI 10.1016/S0306-4530(03)00054-4
   Carlson LE, 2013, J CLIN ONCOL, V31, P3119, DOI 10.1200/JCO.2012.47.5210
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   Chen G, 2015, J HUAZHONG U SCI-MED, V35, P808, DOI 10.1007/s11596-015-1511-5
   Chen Z, 2008, J ALTERN COMPLEM MED, V14, P1049, DOI 10.1089/acm.2008.0039
   Choedon T, 2010, J ETHNOPHARMACOL, V129, P208, DOI 10.1016/j.jep.2010.03.011
   Clairet AL, 2019, MED ONCOL, V36, P0, DOI 10.1007/s12032-019-1267-z
   Communication Strategy Research Office Center for International Communication Studies, 2015, 2015 CHINA NATL IMAG, V0, P0
   Costa PT, 2015, HEMATOL ONCOL, V33, P280
   Courneya KS, 2008, CURR ONCOL, V15, P262
   DAlessandro E, 2013, ACUPUNCT MED, V31, P23, DOI 10.1136/acupmed-2012-010206
   Campos MPD, 2011, J ALTERN COMPLEM MED, V17, P505, DOI 10.1089/acm.2010.0571
   De Pergola G, 2013, J OBES, V2013, P0, DOI 10.1155/2013/291546
   Defo BK, 2014, GLOBAL HEALTH ACTION, V7, P17, DOI 10.3402/gha.v7.22443
   del Giglio Adriana Braz, 2013, JOURNAL OF DIETARY SUPPLEMENTS, V10, P325, DOI 10.3109/19390211.2013.830676
   Denlinger C, 2016, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY - SURVIVORSHIP, Version 2, P0
   Department of Primary Care Office of Health Care Ministry of Health of Brazil, 2008, NATL POL INT COMPL P, V0, P0
   Desai AG, 2008, CURR DRUG METAB, V9, P581, DOI 10.2174/138920008785821657
   Deshmukh V, 2014, SUPPORT CARE CANCER, V22, P3007, DOI 10.1007/s00520-014-2294-0
   Doll Richard, 2004, BMJ, V328, P1519, DOI 10.1136/bmj.38142.554479.AE
   Donoyama N, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0196638
   Ettinger D S, 2015, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY, V0, P0
   Ezzo J, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003475.pub2
   Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
   Fernandez T, 2003, J ETHNOPHARMACOL, V85, P81, DOI 10.1016/S0378-8741(02)00361-6
   Ferraz Ivana Santos, 2020, ENFERMERÍA ACTUAL DE COSTA RICA, V0, PP196, DOI 10.15517/revenf.v0i38.37750
   Gallagher EJ, 2013, DIABETES CARE, V36, PS233, DOI 10.2337/dcS13-2001
   Gallagher EJ, 2015, PHYSIOL REV, V95, P727, DOI 10.1152/physrev.00030.2014
   Gallego-Pérez DF, 2020, REV PANAM SALUD PUBL, V44, P0, DOI 10.26633/RPSP.2020.143
   Gallicchio L, 2021, JNCI-J NATL CANCER I, V113, P1136, DOI 10.1093/jnci/djab049
   Garland SN, 2021, J CANCER SURVIV, V15, P951, DOI 10.1007/s11764-021-01001-1
   Geerse OP, 2018, CANCER-AM CANCER SOC, V124, P4435, DOI 10.1002/cncr.31723
   Gelband H, 2016, LANCET, V387, P2133, DOI 10.1016/S0140-6736(15)00755-2
   Gerson-Cwilich Raquel, 2006, CLIN TRANSL ONCOL, V8, P200
   Gilchrist SC, 2020, JAMA ONCOL, V6, P1210, DOI 10.1001/jamaoncol.2020.2045
   Giordano A, 2019, NUTRIENTS, V11, P0, DOI 10.3390/nu11102376
   Giovannucci E, 2010, J CLIN ONCOL, V28, P4081, DOI 10.1200/JCO.2009.27.3219
   Girdhani S, 2005, J CANCER RES THER, V1, P129
   Gomez-Martinez R, 2007, PEDIATR BLOOD CANCER, V49, P820, DOI 10.1002/pbc.21101
   Gopal S, 2021, JAMA-J AM MED ASSOC, V326, P809, DOI 10.1001/jama.2021.12778
   Grant SJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735418823266
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Greenlee Heather, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP346, DOI 10.1093/jncimonographs/lgu041
   He W, 2013, J TRADIT CHIN MED, V33, P403, DOI 10.1016/S0254-6272(13)60187-9
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Henderson V, 2012, BREAST CANCER RES TR, V131, P99, DOI 10.1007/s10549-011-1738-1
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Holmboe-Ottesen G, 2012, FOOD NUTR RES, V56, P0, DOI 10.3402/fnr.v56i0.18891
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Hou YN, 2019, CANCER J, V25, P357, DOI 10.1097/PPO.0000000000000403
   Hsu WC, 2015, DIABETES CARE, V38, P150, DOI 10.2337/dc14-2391
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Islami F, 2018, CA-CANCER J CLIN, V68, P31, DOI 10.3322/caac.21440
   Jeon J, 2018, ANN INTERN MED, V169, P684, DOI 10.7326/M18-1250
   Jia Libin, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP58, DOI 10.1093/jncimonographs/lgx007
   Jiang H, 2018, JAMA NETW OPEN, V1, P0, DOI 10.1001/jamanetworkopen.2018.0713
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2006, COLL TRAD HEAL HIV P, V0, P0
   Key T, 2004, PUBLIC HEALTH NUTR, V7, P187, DOI 10.1079/PHN2003588
   Kiecolt-Glaser JK, 2014, J CLIN ONCOL, V32, P1040, DOI 10.1200/JCO.2013.51.8860
   Kinkead B, 2018, CANCER-AM CANCER SOC, V124, P546, DOI 10.1002/cncr.31064
   Knaul FM, 2011, CLOSING THE CANCER DIVIDE. A BLUEPRINT TO EXPAND ACCESS IN LOW AND MIDDLE INCOME COUNTRIES, V0, P0
   Krohn M, 2011, SUPPORT CARE CANCER, V19, P1303, DOI 10.1007/s00520-010-0946-2
   Kumar DRN, 2015, PAK J PHARM SCI, V28, P83
   Kumar D, 2016, SOUTH ASIAN J CANCER, V5, P8, DOI 10.4103/2278-330X.179689
   Kumar S, 2013, CURR OPIN SUPPORT PA, V7, P216, DOI 10.1097/SPC.0b013e3283610255
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Labidi S, 2020, B CANCER, V107, P209, DOI 10.1016/j.bulcan.2019.10.007
   Lacomba MT, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/bmj.b5396
   Ladas EJ, 2014, PEDIATR BLOOD CANCER, V61, P687, DOI 10.1002/pbc.24791
   Latorre Palma Claudia G, 2016, JOURNAL OF DIETARY SUPPLEMENTS, V13, P221, DOI 10.3109/19390211.2015.1008612
   Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602
   Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200
   Lee BL, 2012, LANCET ONCOL, V13, PE95, DOI 10.1016/S1470-2045(11)70323-0
   Lengacher CA, 2016, J CLIN ONCOL, V34, P2827, DOI 10.1200/JCO.2015.65.7874
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Li JX, 2011, CURR ONCOL REP, V13, P290, DOI 10.1007/s11912-011-0169-9
   Ligibel JA, 2017, NPJ BREAST CANCER, V3, P0, DOI 10.1038/s41523-017-0040-8
   Ligibel JA, 2014, J CLIN ONCOL, V32, P3568, DOI 10.1200/JCO.2014.58.4680
   Lim EJ, 2017, J ALTERN COMPLEM MED, V23, P8, DOI 10.1089/acm.2016.0263
   Lin PJ, 2018, CURR ONCOL REP, V20, P0, DOI 10.1007/s11912-018-0657-2
   Linos E, 2008, JNCI-J NATL CANCER I, V100, P1352, DOI 10.1093/jnci/djn305
   Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508
   Liu J, 2021, ANN PALLIAT MED, V10, P1895, DOI 10.21037/apm-20-865
   Liu J, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420944491
   Liu J, 2019, CANCER J, V25, P367, DOI 10.1097/PPO.0000000000000404
   Livingston J, 2012, IMPROVISING MEDICINE IN AN AFRICAN ONCOLOGY WARD, V0, P0, DOI DOI 10.1215/9780822395768
   LoConte NK, 2018, J CLIN ONCOL, V36, P83, DOI 10.1200/JCO.2017.76.1155
   de Paula LCL, 2015, J ALTERN COMPLEM MED, V21, P22, DOI 10.1089/acm.2014.0127
   Lopes Gilberto, 2019, J GLOB ONCOL, V5, P1, DOI 10.1200/JGO.18.00213
   Lopez G, 2019, CANCER J, V25, P311, DOI 10.1097/PPO.0000000000000401
   López-Gil S, 2017, DRUG METAB REV, V49, P338, DOI 10.1080/03602532.2017.1335750
   Ly, 2016, CANC THER ONCOL INT, V2, P0
   Ly, 2018, J TUMOR MED PREV, V3, P0
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   MacLeod, 2017, J NATL CANCER INST M, V2017, P0
   Malvicini M, 2018, MOL CANCER THER, V17, P966, DOI 10.1158/1535-7163.MCT-17-0193
   Mao, 2017, J NATL CANCER INST M, V2017, P0
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2017, J ONCOL PRACT, V13, PE207, DOI 10.1200/JOP.2016.015081
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Martinez R, 2020, LANCET GLOB HEALTH, V8, PE511, DOI 10.1016/S2214-109X(20)30035-8
   Mathur P, 2020, JCO GLOB ONCOL, V6, P1063, DOI 10.1200/GO.20.00122
   Mclntyre D, 2007, LEARNING EXPERIENCE, V0, P0
   McQuade JL, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/504507
   Boccolini PDM, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-2842-8
   Moadel AB, 2007, J CLIN ONCOL, V25, P4387, DOI 10.1200/JCO.2006.06.6027
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Molina AI, 2005, MEDICINA-BUENOS AIRE, V65, P390
   Moral-Munoz JA, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419846401
   Mustian KM, 2016, SEMIN ONCOL NURS, V32, P383, DOI 10.1016/j.soncn.2016.09.002
   Mustian Karen M, 2012, ONCOL HEMATOL REV, V8, P81
   Mustian KM, 2013, J CLIN ONCOL, V31, P3233, DOI 10.1200/JCO.2012.43.7707
   Nahleh Z, 2008, CURR ONCOL, V15, P271
   Nekhlyudov L, 2019, JNCI-J NATL CANCER I, V111, P1120, DOI 10.1093/jnci/djz089
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Noto Y, 2010, J ANESTH, V24, P827, DOI 10.1007/s00540-010-1028-9
   OHara GA, 2017, PLOS NEGLECT TROP D, V11, P0, DOI 10.1371/journal.pntd.0005842
   Office of Cancer Complementary and Alternative Medicine National Cancer Institute, 2016, INT ACT, V0, P0
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Palliyaguru DL, 2016, MOL NUTR FOOD RES, V60, P1342, DOI 10.1002/mnfr.201500756
   Qazi AK, 2018, CARCINOGENESIS, V39, P522, DOI 10.1093/carcin/bgy024
   Rack B, 2010, BREAST CARE, V5, P395, DOI 10.1159/000322677
   Raghavendra RM, 2009, INTEGR CANCER THER, V8, P37, DOI 10.1177/1534735409331456
   Raimi IO, 2020, J HERB MED, V23, P0, DOI 10.1016/j.hermed.2020.100371
   Rao MR, 2009, COMPLEMENT THER MED, V17, P1, DOI 10.1016/j.ctim.2008.05.005
   Reitsma MB, 2017, LANCET, V389, P1885, DOI 10.1016/S0140-6736(17)30819-X
   Rocha V, 2017, J GLOB ONCOL, V3, P701, DOI 10.1200/JGO.2016.006809
   Rojas TR, 2018, INTEGR CANCER THER, V17, P52, DOI 10.1177/1534735416681642
   Rosenbaum E, 2004, SUPPORT CARE CANCER, V12, P293, DOI 10.1007/s00520-004-0599-0
   Rtveladze K, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0068785
   Ruiz GG, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0159857
   Samano Eliana Sueco Tibana, 2004, SAO PAULO MED. J., V122, P60
   Sánchez Ricardo, 2015, REV. SALUD PÚBLICA, V17, P699, DOI 10.15446/rsap.v17n5.38695
   Araújo MDS, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/676984
   Shah SC, 2019, J GLOB ONCOL, V5, P0, DOI 10.1200/JGO.18.00200
   Shetty N, 2019, INDIAN J MED PAEDIAT, V40, P365, DOI 10.4103/ijmpo.ijmpo_200_17
   Shipkowski KA, 2018, FOOD CHEM TOXICOL, V118, P963, DOI 10.1016/j.fct.2018.04.007
   Sitarek P, 2020, CANCERS, V12, P0, DOI 10.3390/cancers12102957
   Smith MC, 2003, ALTERN THER HEALTH M, V9, P40
   Soden K, 2004, PALLIATIVE MED, V18, P87, DOI 10.1191/0269216304pm874oa
   Soerjomataram I, 2012, BMC MED RES METHODOL, V12, P0, DOI 10.1186/1471-2288-12-125
   Stubbe Dorothy E, 2018, FOCUS (AM PSYCHIATR PUBL), V16, P60, DOI 10.1176/appi.focus.20170052
   Sun LY, 2017, J GLOB ONCOL, V3, P692, DOI 10.1200/JGO.2016.007955
   Sun LY, 2018, INTEGR CANCER THER, V17, P885, DOI 10.1177/1534735418777117
   Sun LY, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211020105
   Sundararajan R, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2019-033410
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Swarm R A, 2019, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY, V0, P0
   Tauchen J, 2019, NAT PROD RES, V33, P2718, DOI 10.1080/14786419.2018.1462180
   Thomson CA, 2016, CONTEMP CLIN TRIALS, V49, P181, DOI 10.1016/j.cct.2016.07.005
   Tian GH, 2021, J EVID-BASED MED, V14, P65, DOI 10.1111/jebm.12420
   Tiloke C, 2018, BIOMED PHARMACOTHER, V108, P457, DOI 10.1016/j.biopha.2018.09.060
   Toth M, 2013, J ALTERN COMPLEM MED, V19, P650, DOI 10.1089/acm.2012.0466
   Tovey P, 2006, INTEGR CANCER THER, V5, P232, DOI 10.1177/1534735406291493
   Trimble EL, 2017, J NATL CANCER INST M, V2017, P0
   Tröndle M, 2021, COMPLEMENT THER MED, V58, P0, DOI 10.1016/j.ctim.2021.102681
   Velicer CM, 2008, J CLIN ONCOL, V26, P665, DOI 10.1200/JCO.2007.13.5905
   Viscuse PV, 2017, CURR OPIN ONCOL, V29, P235, DOI 10.1097/CCO.0000000000000376
   Vyas Purvi, 2010, AYU, V31, P417, DOI 10.4103/0974-8520.82029
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wang LM, 2017, JAMA-J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596
   Ward ZJ, 2021, LANCET ONCOL, V22, P1301, DOI 10.1016/S1470-2045(21)00403-4
   Weeks J, 2020, J ALTERN COMPLEM MED, V26, P82, DOI 10.1089/acm.2020.29082.jjw
   WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, V0, P1
   WHO, 2013, WORLD MALARIA REPORT 2013, V0, P1
   Wild CP, 2020, WORLD CANCER REPORT: CANCER RESEARCH FOR CANCER PREVENTION, V0, P0
   Williams AF, 2002, EUR J CANCER CARE, V11, P254, DOI 10.1046/j.1365-2354.2002.00312.x
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   World Health Organization, 2012, WORLD HEALTH ORGAN TECH REP SER, V0, P1
   World Health Organization, 2002, PROGRAMME ON TRADITIONAL MEDICINE. WHO TRADITIONAL MEDICINE STRATEGY 2002-2005, V0, P0
   Wu M, 2015, ONCOTARGET, V6, P38283, DOI 10.18632/oncotarget.5711
   Würtzen H, 2013, EUR J CANCER, V49, P1365, DOI 10.1016/j.ejca.2012.10.030
   Xiang Y, 2018, J PAIN RES, V11, P83, DOI 10.2147/JPR.S152743
   Xu YC, 2020, J PAIN SYMPTOM MANAG, V59, P966, DOI 10.1016/j.jpainsymman.2019.10.018
   Xu Yun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP19, DOI 10.1093/jncimonographs/lgx015
   Yang MX, 2021, BIOMED PHARMACOTHER, V140, P0, DOI 10.1016/j.biopha.2021.111727
   Yang MX, 2021, PHYTOMEDICINE, V82, P0, DOI 10.1016/j.phymed.2021.153459
   Yeh HC, 2020, OBESITY, V28, P1678, DOI 10.1002/oby.22936
   Yeung KS, 2018, ONCOLOGY-NY, V32, P516
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zainal NZ, 2013, PSYCHO-ONCOLOGY, V22, P1457, DOI 10.1002/pon.3171
   Zeng YC, 2018, INTEGR CANCER THER, V17, P737, DOI 10.1177/1534735418777109
   Zetzl T, 2021, SUPPORT CARE CANCER, V29, P2973, DOI 10.1007/s00520-020-05794-2
   Zhang YB, 2020, BRIT J CANCER, V122, P1085, DOI 10.1038/s41416-020-0741-x
NR 232
TC 325
Z9 376
U1 9
U2 178
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-9235
EI 1542-4863
J9 CA-CANCER J CLIN
JI CA-Cancer J. Clin.
PD MAR 15
PY 2022
VL 72
IS 2
BP 144
EP 164
DI 10.3322/caac.21706
EA NOV 2021
PG 21
WC Oncology
SC Oncology
GA ZO0AX
UT WOS:000715927300001
PM 34751943
DA 2026-01-16
ER

PT J
AU Cózar, L
   Reyes, A
   Núñez, C
   López-Martínez, AE
   Serrano-Ibáñez, ER
   Esteve, R
   Marcos, E
   Ramírez-Maestre, C
AF Cozar, Luz
   Reyes, Angela
   Nunez, Cristina
   Lopez-Martinez, Alicia E.
   Serrano-Ibanez, Elena R.
   Esteve, Rosa
   Marcos, Estefania
   Ramirez-Maestre, Carmen
TI VARIABLES PSICOL?GICAS IMPLICADAS EN EL ABUSO O CONSUMO INDEBIDO DE OPIOIDES EN PACIENTES CON DOLOR CR?NICO NO ONCOL?GICO br
SO BEHAVIORAL PSYCHOLOGY-PSICOLOGIA CONDUCTUAL
LA English
DT Article
DE Self-enhancing humor; neuroticism; extraversion; chronic pain; opioids; abuse
ID chronic pain patients; prescription; prevalence; validation; mortality; screener; health; humor
AB Psychological variables can be used to predict the risk of prescription opioid abuse. The aim of the present study was to analyse the predictive value of a set of these variables. Specifically, we analysed the association between the potential abuse and misuse of opioids and self-affirming mood, neuroticism, extraversion, anxiety and/or depression symptoms, and perceived pain intensity. The sample comprised 60 patients with chronic non-oncological pain (mean age= 60 years; 77% women, 78% married). Two stepwise multiple linear regression analyses were performed. The results indicate that anxiety and/or depression symptoms were the only variables associated with the potential abuse and current misuse of prescription opioids. We suggest the need for prior psychological assessment before deciding to initiate pharmacological therapy with opioids. Any anxiety or depression symptoms in these patients should be addressed before prescribing opioids.
C1 [Cozar, Luz; Reyes, Angela; Nunez, Cristina; Lopez-Martinez, Alicia E.; Serrano-Ibanez, Elena R.; Esteve, Rosa; Marcos, Estefania; Ramirez-Maestre, Carmen] Univ Malaga, Malaga, Spain.
C3 Universidad de Malaga
RP Serrano-Ibáñez, ER (corresponding author), Univ Malaga, Dept Personalidad Evaluac & Tratamiento Psicol, Fac Psicol, Malaga 29071, Spain.
EM elenarserrano@uma.es
CR Arteta J, 2016, PAIN MED, V17, P295, DOI 10.1111/pme.12886
   Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Butler SF, 2008, J PAIN, V9, P360, DOI 10.1016/j.jpain.2007.11.014
   Butler SF, 2013, PAIN MED, V14, P1032, DOI 10.1111/pme.12098
   Butler SF, 2010, CLIN J PAIN, V26, P770, DOI 10.1097/AJP.0b013e3181f195ba
   Calvo-Falcón R, 2017, REV. SOC. ESP. DOLOR, V24, P313, DOI 10.20986/resed.2017.3550/2016
   Camacho L, 2002, REVISTA DE PSICOLOGIA DE LA SALUD, V14, P3
   Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009
   Cicero TJ, 2009, PAIN, V144, P20, DOI 10.1016/j.pain.2009.01.026
   Collado A, 2004, REV SOC ESPAR IOLA D, V11, P203
   Coloma-Carmona A, 2017, REV CLIN ESP, V217, P315, DOI 10.1016/j.rce.2017.03.007
   Dubey C, 2010, J INDIAN ACAD APPL P, V36, P107
   Dueñas M, 2015, PAIN MED, V16, P811, DOI 10.1111/pme.12640
   Mesas AE, 2011, MED CLIN-BARCELONA, V137, P55, DOI 10.1016/j.medcli.2010.09.006
   Domínguez MJF, 2018, ATEN PRIM, V50, P39, DOI 10.1016/j.aprim.2018.09.003
   Fernandez-Castillo A, 2007, BEHAV PSYCHOL, V15, P281
   Ferrari R, 2014, PAIN RES TREAT, V2014, P0, DOI 10.1155/2014/584986
   Gatchel RJ, 2007, PSYCHOL BULL, V133, P581, DOI 10.1037/0033-2909.133.4.581
   Serecigni JG, 2018, ADICCIONES, V30, P87, DOI 10.20882/adicciones.936
   Ibanez MI, 1999, ANALISIS Y MODIFICACION DE CONDUCTA, V25, P849
   Jaiswal A, 2016, HEALTHCARE-BASEL, V4, P0, DOI 10.3390/healthcare4020034
   Jarana L, 1990, APUNTES PSICOLOGIA, V30, P17
   Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3
   Kaiser U, 2017, PAIN, V158, P1853, DOI 10.1097/j.pain.0000000000000902
   Kaye AD, 2017, PAIN PHYSICIAN, V20, P0
   Kornor H, 2007, BMC PSYCHIATRY, V7, P0, DOI 10.1186/1471-244X-7-37
   Kumar A, 2015, INT J ED PSYCHOL RES, V4, P87
   Langley Paul C, 2011, J MED ECON, V14, P367, DOI 10.3111/13696998.2011.583303
   Carballo JL, 2016, PAPEL PSICOL, V37, P45
   Martin RA, 2003, J RES PERS, V37, P48, DOI 10.1016/S0092-6566(02)00534-2
   Martin RA, 2004, HUMOR, V17, P1, DOI 10.1515/humr.2004.005
   Mendiburo A, 2011, BOLET N PSICOLOG A, V102, P89
   Muriel J, 2018, ANALES DE LA REAL ACADEMIA NACIONAL DE FARMACIA, V84, P204
   Nordmann S, 2013, PAIN PHYSICIAN, V16, P89
   OBrien T, 2017, EUR J PAIN, V21, P3, DOI 10.1002/ejp.970
   PARDO A, 2005, ANALISIS DE DATOS CON SPSS 13 BASE, V0, P0
   Passik SD, 2011, PAIN MED, V12, PS36, DOI 10.1111/j.1526-4637.2011.01130.x
   Perez M, 2018, REV INVESTIGACION ED, V3, P2530, DOI 10.37536/RIECS.2018.3.1.71
   Pérez-Aranda A, 2019, EUR J PAIN, V23, P220, DOI 10.1002/ejp.1309
   Puebla Diaz F, 2005, ONCOLOGIA (MADRID), V28, P33
   Quintana JM, 2003, ACTA PSYCHIAT SCAND, V107, P216, DOI 10.1034/j.1600-0447.2003.00062.x
   Ramirez C, 2001, ANALES DE PSICOLOGIA, V17, P129
   Ramírez-Maestre C, 2020, EUR J PAIN, V24, P1357, DOI 10.1002/ejp.1583
   Ray WA, 2016, JAMA-J AM MED ASSOC, V315, P2415, DOI 10.1001/jama.2016.7789
   Rodríguez MJ, 2006, REV. SOC. ESP. DOLOR, V13, P525
   Espinar SS, 2016, REVISTA DE PSICOLOGÍA DE LA SALUD, V4, P93, DOI 10.21134/pssa.v4i1.917
   Secades R, 2003, PSICOTHEMA, V15, P650
   Miñana JS, 2012, ATEN PRIM, V44, P335, DOI 10.1016/j.aprim.2011.06.009
   Soriano J, 2005, B PSICOL, V84, P91
   Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087
   Vicente-Herrero MT, 2016, REV. SOC. ESP. DOLOR, V23, P64
   Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0
   WASSERTHEIL S, 1970, BIOMETRICS, V26, P588, DOI 10.2307/2529115
   Wilsey BL, 2008, PAIN MED, V9, P1107, DOI 10.1111/j.1526-4637.2007.00401.x
NR 54
TC 0
Z9 0
U1 0
U2 8
PU FUNDACION VECA PARA AVANCE PSICOLOGIA
PI GRANADA
PA APARTADO CORREOS 1245, GRANADA, 18080, SPAIN
SN 1132-9483
EI 
J9 BEHAV PSYCHOL
JI Behav. Psychol.
PD JUN 15
PY 2022
VL 30
IS 2
BP 517
EP 532
DI 10.51668/bp.8322211s
PG 16
WC Psychology, Clinical
SC Psychology
GA 5A8BQ
UT WOS:000863107000001
DA 2026-01-16
ER

PT J
AU Yao, ZQ
   Xu, ZB
   Xu, TL
   Liu, XW
   Xu, S
   Wan, CJ
   Zhou, X
AF Yao, Ziqian
   Xu, Zhongbo
   Xu, Tielong
   Liu, Xiaowu
   Xu, Sheng
   Wan, Chanjun
   Zhou, Xu
TI Moxibustion for alleviating chemotherapy-induced gastrointestinal adverse effects: A systematic review of randomized controlled trials
SO COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE
LA English
DT Review
DE Moxibustion; Gastrointestinal adverse effects; Chemotherapy; Malignant tumours; Systematic review
ID ulcerative-colitis; acupuncture; nausea
AB Objective: This systematic review aims to assess whether moxibustion is effective and safe for gastrointestinal adverse effects, a common and thorny issue arising from chemotherapy. Methods: Seven electronic databases were searched up to August 28, 2021, to identify randomized controlled trials (RCTs) comparing moxibustion versus non-moxibustion treatments for various gastrointestinal adverse effects after chemotherapy. The Karnofsky performance status (KPS) and quality of life scores and the incidence of moxibustion-related adverse events were also investigated. Effects in meta-analyses were measured by risk ratios (RRs) or mean differences (MDs). Results: Thirty-two RCTs (n = 2990) were included. Compared to the controls, moxibustion significantly reduced the incidences of nausea/vomiting (RR 0.70, 95% CI 0.61-0.79), severe nausea/vomiting (RR 0.39, 95% CI 0.29-0.51), diarrhoea (RR 0.56, 95% CI 0.38-0.82), constipation (RR 0.59, 95% CI 0.44-0.78), and abdominal distension (RR 0.60, 95% CI 0.46-0.78). The KPS (MD 7.53, 95% CI 3.42-11.64) and quality of life (MD 8.88, 95% CI 0.96-16.80) scores were also significantly improved after moxibustion. The results did not support a benefit of moxibustion on inappetence (RR 0.69, 95% CI 0.40-1.22) or abdominal pain (RR 0.60, 95% CI 0.28-1.30). All adverse events related to moxibustion were mild. Conclusions: Moderate-to very-low-quality evidence suggests that moxibustion may be safely used as an adjuvant treatment after chemotherapy to reduce the incidences of nausea and vomiting, diarrhoea, constipation, and abdominal distension and improve the performance status and quality of life in patients with malignant tumours. Its effects on abdominal pain and inappetence are uncertain.
C1 [Yao, Ziqian; Xu, Tielong; Liu, Xiaowu; Xu, Sheng; Zhou, Xu] Jiangxi Univ Chinese Med, Evidence based Med Res Ctr, Nanchang, Peoples R China.
   [Xu, Zhongbo] Jiangxi Univ Chinese Med, Dept Emergency, Affiliated Hosp, Nanchang, Peoples R China.
   [Wan, Chanjun] Jiangxi Univ Chinese Med, Dept Cardiol, Affiliated Hosp, Nanchang, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine
RP Zhou, X (corresponding author), Jiangxi Univ Chinese Med, Evidence based Med Res Ctr, Nanchang, Peoples R China.; Wan, CJ (corresponding author), Jiangxi Univ Chinese Med, Dept Cardiol, Affiliated Hosp, Nanchang, Peoples R China.
EM yaoziqian@hotmail.com; 103977986@qq.com; jxciq_xtl@126.com; lxw970309@163.com; 29576964@qq.com; vanjun86@163.com; zhouxu_ebm@hotmail.com
FU National Natural Science Foundation China [81904057]; Degree and Postgraduate Education Reform Project of Jiangxi University of Chinese Medicine [JZYJG-19-05]; Education Science 13th Five-year Plan Project of Jiangxi Province [20YB148]; Teaching Reform Project of Colleges and Universities Jiangxi province [JXJG-19-12-14]; Jiangxi University of Chi-nese Medicine [5142001011]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Adel Nelly, 2017, AM J MANAG CARE, V23, P0
   Apfel CC, 1900, V350, V0, P0
   Bao CH, 2019, WORLD J GASTROENTERO, V25, P4696, DOI 10.3748/wjg.v25.i32.4696
   Cao J, 2019, THESIS HUNAN U CHINE, V0, P0
   Chen F, 2015, CHINESE NURSING RES, V20, P990
   Choi TY, 2017, MATURITAS, V100, P33, DOI 10.1016/j.maturitas.2017.03.314
   Cui D, 2010, J CHANGCHUN U CHIN M, V26, P390
   Cui JW, 2021, VET SCI, V8, P0, DOI 10.3390/vetsci8080149
   El Kheir DYM, 2019, J TAIBAH UNIV MED SC, V14, P448, DOI 10.1016/j.jtumed.2019.08.004
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688
   Friendlander AH, 2009, SPEC CARE DENT, V29, P147, DOI 10.1111/j.1754-4505.2009.00088.x
   Gervais C, 2016, B CANCER, V103, P794, DOI 10.1016/j.bulcan.2016.05.010
   Gottschling S, 2008, KLIN PADIATR, V220, P365, DOI 10.1055/s-0028-1086039
   Guo J, 2013, J BETHUNE MILITARY M, V11, P553
   Hao Z, 2014, THESIS NANJING U TRA, V0, P0
   2011, 1900, V343, V0, PPD5928, DOI 10.1136/BMJ.D5928
   Hu JJ, 2020, ANN PALLIAT MED, V9, P709, DOI 10.21037/apm.2020.02.31
   Hua Q, 2014, HEILONGJIANG MED J, V38, P588
   Huang Q, 2009, CHIN J NEW CLIN MED, V2, P1134
   Huang Q, 2008, J GUANGXI MED U, V25, P121
   IWA M, 1994, AM J CHINESE MED, V22, P119, DOI 10.1142/S0192415X94000152
   Lan HX, 2013, J GUANGXI U CHIN MED, V16, P37, DOI 10.3969/J.ISSN.1008-7486.2013.02.016
   Lee DH, 2010, BMC GASTROENTEROL, V10, P0, DOI 10.1186/1471-230X-10-36
   Lee MS, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-130
   Lee SU, 2020, J ORTHOP SURG RES, V15, P0, DOI 10.1186/s13018-020-02060-3
   Li J, 2018, POPUL SCI TECHNOL, V20, P29
   Li SQ, 1900, V2021, V0, P0, DOI DOI 10.1007/s11655-11021-13450-11652
   Li X, 2017, CHIN J URBAN RURAL E, V32, P91
   Li Y, 2016, CLINICAL RESEARCH WITH MEDICINE MOXA MOXIBUSTION ON CHEMOTHERAPY INDUCED NAUSEA AND VOMITING, V0, P0
   Liang X, 2016, CHIN J WOMAN CHILD H, V27, P557
   Lin L, 2020, LASER MED SCI, V35, P823, DOI 10.1007/s10103-019-02863-9
   Lin MJ, 2019, TRADITIONAL CHINESE MEDICINE, V41, P1205, DOI 10.3760/cma.j.issn.1673-4246.2019.11.012
   Liu C, 2016, CLIN J CHIN MED, V8, P92
   Liu Li, 2017, ZHEN CI YAN JIU, V42, P240
   Liu Q, 2013, GUIDE CHIN MED, V11, P752
   Liu Y, 2021, CHIN J CONVALESCENT, V30, P382
   Long S, 2012, J NEW CHIN MED, V44, P138
   Lu Y, 2014, CLIN J CHIN MED, V6, P34
   Ma Y, 2015, HUNAN J TRADIT CHIN, V11, P95
   McGuire S, 2016, ADV NUTR, V7, P418, DOI 10.3945/an.116.012211
   Palmer MK, 1979, BR J CANCER, V45, P484
   Qin-Feng Huang, 2007, ZHONGGUO ZHEN JIU, V27, P769
   Qiu C, 2008, CHIN J MODERN NURS, V0, P352
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Shi M, 2018, CHIN J OTORHINOLARYN, V26, P69
   李玲, 2016, 时珍国医国药 LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH, V27, P1417
   Simino GP, 1900, V9, V0, P0
   Song Q, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019480
   Stein DJ, 2017, GASTROENTEROL CLIN N, V46, P875, DOI 10.1016/j.gtc.2017.08.015
   Su Q, 2015, MOD NURS, V0, P73
   Tang BZ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/5105108
   Tang HY, 2021, ANN TRANSL MED, V9, P0, DOI 10.21037/atm-21-2779
   Tao Y, 2018, CLIN J CHIN MED, V10, P55
   Tian Y, 2012, GUANGMING J CHIN MED, V27, P2043
   Wang Wen-Yan, 2020, ZHEN CI YAN JIU, V45, P771, DOI 10.13702/j.1000-0607.190881
   Wang Y, 2019, WOMENS HLTH RES, V27, P25
   Webster Kimberly, 2003, HEALTH QUAL LIFE OUTCOMES, V1, P79, DOI 10.1186/1477-7525-1-79
   Wu C, 2017, CHIN MED MODERN DIST, V15, P116
   Wu HG, 1999, WORLD J GASTROENTERO, V5, P515
   Xu S, 2010, THE CLINICAL STUDY OF MOXIBUSTION PREVENTING AND CONTROLLING NAUSEA AND VOMIT BY BREAST CHEMORADIOTHERAPY, V0, P0
   Xu X, 2017, TRADIT CHIN MED RES, V30, P58
   Xu Y, 2014, THESIS NANJING U TRA, V0, P0
   Yang LL, 2021, ANN PALLIAT MED, V10, P3988, DOI 10.21037/apm-20-1266
   Yao F, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8645727
   Yao J, 2018, THESIS GUANGZHOU U T, V0, P0
   [姚望 Yao Wang], 2019, 中国肿瘤临床 CHINESE JOURNAL OF CLINICAL ONCOLOGY, V46, P780
   Ye H, 2015, CLIN J CHIN MED, V7, P120
   Yi J, 2019, CONTEMP MED, V25, P113, DOI 10.3969/J.ISSN.1009-4393.2019.35.043
   Yu Shu-Guang, 2018, ZHEN CI YAN JIU, V43, P747, DOI 10.13702/j.1000-0607.180623
   Zhang M, 2017, SHAANXI J TRADIT CHINESE MED, V38, P1690, DOI 10.3969/J.ISSN.1000-7369.2017.12.024
   Zhang Na, 2014, ZHEN CI YAN JIU, V39, P508
   Zhang X, 2019, J QIQIHAR MED U, V40, P1359
   Zhang Y, 2015, J MED INFORM, V29, P181
   钟少文, 2011, 中药材 JOURNAL OF CHINESE MEDICINAL MATERIALS, V34, P1007
   Zhou X, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6128673
   Zhu LP, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2890465
   [左晓琳 Zuo Xiaolin], 2016, 中国循证医学杂志 CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE, V16, P828
NR 79
TC 13
Z9 14
U1 1
U2 62
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1744-3881
EI 1873-6947
J9 COMPLEMENT THER CLIN
JI Complement. Ther. Clin. Pract.
PD FEB 15
PY 2022
VL 46
IS 
BP 
EP 
DI 10.1016/j.ctcp.2021.101527
EA JAN 2022
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 0X3RQ
UT WOS:000789628400014
PM 34999499
DA 2026-01-16
ER

PT J
AU Katta, MR
   Valisekka, SS
   Agarwal, P
   Hameed, M
   Shivam, S
   Kaur, J
   Prasad, S
   Bethineedi, LD
   Lavu, DV
   Katamreddy, Y
AF Katta, Maanya Rajasree
   Valisekka, Sai Sudha
   Agarwal, Pahel
   Hameed, Maha
   Shivam, Swadha
   Kaur, Jasneet
   Prasad, Sakshi
   Bethineedi, Lakshmi Deepak
   Lavu, Diti Vinuthna
   Katamreddy, Yamini
TI Non-pharmacological integrative therapies for chronic cancer pain.
SO Journal of oncology pharmacy practice : official publication of the International
LA English
DT Review
DE Chronic cancer pain; non-pharmacological; patient education; physical therapy; psychosocial therapy
AB OBJECTIVE: Chronic pain is one of the most detrimental symptoms exhibited by  cancer patients, being an indication for opioid therapy in up to half of the  patients' receiving chemotherapy and in 90% of advanced cases. Various successful  non-pharmacological integrative therapy options have been explored and  implemented to improve the quality of life in these patients. This review aims to  highlight the mechanisms implicated; assessment tools used for cancer pain and  summarize current evidence on non-pharmacological approaches in the treatment of  chronic cancer pain. DATA SOURCES: A review of the literature was conducted using  a combination of MeSH keywords including "Chronic cancer pain," "Assessment,"  "Non-pharmacological management," and "Integrative therapy." DATA SUMMARY: Data  on the approach and assessment of chronic cancer pain as well as  non-pharmacological integrative options have been displayed with the help of  figures and tables. Of note, non-pharmacological integrative management was  divided into three subcategories; physical therapy (involving exercise,  acupuncture, massage, and transcutaneous electric nerve stimulation),  psychosocial therapy (e.g. mindful practices, supportive therapy), and herbal  supplementation. CONCLUSIONS: The use of non-pharmacological integrative therapy  in the management of chronic cancer pain has been grossly underestimated and must  be considered before or as an adjuvant of other treatment regimens to ensure  appropriate care.
C1 28577Gandhi Medical College, Hyderabad, Telangana, India.
   77058Sri Venkateshwara Medical College, Tirupati, AP, India.
   77034Bhaskar Medical College, Hyderabad, Telangana, India.
   288867AlFaisal University, College of Medicine, Riyadh, Kingdom of Saudi Arabia.
   77034Bhaskar Medical College, Hyderabad, Telangana, India.
   75257Government Medical College, Amritsar, India.
   Faculty of Medicine, National Pirogov Memorial Medical University, Vinnytsya, Ukraine.
   77033Andhra Medical College, Visakhapatnam, AP, India.
   28664Siddhartha Medical College, AP, India.
   24430West Anaheim Medical Center, CA, USA.
NR 0
TC 0
SN 1477-092
EI 
J9 J Oncol Pharm Pract
PD MAY 10
PY 2022
VL 28
IS 8
BP 1859
EP 1868
DI 10.1177/10781552221098437
PG 9
WC Humans; Chronic Pain; therapy; Quality of Life; Cancer Pain; therapy; Massage; Neoplasms; complications
UT PubMed:35532081
PM 35532081
DA 2022-05-10
ER

PT J
AU Caiado-Vencio, R
   Raffa, PEAZ
   Lopes, BM
   Cobucci, FLR
   Vieira, RVG
   Franceschini, PR
   de, Aguiar PHP
AF Caiado-Vencio, Rafael
   Raffa, Paulo Eduardo Albuquerque Zito
   Lopes, Bruna Marques
   Cobucci, Fernanda Lopes Rocha
   Vieira, Raphael Vinícius Gonzaga
   Franceschini, Paulo Roberto
   de Aguiar, Paulo Henrique Pires
TI Success of lateral cervical spinal cord stimulation for the treatment of chronic
SO Surgical neurology international
LA English
DT Journal Article
DE Epidural lead; Lateral spinal cord; Neurostimulation; Schwannoma; Spinal cord stimulation
AB BACKGROUND: Spinal cord stimulation (SCS) is traditionally performed by  implanting surgical leads along the midline of the spinal cord, over the dorsal  columns. Here, we present a patient who successfully underwent lateral cervical  SCS to treat chronic refractory neuropathic pain. METHODS: A 46-year-old female,  with a schwannoma involving the right axillary nerve, presented with a chronic  refractory right upper extremity pain syndrome. The tumor was located between the  fibers of the teres minor and the posterior deltoid, and measured 2.2 cm in  diameter. After 8 months of analgesics, opioids, physiotherapy, and acupuncture,  the patient underwent surgery; however, the tumor was unresectable (i.e., due to  significant adjacent vascular/neural structures). Three months later, she had a  midline C6-C7 laminectomy for placement of a right-sided epidural SCS lead (i.e.,  containing 16 electrode contacts). RESULTS: Within 4 days following this SCS  procedure, the patient's pain completely resolved; at 10 postoperative months,  she still remains pain free. CONCLUSION: Lateral SCS at the C6-C7 level provided  a safe and effective option for the relief of chronic neuropathic pain attributed  to an unresectable schwannoma of the right axillary nerve in a 46-year-old  female.
C1 Department of Medicine, Pontifical Catholic University of Goiás, Goiânia, Goiás, Brazil.
   Department of Medicine, Catanduva Medical School (FAMECAUNIFIPA), Catanduva, Brazil.
   Department of Medicine, Faculty of Medical Sciences, Santa Casa de São Paulo, Brazil.
   Department of Medicine, Faculdade de Medicina do ABC, Brazil.
   Department of Neurosurgery, Santa Paula Hospital, São Paulo, Brazil.
   Department of Neurology and Neurosurgery, University of Caxias do Sul, Rio Grande do Sul, Brazil.
   Department of Neurology, Pontifical Catholic University of São Paulo, Sao Paulo, Brazil.
NR 0
TC 0
SN 2152-780
EI 2229-509
J9 Surg Neurol Int
PD MAR 5
PY 2022
VL 13
IS 
BP 52
EP 52
DI 10.25259/SNI_853_2021
PG 0
UT PubMed:35242418
PM 35242418
DA 2022-03-05
ER

PT J
AU Wei, J
   Yang, Z
   Lin, Q
   Xu, H
   Lai, F
   Han, Y
   Li, J
   Cui, S
AF Wei, Jinqiang
   Yang, Zihong
   Lin, Qiutian
   Xu, Haiyan
   Lai, Fang
   Han, Yun
   Li, Jun
   Cui, Shuai
TI Bibliometric and visualized analysis of electroacupuncture in the past 10 years.
SO Complementary therapies in medicine
LA English
DT Journal Article
DE CiteSpace; Cooperation; Electroacupuncture; Research status
AB BACKGROUND: There are many studies that have interrogated the evolution and use  of electroacupuncture (EA). We aimed to evaluate the research status, cooperation  and development of EA in the past 10 years. METHODS: We obtained data on the EA  from the Web of Science core collection database. CiteSpace 5.7. R1 software was  used to assess research cooperation through analysis of authors, institutions and  countries. In addition, keyword cluster analysis, references and burst detection  were analyzed to explore research hotspots and trends in the field of EA.  RESULTS: We included a total of 3019 citing literature and 78,235 cited  literature for analysis. The data showed that there has been a rise in the global  number of EA studies in the past decade. Besides, the data demonstrated that  China has made outstanding contribution in the development of EA. Whereas there  is inter-agency cooperation in China, there is less cooperation with other  countries. In addition, we showed frequent use of keywords such as "expression",  "stimulation", or "pain". Besides, neuroscience was the main research area,  followed by general medicine and oncology. Furthermore, with the improved  research methods and technologies, there is enhanced overall quality of the  studies. CONCLUSION: Taken together, our findings demonstrate a steady increase  in the studies involving EA. However, the studies are unevenly distributed among  countries and thus there is need for closer international cooperation.
C1 The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
   The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
   The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
   The Seventh Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
   The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
   The Second Affiliated Hospital of Guangzhou University ofChinese Medicine, Guangzhou, China
   Chao En-Xiang Famous Chinese Medicine ExpertInheritance Studio, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou,Guangdong, China. 
   The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
   The Second Affiliated Hospital of Guangzhou University ofChinese Medicine, Guangzhou, China
   Chao En-Xiang Famous Chinese Medicine ExpertInheritance Studio, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou,Guangdong, China.
   The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China
   The Second Affiliated Hospital of Guangzhou University ofChinese Medicine, Guangzhou, China.
   Research Institute of Acupuncture and Meridian, Anhui University of Chinese Medicine, Hefei, China
   South China Research Center for Acupuncture &Moxibustion, Medical College of Acupuncture-Moxibustion and Rehabilitation,Guangzhou University of Chinese Medicine, Guangzhou, China.
EM 13016090@qq.com
NR 0
TC 0
SN 1873-696
EI 
J9 Complement Ther Med
PD JUN 11
PY 2022
VL 69
IS 
BP 102846
EP 102846
DI 10.1016/j.ctim.2022.102846
PG 0
WC Bibliometrics; China; Electroacupuncture; Humans; Publications; Software
UT PubMed:35688327
PM 35688327
DA 2022-06-11
ER

PT J
AU El Iskandarani, S
   Deng, GRY
AF El Iskandarani, Sarah
   Deng, Gary
TI Acupuncture in hematologic malignancies and hematopoietic cell transplantation
SO BLOOD REVIEWS
LA English
DT Review
DE Acupuncture; Cancer symptoms; Lymphoma; Leukemia; Integrative medicine
ID chemotherapy-induced nausea; cancer-related fatigue; quality-of-life; pain; complementary; medicine; pathophysiology; management; diagnosis; survivors
AB Acupuncture is an integrative medicine modality that has been used historically and studied recently for man-aging various symptoms and diseases. Patients with hematological malignancies often experience a high symptom burden including pain, fatigue, nausea, vomiting, and insomnia. Pharmacological interventions are the mainstay of managing these symptoms, although they may not provide adequate control or are not well tolerated due to side effects. There have been many randomized controlled trials of acupuncture on reduction of these symptoms. In this review, we will summarize the current evidence on the effect of acupuncture on the man-agement of common symptoms experienced by patients with hematological malignancies and the current un-derstanding of acupuncture's mechanism of action. The evidence is the strongest for reducing pain and nausea vomiting, less strong for symptoms such as peripheral neuropathy, fatigue, constipation, insomnia, night sweat, and pruritus.
C1 [El Iskandarani, Sarah; Deng, Gary] Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center
RP Deng, GRY (corresponding author), Mem Sloan Kettering Canc Ctr, Integrat Med Serv, New York, NY 10065 USA.
EM dengg@mskcc.org
FU Patient -Centered Outcomes Research Institute (PCORI) [CER-2019C1-15392]; NIH/NCI Cancer Center Support Grant [P30 CA008748]; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR ANDERSSON S, 1995, MED HYPOTHESES, V45, P271, DOI 10.1016/0306-9877(95)90117-5
   Arranz L, 2017, BLOOD REV, V31, P306, DOI 10.1016/j.blre.2017.05.001
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bayo J, 2012, CLIN TRANSL ONCOL, V14, P413, DOI 10.1007/s12094-012-0818-y
   Bell TJ, 2009, PAIN MED, V10, P35, DOI 10.1111/j.1526-4637.2008.00495.x
   Bourin M, 2018, SOJ PHARMACY & PHARMACEUTICAL SCIENCES, V5, P1, DOI 10.15226/2374-6866/5/3/00185
   Brondum L, 2022, SCAND J CARING SCI, V36, P1046, DOI 10.1111/scs.12991
   Bryant AL, 2018, ONCOL NURS FORUM, V45, P653, DOI 10.1188/18.ONF.653-664
   Burger R, 2013, TRANSFUS MED HEMOTH, V40, P336, DOI 10.1159/000354194
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   Chon TY, 2019, MED ACUPUNCT, V31, P164, DOI 10.1089/acu.2019.1343
   Chung VCH, 2021, BRIT MED BULL, V137, P70, DOI 10.1093/bmb/ldaa046
   Cohen MZ, 2012, J PAIN SYMPTOM MANAG, V44, P168, DOI 10.1016/j.jpainsymman.2011.08.011
   Colvin LA, 2019, PAIN, V160, PS1, DOI 10.1097/j.pain.0000000000001540
   Copelan EA, 2006, NEW ENGL J MED, V354, P1813, DOI 10.1056/NEJMra052638
   DAMICO JF, 1991, FERTIL STERIL, V55, P754
   De Valois B, 2003, FOCUS ALTERNAT COMPL, V8, P134
   Deng G, 2020, PAIN MED, V21, P636, DOI 10.1093/pm/pnz190
   Deng G, 2018, SUPPORT CARE CANCER, V26, P657, DOI 10.1007/s00520-017-3881-7
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021
   Evans LS, 2003, LANCET, V362, P139, DOI 10.1016/S0140-6736(03)13868-8
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Farmer AD, 2018, LANCET GASTROENTEROL, V3, P203, DOI 10.1016/S2468-1253(18)30008-6
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Gertz MA, 2014, BLOOD, V124, P882, DOI 10.1182/blood-2014-03-544759
   GOBBI PG, 1990, CANCER-AM CANCER SOC, V65, P2074, DOI 10.1002/1097-0142(19900501)65:9<2074::AID-CNCR2820650931>3.0.CO;2-O
   GOBBI PG, 1983, CANCER-AM CANCER SOC, V51, P1934, DOI 10.1002/1097-0142(19830515)51:10<1934::AID-CNCR2820511030>3.0.CO;2-R
   Götze H, 2019, J GERIATR ONCOL, V10, P55, DOI 10.1016/j.jgo.2018.05.011
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Han CH, 2021, CLIN EPIDEMIOL, V13, P907, DOI 10.2147/CLEP.S324193
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Harris P, 1997, COMPLEMENT THER MED, V5, P156, DOI 10.1016/S0965-2299(97)80059-3
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hesketh PJ, 2017, J CLIN ONCOL, V35, P3240, DOI 10.1200/JCO.2017.74.4789
   Ho RST, 2022, INTEGR MED RES, V11, P0, DOI 10.1016/j.imr.2021.100771
   Ho RST, 2021, ACUPUNCT MED, V39, P3, DOI 10.1177/0964528420920299
   Hogberg K, 2019, SOC HLTH BEHAV, V2, P17
   Holm ACES, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/579321
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Hui KKS, 2010, AUTON NEUROSCI-BASIC, V157, P81, DOI 10.1016/j.autneu.2010.03.022
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jiang YH, 2010, CHIN J INTEGR MED, V16, P71, DOI 10.1007/s11655-010-0070-7
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Kaptchuk TJ, 2000, WEB HAS NO WEAVER, V0, P0
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kumar S S, 2003, INDIAN J DERMATOL VENEREOL LEPROL, V69, P12
   Kurzrock R, 2001, CANCER, V92, P1684, DOI 10.1002/1097-0142(20010915)92:6+<1684::AID-CNCR1497>3.0.CO;2-Z
   Langevin Helene M, 2002, ANATOMICAL RECORD, V269, P257, DOI 10.1002/ar.10185
   Lee YH, 2020, CLIN EXP DENT RES, V6, P90, DOI 10.1002/cre2.253
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Li MX, 2019, COMPLEMENT THER MED, V43, P247, DOI 10.1016/j.ctim.2019.02.013
   Li QW, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-00333-x
   Manchikanti L, 2018, EXPERT REV ANTICANC, V18, P705, DOI 10.1080/14737140.2018.1474103
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   McCrae CS, 2020, J SLEEP RES, V29, P0, DOI 10.1111/jsr.13020
   MDAnderson, 2021, ADULT ANTIEMETIC MAN, V0, P0
   Mesía R, 2019, CURR TREAT OPTION ON, V20, P0, DOI 10.1007/s11864-019-0686-6
   Meyer-Hamme G, 2021, J DIABETES, V13, P469, DOI 10.1111/1753-0407.13130
   Mu JL, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD013814
   Muacevic A, 2021, CUREUS J MED SCIENCE, V12, P0
   Navari RM, 2016, NEW ENGL J MED, V374, P1356, DOI 10.1056/NEJMra1515442
   NIH, 2021, DRUGS APPROVED DIFFE, V0, P0
   Niscola P, 2008, BONE MARROW TRANSPL, V41, P757, DOI 10.1038/bmt.2008.3
   Niscola P, 2011, INDIAN J PALLIAT CAR, V17, P175, DOI 10.4103/0973-1075.92333
   Niscola P, 2011, EXPERT REV HEMATOL, V4, P81, DOI 10.1586/ehm.10.79
   Oerlemans S, 2013, HAEMATOLOGICA, V98, P479, DOI 10.3324/haematol.2012.064907
   Ouyang Ba-Si, 2010, ZHONGGUO ZHEN JIU, V30, P840
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Quasthoff S, 2002, J NEUROL, V249, P9, DOI 10.1007/PL00007853
   Rischer J, 2009, BONE MARROW TRANSPL, V44, P121, DOI 10.1038/bmt.2008.430
   Rosenberg SM, 2013, J THORAC DIS, V5, PS55, DOI 10.3978/j.issn.2072-1439.2013.06.20
   Smith CA, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004046.pub4
   Song GQ, 2019, INFLAMM BOWEL DIS, V25, P1129, DOI 10.1093/ibd/izy371
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Stone JAM, 2010, CURR TREAT OPTION ON, V11, P118, DOI 10.1007/s11864-010-0128-y
   Vendrell I, 2015, MEDIAT INFLAMM, V2015, P0, DOI 10.1155/2015/984570
   Viera AJ, 2003, AM FAM PHYSICIAN, V67, P1019
   Wang XP, 2018, J CANCER RES THER, V14, PS600, DOI 10.4103/0973-1482.183174
   Wang XS, 2002, J CLIN ONCOL, V20, P1319, DOI 10.1200/JCO.20.5.1319
   Wardley AM, 2020, ACUFOCIN RANDOMIZED, V0, P0
   Yosipovitch G, 2010, DERMATOL THER, V23, P590, DOI 10.1111/j.1529-8019.2010.01366.x
   Yu C, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/208690
   Yu Z, 2020, WORLD J GASTROENTERO, V26, P0, DOI 10.3748/wjg.v26.i23.3182
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Yung L, 2003, LANCET, V361, P943, DOI 10.1016/S0140-6736(03)12777-8
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 91
TC 4
Z9 5
U1 2
U2 14
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0268-960X
EI 1532-1681
J9 BLOOD REV
JI Blood Rev.
PD NOV 15
PY 2022
VL 56
IS 
BP 
EP 
DI 10.1016/j.blre.2022.100985
EA OCT 2022
PG 10
WC Hematology
SC Hematology
GA 5U2UP
UT WOS:000876408800004
PM 35725779
DA 2026-01-16
ER

PT J
AU Kwon, K
   Kerin-Ayres, K
   Lacey, JJL
   Grant, S
AF Kwon, K.
   Kerin-Ayres, Kim
   Lacey, Judith J. L.
   Grant, Suzanne
TI Acupuncture for treating a symptom cluster (pain, fatigue, sleep, neuropathy) for women with breast cancer: A feasibility study
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 [Kwon, K.; Lacey, Judith J. L.; Grant, Suzanne] Western Sydney Univ, Natl Inst Complementary Med, Westmead, NSW, Australia.
   [Kerin-Ayres, Kim; Lacey, Judith J. L.; Grant, Suzanne] Chris Obrien Lifehouse, Support Care, Camperdown, NSW, Australia.
   [Lacey, Judith J. L.] Univ Sydney, Med Sch, Sydney, NSW, Australia.
C3 Western Sydney University; Chris O'Brien Lifehouse; University of Sydney
CR Cheng KKF, 2014, EUR J ONCOL NURS, V18, P3, DOI 10.1016/j.ejon.2013.10.005
NR 1
TC 0
Z9 0
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
EI 1743-7563
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD NOV 15
PY 2022
VL 18
IS 
BP 213
EP 214
DI 
PG 2
WC Oncology
SC Oncology
GA 5N7GN
UT WOS:000871956500361
DA 2026-01-16
ER

PT J
AU Kannan, P
   Lam, HY
   Ma, TK
   Lo, CN
   Mui, TY
   Tang, WY
AF Kannan, Priya
   Lam, Hiu Ying
   Ma, Tsz Kiu
   Lo, Chiu Ngai
   Mui, Ting Yan
   Tang, Wing Yan
TI Efficacy of physical therapy interventions on quality of life and upper quadrant pain severity in women with post-mastectomy pain syndrome: a systematic review and meta-analysis
SO QUALITY OF LIFE RESEARCH
LA English
DT Review
DE Acupuncture; Decongestive therapy; Exercise; Post-mastectomy pain syndrome; Quality of Life
ID breast-cancer survivors; exercise therapy; shoulder pain; single-blind; impact; prevalence; program; surgery; trial
AB Purpose To determine the efficacy of physical therapy interventions on quality of life (QoL) and pain severity in post-mastectomy pain syndrome (PMPS). Methods Multiple databases were searched from database inception to October 2020. Searches were limited to human studies published in either English or Chinese in peer-reviewed journals with full text available for randomized controlled trials conducted on females. Trials comparing the effectiveness of physical therapy interventions against control conditions on QoL and pain were included. Results Eighteen trials were included in the review. The pooled analysis of the four exercise trials revealed a significant effect of the intervention on general [standardized mean difference [SMD]: 0.87 (95%CI: 0.36, 1.37); p = 0.001], physical [SMD: 0.34 (95%CI: 0.01, 0.66); p = 0.044], and mental health components [SMD: 0.27 (95%CI: 0.03, 0.51); p = 0.027] of QoL compared with the control condition. Meta-analyses of six exercise trials, two myofascial release trials, and two acupuncture trials revealed a significant improvement in pain severity in the treatment group than in the control group. However, meta-analyses of two studies revealed a non-significant effect of compression therapy compared to control on pain severity. Conclusion Our meta-analyses found that exercise is beneficial for improving the QoL and pain severity of women with PMPS. Future studies are needed to determine the optimal parameters for exercise interventions designed to improve QoL and pain severity in women with PMPS. The effect of acupuncture, myofascial release, and compression therapy remains inconclusive, and future research is required to validate the effect of these interventions on PMPS.
C1 [Kannan, Priya; Lam, Hiu Ying; Ma, Tsz Kiu; Lo, Chiu Ngai; Mui, Ting Yan; Tang, Wing Yan] Hong Kong Polytech Univ, Dept Rehabil Sci, Hung Hom, Kowloon, Hong Kong, Peoples R China.
C3 Hong Kong Polytechnic University
RP Kannan, P (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Hung Hom, Kowloon, Hong Kong, Peoples R China.
EM priya.kannan@polyu.edu.hk
CR Ammitzboll G, 2020, BREAST CANCER RES TR, V179, P173, DOI 10.1007/s10549-019-05461-z
   Unknown -, 2020, J PHYSIOTHER, V66, P59, DOI 10.1016/j.jphys.2019.08.005
   Ashing-Giwa KT, 2009, ONCOL NURS FORUM, V36, P79, DOI 10.1188/09.ONF.79-88
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Beyaz SG, 2016, CHINESE MED J-PEKING, V129, P66, DOI 10.4103/0366-6999.172589
   Bland M, 2015, INT J STAT MED RES, V4, P57, DOI 10.6000/1929-6029.2015.04.01.6
   Caffo O, 2003, BREAST CANCER RES TR, V80, P39, DOI 10.1023/A:1024435101619
   Cantarero-Villanueva I, 2012, PAIN MED, V13, P1509, DOI 10.1111/j.1526-4637.2012.01481.x
   Castro-Martín E, 2017, ARCH PHYS MED REHAB, V98, P832, DOI 10.1016/j.apmr.2016.11.019
   Cheema B, 2008, BREAST CANCER RES TR, V109, P9, DOI 10.1007/s10549-007-9638-0
   Conejo I, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2236-3
   Couceiro Tania Cursino de Menezes, 2009, REV. BRAS. ANESTESIOL., V59, P358
   De Groef A, 2015, ARCH PHYS MED REHAB, V96, P1140, DOI 10.1016/j.apmr.2015.01.006
   Couceiro TCD, 2014, PAIN MANAG NURS, V15, P731, DOI 10.1016/j.pmn.2013.07.011
   Dong XS, 2019, HEALTH QUAL LIFE OUT, V17, P0, DOI 10.1186/s12955-019-1183-0
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   García-Ceberino JM, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17010344
   GONG Y, 2020, MEDICINE, V0, P0
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1303, DOI 10.1016/j.jclinepi.2011.04.014
   Hammond EA, 2020, NEUROREHAB NEURAL RE, V34, P235, DOI 10.1177/1545968319899918
   Hansdorfer-Korzon R, 2016, PATIENT PREFER ADHER, V10, P0, DOI 10.2147/PPA.S108326
   Hoskins CN, 1996, PSYCHO-ONCOLOGY, V5, P31, DOI 10.1002/(SICI)1099-1611(199603)5:1<31::AID-PON210>3.0.CO;2-2
   Hwang JH, 2008, YONSEI MED J, V49, P443, DOI 10.3349/ymj.2008.49.3.443
   Irwin ML, 2008, CANCER-AM CANCER SOC, V112, P2593, DOI 10.1002/cncr.23446
   Johansson K, 2020, LYMPHAT RES BIOL, V18, P129, DOI 10.1089/lrb.2018.0064
   Kuehn T, 2000, BREAST CANCER RES TR, V64, P275, DOI 10.1023/A:1026564723698
   Lee SA, 2010, CLIN REHABIL, V24, P600, DOI 10.1177/0269215510362324
   Liberati A, 2009, ANN INTERN MED, V151, PW65, DOI 10.7326/0003-4819-151-4-200908180-00136
   Ligabue MB, 2019, BREAST CANCER RES TR, V175, P191, DOI 10.1007/s10549-019-05136-9
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Melam GR, 2016, BMC WOMENS HEALTH, V16, P0, DOI 10.1186/s12905-016-0303-9
   Mullen EJ, 2006, RES SOCIAL WORK PRAC, V16, P84, DOI 10.1177/1049731505280950
   Nyrop KA, 2017, ONCOLOGIST, V22, P1238, DOI 10.1634/theoncologist.2017-0174
   Paulo TRS, 2019, HEALTH QUAL LIFE OUT, V17, P0, DOI 10.1186/s12955-019-1090-4
   Paxton RJ, 2012, CANCER-AM CANCER SOC, V118, P4024, DOI 10.1002/cncr.27389
   Pilat A, 2012, FASCIA: THE TENSIONAL NETWORK OF THE HUMAN BODY, V0, P311
   Quinlan-Woodward J, 2016, ONCOL NURS FORUM, V43, P725, DOI 10.1188/16.ONF.725-732
   Serra-Añó P, 2019, SUPPORT CARE CANCER, V27, P2633, DOI 10.1007/s00520-018-4544-z
   Silver J, 2007, J SURG ONCOL, V95, P427, DOI 10.1002/jso.20780
   Singh B, 2018, ARCH PHYS MED REHAB, V99, P2621, DOI 10.1016/j.apmr.2018.03.026
   Tatham B, 2013, PHYSIOTHER CAN, V65, P321, DOI 10.3138/ptc.2012-06
   Lacomba MT, 2010, CLIN J PAIN, V26, P320, DOI 10.1097/AJP.0b013e3181c4904a
   Vacek PM, 2003, QUAL LIFE RES, V12, P527, DOI 10.1023/A:1025098108717
   VINOKUR AD, 1990, CANCER-AM CANCER SOC, V65, P1242, DOI 10.1002/1097-0142(19900301)65:5<1242::AID-CNCR2820650535>3.0.CO;2-1
   Waltho D, 2016, J SURG, V59, P342 350, DOI 10.1503/cjs.000716
   Wan X, 2014, BMC MED RES METHODOL, V14, P0, DOI 10.1186/1471-2288-14-135
   Wenzel LB, 1999, CANCER, V86, P1768, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1768::AID-CNCR19>3.0.CO;2-O
   Zeng YC, 2014, BREAST CANCER-TOKYO, V21, P262, DOI 10.1007/s12282-014-0521-7
NR 50
TC 18
Z9 25
U1 2
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD APR 15
PY 2022
VL 31
IS 4
BP 951
EP 973
DI 10.1007/s11136-021-02926-x
EA JUN 2021
PG 23
WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational Health
GA 0A4WL
UT WOS:000668047300001
PM 34185226
DA 2026-01-16
ER

PT J
AU Prinsloo, S
   Rosenthal, DI
   Garcia, MK
   Meng, ZQ
   Cohen, L
AF Prinsloo, Sarah
   Rosenthal, David, I
   Garcia, Mary Kay
   Meng, Zhiqiang
   Cohen, Lorenzo
TI Cross-Cultural Brain Activity Differences Between True and Sham Acupuncture for Xerostomia During Head and Neck Cancer Radiotherapy
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE placebo; acupuncture; EEG; culture; xerostomia; cancer; radiation
ID radiation-induced xerostomia; resolution electromagnetic tomography; placebo acupuncture; randomized-trial; back-pain; eeg; localization; sensation; contexts; loreta
AB Background: A prior phase III, multicenter (United States and China), clinical trial found true acupuncture (TA) resulted in lower xerostomia scores 12 months after radiotherapy than that of a standard care control group. This small pilot study examined brain function changes comparing TA to sham acupuncture (SA) in US and Fudan patients undergoing head and neck radiotherapy. Methods: To determine cerebral activity during TA versus SA acupuncture, patients underwent electroencephalogram evaluation (EEG) immediately prior, during and after both conditions. Acupuncture occurred during weeks 3 to 5 of radiotherapy, with patients receiving either TA or SA, followed 2 to 3 days later by the other treatment in a counterbalanced manner. Results: In the TA minus SA condition (N = 14 Fudan; N = 13 US), most changes were in the delta (0.5-3.5 Hz) and alpha (8-12 Hz) bandwidths. Delta was present in the frontal gyrus and parahippocampal gyrus. Alpha was present in the anterior and posterior cingulate, lingual gyrus, amygdala, precuneus, medial frontal gyrus, fusiform gyrus, and superior frontal gyrus. Maximal cortical differences in the Fudan cohort between TA and SA were in areas previously shown to be associated with (TA). In the US cohort, maximal differences between TA and SA were associated with areas which are usually decreased in TA conditions. Conclusions: There were distinct differences in brain function between those receiving TA and SA and there were clear differences between cultures, helping to explain the lack of placebo effect in the Fudan participants and strong placebo effect in the US patients.
C1 [Prinsloo, Sarah; Rosenthal, David, I; Garcia, Mary Kay; Cohen, Lorenzo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Meng, Zhiqiang] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China.
C3 University of Texas System; UTMD Anderson Cancer Center; Fudan University
RP Prinsloo, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, 1515 Holcombe Blvd,Unit 1414,FCT5-6006, Houston, TX 77030 USA.
EM SPrinsloo@MDAnderson.org
FU United States National Cancer Institute (NCI) [CA148707]; NCI Cancer Center Support Grant [CA016672]; Richard E. Haynes Distinguished Professorship for Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center; National Center for Complementary and Integrative Health [1K01AT008485-01]; Rising Tide Foundation; American Cancer Society
CR Alahmadi N, 2016, FRONT HUM NEUROSCI, V10, P0, DOI 10.3389/fnhum.2016.00559
   Asghar AU, 2010, BRAIN RES, V1315, P111, DOI 10.1016/j.brainres.2009.12.019
   Bai LJ, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-73
   Bertram U, 1967, ACTA ODONTOL SCAND, V25, P1
   Blom M, 1996, ORAL ONCOL, V32B, P182
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Congedo M, 2004, IEEE T NEUR SYS REH, V12, P387, DOI 10.1109/TNSRE.2004.840492
   Deng G, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-37
   Dierks T, 2000, CLIN NEUROPHYSIOL, V111, P1817, DOI 10.1016/S1388-2457(00)00427-2
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Garcia MK, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.16910
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Han SH, 2014, NEUROIMAGE, V99, P293, DOI 10.1016/j.neuroimage.2014.05.062
   Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083
   Hedden T, 2008, PSYCHOL SCI, V19, P12, DOI 10.1111/j.1467-9280.2008.02038.x
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Humbert IA, 2009, NEUROIMAGE, V44, P982, DOI 10.1016/j.neuroimage.2008.10.012
   Jensen MP, 2008, J PAIN, V9, P193, DOI 10.1016/j.jpain.2007.11.003
   Kong J, 2009, NEUROIMAGE, V47, P1066, DOI 10.1016/j.neuroimage.2009.05.087
   Li CF, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0097502
   Li LX, 2016, CHIN J INTEGR MED, V22, P549, DOI 10.1007/s11655-015-2145-y
   Li N, 2008, IEEE ENG MED BIO, V0, PP1108, DOI 10.1109/IEMBS.2008.4649354
   Madsen MV, 2009, BMJ-BRIT MED J, V338, P0, DOI 10.1136/bmj.a3115
   Malallah OS, 2018, INT J PHARMACEUT, V541, P157, DOI 10.1016/j.ijpharm.2018.02.004
   Manheimer E, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005111.pub3
   McDowell LJ, 2018, INT J RADIAT ONCOL, V102, P340, DOI 10.1016/j.ijrobp.2018.05.060
   Meng ZQ, 2012, CANCER-AM CANCER SOC, V118, P3337, DOI 10.1002/cncr.26550
   MOSS EM, 1985, NEUROPSYCHOLOGIA, V23, P131, DOI 10.1016/0028-3932(85)90054-5
   Mu Y, 2015, P NATL ACAD SCI USA, V112, P15348, DOI 10.1073/pnas.1509839112
   Mulert C, 2004, NEUROIMAGE, V22, P83, DOI 10.1016/j.neuroimage.2003.10.051
   Park Jongbae, 2002, ACUPUNCT MED, V20, P168
   Park JJ, 2009, ACUPUNCT MED, V27, P93, DOI 10.1136/aim.2009.001495
   Prinsloo S, 2018, INT C INT MED HLTH M, V0, P0
   Sakai S, 2007, AUTON NEUROSCI-BASIC, V133, P158, DOI 10.1016/j.autneu.2007.01.001
   Sakatani K, 2010, ADV EXP MED BIOL, V662, P455, DOI 10.1007/978-1-4419-1241-1_65
   Shi GX, 2012, TRIALS, V13, P0, DOI 10.1186/1745-6215-13-42
   Simcock R, 2013, ANN ONCOL, V24, P776, DOI 10.1093/annonc/mds515
   Streitberger K, 2008, J ALTERN COMPLEM MED, V14, P505, DOI 10.1089/acm.2007.0552
   Suzuki M, 2012, ARCH INTERN MED, V172, P878, DOI 10.1001/archinternmed.2012.1233
   Thatcher RW, 2012, HUM BRAIN MAPP, V33, P1062, DOI 10.1002/hbm.21271
   Tsao GJ, 2015, LARYNGOSCOPE, V125, P1972, DOI 10.1002/lary.25252
   Vitacco D, 2002, HUM BRAIN MAPP, V17, P4, DOI 10.1002/hbm.10038
   Volinn E, 2013, J ALTERN COMPLEM MED, V19, P435, DOI 10.1089/acm.2010.0786
   Wang K, 2014, NEUROREPORT, V25, P656, DOI 10.1097/WNR.0000000000000152
   Wang Y, 2014, NEUROREPORT, V25, P110, DOI 10.1097/WNR.0000000000000077
   Worrell GA, 2000, BRAIN TOPOGR, V12, P273, DOI 10.1023/A:1023407521772
   Wymbs NF, 2015, CEREB CORTEX, V25, P4213, DOI 10.1093/cercor/bhu144
   Yi GS, 2013, COGN NEURODYNAMICS, V7, P79, DOI 10.1007/s11571-012-9221-1
   Yu HT, 2018, IEEE T NEUR SYS REH, V26, P977, DOI 10.1109/TNSRE.2018.2828143
   Zhao L, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0099538
   Zumsteg D, 2005, NEUROLOGY, V65, P1657, DOI 10.1212/01.wnl.0000184516.32369.1a
   Zumsteg D, 2006, CLIN NEUROPHYSIOL, V117, P1602, DOI 10.1016/j.clinph.2006.04.008
NR 52
TC 2
Z9 2
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD MAY 15
PY 2022
VL 21
IS 
BP 
EP 
DI 10.1177/15347354221101630
PG 9
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA 1M8DM
UT WOS:000800196100001
PM 35603438
DA 2026-01-16
ER

PT J
AU Church, D
   Stapleton, P
   Vasudevan, A
   O'Keefe, T
AF Church, Dawson
   Stapleton, Peta
   Vasudevan, Anitha
   O'Keefe, Tom
TI Clinical EFT as an evidence-based practice for the treatment of psychological and physiological conditions: A systematic review
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Review
DE emotional freedom techniques (EFT); anxiety; depression; PTSD; somatic symptoms; pain; insomnia; obesity
ID emotional freedom techniques; posttraumatic-stress-disorder; cognitive-behavioral therapy; meridian-based intervention; ptsd remediation; controlled-trial; anxiety; veterans; metaanalysis; symptoms
AB Background: Since the turn of the century, Emotional Freedom Techniques (EFT) has come into widespread use in medical and psychological treatment settings. It is also used as self-help by tens of millions of people each year. Clinical EFT, the manualized form of the method, has been validated as an "evidence-based " practice using criteria published by the American Psychological Association (APA) Division 12 Task Force on Empirically Validated Therapies. Its three essential ingredients are exposure, cognitive framing, and acupressure. Objectives: In 2013 we published a paper defining Clinical EFT and reviewing published research. It has been viewed or downloaded over 36,000 times, indicating widespread interest in this treatment modality. Here we update our findings based on subsequently published literature and propose directions for future research. Method: We performed a systematic review of the literature to identify randomized controlled trials (RCTs) and meta-analyses. Retrieval of 4,167 results resulted in the identification of 56 RCTs (n = 2,013), 41 of which were published subsequent to our earlier review, as well as eight meta-analyses. Results: RCTs have found EFT treatment to be effective for (a) psychological conditions such as anxiety, depression, phobias, and posttraumatic stress disorder (PTSD); (b) physiological issues such as pain, insomnia, and autoimmune conditions; (c) professional and sports performance; and (d) biological markers of stress. Meta-analyses evaluating the effect of EFT treatment have found it to be "moderate " to "large. " Successful independent replication studies have been carried out for anxiety, depression, PTSD, phobias, sports performance, and cortisol levels. We outline the next steps in EFT research. These include determining its impact on cancer, heart disease, diabetes, and cognitive impairment; analysis of the large-scale datasets made possible by mobile apps; and delivery through channels such as virtual practitioner sessions, artificial intelligence agents, online courses, apps, virtual reality platforms, and standardized group therapy. Conclusions: Subsequent research has confirmed the conclusions of earlier studies. These find Clinical EFT to be efficacious for a range of psychological and physiological conditions. Comparatively few treatment sessions are required, treatment is effective whether delivered in person or virtually, and symptom improvements persist over time. Treatment is associated with measurable biological effects in the dimensions of gene expression, brain synchrony, hormonal synthesis, and a wide range of biomarkers. Clinical EFT is a stable and mature method with an extensive evidence base. Its use in primary care settings as a safe, rapid, reliable, and effective treatment for both psychological and medical diagnoses continues to grow.
C1 [Church, Dawson; Vasudevan, Anitha] Natl Inst Integrat Healthcare, Petaluma, CA 95404 USA.
   [Stapleton, Peta; O'Keefe, Tom] Bond Univ, Dept Soc & Design, Gold Coast, Qld, Australia.
C3 Bond University
RP Church, D (corresponding author), Natl Inst Integrat Healthcare, Petaluma, CA 95404 USA.
EM dawsonchurch@gmail.com
CR Abdi MR, 2015, APPL MATH ENG MANAGE, V3, P476
   AlHadethe A, 2015, JOURNAL OF TRAUMATIC STRESS DISORDERS & TREATMENT, V04, P0, DOI 10.4172/2324-8947.1000145
   American Psychological Association (APA), 2021, PSYCH TREATM, V0, P0
   Anderson K, 2019, ENERGY PSYCHOLOGY, V11, P31, DOI 10.9769/epj.2019.11.2.ka
   Unknown -, 2017, ELIFE, V6, P0, DOI 10.7554/eLife.23693
   Unknown -, 2007, SHOCK AWE HITS HOME, V0, P0
   Unknown -, 2015, SCIENCE, V349, P0, DOI 10.1126/SCIENCE.AAC4716
   Unknown -, 2006, EVIDENCE BASED PRACT, V0, P0
   Unknown -, 2012, ENERGY PSYCHOL THEOR, V0, P0, DOI DOI 10.9769/EPJ.2012.4.1.PS.TS.BP
   Unknown -, 2008, TREATMENT OF POSTTRAUMATIC STRESS DISORDER: AN ASSESSMENT OF THE EVIDENCE, V0, P0
   Unknown -, 2009, ENERGY PSYCHOL THEOR, V0, P0, DOI DOI 10.9769/EPJ.2009.1.1.KS
   Unknown -, 2017, CLINICAL PRACTICE GUIDELINE FOR THE TREATMENT OF POSTTRAUMATIC STRESS DISORDER (PTSD) IN ADULTS, V0, P0
   Babamahmoodi A, 2015, IRAN J ALLERGY ASTHM, V14, P37
   Bach D, 2019, J EVID-BASED INTEGR, V24, P0, DOI 10.1177/2515690X18823691
   Baghini AA, 2020, V13, V0, P625
   Baker AH, 2010, ENERGY PSYCHOL, V2, P13, DOI 10.9769/EPJ.2010.2.2
   Baker BS, 2015, EUR J INTEGR MED, V7, P136, DOI 10.1016/j.eujim.2014.10.004
   Baker M, 2016, NATURE, V533, P452, DOI 10.1038/533452a
   Bakir N, 2022, PERSPECT PSYCHIATR C, V58, P1502, DOI 10.1111/ppc.12957
   Balha S M, 2020, INTERNATIONAL JOURNAL OF NOVEL RESEARCH IN HEALTHCARE AND NURSING, V7, P30
   Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a
   Beutler LE, 2005, EVIDENCE BASED PRACT, V0, P0
   Boath E, 2014, CURRENT RESEARCH IN PSYCHOLOGY, V5, P64, DOI 10.3844/crpsp.2014.64.72
   Boath E, 2014, EURO J INTEGR MED, V6, P614, DOI 10.1016/J.EUJIM.2014.07.011
   Boath E, 2013, INNOVATIVE PRACTICE, V1, P1
   Boath E, 2017, SOC WORK EDUC, V36, P715, DOI 10.1080/02615479.2017.1297394
   Bougea AM, 2013, EXPLORE-NY, V9, P91, DOI 10.1016/j.explore.2012.12.005
   Brattberg G, 2008, INTEGRATIVE MEDICINE: A CLINICIANS JOURNAL, V7, P30
   Callahan R, 1985, FIVE MINUTE PHOBIA CURE, V0, P0
   Chambless D, 1996, THE CLINICAL PSYCHOLOGIST, V51, P5
   Chambless DL, 1998, CLIN PSYCHOL-UK, V51, P3
   Chambless DL, 1998, J CONSULT CLIN PSYCH, V66, P7, DOI 10.1037/0022-006X.66.1.7
   Chatwin Hannah, 2016, INTEGR MED (ENCINITAS), V15, P27
   Church D, 2009, OPEN SPORTS SCI. J, V2, P94, DOI 10.2174/1875399X00902010094
   Church D, 2009, EFT MINI MANUAL, V0, P0
   Church D, 2018, THE EFT MANUAL, V3rd, P0
   Church D, 2012, TRAUMATOLOGY, V18, P73, DOI 10.1177/1534765611426788
   Church D, 2012, SPORT J, V0, P1
   Church D, 2019, PSYCHOLOGY, V10, P941, DOI 10.4236/psych.2019.107061
   Church D, 2010, ANTI AGING THER, V13, P35
   Church D, 2010, INTEGRATIVE MED, V9, P40
   Church D, 2013, INT J SCI RES REP, V2, P315, DOI 10.9734/JSRR/2013/3500
   Church D, 2014, TRAUMATOLOGY, V20, P172, DOI 10.1037/H0099831
   Church D, 2013, THE EFT MANUAL, V3rd, P0
   Church D, 2009, INT J HEALING CARING, V9, P1
   Church D, 2013, PSYCHOLOGY, V4, P645, DOI 10.4236/PSYCH.2013.48092
   Church D, 2017, HUFFINGTON POST, V0, P0
   Church Dawson, 2022, ADV MIND BODY MED, V36, P13
   Church D, 2020, JMIR MHEALTH UHEALTH, V8, P0, DOI 10.2196/18545
   Church D, 2020, J NERV MENT DIS, V208, P632, DOI 10.1097/NMD.0000000000001222
   Church D, 2019, J NERV MENT DIS, V207, P315, DOI 10.1097/NMD.0000000000000975
   Church D, 2018, J NERV MENT DIS, V206, P783, DOI 10.1097/NMD.0000000000000878
   Church D, 2018, EXPLORE-NY, V14, P131, DOI 10.1016/j.explore.2017.10.009
   Church D, 2018, J EVID-BASED INTEGR, V23, P0, DOI 10.1177/2156587218756510
   Church D, 2018, AM J HEALTH PROMOT, V32, P112, DOI 10.1177/0890117116661154
   Church Dawson, 2017, PERM J, V21, P16, DOI 10.7812/tpp/16-100
   Church D, 2016, ARCHIVES OF SCIENTIFIC PSYCHOLOGY, V4, P38, DOI 10.1037/arc0000028
   Church D, 2016, EXPLORE-NY, V12, P355, DOI 10.1016/j.explore.2016.06.012
   Church Dawson, 2012, DEPRESS RES TREAT, V2012, P257172, DOI 10.1155/2012/257172
   Church D, 2014, EXPLORE-NY, V10, P162, DOI 10.1016/j.explore.2014.02.005
   Church D, 2014, EXPLORE-NY, V10, P24, DOI 10.1016/j.explore.2013.10.006
   Church D, 2013, J NERV MENT DIS, V201, P153, DOI 10.1097/NMD.0b013e31827f6351
   Church D, 2012, J NERV MENT DIS, V200, P891, DOI 10.1097/NMD.0b013e31826b9fc1
   Cici R, 2022, ALTERN THER HEALTH M, V28, P20
   Clond M, 2016, J NERV MENT DIS, V204, P388, DOI 10.1097/NMD.0000000000000483
   Craig G, 2008, THE EFT MANUAL, V0, P0
   Craig G, 1995, EMOTIONAL FREEDOM TECHNIQUES: THE MANUAL, V0, P0
   Craig G, 2009, INTERNATIONAL JOURNAL OF HEALING AND CARING, V9, P1
   Curtin KB, 2017, SCAND J PAIN, V17, P156, DOI 10.1016/j.sjpain.2017.08.006
   CD, 2016, JOURNAL OF SLEEP DISORDERS TREATMENT & CARE, V05, P0, DOI 10.4172/2325-9639.1000171
   Department of Applied Psychology Akamai University Hilo HI, 2016, ENERGY PSYCHOLOGY, V8, P17, DOI 10.9769/epj.2016.8.1.mm
   DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102
   Di Rienzo F, 2019, PSYARXIV, V0, P0, DOI DOI 10.31234/osf.io/s3hce
   Diamandis PH, 2020, FUTURE IS FASTER YOU, V0, P0
   Diamond John, 1985, LIFE ENERGY, V0, P0
   Dincer B, 2020, EXPLORE-NY, V0, P0, DOI DOI 10.1016/j.explore.2020.11.006
   Dincer B, 2021, EXPLORE-NY, V17, P109, DOI 10.1016/j.explore.2020.11.012
   Dominguez SK, 2017, FRONT PSYCHOL, V8, P0, DOI 10.3389/fpsyg.2017.01425
   Eley TC, 1997, CURR OPIN NEUROBIOL, V7, P279, DOI 10.1016/S0959-4388(97)80017-7
   Energy Psychology, 2017, WORK PAP AUTH REV EN, V0, P0
   Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583
   Feinstein D, 2009, ENERGY PSYCHOLOGY: THEORY, V0, P0
   Feinstein D, 2022, FRONT PSYCHOL, V13, P0, DOI 10.3389/fpsyg.2022.856209
   Feinstein David, 2021, ADV MIND BODY MED, V35, P17
   Feinstein D, 2015, THE NEUROPSYCHOTHERAPIST, V0, PP38, DOI 10.12744/tnpt(10)038-049
   Feinstein D, 2010, REV GEN PSYCHOL, V14, P283, DOI 10.1037/a0021252
   Fernandez E, 2021, CLIN PSYCHOL PSYCHOT, V28, P1535, DOI 10.1002/cpp.2594
   Flint GA, 2005, TRAUMA TREATMENT TEC, V0, P125
   Food and Drug Administration (FDA), 1998, GUID IND E9 STAT PRI, V0, P0
   Fox L, 2013, ENERGY PSYCHOL THEORY RES TREAT, V5, P15, DOI 10.9769/EPJ.2013.5.2
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Gaesser AH, 2020, PROMOTING MIND BODY, V0, PP283, DOI 10.1037/0000157-020
   Gaesser AH, 2017, J ALTERN COMPLEM MED, V23, P102, DOI 10.1089/acm.2015.0316
   Gamble A, 2020, ASLIB J INFORM MANAG, V72, P509, DOI 10.1108/AJIM-11-2019-0316
   Gaudiano BA, 2012, RES SOCIAL WORK PRAC, V22, P647, DOI 10.1177/1049731512448468
   Geronilla L, 2016, ENERGY PSYCHOLOGY, V8, P29, DOI 10.9769/epj.2016.8.2.lg
   Ghaderi Z, 2021, IRAN J NURS MIDWIFE, V26, P531, DOI 10.4103/ijnmr.IJNMR_188_19
   Gilomen SA, 2015, J BEHAV THER EXP PSY, V48, P140, DOI 10.1016/j.jbtep.2015.03.012
   Glisenti K, 2021, J EAT DISORD, V9, P0, DOI 10.1186/s40337-020-00358-5
   Goodheart GJ, 1987, YOULL BE BETTER, V0, P0
   Gorman J M, 1996, DEPRESS ANXIETY, V4, P160, DOI 10.1002/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J
   Gurret JM, 2012, ENERGY PSYCHOLOGY, V4, P26, DOI 10.9769/EPJ.2012.4.2.JPH
   Hartung J, 2012, ENERGY PSYCHOLOGY, V4, P33, DOI 10.9769/EPJ.2012.4.1.JH
   Hodge P, 2011, ENERGY PSYCHOLOGY JOURNAL, V3, P13, DOI https://doi.org/10.9769/EPJ.2011.3.2.PMH.CYJ
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Inangil D, 2020, EUR J INTEGR MED, V33, P0, DOI 10.1016/j.eujim.2019.101041
   Jain S, 2012, ENERGY PSYCHOL THEOR, V4, P13, DOI 10.9769/EPJ.2012.4.2.SJ
   Jasubhai DS, 2018, INTERNATIONAL JOURNAL OF EMERGENCY MENTAL HEALTH AND HUMAN RESILIENCE, V20, P0, DOI 10.4172/1522-4821.1000403
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Jones S, 2011, ENERGY PSYCHOLOGY: THEORY, V0, P0
   Kaiser Jocelyn, 2012, SCIENCE, V0, P0, DOI DOI 10.1126/SCIENCE.AAL0628
   Karatzias T, 2011, J NERV MENT DIS, V199, P372, DOI 10.1097/NMD.0b013e31821cd262
   König N, 2019, BRAIN SCI, V9, P0, DOI 10.3390/brainsci9080206
   Kornstein SG, 2019, J CLIN PSYCHIAT, V80, P0, DOI 10.4088/JCP.18m12378
   Kwak HY, 2020, EXPLORE-NY, V16, P170, DOI 10.1016/j.explore.2019.08.006
   Lambrou P, 2003, SUBTLE ENERG. ENERGY MED, V14, P239
   Lane J, 2009, EPJ, V1, P31, DOI 10.9769/EPJ.2009.1.1.JRL
   Ledger KE, 2019, INT J HEAL CARING, V19, P3
   Lee JH, 2013, PSYCHOTHER PSYCHOSOM, V82, P55
   Lee J-H, 2011, J ORIENT NEUROPSYCHIATRY, V22, P101, DOI 10.7231/JON.2011.22.4.101
   Lee JH, 2015, ENERGY PSYCHOLOGY, V7, P22, DOI 10.9769/epj.2015.7.1.jhl
   Llewellyn-Edwards T, 2012, JOURNAL FOR THE NATIONAL COUNCIL OF PSYCHOTHERAPISTS, V1, P14
   Llewellyn-Edwards T, 2013, CLIN EFT HDB, V2, P2
   Madoni E R, 2018, J. BIMBINGAN KONSELING, V0, P28
   Mavranezouli I, 2020, PSYCHOL MED, V50, P542, DOI 10.1017/S0033291720000070
   Mavranezouli I, 2020, J CHILD PSYCHOL PSYC, V61, P18, DOI 10.1111/jcpp.13094
   McCallion F, 2012, ENERGY PSYCHOL THEOR, V4, P35, DOI 10.9769/EPJ.2012.4.2.FM
   Mehdipour Asieh, 2022, J COMPLEMENT INTEGR MED, V19, P737, DOI 10.1515/jcim-2020-0245
   Mishkind MC, 2017, CURR PSYCHIAT REP, V19, P0, DOI 10.1007/s11920-017-0836-0
   Mollon P, 2007, PRIMARY CARE COMMUN, V12, P123, DOI 10.1080/17468840701750836
   Napadow V, 2007, PAIN, V130, P254, DOI 10.1016/j.pain.2006.12.003
   National Institute for Health Clinical Excellence (NICE), 2009, END CLIN GUID 2008 2, V0, P0
   Nelms JA, 2016, EXPLORE-NY, V12, P416, DOI 10.1016/j.explore.2016.08.001
   Noble C, 2021, B PSYCHOL, V1, P100022, DOI 10.1016/j.etdah.2021.100022
   Norcross JC, 2019, PSYCHOTHERAPY, V56, P391, DOI 10.1037/pst0000228
   North Carolina State University, 2015, ENERGY PSYCHOLOGY, V7, P13, DOI 10.9769/epj.2015.11.01.an
   Ortner N, 2014, ENERGY PSYCHOLOGY: THEORY, V0, P0
   PalmerHoffman J, 2011, ENERGY PSYCHOL, V3, P1, DOI 10.9769/EPJ.2011.3.1.JPH
   Pasahow R, 2010, ENERGY PSYCHOLOGY JOURNAL, V2, P57, DOI 10.9769/EPJ.2010.2.2.RP
   Patterson SL, 2016, NURS EDUC TODAY, V40, P104, DOI 10.1016/j.nedt.2016.02.003
   Popescu A, 2021, ENERGY PSYCHOL THEOR, V13, P12, DOI 10.9769/EPJ.2021.13.1.AP
   Rahmi T, 2012, PEDAGOGI, V12, P107, DOI 10.24036/pedagogi.v12i2.2212
   Rizzo A, 2017, EUR J PSYCHOTRAUMATO, V8, P0, DOI 10.1080/20008198.2017.1414560
   Rogers R, 2015, ENERGY PSYCHOLOGY, V7, P26, DOI 10.9769/epj.2015.7.2.rr
   Rotheram M, 2012, SPORT PSYCHOL, V26, P551, DOI 10.1123/tsp.26.4.551
   Rowe JE, 2005, COUNSELING CLIN PSYC, V2, P104, DOI 10.1002/JCLP.10189
   Salas MM, 2011, EXPLORE-NY, V7, P155, DOI 10.1016/j.explore.2011.02.005
   Samueli Institute, 2015, ENERGY PSYCHOLOGY, V7, P33, DOI 10.9769/epj.2015.7.2.sl
   Santa Rosa CA, 2022, ENERGY PSYCHOLOGY, V14, P22, DOI 10.9769/epj.2022.14.1.jf
   School of Psychology Bond University Gold Coast Queensland 4229 Australia, 2019, OBM INTEGRATIVE AND COMPLEMENTARY MEDICINE, V4, P1, DOI 10.21926/obm.icm.1904065
   School of Psychology Bond University Gold Coast Queensland 4229 Australia, 2018, OBM INTEGRATIVE AND COMPLEMENTARY MEDICINE, V4, P1, DOI 10.21926/obm.icm.1901010
   School of Psychology Bond University Queensland Australia, 2016, ENERGY PSYCHOLOGY, V8, P18, DOI 10.9769/epj.2016.8.2.ps
   School of Psychology Bond University Queensland Australia, 2018, OBM INTEGRATIVE AND COMPLEMENTARY MEDICINE, V3, P1, DOI 10.21926/obm.icm.1803014
   Sebastian B, 2017, EXPLORE-NY, V13, P16, DOI 10.1016/j.explore.2016.10.001
   SELIGMAN MEP, 1995, AM PSYCHOL, V50, P965, DOI 10.1037/0003-066X.50.12.965
   Sezgin N, 2009, ENERGY PSYCHOLOGY: THEORY, V0, P0
   Smith TG, 1989, IND TRUJILLO 0829, V25, P93
   Song S-Y, 2014, J ORIENTAL NEUROPSYC, V25, P29, DOI 10.7231/jon.2014.25.1.029
   Souilm N, 2022, SCI REP-UK, V12, P0, DOI 10.1038/s41598-022-10456-w
   Spielmans GI, 2020, J NERV MENT DIS, V208, P628, DOI 10.1097/NMD.0000000000001181
   Stapleton P, 2020, OPEN JOURNAL OF SOCIAL SCIENCES, V08, P158, DOI 10.4236/jss.2020.82014
   Stapleton P, 2022, C PRESENTATION 11 AN, V0, P0
   Stapleton P, 2021, C HELD OM I RHIN NEW, V0, P0
   Stapleton P, 2020, HELIYON, V6, P0, DOI 10.1016/j.heliyon.2020.e04058
   Stapleton P, 2020, PSYCHOL TRAUMA-US, V12, P869, DOI 10.1037/tra0000563
   Stapleton P, 2020, J ALTERN COMPLEM MED, V26, P98, DOI 10.1089/acm.2019.0309
   Stapleton P, 2017, COMPLEMENT THER CLIN, V28, P136, DOI 10.1016/j.ctcp.2017.06.004
   Stapleton P, 2016, APPL PSYCHOL-HLTH WE, V8, P232, DOI 10.1111/aphw.12070
   Stapleton P, 2016, EXPLORE-NY, V12, P113, DOI 10.1016/j.explore.2015.12.001
   Stapleton Peta, 2013, ISRN PSYCHIATRY, V2013, P573532, DOI 10.1155/2013/573532
   Stapleton P, 2011, BEHAV CHANGE, V28, P1, DOI 10.1375/bech.28.1.1
   Stein PK, 2011, ENERGY PSYCHOLOGY: THEORY, V0, P0
   Swingle P G, 2004, SUBTLE ENERGIES ENERGY MEDICINE, V15, P75
   Swingle PG, 2010, ENERGY PSYCHOLOGY: THEORY, V0, P0
   Tack L, 2021, ECLINICALMEDICINE, V39, P0, DOI 10.1016/j.eclinm.2021.101081
   Thomas RM, 2017, ENERGY PSYCHOLOGY, V9, P26, DOI 10.9769/epj.2017.9.1.rt
   Thompson Mark, 2015, TIME, V185, P40
   Tolin DF, 2015, CLIN PSYCHOL-SCI PR, V22, P317, DOI 10.1111/cpsp.12122
   Vural PI, 2019, COMPLEMENT THER CLIN, V35, P224, DOI 10.1016/j.ctcp.2019.02.011
   Waite WL, 2003, THE SCIENTIFIC REVIEW OF MENTAL HEALTH PRACTICE: OBJECTIVE INVESTIGATIONS OF CONTROVERSIAL AND UNORTHODOX CLAIMS IN CLINICAL PSYCHOLOGY, V0, P0
   Wampold BE, 2005, J CONSULT CLIN PSYCH, V73, P914, DOI 10.1037/0022-006X.73.5.914
   Wells S, 2003, J CLIN PSYCHOL, V59, P943, DOI 10.1002/jclp.10189
   Wittfoth D, 2022, NEUROIMAGE-CLIN, V34, P0, DOI 10.1016/j.nicl.2022.102996
   Wittfoth D, 2020, BMC NEUROSCI, V21, P0, DOI 10.1186/s12868-020-00597-x
   Yount Garret, 2019, GLOB ADV HEALTH MED, V8, P2164956119832500, DOI 10.1177/2164956119832500
NR 186
TC 34
Z9 43
U1 1
U2 37
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
EI 
J9 FRONT PSYCHOL
JI Front. Psychol.
PD NOV 10
PY 2022
VL 13
IS 
BP 
EP 
DI 10.3389/fpsyg.2022.951451
PG 40
WC Psychology, Multidisciplinary
SC Psychology
GA 6P2VG
UT WOS:000890791800001
PM 36438382
DA 2026-01-16
ER

PT J
AU Xue, YH
   Liu, F
   Huangfu, SH
   Jiang, YL
   Wang, XF
AF Xue, Yahong
   Liu, Fei
   Huangfu, Shaohua
   Jiang, Yunlin
   Wang, Xiaofeng
TI Electroacupuncture Treatment Alleviated Intracolonic Capsaicin-Induced Rectal Visceral Pain by Inhibiting the Expressions of TRPV1 and P2X4R and Blocking MAPK Pathway
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE rectal visceral pain; electroacupuncture; transient receptor potential vanilloid 1
AB Background: Electroacupuncture (EA) treatment can alleviate chronic neuropathic pain, like visceral pain, but the underlying mechanism remains unclear.Methods: Herein, rats were intracolonically injected with capsaicin to create a visceral (rectal) pain model. Then rats were treated with EA. The number of visceral pain-related behaviors, along with the mechanical pain thresholds of the rats' tail, metapedes and abdomen, were recorded. Meanwhile, the pathology of rectal tissue was observed by hematoxylin-eosin staining. The expressions of inflammatory factors (interleukin (IL)-1 beta, IL-6 and tumor necrosis factor (TNF-alpha)) and glial fibrillary acidic protein (GFAP) in the rat spinal cord or serum were assessed using enzyme-linked immunosorbent assay or Western blot. Likewise, the expression level of oxycocin-42 (OX42), GFAP, transient receptor potential vanilloid 1 (TRPV1), P2X4 receptor (P2X4R) and mitogen-activated protein kinase (MAPK) pathway-related proteins were determined by immunofluorescence or Western blot in the rats' spinal cord.Results: The increased visceral behavioral pain, mechanical pain threshold, secretion of inflammatory factors, edema of rectal mucosa and activation of spinal glial cells induced by capsaicin were all reversed by EA treatment. Additionally, the upregulation of TRPV1 and P2X4R as well as the activation of the MAPK pathway caused by capsaicin was offset by EA treatment.Conclusions: EA treatment ameliorates rats' rectal visceral pain by repressing TRPV1 and P2X4R expression levels as well as blocking MAPK pathway.
C1 [Xue, Yahong; Liu, Fei; Huangfu, Shaohua; Wang, Xiaofeng] Nanjing Univ Chinese Med, Proctol Dept, Nanjing Hosp Chinese Med, Nanjing 210000, Jiangsu, Peoples R China.
   [Jiang, Yunlin] Nanjing Univ Chinese Med, Surg Chinese Med, Nanjing Hosp Chinese Med, Nanjing 210000, Jiangsu, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Xue, YH; Wang, XF (corresponding author), Nanjing Univ Chinese Med, Proctol Dept, Nanjing Hosp Chinese Med, Nanjing 210000, Jiangsu, Peoples R China.
EM wangxiaofe_wxf@163.com; xueyahong_1983@126.com
FU National Natural Science Foundation of China [82004362]
CR Ali U, 2020, BIOMED PHARMACOTHER, V125, P0, DOI 10.1016/j.biopha.2020.109898
   Baba K, 2021, NEUROSCI RES, V170, P273, DOI 10.1016/j.neures.2020.12.007
   Basso AR, 2021, J ETHNOPHARMACOL, V269, P0, DOI 10.1016/j.jep.2020.113712
   Bujak JK, 2019, FRONT ONCOL, V9, P0, DOI 10.3389/fonc.2019.01087
   Du WB, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8138017
   Feng B, 2020, J NEURAL TRANSM, V127, P415, DOI 10.1007/s00702-019-02088-8
   Fu R, 2021, NEUROSCI LETT, V750, P0, DOI 10.1016/j.neulet.2021.135773
   Grundy L, 2019, ANNU REV PHYSIOL, V81, P261, DOI 10.1146/annurev-physiol-020518-114525
   Halievski K, 2020, J PHARMACOL EXP THER, V375, P202, DOI 10.1124/jpet.120.265017
   Hsu HC, 2019, ACUPUNCT MED, V37, P356, DOI 10.1136/acupmed-2017-011469
   Jiang GX, 2019, ACUPUNCT MED, V37, P116, DOI 10.1136/acupmed-2017-011559
   Jin X, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8828846
   Jin Y, 2021, ACUPUNCT MED, V39, P708, DOI 10.1177/09645284211020766
   Kelly RB, 2019, AM FAM PHYSICIAN, V100, P89
   King JL, 2021, PHARMACEUTICS, V13, P0, DOI 10.3390/pharmaceutics13071053
   Leoni C, 2022, AM J MED GENET A, V188, P3287, DOI 10.1002/ajmg.a.62917
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Li YH, 2019, J PAIN RES, V12, P2663, DOI 10.2147/JPR.S205987
   Liu YT, 2018, J MOL NEUROSCI, V66, P279, DOI 10.1007/s12031-018-1172-5
   Long T, 2020, J HEADACHE PAIN, V21, P0, DOI 10.1186/s10194-019-1070-4
   Lucarini E, 2021, BIOMEDICINES, V9, P0, DOI 10.3390/biomedicines9111671
   Matsui K, 2020, J PHARMACOL SCI, V143, P60, DOI 10.1016/j.jphs.2020.01.006
   Morales-Soto W, 2019, CELL MOL GASTROENTER, V7, P433, DOI 10.1016/j.jcmgh.2018.11.005
   Shi CX, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917725636
   Wang JY, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2134-8
   Wei TH, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21134693
   Zhan MX, 2021, J PAIN RES, V14, P1201, DOI 10.2147/JPR.S303595
   Zhao JM, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/4956179
   Zhao YX, 2020, J PAIN RES, V13, P239, DOI 10.2147/JPR.S241101
   Zheng YY, 2021, MOL MED REP, V23, P0, DOI 10.3892/mmr.2020.11814
NR 30
TC 1
Z9 1
U1 1
U2 4
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393-974X
EI 1724-6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD SEP-OCT 15
PY 2022
VL 36
IS 5
BP 1369
EP 1378
DI 10.23812/j.biol.regul.homeost.agents.20223605.147
PG 10
WC Endocrinology & Metabolism; Immunology; Medicine, Research & Experimental; Physiology
SC Endocrinology & Metabolism; Immunology; Research & Experimental Medicine; Physiology
GA C1RB3
UT WOS:000959762400001
DA 2026-01-16
ER

PT J
AU Li, H
   Schlaeger, JM
   Patil, CL
   Danciu, OC
   Xia, Y
   Sun, J
   Doorenbos, AZ
AF Li, Hongjin
   Schlaeger, Judith M
   Patil, Crystal L
   Danciu, Oana C
   Xia, Yinglin
   Sun, Jun
   Doorenbos, Ardith Z
TI Feasibility of Acupuncture and Exploration of Metabolomic Alterations for
SO Biological research for nursing
LA English
DT Journal Article
DE acupuncture; breast cancer; metabolites; psychoneurological symptoms
AB OBJECTIVE: Approximately 24-68% of breast cancer survivors report co-occurring  psychoneurological symptoms of pain, fatigue, sleep disturbance, depression, and  anxiety during and after cancer treatment. This study aimed to assess the  feasibility and acceptability of acupuncture for the treatment of multiple  psychoneurological symptoms among breast cancer survivors and explore metabolomic  changes before and after acupuncture. METHODS: We conducted a single-arm,  prospective pilot study of breast cancer survivors with at least two moderate to  severe psychoneurological symptoms (>3 on a 0-10 scale). Acupuncture was  administered twice weekly for 5 weeks, for 30 minutes per session. Along with  Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaires,  a fasting serum comprehensive hydrophilic metabolites panel was analyzed at  baseline and after acupuncture. RESULTS: Eight participants (mean age 52.5 ±  10.9 years; 62.5% Black) were enrolled. Feasibility was supported, with 67%  recruitment, 87.5% retention, and 98% acceptability. Post intervention, PROMIS  T-scores were reduced for all psychoneurological symptoms. Significant  differences in serum metabolites before and after acupuncture were F-1,6/2,6-DP,  glutathione disulfide, phosphorylcholine, 6-methylnicotinamide, glutathione, and  putrescine (variable importance of projection values larger than 1.5 and p values  <0.05). Pathway analysis indicated that glutathione metabolism (p = 0.002, q =  0.071), and arginine and proline metabolisms (p = 0.009, q = 0.166) were  potentially involved in mechanisms of acupuncture. CONCLUSIONS: Acupuncture to  reduce multiple psychoneurological symptoms among breast cancer survivors was  feasible and acceptable. Study findings also shed light on the metabolic pathways  involved in the acupuncture response and will be tested in future studies.
C1 Department of Human Development Nursing Science, College of Nursing, 14681University of Illinois Chicago, Chicago, IL, USA.
   Cancer Center, 14681University of Illinois Chicago, Chicago, IL, USA.
   Department of Human Development Nursing Science, College of Nursing, 14681University of Illinois Chicago, Chicago, IL, USA.
   Department of Human Development Nursing Science, College of Nursing, 14681University of Illinois Chicago, Chicago, IL, USA.
   Cancer Center, 14681University of Illinois Chicago, Chicago, IL, USA.
   College of Medicine, 14681University of Illinois Chicago, Chicago, IL, USA.
   College of Medicine, 14681University of Illinois Chicago, Chicago, IL, USA.
   Cancer Center, 14681University of Illinois Chicago, Chicago, IL, USA.
   College of Medicine, 14681University of Illinois Chicago, Chicago, IL, USA.
   Cancer Center, 14681University of Illinois Chicago, Chicago, IL, USA.
   Department of Biobehavioral Nursing Science, College of Nursing, 14681University
NR 0
TC 0
SN 1552-417
EI 1099-800
J9 Biol Res Nurs
PD OCT 29
PY 2022
VL 25
IS 2
BP 326
EP 335
DI 10.1177/10998004221136567
PG 9
WC Humans; Adult; Middle Aged; Female; Breast Neoplasms; complications; Cancer Survivors; Prospective Studies; Pilot Projects; Feasibility Studies; Acupuncture Therapy
UT PubMed:36306737
PM 36306737
DA 2022-10-29
ER

PT J
AU Abe, H
   Inoue, R
   Tsuchida, R
   Ando, M
   Saita, K
   Konishi, M
   Edamura, T
   Ogawa, A
   Matsuoka, Y
   Sumitani, M
AF Abe, Hiroaki
   Inoue, Reo
   Tsuchida, Rikuhei
   Ando, Masae
   Saita, Kosuke
   Konishi, Mitsuru
   Edamura, Tatsuma
   Ogawa, Asao
   Matsuoka, Yutaka
   Sumitani, Masahiko
TI Efficacy of treatments for pain and numbness in cancer survivors: a systematic review and meta-analysis
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Review; Early Access
DE Meta-analysis; cancer survivors; pain; numbness; treatment
ID induced peripheral neuropathy; quality-of-life; randomized controlled-trial; inhibitor-associated arthralgia; low-back-pain; musculoskeletal symptoms; exercise intervention; american society; physical-therapy; trigger points
AB Background: Pain and numbness in cancer survivors frequently have negative impacts on quality of life (QoL). This meta-analysis aimed to identify the current treatment options for pain and numbness in cancer survivors and to evaluate their effects.Methods: Cancer survivors were defined as patients diagnosed with cancer who had completed active cancer treatment, whose conditions were stable, and who had no evidence of recurrent or progressive disease. A systematic search through the PubMed, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Web of Science, PsycInfo, and CINAHL databases was conducted, which targeted randomized controlled trials (RCTs) published until April 2022 that evaluated any type of treatment for pain or numbness in cancer survivors. A meta-analysis was conducted using the random-effects model to obtain the effect sizes of 7 types of treatments: opioid therapy, nonopioid pharmacotherapy, interventional therapy, acupuncture, education/cognitive behavioral therapy (CBT), physical exercise, and alternative medicine.Results: A total of 36 studies involving 2,870 cancer survivors were included. Among them, 35 (n=2,813) were included in the meta-analysis for pain. The analysis suggested that physical exercise [n=761; 13 studies; standardized mean difference (SMD) -0.84; 95% confidence interval (CI): -1.14 to -0.55], acupuncture (n=409; 3 studies; SMD -0.80; 95% CI: -1.04 to -0.56), and alternative medicine (n=206; 6 studies; SMD -0.44; 95% CI: -0.71 to -0.16) could significantly reduce pain. Nonopioid pharmacotherapy and education/ CBT did not demonstrate significant effects. No studies were identified that investigated the effects of opioid therapy or interventional therapy on pain. Regarding numbness, 5 studies (n=566) were included in the meta analysis. Acupuncture (n=99; 2 studies) did not demonstrate significant effects on numbness, and the effects of nonopioid pharmacotherapy, education/CBT, and physical exercise could not be determined due to the small number of included studies. No studies were identified that investigated the effects of opioid therapy, interventional therapy, or alternative medicine on numbness.Conclusions: This meta-analysis suggested that physical exercise, acupuncture, and alternative medicine may reduce pain in cancer survivors, with a very small to moderate amount of evidence. The effect of treatments for numbness could not be determined due to the limited number of included studies. Further studies are needed, particularly on widely used pharmacotherapy.
C1 [Abe, Hiroaki; Konishi, Mitsuru; Sumitani, Masahiko] Univ Tokyo Hosp, Dept Pain & Palliat Med, Tokyo, Japan.
   [Inoue, Reo; Tsuchida, Rikuhei; Ando, Masae; Saita, Kosuke; Edamura, Tatsuma] Univ Tokyo Hosp, Pain Relief Ctr, Dept Anesthesiol, Tokyo, Japan.
   [Ogawa, Asao] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Tokyo, Japan.
   [Matsuoka, Yutaka] Natl Canc Ctr, Ctr Publ Hlth Sci, Tokyo, Japan.
   [Sumitani, Masahiko] Univ Tokyo Hosp, Dept Pain & Palliat Med, 7-3-1 Hongo, Bunkyo, Tokyo 1138655, Japan.
C3 University of Tokyo; University of Tokyo; National Cancer Center - Japan; National Cancer Center - Japan
RP Sumitani, M (corresponding author), Univ Tokyo Hosp, Dept Pain & Palliat Med, 7-3-1 Hongo, Bunkyo, Tokyo 1138655, Japan.
EM SUMITANIM-ANE@h.u-tokyo.ac.jp
FU National Cancer Center Research and Development Fund;  [30-A-17];  [2021-A-17]; Grants-in-Aid for Scientific Research [20K10461] Funding Source: KAKEN
CR Alberts NM, 2020, JCO CLIN CANCER INFO, V4, P1014, DOI 10.1200/CCI.20.00070
   Aziz NM, 2003, SEMIN RADIAT ONCOL, V13, P248, DOI 10.1016/S1053-4296(03)00024-9
   Baglia ML, 2019, CANCER-AM CANCER SOC, V125, P2262, DOI 10.1002/cncr.32051
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkaa048
   Boing L, 2020, MATURITAS, V141, P71, DOI 10.1016/j.maturitas.2020.06.022
   Burch JB, 2020, APPL PSYCHOPHYS BIOF, V45, P99, DOI 10.1007/s10484-020-09462-3
   Burton AW, 2007, PAIN MED, V8, P189, DOI 10.1111/j.1526-4637.2006.00220.x
   Cantarero-Villanueva I, 2017, PAIN MED, V18, P1366, DOI 10.1093/pm/pnx026
   Cantarero-Villanueva I, 2012, PAIN MED, V13, P1509, DOI 10.1111/j.1526-4637.2012.01481.x
   Castro-Martín E, 2017, ARCH PHYS MED REHAB, V98, P832, DOI 10.1016/j.apmr.2016.11.019
   Chen ZY, 2021, COMPLEMENT THER MED, V59, P0, DOI 10.1016/j.ctim.2021.102737
   Cochrane Training, 2022, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, V0, P0
   Conejo I, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2236-3
   Couto N, 2022, SCI REP-UK, V12, P0, DOI 10.1038/s41598-022-14213-x
   Cramer JD, 2018, OTOLARYNG HEAD NECK, V159, P853, DOI 10.1177/0194599818783964
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   da Silva FP, 2019, J MANIP PHYSIOL THER, V42, P503, DOI 10.1016/j.jmpt.2018.12.007
   De Groef A, 2018, CLIN REHABIL, V32, P451, DOI 10.1177/0269215517730863
   De Groef A, 2018, ARCH PHYS MED REHAB, V99, P1342, DOI 10.1016/j.apmr.2017.12.032
   Denlinger CS, 2014, J NATL COMPR CANC NE, V12, P488, DOI 10.6004/jnccn.2014.0054
   Sosa-Reina MD, 2017, BIOMED RES INT, V2017, P0, DOI 10.1155/2017/2356346
   Eaton LH, 2021, INT J CLIN EXP HYP, V69, P422, DOI 10.1080/00207144.2021.1951119
   Ellison N, 1997, J CLIN ONCOL, V15, P2974, DOI 10.1200/JCO.1997.15.8.2974
   Fernández-Lao C, 2012, CLIN J PAIN, V28, P113, DOI 10.1097/AJP.0b013e318225dc02
   Fields J, 2016, J PAIN SYMPTOM MANAG, V52, P548, DOI 10.1016/j.jpainsymman.2016.03.010
   Fu MR, 2022, JMIR CANCER, V8, P0, DOI 10.2196/29485
   Galiano-Castillo N, 2016, CANCER-AM CANCER SOC, V122, P3166, DOI 10.1002/cncr.30172
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Glare PA, 2014, J CLIN ONCOL, V32, P1739, DOI 10.1200/JCO.2013.52.4629
   Haddad AR, 2021, WORLD NEUROSURG, V151, P225, DOI 10.1016/j.wneu.2021.04.075
   Hamood R, 2018, BREAST CANCER RES TR, V167, P157, DOI 10.1007/s10549-017-4485-0
   Hayden JA, 2005, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD000335.pub2
   Hayden JA, 2021, J PHYSIOTHER, V67, P252, DOI 10.1016/j.jphys.2021.09.004
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Hilton L, 2017, ANN BEHAV MED, V51, P199, DOI 10.1007/s12160-016-9844-2
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Izquierdo-Alventosa R, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17103634
   Jairam V, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.13605
   Jiang JR, 2019, J CLIN ONCOL, V37, P135, DOI 10.1200/JCO.18.00896
   Kelleher SA, 2021, SUPPORT CARE CANCER, V29, P5361, DOI 10.1007/s00520-021-06126-8
   Kim YH, 2017, OBSTET GYNECOL, V129, P870, DOI 10.1097/AOG.0000000000001988
   Lengacher CA, 2016, J CLIN ONCOL, V34, P2827, DOI 10.1200/JCO.2015.65.7874
   Limakatso K, 2020, PLOS ONE, V15, P0, DOI 10.1101/19008961
   Lu GL, 2020, SUPPORT CARE CANCER, V28, P1587, DOI 10.1007/s00520-019-05186-1
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Makary MM, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-017-18870-1
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   McNeely ML, 2008, CANCER, V113, P214, DOI 10.1002/cncr.23536
   Mishra SI, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007566.pub2
   Mols F, 2014, SUPPORT CARE CANCER, V22, P2261, DOI 10.1007/s00520-014-2255-7
   Mols F, 2013, J CLIN ONCOL, V31, P2699, DOI 10.1200/JCO.2013.49.1514
   Mu JL, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD013814
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Nyrop KA, 2017, ONCOLOGIST, V22, P1238, DOI 10.1634/theoncologist.2017-0174
   ORiordan C, 2014, ARCH PHYS MED REHAB, V95, P770, DOI 10.1016/j.apmr.2013.11.015
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Patel K, 2020, EUR J PAIN, V24, P1440, DOI 10.1002/ejp.1612
   Paulo TRS, 2019, HEALTH QUAL LIFE OUT, V17, P0, DOI 10.1186/s12955-019-1090-4
   Peng N, 2018, BREAST, V37, P18, DOI 10.1016/j.breast.2017.08.003
   Piras A, 2021, EUR REV MED PHARMACO, V25, P3647, DOI 10.26355/eurrev_202105_25930
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Rangon FB, 2018, J BODYW MOV THER, V22, P69, DOI 10.1016/j.jbmt.2017.04.005
   Roberts KE, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012988.pub2
   Rogers ML, 2000, EUR J CARDIO-THORAC, V18, P711, DOI 10.1016/S1010-7940(00)00569-8
   Rowland JH, 2011, MORBIDITY AND MORTALITY WEEKLY REPORT, V60, P269
   Salehifar E, 2020, CLIN DRUG INVEST, V40, P249, DOI 10.1007/s40261-019-00882-6
   Sanford NN, 2019, CANCER-AM CANCER SOC, V125, P4310, DOI 10.1002/cncr.32450
   Serra-Añó P, 2019, SUPPORT CARE CANCER, V27, P2633, DOI 10.1007/s00520-018-4544-z
   Shapiro AC, 2016, BREAST CANCER RES TR, V155, P501, DOI 10.1007/s10549-016-3710-6
   Shergill Y, 2022, PAIN RES MANAG, V2022, P0, DOI 10.1155/2022/4020550
   Sielski R, 2017, INT J BEHAV MED, V24, P25, DOI 10.1007/s12529-016-9572-9
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith SK, 2019, SUPPORT CARE CANCER, V27, P1775, DOI 10.1007/s00520-018-4431-7
   Tanabe Y, 2013, INT J CLIN ONCOL, V18, P132, DOI 10.1007/s10147-011-0352-x
   Tekur P, 2012, COMPLEMENT THER MED, V20, P107, DOI 10.1016/j.ctim.2011.12.009
   Tsai CL, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-94466-0
   Ughreja RA, 2021, COMPLEMENT THER CLIN, V45, P0, DOI 10.1016/j.ctcp.2021.101477
   Valenza MC, 2017, CLIN REHABIL, V31, P753, DOI 10.1177/0269215516651978
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wan X, 2014, BMC MED RES METHODOL, V14, P0, DOI 10.1186/1471-2288-14-135
   Wang L, 2021, CLIN REHABIL, V35, P342, DOI 10.1177/0269215520968251
   Weir CJ, 2018, BMC MED RES METHODOL, V18, P0, DOI 10.1186/s12874-018-0483-0
   Wewege MA, 2018, J BACK MUSCULOSKELET, V31, P889, DOI 10.3233/BMR-170920
   WHO, 2018, WHO GUI PHARM RAD MA, V0, P0
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
   Yang GS, 2017, CANCER NURS, V40, PE26, DOI 10.1097/NCC.0000000000000409
NR 91
TC 4
Z9 5
U1 0
U2 13
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD OCT 12
PY 2022
VL 0
IS 
BP 
EP 
DI 10.21037/apm-22-420
EA OCT 2022
PG 23
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 6L7NE
UT WOS:000888367700001
PM 36408559
DA 2026-01-16
ER

PT J
AU Wang, C
   Zhu, JC
   Zheng, ZW
   Xiong, YZ
   Ma, XF
   Gong, YC
   He, YL
AF Wang, Chao
   Zhu, Jun-Chen
   Zheng, Zhi-Wen
   Xiong, Ying-Zong
   Ma, Xing-Fu
   Gong, Yue-Cheng
   He, Ye-Lin
TI [Effects of acupotomy on partial movement gait and serum tumor necrosis factor-α,
SO Zhongguo gu shang = China journal of orthopaedics and traumatology
LA chi
DT Journal Article
DE Acupotomy therapy; Gait analysis; Interleukin-1β; Osteoarthritis, knee; Tumor necrosis factor-α
AB OBJECTIVE: To explore effects of acupotomy on pain, function, gait and serum  inflammatory factors in patients with knee osteoarthritis(KOA). METHODS: From  December 2017 to June 2019, 110 patients with KOA were collected and divided into  acupotomy group(56 cases) and western medicine group(54 cases) by using random  number table method. In acupotomy group, there were 16 males and 40 females, aged  from 46 to 74 years old with an average of (62.98±6.68) years old, the course of  disease ranged from 1 to 240 months with an average of 24.5(15.25, 33.00)  months;were treated with acupotomy on the pain points around knee joint once a  week for 3 weeks. In western medicine group, there were 18 males and 36 females,  aged from 47 to 73 years old with an average of (64.19±5.98 ) years old;the  course of disease ranged from 1 to 220 months with an average of 25.00(13.75,  33.00) months;were took celecoxib capsule orally, 200 mg once a day for 3 weeks.  Oxford Knee Score(OKS) was performed before treatment, 3 weeks and 3 months after  treatment. Gait kinematics analysis and serum levels of tumor necrosis  factor-α(TNF-α) and interleukin-1β (IL-1β) were measured before and after  treatment for 3 weeks. RESULTS: All patients were followed up from 6 to 24 months  with an average of(15.03±4.55) months. OKS between two groups decreased  significantly at 3 weeks and 3 months after treatment(P<0.001). Functional scores  and overall scores in acupotomology group were significantly decreased at 3  months compared with 3 weeks after treatment(P<0.001). OKS of acupotomy group  were significantly lower than those of western medicine group at 3 weeks and 3  months after treatment(P<0.05). Gait speed, frequency and length between two  groups were significantly improved at 3 weeks after treatment(P<0.05). At 3 weeks  after treatment, gait freguency of acupotomy group was significantly improved  compared with western medicine group(P<0.05). TNF-α and IL-1β were significantly  lower in both groups at 3 weeks after treatment than before treatment(P<0.05). At  3 weeks after treatment, level of IL-1 β was lower in western medicine group than  in acupotomy group(P<0.05), and difference in TNF-α level was not statistically  significant(P>0.05). CONCLUSION: Acupotomology of pain points could significantly  improve pain, function, gait, and decreased serum inflammatory factors at early  to mid stage of KOA patients, in particular, it is superior to non-steroidal  anti-inflammatory drugs in terms of knee function recovery and cadence  improvement.
C1 The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, Anhui, China.
   The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, Anhui, China.
   The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, Anhui, China.
   The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, Anhui, China.
   The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, Anhui, China.
   The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, Anhui, China.
   The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, Anhui, China.
NR 0
TC 0
SN 
EI 1003-003
J9 Zhongguo Gu Shang
PD SEP 21
PY 2022
VL 35
IS 9
BP 848
EP 52
DI 10.12200/j.issn.1003-0034.2022.09.009
PG -796
WC Acupuncture Therapy; Aged; Anti-Inflammatory Agents, Non-Steroidal; therapeutic use; Celecoxib; therapeutic use; Female; Gait; Humans; Interleukin-1beta; Male; Middle Aged; Osteoarthritis, Knee; drug therapy; Pain; drug therapy; Tumor Necrosis Factor-alpha
UT PubMed:36124455
PM 36124455
DA 2022-09-21
ER

PT J
AU Geagea, D
   Tyack, Z
   Kimble, R
   Polito, V
   Ayoub, B
   Terhune, DB
   Griffin, B
AF Geagea, Dali
   Tyack, Zephanie
   Kimble, Roy
   Polito, Vince
   Ayoub, Bassel
   Terhune, Devin B
   Griffin, Bronwyn
TI Clinical Hypnosis for Procedural Pain and Distress in Children: A Scoping Review.
SO Pain medicine (Malden, Mass.)
LA English
DT Journal Article
DE Children; Clinical Hypnosis; Distress; Procedural Pain; Scoping Review
AB OBJECTIVE: Pain and distress are common in children undergoing medical  procedures, exposing them to acute and chronic biopsychosocial impairments if  inadequately treated. Clinical hypnosis has emerged as a potentially beneficial  treatment for children's procedural pain and distress due to evidence of  effectiveness and potential superiority to other psychological interventions.  However, systematic reviews of clinical hypnosis for children's procedural pain  and distress have been predominantly conducted in children undergoing oncology  and needle procedures and are lacking in broader pediatric contexts. This scoping  review maps the evidence of clinical hypnosis for children's procedural pain and  distress across broad pediatric contexts while highlighting knowledge gaps and  areas requiring further investigation. METHODS: Published databases (PubMed,  Cochrane Library, PsycINFO, Embase, CINAHL, Scopus, and Web of Science) and grey  literature were searched in addition to hand-searching reference lists and key  journals (up to May 2022). Two independent reviewers screened the titles and  abstracts of search results followed by a full-text review against eligibility  criteria. Articles were included if they involved a clinical hypnosis  intervention comprising an induction followed by therapeutic suggestions for pain  and distress in children undergoing medical procedures. This review followed the  Arksey and O'Malley (2005) methodology and incorporated additional scoping review  recommendations by the Joanna Briggs Institute and Preferred Reporting Items for  Systematic Reviews and Meta-Analyses. RESULTS: A total of 38 eligible studies  involving 2,205 children were included after 4,775 articles were screened.  Research on clinical hypnosis for children's procedural pain and distress was  marked by a lack of fidelity measures and qualitative data as well as by  inadequate intervention reporting and high attrition rates. Evidence regarding  the safety of clinical hypnosis, pain unpleasantness outcomes, factors  influencing outcomes, as well as barriers and facilitators to implementing  hypnosis and study procedures was also lacking. Clinical hypnosis has potential  benefits for children's procedural pain and distress based on evidence of  superiority to control conditions and nonpharmacological interventions (e.g.,  distraction, acupressure) with moderate to large effect sizes as reported in 76%  of studies. However, heterogeneous interventions, contexts, study designs, and  populations were identified, and the certainty of the evidence was not evaluated.  CONCLUSIONS: The review suggests potential benefits of clinical hypnosis for  children's procedural pain and distress and thus provides a precursor for further  systematic reviews and trials investigating the effectiveness of clinical  hypnosis. The review also indicates the need to further explore the feasibility,  acceptability, implementation, and safety of clinical hypnosis in children  undergoing painful procedures. Based on the review, researchers implementing  clinical hypnosis should adequately report interventions or use treatment  manuals, follow recommended research guidelines, and assess the fidelity of  intervention delivery to promote replicating and comparing interventions. The  review also highlights common methodological shortcomings of published trials to  avoid, such as the lack of implementation frameworks, small sample sizes,  inadequate reporting of standard care or control conditions, and limited evidence  on pain unpleasantness outcomes.
C1 Child Health Research Centre, Centre for Children's Burns and Trauma Research, The University of Queensland, Brisbane, Australia.
   Child Health Research Centre, Centre for Children's Burns and Trauma Research, The University of Queensland, Brisbane, Australia.
   Australian Centre for Health Service Innovation and Centre for Healthcare 
   Centre for Children's Burns and Trauma Research, Queensland Children's Hospital, The University of Queensland, Brisbane, Australia.
   School of Psychological Sciences, Macquarie University, Sydney, Australia.
   Faculty of Health, Queensland University of Technology, Brisbane, Australia.
   Department of Psychology, Goldsmiths University of London, London, UK.
   Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, 
   School of Nursing and Midwifery, Griffith University, Nathan, Queensland, Australia.
NR 0
TC 0
SN 1526-463
EI 1526-237
J9 Pain Med
PD DEC 1
PY 2022
VL 24
IS 6
BP 661
EP 702
DI 10.1093/pm/pnac186
PG 41
WC Child; Humans; Hypnosis; Needles; Pain; psychology; Pain, Procedural; therapy; Punctures
UT PubMed:36448690
PM 36448690
DA 2022-12-01
ER

PT J
AU Brozovic, G
   Lesar, N
   Janev, D
   Bosnjak, T
   Muhaxhiri, B
AF Brozovic, Gordana
   Lesar, Nikola
   Janev, Dimitar
   Bosnjak, Tomislav
   Muhaxhiri, Burim
TI CANCER PAIN AND THERAPY
SO ACTA CLINICA CROATICA
LA English
DT Article; Proceedings Paper
DE cancer pain; opioids; non-opioids; adjuvant drugs; regional nerve block; integrative medicine
ID management; update
AB Cancer pain is not a homogenous and clearly understood pathological process. The best treatment is a combination of drug and non-drug measures. Pain is divided into visceral, bone or neuropathic pain and has characteristics of continuous or intermittent pain. Cancer bone pain therapy remains centered on strong opioid, radiotherapy and bisphosphonates. Invasive procedures are aimed to improve neurological function, ambulation and pain relief. Solid tumors often demand surgery. Treatment of acute postoperative pain is crucial for the prevention of chronic pain. Chemotherapy and radiation sometimes also cause pain. The management of cancer pain has improved because of rapid diagnosis and treatment, understanding of analgesics and the cooperation of patients and their family. The presence of special pain centers in hospitals also raise standard of cancer pain management. Drug therapy with non-opioid, opioid and adjuvant drugs is the base of such management. The side effects must be monitored and timely treated. Methods of regional nerve blockade in pain control are numerous. Placement of epidural, intrathecal and subcutaneous catheters, conductive nerve blocks with continuous delivery of mixed local anesthetics are very successful for selected patients. Conventional physical therapy involving lymphatic drainage is useful. Acupuncture, psychotherapy and similar methods are also applicable.
C1 [Brozovic, Gordana; Lesar, Nikola; Janev, Dimitar; Bosnjak, Tomislav; Muhaxhiri, Burim] Univ Hosp Tumors, Sestre Milosrdnice Univ Hosp Ctr, Div Anaesthesiol Reanimatol & Intens Care Med, Zagreb, Croatia.
   [Brozovic, Gordana] Josip Juraj Strossmayer Univ Osijek, Fac Dent Med & Hlth, Osijek, Croatia.
C3 University of Zagreb; University of JJ Strossmayer Osijek
RP Brozovic, G (corresponding author), Sestre Milosrdnice Univ Hosp Ctr, Div Anaesthesiol Reanimatol & Intens Care Med, Ilica 197, Zagreb, Croatia.
EM brozovic.gordana@gmail.com
CR Ahmedzai SH, 2015, SUPPORT CARE CANCER, V23, P823, DOI 10.1007/s00520-014-2435-5
   Anderson PM, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12061675
   Balkic J, 2020, NUTR HOSP, V37, P577, DOI 10.20960/nh.02822
   Bender JL, 2013, SUPPORT CARE CANCER, V21, P1253, DOI 10.1007/s00520-012-1655-9
   Bennett MI, 2017, PAIN, V158, PS74, DOI 10.1097/j.pain.0000000000000825
   Brozovic G, 2015, PERIOD BIOL, V117, P219
   Caraceni A, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11040510
   Chapman EJ, 2020, PALLIATIVE MED, V34, P444, DOI 10.1177/0269216319896955
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Gibbins J, 2014, PALLIATIVE MED, V28, P71, DOI 10.1177/0269216313486310
   Greco MT, 2014, J CLIN ONCOL, V32, P4149, DOI 10.1200/JCO.2014.56.0383
   Kane CM, 2018, PALLIATIVE MED, V32, P276, DOI 10.1177/0269216317711826
   Maindet C, 2019, SUPPORT CARE CANCER, V27, P3119, DOI 10.1007/s00520-019-04829-7
   Marinangeli F, 1900, V17, V0, P34
   Operating Unit University Hospital for Tumors Sestre milosrdnice University Hospital Center Zagreb Croatia, 2020, LIBRI ONCOLOGICI CROATIAN JOURNAL OF ONCOLOGY, V48, P8, DOI 10.20471/lo.2020.48.01.02
   Pawasarat IM, 2020, J PALLIAT MED, V23, P809, DOI 10.1089/jpm.2019.0374
   Porta-Sales J, 2017, PALLIATIVE MED, V31, P5, DOI 10.1177/0269216316639793
   Rados I, 2013, EUR NEUROL, V69, P27, DOI 10.1159/000338265
   Rivera CE, 2018, PHYS MED REH CLIN N, V29, P73, DOI 10.1016/j.pmr.2017.08.007
   Smith FL, 1998, PHARMACOL BIOCHEM BE, V60, P559, DOI 10.1016/S0091-3057(98)00012-4
   Subramanian CR, 2021, CUREUS J MED SCIENCE, V13, P0, DOI 10.7759/cureus.13332
   van den Beuken-van Everdingen MHJ, 2017, PAIN PRACT, V17, P409, DOI 10.1111/papr.12459
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Vardeh D, 2016, J PAIN, V17, PT50, DOI 10.1016/j.jpain.2016.03.001
NR 25
TC 18
Z9 25
U1 0
U2 14
PU SESTRE MILOSRDNICE UNIV HOSPITAL
PI ZAGREB
PA VINOGRADSKA C 29, ZAGREB, HR-10000, CROATIA
SN 0353-9466
EI 1333-9451
J9 ACTA CLIN CROAT
JI Acta Clin. Croat.
PD JUN 15
PY 2022
VL 61
IS 
BP 103
EP 108
DI 10.20471/acc.2022.61.s2.13
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 7I6WQ
UT WOS:000904026200014
PM 36824638
DA 2026-01-16
ER

PT J
AU Panicker, L
   Prasun, MA
   Stockmann, C
   Simon, J
AF Panicker, Latha
   Prasun, Marilyn A.
   Stockmann, Cherrill
   Simon, Jolene
TI Evaluation of Chronic, Noncancer Pain Management Initiative in a Multidisciplinary Pain Clinic
SO PAIN MANAGEMENT NURSING
LA English
DT Article
ID opioids; reduction; therapy
AB Background: Chronic pain management is a major challenge for primary care providers (PCPs). PCPs manage many patients with chronic pain and other comorbidities including mental health problems like post-traumatic stress disorder (PTSD) and depression. Chronic pain and opioid problems are a national crisis, particularly among veterans (U.S. Department of Veterans Affairs, 2019). There are many veterans with chronic non-cancer pain who are being treated with opioids. Chronic opioid use has contributed to an epidemic of opioid-related adverse events (VA, 2017). Opioids not only result in poor pain control, but have associated risks such as misuse, overdose, and diversion which may be fatal (Frieden & Houry, 2016). Aims: The aim of this project was to evaluate chronic non-cancer pain management of veterans using an advanced practice registered nurse (APRN)-led multidisciplinary team approach to incorporate non-opioid and non-pharmacologic modalities to affect self-reported pain and use of prescribed opioids. Methods: A retrospective quality improvement (QI) project was conducted in the multidisciplinary pain (MDP) clinic. The APRN used a biopsychosocial approach for chronic pain management guided by the Plan, Do, Study, Act (PDSA) cycle framework. Thirty-four patients who were utilizing opioids for pain management were included using convenience sampling from the MDP clinic. The APRN educated and treated patients with non-opioid medications and non-pharmacolog therapies. A 10-point pain scale and morphine equivalent daily dose (MEDD) were utilized pre- and post-intervention to evaluate the MDP clinic. Results: Participants were predominantly male (91.8%), with a mean age of 63.18 +/- 15.39 years, and 36.4% of whom were retired. Only 20.6% of the participants reported the use of opioids for <12 months. Low back pain (93%) was the most common pain location. The mean baseline MEDD was 41.04 and the post tapered MEDD was 23.05; this revealed a significant decline in MEDD (p <.00 01). A decline was also found between pre- and post-pain scores (ranges 0-8). There was a significant reported decline in pain scores with a baseline of 6.11 to post tapering pain of 3.1 (t = 4.99, df = 28, p <.0 001). Participants preferred non-opioid medications 94% and non-pharmacologic therapy 86%, like physical therapy, yoga, and acupuncture. Fifty-one percent of patients were referred for injections and 46% were referred to primary care behavior health, which includes pain school, sleep hygiene classes, and cognitive behavior therapy. Conclusions: APRNs are in a key position to assess and treat patients based on current evidence while facilitating opioid titration. This initiative highlights that safe tapering of opioids is possible when utilizing a multidisciplinary approach for chronic pain management. Findings support the use of non-pharmacologic and non-opioid therapy for chronic pain management which can result in reduced patient-reported pain. Further research is warranted to examine both pharmacologic (non-opioid) and non-pharmacologic strategies that promote pain management while tapering opioids. Published by Elsevier Inc. on behalf of American Society for Pain Management Nursing.
C1 [Panicker, Latha; Prasun, Marilyn A.; Stockmann, Cherrill] Illinois State Univ, Mennonite Coll Nursing, Normal, IL 61761 USA.
   [Panicker, Latha; Simon, Jolene] Edward Hines Jr VA Hosp, Hines, IL USA.
C3 Illinois State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital
RP Panicker, L (corresponding author), 800 S Wilmette Ave, Westmont, IL 60559 USA.
EM latha.panicker@va.gov
CR Ashton-James CE, 2019, PAIN, V160, P1586, DOI 10.1097/j.pain.0000000000001543
   Centers for Disease Control and Prevention (CDC), 2018, CALC TOT DAIL DOS OP, V0, P0
   Centers for Disease Control and Prevention (CDC), 2020, COMPR LOOK DRUG OV U, V0, P0
   Centers for Disease Control and Prevention (CDC), 2019, MAN CHRON PAIN, V0, P0
   Centers for Disease Control and Prevention (CDC), 2019, INF PROV SAF PRESCR, V0, P0
   Centers for Disease Control and Prevention(CDC), 2016, CDC GUID PRESCR OP C, V0, P0
   Chou Roger, 2014, EVID REP TECHNOL ASSESS (FULL REP), V0, PP1, DOI 10.23970/AHRQEPCERTA218
   Christo PJ, 2020, J LAW MED ETHICS, V48, P241, DOI 10.1177/1073110520935335
   Costello M, 2016, MEDSURG NURSING, V25, P307
   Ding Y, 2020, TOTAL EXPENSES, V0, P0
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Frank JW, 2016, PAIN MED, V17, P1838, DOI 10.1093/pm/pnw078
   Frieden TR, 2016, NEW ENGL J MED, V374, P1501, DOI 10.1056/NEJMp1515917
   Furlan AD, 2011, PAIN RES MANAG, V16, P337, DOI 10.1155/2011/465281
   Gauthier K, 2019, MULTIDISCIPLINARY TREATMENT PROGRAMS FOR PATIENTS WITH CHRONIC NON-MALIGNANT PAIN: A REVIEW OF CLINICAL EFFECTIVENESS, V0, P0
   Giron SE, 2015, PAIN MANAG NURS, V16, P819, DOI 10.1016/j.pmn.2015.04.001
   Harden P, 2015, PAIN MED, V16, P1975, DOI 10.1111/pme.12812
   Hassan S, 2020, PAIN MED, V21, P836, DOI 10.1093/pm/pnz291
   Kertesz SG, 2020, J LAW MED ETHICS, V48, P259, DOI 10.1177/1073110520935337
   Kligler BE, 2016, ALTERN COMPLEMENT TH, V22, P237, DOI 10.1089/act.2016.29080.bek
   Krebs EE, 2018, JAMA-J AM MED ASSOC, V319, P872, DOI 10.1001/jama.2018.0899
   Lin LW, 2019, AM J PREV MED, V57, P106, DOI 10.1016/j.amepre.2019.01.016
   Lumish R, 2018, J GERONTOL NURS, V44, P9, DOI 10.3928/00989134-20171213-04
   Mehl-Madrona L, 2016, J ALTERN COMPLEM MED, V22, P621, DOI 10.1089/acm.2015.0212
   Nicholas MK, 2020, PAIN, V161, P509, DOI 10.1097/j.pain.0000000000001763
   Salmond S, 2019, ORTHOP NURS, V38, P95, DOI 10.1097/NOR.0000000000000521
   Sullivan MD, 2017, J PAIN, V18, P308, DOI 10.1016/j.jpain.2016.11.003
   USDepartment of Veterans Affairs, 2019, TRANSF TREATM CHRON, V0, P0
   USDepartment of Veterans Affairs, 2017, VA DOD CLIN PRACT GU, V0, P0
   USFood & Drug Administration, 2017, UPDATE FDA DRUG SAFE, V0, P0
   Weeks E, 2018, KANSAS LAW REV, V67, P1132
   Yi P, 2015, PAIN MED, V16, PS32, DOI 10.1111/pme.12914
NR 33
TC 8
Z9 8
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1524-9042
EI 1532-8635
J9 PAIN MANAG NURS
JI Pain Manag. Nurs.
PD APR 15
PY 2022
VL 23
IS 2
BP 122
EP 127
DI 10.1016/j.pmn.2021.09.003
EA MAR 2022
PG 6
WC Nursing
SC Nursing
GA ZW4ST
UT WOS:000771205500004
PM 34756689
DA 2026-01-16
ER

PT J
AU Wei, JQ
   Yang, ZH
   Lin, QT
   Xu, HY
   Lai, F
   Han, Y
   Li, J
   Cui, S
AF Wei, Jinqiang
   Yang, Zihong
   Lin, Qiutian
   Xu, Haiyan
   Lai, Fang
   Han, Yun
   Li, Jun
   Cui, Shuai
TI Bibliometric and visualized analysis of electroacupuncture in the past 10 years
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE Electroacupuncture; CiteSpace; Research status; Cooperation
ID induced neuropathic pain; irritable-bowel-syndrome; spinal-cord; research trends; acupuncture therapy; stem-cells; rats; injury; mechanisms; expression
AB Background: There are many studies that have interrogated the evolution and use of electroacupuncture (EA). We aimed to evaluate the research status, cooperation and development of EA in the past 10 years. Methods: We obtained data on the EA from the Web of Science core collection database. CiteSpace 5.7. R1 software was used to assess research cooperation through analysis of authors, institutions and countries. In addition, keyword cluster analysis, references and burst detection were analyzed to explore research hotspots and trends in the field of EA. Results: We included a total of 3019 citing literature and 78,235 cited literature for analysis. The data showed that there has been a rise in the global number of EA studies in the past decade. Besides, the data demonstrated that China has made outstanding contribution in the development of EA. Whereas there is inter-agency cooperation in China, there is less cooperation with other countries. In addition, we showed frequent use of keywords such as "expression", "stimulation", or "pain". Besides, neuroscience was the main research area, followed by general medicine and oncology. Furthermore, with the improved research methods and technologies, there is enhanced overall quality of the studies. Conclusion: Taken together, our findings demonstrate a steady increase in the studies involving EA. However, the studies are unevenly distributed among countries and thus there is need for closer international cooperation.
C1 [Wei, Jinqiang; Yang, Zihong; Lin, Qiutian; Lai, Fang; Han, Yun; Li, Jun] Guangzhou Univ Chinese Med, Clin Coll 2, 36 Yongan St, Guangzhou, Guangdong, Peoples R China.
   [Xu, Haiyan] Guangzhou Univ Chinese Med, Clin Coll 7, Guangzhou, Peoples R China.
   [Lai, Fang; Han, Yun; Li, Jun] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Cui, Shuai] Anhui Univ Chinese Med, Res Inst Acupuncture & Meridian, Hefei, Peoples R China.
   [Cui, Shuai] Guangzhou Univ Chinese Med, Med Coll Acupuncture Moxibust & Rehabil, South China Res Ctr Acupuncture & Moxibust, Guangzhou, Peoples R China.
   [Lai, Fang; Han, Yun] Guangdong Prov Hosp Chinese Med, Chao En Xiang Famous Chinese Med Expert Inheritan, Guangzhou, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Anhui University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Lai, F (corresponding author), Guangzhou Univ Chinese Med, Clin Coll 2, 36 Yongan St, Guangzhou, Guangdong, Peoples R China.
EM 13016090@qq.com
FU National Natural Science Foundation of China [81703856]; Guangdong Provincial Key Laboratory of Research on Emergency in TCM [2017B030314176]
CR Burnstock G, 2014, SCIENCE, V346, P0
   Chen CM, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0223994
   Chen CM, 2006, J AM SOC INF SCI TEC, V57, P359, DOI 10.1002/asi.20317
   Chen YY, 2008, ACUPUNCTURE ELECTRO, V33, P19, DOI 10.3727/036012908803861212
   Choi DC, 2010, NEUROBIOL DIS, V39, P272, DOI 10.1016/j.nbd.2010.04.003
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Fang JQ, 2018, LIFE SCI, V200, P69, DOI 10.1016/j.lfs.2018.03.028
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Han JS, 2011, PAIN, V152, PS41, DOI 10.1016/j.pain.2010.10.012
   Harbi SA, 2020, NAT MED, V9, P1, DOI 10.1038/s41591-020-0897-1
   Huang C, 2002, BRAIN RES, V945, P20, DOI 10.1016/S0006-8993(02)02503-9
   Huang L, 2021, J PAIN RES, V14, P343, DOI 10.2147/JPR.S292657
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Jia LL, 2020, OXID MED CELL LONGEV, V2020, P0, DOI 10.1155/2020/9187406
   Jia XJ, 2016, CHIN ARCH TRAD CHIN, V34, P1404
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Law SK, 2015, AM J OPHTHALMOL, V160, P256, DOI 10.1016/j.ajo.2015.04.033
   Li J, 2017, CITESPACE: TEXT MINING AND VISUALIZATION IN SCIENTIFIC LITERATURE, V2nd, P0
   Li LL, 2018, CHIN J INTEGR MED, V24, P822, DOI 10.1007/s11655-017-2924-8
   Li RR, 2020, J PAIN RES, V13, P1901, DOI 10.2147/JPR.S258739
   Li XY, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-37
   Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0
   Lu CC, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.00294
   Lu KW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22123
   Lu YW, 2020, BIOMED RES INT, V2020, P0, DOI 10.1155/2020/3901528
   Mao CL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7486041
   Mao XJ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020137
   Miao M, 2020, CHIN J MED SCI RES M, V33, P249
   Nardini C, 2014, SCIENCE, V346, P0
   Ning YZ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000022068
   Qu ZY, 2020, J PAIN RES, V13, P25, DOI 10.2147/JPR.S226922
   Shi XH, 2021, BRAIN BEHAV, V11, P0, DOI 10.1002/brb3.1927
   Song YF, 2020, AM J CHINESE MED, V48, P77, DOI 10.1142/S0192415X20500044
   Song YY, 2020, CHIN J INTEGR MED, V26, P473, DOI 10.1007/s11655-020-3092-9
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wang WH, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/5419407
   Wang Y, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0059449
   Wang YJ, 2019, BIOL RES NURS, V21, P5, DOI 10.1177/1099800418804896
   Wu L, 2021, ANN PALLIAT MED, V10, P3194, DOI 10.21037/apm-21-477
   Xing D, 2018, INT J RHEUM DIS, V21, P1372, DOI 10.1111/1756-185X.13327
   Xiong L, 2003, CHINESE MED J-PEKING, V116, P108
   Xu M, 2019, CHIN HOSP MANAG, V39, P0
   Xue M, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21186524
   Yang FM, 2020, CHIN J INTEGR MED, V26, P310, DOI 10.1007/s11655-019-3150-3
   Yang Y, 2020, NEUROREPORT, V31, P1072, DOI 10.1097/WNR.0000000000001518
   Yao LM, 2020, CHEMOSPHERE, V245, P0, DOI 10.1016/j.chemosphere.2019.125627
   Yeo S, 2014, BMC COMPLEM ALTERN M, V0, P14
   Yeung WF, 2011, SLEEP, V34, P807, DOI 10.5665/SLEEP.1056
   Zhan J, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2017-017153
   Zhang JH, 2021, FRONT NEUROSCI-SWITZ, V14, P0, DOI 10.3389/fnins.2020.620555
   Zhang JY, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/9786482
   Zhang JF, 2017, MOL MED REP, V16, P2185, DOI 10.3892/mmr.2017.6801
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang Y, 2020, J KING SAUD UNIV SCI, V32, P1366, DOI 10.1016/j.jksus.2019.11.029
   Zhang YY, 2020, CHIN J INTEGR MED, V0, P0
   Zhao JM, 2018, CHIN J INTEGR MED, V24, P328, DOI 10.1007/s11655-018-2838-0
   Zhao TT, 2021, J PAIN RES, V14, P1399, DOI 10.2147/JPR.S306594
   Zhao YX, 2020, J PAIN RES, V13, P239, DOI 10.2147/JPR.S241101
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zheng Y, 2020, NEURAL PLAST, V2020, P0, DOI 10.1155/2020/8818328
   Zheng YY, 2020, BRAIN RES BULL, V162, P1, DOI 10.1016/j.brainresbull.2020.04.020
   Zheng Z, 2019, PAIN MED, V20, P397, DOI 10.1093/pm/pny113
   Zhong YJ, 2020, J TRADIT CHIN MED, V40, P707, DOI 10.19852/j.cnki.jtcm.2020.05.001
   Zhou J, 2019, BIOMED RES INT, V2019, P0, DOI 10.1155/2019/7491281
   Zhou X, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/9254503
   Zhou ZD, 2020, MOL MED REP, V22, P751, DOI 10.3892/mmr.2020.11161
   Zhu Y, 2017, BRAIN RES BULL, V131, P123, DOI 10.1016/j.brainresbull.2017.04.003
   Zhu YZ, 2012, NEURAL REGEN RES, V7, P207, DOI 10.3969/j.issn.1673-5374.2012.03.009
   Zou F, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8839491
NR 70
TC 6
Z9 7
U1 2
U2 105
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD OCT 15
PY 2022
VL 69
IS 
BP 
EP 
DI 10.1016/j.ctim.2022.102846
EA JUN 2022
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 2T5KG
UT WOS:000822512800003
PM 35688327
DA 2026-01-16
ER

PT J
AU Ehret, CJ
   Almodallal, Y
   Le-Rademacher, JG
   Martin, NA
   Moynagh, MR
   Rajotia, A
   Jatoi, A
AF Ehret, Christopher J
   Almodallal, Yahya
   Le-Rademacher, Jennifer G
   Martin, Nichole A
   Moynagh, Michael R
   Rajotia, Arush
   Jatoi, Aminah
TI Hiccups in patients with cancer: a multi-site, single-institution study of
SO BMC cancer
LA English
DT Journal Article
DE Complications; Hiccups; Morbidity; Palliation
AB BACKGROUND: To our knowledge, previous studies have not investigated hiccups in  patients with cancer with detailed patient-level data with the goal of capturing  a broad spectrum of hiccup symptomatology. METHODS: This multi-site, single  institution study examined consecutive medical records to better understand  hiccups in patients with cancer. RESULTS: A total of 320 patients are the focus  of this report. The median age of patients when hiccups were first reported in  the medical record was 63 years (range: 21, 97 years) with 284 (89%) men and 36  (11%) women. The most common diagnose was gastrointestinal cancer. Hiccups most  frequently occurred daily, as seen in 194 patients (62%), and the most common  duration was less than 1 week, as seen in 146 patients (47%). However, nine  patients had had daily hiccups for greater than 6 weeks, and 5 had symptoms for  years. Cited etiology was non-chemotherapy medications in 36 (11%) and cancer  chemotherapy in 19 (6%). Complications occurred in approximately a third and  included insomnia in 51 patients (16%); hospitalization or emergency department  visit in 34 (11%); and musculoskeletal pain in 23 (7%). Baclofen was the single  most prescribed agent for hiccup palliation, but 100 patients received more than  one medication. Medical procedures, which included acupuncture, paracentesis, or  phrenic nerve block, were performed in 5 patients. In 234 patients (73%), the  medical record documented hiccup cessation. CONCLUSIONS: Hiccups appear to be  highly problematic in a small subset of patients with cancer with no well-defined  palliative approaches.
C1 Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
   Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
   Division of Clinical Trials and Biostatistics, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
   Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
   Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
   Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
   Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. jatoi.aminah@mayo.edu.
NR 0
TC 0
SN 1471-240
EI 
J9 BMC Cancer
PD JUN 16
PY 2022
VL 22
IS 1
BP 659
EP 659
DI 10.1186/s12885-022-09760-5
PG 0
WC Baclofen; therapeutic use; Female; Hiccup; complications; Humans; Male; Neoplasms; drug therapy; Palliative Care; Sleep Initiation and Maintenance Disorders; complications
UT PubMed:35705907
PM 35705907
DA 2022-06-16
ER

PT J
AU Oberoi, D
   Reed, EN
   Piedalue, KA
   Landmann, J
   Carlson, LE
AF Oberoi, Devesh
   Reed, Erica N.
   Piedalue, Katherine-Ann
   Landmann, Jessa
   Carlson, Linda E.
TI Exploring patient experiences and acceptability of group vs. individual acupuncture for Cancer-related pain: a qualitative study
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Oncology; Acupuncture; Group acupuncture; Individual acupuncture; Qualitative; Patient experience; Social support; Patient privacy
ID integrative oncology; complementary; chemotherapy; therapy; trial
AB Background: Individual acupuncture (AP) is a safe and effective treatment for cancer-related pain and other symptoms in cancer survivors. However, access to individual AP is limited, and costs can be prohibitive. Group AP could be a more cost-effective alternative as it is less expensive and non-inferior to individual AP for pain relief. Despite growing evidence in favour of group AP, patient acceptability and experience of group AP in cancer patients is relatively unknown. This exploratory study sought to compare patient experiences and acceptability of group versus individual AP in cancer patients. Methods: Semi-structured, open-ended, in-depth interviews were conducted in a subset of 11 cancer patients enrolled in a randomized non-inferiority trial of group vs. individual AP for cancer pain. Participants for this study were recruited via purposive sampling, aiming for diversity in age, sex, education, employment, cancer types, and treatment arms. Data was analyzed using inductive thematic analysis. Results: Two major themes were identified: a) overall experience of AP treatment b) value of AP. Participants across both treatment arms acknowledged improvement in pain, quality of sleep, mood and fatigue. Participants in the group AP arm reported a significant increase in perceived social support, while participants in the individual arm valued privacy and one-on-one interaction with the acupuncturist. Although some participants in the group arm had privacy-related concerns before the commencement of the program, these concerns waned after a few AP sessions. Participants across both the treatment arms reported cordial clinician-patient relationship with the acupuncturist. Willingness to pursue AP treatment in the future was comparable across both the treatment arms and was limited by out-of-pocket costs. Conclusion: Patient acceptability and experience of treatment in group AP was on par with individual AP. Group AP may further augment perceived social support among patients and privacy concerns, if any, subside after a few sessions.
C1 [Oberoi, Devesh; Reed, Erica N.; Piedalue, Katherine-Ann; Carlson, Linda E.] Univ Calgary, Cumming Sch Med, Dept Oncol, Div Psychosocial Oncol, Calgary, AB, Canada.
   [Landmann, Jessa] Vive Integrat Hlth Grp, 1889-45 St NW, Calgary, AB, Canada.
   [Carlson, Linda E.] Tom Baker Canc Clin, Dept Psychosocial Oncol, Canc Control Alberta, Holy Cross Site,2202 2nd St SW, Calgary, AB T2S 3C1, Canada.
C3 University of Calgary; Tom Baker Cancer Clinic; University of Calgary
RP Carlson, LE (corresponding author), Univ Calgary, Cumming Sch Med, Dept Oncol, Div Psychosocial Oncol, Calgary, AB, Canada.; Carlson, LE (corresponding author), Tom Baker Canc Clin, Dept Psychosocial Oncol, Canc Control Alberta, Holy Cross Site,2202 2nd St SW, Calgary, AB T2S 3C1, Canada.
EM lcarlso@ucalgary.ca
FU Enbridge Research Chair in Psychosocial Oncology - Canadian Cancer Society Alberta/NWT Division; Alberta Cancer Foundation
CR Unknown -, 1999, DOING QUALITATIVE RESEARCH, V0, P0
   Asprey A, 2012, ACUPUNCT MED, V30, P163, DOI 10.1136/acupmed-2012-010150
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Beer TM, 2010, UROLOGY, V76, P1182, DOI 10.1016/j.urology.2010.03.033
   Bishop FL, 2011, BMC HEALTH SERV RES, V11, P0, DOI 10.1186/1472-6963-11-129
   Brandao T, 2017, PSYCHO-ONCOLOGY, V26, P917, DOI 10.1002/pon.4230
   Brick WG, 2016, J CLIN ONCOL, V34, P0, DOI 10.1200/JCO.2016.34.15_suppl.e21592
   Chao MT, 2012, J ALTERN COMPLEM MED, V18, P561, DOI 10.1089/acm.2011.0128
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Chuang E, 2018, J ALTERN COMPLEM MED, V24, P336, DOI 10.1089/acm.2017.0262
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021
   Joffe H, 2003, RES METHODS CLIN HLT, V0, P56
   Kligler B, 2018, PAIN MED, V19, P393, DOI 10.1093/pm/pnx134
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   Pfab F, 2006, DTSCH Z AKUPUNKT, V49, P45, DOI 10.1078/0415-6412-00165
   Qureshi M, 2018, INTEGR CANCER THER, V17, P844, DOI 10.1177/1534735418762496
   Reed EN, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7209548
   Running A, 2012, CURR PAIN HEADACHE R, V16, P325, DOI 10.1007/s11916-012-0275-x
   Simcock R, 2009, ACUPUNCT MED, V27, P109, DOI 10.1136/aim.2009.000935
   Tippens KM, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-293
   Tofthagen C, 2015, J PALLIAT MED, V18, P878, DOI 10.1089/jpm.2015.0143
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Wang T, 2018, BMC PALLIAT CARE, V17, P0, DOI 10.1186/s12904-018-0346-9
   Warth M, 2020, CURR ONCOL REP, V22, P0, DOI 10.1007/s11912-020-0870-7
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012508.pub2
   Witt Claudia, 2006, ACUPUNCTURE IN MEDICINE, V24, P33, DOI 10.1136/aim.24.Suppl.33
NR 30
TC 9
Z9 9
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD JUN 13
PY 2022
VL 22
IS 1
BP 
EP 
DI 10.1186/s12906-022-03600-6
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 2C2BG
UT WOS:000810679300004
PM 35698124
DA 2026-01-16
ER

PT J
AU Wang, FJ
   Shi, S
   Wang, YQ
   Wang, K
   Fan, SD
   Zhang, YN
   Feng, CC
   Ju, ZY
AF Wang Feng-jiao
   Shi She
   Wang Yong-qiang
   Wang Ke
   Fan Shen-dong
   Zhang Ya-nan
   Feng Chen-chen
   Ju Zi-yong
TI Protective Mechanism of Electroacupuncture on Peripheral Neurotoxicity Induced by Oxaliplatin in Rats
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE electroacupuncture; oxaliplatin; peripheral neuropathy; dorsal root ganglion; nuclear factor-erythroid-2-related factor 2
ID clinical-practice; neuropathic pain; acupuncture; activation; cancer; trial
AB Objective To study the effect of electroacupuncture (EA) on oxaliplatin-induced peripheral neuropathy (OIPN) in rats. Methods Male Sprague-Dawley rats were equally divided into 3 groups using a random number table: the control group, the OIPN group, and the EA (OIPN + EA) group, with 10 rats in each. The time courses of mechanical, cold sensitivity, and microcirculation blood flow intensity were determined. The morphology of the dorsal root ganglion (DRG) was observed by electron microscopic examination. The protein levels of nuclear factor E2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), and the transient receptor potential (TRP) protein family in DRGs were assayed by Western blot. Results EA treatment significantly reduced mechanical allodynia and cold allodynia in OIPN rats (P<0.01). Notably, oxaliplatin treatment resulted in impaired microcirculatory blood flow and pathomorphological defects in DRGs (P<0.01). EA treatment increased the microcirculation blood flow and attenuated the pathological changes induced by oxaliplatin (P<0.01). In addition, the expression levels of Nrf2 and HO-1 were down-regulated, and the TRP protein family was over-expressed in the DRGs of OIPN rats (P<0.01). EA increased the expression levels of Nrf2 and HO-1 and decreased the level of TRP protein family in DRG (P<0.05 or P<0.01). Conclusion EA may be a potential alternative therapy for OIPN, and its mechanism may be mainly mediated by restoring the Nrf2/HO-1 signaling pathway.
C1 [Wang Feng-jiao; Shi She; Fan Shen-dong; Ju Zi-yong] Shanghai Univ Tradit Chinese Med, Coll Acumox & Tuina, Shanghai 201203, Peoples R China.
   [Wang Yong-qiang] Shanghai Univ Tradit Chinese Med, Dept Anesthesiol, Shuguang Hosp, Shanghai 200120, Peoples R China.
   [Wang Ke; Zhang Ya-nan; Feng Chen-chen] Shanghai Univ Tradit Chinese Med, Acupuncture Anesthesia Clin Res Inst, Yueyang Hosp Integrated Tradit Chinese & Western, Shanghai 200437, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Ju, ZY (corresponding author), Shanghai Univ Tradit Chinese Med, Coll Acumox & Tuina, Shanghai 201203, Peoples R China.
EM juziyong@hotmail.com
FU National Natural Science Foundation of China [81874506]; Shanghai Clinical Research Center for Acupuncture and Moxibustion [20MC1920500]
CR Ali U, 2020, CHIN J INTEGR MED, V26, P643, DOI 10.1007/s11655-019-3175-7
   Benson A III, 2018, J NATL COMPR CANC NE, V16, P874, DOI 10.6004/jnccn.2018.0061
   Boyette-Davis J, 2011, EXP NEUROL, V229, P353, DOI 10.1016/j.expneurol.2011.02.019
   Boyette-Davis J, 2011, PAIN, V152, P308, DOI 10.1016/j.pain.2010.10.030
   Chen ZH, 2020, CHIN J INTEGR MED, V26, P375, DOI 10.1007/s11655-019-3038-2
   Chukyo A, 2018, NEUROPEPTIDES, V67, P95, DOI 10.1016/j.npep.2017.12.002
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Gebremedhn EG, 2018, BMC CANCER, V18, P0, DOI 10.1186/s12885-018-4185-0
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Griffith KA, 2017, J PAIN SYMPTOM MANAG, V54, P701, DOI 10.1016/j.jpainsymman.2017.07.033
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Ju ZY, 2013, NEURAL REGEN RES, V8, P2350, DOI 10.3969/j.issn.1673-5374.2013.25.006
   Kang LM, 2021, J NEUROL, V268, P3269, DOI 10.1007/s00415-020-09942-w
   Komirishetty P, 2016, NEUROCHEM RES, V41, P2029, DOI 10.1007/s11064-016-1914-0
   Lee JH, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22168811
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Molassiotis A, 2021, ACUPUNCT MED, V39, P41, DOI 10.1177/0964528420920285
   Nash J, 2019, ACUPUNCT MED, V37, P3, DOI 10.1136/acupmed-2018-011666
   Pozzi E, 2020, EXP NEUROL, V334, P0, DOI 10.1016/j.expneurol.2020.113458
   Shen Y, 2015, NEUROBIOL DIS, V79, P100, DOI 10.1016/j.nbd.2015.04.012
   Siegelmann-Danieli N, 2020, J ALTERN COMPLEM MED, V26, P758, DOI 10.1089/acm.2020.0060
   Singh R, 2021, EXPERT OPIN THER TAR, V25, P529, DOI 10.1080/14728222.2021.1956464
   Storey DJ, 2010, ANN ONCOL, V21, P1657, DOI 10.1093/annonc/mdp594
   Sun H, 2019, OXID MED CELL LONGEV, V2019, P0, DOI 10.1155/2019/3142732
   Wei GL, 2021, J PERIPHER NERV SYST, V26, P35, DOI 10.1111/jns.12432
   Wu B, 2021, FRONT MOL NEUROSCI, V14, P0, DOI 10.3389/fnmol.2021.690858
   Wu CY, 2015, CRIT CARE, V19, P0, DOI 10.1186/s13054-015-1135-y
   Xiao WH, 2012, NEUROSCIENCE, V203, P194, DOI 10.1016/j.neuroscience.2011.12.023
   Yang Y, 2019, BIOMED RES INT, V2019, P0, DOI 10.1155/2019/5347804
   Yang Y, 2018, FREE RADICAL BIO MED, V120, P13, DOI 10.1016/j.freeradbiomed.2018.03.007
   Yu JB, 2013, ANESTH ANALG, V116, P239, DOI 10.1213/ANE.0b013e31826f0a4a
   Zhang HW, 2021, NEUROREPORT, V32, P284, DOI 10.1097/WNR.0000000000001589
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
NR 36
TC 2
Z9 2
U1 2
U2 20
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1672-0415
EI 1993-0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD SEP 15
PY 2022
VL 28
IS 9
BP 833
EP 839
DI 10.1007/s11655-022-2896-1
EA JUL 2022
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 3Z1PO
UT WOS:000824866200001
PM 35799085
DA 2026-01-16
ER

PT J
AU Wang, MA
   Molassiotis, A
AF Wang, Mian
   Molassiotis, Alex
TI Mapping chemotherapy-induced peripheral neuropathy phenotype and health-related quality of life in patients with cancer through exploratory analysis of multimodal assessment data
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Chemotherapy; Peripheral neuropathy; Symptom cluster; Health-related quality of life; Patients; Cancer
ID symptoms; pain; neurotoxicity; prevalence; validation; women; score; cipn
AB Purpose Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of anticancer treatment based on neurotoxic agents, which may affect function and health-related quality of life (HRQoL) in patients with cancer. This exploratory study aimed to identify the phenotype of CIPN and examine the association of CIPN with general symptoms and HRQoL in patients with cancer. Methods A secondary analysis was performed on the baseline multimodal assessment data of 87 patients with cancer who participated in a randomized trial examining the effectiveness of an 8-week acupuncture protocol in managing CIPN. The data used for this study include patient-reported CIPN, general symptoms, and HRQoL, neurological examinations, and clinician-based grading of CIPN. Descriptive statistics, non-parametric tests, and hierarchical cluster analysis were used for data analysis. Results Patients with CIPN experienced a series of symptoms, with numbness, tingling, and discomfort in the hands and feet being the most prominent descriptors pertaining to CIPN. Increased severity of CIPN was associated with higher distress from general symptoms and lower physical well-being. These CIPN-specific and general symptoms formed five independent symptom clusters, including two sensory neuropathy symptom clusters, a sensorimotor neuropathy one, a neuro-psychological one, and an autonomic symptom cluster. Painful CIPN was significantly associated with higher symptom burden, lower physical well-being, and impaired tendon reflex. No significant difference was found between type of neurotoxic agents in symptom burden, neurological signs, and HRQoL. Conclusion Researchers and clinicians should pay attention to the characteristics and impact of CIPN from multiple aspects, so as to develop targeted interventions to meet patients' holistic needs. Painful CIPN warrants particular attention as it is associated with higher symptom burden and lower physical well-being in patients with cancer.
C1 [Wang, Mian; Molassiotis, Alex] Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China.
C3 Hong Kong Polytechnic University
RP Molassiotis, A (corresponding author), Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China.
EM alex.molasiotis@polyu.edu.hk
FU Hong Kong's Health & Medical Research Fund [12131801]
CR Bennedsgaard K, 2020, CANCER MED-US, V9, P5114, DOI 10.1002/cam4.3129
   Bonhof CS, 2020, SUPPORT CARE CANCER, V28, P5933, DOI 10.1007/s00520-020-05438-5
   Bonhof CS, 2021, J CANCER SURVIV, V15, P190, DOI 10.1007/s11764-020-00923-6
   Bonhof CS, 2018, GYNECOL ONCOL, V149, P455, DOI 10.1016/j.ygyno.2018.03.052
   Brown TJ, 2019, JAMA ONCOL, V5, P750, DOI 10.1001/jamaoncol.2018.6771
   Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Dolan ME, 2017, CLIN CANCER RES, V23, P5757, DOI 10.1158/1078-0432.CCR-16-3224
   Dong ST, 2016, J PAIN SYMPTOM MANAG, V51, P88, DOI 10.1016/j.jpainsymman.2015.07.013
   FACIT group, 2003, FACT GOG NTX SCOR GU, V0, P0
   Forstenpointner J, 2021, PAIN, V162, P718, DOI 10.1097/j.pain.0000000000002058
   Frigeni B, 2011, J PERIPHER NERV SYST, V16, P228, DOI 10.1111/j.1529-8027.2011.00351.x
   Geber C, 2013, PAIN, V154, P2877, DOI 10.1016/j.pain.2013.08.028
   Haryani H, 2017, ONCOL NURS FORUM, V44, PE111, DOI 10.1188/17.ONF.E111-E123
   Hong JS, 2014, CURR ONCOL, V21, P174, DOI 10.3747/co.21.1984
   Huang HQ, 2007, INT J GYNECOL CANCER, V17, P387, DOI 10.1111/j.1525-1438.2007.00794.x
   Kerckhove N, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00086
   Kim M, 2021, CANCER NURS, V44, P145, DOI 10.1097/NCC.0000000000000764
   Knoerl R, 2018, PAIN MANAG NURS, V19, P354, DOI 10.1016/j.pmn.2018.01.001
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Lakshman A, 2017, CL LYMPH MYELOM LEUK, V17, P513, DOI 10.1016/j.clml.2017.06.035
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu LC, 2019, CANCER MED-US, V8, P963, DOI 10.1002/cam4.1976
   McCorkle R, 1998, USERS MANUAL SYMPTOM, V0, P0
   McCrary JM, 2017, SUPPORT CARE CANCER, V25, P3485, DOI 10.1007/s00520-017-3772-y
   Miaskowski C, 2019, CLIN J PAIN, V35, P37, DOI 10.1097/AJP.0000000000000649
   Miaskowski C, 2017, JNCI-J NATL CANCER I, V109, P0, DOI 10.1093/jnci/djw253
   Molassiotis A, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5302-4
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Osumi M, 2019, J HAND THER, V32, P41, DOI 10.1016/j.jht.2017.06.003
   Selvy M, 2020, J CLIN MED, V9, P0, DOI 10.3390/jcm9082400
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shah A, 2018, J NEUROL NEUROSUR PS, V89, P636, DOI 10.1136/jnnp-2017-317215
   Sharma KR, 2007, J PERIPHER NERV SYST, V12, P223, DOI 10.1111/j.1529-8027.2007.00143.x
   Simon NB, 2017, QUAL LIFE RES, V26, P2763, DOI 10.1007/s11136-017-1635-0
   Timmins HC, 2020, J PAIN, V21, P44, DOI 10.1016/j.jpain.2019.06.011
   Ventzel L, 2018, PAIN MED, V19, P1813, DOI 10.1093/pm/pnx231
   Ventzel L, 2016, PAIN, V157, P560, DOI 10.1097/j.pain.0000000000000404
   Wang M, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-6352-3
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Wolf SL, 2012, SUPPORT CARE CANCER, V20, P625, DOI 10.1007/s00520-011-1141-9
   Zhi WI, 2019, BREAST CANCER RES TR, V178, P587, DOI 10.1007/s10549-019-05416-4
NR 42
TC 5
Z9 6
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAY 15
PY 2022
VL 30
IS 5
BP 4007
EP 4017
DI 10.1007/s00520-022-06821-0
EA JAN 2022
PG 11
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA ZY3CD
UT WOS:000744869400001
PM 35059866
DA 2026-01-16
ER

PT J
AU Rodondi, PY
   Fernandez, A
   Dubois, J
   Ungarelli-McEvoy, C
   Bourqui, A
   Evéquoz, Y
   Luethi, E
   Zurron, N
   Berna, C
AF Rodondi, Pierre-Yves
   Fernandez, Aurore
   Dubois, Julie
   Ungarelli-McEvoy, Caitriona
   Bourqui, Angélique
   Evéquoz, Yves
   Luethi, Emmanuelle
   Zurron, Noemi
   Berna, Chantal
TI [Integrative medicine: scientific literature in 2021].
SO Revue medicale suisse
LA fre
DT Review
AB To illustrate the novelties in integrative and complementary medicine in 2021,  the authors present a selection of six articles. One of them is specifically  related to COVID-19. The other articles deal with themes that are always relevant  and where complementary approaches represent a real added value. Two articles  focus on low back pain, a common problem in primary care medicine. The others  examine acupuncture in the oncological context, the use of therapeutic  suggestions in an operative context, and Tai Chi. The authors thus provide an  overview of the range of possible complementary therapeutic approaches that are  increasingly supported by evidence, inviting them to be better integrated into  clinical practice.
C1 Institut de médecine de famille, Faculté des sciences et de médecine, Université de Fribourg, 1700 Fribourg.
   Centre de médecine intégrative et complémentaire et Centre d'antalgie, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
   Institut de médecine de famille, Faculté des sciences et de médecine, Université de Fribourg, 1700 Fribourg.
   Centre de médecine intégrative et complémentaire et Centre d'antalgie, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
   Institut de médecine de famille, Faculté des sciences et de médecine, Université de Fribourg, 1700 Fribourg.
   Institut de médecine de famille, Faculté des sciences et de médecine, Université de Fribourg, 1700 Fribourg.
   Institut de médecine de famille, Faculté des sciences et de médecine, Université de Fribourg, 1700 Fribourg.
   Centre de médecine intégrative et complémentaire et Centre d'antalgie, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
   Centre de médecine intégrative et complémentaire et Centre d'antalgie, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
NR 0
TC 0
SN 
EI 1660-937
J9 Rev Med Suisse
PD JAN 21
PY 2022
VL 18
IS 764-5
BP 40
EP 44
DI 10.53738/REVMED.2022.18.764-65.40
PG 4
WC Acupuncture Therapy; COVID-19; Complementary Therapies; Humans; Integrative Medicine
UT PubMed:35048578
PM 35048578
DA 2022-01-21
ER

PT J
AU Zhou, LL
   Zhu, SG
   Fang, Y
   Huang, SS
   Huang, JF
   Hu, ZD
   Chen, JY
   Zhang, X
   Wang, JY
AF Zhou, Li-Li
   Zhu, Shi-Guo
   Fang, Yuan
   Huang, Shi-Shi
   Huang, Jie-Fan
   Hu, Ze-Di
   Chen, Jin-Yu
   Zhang, Xiong
   Wang, Jian-Yong
TI Neck pain and absence of cranial nerve symptom are clues of cervical myelopathy mimicking stroke: Two case reports
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE Cervical cord; Spinal cord diseases; Stroke; Neck pain; Cranial nerves; Hematoma; epidural; spinal; Neoplasm metastasis; Case report
ID spinal-epidural-hematoma; tissue-plasminogen activator; clinical characteristics; hemiparesis; thrombolysis; acupuncture; management; diagnosis
AB BACKGROUND Cervical myelopathy is a potential stroke imitator, for which intravenous thrombolysis would be catastrophic. CASE SUMMARY We herein present two cases of cervical myelopathy. The first patient presented with acute onset of right hemiparesis and urinary incontinence, and the second patient presented with sudden-onset right leg monoplegia. The initial diagnoses for both of them were ischemic stroke. However, both of them lacked cranial nerve symptom and suffered neck pain at the beginning of onset. Their cervical spinal cord lesions were finally confirmed by cervical computed tomography. A literature review showed that neck pain and absence of cranial nerve symptom are clues of cervical myelopathy. CONCLUSION The current report and the review remind us to pay more attention to these two clues in suspected stroke patients, especially those within the thrombolytic time window.
C1 [Zhou, Li-Li; Zhu, Shi-Guo; Fang, Yuan; Huang, Shi-Shi; Huang, Jie-Fan; Hu, Ze-Di; Chen, Jin-Yu; Zhang, Xiong; Wang, Jian-Yong] Wenzhou Med Univ, Affiliated Hosp 2, Inst Geriatr Neurol, Dept Neurol, Wenzhou 325027, Zhejiang, Peoples R China.
   [Zhou, Li-Li; Zhu, Shi-Guo; Fang, Yuan; Huang, Shi-Shi; Huang, Jie-Fan; Hu, Ze-Di; Chen, Jin-Yu; Zhang, Xiong; Wang, Jian-Yong] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou 325027, Zhejiang, Peoples R China.
   [Wang, Jian-Yong] Wenzhou Med Univ, Affiliated Hosp 2, Inst Geriatr Neurol, Dept Neurol, B305-B307 Biomed Res Bldg, Wenzhou 325027, Zhejiang, Peoples R China.
   [Wang, Jian-Yong] Wenzhou Med Univ, Yuying Childrens Hosp, B305-B307 Biomed Res Bldg, Wenzhou 325027, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University
RP Wang, JY (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Inst Geriatr Neurol, Dept Neurol, B305-B307 Biomed Res Bldg, Wenzhou 325027, Zhejiang, Peoples R China.; Wang, JY (corresponding author), Wenzhou Med Univ, Yuying Childrens Hosp, B305-B307 Biomed Res Bldg, Wenzhou 325027, Zhejiang, Peoples R China.
EM wangjianyong2020@126.com
FU Wenzhou Municipal Science and Technology Bureau [Y2020065]; Education Foundation of Zhejiang [Y202044311]; Fundamental Research Funds for Wenzhou Medical University [KYYW202030]
CR Adamson DC, 2004, SURG NEUROL, V62, P156, DOI 10.1016/j.surneu.2003.10.040
   Al Khathaami AM, 2020, NEUROSCIENCES, V25, P38, DOI 10.17712/nsj.2020.1.20190096
   Bailey KC, 2012, J NEURORADIOLOGY, V39, P132, DOI 10.1016/j.neurad.2011.03.001
   Brihaye J, 1988, ADV TECH STAND NEUROSURG, V16, P121
   Buyukgol H, 2015, AM J EMERG MED, V33, P0, DOI 10.1016/j.ajem.2015.01.018
   Chen CL, 2020, J EMERG MED, V58, PE185, DOI 10.1016/j.jemermed.2020.01.009
   CONSTANS JP, 1983, J NEUROSURG, V59, P111, DOI 10.3171/jns.1983.59.1.0111
   DSouza M, 2008, CEREBROVASC DIS, V26, P665, DOI 10.1159/000172974
   Domenicucci M, 2017, J NEUROSURG-SPINE, V27, P198, DOI 10.3171/2016.12.SPINE15475
   Emamhadi Mohammadreza, 2019, ASIAN J NEUROSURG, V14, P286, DOI 10.4103/ajns.ajns_333_17
   Feigin VL, 2017, CIRC RES, V120, P439, DOI 10.1161/CIRCRESAHA.116.308413
   Gibson LM, 2013, J ROY COLL PHYS EDIN, V43, P114, DOI 10.4997/JRCPE.2013.205
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Holtas S, 1996, RADIOLOGY, V199, P409, DOI 10.1148/radiology.199.2.8668786
   Hsieh CF, 2006, EUR J EMERG MED, V13, P36, DOI 10.1097/00063110-200602000-00009
   Huang DW, 2020, NEUROSCIENCES, V25, P316, DOI 10.17712/nsj.2020.4.20200027
   Inatomi Y, 2020, J STROKE CEREBROVASC, V29, P0, DOI 10.1016/j.jstrokecerebrovasdis.2020.105030
   Ishikawa E, 2008, NEUROL INDIA, V56, P98, DOI 10.4103/0028-3886.39332
   Keselman B, 2019, EUR J NEUROL, V26, P1091, DOI 10.1111/ene.13944
   LAWTON MT, 1995, J NEUROSURG, V83, P1, DOI 10.3171/jns.1995.83.1.0001
   Lee JH, 2011, SPINE, V36, PE891, DOI 10.1097/BRS.0b013e3181fc1e38
   Lemmens R, 2012, ACTA NEUROL BELG, V112, P291, DOI 10.1007/s13760-012-0079-0
   Lin IY, 2004, ANN EMERG MED, V44, P183, DOI 10.1016/j.annemergmed.2004.02.041
   Liou KC, 2012, AM J EMERG MED, V30, P0, DOI 10.1016/j.ajem.2011.06.018
   LOBITZ B, 1995, SOUTHERN MED J, V88, P580, DOI 10.1097/00007611-199505000-00015
   Marinella MA, 1996, ANN EMERG MED, V27, P514
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Matsumoto H, 2012, J SPINAL CORD MED, V35, P262, DOI 10.1179/2045772312Y.0000000014
   Mesfin A, 2015, J AM ACAD ORTHOP SUR, V23, P38, DOI 10.5435/JAAOS-23-01-38
   Morimoto T, 2016, SPINE, V41, PE437, DOI 10.1097/BRS.0000000000001243
   Moulin S, 2019, CURR OPIN NEUROL, V32, P54, DOI 10.1097/WCO.0000000000000620
   Nakanishi K, 2011, ADV ORTHOP, V2011, P0, DOI 10.4061/2011/516382
   Nguyen PL, 2015, J EMERG MED, V49, P244, DOI 10.1016/j.jemermed.2014.12.072
   OBRIEN PA, 1987, AGE AGEING, V16, P319, DOI 10.1093/ageing/16.5.319
   Ofluloglu E, 2009, TURK NEUROSURG, V19, P99
   Park J, 2013, SPINE J, V13, PE59, DOI 10.1016/j.spinee.2013.06.024
   Patel Ravish, 2018, BMJ CASE REP, V2018, P0, DOI 10.1136/bcr-2017-222686
   Rahangdale R, 2020, NEUROLOGY, V95, P496, DOI 10.1212/WNL.0000000000010511
   Rao R, 2002, J BONE JOINT SURG AM, V84A, P1872, DOI 10.2106/00004623-200210000-00021
   Romaniuc A, 2020, ACTA NEUROL BELG, V120, P495, DOI 10.1007/s13760-018-0939-3
   Sakamoto N, 2003, ARCH NEUROL-CHICAGO, V60, P783, DOI 10.1001/archneur.60.5.783
   Schmidley James W, 2013, ACUTE MED, V12, P30
   Sequeira D, 2016, PREHOSP EMERG CARE, V20, P723, DOI 10.3109/10903127.2016.1168889
   Shima H, 2012, NAGOYA J MED SCI, V74, P207
   Son S, 2012, NEUROLOGIST, V18, P41, DOI 10.1097/NRL.0b013e31823d7ade
   Szeto CLC, 2022, CEREBROVASC DIS, V51, P265, DOI 10.1159/000518525
   Tay MRJ, 2021, AM J PHYS MED REHAB, V100, PE133, DOI 10.1097/PHM.0000000000001655
   Teles Pedro, 2020, SURG NEUROL INT, V11, P157, DOI 10.25259/sni_161_2020
   Terabe S, 2015, JPN J CLIN ONCOL, V45, P584, DOI 10.1093/jjco/hyv034
   Toledano M, 2013, NEUROL CLIN, V31, P287, DOI 10.1016/j.ncl.2012.09.003
   Tsou A, 2019, AM J EMERG MED, V37, P0, DOI 10.1016/j.ajem.2019.03.044
   Wang CC, 2009, EUR SPINE J, V18, PS210, DOI 10.1007/s00586-008-0819-2
   Winkler DT, 2009, STROKE, V40, P1522, DOI 10.1161/STROKEAHA.108.530352
NR 53
TC 2
Z9 3
U1 0
U2 3
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
EI 
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD NOV 16
PY 2022
VL 10
IS 32
BP 11835
EP 11844
DI 10.12998/wjcc.v10.i32.11835
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 6J2ZY
UT WOS:000886696700015
PM 36405285
DA 2026-01-16
ER

PT J
AU Abushukur, Y
   Cascardo, C
   Ibrahim, Y
   Teklehaimanot, F
   Knackstedt, R
AF Abushukur, Yasmine
   Cascardo, Camilla
   Ibrahim, Yousef
   Teklehaimanot, Fayven
   Knackstedt, Rebecca
TI Improving Breast Surgery Outcomes Through Alternative Therapy: A Systematic
SO Cureus
LA English
DT Review
DE alternative medicine; breast; breast and endocrine surgery; breast cancer; complementary medicine; integrative medicine
AB Enhanced recovery after surgery (ERAS) protocols are the current standard of care  when it comes to improving post-surgical outcomes in breast cancer patients.  Compliance with all protocol items is required in order for patients to  experience significant benefits. Given that the ERAS protocols involve numerous  medications which each have unique side effect profiles and medication  interactions, this is often difficult to accomplish. Additionally, breast cancer  patients are often left with a large psychological burden, which ERAS protocols  fail to address. This review aims to determine the role that alternative  therapies can play in improving both the emotional and physical strains patients  experience during the post-operative stage of recovery. A PubMed search was  conducted using the following search terms ("alternative medicine" or  "complementary medicine" or "integrative medicine" or "holistic medicine" or  "natural medicine" or "mediation" or "aromatherapy" or "music" or "art" or  "reiki" or "massage") and ("surgery") and ("pain"). Studies selected for this  review include articles published or translated in English that addressed  alternative medical interventions affecting pre-, peri-, or post-operative  outcomes in breast biopsies, surgeries, or breast-related procedures. Eighteen  articles fit the inclusion criteria, with seven addressing music, five addressing  meditation, yoga, and guided imagery, five addressing massage, one addressing  myofascial release, four addressing aromatherapy, two addressing acupuncture, and  three addressing hypnosis. Most forms of alternative therapies offered some  benefit to patients following breast-related procedures, many resulting in  improvements in post-operative outcomes including pain, fatigue, energy, stress,  anxiety, mood, and depression. The reviewed studies demonstrated numerous  benefits to integrating alternative medicine into standardized therapy to improve  postoperative outcomes. Most studies analyzed did not include placebo controls as  including proper placebos was often not feasible. Future studies with larger  sample sizes are needed to better quantify the benefits patients receive from  these noninvasive, low-risk complementary therapies.
C1 Medicine, Oakland University William Beaumont School of Medicine, Royal Oak, USA.
   Medicine, Oakland University William Beaumont School of Medicine, Royal Oak, USA.
   Medicine, Oakland University William Beaumont School of Medicine, Roha, USA.
   Medicine, Michigan State University College of Osteopathic Medicine, Detroit, USA.
   Plastic Surgery, Cleveland Clinic, Cleveland, USA.
NR 0
TC 0
SN 2168-818
EI 2168-818
J9 Cureus
PD APR 29
PY 2022
VL 14
IS 3
BP e23443
EP e23443
DI 10.7759/cureus.23443
PG 1
UT PubMed:35481320
PM 35481320
DA 2022-04-29
ER

PT J
AU Widgren, Y
   Fransson, P
   Efverman, A
AF Widgren, Ylva
   Fransson, Per
   Efverman, Anna
TI Acupuncture in Patients Undergoing Cancer Therapy: Their Interest and Belief in
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture therapy; attitudes; cancer survivors; complementary and alternative medicine; expectations; oncology nursing
AB OBJECTIVES: Since pre-existing expectations, that is, beliefs, in a treatment may  modify outcomes, and acupuncture studies often fail to measure expectations, we  wanted to investigate the use of acupuncture, interest, and belief in acupuncture  effects among patients undergoing cancer therapy. METHOD: A cross-sectional  design, where the participants answered a study-specific questionnaire with  questions regarding their use of, interest and belief in acupuncture treatment.  RESULTS: A total of 457 patients with cancer (48% men, mean age 65 years)  answered the questionnaire. Acupuncture was used by 4 (1%) patients during their  cancer therapy, and 368 (83%) expressed an interest in receiving acupuncture. Of  the 457 patients, 289 (63%) believed acupuncture to be effective for at least 1  of 17 requested symptoms, most commonly pain (56% of the patients) and muscle  tension (40%). They believed acupuncture to be effective for a mean value 3 of  the 17 requested symptoms. Women (P < .001), and patients 41 to 65 years  (P < .001), expressed a stronger belief in acupuncture effects than others.  CONCLUSIONS: Men and older patients expressed weaker beliefs in acupuncture  effects than other patients, indicating the importance of collecting expectancy  data in future randomized sham-controlled acupuncture studies to be able to treat  expectancy as an effect-modifier. The high interest and beliefs in acupuncture  effects found also indicate that acupuncture should be available for patients  with cancer, for side effects where acupuncture has shown to be effective. In a  clinical setting, older men might need more encouragement regarding positive  expected outcomes of the acupuncture treatment than younger women.
C1 University of Gävle, Gavle, Sweden.
   Region Hospital of Sundsvall-Härnösand, County Council of Västernorrland, 
   Umeå University, Umeå, Sweden.
   Umeå University Hospital, Umeå, Sweden.
   University of Gävle, Gavle, Sweden.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD FEB 26
PY 2022
VL 21
IS 
BP 15347354221077277
EP 15347354221077277
DI 10.1177/15347354221077277
PG 1
WC Acupuncture; Acupuncture Therapy; Aged; Cross-Sectional Studies; Female; Humans; Male; Neoplasms; therapy; Pain; etiology
UT PubMed:35212241
PM 35212241
DA 2022-02-26
ER

PT J
AU Zhong, XL
   Zhang, ZD
   Li, JY
   Liu, DD
   Ma, C
   Wang, GN
AF Zhong, Xuelai
   Zhang, Zhaodi
   Li, Jiaying
   Liu, Dandan
   Ma, Chao
   Wang, Guonian
TI Effects of Electroacupuncture on Gastrointestinal Motility Function, Pain, and Inflammation via Transient Receptor Potential Vanilloid 1 in a Rat Model after Colonic Anastomoses
SO DISEASE MARKERS
LA English
DT Article
ID nf-kappa-b; mechanism; trpv1; acupuncture; expression; acupoint; target
AB Background. Complications after colon surgery are a major obstacle to postoperative recovery. The purpose of this study was to investigate the effect of electroacupuncture (EA) at Zusanli (ST36) on gastrointestinal motility in rats after colonic anastomosis and the mechanism of transient receptor potential vanillin 1 (TRPV1) channel in regulating gastrointestinal motility, pain, and inflammation. Methods. The rats were randomly divided into six groups, including the control, model, EA, sham-EA, capsaicin, and capsaicin+EA groups, with preoperative capsaicin pretreatment and EA treatment at ST36 acupoint after surgery. Rats were treated using EA at ST36 or sham acupoints after surgery for 5 days. Capsaicin was intraperitoneally injected into rats 3 hours before surgery. Gastrointestinal motility was assessed by measuring the gastric residue, small intestinal propulsion in vivo, contractile tension, and frequency of isolated muscle strips in vitro. The mechanical withdrawal threshold (MWT) of abdominal incision skin and spontaneous nociceptive scores were observed and recorded in rats after colon anastomosis. The expressions of TRPV1, substance P (SP), neurokinin 1 (NK1) receptor, nuclear factor kappa-B (NF-kappa B), interleukin- (IL-) 6, L-1 beta, and tumor necrosis factor- (TNF-) alpha were determined. Results. Compared with the model group, electroacupuncture at ST36 point could significantly reduce the residual rate of stomach in rats after operation and increase the propulsive force of the small intestine and the contraction tension of the isolated smooth muscle. Electroacupuncture also increased postoperative day 3 MWT values and decreased postoperative spontaneous nociception scores. In addition, electroacupuncture treatment downregulated the expressions of IL-6, IL-1 beta, TNF-alpha, TRPV1, NF-kappa B, SP, and NK1 receptors in the colon tissue of rats after colonic anastomosis. Conclusions. Our study showed that electroacupuncture at ST36 acupoint could improve gastrointestinal motility in rats after colonic anastomosis and relieve intestinal inflammation and pain. The mechanism may be to inhibit the activation of NF-kappa B and SP/NK1 receptor signaling pathways by inhibiting TRPV1.
C1 [Zhong, Xuelai; Zhang, Zhaodi; Li, Jiaying; Liu, Dandan] Harbin Med Univ, Dept Anesthesiol, Canc Hosp, Harbin 150081, Peoples R China.
   [Ma, Chao] Fourth Hosp Harbin Med Univ, Dept Anesthesiol, Harbin 150081, Peoples R China.
   [Wang, Guonian] Fourth Hosp Harbin Med Univ, Dept Anesthesiol, 150 Haping Rd, Harbin 150081, Peoples R China.
   [Wang, Guonian] Heilongjiang Acad Med Sci, Pain Res Inst, 150 Haping Rd, Harbin 150081, Peoples R China.
C3 Harbin Medical University
RP Wang, GN (corresponding author), Fourth Hosp Harbin Med Univ, Dept Anesthesiol, 150 Haping Rd, Harbin 150081, Peoples R China.; Wang, GN (corresponding author), Heilongjiang Acad Med Sci, Pain Res Inst, 150 Haping Rd, Harbin 150081, Peoples R China.
EM shelley9135@163.com; jody1982@163.com; 1375266310@qq.com; 714633347@qq.com; machao2019@yeah.net; 600638@hrbmu.edu.cn
FU National Natural Science Foundation of China [8177051154, 8170150971]
CR Allais L, 2016, PATHOBIOLOGY, V84, P1, DOI 10.1159/000446568
   Bujak JK, 2019, FRONT ONCOL, V9, P0, DOI 10.3389/fonc.2019.01087
   Cai GX, 2011, WORLD J GASTROENTERO, V17, P1594, DOI 10.3748/wjg.v17.i12.1594
   Chen KB, 2019, INT J SURG, V70, P93, DOI 10.1016/j.ijsu.2019.08.034
   Chen YD, 2020, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.00180
   Chon TY, 2013, MAYO CLIN PROC, V88, P1141, DOI 10.1016/j.mayocp.2013.06.009
   Fraser GL, 2009, EUR J PHARMACOL, V604, P132, DOI 10.1016/j.ejphar.2008.12.011
   Guo Y, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000024342
   Huang H, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6616886
   Huang Jinghui, 2006, INT J BIOMED SCI, V2, P64
   Kargbo Robert B, 2019, ACS MED CHEM LETT, V10, P143, DOI 10.1021/acsmedchemlett.8b00618
   Kehlet H, 2018, PAIN, V159, PS11, DOI 10.1097/j.pain.0000000000001243
   Lan L, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008487.pub2
   Li NC, 2021, J INFLAMM RES, V14, P7191, DOI 10.2147/JIR.S341581
   Li Y, 2019, J TRADIT CHIN MED, V39, P740
   Liang C, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13318
   Liang QK, 2018, SAUDI J GASTROENTERO, V24, P228, DOI 10.4103/sjg.SJG_505_17
   Lin JG, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0128037
   Lin TH, 2017, ADV PROTEIN CHEM STR, V107, P117, DOI 10.1016/bs.apcsb.2016.11.002
   Liu F, 2014, ACUPUNCT MED, V32, P340, DOI 10.1136/acupmed-2013-010460
   Ma FQ, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-68132-w
   Mao XY, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023014
   Moriello AS, 2016, METHODS MOL BIOL, V1412, P65, DOI 10.1007/978-1-4939-3539-0_7
   Pei LX, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000010877
   Qiao Cui Xia, 2020, ZHEN CI YAN JIU, V45, P180, DOI 10.13702/j.1000-0607.190358
   Shang JJ, 2013, WORLD J GASTROENTERO, V19, P8071, DOI 10.3748/wjg.v19.i44.8071
   Shi HL, 2015, WORLD J GASTROENTERO, V21, P4852, DOI 10.3748/wjg.v21.i16.4852
   Song SN, 2019, MOL IMMUNOL, V106, P143, DOI 10.1016/j.molimm.2018.12.023
   Sousa-Valente J, 2018, SEMIN IMMUNOPATHOL, V40, P229, DOI 10.1007/s00281-018-0673-1
   Sun HZ, 2018, J PHYSIOL PHARMACOL, V69, P419, DOI 10.26402/jpp.2018.3.08
   Suvas S, 2017, J IMMUNOL, V199, P1543, DOI 10.4049/jimmunol.1601751
   Takahashi T, 2013, INT REV NEUROBIOL, V111, P273, DOI 10.1016/B978-0-12-411545-3.00014-6
   Tang L, 2020, DIGEST DIS SCI, V65, P1689, DOI 10.1007/s10620-019-05960-5
   Yang F, 2017, PROTEIN CELL, V8, P169, DOI 10.1007/s13238-016-0353-7
   Yang J, 2017, BIOMED RES INT, V2017, P0, DOI 10.1155/2017/5068347
   Yang NN, 2021, THERANOSTICS, V11, P4078, DOI 10.7150/thno.52574
   Yu Y, 2018, J NEUROIMMUNOL, V320, P80, DOI 10.1016/j.jneuroim.2018.05.001
   Yu Z, 2016, WORLD J GASTROENTERO, V22, P1834, DOI 10.3748/wjg.v22.i5.1834
   Zhang K, 2021, CHIN J INTEGR MED, V27, P933, DOI 10.1007/s11655-020-3435-6
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao YX, 2021, ACUPUNCT MED, V39, P135, DOI 10.1177/0964528420920288
   Zheng Y, 2020, NEURAL PLAST, V2020, P0, DOI 10.1155/2020/8818328
NR 42
TC 6
Z9 9
U1 1
U2 30
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0278-0240
EI 1875-8630
J9 DIS MARKERS
JI Dis. Markers
PD JUL 5
PY 2022
VL 2022
IS 
BP 
EP 
DI 10.1155/2022/5113473
PG 14
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology
GA 3F6LB
UT WOS:000830777300001
PM 35845135
DA 2026-01-16
ER

PT J
AU Wan, QY
   Chen, H
   Wang, XQ
   Xi, HQ
   Zheng, SY
   Luo, ST
   Wu, WZ
   Pan, R
AF Wan, Qingyun
   Chen, Hao
   Wang, Xiaoqiu
   Xi, Hanqing
   Zheng, Shiyu
   Luo, Shuting
   Wu, Wenzhong
   Pan, Rui
TI Effectiveness of different acupuncture therapies for chronic cancer pain A protocol for systematic review and Bayesian network meta-analysis
SO MEDICINE
LA English
DT Review
DE a systematic review; acupuncture; chronic cancer pain; network meta-analysis
ID inconsistency; quality
AB Background: Pain is a common and distressing symptom experienced by cancer patients. Previous research found acupuncture was associated with significant reductions in pain intensity and opioid use. Acupuncture therapies are various, and the difference in efficacy and safety has never been assessed. This paper aims to assess and rank the effectiveness of the different acupuncture methods and provide an acupuncture treatment guideline for relieving chronic pain in cancer survivors. Methods: Four English databases (PubMed, Embase, Cochrane library, and Web of Science) and 4 Chinese databases (China National Knowledge Infrastructure, Wanfang Data, and Chinese Biomedical Literature Database) will be searched for randomized controlled trials (RCTs) published from the database inception to November 30, 2021. The primary outcomes will be patient-reported pain intensity measured by the Brief Pain Inventory, Visual Analog Scale, Verbal Rating Scale, Numerical Rating Scale, and other valid outcome measures. The Grading of Recommendations Assessment, and Development and Evaluation System will evaluate the quality of evidence. Bayesian network meta-analysis will be performed in WinBUGS V.1.4.3 to determine the comparative effectiveness of the acupuncture therapies. Results: This study will quantify the effectiveness of each acupuncture intervention for chronic cancer pain with pain scores and the use of analgesics. The adverse events of acupuncture treatment for cancer pain will also be reported. Conclusion: The conclusion of our study will help physicians and patients choose suitable acupuncture methods to manage cancer pain.
C1 [Wan, Qingyun; Wang, Xiaoqiu; Xi, Hanqing; Zheng, Shiyu; Luo, Shuting; Wu, Wenzhong] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Nanjing, Peoples R China.
   [Chen, Hao] Nanjing Univ Chinese Med, Nanjing, Peoples R China.
   [Pan, Rui] Nanjing Med Univ, Jiangsu Canc Hosp, Affiliated Canc Hosp, Nanjing, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing Medical University
RP Wu, WZ (corresponding author), Nanjing Univ Chinese Med, Dept Acupuncture & Rehabil, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM maerta_zhongacu@163.com
FU key research and development program of Jiangsu Province [BE2021751]; Nursing Advantage Discipline Project of Nanjing University of Chinese Medicine [2019YSHL091]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Anshasi HA, 2018, COMPLEMENT THER CLIN, V32, P163, DOI 10.1016/j.ctcp.2018.06.013
   Arthur J, 2019, NAT REV CLIN ONCOL, V16, P213, DOI 10.1038/s41571-018-0143-7
   Bom PRD, 2019, RES SYNTH METHODS, V10, P497, DOI 10.1002/jrsm.1352
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Chua IS, 2019, JAMA ONCOL, V5, P734, DOI 10.1001/jamaoncol.2019.0042
   Cummings M, 2018, BMJ-BRIT MED J, V360, P0, DOI 10.1136/bmj.k970
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Henson LA, 2020, J CLIN ONCOL, V38, P905, DOI 10.1200/JCO.19.00470
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Jiang CC, 2019, JAMA ONCOL, V5, P1224, DOI 10.1001/jamaoncol.2019.1439
   Lin JG, 2012, AM J CHINESE MED, V40, P219, DOI 10.1142/S0192415X12500176
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Moher D, 2015, SYST REV-LONDON, V4, P0, DOI 10.1186/2046-4053-4-1
   NCCN, 2017, CLIN PRACTICE GUIDEL, V0, P0
   Paley CA, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub2
   Salanti G, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0099682
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Sharfstein JM, 2019, JAMA-J AM MED ASSOC, V322, P809, DOI 10.1001/jama.2019.9794
   Smith EML, 2019, J CLIN ONCOL, V37, P1686, DOI 10.1200/JCO.19.00936
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Veroniki AA, 2013, INT J EPIDEMIOL, V42, P332, DOI 10.1093/ije/dys222
   Vickers AJ, 2014, JAMA-J AM MED ASSOC, V311, P955, DOI 10.1001/jama.2013.285478
   Vitzthum LK, 1900, P20202, V0, P0
NR 27
TC 0
Z9 1
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN 28
PY 2022
VL 101
IS 4
BP 
EP 
DI 10.1097/MD.0000000000027965
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA YP0YM
UT WOS:000748355900070
PM 35089187
DA 2026-01-16
ER

PT J
AU Choi, TY
   Ang, L
   Jun, JH
   Alraek, T
   Lee, MS
AF Choi, Tae-Young
   Ang, Lin
   Jun, Ji Hee
   Alraek, Terje
   Lee, Myeong Soo
TI Acupuncture and Moxibustion for Cancer-Related Fatigue: An Overview of Systematic Reviews and Meta-Analysis
SO CANCERS
LA English
DT Review
DE complementary medicine; acupuncture; cancer; fatigue; systematic review
ID breast-cancer; safety; therapy; quality
AB Simple Summary Acupuncture, per se, is not used for treating cancer. However, acupuncture is used for treating several cancer-related symptoms, such as, for example, pain, antiestrogen-induced hot flashes, as well as cancer-related fatigue (CRF). There are several studies that assess the evidence of acupuncture for palliative cancer treatment; but there are none for CRF. The aim of this overview, therefore, was to comprehensively summarize and critically evaluate the current evidence of the efficacy of AT in the management of CRF. Although acupuncture (AT) is used in the treatment of CRF, the evidence from different systematic reviews (SRs) of AT has not yet been comprehensively evaluated. Moxibustion, which is a treatment method that is well established within Traditional East Asian Medicine, applies the heat of burning herbs towards or onto special points on the skin. Commonly, the herb Artemisia vulgaris, is used. It has been used for palliative cancer care, as well as for CRF. The aim of this overview was to evaluate the efficacy of AT and moxibustion in the management of CRF. Eleven databases were searched through for studies that were published from their dates of inception to February 2022. The study selection, the data extraction, and the assessment were performed independently by two researchers. The methodological and report quality were assessed by using the Assessment of Multiple Systematic Reviews-2 (AMSTAR-2) tool. The evidence quality was evaluated by using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Fifteen SRs on AT (n = 10) and moxibustion (n = 5) treatments for CRF were included, and they include 169 randomized controlled trials and 14,392 participants. All of the SRs that were evaluated by the AMASTAR-2 had more than one deficiency, and so all of the SRs were rated as either low or critically low. For the GRADE, 18 outcomes were rated as very-low-quality evidence, 13 as low-quality evidence, 3 as moderate-quality evidence, and 0 as high-quality evidence. Most of the SRs reached the potential benefits of AT for CRF. No serious adverse effects were identified. In conclusion, the evidence suggests that, despite the advantages of AT in terms of the improvement in and the safety of the treatment of CRF, the methodological quality of most of these studies is low, which limits our ability to draw definitive meanings. Further research of high quality is needed in order to confirm these findings.
C1 [Choi, Tae-Young; Ang, Lin; Jun, Ji Hee; Lee, Myeong Soo] Korea Inst Oriental Med, KM Sci Res Div, Daejeon 34054, South Korea.
   [Alraek, Terje] Kristiania Univ Coll, Sch Hlth Sci, N-0107 Oslo, Norway.
   [Alraek, Terje] Arctic Univ Norway, Dept Community Med, Natl Res Ctr Complementary & Alternat Med NAFKAM, Fac Hlth Sci,UiT, N-9037 Tromso, Norway.
C3 Korea Institute of Oriental Medicine (KIOM); Kristiania University College; UiT The Arctic University of Tromso
RP Lee, MS (corresponding author), Korea Inst Oriental Med, KM Sci Res Div, Daejeon 34054, South Korea.
EM superoung@kiom.re.kr; anglin2808@gmail.com; zhixi04@kiom.re.kr; terje.alrak@uit.no; drmslee@gmail.com
FU Korea Institute of Oriental Medicine, Korea [KSN2021210]; Pink Ribbon [207697-2019]
CR Berger AM, 2015, J NATL COMPR CANC NE, V13, P1012, DOI 10.6004/jnccn.2015.0122
   Cella D, 2001, J CLIN ONCOL, V19, P3385, DOI 10.1200/JCO.2001.19.14.3385
   Cybularz PA, 2015, MED ACUPUNCT, V27, P224, DOI 10.1089/acu.2015.1099
   Dong Jia-Zi, 2018, ZHEN CI YAN JIU, V43, P335, DOI 10.13702/j.1000-0607.171010
   Ebede CC, 2017, MED CLIN N AM, V101, P1085, DOI 10.1016/j.mcna.2017.06.007
   Escalante CP, 2009, J GEN INTERN MED, V24, P412, DOI 10.1007/s11606-009-1056-z
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Grant SJ, 2015, INTEGR CANCER THER, V14, P258, DOI 10.1177/1534735415572879
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   Han JQ, 2021, EVID BASED NURS, V7, P719, DOI 10.12102/JI.SN.2095-8668.2021.06.002
   Han Q, 2020, J ADV NURS, V76, P1924, DOI 10.1111/jan.14375
   He XR, 2013, ASIAN PAC J CANCER P, V14, P3067, DOI 10.7314/APJCP.2013.14.5.3067
   Hilfiker R, 2018, BRIT J SPORT MED, V52, P651, DOI 10.1136/bjsports-2016-096422
   Höxtermann MD, 2022, CANCER-AM CANCER SOC, V128, P2159, DOI 10.1002/cncr.34165
   Hu Y, 2020, J CHENGDU UNIV TRADIT CHIN MED, V43, P65, DOI 10.13593/J.CNKI.51-1501/R.2020.03.065
   Huang SY, 2021, CHINA MOD MED, V28, P15
   Iop A, 2004, ANN ONCOL, V15, P712, DOI 10.1093/annonc/mdh102
   Jang A, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420949679
   Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010
   Kristoffersen AE, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2762-7
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee S, 2014, SUPPORT CARE CANCER, V22, P1429, DOI 10.1007/s00520-014-2161-z
   Lin ZP, 2009, AM J CHINESE MED, V37, P471, DOI 10.1142/S0192415X09006989
   Ling WM, 2014, ONCOL NURS FORUM, V41, P581, DOI 10.1188/14.ONF.581-592
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Minton O, 2008, BREAST CANCER RES TR, V112, P5, DOI 10.1007/s10549-007-9831-1
   Posadzki P, 2013, SUPPORT CARE CANCER, V21, P2067, DOI 10.1007/s00520-013-1765-z
   Prue G, 2006, EUR J CANCER, V42, P846, DOI 10.1016/j.ejca.2005.11.026
   Shea BJ, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j4008
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Stasi R, 2003, CANCER-AM CANCER SOC, V98, P1786, DOI 10.1002/cncr.11742
   Tan JY, 2021, COMPLEMENT THER CLIN, V45, P0, DOI 10.1016/j.ctcp.2021.101490
   Wang XS, 2015, GYNECOL ONCOL, V136, P446, DOI 10.1016/j.ygyno.2014.10.013
   White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485
   Wu XY, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16776
   Yang L, 2016, CHIN J INTEGR MED, V22, P67, DOI 10.1007/s11655-015-2105-6
   Yim YK, 2007, EVID-BASED COMPL ALT, V4, P51, DOI 10.1093/ecam/nel054
   Yin Yuan, 2017, ZHEN CI YAN JIU, V42, P149
   [余婷 Yu Ting], 2020, 世界科学技术：中医药现代化 MODERNIZATION OF TRADITIONAL CHINESE MEDICINE AND MATERIA MEDICA--WORLD SCIENCE AND TECHNOLOGY, V22, P4175
   Yuan C, 2020, J YUNNAN UNIV TRADIT CHIN MED, V43, P61, DOI 10.19288/j.cnki.issn.1000-2723.2020.04.011
   Zeng YC, 2014, INTEGR CANCER THER, V13, P193, DOI 10.1177/1534735413510024
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   Zhao YY, 2020, J TRADIT CHIN MED, V40, P738, DOI 10.19852/j.cnki.jtcm.2020.05.003
NR 44
TC 16
Z9 20
U1 0
U2 22
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY 15
PY 2022
VL 14
IS 10
BP 
EP 
DI 10.3390/cancers14102347
PG 14
WC Oncology
SC Oncology
GA 1P2US
UT WOS:000801870800001
PM 35625952
DA 2026-01-16
ER

PT J
AU Jones, KF
   Wechsler, S
   Zulewski, D
   Wood, L
AF Jones, Katie Fitzgerald
   Wechsler, Stephen
   Zulewski, David
   Wood, Lisa
TI Pharmacological and Nonpharmacological Management of Chemotherapy-Induced
SO Journal of palliative medicine
LA English
DT Journal Article
DE chemotherapy-induced neuropathy; chronic pain; neuropathic pain; peripheral neuropathy
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and  debilitating side effect of cancer treatment with no effective preventative  strategy or definitive treatment. Purpose: To synthesize empiric literature from  randomized controlled trials (RCTs) of pharmacological and nonpharmacological  management of CIPN. Data Sources: Articles published between January 1, 2010, and  February 28, 2021, were identified using keywords searching Medline, PubMed,  CINAHL, Web of Science, Cochrane Library, and Embase. Study Selection: RCTs that  recruited individuals who were post-chemotherapy and experienced persistent CIPN  symptoms. Data Extraction and Synthesis: Three independent reviewers screened a  total of 2023 abstracts. After screening, full-text review, and quality  appraisal, 22 articles were included in this review. Data related to study  design, participant characteristics, interventions, controls, outcome measures,  and relevant findings were extracted from full texts. Descriptive quantitative  summaries were calculated and narrative analysis was performed. Results: Of the  22 studies, 4 investigated pharmacologic treatments, 2 compared acupuncture to  pharmacologic treatments, and 16 studies examined nonpharmacologic treatments.  Pharmacologic studies reported mixed results with evidence of participant  response varying by history of chemotherapeutic agent. Acupuncture,  exercise/physical therapy, and neurofeedback appear to be effective treatments  for CIPN. Evidence regarding biophysical agents and cognitive-behavioral therapy  is equivocal. Scrambler therapy is not supported. Limitations: Studies included  in this review share several limitations, including widely variable outcome  measures, small and demographically homogenous samples, and nonstandardized  treatment protocols. Conclusion: This scoping review summarized the current body  of high-quality RCTs investigating treatment for CIPN. The majority of studies in  this review reports benefits of pharmacologic and nonpharmacologic interventions,  although management may require a multipronged approach and should be tailored to  the individual. Clinical implications are proposed and suggestions made for  future research include implementation of standardized intervention protocols,  use of outcome measures representative of the spectrum of CIPN symptoms, and  stratification by the chemotherapeutic agent.
C1 William F. Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA.
   Massachusetts General Hospital Institute for Health Professionals, School of Rehabilitation Science, Boston, Massachusetts, USA.
   William F. Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA.
   William F. Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, USA.
NR 0
TC 0
SN 1557-774
EI 1096-621
J9 J Palliat Med
PD FEB 8
PY 2022
VL 25
IS 6
BP 964
EP 995
DI 10.1089/jpm.2021.0512
PG 31
WC Acupuncture Therapy; Antineoplastic Agents; adverse effects; Drug-Related Side Effects and Adverse Reactions; Humans; Peripheral Nervous System Diseases; chemically induced; Randomized Controlled Trials as Topic
UT PubMed:35128938
PM 35128938
DA 2022-02-08
ER

PT J
AU Narayanan, S
   Reddy, A
   Lopez, G
   Liu, WL
   Ali, S
   Bruera, E
   Cohen, L
   Yennurajalingam, S
AF Narayanan, Santhosshi
   Reddy, Akhila
   Lopez, Gabriel
   Liu, Wenli
   Ali, Sara
   Bruera, Eduardo
   Cohen, Lorenzo
   Yennurajalingam, Sriram
TI Sleep disturbance in cancer patients referred to an ambulatory integrative oncology consultation
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Insomnia; Integrative oncology; Complementary medicine; Sleep disturbance; Patient-reported outcomes
ID insomnia; prevalence; health; complementary; medicine; fatigue; quality; adults; associations; relaxation
AB Background Sleep disturbance (SD) is highly prevalent in oncology and negatively affects quality of life and mortality. Evidence supports the use of integrative oncology (IO) practices to treat SD, but there is limited published data on the characteristics of SD and factors associated with SD in IO. We determined the prevalence, severity, and factors associated with SD among cancer patients seen in an ambulatory IO consultation. Methods Patients with cancer referred for initial outpatient IO consultation in 2017 were eligible. Patient demographics, clinical characteristics, and patient-reported outcomes (Edmonton Symptom Assessment Scale (ESAS), Measure Yourself Concerns and Wellbeing (MYCaW), PROMIS-10) were retrospectively reviewed. Results One thousand five hundred twenty patients were included in the analysis. The majority (70%) were women with breast cancer (42%). Nine hundred seventy-one (64%) patients reported significant SD with ESAS Sleep >= 4, yet only 11% expressed poor sleep as their primary or secondary concern for the IO consultation. The median SD (IQR) was 5 (3,7). ESAS scores for fatigue (adjusted OR 1.16; CI 1.07-1.26, p < 0.001), pain (adjusted OR 1.07; CI 1.00-1.15, p < 0.05), hot flashes (adjusted OR 1.14; CI 1.07-1.22, p < 0.001), well-being (adjusted OR 1.33; CI 1.22-1.46, p < 0.001), and psychological distress score (anxiety and depression) (adjusted OR 1.16; CI 1.01-1.11, p < 0.01) were independently associated with SD in multivariate analysis. Acupuncture was the most frequent intervention prescribed, 175 (35%). Other modalities included oncology massage (15%), health psychology (5%), and meditation (1%). Conclusions Although 64% of patients seeking IO consultation reported clinically significant SD, only 11% were seeking integrative approaches for managing SD. ESAS fatigue, hot flashes, well-being, and psychological symptoms were significantly associated with SD.
C1 [Narayanan, Santhosshi; Reddy, Akhila; Lopez, Gabriel; Liu, Wenli; Ali, Sara; Bruera, Eduardo; Cohen, Lorenzo; Yennurajalingam, Sriram] Univ Texas MD Anderson Canc, Dept Palliat Rehabil & Integrat Med, Unit 1414,1515 Holcombe Blvd, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Narayanan, S (corresponding author), Univ Texas MD Anderson Canc, Dept Palliat Rehabil & Integrat Med, Unit 1414,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM snarayanan2@mdanderson.org
CR Alfano CM, 2011, BREAST CANCER RES TR, V130, P243, DOI 10.1007/s10549-011-1530-2
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V0, P0, DOI DOI 10.1176/appi.books.9780890425596
   Unknown -, 2005, AM ACAD SLEEP MED, V2nd, P0, DOI [DOI 10.1007/978-1-4939-6578-6_27, 10.1007/978-1-4939-6578-6_27]
   Blanaru M, 2012, MENT ILLN, V4, P59, DOI 10.4081/mi.2012.e13
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Bruera E, 1991, J PALLIAT CARE, V7, P6
   Cheng KKF, 2013, EUR J CANCER CARE, V22, P70, DOI 10.1111/j.1365-2354.2012.01372.x
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   Fiorentino Lavinia, 2011, DRUG DISCOV TODAY DIS MODELS, V8, P167
   Garland SN, 2018, SLEEP HEALTH, V4, P160, DOI 10.1016/j.sleh.2018.01.003
   Garland SN, 2014, J CLIN ONCOL, V32, P449, DOI 10.1200/JCO.2012.47.7265
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   Hui D, 2015, CANCER-AM CANCER SOC, V121, P3027, DOI 10.1002/cncr.29437
   Hoang HTX, 2020, SLEEP BREATH, V24, P241, DOI 10.1007/s11325-019-01839-x
   Irwin MR, 2016, BIOL PSYCHIAT, V80, P40, DOI 10.1016/j.biopsych.2015.05.014
   Irwin MR, 2015, ANNU REV PSYCHOL, V66, P143, DOI 10.1146/annurev-psych-010213-115205
   Jeon MS, 2021, NEURO-ONCOL PRACT, V8, P48, DOI 10.1093/nop/npaa057
   Kashani Fahimeh, 2014, IRAN J NURS MIDWIFERY RES, V19, P113
   Liou KT, 2019, PAIN MED, V20, P2060, DOI 10.1093/pm/pnz087
   Lopez G, 2017, J CANCER, V8, P395, DOI 10.7150/jca.17506
   Mercier J, 2018, SLEEP, V41, P0, DOI 10.1093/sleep/zsy149
   Mustian Karen M, 2013, EUR MED J ONCOL, V1, P106
   Navo MA, 2004, J CLIN ONCOL, V22, P671, DOI 10.1200/JCO.2004.04.162
   Palesh OG, 2010, J CLIN ONCOL, V28, P292, DOI 10.1200/JCO.2009.22.5011
   Parvaneh K, 2014, ASIA PAC J CLIN NUTR, V23, P84, DOI 10.6133/apjcn.2014.23.1.02
   Paterson C, 2007, COMPLEMENT THER MED, V15, P38, DOI 10.1016/j.ctim.2006.03.006
   Qaseem A, 2016, ANN INTERN MED, V165, P125, DOI 10.7326/M15-2175
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Rios P, 2019, SYST REV-LONDON, V8, P0, DOI 10.1186/s13643-019-1163-9
   Rosen IM, 2019, J CLIN SLEEP MED, V15, P1671, DOI 10.5664/jcsm.8062
   Rusch HL, 2019, ANN NY ACAD SCI, V1445, P5, DOI 10.1111/nyas.13996
   Sahin ZA, 2015, COMPLEMENT THER CLIN, V21, P277, DOI 10.1016/j.ctcp.2015.10.002
   Savard J, 2001, SLEEP, V24, P583, DOI 10.1093/sleep/24.5.583
   Shinjyo N, 2020, J EVID-BASED INTEGR, V25, P0, DOI 10.1177/2515690X20967323
   Siu PM, 2021, JAMA NETW OPEN, V4, P0, DOI 10.1001/jamanetworkopen.2020.37199
   Tucker JA, 2021, INT J BEHAV MED, V28, P140, DOI 10.1007/s12529-020-09950-0
   WEYERER S, 1991, SLEEP, V14, P392
   White CM, 2020, ANN PHARMACOTHER, V54, P815, DOI 10.1177/1060028019900504
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Yennurajalingam S, 2021, BMJ SUPPORT PALLIAT, V11, P170, DOI 10.1136/bmjspcare-2019-001877
   Yennurajalingam S, 2017, BMJ SUPPORT PALLIAT, V7, P274, DOI 10.1136/bmjspcare-2015-000847
   Yennurajalingam S, 2016, J PALLIAT MED, V19, P849, DOI 10.1089/jpm.2015.0276
NR 42
TC 7
Z9 9
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAR 15
PY 2022
VL 30
IS 3
BP 2417
EP 2425
DI 10.1007/s00520-021-06668-x
EA NOV 2021
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA YQ4FB
UT WOS:000717397300001
PM 34762218
DA 2026-01-16
ER

PT J
AU Ehret, CJ
   Almodallal, Y
   Le-Rademacher, JG
   Martin, NA
   Moynagh, MR
   Rajotia, A
   Jatoi, A
AF Ehret, Christopher J.
   Almodallal, Yahya
   Le-Rademacher, Jennifer G.
   Martin, Nichole A.
   Moynagh, Michael R.
   Rajotia, Arush
   Jatoi, Aminah
TI Hiccups in patients with cancer: a multi-site, single-institution study of etiology, severity, complications, interventions, and outcomes
SO BMC CANCER
LA English
DT Article
DE Hiccups; Morbidity; Complications; Palliation
ID dexamethasone; baclofen; gabapentin; therapy
AB Background To our knowledge, previous studies have not investigated hiccups in patients with cancer with detailed patient-level data with the goal of capturing a broad spectrum of hiccup symptomatology. Methods This multi-site, single institution study examined consecutive medical records to better understand hiccups in patients with cancer. Results A total of 320 patients are the focus of this report. The median age of patients when hiccups were first reported in the medical record was 63 years (range: 21, 97 years) with 284 (89%) men and 36 (11%) women. The most common diagnose was gastrointestinal cancer. Hiccups most frequently occurred daily, as seen in 194 patients (62%), and the most common duration was less than 1 week, as seen in 146 patients (47%). However, nine patients had had daily hiccups for greater than 6 weeks, and 5 had symptoms for years. Cited etiology was non-chemotherapy medications in 36 (11%) and cancer chemotherapy in 19 (6%). Complications occurred in approximately a third and included insomnia in 51 patients (16%); hospitalization or emergency department visit in 34 (11%); and musculoskeletal pain in 23 (7%). Baclofen was the single most prescribed agent for hiccup palliation, but 100 patients received more than one medication. Medical procedures, which included acupuncture, paracentesis, or phrenic nerve block, were performed in 5 patients. In 234 patients (73%), the medical record documented hiccup cessation. Conclusions Hiccups appear to be highly problematic in a small subset of patients with cancer with no well-defined palliative approaches.
C1 [Ehret, Christopher J.; Almodallal, Yahya; Martin, Nichole A.; Rajotia, Arush; Jatoi, Aminah] Mayo Clin, Dept Oncol, 200 First St SW, Rochester, MN 55905 USA.
   [Le-Rademacher, Jennifer G.] Mayo Clin, Div Clin Trials & Biostat, 200 First St SW, Rochester, MN 55905 USA.
   [Moynagh, Michael R.] Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Jatoi, A (corresponding author), Mayo Clin, Dept Oncol, 200 First St SW, Rochester, MN 55905 USA.
EM jatoi.aminah@mayo.edu
FU Mayo Clinic
CR Unknown -, 2021, CHRON HICC, V0, P0
   Unknown -, 2021, HICC CHRON, V0, P0
   BURCHARTH F, 1974, ACTA CHIR SCAND, V140, P340
   Ehret C, 2022, AM J HOSP PALLIAT ME, V39, P147, DOI 10.1177/10499091211006923
   GUELAUD C, 1995, EUR RESPIR J, V8, P235, DOI 10.1183/09031936.95.08020235
   Hendrix K, 2019, CURR ONCOL REP, V21, P0, DOI 10.1007/s11912-019-0857-4
   Hosoya R, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0172057
   Jatoi A, 2022, BMJ SUPPORT PALLIAT, V12, P475, DOI 10.1136/bmjspcare-2022-003676
   Lee GW, 2013, ONCOLOGIST, V18, P1229, DOI 10.1634/theoncologist.2013-0224
   Liaw CC, 2005, J PAIN SYMPTOM MANAG, V30, P359, DOI 10.1016/j.jpainsymman.2005.08.008
   Mirijello A, 2013, INT J CLIN PRACT, V67, P918, DOI 10.1111/ijcp.12184
   Moretti R, 1999, EUR J NEUROL, V6, P617, DOI 10.1046/j.1468-1331.1999.650617.x
   Moretto EN, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008768.pub2
   Porzio G, 2010, CLIN NEUROPHARMACOL, V33, P179, DOI 10.1097/WNF.0b013e3181de8943
   RAMIREZ FC, 1992, AM J GASTROENTEROL, V87, P1789
   Steger M, 2015, ALIMENT PHARM THER, V42, P1037, DOI 10.1111/apt.13374
   Thompson DF, 2013, ANN PHARMACOTHER, V47, P897, DOI 10.1345/aph.1S018
   Vardy J, 2006, BRIT J CANCER, V94, P1011, DOI 10.1038/sj.bjc.6603048
   Walsh D, 2000, SUPPORT CARE CANCER, V8, P175, DOI 10.1007/s005200050281
   Wang T, 2014, INTERN MED J, V44, P1205, DOI 10.1111/imj.12542
   Zhang CE, 2014, TRIALS, V15, P0, DOI 10.1186/1745-6215-15-295
   Zhang Ruifu, 2004, YINGYONG SHENGTAI XUEBAO, V15, P295
NR 22
TC 4
Z9 5
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 15
PY 2022
VL 22
IS 1
BP 
EP 
DI 10.1186/s12885-022-09760-5
PG 5
WC Oncology
SC Oncology
GA 2D7SI
UT WOS:000811741400001
PM 35705907
DA 2026-01-16
ER

PT J
AU Sheng, G
   Yang, J
   Rong, P
   Yang, X
AF Sheng, Guanyun
   Yang, Jing
   Rong, Peng
   Yang, Xueyi
TI Effects of Warm Needle Acupuncture plus Xitong Waixi Lotion in Patients with Knee
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB OBJECTIVE: To evaluate the effect of warm needle acupuncture plus Xitong Waixi  lotion on the levels of IL-1, TNF-α, and MMP-3 in patients with knee  osteoarthritis. METHODS: Eighty patients with knee osteoarthritis admitted to our  hospital from October 2019 to June 2021 were recruited and assigned via the  random number table method at a ratio of 1 : 1 to receive either Xitong Waixi  lotion (conventional group) or warm needle acupuncture plus Xitong Waixi lotion  (combined group). Outcome measures included clinical efficacy, inflammatory  cytokine level, Western Ontario and McMaster Universities Arthritis Index (WOMAC)  score, visual analogue scale (VAS) score, Hospital for Special Surgery (HSS) knee  score, and adverse reactions. RESULTS: Warm needle acupuncture plus Xitong Waixi  lotion was associated with a significantly higher clinical efficacy versus Xitong  Waixi lotion alone (P=0.006). Patients in the combined group had significantly  lower levels of interleukin (IL)-1, tumor necrosis factor-α (TNF-α), and matrix  metalloproteinase-3 (MMP-3) than those in the conventional group (P=0.020). Warm  needle acupuncture plus Xitong Waixi lotion resulted in significantly lower WOMAC  scores and VAS scores and higher HSS scores for the patients versus Xitong Waixi  lotion (P=0.012). The two groups had a similar incidence of adverse events  (P=0.068). CONCLUSION: Warm needle acupuncture plus Xitong Waixi lotion  effectively alleviates the inflammatory response and knee pain in patients with  knee osteoarthritis, with significant clinical effects and a high safety profile.
C1 Department of Orthopaedics, Liuzhou Traditional Chinese Medical Hospital, Guangxi University of Chinese Medicine, Liuzhou 545001, China.
   Intensive Care Unit, Liuzhou Traditional Chinese Medical Hospital, Guangxi University of Chinese Medicine, Liuzhou 545001, China.
   Graduate School, Guangxi University of Chinese Medicine, Nanning 530000, China.
   Department of Orthopaedics, Liuzhou Traditional Chinese Medical Hospital, Guangxi University of Chinese Medicine, Liuzhou 545001, China.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD AUG 16
PY 2022
VL 2022
IS 
BP 5467712
EP 5467712
DI 10.1155/2022/5467712
PG 0
UT PubMed:35966733
PM 35966733
DA 2022-08-16
ER

PT J
AU Jia, YJ
   Li, TY
   Han, P
   Chen, Y
   Pan, LJ
   Jia, CS
AF Jia, Ye-juan
   Li, Tian-yu
   Han, Peng
   Chen, Yu
   Pan, Li-jia
   Jia, Chun-sheng
TI Effects of different courses of moxibustion treatment on intestinal flora and inflammation of a rat model of knee osteoarthritis
SO JOURNAL OF INTEGRATIVE MEDICINE-JIM
LA English
DT Article
DE Knee osteoarthritis; Different courses; Moxibustion treatment; Intestinal flora; Inflammatory cytokines
ID interleukin-10; microbiota; arthritis; alpha; pain
AB Objective: This study was done to determine the effects of different courses of moxibustion on a rat knee osteoarthritis (KOA) model, and explore the dose-effect relationship of moxibustion on KOA from the perspectives of intestinal flora and inflammatory factors. Methods: Wistar rats were randomly divided into five groups: normal, model, moxibustion for 2 weeks, moxibustion for 4 weeks and moxibustion for 6 weeks groups (n = 5 each group). A KOA rat model was induced by monosodium iodoacetate, and moxibustion intervention was performed at the acupoints "Dubi " (ST35) and "Zusanli " (ST36), once every other day. Pathologic changes in the cartilage of rat knee joints were assessed after intervention, and fecal samples were subjected to 16S rRNA high-throughput sequencing for microbial diversity analysis. Results: Damage to the knee articular cartilage was obvious in the model group, which also had increased levels of pro-inflammatory factors, decreased levels of anti-inflammatory factors, and intestinal flora dis -orders with decreased diversity. The degree of cartilage damage in the 4 and 6 weeks of moxibustion groups was significantly improved compared with the model group. The 4 and 6 weeks of moxibustion groups also demonstrated reduced levels of interleukin-1b and tumor necrosis factor-a and increased levels of interleukin-10 (P < 0.05). Both the abundance and diversity of the intestinal flora were increased, approaching those of the normal group. Abundances of probiotics Eubacterium coprostanoligenes group and Ruminococcaceae UCG-014 increased, while that of the pathogenic bacteria Lachnospiraceae NK4A136 group decreased (P < 0.05). Although the abundance of Lachnospiraceae NK4A136 group decreased in the 2 weeks of moxibustion group compared with the model group (P < 0.05), there was no statistically significant difference in serum inflammatory factors, flora species diversity or degree of pathological damage compared with the model group. Conclusion: Moxibustion treatment led to significant improvements in the intestinal flora and inflamma -tory factors of rats with KOA. Moxibustion treatment of 4 and 6 weeks led to better outcomes than the 2-week course. Moxibustion for 4 and 6 weeks can regulate intestinal flora dysfunction with increased pro-biotics and reduced pathogenic bacteria, reduce pro-inflammatory factors and increase anti-inflammatory factors. No significant differences were seen between the effects of moxibustion for 4 weeks and 6 weeks. Please cite this article as: Jia YJ, Li TY, Han P, Chen Y, Pan LJ, Jia CS. Effects of different courses of moxibustion treatment on intestinal flora and inflammation of a rat model of knee osteoarthritis. J Integr Med. 2022; 20(2): 173-181. (c) 2022 The Authors. Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Jia, Ye-juan; Li, Tian-yu; Han, Peng; Chen, Yu; Pan, Li-jia; Jia, Chun-sheng] Hebei Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Shijiazhuang 050200, Hebei, Peoples R China.
C3 Hebei University of Chinese Medicine
RP Jia, CS (corresponding author), Hebei Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Shijiazhuang 050200, Hebei, Peoples R China.
EM jia7158@163.com
FU National Natural Science Foundation of China [81173342, 81473773, XCXZZBS2021017]
CR Abbafati C, 2020, LANCET, V396, P1204
   Asjid R, 2019, JCPSP-J COLL PHYSICI, V29, P1067, DOI 10.29271/jcpsp.2019.11.1067
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140-6736(11)60243-2
   Boer CG, 2019, NAT COMMUN, V10, P0, DOI 10.1038/s41467-019-12873-4
   Botha-Scheepers S, 2008, ANN RHEUM DIS, V67, P1165, DOI 10.1136/ard.2007.084657
   Chen M, 2021, J ETHNOPHARMACOL, V268, P0, DOI 10.1016/j.jep.2020.113695
   Chen Yu, 2020, ZHONGGUO ZHEN JIU, V40, P913, DOI 10.13703/j.0255-2930.20200310-k0011
   Chen Y, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/3196427
   Choi TY, 2017, MATURITAS, V100, P33, DOI 10.1016/j.maturitas.2017.03.314
   Choi TY, 2012, RHEUMATOL INT, V32, P2969, DOI 10.1007/s00296-012-2367-7
   Clemente JC, 2018, BMJ-BRIT MED J, V360, P0, DOI 10.1136/bmj.j5145
   Darnaud M, 2018, GASTROENTEROLOGY, V154, P1009, DOI 10.1053/j.gastro.2017.11.003
   Derrien M, 2008, APPL ENVIRON MICROB, V74, P1646, DOI 10.1128/AEM.01226-07
   Dong YH, 2019, FOOD FUNCT, V10, P3880, DOI 10.1039/C9FO00583H
   Du JX, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-33
   Felson DT, 2000, ANN INTERN MED, V133, P726, DOI 10.7326/0003-4819-133-9-200011070-00015
   Guss JD, 2019, OSTEOARTHR CARTILAGE, V27, P129, DOI 10.1016/j.joca.2018.07.020
   Helmark IC, 2010, ARTHRITIS RES THER, V12, P0, DOI 10.1186/ar3064
   Hu XF, 2020, POSTGRAD MED, V132, P495, DOI 10.1080/00325481.2020.1744335
   Järvinen K, 2008, CLIN EXP RHEUMATOL, V26, P275
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Li A, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003244
   Li BR, 2021, J INTEGR MED-JIM, V19, P144, DOI 10.1016/j.joim.2020.12.004
   Liu M, 2021, ARTHRITIS RES THER, V23, P0, DOI 10.1186/s13075-021-02442-w
   Ma YY, 2018, EXP ANIM TOKYO, V67, P271, DOI 10.1538/expanim.17-0142
   Miyamoto S, 2016, BMC MUSCULOSKEL DIS, V17, P0, DOI 10.1186/s12891-016-0985-z
   Zacaron KAM, 2018, J INTEGR MED-JIM, V16, P106, DOI 10.1016/j.joim.2018.02.002
   Ohira H, 2017, J ATHEROSCLER THROMB, V24, P660, DOI 10.5551/jat.RV17006
   Pitcher T, 2016, JOVE-J VIS EXP, V0, P0, DOI DOI 10.3791/53746
   Qin RB, 2021, J AGR FOOD CHEM, V69, P3209, DOI 10.1021/acs.jafc.0c08187
   Schneeberger M, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16643
   Schott EM, 2018, JCI INSIGHT, V3, P0, DOI 10.1172/jci.insight.95997
   Si X, 2018, MOL NUTR FOOD RES, V62, P0, DOI 10.1002/mnfr.201700670
   Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Song GM, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002790
   Szychlinska MA, 2019, HELIYON, V5, P0, DOI 10.1016/j.heliyon.2019.e01134
   Tian BM, 2021, MOL NUTR FOOD RES, V65, P0, DOI 10.1002/mnfr.202000745
   Udo M, 2016, OSTEOARTHR CARTILAGE, V24, P1284, DOI 10.1016/j.joca.2016.02.005
   Watkins LR, 2020, BRAIN BEHAV IMMUN, V90, P155, DOI 10.1016/j.bbi.2020.08.005
   Wu YR, 2019, CHIN J INTEGR MED, V25, P716, DOI 10.1007/s11655-019-3224-2
   Yu H, 2020, MEDICINE, V99, P23035
   Zhao L, 2014, ARTHRITIS RES THER, V16, P0, DOI 10.1186/ar4590
   Zhuge AX, 2020, APPL MICROBIOL BIOT, V104, P7437, DOI 10.1007/s00253-020-10749-y
NR 43
TC 26
Z9 34
U1 8
U2 51
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-4964
EI 
J9 J INTEGR MED-JIM
JI J. Integr. Med.-JIM
PD MAR 15
PY 2022
VL 20
IS 2
BP 173
EP 181
DI 10.1016/j.joim.2022.01.004
EA MAR 2022
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 0G2EJ
UT WOS:000777863400010
PM 35101368
DA 2026-01-16
ER

PT J
AU Xi, Z
   Wei, X
   Ye, Z
   Wang, K
   Zhou, J
AF Xi, Ziqi
   Wei, Xuqiang
   Ye, Zi
   Wang, Ke
   Zhou, Jia
TI Acupuncture for adult lung cancer of patient-reported outcomes: A systematic
SO Frontiers in oncology
LA English
DT Journal Article
DE PROs = patient-reported outcomes; acupuncture; lung cancer; meta-analysis; systematic review
AB PURPOSE: This systematic review and meta-analysis aims to assess the effects of  acupuncture on patient-reported outcomes (PROs) in adults with lung cancer.  METHODS: Electronic databases including PubMed, Embase, Cochrane Library, Web of  Science, China National Knowledge Infrastructure (CNKI), China Science and  Technology Journal Database (CQVIP), Wanfang Data, SinoMed, and gray literatures  were retrieved from inception to 1 July 2022 for randomized controlled trials  (RCTs). Acupuncture was defined as an experimental intervention, and the patients  of the control groups included either treatment including conventional therapy  (usual care, sham/placebo acupuncture, pharmacotherapy including Western medicine  and Chinese traditional medicine). PROs for this study were measured by seven  scales of primary outcomes including the Karnofsky Performance Status (KPS),  European Organization for Research and Treatment of Cancer Quality of Life  Questionnaire, Functional Assessment of Cancer Therapy-Lung, Functional  Assessment of Cancer Therapy Lung Cancer Subscale, Leicester Cough Questionnaire  (LCQ score), the Medical Outcomes Study (MOS) item short form health survey  (SF-36), and the St George's Respiratory Questionnaire, and 12 scales of  secondary outcomes. Cochrane Collaboration's tool was used to assess the risks of  bias. Data were combined and analyzed with RevMan 5.4 and Stata/SE 16.0. RESULTS:  We retrieved 3,002 lung cancer patients from 33 trials. KPS included with 1,000  patients showed that acupuncture could significantly improve the quality of life  (QOL) compared with the control group regardless of different  tumor-node-metastasis stages or the different stages of disease. The study showed  that acupuncture significantly improved lung cancer-related symptoms in the QOL,  pain, nausea and vomiting, insomnia, anxiety and depression, fatigue, and  constipation compared with the control group. Eight RCTs reported the occurrence  of adverse events, whereas four reported none and four RCTs reported that the  events in the observation group were significantly less than those in the control  group. CONCLUSION: Acupuncture proved to be a promising intervention, both  postoperatively and after chemotherapy, and should be recommended as a beneficial  alternative strategy to promote PROs in lung cancer patients at all stages of  application. Considering the low quality, we suggest more rigorous clinical  trials of acupuncture for lung cancer in the future and more emphasis on the  effect of acupuncture in patients with lung cancer on their PROs, mainly in the  aspect of the QOL. SYSTEMATIC REVIEW REGISTRATION:  https://www.crd.york.ac.uk/prospero/display_record.php?, identifier  [CRD42021274122].
C1 Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, China.
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, China.
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, China.
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, China.
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD SEP 20
PY 2022
VL 12
IS 
BP 921151
EP 921151
DI 10.3389/fonc.2022.921151
PG 0
UT PubMed:36119472
PM 36119472
DA 2022-09-20
ER

PT J
AU Klose, P
   Kuemmel, S
   Voiss, P
AF Klose, Petra
   Kummel, S.
   Voiss, P.
TI Traditional Chinese medicine in integrative oncology
SO ONKOLOGIE
LA German
DT Article
DE Acupuncture; Acupressure; Cancer; TCM; Integrative oncology
ID chemotherapy-induced nausea; breast-cancer survivors; hot flashes; acupuncture; trial; acupressure; efficacy; fatigue
AB Therapies from traditional Chinese medicine (TCM) are increasingly being integrated into western treatment concepts within the framework of integrative oncology. The focus is on reducing the side effects of oncological treatment, improving the quality of life, promoting a healthy lifestyle and strengthening and harmonizing the patient. There is good evidence for a number of TCM procedures, especially for acupuncture/acupressure to relieve pain (caused by chemotherapy, aromatase inhibitors or the cancer itself). Sleep, cognition and menopausal symptoms can also be improved by acupuncture/acupressure. Ginseng for fatigue and ginger for nausea can be tried as single drugs. Evidence-based medicine has also driven research in TCM, and methodologically high-quality study results are now available that are worthy of critical consideration.
C1 [Klose, Petra; Kummel, S.; Voiss, P.] KEM Evang Kliniken Essen Mitte, Klin Nat Heilkunde & Integrat Med, Deimelsberg 34a, D-45276 Essen, Germany.
   [Kummel, S.; Voiss, P.] KEM Evang Kliniken Essen Mitte, Klin Senol Interdisziplinares Brustkrebszentrum, Essen, Germany.
RP Klose, P (corresponding author), KEM Evang Kliniken Essen Mitte, Klin Nat Heilkunde & Integrat Med, Deimelsberg 34a, D-45276 Essen, Germany.
EM p.klose@kem-med.com
CR Arbeitsgemeinschaft Gynakologische Onkologie Kommission Mamma, 2021, EMPF GYN ONK KOMM MA, V0, P0
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Barton DL, 2013, JNCI-J NATL CANCER I, V105, P1230, DOI 10.1093/jnci/djt181
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Brinkhaus B, 2019, BREAST CANCER RES TR, V178, P617, DOI 10.1007/s10549-019-05431-5
   Crichton M, 2019, J ACAD NUTR DIET, V119, P2055, DOI 10.1016/j.jand.2019.06.009
   European Medicines Agency, 2014, COMM HERB MON PAN GI, V0, P0
   European Medicines Agency, 2012, COMM HERB MON ZING O, V0, P0
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Garland SN, 2017, MENOPAUSE, V24, P517, DOI 10.1097/GME.0000000000000779
   Genovese TJ, 2021, J PAIN SYMPTOM MANAG, V62, PE192, DOI 10.1016/j.jpainsymman.2021.03.002
   Genovese TJ, 2019, PAIN MED, V20, P191, DOI 10.1093/pm/pny067
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Höxtermann MD, 2022, CANCER-AM CANCER SOC, V128, P2159, DOI 10.1002/cncr.34165
   Jung SY, 2017, J GASTRIC CANCER, V17, P11
   Leitlinienprogramm Onkologie, 2021, S3 LEITL KOMPL BEH O, V0, P0
   Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft [DKG] AWMF), 2018, S3 LEITL PRAV DIAG T, V0, P0
   Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft [DKG] AWMF), 2019, S3 LEITL MAG DIAG TH, V0, P0
   Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft [DKG] AWMF), 2020, S3 LEITLINIE DIAGNOS, V0, P0
   Liou KT, 2020, CANCER-AM CANCER SOC, V126, P3042, DOI 10.1002/cncr.32847
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   Liu YH, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/2504021
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Miao J, 2017, INT J NURS STUD, V70, P27, DOI 10.1016/j.ijnurstu.2017.02.014
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Ni XS, 2019, SUPPORT CARE CANCER, V27, P3701, DOI 10.1007/s00520-019-04911-0
   Ni XX, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420980825
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Romero SAD, 2020, MENOPAUSE, V27, P913, DOI 10.1097/GME.0000000000001545
   Tong TS, 2018, MED SCI MONITOR, V24, P2919, DOI 10.12659/MSM.909712
   Wayne PM, 2014, ARCH PHYS MED REHAB, V95, P2470, DOI 10.1016/j.apmr.2014.05.005
   Yang MX, 2021, NPJ BREAST CANCER, V7, P0, DOI 10.1038/s41523-021-00355-0
   Pan YQ, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420940394
   Zhou J, 2017, CURR ONCOL, V24, PE1, DOI 10.3747/co.24.3296
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
   Zick SM, 2016, JAMA ONCOL, V2, P1470, DOI 10.1001/jamaoncol.2016.1867
   Zick SM, 2009, SUPPORT CARE CANCER, V17, P563, DOI 10.1007/s00520-008-0528-8
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
NR 42
TC 0
Z9 0
U1 1
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2731-7226
EI 2731-7234
J9 ONKOLOGIE-GER
JI Onkologie
PD NOV 15
PY 2022
VL 28
IS 11
BP 1024
EP 1032
DI 10.1007/s00761-022-01234-4
EA SEP 2022
PG 9
WC Oncology
SC Oncology
GA 5V2LC
UT WOS:000859626600001
DA 2026-01-16
ER

PT J
AU El, Iskandarani S
   Deng, G
AF El Iskandarani, Sarah
   Deng, Gary
TI Acupuncture in hematologic malignancies and hematopoietic cell transplantation.
SO Blood reviews
LA English
DT Review
DE Acupuncture; Cancer symptoms; Integrative medicine; Leukemia; Lymphoma
AB Acupuncture is an integrative medicine modality that has been used historically  and studied recently for managing various symptoms and diseases. Patients with  hematological malignancies often experience a high symptom burden including pain,  fatigue, nausea, vomiting, and insomnia. Pharmacological interventions are the  mainstay of managing these symptoms, although they may not provide adequate  control or are not well tolerated due to side effects. There have been many  randomized controlled trials of acupuncture on reduction of these symptoms. In  this review, we will summarize the current evidence on the effect of acupuncture  on the management of common symptoms experienced by patients with hematological  malignancies and the current understanding of acupuncture's mechanism of action.  The evidence is the strongest for reducing pain and nausea vomiting, less strong  for symptoms such as peripheral neuropathy, fatigue, constipation, insomnia,  night sweat, and pruritus.
C1 Memorial Sloan Kettering Cancer Center, Integrative Medicine Service, New York, NY, USA.
   Memorial Sloan Kettering Cancer Center, Integrative Medicine Service, New York, NY, USA.
EM dengg@mskcc.org
NR 0
TC 0
SN 1532-168
EI 0268-960
J9 Blood Rev
PD JUN 21
PY 2022
VL 56
IS 
BP 100985
EP 100985
DI 10.1016/j.blre.2022.100985
PG 0
WC Humans; Sleep Initiation and Maintenance Disorders; etiology; Acupuncture Therapy; adverse effects; Nausea; etiology; Vomiting; etiology; Fatigue; etiology; Hematopoietic Stem Cell Transplantation; adverse effects; Pain; etiology; Hematologic Neoplasms; therapy
UT PubMed:35725779
PM 35725779
DA 2022-06-21
ER

PT J
AU Cho, E
   Park, CH
   Cho, SY
AF Cho, Eunae
   Park, Chang-Hwan
   Cho, Seo Yeon
TI Single balloon enteroscopy-guided endoscopic retrograde pancreatography for the treatment of a symptomatic pancreatic pseudocyst complicated by pancreaticojejunostomy stricture: A case report
SO MEDICINE
LA English
DT Article
DE altered gastrointestinal anatomy; case report; endoscopic retrograde; enteroscopy; pancreatic pseudocyst; pancreatography
ID assisted enteroscopy; cholangiopancreatography; drainage; pancreaticoduodenectomy; multicenter; experience; ercp
AB Rationale: Endoscopic treatment of a pancreatic pseudocyst complicated by pancreaticojejunostomy (PJ) stricture is challenging. Patient concerns: A 76-year-old woman presented with worsening abdominal pain and dyspepsia. She had been receiving adjuvant chemotherapy (capecitabine and cisplatin) for 4 months after pylorus-preserving pancreaticoduodenectomy (PPPD) for the treatment of extrahepatic cholangiocarcinoma. Diagnoses: Laboratory findings included elevated serum amylase (145 U/L) and lipase (437 U/L) levels. Abdominal computed tomography (CT) showed a pancreatic pseudocyst of approximately 3 cm in size and pancreatic duct dilatation in the remnant pancreas. According to the Response Evaluation Criteria in Solid Tumors, cholangiocarcinoma is a stable disease. Interventions and outcomes: Endoscopic drainage of the pancreatic pseudocyst was planned. Single-balloon enteroscopy (SBE)-guided endoscopic retrograde pancreatography (ERP) with endoscopic ultrasonography (EUS) using a mini probe demonstrated a membranous PJ stricture and a pancreatic pseudocyst. Endoscopic pseudocyst drainage using a 7-Fr plastic stent was successfully performed after needle-knife incision of the PJ stricture. Follow-up abdominal CT after 3 weeks showed complete resolution of the pseudocyst. Chemotherapy was resumed. Lessons: SBE-guided ERP with EUS using a mini probe may be an effective and safe treatment in a patient with a pancreatic pseudocyst complicated by membranous PJ stricture after PPPD.
C1 [Cho, Eunae; Park, Chang-Hwan; Cho, Seo Yeon] Chonnam Natl Univ, Dept Internal Med, Div Gastroenterol, Sch Med, Gwangju, South Korea.
C3 Chonnam National University
RP Park, CH (corresponding author), Chonnam Natl Univ Hosp, Dept Internal Med, Div Gastroentero, 42 Jebong Ro, Gwangju, South Korea.
EM p1052ccy@hanmail.net
FU Chonnam National University Hospital Biomedical Research Institute [BCRI22067]
CR Basiliya K, 2021, ENDOSCOPY, V53, P266, DOI 10.1055/a-1200-0199
   Benson AB III, 2021, J NATL COMPR CANC NE, V19, P541, DOI 10.6004/jnccn.2021.0022
   Chahal P, 2006, ENDOSCOPY, V38, P1241, DOI 10.1055/s-2006-945003
   Chen YI, 2017, GASTROINTEST ENDOSC, V85, P170, DOI 10.1016/j.gie.2016.07.031
   Demirjian AN, 2010, HPB, V12, P482, DOI 10.1111/j.1477-2574.2010.00214.x
   Fujii LL, 2013, GASTROINTEST ENDOSC, V78, P854, DOI 10.1016/j.gie.2013.05.016
   Ghazanfar MA, 2018, ANZ J SURG, V88, P626, DOI 10.1111/ans.14073
   Itoi T, 2013, DIGEST ENDOSC, V25, P241, DOI 10.1111/den.12048
   Itokawa F, 2014, DIGEST ENDOSC, V26, P136, DOI 10.1111/den.12254
   Krutsri C, 2019, WORLD J GASTROENTERO, V25, P3313, DOI 10.3748/wjg.v25.i26.3313
   Matsumoto I, 2022, ANN GASTROENT SURG, V6, P412, DOI 10.1002/ags3.12528
   Morgan KA, 2010, HPB, V12, P211, DOI 10.1111/j.1477-2574.2009.00154.x
   Muthusamy VR, 2016, GASTROINTEST ENDOSC, V83, P481, DOI 10.1016/j.gie.2015.11.027
   Nabeshima T, 2018, INTERNAL MED, V57, P357, DOI 10.2169/internalmedicine.9133-17
   Oh CH, 2021, CLIN ENDOSC, V54, P505, DOI 10.5946/ce.2021.185
   Park BK, 2016, DIGEST DIS SCI, V61, P293, DOI 10.1007/s10620-015-3861-z
   Schneider M, 2019, WORLD J GASTROENTERO, V25, P3538, DOI 10.3748/wjg.v25.i27.3538
   Shah RJ, 2013, GASTROINTEST ENDOSC, V77, P593, DOI 10.1016/j.gie.2012.10.015
   van der Merwe SW, 2022, ENDOSCOPY, V54, P185, DOI 10.1055/a-1717-1391
   Vila JJ, 2010, WORLD J GASTRO ENDOS, V2, P193, DOI 10.4253/wjge.v2.i6.193
   Yane K, 2017, ENDOSCOPY, V49, P69, DOI 10.1055/s-0042-118301
NR 21
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 28
PY 2022
VL 101
IS 43
BP 
EP 
DI 10.1097/MD.0000000000031293
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 5V5UQ
UT WOS:000877294300069
PM 36316922
DA 2026-01-16
ER

PT J
AU Robinson, CL
   Berger, A
   Sottosanti, E
   Li, M
   Kaneb, A
   Keefe, J
   Kim, E
   Kaye, AD
   Viswanath, O
   Urits, I
AF Robinson, Christopher L
   Berger, Amnon
   Sottosanti, Emily
   Li, Michael
   Kaneb, Alicia
   Keefe, Joseph
   Kim, Edward
   Kaye, Alan D
   Viswanath, Omar
   Urits, Ivan
TI Acupuncture as Part of Multimodal Analgesia for Chronic Pain.
SO Orthopedic reviews
LA English
DT Journal Article
DE Acupuncture; Cancer; Chronic Abdominal Pain; Comprehensive Medicine; Neck Pain
AB BACKGROUND: Chronic pain is a multifactorial condition that is afflicting  populations worldwide causing an increasing economic, physical, mental, and  emotional burden. Treatments range from medications to interventional procedures  to complementary and alternative medicine (CAM), such as acupuncture. This review  aims to discuss the use of acupuncture in the treatment of chronic pain, proposed  mechanisms, indications, and efficacy for various chronic pain conditions.  RESULTS: Evidence is varied on the efficacy and quality of data on the use of  acupuncture in the treatment of chronic pain. Recent studies have demonstrated  promising results in the support of acupuncture for the use in the treatment of  cancer, neck, and back pain, functional dyspepsia, and various chronic abdominal  pain syndromes. CONCLUSION: Acupuncture, deemed well-tolerated and safe to use,  has been increasingly studied and is regarded as effective in clinical practice,  but its efficacy is limited by the lack of well-conducted, high-quality clinical  trials, lower quality evidence, and conflicting study results. Additionally, the  exact analgesic mechanism of acupuncture remains to be fully elucidated.  Increasing evidence supports the role of acupuncture as therapy in the treatment  of cancer, neck, and back pain and functional dyspepsia. Further rigorous studies  are needed to fully assess the use of acupuncture in various chronic pain  conditions, determine its indications, and optimal treatment schedule. Overall,  future studies could benefit from better designed experimental studies, larger  groups, and more objectives ways to measure pain reduction and symptom  improvement.
C1 Anesthesiology, BIDMC.
   Anesthesiology, BIDMC.
   Anesthesiology, BIDMC.
   Anesthesiology, BIDMC.
   Anesthesiology, BIDMC.
   Anesthesiology, BIDMC.
   Anesthesiology, BIDMC.
   Anesthesiology, BIDMC.
   Anesthesiology, BIDMC.
   Anesthesiology, BIDMC.
NR 0
TC 0
SN 2035-816
EI 2035-823
J9 Orthop Rev (Pavia)
PD SEP 29
PY 2022
VL 14
IS 3
BP 38321
EP 38321
DI 10.52965/001c.38321
PG 0
UT PubMed:36168395
PM 36168395
DA 2022-09-29
ER

PT J
AU Lu, C
   Bao, WL
   Deng, DH
   Li, RR
   Li, GL
   Zou, SL
   Wang, Y
AF Lu, Chao
   Bao, Wenlong
   Deng, Dehou
   Li, Rongrong
   Li, Guangliang
   Zou, Shanlin
   Wang, Yan
TI Efficacy of electroacupuncture with different frequencies in the treatment of chemotherapy-induced peripheral neuropathy: A study protocol for a randomized controlled trial
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE electroacupuncture; chemotherapy-induced peripheral neuropathy; randomized controlled trial; protocol; Mecobalamin
ID nerve-conduction; clinical-trials; acupuncture; management; cancer; diagnosis
AB Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication in patients with cancer during chemotherapy. It mainly leads to severe numbness of the hands and feet and causes great pain in patients. Electroacupuncture (EA) is considered to be beneficial in improving peripheral neuropathy and relieving numbness of the hands and feet. This trial aims to evaluate the therapeutic effect of different frequencies of EA on CIPN in patients with cancer. Methods and analysis: This study is a randomized controlled trial. In total, 160 eligible CIPN patients are randomly assigned to the 2 Hz EA group, 100 Hz EA group, 2/100 Hz EA group, and control group in the ratio of 1:1:1:1. All patients in the EA treatment groups receive treatment with EA three times a week for 4 weeks and following up for 4 weeks. The patients in the control group are given Mecobalamin (MeCbl) tablets orally, one tablet at a time, three times a day, for 4 weeks, and following up for 4 weeks. The primary outcome measures are the participant neurotoxicity questionnaire (PNQ) and the peripheral neurotoxicity assessment rating (NCI CTCAE V5.0). Secondary outcomes are the quality of life scale (EORTC QLQ-C30) and the measurement of peripheral nerve conduction velocity (NCV). The results are evaluated at baseline, post-treatment phase, and following up for 4 weeks. All major analyses are based on the intention to treat principle. Ethics/dissemination: This protocol was approved by the Medical Ethics Committee of the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) on 7 December 2021. The license number is IRB-2021-458. This study provides clinical efficacy data of different frequencies of EA in the treatment of CIPN. The results help to prove whether EA is an effective therapy for CIPN and optimize the frequency of EA for CIPN. The results of this study are shared with health care professionals, the public, and relevant organizations through the publication of manuscripts and conference reports.
C1 [Lu, Chao; Bao, Wenlong; Deng, Dehou; Zou, Shanlin; Wang, Yan] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Tradit Chinese Med Dept, Canc Hosp, Hangzhou, Peoples R China.
   [Li, Rongrong] Zhejiang Univ Tradit Chinese Med, Clin Med Coll 3, Hangzhou, Peoples R China.
   [Li, Guangliang] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Breast Med Oncol Dept, Canc Hosp, Hangzhou, Peoples R China.
C3 Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital; Zhejiang Chinese Medical University; Zhejiang Cancer Hospital; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS
RP Lu, C (corresponding author), Univ Chinese Acad Sci, Zhejiang Canc Hosp, Tradit Chinese Med Dept, Canc Hosp, Hangzhou, Peoples R China.
EM 1069103617@qq.com
FU Program of Science Research Foundation of Zhejiang Provincial TCM Administration;  [2022ZB058]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   AL-Atiyyat N, 2017, INT J PALLIAT NURS, V23, P13, DOI 10.12968/ijpn.2017.23.1.13
   Basch E, 2014, JNCI-J NATL CANCER I, V106, P0, DOI 10.1093/jnci/dju244
   Carvalho LF, 2017, CLIN EXP PHARMACOL P, V44, P971, DOI 10.1111/1440-1681.12803
   Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   [崔光卫 Cui Guangwei], 2017, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V32, P2670
   Domkundwar S, 2017, J ULTRASOUND, V20, P111, DOI 10.1007/s40477-016-0232-3
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Han YJ, 2018, MINERVA ENDOCRINOL, V43, P11, DOI 10.23736/S0391-1977.16.02505-0
   Hausheer FH, 2006, SEMIN ONCOL, V33, P15, DOI 10.1053/j.seminoncol.2005.12.010
   Hwang MS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019837
   Jiang DQ, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011390
   Lee JS, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-124
   Lee S, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-225
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   MacPherson H, 2010, ACUPUNCT MED, V28, P83, DOI 10.1136/aim.2009.001370
   McCrary JM, 2017, SUPPORT CARE CANCER, V25, P3485, DOI 10.1007/s00520-017-3772-y
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Park SB, 2009, J CLIN ONCOL, V27, P1243, DOI 10.1200/JCO.2008.19.3425
   Renn CL, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-29
   Sawangjit R, 2020, J ALTERN COMPLEM MED, V26, P1117, DOI 10.1089/acm.2020.0068
   Schröder S, 2007, EUR J NEUROL, V14, P276, DOI 10.1111/j.1468-1331.2006.01632.x
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shimozuma K, 2012, SUPPORT CARE CANCER, V20, P3355, DOI 10.1007/s00520-012-1492-x
   Shimozuma K, 2009, SUPPORT CARE CANCER, V17, P1483, DOI 10.1007/s00520-009-0613-7
   Sun XJ, 2012, SHANGHAI J ACUPUNCT MOXIBUSTION, V31, P727, DOI 10.3969/J.ISSN.1005-0957.2012.10.727
   Tsubaki M, 2015, INT J CANCER, V137, P243, DOI 10.1002/ijc.29367
   Wozniak KM, 2018, CANCER RES, V78, P817, DOI 10.1158/0008-5472.CAN-17-1467
   Wozniak KM, 2016, CANCER RES, V76, P3332, DOI 10.1158/0008-5472.CAN-15-2525
   Xiang Y, 2018, CHIN J INTEGR MED CARDIO-/CEREBROVASC DIS, V16, P1168
   Xiaobing C, 2012, CHIN MED PHARM, V2, P38
   Yokoyama S, 2022, SUPPORT CARE CANCER, V30, P1765, DOI 10.1007/s00520-021-06585-z
   Yuanyuan L, 2019, J ZHEJIANG CHIN MED, V43, P0, DOI 10.16466/j.issn1005-5509.2019.05.024
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zhang M, 2013, NEURAL PLAST, V2013, P0, DOI 10.1155/2013/424651
NR 39
TC 8
Z9 8
U1 2
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD JUL 28
PY 2022
VL 13
IS 
BP 
EP 
DI 10.3389/fneur.2022.843886
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 3S1CX
UT WOS:000839341600001
PM 35968286
DA 2026-01-16
ER

PT J
AU Almeida, TCD
   Zatta, SM
   Paiva, LD
   de Carvalho, LEW
   Schoueri, J
   de Abreu, LC
   Fonseca, FLA
   Adami, F
AF do Carmo Almeida, Tabata Cristina
   Zatta, Simone Meneghette
   da Silva Paiva, Laercio
   de Carvalho, Luis Eduardo Werneck
   Schoueri, Jean
   de Abreu, Luiz Carlos
   Fonseca, Fernando Luiz Affonso
   Adami, Fernando
TI Reduction on Proinflammatory Cytokines after Application of Transcutaneous Electrical Nerve Stimulation (TENS) in Patients with a Breast Cancer: A Nonrandomized, Open, and Single-Arm Study Protocol with Paired Analysis
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID postoperative pain management; inflammation; electroacupuncture; blood
AB Background. Transcutaneous electrical nerve stimulation (TENS) has been used as analgesic therapy in many diseases. It is already known that studies that have observed the relationship between pain and cytokines have found that patients who report less severe pain have less production of proinflammatory cytokines. However, one another accepted mechanism is that decreasing proinflammatory cytokines results in decreased pain intensity. Analyzing the literature, the authors describe that, in addition to the analgesic effect, TENS has shown systemic effects, and clinically, the reduction of proinflammatory cytokines could be a protective factor against inflammation. To test the inflammatory effect of TENS, we researched the literature for clinical conditions that suggest that proinflammatory cytokines are one of the main mediators of the disease process. Chronic inflammation is one of the risk factors mentioned for the development of a new cancer; at the same time, it is indicated as an indicator of the worst prognosis. Studies also suggest that the worst prognosis of breast cancer, one of the types with the highest incidence in the world, may be related to increased inflammatory activity. Considering that inflammation is increased in breast cancer and that TENS can reduce proinflammatory cytokines even without blocking the pain pathway, our hypothesis is that the anti-inflammatory effect of TENS can bring benefits to these patients. The aim of this study will be to evaluate the effect of TENS on blood reduction of proinflammatory cytokines in breast cancer patients. Methods. This study will evaluate at least 59 patients, over 18 years of age, diagnosed with breast cancer, but who have not yet started any treatment. All patients will be submitted to TENS intervention (Ibramed, Model Neurodyn III, parameters: VIF-turn on, frequency-2-247 Hz, pulse size-50-500 mu s, and intensity (mA)-maximum tolerated by the patient), and the data will be analyzed in the pre- and postintervention of each patient. The application has a total duration of 30 minutes, and 8 ml of blood will be collected before and after the intervention. Proinflammatory (IL-1, IL-2, IL-6, IL-7, and TNF-alpha) and anti-inflammatory (IL-4, IL-10, IL-13, and FTC beta) cytokines will be analyzed. As a primary endpoint, we will analyze the reduction in blood concentration of proinflammatory cytokines, and as secondary endpoints, we will analyze the size of the effect according to each type of proinflammatory cytokine, describe the effect size of the reduction according to the breast cancer immunohistochemistry, and analyze the effect of TENS on anti-inflammatory cytokines. This study is approved by the Research Ethics Committee (Centro Universitario FMABC, Brazil) and registered in the Brazilian Clinical Trials (Search text: RBR-10jbwh47).
C1 [do Carmo Almeida, Tabata Cristina; da Silva Paiva, Laercio; de Carvalho, Luis Eduardo Werneck; Schoueri, Jean; Adami, Fernando] Ctr Univ FMABC, Lab Epidemiol & Analise Dados, Av Lauro Gomes 2000, BR-09060870 Santo Andre, SP, Brazil.
   [Zatta, Simone Meneghette] Clin Res, Pesquisare Saude, Av Dom Pedro 2,Room 53, BR-09060110 Santo Andre, SP, Brazil.
   [de Carvalho, Luis Eduardo Werneck] Oncol Brasil Ensino & Pesquisa, Av Visc de Souza Franco 570, BR-66053000 Belem, Para, Brazil.
   [de Abreu, Luiz Carlos] Ctr Univ FMABC, Lab Delineamento Estudos & Escrita Cient, Av Lauro Gomes 2000, BR-09060870 Santo Andre, SP, Brazil.
   [Fonseca, Fernando Luiz Affonso] Ctr Univ FMABC, Lab Anal Clin, Av Lauro Gomes 2000, BR-09060870 Santo Andre, SP, Brazil.
   [Fonseca, Fernando Luiz Affonso] Univ Fed Sao Paulo UNIFESP, Dept Ciencias Farmaceut, Sao Paulo, SP, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP)
RP Almeida, TCD (corresponding author), Ctr Univ FMABC, Lab Epidemiol & Analise Dados, Av Lauro Gomes 2000, BR-09060870 Santo Andre, SP, Brazil.
EM tabatacristina@yahoo.com.br; szatta50@gmail.com; laercio.paiva@fmabc.br; dreduardocarvalho@oncologicadobrasil.com.br; jean.schoueri@gmail.com; luiz.abreu@fmabc.br; profferfonseca@gmail.com; fernando.adami@fmabc.br
CR Atsumi T, 2014, CANCER RES, V74, P8, DOI 10.1158/0008-5472.CAN-13-2322
   de Oliveira CMB, 2011, REV BRAS ANESTESIOL, V61, P255, DOI 10.1016/S0034-7094(11)70029-0
   Beilin B, 2003, ANESTH ANALG, V97, P822, DOI 10.1213/01.ANE.0000078586.82810.3B
   Beilin B, 2003, ANESTHESIOLOGY, V98, P151, DOI 10.1097/00000542-200301000-00024
   Ben-Baruch A, 2003, BREAST CANCER RES, V5, P31, DOI 10.1186/bcr554
   Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cramp AFL, 2000, CLIN PHYSIOL, V20, P150
   Cruz FM, 2013, REV BRASILEIRA ONCOL, V9, P0
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Almeida TCD, 2018, MEDIAT INFLAMM, V2018, P0, DOI 10.1155/2018/1094352
   Figueiredo Cláudia Roberta LV, 2019, J. BRAS. PATOL. MED. LAB., V55, P321, DOI 10.5935/1676-2444.20190029
   Fiorelli A, 2016, EUR J CARDIO-THORAC, V49, P339, DOI 10.1093/ejcts/ezv097
   Fiorelli A, 2012, EUR J CARDIO-THORAC, V41, P861, DOI 10.1093/ejcts/ezr108
   Gonçalves João, 2014, ARQ MED, V28, P08
   Igwea SE, 2016, COMPLEMENT THER CLIN, V24, P86, DOI 10.1016/j.ctcp.2016.05.001
   Jauregui Julio J, 2016, SURG TECHNOL INT, V28, P296
   Jemal Ahmedin, 2011, CA CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Johnson MI, 2016, COCHRANE LIB, V2015, P0
   Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892
   Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010
   Kozlowski L, 2003, ROCZ AKAD MED BIALYMST, V48, P82
   Kraychete Durval Campos, 2006, REV. BRAS. REUMATOL., V46, P199
   Martin L, 2010, J CLIN ONCOL, V28, P4376, DOI 10.1200/JCO.2009.27.1916
   Moran F, 2011, J PAIN, V12, P929, DOI 10.1016/j.jpain.2011.02.352
   Ngai SPC, 2010, RESP PHYSIOL NEUROBI, V173, P29, DOI 10.1016/j.resp.2010.06.005
   Ouyang BS, 2011, CHIN J INTEGR MED, V17, P505, DOI 10.1007/s11655-011-0783-2
   Ouyang Ba-Si, 2010, ZHONGGUO ZHEN JIU, V30, P840
   Pantaleao MA, 2011, J PAIN, V12, P581, DOI 10.1016/j.jpain.2010.11.001
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Schleder Juliana Carvalho, 2017, REV. DOR, V18, P316, DOI 10.5935/1806-0013.20170122
   Sharma Nidhi, 2017, J MIDLIFE HEALTH, V8, P36, DOI 10.4103/jmh.JMH_60_16
   Shavit Y, 2006, J NEUROIMMUNE PHARM, V1, P443, DOI 10.1007/s11481-006-9043-1
   Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007
   Song C, 2009, PHARMACOPSYCHIATRY, V42, P182, DOI 10.1055/s-0029-1202263
   Vance CGT, 2014, PAIN MANAG, V4, P197, DOI 10.2217/PMT.14.13
   Viechtbauer W, 2015, J CLIN EPIDEMIOL, V68, P1375, DOI 10.1016/j.jclinepi.2015.04.014
   Wang Jun-lu, 2008, ZHEN CI YAN JIU, V33, P26
   Yan L, 2006, EUR J CANCER, V42, P793, DOI 10.1016/j.ejca.2006.01.013
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
NR 41
TC 3
Z9 3
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PD FEB 18
PY 2022
VL 2022
IS 
BP 
EP 
DI 10.1155/2022/1350813
PG 8
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA ZR1LK
UT WOS:000767553500001
PM 35241969
DA 2026-01-16
ER

PT J
AU Wu, P
   Zhu, L
   Zheng, SY
   Li, JX
   Wu, MD
   Wang, WJ
   Hou, YC
   Li, J
   Wu, HG
AF Wu, Pin
   Zhu, Lu
   Zheng, Shi-Yu
   Li, Jun-Xiong
   Wu, Meng -Die
   Wang, Wen-Jia
   Hou, Yu-Chao
   Li, Jing
   Wu, Huan-Gan
TI Transcutaneous Electrical Acupoint Stimulation for Moderate to Severe Pain in Hepatocellular Carcinoma: A Protocol for a Randomized Controlled Trial
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE protocol; hepatocellular carcinoma; TEAS; pain
ID cancer pain; acupuncture; prevalence; management
AB Background: Cancer-related pain is one of the primary symptoms of patients with hepatocellular carcinoma (HCC). Previous studies have shown that transcutaneous electrical acupoint stimulation (TEAS) is effective in treating patients with acute or chronic pain. In China, it is indispensable to evaluate the efficacy of TEAS in combination with opioids for the treatment of moderate to severe HCC-related pain.Methods/Design: This is a single-center clinical, prospective randomized controlled clinical trial protocol. 104 patients will be randomly divided into the observation group and the control group in a ratio of 1:1.In addition to routine cancer pain medication, the two groups of patients will receive TEAS treatment twice a day for one week. Acupoints will include bilateral Hegu(LI4), Neiguan (PC6), Zusanli(ST36), Taichong(LR3), Ganshu(BL18), Geshu(BL17), Qimen(LR14), and Zhangmen(LR13). The treatment time is from 9:00 a.m. to 11:00 p.m. and from 4:00 p.m. to 6:00 p.m. The primary outcome measures are the Numerical Rating Scale (NRS) and the secondary outcome measures include the Brief Pain Inventory(BPI), dosage and administration duration of opioid drugs, frequency of nausea, vomiting and defecation, Karnofsky Performance Status Scale (KPS), Quality of life scale (QOL), Brief Fatigue Inventory (BFI). The outcome measures will be evaluated at baseline, during treatment and 1 week after treatment.Discussion: Results of this trial are expected to clarify the value of TEAS stimulation performed on specific points in the management of moderate to severe pain in HCC.Trial registration: Chinese clinical trial registry, ChiCTR2100044615 (http://www.chictr.org.cn), Registered on 24 March 2021.
C1 [Wu, Pin; Zhu, Lu; Zheng, Shi-Yu; Li, Jun-Xiong; Wu, Meng -Die; Wang, Wen-Jia; Hou, Yu-Chao; Li, Jing; Wu, Huan-Gan] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Acupuncture, Shanghai, Peoples R China.
   [Wu, Huan-Gan] Shanghai Univ Tradit Chinese Med, Key Lab Acupuncture & Immunol Effects, Shanghai, Peoples R China.
   [Li, Jing] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Acupuncture, 110 Ganhe Rd, Shanghai 200437, Peoples R China.
   [Wu, Huan-Gan] Shanghai Univ Tradit Chinese Med, Dept Key Lab Acupuncture & Immunol Effects, 650 South Wanping Rd, Shanghai 200437, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Li, J (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Acupuncture, 110 Ganhe Rd, Shanghai 200437, Peoples R China.; Wu, HG (corresponding author), Shanghai Univ Tradit Chinese Med, Dept Key Lab Acupuncture & Immunol Effects, 650 South Wanping Rd, Shanghai 200437, Peoples R China.
EM 1971921250@qq.com; wuhuangan@126.com
FU Science and Technology Innovation Action Plan [20Y21902800]; Qihuang scholar in the National Support Program for Leading Talents of Traditional Chinese Medicine
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Carr BI, 2010, J PAIN, V11, P988, DOI 10.1016/j.jpain.2010.01.265
   Chauny JM, 2016, PAIN, V157, P355, DOI 10.1097/j.pain.0000000000000382
   Christian-Miller N, 2018, J HEPATOCELL CARCINO, V5, P75, DOI 10.2147/JHC.S145450
   Chung YC, 2014, INT J NURS STUD, V51, P370, DOI 10.1016/j.ijnurstu.2013.06.007
   Cui H, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.692088
   Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Gharibo CG, 2011, PAIN PHYSICIAN, V14, P499
   Han Jisheng, 2011, FRONT MED, V5, P141, DOI 10.1007/s11684-011-0136-8
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Huang LP, 2017, TURK J MED SCI, V47, P1267, DOI 10.3906/sag-1611-35
   Ibrahim NM, 2018, PAIN MED, V19, P550, DOI 10.1093/pm/pnx087
   Kaiser K, 2014, SUPPORT CARE CANCER, V22, P919, DOI 10.1007/s00520-013-2039-5
   Lambert C, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen074
   Lee A, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub3
   Li Jinxia, 2017, ZHONGGUO ZHEN JIU, V37, P1276, DOI 10.13703/j.0255-2930.2017.12.006
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   Marrero JA, 2018, HEPATOLOGY, V68, P723, DOI 10.1002/hep.29913
   Meade CS, 2010, J SUBST ABUSE TREAT, V38, P12, DOI 10.1016/j.jsat.2009.05.010
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Sanft T, 2019, J NATL COMPR CANC NE, V17, P785, DOI 10.6004/jnccn.2019.0034
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Shen YF, 2009, J OROFAC PAIN, V23, P353
   Sykes J, 1997, BRIT MED J, V315, P867, DOI 10.1136/bmj.315.7112.867
   Tsoris A, 2021, STATPEARLS, V0, P0
   Vargas-Schaffer G, 2010, CAN FAM PHYSICIAN, V56, P514
   Wei G, 2003, BIOCHEM PHARMACOL, V65, P1761, DOI 10.1016/S0006-2952(03)00085-6
   Xu LL, 2018, J CANCER RES THER, V14, P99, DOI 10.4103/jcrt.JCRT_736_17
   Yuan CS, 2002, J CLIN PHARMACOL, V42, P899, DOI 10.1177/009127002401102812
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 34
TC 1
Z9 1
U1 3
U2 17
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2022
VL 15
IS 
BP 
EP 
DI 10.2147/JPR.S361821
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 2Z1VX
UT WOS:000826374700001
PM 35832212
DA 2026-01-16
ER

PT J
AU Chang, XS
   Zhu, YJ
   Peng, JJ
   Wu, XY
   Wang, W
   Liu, YH
   Zhan, DD
   Chen, YD
   Zhang, HB
AF Chang, Xue-Song
   Zhu, Yan-Juan
   Peng, Jian-Jun
   Wu, Xiao-Yu
   Wang, Wei
   Liu, Yi-Hong
   Zhan, Dan-Dan
   Chen, Ya-Dong
   Zhang, Hai-Bo
TI [Clinical observation on acupuncture for symptom burden in gastric cancer
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture; adjuvant chemotherapy; frequency of treatment; gastric cancer; randomized controlled trial (RCT); symptom burden
AB OBJECTIVE: To observe the efficacy of acupuncture on symptom burden in patients  with gastric cancer during adjuvant chemotherapy after gastrectomy. METHODS: A  total of 58 patients were randomized into a high-dose acupuncture group (19  cases, 5 cases dropped off), a low-dose acupuncture group (20 cases, 6 cases  dropped off) and a control group (19 cases, 2 cases dropped off). Conventional  chemotherapy and antiemetic treatment were adopted in the control group. On the  basis of the treatment in the control group, acupuncture was applied 7 times each  chemotherapy cycle for totally 21 times in the high-dose acupuncture group, and 3  times each chemotherapy cycle for totally 9 times in the low-dose acupuncture  group. Baihui (GV 20), Zusanli (ST 36), Neiguan (PC 6), etc. were selected in the  two acupuncture groups, as well as back-shu points selected by the meridian heat  sensing technique. Electroacupuncture was connected to ipsilateral Zusanli (ST  36) and Neiguan (PC 6), with continuous wave, 2 Hz in frequency for 20 min. The  Edmonton symptom assessment system (ESAS) score was observed on day 1-7, 14, and  21 of each cycle of chemotherapy respectively in the 3 groups. RESULTS: The  symptom burden was worst within 7 days of each cycle of chemotherapy in the 3  groups. After the 3rd chemotherapy cycle, the total score of ESAS in the low-dose  acupuncture group was lower than the control group (P<0.05), the total score and  the scores of feeling of non-well being, pain and shortness of breath of ESAS in  the acupuncture group (the high-dose acupuncture group combined with the low-dose  acupuncture group) were lower than the control group (P<0.05). CONCLUSION:  Acupuncture shows promising effect in controlling symptom burden during adjuvant  chemotherapy in gastric cancer patients after gastrectomy.
C1 Guangdong Provincial Hospital of TCM, Second Affiliated Hospital of Guangzhou University of CM, Guangzhou 510120, China.
   Guangdong Provincial Hospital of TCM, Second Affiliated Hospital of Guangzhou University of CM, Guangzhou 510120, China
   Guangdong Provincial Key Laboratory ofClinical Research on TCM Syndrome
   Guangdong-Hong Kong-Macau Joint Lab on ChineseMedicine and Immune Disease Research.
   First Affiliated Hospital, Sun Yat-sen University.
   Jiangsu Province Hospital of CM/Affiliated Hospital of Nanjing University of Chinese Medicine.
   Guangdong Provincial Hospital of TCM, Second Affiliated Hospital of Guangzhou University of CM, Guangzhou 510120, China.
   Guangdong Provincial Hospital of TCM, Second Affiliated Hospital of Guangzhou University of CM, Guangzhou 510120, China.
   Second Clinical Medical College of Guangzhou University of CM.
   Guangdong Provincial Hospital of TCM, Second Affiliated Hospital of Guangzhou University of CM, Guangzhou 510120, China.
   Guangdong Provincial Hospital of TCM, Second Affiliated Hospital of Guangzhou University of CM, Guangzhou 510120, China
   Guangdong Provincial Key Laboratory ofClinical Research on TCM Syndrome
   Guangdong-Hong Kong-Macau Joint Lab on ChineseMedicine and Immune Disease Research
   State Key Laboratory of Dampness Syndromeof Chinese Medicine.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD NOV 19
PY 2022
VL 42
IS 11
BP 1226
EP 32
DI 10.13703/j.0255-2930.20211106-k0004
PG -1194
WC Humans; Acupuncture Points; Stomach Neoplasms; drug therapy; Acupuncture Therapy; Gastrectomy; adverse effects; Chemotherapy, Adjuvant
UT PubMed:36397219
PM 36397219
DA 2022-11-19
ER

PT J
AU Church, D
   Stapleton, P
   Vasudevan, A
   O'Keefe, T
AF Church, Dawson
   Stapleton, Peta
   Vasudevan, Anitha
   O'Keefe, Tom
TI Clinical EFT as an evidence-based practice for the treatment of psychological and
SO Frontiers in psychology
LA English
DT Journal Article
DE PTSD; anxiety; depression; emotional freedom techniques (EFT); insomnia; obesity; pain; somatic symptoms
AB BACKGROUND: Since the turn of the century, Emotional Freedom Techniques (EFT) has  come into widespread use in medical and psychological treatment settings. It is  also used as self-help by tens of millions of people each year. Clinical EFT, the  manualized form of the method, has been validated as an "evidence-based" practice  using criteria published by the American Psychological Association (APA) Division  12 Task Force on Empirically Validated Therapies. Its three essential ingredients  are exposure, cognitive framing, and acupressure. OBJECTIVES: In 2013 we  published a paper defining Clinical EFT and reviewing published research. It has  been viewed or downloaded over 36,000 times, indicating widespread interest in  this treatment modality. Here we update our findings based on subsequently  published literature and propose directions for future research. METHOD: We  performed a systematic review of the literature to identify randomized controlled  trials (RCTs) and meta-analyses. Retrieval of 4,167 results resulted in the  identification of 56 RCTs (n = 2,013), 41 of which were published subsequent to  our earlier review, as well as eight meta-analyses. RESULTS: RCTs have found EFT  treatment to be effective for (a) psychological conditions such as anxiety,  depression, phobias, and posttraumatic stress disorder (PTSD); (b) physiological  issues such as pain, insomnia, and autoimmune conditions; (c) professional and  sports performance; and (d) biological markers of stress. Meta-analyses  evaluating the effect of EFT treatment have found it to be "moderate" to "large."  Successful independent replication studies have been carried out for anxiety,  depression, PTSD, phobias, sports performance, and cortisol levels. We outline  the next steps in EFT research. These include determining its impact on cancer,  heart disease, diabetes, and cognitive impairment; analysis of the large-scale  datasets made possible by mobile apps; and delivery through channels such as  virtual practitioner sessions, artificial intelligence agents, online courses,  apps, virtual reality platforms, and standardized group therapy. CONCLUSIONS:  Subsequent research has confirmed the conclusions of earlier studies. These find  Clinical EFT to be efficacious for a range of psychological and physiological  conditions. Comparatively few treatment sessions are required, treatment is  effective whether delivered in person or virtually, and symptom improvements  persist over time. Treatment is associated with measurable biological effects in  the dimensions of gene expression, brain synchrony, hormonal synthesis, and a  wide range of biomarkers. Clinical EFT is a stable and mature method with an  extensive evidence base. Its use in primary care settings as a safe, rapid,  reliable, and effective treatment for both psychological and medical diagnoses  continues to grow.
C1 National Institute for Integrative Healthcare, Petaluma, CA, United States.
   Department of Society and Design, Bond University, Gold Coast, QLD, Australia.
   National Institute for Integrative Healthcare, Petaluma, CA, United States.
   Department of Society and Design, Bond University, Gold Coast, QLD, Australia.
NR 0
TC 0
SN 1664-107
EI 1664-107
J9 Front Psychol
PD NOV 29
PY 2022
VL 13
IS 
BP 951451
EP 951451
DI 10.3389/fpsyg.2022.951451
PG 0
UT PubMed:36438382
PM 36438382
DA 2022-11-29
ER

PT J
AU Wang, J
   Xia, Q
   Zhu, FY
   Huang, W
   Meng, YT
   Wang, YP
   Liu, YM
   Liu, XJ
   Li, HL
   Sun, B
AF Wang, Jing
   Xia, Qing
   Zhu, Fangyi
   Huang, Wei
   Meng, Yanting
   Wang, Yanping
   Liu, Yumei
   Liu, Xijun
   Li, Hulun
   Sun, Bo
TI Effects of Acupuncture on Adverse Events in Colonoscopy: A Systematic Review and Meta-analysis of Randomized Controlled Trials
SO PAIN AND THERAPY
LA English
DT Review
DE Acupuncture; Adverse events; Colonoscopy; Meta-analysis; Systematic review
ID abdominal-pain; electroacupuncture; stimulation; quality; complications; analgesia; sedation; cancer; grade; time
AB Introduction Acupuncture has gradually penetrated into many disciplines in clinical medicine, such as surgery, anesthesia, and outpatient examinations. Although a number of clinical trials have investigated the effects of acupuncture on colonoscopy, the results were inconsistent. In this meta-analysis, we analyzed the effects of acupuncture on colonoscopy to provide evidence for subsequent research and clinical application of acupuncture in colonoscopy. Methods This meta-analysis was performed using Review Manager version 5.4 and Stata version 16 software. The primary outcome was the incidence of adverse events, and the secondary outcomes included patients' anxiety score before colonoscopy, time to insert the colonoscope, total detection time, propofol consumption, patients' pain score, and patient satisfaction rate. Results The results showed that the incidence of adverse events (odds ratio [OR] 0.27, 95% confidence interval [CI] 0.16-0.43, P = 0.00, I-2 = 25%), patients' pain score (mean difference [MD] - 1.03, 95% CI - 1.45 to - 0.62, P = 0.00, I-2 = 94%), and time to insert the colonoscope (MD = - 2.54, 95% CI - 4.96 to - 0.13, P = 0.04, I-2 = 0%) were significantly lower in the treatment group than in the control group. Compared with the control group, the satisfaction rate of patients (OR 2.53, 95% CI 1.56-4.10, P = 0.00, I-2 = 47%) in the treatment group was significantly improved. There was no significant between-group difference in patients' anxiety score, the total detection time, and propofol dosage. Conclusions During colonoscopy, acupuncture can significantly reduce the incidence of adverse events, relieve patients' pain, and improve patient satisfaction. Registration PROSPERO registration number CRD42022324428.
C1 [Wang, Jing; Zhu, Fangyi; Huang, Wei; Meng, Yanting; Wang, Yanping; Liu, Yumei; Liu, Xijun; Li, Hulun; Sun, Bo] Harbin Med Univ, Dept Neurobiol, Sch Basic Med Sci, 157 Hlth Rd, Harbin 150081, Heilongjiang, Peoples R China.
   [Xia, Qing] Harbin Med Univ, Dept Biochem & Mol Biol, Sch Basic Med Sci, Harbin, Heilongjiang, Peoples R China.
   [Li, Hulun] Harbin Med Univ, Minist Educ, Key Lab Myocardial Ischemia, Harbin, Heilongjiang, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical University
RP Li, HL; Sun, B (corresponding author), Harbin Med Univ, Dept Neurobiol, Sch Basic Med Sci, 157 Hlth Rd, Harbin 150081, Heilongjiang, Peoples R China.
EM lihl@hrbmu.edu.cn; sunbo72022@163.com
FU National Natural Science Foundation of China [81771305, 81870955]; HMU Marshal Initiative Funding [HMUMIF21019]
CR Acar HV, 2016, COMPLEMENT THER MED, V29, P48, DOI 10.1016/j.ctim.2016.09.013
   Allison JE, 2001, NEW ENGL J MED, V344, P1022
   Benrick A, 2017, FASEB J, V31, P3288, DOI 10.1096/fj.201601381R
   Burford-Mason A, 2003, CAN FAM PHYSICIAN, V49, P1588
   Chavez LM, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18112270
   Chen Tong-yu, 2015, ZHEN CI YAN JIU, V40, P461
   Chen Y, 2002, HU LI XUE ZA ZHI, V17, P86
   Chen YQ, 2015, INT J CLIN EXP MED, V8, P5972
   Chen YJ, 2014, GASTROENTEROL NURS, V37, P273, DOI 10.1097/SGA.0000000000000054
   Chen YM, 2021, ACUPUNCT MED, V39, P292, DOI 10.1177/0964528420960479
   Cole SR, 2013, MED J AUSTRALIA, V198, P327, DOI 10.5694/mja12.11357
   Corte CJ, 2016, J GASTROEN HEPATOL, V31, P32, DOI 10.1111/jgh.13056
   de Sire A, 2022, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.829875
   Eberl S, 2020, ACUPUNCT MED, V38, P131, DOI 10.1136/acupmed-2017-011459
   Eckardt VF, 1999, GASTROINTEST ENDOSC, V49, P560, DOI 10.1016/S0016-5107(99)70382-2
   Fanti L, 2003, AM J GASTROENTEROL, V98, P312, DOI 10.1016/S0002-9270(02)05899-9
   FROEHLICH F, 1994, ENDOSCOPY, V26, P231, DOI 10.1055/s-2007-1008949
   Ginsberg G, 2003, GASTROINTEST ENDOSC, V58, P777, DOI 10.1016/S0016-5107(03)02016-9
   Goh YL, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/871217
   Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Häfner M, 2007, EUR J RADIOL, V61, P409, DOI 10.1016/j.ejrad.2006.07.034
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Harbach H, 2007, EUR J ANAESTH, V24, P370, DOI 10.1017/S0265021506001906
   HERMAN LL, 1993, GASTROINTEST ENDOSC, V39, P388, DOI 10.1016/S0016-5107(93)70111-X
   Hideaki W, 2015, ACUPUNCT MED, V33, P451, DOI 10.1136/acupmed-2015-010784
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hsieh YH, 2011, WORLD J GASTROENTERO, V17, P2236, DOI 10.3748/wjg.v17.i17.2236
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kim WH, 2000, GASTROINTEST ENDOSC, V52, P600, DOI 10.1067/mge.2000.109802
   Lee SK, 2006, J CLIN GASTROENTEROL, V40, P711, DOI 10.1097/00004836-200609000-00010
   LI CK, 1991, DEUT MED WOCHENSCHR, V116, P367, DOI 10.1055/s-2008-1063621
   Liakakos T, 2001, DIGEST SURG, V18, P260, DOI 10.1159/000050149
   Liu X, 2015, ACUPUNCT MED, V33, P270, DOI 10.1136/acupmed-2014-010749
   Luo YY, 2019, XIAN DAI SHENG WU YI XUE JIN ZHAN, V19, P924
   Luo YY, 2018, ZHONG GUO SHI YAN ZHEN DUAN XUE, V22, P1804
   Millien Valentine Ongeri, 2020, CURR GASTROENTEROL REP, V22, P28, DOI 10.1007/s11894-020-00764-4
   Mori H, 2000, J AUTONOM NERV SYST, V79, P93, DOI 10.1016/S0165-1838(99)00099-5
   Ni Yu-Fei, 2009, ZHEN CI YAN JIU, V34, P339
   Nishijo K, 1997, NEUROSCI LETT, V227, P165, DOI 10.1016/S0304-3940(97)00337-6
   Pedersen L, 2020, SCAND J GASTROENTERO, V55, P979, DOI 10.1080/00365521.2020.1792541
   Purcell GP, 1997, INTERNATIONAL JOURNAL ON DIGITAL LIBRARIES, V1, P288, DOI 10.1007/s007990050023
   Rex DK, 2015, GASTROINTEST ENDOSC, V81, P31, DOI 10.1016/j.gie.2014.07.058
   Smith RA, 2014, CA-CANCER J CLIN, V64, P31, DOI 10.3322/caac.21212
   Stoicea N, 2015, FRONT MED, V2, P0, DOI 10.3389/fmed.2015.00087
   Streitberger K, 2006, AUTON NEUROSCI-BASIC, V129, P107, DOI 10.1016/j.autneu.2006.07.015
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Waki H, 2017, ACUPUNCT MED, V35, P339, DOI 10.1136/acupmed-2016-011247
   Weisfeld CC, 2021, J ALTERN COMPLEM MED, V27, P717, DOI 10.1089/acm.2020.0504
   Whitlock EP, 2008, ANN INTERN MED, V149, P638, DOI 10.7326/0003-4819-149-9-200811040-00245
   Winawer S J, 1993, EUR J CANCER PREV, V2 Suppl 2, P83, DOI 10.1097/00008469-199306000-00014
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 54
TC 8
Z9 8
U1 2
U2 14
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8237
EI 2193-651X
J9 PAIN THER
JI PAIN THER.
PD DEC 15
PY 2022
VL 11
IS 4
BP 1095
EP 1112
DI 10.1007/s40122-022-00415-8
EA AUG 2022
PG 18
WC Clinical Neurology
SC Neurosciences & Neurology
GA 5X6DI
UT WOS:000835636500001
PM 35922617
DA 2026-01-16
ER

PT J
AU He, YH
   Zhang, HB
   Li, YF
   Long, SQ
   Xiao, SJ
   May, BH
   Zhang, AL
   Guo, XF
   Xue, CC
   Lu, CJ
AF He, Yihan
   Zhang, Haibo
   Li, Yifang
   Long, Shunqin
   Xiao, Shujing
   May, Brian H.
   Lin Zhang, Anthony
   Guo, Xinfeng
   Xue, Charlie Changli
   Lu, Chuanjian
TI Acupuncture combined with opioids for cancer pain: a pilot pragmatic randomized controlled trial
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE acupuncture; cancer pain; pharmacological analgesics; pragmatic trial
ID induced nausea; breast-cancer
AB Objective: Given the existing evidence for the analgesic effect of acupuncture, the current study aimed to assess whether acupuncture could be feasible and manageable as an adjunctive therapy for cancer pain in a real-world hospital setting. Methods: Thirty patients in an Oncology department with moderate or severe pain were recruited and randomized to an adjunctive acupuncture group or control group, who received pharmacotherapy for pain management without acupuncture. The duration of the treatment course was 1 week with a 2-week follow-up. In total, four acupuncture sessions were administered, on days 1/2/4/6 of the trial. Pain intensity was measured using a numerical rating scale (NRS) and the daily opioid dose was recorded. Results: The overall trends favored acupuncture for both pain intensity and daily opioid consumption. The proportion of participants experiencing at least a 2-point reduction in the NRS at the end of the treatment was 93% (n = 14/15) for the acupuncture group and 57% (n = 8/14) for the control group (risk difference (RD) 36.1%, 95% confidence interval (CI) [7.4%-65.0%]; relative risk (RR) 1.63, 95% CI [1.02-2.62]; p = 0.04). There were no serious adverse events and no dropouts during the treatment. Conclusion: This pilot study showed that adding acupuncture to routine analgesia for patients with cancer pain was feasible and acceptable to patients. The clinical effects of adding acupuncture as an adjunctive therapy need to be further evaluated.
C1 [He, Yihan; Guo, Xinfeng; Xue, Charlie Changli; Lu, Chuanjian] Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Affiliated Hosp 2, China Australia Int Res Ctr Chinese Med,Guangdong, 111 Dade Rd, Guangzhou 510120, Peoples R China.
   [He, Yihan; May, Brian H.; Lin Zhang, Anthony; Xue, Charlie Changli; Lu, Chuanjian] RMIT Univ, Sch Hlth & Biomed Sci, China Australia Int Res Ctr Chinese Med, Melbourne, Vic, Australia.
   [Zhang, Haibo; Long, Shunqin; Xiao, Shujing] Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Affiliated Hosp 2, Dept Oncol,Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China.
   [Li, Yifang] Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Affiliated Hosp 2, Guangdong Prov Hosp Chinese Med,Dept Tradit Thera, Guangzhou, Peoples R China.
   [Lu, Chuanjian] Tradit Chinese Med Syndrome, Guangdong Prov Key Lab Clin Res, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Royal Melbourne Institute of Technology (RMIT); Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Xue, CC; Lu, CJ (corresponding author), Guangzhou Univ Chinese Med, Guangdong Prov Acad Chinese Med Sci, Affiliated Hosp 2, China Australia Int Res Ctr Chinese Med,Guangdong, 111 Dade Rd, Guangzhou 510120, Peoples R China.
EM charlie.xue@rmit.edu.au; luchuanjian888@vip.sina.com
FU Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine (2018) [YN2018QL04]; Research Project of Traditional Chinese Medicine Bureau of Guangdong Province (2019) [20191126]; Guangdong Provincial Academy of Chinese Medical Sciences, China; RMIT University through the China-Australia International Research Center for Chinese Medicine
CR Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Chalkidou K, 2012, CLIN TRIALS, V9, P436, DOI 10.1177/1740774512450097
   Chen YJ, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5281039
   Craig Peter, 2008, BMJ, V337, Pa1655, DOI 10.1136/bmj.a1655
   Deng SZ, 2015, EXP THER MED, V10, P1247, DOI 10.3892/etm.2015.2653
   Enblom A, 2017, ACUPUNCT MED, V35, P251, DOI 10.1136/acupmed-2015-011007
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   He YH, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-025564
   He YH, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2017-018494
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lin YZ, 2015, CONTEMP CLIN TRIALS, V45, P21, DOI 10.1016/j.cct.2015.07.011
   Linden A, 2017, J EVAL CLIN PRACT, V23, P1309, DOI 10.1111/jep.12792
   Mallick-Searle T, 2017, J AM ASSOC NURSE PRA, V29, P704, DOI 10.1002/2327-6924.12532
   Mercadante S, 2020, PAIN MED, V21, PE215, DOI 10.1093/pm/pnz254
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Nicholson BD, 2017, POSTGRAD MED, V129, P111, DOI 10.1080/00325481.2017.1243004
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Patsopoulos Nikolaos A, 2011, DIALOGUES CLIN NEUROSCI, V13, P217
   Porzsolt F, 2013, J PUBLIC HEALTH-HEID, V21, P307, DOI 10.1007/s10389-012-0544-5
   Sedaghat AR, 2019, OTOLARYNG HEAD NECK, V161, P551, DOI 10.1177/0194599819852604
   Sox HC, 2016, JAMA-J AM MED ASSOC, V316, P1205, DOI 10.1001/jama.2016.11409
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wong CHL, 2019, J PAIN SYMPTOM MANAG, V58, P1002, DOI 10.1016/j.jpainsymman.2019.08.002
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 28
TC 8
Z9 10
U1 7
U2 41
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD APR 15
PY 2022
VL 40
IS 2
BP 133
EP 141
DI 10.1177/09645284211056016
EA NOV 2021
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA ZJ1IF
UT WOS:000717645600001
PM 34755569
DA 2026-01-16
ER

PT J
AU Liu, J
   Wang, MM
   Yang, DH
   Cui, XX
AF Liu, Jie
   Wang, Meng-Meng
   Yang, Dian-Hui
   Cui, Xin-Xin
TI [Mechanisms of liver-soothing and mind-regulating acupuncture mediating opioid
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Interleukin-6; Migraine; Opioid receptors;Interleukin-1β; Tumor necrosis factor-α; “Shugan Tiaoshen” (liver-soothing and mind-regulating) acupuncture
AB OBJECTIVE: To observe the effect of "Shugan Tiaoshen"(liver-soothing and  mind-regulating) acupuncture on behavior reactions, opioid receptor expressions  in the anterior cingulate cortex tissue and inflammatory factors in the serum in  migraine rats, in order to explore its mechanism underlying improvement of  migraine. METHODS: In the first part of this study, forty male Wistar rats were  randomized into control, model, routine acupuncture and "Shugan Tiaoshen"  acupuncture groups (n=10/group), and in the second part, other 40 more male  Wistar rats were randomized into low, medium and high dosage of blocker of  μopioid receptor (OPRM）CTOP5 and PBS groups (n=10/group, for validating the  involvement of opioid receptor in the effect of "Shugan Tiaoshen"). The migraine  model was established by subcutaneous injection of glyceryl trinitrate. Routine  acupuncture was applied to "Baihui" (GV20) and bilateral"Fengchi" (GB20), and  "Shugan Tiaoshen" acupuncture applied to GV20, and bila-teral GB20, "Neiguan"  (PC6) and "Taichong" (LR3), with the needles retained for 30 min. Behavior  responses (head scratching, tail biting, cage climbing and number of going there  and back) were scaled. Serum IL-1β, IL-6 and TNF-α were detected by ELISA, and  the expression levels of opioid receptor μ, δ and κ (OPRM, OPRD, OPRK) mRNAs and  proteins in the anterior cingulate cortex were detected by fluorescence  quantitative PCR and Western blot separately. In the second part of this study,  CTOP solution (5μL at concentrations of 20μg/μL,10μg/μL and 5μg/μL) or PBS was  injected into the bilateral rostral portions of anterior cingulate cortex 30 min  before every "Shugan Tiaoshen" acupuncture intervention, followed by observing  the behavioral changes and assaying the contents of serum IL-1β, IL-6 and TNF-α.  RESULTS: After modeling, the behavioral score, serum IL-1β, IL-6 and TNF-α  contents were significantly increased in the model group relevant to the control  group (P<0.05), and the beha-vioral score had no significant difference among the  model and two acupuncture groups before intervention (P>0.05). Whereas the  expression levels of OPRM, OPRD and OPRK mRNAs and proteins had a slight increase  in the model group (P>0.05). After the intervention, the behavioral score, serum  IL-1β, IL-6 and TNF-α contents were significantly decreased and the expression  levels of OPRM, OPRD and OPRK mRNAs (2.150, 1.066 and 0.805 folds in the "Shugan  Tiaoshen" group) and proteins (2.273, 0.901 and 0.893 folds in the "Shugan  Tiaoshen" group) notably up-regulated in both "Shugan Tiaoshen" and routine  acupuncture groups relevant to the model group (P<0.01, P<0.05), showing that the  biggest up-regulation of mRNA expression was OPRM. Comparison between two  acupuncture groups showed that the behavioral score, and serum IL-1β, IL-6 and  TNF-α contents were significantly lower, and the expression levels of OPRM, OPRD  and OPRK mRNAs and proteins obviously higher in the "Shugan Tiaoshen" group than  those in the routine acupuncture group (P<0.01,P<0.05). Results of the second  part of this study showed that after injection of antagonist CTOP of OPRM, the  therapeutic effect of "Shugan Tiaoshen" acupuncture was weakened in the reduction  of behavioral score and serum IL-1β, IL-6 and TNF-α contents, being minimal,  moderate and maximum in the high, medium and low dose of antagonist relevant to  PBS in sequence (P<0.05, P<0.01). CONCLUSION: "Shugan Tiaoshen" acupuncture can  mitigate pain in migraine rats, which may be associated with its function in  up-regulating the expressions of opioid receptors (especially OPRM), and in  inhibiting inflammatory reaction in the anterior cingulate cortex.
C1 Department of Traditional Chinese Medicine, The Second Hospital of Shandong University, Jinan 250033, China.
   College of Acupuncture-moxibustion and Tuina, Shandong University of Traditional Chinese Medicine, Jinan 250355.
   College of Acupuncture-moxibustion and Tuina, Shandong University of Traditional Chinese Medicine, Jinan 250355
   Department of Acupuncture-moxibustion of TheAffiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan250014.
   Medical Teaching and Research Section of Shandong Medical College, Jinan 250024.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUN 29
PY 2022
VL 47
IS 6
BP 510
EP 6
DI 10.13702/j.1000-0607.20210691
PG -504
WC Acupuncture Therapy; methods; Animals; Interleukin-6; Liver; Male; Migraine Disorders; genetics; Rats; Rats, Wistar; Receptors, Opioid; genetics; Tumor Necrosis Factor-alpha; genetics
UT PubMed:35764518
PM 35764518
DA 2022-06-29
ER

PT J
AU McMahon, D
   Kadiyala, S
   Estores, IM
AF McMahon, David
   Kadiyala, Sushma
   Estores, Irene M
TI Acupuncture, Shingles, and Allergen Immunotherapy.
SO Medical acupuncture
LA English
DT Journal Article
DE dermatologic conditions; musculoskeletal pain; neurological disorders
AB Background: The Varicella-zoster virus (VZV) remains dormant in the dorsal root  ganglia and can become reactive later in a person's life. Factors such as stress,  trauma, chronic disease, systemic illness, immune disorders, and age-related  decline in host immunologic responses can potentially incite reactivation.  Activation of VZV resulting in shingles following acupuncture has been reported  in the literature previously, and some mechanisms have been proposed for this  observation. Case: A patient with a history of total thyroidectomy for thyroid  cancer presented with chronic neck pain. She was clinically and biochemically in  a euthyroid state and on thyroid replacement therapy. She had a history of  chickenpox, at age 13, and seasonal allergies. After her first acupuncture  session, she received an allergy shot for her seasonal allergies. A day after the  procedure, she developed a vesicular rash and was subsequently diagnosed with  acute Herpes zoster. Subsequent acupuncture was withheld following this event.  She received acyclovir and applied topical Aloe vera to the cutaneous lesions,  and developed mild scarring, but did not experience postherpetic neuralgia.  Conclusions: Acupuncture is a minor trauma that can predispose a patient to  reactivation of VZV and shingles in the setting of immune activation with  allergen immunotherapy.
C1 Integrative Medicine Program and University of Florida Health, Gainsville, Florida, USA.
   Division of Endocrinology, University of Florida Health, Gainsville, Florida, USA.
   Integrative Medicine Program and University of Florida Health, Gainsville, Florida, USA.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD JAN 4
PY 2022
VL 33
IS 6
BP 443
EP 446
DI 10.1089/acu.2020.1521
PG 3
UT PubMed:34976278
PM 34976278
DA 2022-01-04
ER

PT J
AU Desideri, I
   Lucidi, S
   Francolini, G
   Meattini, I
   Ciccone, LP
   Salvestrini, V
   Valzano, M
   Morelli, I
   Angelini, L
   Scotti, V
   Bonomo, P
   Greto, D
   Terziani, F
   Becherini, C
   Visani, L
   Livi, L
AF Desideri, Isacco
   Lucidi, Sara
   Francolini, Giulio
   Meattini, Icro
   Ciccone, Lucia Pia
   Salvestrini, Viola
   Valzano, Marianna
   Morelli, Ilaria
   Angelini, Lucia
   Scotti, Vieri
   Bonomo, Pierluigi
   Greto, Daniela
   Terziani, Francesca
   Becherini, Carlotta
   Visani, Luca
   Livi, Lorenzo
TI Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833)
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Arthralgia; Breast cancer; Aromatase inhibitors; Dietary supplement; Quality of life
ID early breast-cancer; musculoskeletal symptoms; postmenopausal women; randomized-trial; adjuvant treatment; joint symptoms; pain; tamoxifen; therapy; acupuncture
AB Aromatase Inhibitors (AIs) are recommended for the adjuvant treatment of hormone receptor positive breast cancer in both high-risk pre-menopausal and post-menopausal population; arthralgia is the main cause of discontinuation of therapy and affects up to 25% of population on AI treatment. The objective of the study was to prospectively evaluate OPERA (R) (GAM-FARMA srl, Milan, Italy), a new dietary supplement where oc-Lipoic acid, Boswellia serrata, Methylsulfonylmethane and Bromelain are combined in a single hard-gelatin capsule to be taken once a day. Fifty-three patients with arthralgia (NCI-CTCAE v4.0 grade >= 1) occurring during AI therapy were enrolled. All patients received OPERA (R) from enrollment (TO) up to sixth months (T3). Patients' AI-related arthralgia was evaluated every two months with VAS Scale, PRAI questionnaire, and CTCAE scale. Primary endpoint was the number of patients with symptom resolution (GO) at T3 if compared to TO, according to CTCAE and VAS scale. Secondary endpoints were decrease in arthralgia intensity measured with PRAI score at T3 compared to baseline, safety of OPERA (R) and rate of AI interruption. Treatment with OPERA (R) supplement was overall well tolerated; no relevant toxicities related to OPERA (R) intake were reported. Seven subjects (13.2%) were not included in the final analysis because of consent withdrawal. 46 participants were eligible for final analysis. According to CTCAE scale, 10 out of 46 patients reported symptoms resolution at 6-month follow-up from the time of enrollment TO (p = 0.0009). According to VAS score, 5 patients reported complete resolution of symptoms at T3 if compared to baseline starting situation TO (p = 0.0222). Analysis of PRAI score showed a significant reduction in arthralgia-related pain perceived (p = 0.0001). OPERA (R) was able to reduce the intensity of arthralgia related to AI therapy. Randomized, double-blind studies are warranted to confirm the effectiveness of this dietary supplement.
C1 [Desideri, Isacco; Francolini, Giulio; Meattini, Icro; Scotti, Vieri; Bonomo, Pierluigi; Greto, Daniela; Becherini, Carlotta] Azienda Osped Univ Careggi, Radiat Oncol Unit, Florence, Italy.
   [Desideri, Isacco; Lucidi, Sara; Meattini, Icro; Ciccone, Lucia Pia; Salvestrini, Viola; Valzano, Marianna; Morelli, Ilaria; Angelini, Lucia; Livi, Lorenzo] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Florence, Italy.
   [Terziani, Francesca] Azienda USL Toscana Sud, Radiotherapy Unit Osped S Donato & Santa Maria Gr, Arezzo, Italy.
   [Visani, Luca] IFCA, Radiotherapy Dept, Florence, Italy.
   [Morelli, Ilaria] Univ Florence, Azienda Osped Univ Careggi, Dept Expt & Clin Biomed Sci, Radiat Oncol Unit, Largo Brambilla 3, I-50134 Florence, Italy.
C3 University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi
RP Morelli, I (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Florence, Italy.; Morelli, I (corresponding author), Univ Florence, Azienda Osped Univ Careggi, Dept Expt & Clin Biomed Sci, Radiat Oncol Unit, Largo Brambilla 3, I-50134 Florence, Italy.
EM ilaria.morelli@unifi.it
CR Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Bodai Balazs I, 2015, PERM J, V19, P48, DOI 10.7812/tpp/14-241
   Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Burstein HJ, 2007, BREAST, V16, P223, DOI 10.1016/j.breast.2007.01.011
   Castel LD, 2015, PATIENT-RELAT OUTCOM, V6, P205, DOI 10.2147/PROM.S47997
   Chien HC, 2020, J CLIN MED, V9, P0, DOI 10.3390/jcm9020566
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Cuzick J, 2010, LANCET ONCOL, V11, P1135, DOI 10.1016/S1470-2045(10)70257-6
   Desideri I, 2017, MED ONCOL, V34, P0, DOI 10.1007/s12032-017-0907-4
   Fenlon D, 2013, J PAIN SYMPTOM MANAG, V46, P523, DOI 10.1016/j.jpainsymman.2012.10.282
   Fernandes R, 2018, SUPPORT CARE CANCER, V26, P3073, DOI 10.1007/s00520-018-4161-x
   Fernandes R, 2016, SUPPORT CARE CANCER, V24, P3633, DOI 10.1007/s00520-016-3256-5
   Goss PE, 2005, JNCI-J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250
   Hack CC, 2020, BREAST, V50, P11, DOI 10.1016/j.breast.2019.12.017
   Hawker GA, 2011, ARTHRIT CARE RES, V63, PS240, DOI 10.1002/acr.20543
   Henry NL, 2019, CANCER-AM CANCER SOC, V125, P2123, DOI 10.1002/cncr.32024
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Henry NL, 2011, CANCER-AM CANCER SOC, V117, P5469, DOI 10.1002/cncr.26230
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Hilditch JR, 1996, MATURITAS, V24, P161, DOI 10.1016/0378-5122(96)01038-9
   Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6
   Ingle JN, 2006, BREAST CANCER RES TR, V99, P295, DOI 10.1007/s10549-006-9207-y
   Jacobsen PB, 2015, PSYCHO-ONCOLOGY, V24, P1578, DOI 10.1002/pon.3756
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kubo M, 2012, ANTICANCER RES, V32, P2331
   Laroche F, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0187165
   Lombard JM, 2016, SUPPORT CARE CANCER, V24, P2139, DOI 10.1007/s00520-015-3001-5
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Menas Pamela, 2012, J ONCOL PHARM PRACT, V18, P387, DOI 10.1177/1078155211434853
   Moscetti L, 2015, TUMORI, V101, P469, DOI 10.5301/tj.5000376
   Nahm N, 2018, ASIA-PAC J CLIN ONCO, V14, P374, DOI 10.1111/ajco.12845
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Presant CA, 2007, CLIN BREAST CANCER, V7, P775, DOI 10.3816/CBC.2007.n.038
   Regan MM, 2011, LANCET ONCOL, V12, P1101, DOI 10.1016/S1470-2045(11)70270-4
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Roberts KE, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012988.pub2
   Saibil S, 2010, CURR ONCOL, V17, P168
   Uhlenbruck G, 2010, IN VIVO, V24, P799
NR 43
TC 4
Z9 4
U1 0
U2 3
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD JUN 6
PY 2022
VL 39
IS 8
BP 
EP 
DI 10.1007/s12032-022-01723-x
PG 8
WC Oncology
SC Oncology
GA 1W5CC
UT WOS:000806790300004
PM 35666314
DA 2026-01-16
ER

PT J
AU Lu, HB
   Ma, RC
   Yin, YY
   Song, CY
   Yang, TT
   Xie, J
AF Lu, Han-Bing
   Ma, Rui-Chen
   Yin, Ying-Ying
   Song, Chun-Yu
   Yang, Ting-Ting
   Xie, Jiao
TI Auricular Acupressure for Improving Sleep Quality in Patients With Lung Cancer A Systematic Review and Meta-analysis
SO HOLISTIC NURSING PRACTICE
LA English
DT Article
DE auricular acupressure; lung cancer; meta-analysis; sleep
ID of-life; symptom clusters; single-blind; disturbance; insomnia; fatigue; pain; interventions; cortisol; women
AB This meta-analysis was conducted to systematically evaluate the efficacy and safety of auricular acupressure on sleep quality in patients with lung cancer. Nine articles with a total of 802 patients were retrieved after searching on 11 electronic databases. Results of the meta-analysis showed that auricular acupressure improved sleep score (standard mean difference: -0.80, 95% confidence intervals: -1.30 to -0.30, P = .002) and reduced sleep disturbance rate (risk ratio: 0.65, 95% confidence intervals: 0.51-0.84, P = .001) and sleep medicine usage (risk ratio: 0.26, 95% confidence intervals: 0.11-0.65, P = .004) significantly. Our review suggests that auricular acupressure is effective and relatively safe in improving sleep quality among patients with lung cancer.
C1 [Lu, Han-Bing; Ma, Rui-Chen; Yin, Ying-Ying; Song, Chun-Yu; Yang, Ting-Ting; Xie, Jiao] Jilin Univ, Sch Nursing, 965 Xinjiang St, Changchun 130021, Jilin, Peoples R China.
C3 Jilin University
RP Xie, J (corresponding author), Jilin Univ, Sch Nursing, 965 Xinjiang St, Changchun 130021, Jilin, Peoples R China.
EM lhbbooya@163.com; 1003373360@qq.com; 386235260@qq.com; 1143361530@qq.com; yangtt19@mails.jlu.edu.cn; 1761458270@qq.com
CR Unknown -, 2005, SLEEP, V28, P1049
   Unknown -, 1990, REPORT OF THE WORKING GROUP ON AURICULAR ACUPUNCTURE NOMENCLATURE, V0, P0
   Bang YY, 2020, APPL NURS RES, V53, P0, DOI 10.1016/j.apnr.2020.151269
   Bian, 2015, CHIN PRACT MED, V31, P43
   Braun DP, 2011, BMC CANCER, V11, P0, DOI 10.1186/1471-2407-11-353
   Chang WP, 2017, EUR J ONCOL NURS, V29, P79, DOI 10.1016/j.ejon.2017.05.008
   Chen ML, 2008, LUNG CANCER, V62, P391, DOI 10.1016/j.lungcan.2008.03.016
   China Association for Acupuncture and Moxibustion, 1988, J TRADIT CHIN MED, V6, P75
   Cleeland CS, 2013, CANCER-AM CANCER SOC, V119, P4333, DOI 10.1002/cncr.28376
   Davidson JR, 2002, SOC SCI MED, V54, P1309, DOI 10.1016/S0277-9536(01)00043-0
   Dean GE, 2015, CANCER NURS, V38, P60, DOI 10.1097/NCC.0000000000000128
   Den Linger CS, 2014, J NATL COMPR CANC NE, V12, P630, DOI 10.6004/jnccn.2014.0067
   Edinger JD, 2005, CLIN PSYCHOL REV, V25, P539, DOI 10.1016/J.CPR.2005.04.003
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Fiorentino Lavinia, 2007, CURR TREAT OPTIONS NEUROL, V9, P337, DOI 10.1007/s11940-007-0019-0
   Gooneratne NS, 2007, LUNG CANCER, V58, P403, DOI 10.1016/j.lungcan.2007.07.011
   Gottfried T, 2020, CANCER MANAG RES, V12, P313, DOI 10.2147/CMAR.S234523
   GROND S, 1994, J PAIN SYMPTOM MANAG, V9, P372, DOI 10.1016/0885-3924(94)90174-0
   Guo X, 2019, TIANJIN NURSING, V27, P352, DOI 10.3969/j.issn.1006-9143.2019.03.035
   Han Q, 2020, J ADV NURS, V76, P1924, DOI 10.1111/jan.14375
   He, 2020, WORLD J SLEEP MED, V7, P1673
   Higgins J, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000049
   Hou Pu-Wei, 2015, EVID BASED COMPLEMENT ALTERNAT MED, V2015, P495684, DOI 10.1155/2015/495684
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Kuo SY, 2016, INT J NURS STUD, V53, P17, DOI 10.1016/j.ijnurstu.2015.10.006
   Langford DJ, 2012, SLEEP MED REV, V16, P397, DOI 10.1016/j.smrv.2011.07.002
   Levin RD, 2005, BRIT J CANCER, V93, P1202, DOI 10.1038/sj.bjc.6602859
   Li LJ, 2020, CHIN MOD DOCT, V58, P92
   Lin L, 2021, BMJ SUPPORT PALLIAT, V11, P32, DOI 10.1136/bmjspcare-2019-001937
   Liu SQ, 2020, WORLD J SLEEP MED, V7, P1327, DOI 10.3969/J.ISSN.2095-7130.2020.08.011
   Liu XR, 2020, HOLIST NURS PRACT, V34, P103, DOI 10.1097/HNP.0000000000000372
   Lu Y, 2017, SHANGHAI NURS, V17, P41, DOI 10.3969/j.issn.1009-8399.2017.01.017
   Luo, 2018, SHANXI ZHONGYIYAO ZA, V47, P1551
   Maciocia G, 2005, FDN CHINESE MED, V2nd, P0
   Morin CM, 2000, PSYCHOSOM MED, V62, P483, DOI 10.1097/00006842-200007000-00005
   Paltiel O, 2004, QUAL LIFE RES, V13, P1699, DOI 10.1007/s11136-004-8745-1
   Papadopoulos D, 2018, J PAIN SYMPTOM MANAG, V55, P1364, DOI 10.1016/j.jpainsymman.2017.12.491
   Sha YS, 2016, TIANJIN J NURSING, V24, P496, DOI 10.3969/J.ISSN.1006-9143.2016.06.010
   Shan QH, 1996, AURICULAR-POINT-PRESSING THERAPY, V0, P0
   Shi ZX, 2018, WORLD LATEST MED INF, V18, P154, DOI 10.19613/J.CNKI.1671-3141.2018.24.064
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Singh B, 2020, SEMIN ONCOL NURS, V36, P0, DOI 10.1016/j.soncn.2020.151076
   Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x
   STRANG P, 1992, ACTA ONCOL, V31, P323, DOI 10.3109/02841869209108179
   Wang, 2012, SHANGHAI J ACUPUNCT, V31, P725
   Wang SY, 2008, J PAIN SYMPTOM MANAG, V35, P258, DOI 10.1016/j.jpainsymman.2007.03.017
   Wu TT, 2021, CANCER NURS, V44, PE323, DOI 10.1097/NCC.0000000000000842
   Wu YC, 2014, J ALTERN COMPLEM MED, V20, P356, DOI 10.1089/acm.2013.0319
   Xue HY, 2020, NEI MONGOL J TRADIT, V39, P166
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeung WF, 2012, SLEEP MED, V13, P971, DOI 10.1016/j.sleep.2012.06.003
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Zhang, 2018, HLTH GUIDE, V43, P262
   Zhong Q, 2019, CHIN J INTEGR MED, V25, P225, DOI 10.1007/s11655-019-3063-1
   Zou C, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0122724
NR 56
TC 10
Z9 10
U1 1
U2 41
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0887-9311
EI 1550-5138
J9 HOLIST NURS PRACT
JI Holist. Nurs. Pract.
PD JUL-AUG 15
PY 2022
VL 36
IS 4
BP E27
EP E37
DI 10.1097/HNP.0000000000000532
PG 11
WC Integrative & Complementary Medicine; Nursing
SC Integrative & Complementary Medicine; Nursing
GA 2D7EP
UT WOS:000811705700002
PM 35708563
DA 2026-01-16
ER

PT J
AU Zeng, JC
   Zhang, RL
   Wei, XJ
   Lin, GH
AF Zeng, Jing-chun
   Zhang, Rui-lin
   Wei, Xiao-jing
   Lin, Guo-hua
TI Acupuncture for improving a case of widespread herpes zoster after non-Hodgkin's lymphoma chemotherapy
SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING
LA English
DT Article
DE Herpes zoster; Varicella Zoster Virus; Acupuncture; Alternative therapy; Chemotherapy; Non-Hodgkin's lymphoma
AB Background: Herpes zoster presents as clustered blisters on one side of the body, accompanied by nerve pain. This is caused by reactivation of the varicella zoster virus, and it occurs primarily in people with weakened immunity. Tumor and chemotherapy drugs can impair the patient's immune function, induce herpes zoster and prolong the course of disease.In these patients, skin changes can last for months and blisters can recur and cause serious complications such as postherpetic neuralgia.Acupuncture is a common alternative therapy for herpes zoster in East Asia. Case presentation: We report a case of an elderly male patient with widespread herpes zoster in the trunk after non-Hodgkin's lymphoma chemotherapy. The patient had received conventional treatment with valaciclovir and mecobalamin within 24 hours of symptom onset. Because neither the clustered blisters nor the nerve pain were improved a week later, acupuncture and related techniques were applied. These included electro-acupuncture, surrounding acupuncture, fire acupuncture, and cupping. The patient recovered 20 days after the herpes zoster attack, and there were no adverse reactions during the treatment process. Conclusions: This case suggests that acupuncture and related techniques are effective interventions for this condition.This case report is innovative because it shows that acupuncture as an adjuvant treatment can improve the skin lesions in patients with HZ after tumour chemotherapy, relieve pain, and shorten the course of HZ. (C) 2021 The Authors. Published by Elsevier Inc.
C1 [Zeng, Jing-chun; Zhang, Rui-lin; Lin, Guo-hua] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Wei, Xiao-jing] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Zeng, JC; Lin, GH (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
EM tcm_zjc@126.com; tcmlin-801@163.com
FU National Natural Science Foundation of China [81574061]; Guangdong Science and TechnologyCommission Foundation [2017A020213019]; Scientific Research Foundation of the First Affiliated Hospital of Guangzhou Uniersity of Chinese Medicine [2019QN23]
CR Cho SF, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep14008
   Forbes HJ, 2012, CURR DERMATOL REP, V1, P39, DOI 10.1007/s13671-011-0004-4
   Glennie MJ, 2007, MOL IMMUNOL, V44, P3823, DOI 10.1016/j.molimm.2007.06.151
   Hamaguchi Y, 2006, J EXP MED, V203, P743, DOI 10.1084/jem.20052283
   Li L, 2018, LIAONING J TRADITION, V45, P2093
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   LiuY YangY, 2013, SHIZHENCHINESEMED, V24, P164
   Na M, 2010, J CHIN DERMATOL, V0, P357
   Yang H, 2018, J CHIN DERMATOL, V51, P699
NR 9
TC 3
Z9 4
U1 2
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1550-8307
EI 1878-7541
J9 EXPLORE-NY
JI Explore-J Sci. Heal.
PD SEP-OCT 15
PY 2022
VL 18
IS 5
BP 608
EP 611
DI 10.1016/j.explore.2021.08.003
EA AUG 2022
PG 4
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 4Q4FF
UT WOS:000856038100021
PM 34417113
DA 2026-01-16
ER

PT J
AU Wang, Y
   Yan, T
   Mu, X
   Dong, H
   Su, J
AF Wang, Yan
   Yan, Tingquan
   Mu, Xiaojing
   Dong, Hong
   Su, Jinman
TI Effects of Moxibustion Combined with Ultrashort Wave on Pain and Oxidative Stress
SO Computational and mathematical methods in medicine
LA English
DT Journal Article
AB OBJECTIVE: To explore the effect of moxibustion instrument combined with  ultrashort wave on pain and oxidative stress in elderly patients with knee  osteoarthritis (KOA). METHOD: 84 elderly patients with knee osteoarthritis  treated in our hospital from May 2020 to June 2021 were randomly divided into  observation group (n = 42) and control group (n = 42). The observation group was  treated with moxibustion instrument combined with ultrashort wave, while the  control group was treated with moxibustion instrument. The clinical efficacy of  the two groups was compared, and the pain of the two groups was evaluated by  visual analogue scale (VAS). Lysholm knee joint score scale and osteoarthritis  index (WOMAC) scale of Western Ontario and McMaster University were used to  evaluate the knee joint function of the two groups, and the levels of  interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α), serum superoxide  dismutase (SOD), serum malondialdehyde (MDA), serum miR-155, and NLRP3 were  detected in the two groups, and the comprehensive quality of life assessment  questionnaire-74 was used, and the adverse reactions were compared between the  two groups. RESULTS: The total effective rate of observation group (90.48%) was  higher than that of control group (69.05%) (P < 0.05). After treatment, VAS,  Lysholm knee joint, WOMAC, quality of life scores, IL-1β, TNF-α, SOD, MDA,  miR-155, and NLRP3 in the observation group were better than those in the control  group, and the differences were statistically significant (P < 0.05). There were  no obvious adverse reactions in both groups. Conclusion. Moxibustion instrument  combined with ultrashort wave can effectively improve knee joint pain, knee joint  function, inflammatory reaction, oxidative stress reaction, and quality of life  in elderly KOA patients, and the therapeutic effect is good.
C1 First Outpatient Department, 971st Hospital, People's Liberation Army Navy, Qingdao, Shandong 266071, China.
   First Outpatient Department, 971st Hospital, People's Liberation Army Navy, Qingdao, Shandong 266071, China.
   First Outpatient Department, 971st Hospital, People's Liberation Army Navy, Qingdao, Shandong 266071, China.
   First Outpatient Department, 971st Hospital, People's Liberation Army Navy, Qingdao, Shandong 266071, China.
   Ten Branches of Recuperation, Navy Qingdao Special Service Convalescent Center, Qingdao, Shandong 266071, China.
NR 0
TC 0
SN 1748-671
EI 1748-670
J9 Comput Math Methods Med
PD MAY 20
PY 2022
VL 2022
IS 
BP 3921021
EP 3921021
DI 10.1155/2022/3921021
PG 0
WC Age Factors; Aged; Humans; Knee Joint; MicroRNAs; Moxibustion; NLR Family, Pyrin Domain-Containing 3 Protein; Osteoarthritis, Knee; metabolism; Oxidative Stress; Pain; etiology; Pain Management; Quality of Life; Superoxide Dismutase; metabolism; Treatment Outcome; Tumor Necrosis Factor-alpha; metabolism; Ultrasonic Therapy
UT PubMed:35586674
PM 35586674
DA 2022-05-20
ER

PT J
AU Öztürk, FG
   Sencan, I
   Özkara, A
   Yapar, A
   Engin, EE
   Öztürk, R
AF Ozturk, Fatma Gokcenur
   Sencan, Irfan
   Ozkara, Adem
   Yapar, Aliekber
   Engin, Eray Erturk
   Ozturk, Recep
TI Knowledge and experiences of complementary and alternative medical practices among patients presenting to an orthopedic clinic: A cross-sectional study
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Traditional medicine; Conventional therapy; Acupuncture; Leech therapy; Cupping; Joint pain; Cross-sectional study; Complementary medicine
AB Introduction: This study aimed to determine the level of knowledge about complementary and alternative medicine (CAM) practices and the frequency of CAM use and treatment among patients who presented to an orthopedic outpatient clinic.& nbsp;Methods: Patients who presented to the orthopedics outpatient clinic of Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital between February 1 and April 1, 2020, were invited to participate in this study. A questionnaire containing 11 questions about 14 different CAM approaches, designed to determine patients' knowledge of and attitudes toward each of these practices, was administered by the responsible physician through face-to-face interviews.& nbsp;Results: A total of 359 patients were included in the study, the mean age was 49.0 +/- 16.1 years and 240 (66.9%) were women. Of the 455 individuals who were considered eligible for the study, 96 refused to participate. The majority of the participants (78.8%) stated that they knew of at least one CAM approach. The most common sources of information were families or friends (54.1%). Of the participants, 30.6% had previously received at least one CAM treatment. About half of the participants (52.6%) stated that they would consider using the methods that they had heard of. The three most commonly known and applied methods were cupping, leech therapy, and acupuncture, respectively. Only 36.4% of the treatments were applied by health professionals.& nbsp;Conclusion: Almost all patients presenting to the orthopedics outpatient clinic had some knowledge of CAM approaches and more than half of them stated that they received such treatments. Health professionals should be aware that society is interested in these practices, regardless of professional support or opposition. All patients presenting to outpatient clinics should be asked about their usage of CAM methods, and the potential interactions of patients' treatments with CAM practices should be considered.
C1 [Ozturk, Fatma Gokcenur; Sencan, Irfan; Ozkara, Adem] Ankara Bilkent City Hosp, Dept Family Med, Ankara, Turkey.
   [Yapar, Aliekber; Engin, Eray Erturk; Ozturk, Recep] Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Dept Orthoped & Traumatol, Ankara, Turkey.
C3 Dr. Abdurrahman Yurtaslan Oncology Hospital
RP Öztürk, R (corresponding author), Dr Abdurrahman Yurtaslan Ankara Oncol Training &, Dept Orthoped & Traumatol, Ankara, Turkey.
EM ozturk_recep@windowslive.com
CR Unknown -, 1994, TURKIYE KLIN J MED E, V0, P0
   Unknown -, 2004, WHO MED STRAT COUNTR, V0, P0
   Ernst E, 2012, J PAIN SYMPTOM MANAG, V43, PE11, DOI 10.1016/j.jpainsymman.2011.11.001
   Ernst E, 2009, MED J AUSTRALIA, V191, P263, DOI 10.5694/j.1326-5377.2009.tb02780.x
   Gonen E, 2022, REPORT TRADITIONAL C, V0, P0
   Kilper A, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2020-037192
   Leach MJ, 2018, COMPLEMENT THER CLIN, V31, P38, DOI 10.1016/j.ctcp.2018.01.011
   Mollahaliloğlu S, 2015, ANKARA MEDICAL JOURNAL, V15, P0, DOI 10.17098/amj.44789
   Ozturk R, 2018, ULUTAS MEDIC J, V4, P152, DOI 10.5455/umj.20171124110044
   Park HL, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/429103
   Qi Z, 2013, WHO TRADITIONAL MEDICINE STRATEGY. 2014-2023, V0, P0
   Resmi Gazete, 2014, RESMI GAZETE 1027, V0, P0
   Resmi Gazete, 2018, RESMI GAZETE 0710, V0, P0
   Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2
   Simsek B, 2017, EUR J INTEGR MED, V15, P68, DOI 10.1016/j.eujim.2017.09.006
   Tutuianu S, 2017, TORN BETWEEN EAST AND WEST: EUROPES BORDER STATES, V0, P1
   WHO, 2000, TRM20001 WHO EDM, V0, P0
NR 17
TC 2
Z9 2
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD APR 15
PY 2022
VL 51
IS 
BP 
EP 
DI 10.1016/j.eujim.2022.102117
EA MAR 2022
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 0O9WA
UT WOS:000783873000001
DA 2026-01-16
ER

PT J
AU Yao, Z
   Xu, Z
   Xu, T
   Liu, X
   Xu, S
   Wan, C
   Zhou, X
AF Yao, Ziqian
   Xu, Zhongbo
   Xu, Tielong
   Liu, Xiaowu
   Xu, Sheng
   Wan, Chanjun
   Zhou, Xu
TI Moxibustion for alleviating chemotherapy-induced gastrointestinal adverse
SO Complementary therapies in clinical practice
LA English
DT Journal Article
DE Chemotherapy; Gastrointestinal adverse effects; Malignant tumours; Moxibustion; Systematic review
AB OBJECTIVE: This systematic review aims to assess whether moxibustion is effective  and safe for gastrointestinal adverse effects, a common and thorny issue arising  from chemotherapy. METHODS: Seven electronic databases were searched up to August  28, 2021, to identify randomized controlled trials (RCTs) comparing moxibustion  versus non-moxibustion treatments for various gastrointestinal adverse effects  after chemotherapy. The Karnofsky performance status (KPS) and quality of life  scores and the incidence of moxibustion-related adverse events were also  investigated. Effects in meta-analyses were measured by risk ratios (RRs) or mean  differences (MDs). RESULTS: Thirty-two RCTs (n = 2990) were included. Compared to  the controls, moxibustion significantly reduced the incidences of nausea/vomiting  (RR 0.70, 95% CI 0.61-0.79), severe nausea/vomiting (RR 0.39, 95% CI 0.29-0.51),  diarrhoea (RR 0.56, 95% CI 0.38-0.82), constipation (RR 0.59, 95% CI 0.44-0.78),  and abdominal distension (RR 0.60, 95% CI 0.46-0.78). The KPS (MD 7.53, 95% CI  3.42-11.64) and quality of life (MD 8.88, 95% CI 0.96-16.80) scores were also  significantly improved after moxibustion. The results did not support a benefit  of moxibustion on inappetence (RR 0.69, 95% CI 0.40-1.22) or abdominal pain (RR  0.60, 95% CI 0.28-1.30). All adverse events related to moxibustion were mild.  CONCLUSIONS: Moderate-to very-low-quality evidence suggests that moxibustion may  be safely used as an adjuvant treatment after chemotherapy to reduce the  incidences of nausea and vomiting, diarrhoea, constipation, and abdominal  distension and improve the performance status and quality of life in patients  with malignant tumours. Its effects on abdominal pain and inappetence are  uncertain.
C1 Evidence-based Medicine Research Centre, Jiangxi University of Chinese Medicine, Nanchang, China. 
   Department of Emergency, The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China. 
   Evidence-based Medicine Research Centre, Jiangxi University of Chinese Medicine, Nanchang, China. 
   Evidence-based Medicine Research Centre, Jiangxi University of Chinese Medicine, Nanchang, China. 
   Evidence-based Medicine Research Centre, Jiangxi University of Chinese Medicine, Nanchang, China. 
   Department of Cardiology, The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China. 
   Evidence-based Medicine Research Centre, Jiangxi University of Chinese Medicine, Nanchang, China.
EM zhouxu_ebm@hotmail.com
NR 0
TC 0
SN 1873-694
EI 
J9 Complement Ther Clin Pract
PD JAN 10
PY 2022
VL 46
IS 
BP 101527
EP 101527
DI 10.1016/j.ctcp.2021.101527
PG 0
WC Antineoplastic Agents; adverse effects; Humans; Moxibustion; Nausea; chemically induced; Randomized Controlled Trials as Topic; Vomiting; chemically induced
UT PubMed:34999499
PM 34999499
DA 2022-01-10
ER

PT J
AU Bonucci, M
   Geraci, A
   Pero, D
   Villivà, C
   Cordella, D
   Condello, M
   Meschini, S
   Del Campo, L
   Tomassi, F
   Porcu, A
   De Lorenzo, F
   Lozupone, F
AF Bonucci, Massimo
   Geraci, Andrea
   Pero, Dina
   Villiva, Cristina
   Cordella, Daniele
   Condello, Maria
   Meschini, Stefania
   Del Campo, Laura
   Tomassi, Franco
   Porcu, Alessandro
   De Lorenzo, Francesco
   Lozupone, Francesco
TI Complementary and Integrative Approaches to Cancer: A Pilot Survey of Attitudes and Habits among Cancer Patients in Italy
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID hexose-correlated compound; alternative medicine use; drug-interactions; breast-cancer; follow-up; cam use; chemotherapy; prevalence; extract; women
AB Background. Cancer patients are among the main consumers of traditional, complementary, integrative, and alternative medicine (TCIM) such as natural products (herbals, integrators, etc.) and mind and body practices (yoga, acupuncture, etc.). Methods. A questionnaire on TCIM was submitted to 415 Italian cancer patients. The questionnaire consisted of three sections: (i) biographical and clinical information; (ii) use of natural substances; and (iii) use of mind-body practices. Results. 406 patients completed the questionnaire. The prevalence of TCIM use was 72.3%. Of them, 75.6% started to use TCIM after a tumor diagnosis. The main reasons for using TCIM were to mitigate side effects (65.0%), to regain physical and mental balance (35.9%), to relieve pain (18.3%), and to improve the efficacy of cancer therapy (16.0%). 44.7% of patients taking natural products used them during conventional therapies (chemotherapy, radiotherapy, etc.), and in 67.5% of cases without consulting a doctor. As a consequence, only about 50% of patients taking natural substances used these compounds appropriately, and the most common errors were related with the purpose of reducing the side effects of the therapy (52.3%) and for boosting immune system (32.1%). Conclusions. There is an impelling need to provide patients with scientifically validated information to raise awareness about the benefits and risks of using TCIM.
C1 [Bonucci, Massimo; Villiva, Cristina; Tomassi, Franco] Assoc Res Integrat Oncol Therapies ARTOI, Rome, Italy.
   [Geraci, Andrea; Lozupone, Francesco] Ist Super Sanita, Italian Ctr Global Hlth, Rome, Italy.
   [Pero, Dina; Del Campo, Laura; Porcu, Alessandro; De Lorenzo, Francesco] Italian Assoc Canc Patients, Relat & Friends AIMaC, Rome, Italy.
   [Cordella, Daniele] Ist Super Sanita, Directorate Gen Informat Technol Unit, Rome, Italy.
   [Condello, Maria; Meschini, Stefania] Ist Super Sanita, Natl Ctr Drug Res & Evaluat, Rome, Italy.
C3 Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)
RP Lozupone, F (corresponding author), Ist Super Sanita, Italian Ctr Global Hlth, Rome, Italy.
EM francesco.lozupone@iss.it
CR Agaguenduez D, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/1534083
   Akkol EK, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13112733
   Arthur K, 2012, INTEGR CANCER THER, V11, P232, DOI 10.1177/1534735411433832
   Behzadmehr R, 2020, COMPLEMENT THER MED, V49, P0, DOI 10.1016/j.ctim.2020.102318
   Bernstein BJ, 2001, ONCOLOGY-NY, V15, P1267
   Berretta M, 2017, ONCOTARGET, V8, P24401, DOI 10.18632/oncotarget.14224
   Buckner CA, 2018, CURR ONCOL, V25, PE275, DOI 10.3747/co.25.3884
   Carlo P, 2011, CANCER FORUM, V35, P21
   Chetan CA, 2010, J ADV PHARM TECHNOL, V1, P245
   Clairet AL, 2019, MED ONCOL, V36, P0, DOI 10.1007/s12032-019-1267-z
   Dufter SA, 2021, J CANCER RES CLIN, V147, P3685, DOI 10.1007/s00432-021-03605-7
   Eldahshan OA, 2015, CYTOTECHNOLOGY, V67, P831, DOI 10.1007/s10616-014-9723-2
   Engdal S, 2009, PHYTOTHER RES, V23, P906, DOI 10.1002/ptr.2750
   Falzone L, 2018, FRONT PHARMACOL, V9, P0, DOI 10.3389/fphar.2018.01300
   Fernández J, 2021, BIOMED PHARMACOTHER, V143, P0, DOI 10.1016/j.biopha.2021.112241
   Fitzmaurice C, 2019, JAMA ONCOL, V5, P1749, DOI 10.1001/jamaoncol.2019.2996
   Gao Q, 2011, ACTA PHARM SIN B, V1, P121, DOI 10.1016/j.apsb.2011.06.009
   Haefeli WE, 2014, EXPERT OPIN DRUG MET, V10, P359, DOI 10.1517/17425255.2014.873786
   Hangai S, 2013, J ALTERN COMPLEM MED, V19, P905, DOI 10.1089/acm.2012.0914
   Harris PE, 2012, INT J CLIN PRACT, V66, P924, DOI 10.1111/j.1742-1241.2012.02945.x
   Hassett MJ, 2006, JNCI-J NATL CANCER I, V98, P1108, DOI 10.1093/jnci/djj305
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Islam MR, 2022, MOLECULES, V27, P0, DOI 10.3390/molecules27072165
   Ito T, 2014, NUTR CANCER, V66, P377, DOI 10.1080/01635581.2014.884232
   Kemppainen LM, 2018, SCAND J PUBLIC HEALT, V46, P448, DOI 10.1177/1403494817733869
   Lin SR, 2020, BRIT J PHARMACOL, V177, P1409, DOI 10.1111/bph.14816
   Mathew L, 2017, INTEGR CANCER THER, V16, P300, DOI 10.1177/1534735417704948
   Mclay JS, 2012, EUR J CLIN PHARMACOL, V68, P811, DOI 10.1007/s00228-011-1181-6
   Meijerman I, 2006, ONCOLOGIST, V11, P742, DOI 10.1634/theoncologist.11-7-742
   Mitra S, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14030759
   Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007
   Pearce A, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0184360
   Pihlak R, 2014, EUR J CANCER CARE, V23, P249, DOI 10.1111/ecc.12132
   Posadzki P, 2013, BRIT J CLIN PHARMACO, V75, P603, DOI 10.1111/j.1365-2125.2012.04350.x
   Richardson MA, 2000, J CLIN ONCOL, V18, P2505, DOI 10.1200/JCO.2000.18.13.2505
   Sauter ER, 2020, EXPERT REV CLIN PHAR, V13, P265, DOI 10.1080/17512433.2020.1738218
   Schink M, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-2028-1
   Scott J A, 2005, EUR J ONCOL NURS, V9, P131, DOI 10.1016/j.ejon.2005.03.012
   Semiglazov VF, 2006, ANTICANCER RES, V26, P1519
   Silva JD, 2020, J TOXICOL ENV HEAL A, V83, P525, DOI 10.1080/15287394.2020.1780658
   Stie M, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14040952
   Suenaga S, 2014, ANTICANCER RES, V34, P141
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tröger W, 2012, BREAST CANCER-BASIC, V6, P173, DOI 10.4137/BCBCR.S10558
   Vapiwala N, 2006, CANCER J, V12, P467, DOI 10.1097/00130404-200611000-00006
   Verhoef MJ, 2009, CHRONIC DIS CAN, V29, P80
   Wanwimolruk S, 2014, EXCLI J, V13, P347
   Weissenstein U, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-6
   Werthmann PG, 2018, HEAD NECK-J SCI SPEC, V40, PE77, DOI 10.1002/hed.25320
   Wode K, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2452-5
   Xing Pan-pan, 2011, YAO XUE XUE BAO, V46, P573
   Yates JS, 2005, SUPPORT CARE CANCER, V13, P806, DOI 10.1007/s00520-004-0770-7
NR 53
TC 9
Z9 10
U1 2
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD AUG 5
PY 2022
VL 2022
IS 
BP 
EP 
DI 10.1155/2022/2923967
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 3Z7XB
UT WOS:000844628800025
PM 35958921
DA 2026-01-16
ER

PT J
AU Kristoffersen, AE
   Wider, B
   Nilsen, JV
   Bjelland, M
   Mora, DC
   Nordberg, JH
   Broderstad, AR
   Nakandi, K
   Stub, T
AF Kristoffersen, Agnete E. E.
   Wider, Barbara
   Nilsen, Jorunn V. V.
   Bjelland, Mona
   Mora, Dana C. C.
   Nordberg, Johanna Hok
   Broderstad, Ann Ragnhild
   Nakandi, Kiwumulo
   Stub, Trine
TI Prevalence of late and long-term effects of cancer (treatment) and use of complementary and alternative medicine in Norway
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Cancer; Late effects; Long-term effects; Complementary therapies; Supportive care; CAM
ID induced peripheral neuropathy; quality-of-life; breast-cancer; childhood-cancer; chronic fatigue; massage therapy; hot flashes; management; lymphedema; survivors
AB Background: The increasing number of patients surviving cancer leads to more people experiencing late and long term-effects from the disease and its treatment. Fatigue, sleep disorders, early menopause, pain, and nerve damage are commonly reported. Methods helping people to recover after cancer treatment are therefore essential. The aims of this study were threefold; (1) to determine the level of cancer patients suffering from late and long-term effects of cancer diagnosis and treatment in Norway, (2) explore complementary and alternative medicine (CAM) modalities used for managing these adversities, and (3) describe self-perceived benefits and harms of the CAM interventions. Methods: The study was conducted in cooperation with the Norwegian Cancer Society (NCS) and consisted of an online cross-sectional study among members of the NCS user panel with present or previous cancer (n = 706). The study was carried out in September/October 2021 using a modified cancer-specific version of the International Questionnaire to Measure Use of Complementary and Alternative Medicine (I-CAM-Q). A total of 315 women and 153 men agreed to participate, resulting in a response rate of 67%. Results: Most of the participants (83%) suffered from late and long-term effects of cancer treatment; mostly fatigue (59.2%), sleep disorder (41.5%), hot flashes (39.2%), nerve damage (polyneuropathy, 38.0%), and pain (36.6%) with a mean number of 5.1 different late and long-term effects. Late and long-term effects were positively associated with younger age and college/university education. Nearly half of the participants experiencing late and long-term effects (43%) reported having used CAM to treat these complaints. Most frequently used were self-help practices (26%) such as relaxation therapy (19%), yoga (14%) and meditation (13%), but also visits to CAM providers were reported by 22%. Herbal- and other natural remedies to treat late and long-term effects were used by 13%. A high percentage of CAM users reported self-perceived improvements of their symptoms (86% for self-help practices, 90% for visits to CAM providers). Few experienced adverse effects of the CAM treatment. Conclusion: A large proportion of cancer patients suffered from a wide range of late and long-term effects of cancer diagnosis and treatment, and they use CAM to treat these complaints to a rather high degree. Relaxation therapy, yoga, meditation, massage, and acupuncture were the most frequently used therapies regardless of complaint. The therapies used are generally considered to be both safe and beneficial for the respective complaint, indicating that the participants seem to be well informed about the choices they make.
C1 [Kristoffersen, Agnete E. E.; Wider, Barbara; Mora, Dana C. C.; Nakandi, Kiwumulo; Stub, Trine] UiT Arctic Univ Norway, Natl Res Ctr Complementary & Alternat Med NAFKAM, Dept Community Med, Tromso, Norway.
   [Bjelland, Mona] Norwegian Canc Soc, Oslo, Norway.
   [Nordberg, Johanna Hok] Reg Canc Ctr Stockholm Gotland, Stockholm, Sweden.
   [Nordberg, Johanna Hok] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Nursing, Stockholm, Sweden.
   [Nordberg, Johanna Hok] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden.
   [Broderstad, Ann Ragnhild] UiT Arctic Univ Norway, Ctr Sami Hlth Res, Dept Community Med, Tromso, Norway.
C3 UiT The Arctic University of Tromso; Karolinska Institutet; Karolinska Institutet; UiT The Arctic University of Tromso
RP Kristoffersen, AE (corresponding author), UiT Arctic Univ Norway, Natl Res Ctr Complementary & Alternat Med NAFKAM, Dept Community Med, Tromso, Norway.
EM agnete.kristoffersen@uit.no
FU UiTThe Arctic University of Norway
CR Abuelgasim KA, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2150-8
   Al-naggar Ra, 2013, WORLD JOURNAL OF MEDICAL SCIENCES, V8, P157, DOI 10.5829/IDOSI.WJMS.2013.8.2.7358
   Ando M, 2009, J PALLIAT MED, V12, P1091, DOI 10.1089/jpm.2009.0143
   Unknown -, 2021, CANC NORW 2020, V0, P0
   Unknown -, 2022, REL TECHN WHAT YOU N, V0, P0
   Unknown -, 2003, ACT 64 27 JUNE 2003, V0, P0
   Unknown -, 2020, SEN ETT KREFTB, V0, P0
   Unknown -, 2020, CHR LAT EFF CANC TRE, V0, P0
   Unknown -, 2020, KEY FIG CANC, V0, P0
   Unknown -, 2013, DECLARATION OF HELSINKI. MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS, V0, P0
   Unknown -, 2012, EXAMPL ACT NOT REQ A, V0, P0
   Unknown -, 2022, LYMFODEM PA GRUNN KR, V0, P0
   Unknown -, 2021, S3 LEITLINIE KOMPLEM, V0, P0
   Unknown -, 2018, LEVE MED ETT KREFT U, V0, P0
   Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Bao YJ, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/170396
   Bissonauth V, 2008, CANCER DETECT PREV, V32, P52, DOI 10.1016/j.cdp.2008.01.005
   Bohn SKH, 2024, J CANCER SURVIV, V18, P375, DOI 10.1007/s11764-022-01202-2
   Boland EG, 2017, CURR OPIN SUPPORT PA, V11, P181, DOI 10.1097/SPC.0000000000000292
   Bower JE, 2014, NAT REV CLIN ONCOL, V11, P597, DOI 10.1038/nrclinonc.2014.127
   Brami C, 2016, CRIT REV ONCOL HEMAT, V98, P325, DOI 10.1016/j.critrevonc.2015.11.014
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Brem S, 2011, CLIN J ONCOL NURS, V15, P63, DOI 10.1188/11.CJON.63-71
   Cambron JA, 2007, J ALTERN COMPLEM MED, V13, P793, DOI 10.1089/acm.2006.6401
   Cancer in Norway, 2021, CANCER INCIDENCE, V0, P0
   Carpenter JS, 1998, CANCER-AM CANCER SOC, V82, P1682, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>3.0.CO;2-0
   Cassileth BR, 2013, CANCER-AM CANCER SOC, V119, P2455, DOI 10.1002/cncr.28093
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Cheuk DKL, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005472.pub3
   Cramer H, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2612-7
   DSilva S, 2012, PSYCHOSOMATICS, V53, P407, DOI 10.1016/j.psym.2012.04.006
   Dahl AA, 2019, J ADOLESC YOUNG ADUL, V8, P304, DOI 10.1089/jayao.2018.0109
   Davidson JR, 2002, SOC SCI MED, V54, P1309, DOI 10.1016/S0277-9536(01)00043-0
   Davis SR, 2010, MENOPAUSE, V17, P1004, DOI 10.1097/gme.0b013e3181d991dd
   DiSipio T, 2013, LANCET ONCOL, V14, P500, DOI 10.1016/S1470-2045(13)70076-7
   Ebede CC, 2017, MED CLIN N AM, V101, P1085, DOI 10.1016/j.mcna.2017.06.007
   Eikeland SA, 2021, ACTA ONCOL, V60, P911, DOI 10.1080/0284186X.2021.1917776
   Eustachi A, 2009, INTEGR CANCER THER, V8, P56, DOI 10.1177/1534735408327996
   Fabi A, 2020, ANN ONCOL, V31, P713, DOI 10.1016/j.annonc.2020.02.016
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Finnegan-John J, 2013, INTEGR CANCER THER, V12, P276, DOI 10.1177/1534735413485816
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Gehring K, 2012, EXPERT REV ANTICANC, V12, P255, DOI 10.1586/era.11.202
   Goldberg SB, 2022, PSYCHOTHER RES, V32, P291, DOI 10.1080/10503307.2021.1933646
   Golshan Mehra, 2006, J SUPPORT ONCOL, V4, P381
   Greco MT, 2014, J CLIN ONCOL, V32, P4149, DOI 10.1200/JCO.2014.56.0383
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hansen F, 2020, ANTHROPOL MED, V27, P330, DOI 10.1080/13648470.2019.1676637
   Harrington CB, 2010, INT J PSYCHIAT MED, V40, P163, DOI 10.2190/PM.40.2.c
   Hayes SC, 2017, GYNECOL ONCOL, V146, P623, DOI 10.1016/j.ygyno.2017.06.004
   Hede K, 2008, J NATL CANCER I, V100, P162, DOI 10.1093/jnci/djn007
   Helsedirektoratet, 2017, NORW DIR HLTH NASJ H, V0, P0
   Henneghan AM, 2015, J HOLIST NURS, V33, P84, DOI 10.1177/0898010114539191
   Herpertz U, 1998, FORTSCHR MED, V116, P36
   Hess SL, 2018, SENEFFEKTER ETTER KR, V0, P1
   Jacobson JS, 2000, J CLIN ONCOL, V18, P668, DOI 10.1200/JCO.2000.18.3.668
   Jansen CE, 2005, ONCOL NURS FORUM, V32, P329, DOI 10.1188/05.ONF.329-342
   Jaradat NA, 2016, J ETHNOPHARMACOL, V178, P1, DOI 10.1016/j.jep.2015.11.050
   Johannesen TB, 2007, ACTA ONCOL, V46, P60, DOI 10.1080/02841860600774026
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Kanakura Y, 2002, AM J CHINESE MED, V30, P37, DOI 10.1142/S0192415X02000041
   Keene MR, 2019, COMPLEMENT THER CLIN, V35, P33, DOI 10.1016/j.ctcp.2019.01.004
   Kim YH, 2013, COMPLEMENT THER MED, V21, P379, DOI 10.1016/j.ctim.2013.06.005
   Kirchhoff AC, 2011, CANCER EPIDEM BIOMAR, V20, P1838, DOI 10.1158/1055-9965.EPI-11-0239
   Kirserud C, 2018, KREFTSYKDOMMER EN BA, V0, P148
   Kiserud Cecilie E, 2018, RECENT RESULTS CANCER RES, V210, P123, DOI 10.1007/978-3-319-64310-6_8
   Klonoff-Cohen H, 2020, PLOS ONE, V15, P0, DOI 10.1371/journal.pone.0229222
   Kristoffersen AE, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03606-0
   Kristoffersen AE, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2762-7
   Lee MS, 2011, ANN ONCOL, V22, P1459, DOI 10.1093/annonc/mdr147
   Lindqvist E, 2017, EUR J OBSTET GYN R B, V211, P112, DOI 10.1016/j.ejogrb.2017.02.021
   Loge JH, 1999, J CLIN ONCOL, V17, P253, DOI 10.1200/JCO.1999.17.1.253
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mahon Suzanne M, 2021, CLIN J ONCOL NURS, V25, P33, DOI 10.1188/21.cjon.s2.33
   Mai QD, 2019, SOC SCI MED, V237, P0, DOI 10.1016/j.socscimed.2019.112424
   Maindet C, 2019, SUPPORT CARE CANCER, V27, P3119, DOI 10.1007/s00520-019-04829-7
   Masmoudi A, 2005, DERMATOL ONLINE J, V11, P12
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Mellblom AV, 2021, SUPPORT CARE CANCER, V29, P2947, DOI 10.1007/s00520-020-05790-6
   Mitchell AJ, 2013, LANCET ONCOL, V14, P721, DOI 10.1016/S1470-2045(13)70244-4
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Mykletun A, 2009, PSYKISKE LIDELSER I NORGE: ET FOLKEHELSEPERSPEKTIV, V0, P0
   Nakandi K, 2022, BMC HEALTH SERV RES, V22, P0, DOI 10.1186/s12913-021-07445-6
   Ness KK, 2008, ARCH PHYS MED REHAB, V89, P128, DOI 10.1016/j.apmr.2007.08.123
   Ness KK, 2009, J CLIN ONCOL, V27, P2382, DOI 10.1200/JCO.2008.21.1482
   Ota KS, 2006, J AM OSTEOPATH ASSOC, V106, P110
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Paice JA, 2011, PAIN, V152, PS84, DOI 10.1016/j.pain.2010.10.010
   Pearson NJ, 2006, ARCH INTERN MED, V166, P1775, DOI 10.1001/archinte.166.16.1775
   Pilkington K, 2021, ACUPUNCTURE CANC PAI, V0, P0
   Pilkington K, 2021, ACUPUNCTURE HOT FLUS, V0, P0
   Pinto AC, 2011, MATURITAS, V70, P343, DOI 10.1016/j.maturitas.2011.09.008
   Pitman A, 2018, BMJ-BRIT MED J, V361, P0, DOI 10.1136/bmj.k1415
   Quandt SA, 2009, J ALTERN COMPLEM MED, V15, P331, DOI 10.1089/acm.2008.0521
   Reinertsen KV, 2017, J PAIN SYMPTOM MANAG, V53, P551, DOI 10.1016/j.jpainsymman.2016.09.011
   Reinertsen Kristin Valborg, 2017, TIDSSKR NOR LAEGEFOREN, V137, P0, DOI 10.4045/tidsskr.17.0040
   Reinertsen KV, 2010, J CANCER SURVIV, V4, P405, DOI 10.1007/s11764-010-0145-7
   Rosenberg EI, 2008, PAIN MED, V9, P1065, DOI 10.1111/j.1526-4637.2008.00477.x
   Ryan TJ, 2012, INT J LOW EXTR WOUND, V11, P5, DOI 10.1177/1534734612438548
   Samuel SR, 2021, J CANCER SURVIV, V15, P799, DOI 10.1007/s11764-020-00972-x
   Saquib J, 2011, INTEGR CANCER THER, V10, P138, DOI 10.1177/1534735410392578
   Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895
   Seland M, 2015, LEUKEMIA LYMPHOMA, V56, P3306, DOI 10.3109/10428194.2015.1036258
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Solem AG, 2018, PLOT DOKUMENTAR EKSI, V5, P24
   Soo JK, 2008, BRIT J DERMATOL, V158, P1350, DOI 10.1111/j.1365-2133.2007.08423.x
   Stein KD, 2008, CANCER-AM CANCER SOC, V112, P2577, DOI 10.1002/cncr.23448
   Su HI, 2010, BREAST CANCER RES TR, V124, P205, DOI 10.1007/s10549-010-0802-6
   Swain Sandra M, 2008, CLIN ADV HEMATOL ONCOL, V6, P455
   Syed Mohammad Salleh Sharifah Nadia, 2021, J COMPLEMENT INTEGR MED, V18, P805, DOI 10.1515/jcim-2020-0205
   Syse Astri, 2008, J CANCER SURVIV, V2, P149, DOI 10.1007/s11764-008-0053-2
   Szabo RA, 2019, CLIMACTERIC, V22, P572, DOI 10.1080/13697137.2019.1646718
   Vistad I, 2007, BJOG-INT J OBSTET GY, V114, P1150, DOI 10.1111/j.1471-0528.2007.01445.x
   White A, 2014, EUR J INTEGR MED, V6, P404, DOI 10.1016/j.eujim.2013.09.006
   Zhang ZJ, 2020, BRAIN BEHAV IMMUN, V88, P88, DOI 10.1016/j.bbi.2020.04.035
NR 120
TC 18
Z9 23
U1 0
U2 23
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD DEC 5
PY 2022
VL 22
IS 1
BP 
EP 
DI 10.1186/s12906-022-03790-z
PG 21
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 6U5UR
UT WOS:000894432100001
PM 36471296
DA 2026-01-16
ER

PT J
AU Mao, JJ
   Ismaila, N
   Bao, T
   Barton, D
   Ben-Arye, E
   Garland, EL
   Greenlee, H
   Leblanc, T
   Lee, RT
   Lopez, AM
   Loprinzi, C
   Lyman, GH
   MacLeod, J
   Master, VA
   Ramchandran, K
   Wagner, LI
   Walker, EM
   Bruner, DW
   Witt, CM
   Bruera, E
AF Mao, Jun J
   Ismaila, Nofisat
   Bao, Ting
   Barton, Debra
   Ben-Arye, Eran
   Garland, Eric L
   Greenlee, Heather
   Leblanc, Thomas
   Lee, Richard T
   Lopez, Ana Maria
   Loprinzi, Charles
   Lyman, Gary H
   MacLeod, Jodi
   Master, Viraj A
   Ramchandran, Kavitha
   Wagner, Lynne I
   Walker, Eleanor M
   Bruner, Deborah Watkins
   Witt, Claudia M
   Bruera, Eduardo
TI Integrative Medicine for Pain Management in Oncology: Society for Integrative
SO Journal of clinical oncology : official journal of the American Society of
LA English
DT Journal Article
AB PURPOSE: The aim of this joint guideline is to provide evidence-based  recommendations to practicing physicians and other health care providers on  integrative approaches to managing pain in patients with cancer. METHODS: The  Society for Integrative Oncology and ASCO convened an expert panel of integrative  oncology, medical oncology, radiation oncology, surgical oncology, palliative  oncology, social sciences, mind-body medicine, nursing, and patient advocacy  representatives. The literature search included systematic reviews,  meta-analyses, and randomized controlled trials published from 1990 through 2021.  Outcomes of interest included pain intensity, symptom relief, and adverse events.  Expert panel members used this evidence and informal consensus to develop  evidence-based guideline recommendations. RESULTS: The literature search  identified 227 relevant studies to inform the evidence base for this guideline.  RECOMMENDATIONS: Among adult patients, acupuncture should be recommended for  aromatase inhibitor-related joint pain. Acupuncture or reflexology or acupressure  may be recommended for general cancer pain or musculoskeletal pain. Hypnosis may  be recommended to patients who experience procedural pain. Massage may be  recommended to patients experiencing pain during palliative or hospice care.  These recommendations are based on an intermediate level of evidence, benefit  outweighing risk, and with moderate strength of recommendation. The quality of  evidence for other mind-body interventions or natural products for pain is either  low or inconclusive. There is insufficient or inconclusive evidence to make  recommendations for pediatric patients. More research is needed to better  characterize the role of integrative medicine interventions in the care of  patients with cancer.Additional information is available at  https://integrativeonc.org/practice-guidelines/guidelines and  www.asco.org/survivorship-guidelines.
C1 Memorial Sloan Kettering Cancer Center, New York, NY.
   American Society of Clinical Oncology, Alexandria, VA.
   Memorial Sloan Kettering Cancer Center, New York, NY.
   University of Michigan School of Nursing, Ann Arbor, MI.
   Lin & Carmel Medical Centers, Clalit Health Services
   Technion Faculty of Medicine, Haifa, Israel.
   College of Social Work, University of Utah, Salt Lake City, UT.
   Fred Hutchinson Cancer Research Center, Seattle, WA.
   Duke University School of Medicine Durham, NC.
   City of Hope Comprehensive Cancer Center, Duarte, CA.
   Thomas Jefferson. Sidney Kimmel Cancer Center, Philadelphia, PA.
   Mayo Clinic, Rochester, MN.
   Fred Hutchinson Cancer Research Center, Seattle, WA.
   Patient Representative, Memorial Sloan Kettering Integrative Medicine Service, New York, NY.
   Winship Cancer Institute of Emory University, Atlanta, GA.
   Stanford University, Palo Alto, CA.
   Wake Forest School of Medicine, Winston-Salem, NC.
   Henry Ford Hospital, Detroit, MI.
   Winship Cancer Institute of Emory University, Atlanta, GA.
   University Hospital Zurich, Zurich, Switzerland.
   MD Anderson Cancer Center, Houston, TX.
NR 0
TC 0
SN 1527-775
EI 
J9 J Clin Oncol
PD SEP 20
PY 2022
VL 40
IS 34
BP 3998
EP 4024
DI 10.1200/JCO.22.01357
PG 26
WC Adult; Child; Humans; Integrative Medicine; Integrative Oncology; Neoplasms; complications; Pain; Pain Management
UT PubMed:36122322
PM 36122322
DA 2022-09-20
ER

PT J
AU Mahasti, S
   Caroline, B
   Bernard, A
   LI, Y
   NIE, JY
   LIU, DQ
   CHEN, DD
   CHEN, CX
   Estevez, L
   LI, WH
   Armand, JP
   ZHU, MS
   JU, LY
AF Mahasti, Saghachian
   Caroline, Barry
   Bernard, Asselain
   LI Yunfen
   NIE Jianyun
   LIU Dequan
   CHEN Dedian
   CHEN Chunxin
   Estevez, Laura
   LI Wenhui
   Armand, Jean-Pierre
   ZHU Miansheng
   JU Liya
TI An international multicentric phase III randomized controlled trial of time-acupoints-space acupuncture for the prevention of chemotherapy-induced fatigue in patients with early stage breast cancer: a study protocol
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE breast neoplasms; chemotherapy; adjuvant; fatigue; immunity; clinical protocols; time-acupoints-space acupuncture
ID multidimensional fatigue; validation; statistics; inventory; women; china
AB OBJECTIVE: To determine the difference in prevention of chemotherapy-induced fatigue between time-acupoints-space acupuncture (ATAS) administered weekly compared to sham acupuncture and non-acupuncture in patients with early breast cancer receiving adjuvant chemotherapy by epirubicine-cyclophosphamide (EC) followed by paclitaxel, as measured by the multi-dimensional fatigue inventory (MFI) over the previous week and Visual Analogue Scale measuring fatigue (VAS-F), and to evaluate the effects of ATAS on self-reported neuropathy pain, sleep, anxiety and depression. METHODS: In this multicenter clinical trial, we have randomized patients into 3 groups: ATAS, Sham and non-acupuncture with an unequal randomization of 2:1:1. A cloud related electronical clinical report form and smartphone platform was established for data entry. Patients with a history of stage I -III breast cancer scheduled to receive adjuvant chemotherapy. Acupuncture will be delivered once a week during chemotherapy with VAS-F evaluation. In order to qualify and quantify the mechanism of fatigue induced by chemotherapy with or without acupuncture, an evaluation of immune profiling was incorporate in this study. RESULTS: The presence and seriousness of chemotherapy-induced fatigue should be considered in therapeutic programs for early breast cancer treatment. Fatigue induced by adjuvant chemotherapy in patients with breast cancer remains a major concern affecting the quality of life significantly. Unfortunately, we do not have effective pharmacological interventions yet. And clinical trials of acupuncture in preventing chemotherapy-induced fatigue in patients with early breast cancer have not been reported. CONCLUSION: The findings of the trial will allow us to determine the effects of acupuncture treatment approach. We will also be able to confirm whether ATAS is better than sham acupuncture and non-acupuncture treatments. (c) 2022 JTCM. All rights reserved.
C1 [Mahasti, Saghachian; Armand, Jean-Pierre] Inst Gustave Roussy, Paris, France.
   [Caroline, Barry] Res Ctr Epidemiol & Publ Hlth, Paris, France.
   [Bernard, Asselain] Inst Curie Paris, Paris, France.
   [LI Yunfen; NIE Jianyun; LIU Dequan; CHEN Dedian; LI Wenhui] Kunming Med Univ, Affiliated Hosp 3, Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China.
   [JU Liya] Preci Med Platform Europe, Paris, France.
   [CHEN Chunxin; Estevez, Laura] MD Anderson Canc Hosp, Madrid, Spain.
   [ZHU Miansheng] ARIATAS, Assoc Rech & Informat Acupuncture Time Acupoin Sp, Paris, France.
   [ZHU Miansheng] Yunnan Zhus Expert workstat, Natl Famous Tradit Chinese Med Expert Mian Sheng, Kunming, Yunnan, Peoples R China.
C3 UNICANCER; Gustave Roussy; UNICANCER; Universite PSL; Institut Curie; Kunming Medical University
RP JU, LY (corresponding author), Preci Med Platform Europe, Paris, France.; LI, WH (corresponding author), Yunnan Prov Canc Hosp, Kunming, Yunnan, Peoples R China.
EM wenhuili2014@163.com; juliya_eiffel@126.com
FU France Ruban Rose; Yunnan Provincial Science and Technology Department Funding [2018IA059]; PreciMed Platform Europe
CR Bower JE, 2000, J CLIN ONCOL, V18, P743, DOI 10.1200/JCO.2000.18.4.743
   Butt Zeeshan, 2008, J NATL COMPR CANC NETW, V6, P448
   Campos MPO, 2011, ANN ONCOL, V22, P1273, DOI 10.1093/annonc/mdq458
   Chen Wanqing, 2016, CHINESE JOURNAL OF CANCER 癌症, V35, P430
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Fillion L, 2003, CANCER NURS, V26, P143, DOI 10.1097/00002820-200304000-00008
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Goldstein D, 2012, J CLIN ONCOL, V30, P1805, DOI 10.1200/JCO.2011.34.6148
   Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1
   Lehmann H, 2013, J INTEGR MED-JIM, V11, P45, DOI 10.3736/jintegrmed2013008
   Ma Z, 2010, ANAL SYNDROME CHARAC, V0, P7
   Mieog JSD, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005002.pub2
   Mock V, 2000, ONCOLOGY-NY, V14, P151
   Munguía-Izquierdo D, 2012, CLIN EXP RHEUMATOL, V30, P0
   Parkin DM, 2006, BREAST J, V12, PS70, DOI 10.1111/j.1075-122X.2006.00205.x
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Senkus E, 2015, ANN ONCOL, V26, PV8, DOI 10.1093/annonc/mdv298
   SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O
   Tian J, 2012, SUPPORT CARE CANCER, V20, P2379, DOI 10.1007/s00520-011-1357-8
NR 19
TC 2
Z9 3
U1 2
U2 14
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD APR 15
PY 2022
VL 42
IS 2
BP 289
EP 295
DI 10.19852/j.cnki.jtcm.2022.02.008
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 1B3ZH
UT WOS:000792376500001
PM 35473351
DA 2026-01-16
ER

PT J
AU Ho, EY
   Agne, RR
   Santana, T
   Thompson, N
   McClendon, G
   Ng, E
   Merrick, S
   Gonzalez, F
   Smith, T
   Drewke, K
   Gutierrez, A
   Floyd, G
   Chao, MT
AF Ho, Evelyn Y.
   Agne, Robert R.
   Santana, Trilce
   Thompson, Nicole
   McClendon, Genevieve
   Ng, Eliza
   Merrick, Shannette
   Gonzalez, Felicia
   Smith, Tenaya
   Drewke, Kathleen
   Gutierrez, Amalia
   Floyd, Gary
   Chao, Maria T.
TI A Communication Perspective on What Patient Advisory Boards Do: Action-Implicative Discourse Analysis and Negotiating Advice
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE acupuncture; pragmatic effectiveness; pain; cancer; implementation; inpatient
ID stakeholder engagement; talk; strategy
AB Stakeholder advisory boards are recognized as an essential and useful part of patient-centered research. However, such engagement can involve exchanges of diverse individual experiences, multiple opinions, and strong feelings in the face of researchers' limitations, deadlines, and agendas. Yet, little work examines how these potential tensions occur and are resolved in actual advisory board meetings. This perspective article describes and employs a communication framework for analyzing a patient advisory council (PAC) for a comparative effectiveness study on acupuncture and pain counseling for inpatients with cancer. The framework, Action-Implicative Discourse Analysis (AIDA), is an observational method that examines challenges through recorded and transcribed, naturally occurring interaction. Our analysis focused on two short excerpts from the first PAC meeting to demonstrate members' navigation of advice-giving and advice-receiving-one in which advice was ultimately implemented by the study team and another in which it was deemed unfeasible. Although advice is inherent to the work of all PACs, it often emerges unannounced as negotiated moments, made up of seemingly minor conversation moves. As a recurring event, advice can and should be analyzed and discussed within PACs to improve communication and team dynamics.
C1 [Ho, Evelyn Y.] Univ San Francisco, Dept Commun Studies, 2130 Fulton St,Commun Studies KA 313, San Francisco, CA 94117 USA.
   [Ho, Evelyn Y.; Chao, Maria T.] Univ Calif San Francisco, Asian Amer Res Ctr Hlth, San Francisco, CA 94143 USA.
   [Ho, Evelyn Y.; McClendon, Genevieve; Ng, Eliza; Merrick, Shannette; Gonzalez, Felicia; Smith, Tenaya; Drewke, Kathleen; Gutierrez, Amalia; Floyd, Gary] Pragmat Res Acupuncture & Counseling eXtended Inp, San Francisco, CA USA.
   [Agne, Robert R.] Auburn Univ, Sch Commun & Journalism, Auburn, AL 36849 USA.
   [Santana, Trilce; Thompson, Nicole; Chao, Maria T.] UCSF, Osher Ctr Integrat Med, San Francisco, CA USA.
   [Merrick, Shannette] Univ Calif Davis, Sch Med, Davis, CA USA.
   [Chao, Maria T.] UCSF, Dept Med, Div Gen Internal Med, San Francisco Gen Hosp, San Francisco, CA USA.
C3 University of San Francisco; University of California System; University of California San Francisco; Auburn University System; Auburn University; University of California System; University of California San Francisco; University of California System; University of California Davis; University of California System; University of California San Francisco
RP Ho, EY (corresponding author), Univ San Francisco, Dept Commun Studies, 2130 Fulton St,Commun Studies KA 313, San Francisco, CA 94117 USA.
EM eyho@usfca.edu
FU Patient-Centered Outcomes Research Institute (PCORI) Award [CER-1609-36220]; Helen Diller Family Foundation; UCSF/Genentech MidCareer Award
CR Agne RR, 2007, DISCOURSE SOC, V18, P549, DOI 10.1177/0957926507079634
   Agne RR, 2019, COMMUN EDUC, V68, P265, DOI 10.1080/03634523.2019.1606433
   Agne RR, 2010, SOUTH COMMUN J, V75, P306, DOI 10.1080/1041794x.2010.504438
   Anderson A, 2019, CLIN THER, V41, P1408, DOI 10.1016/j.clinthera.2019.06.006
   Castor T, 2016, MANAGE COMMUN Q, V30, P472, DOI 10.1177/0893318916646454
   Concannon TW, 2014, J GEN INTERN MED, V29, P1692, DOI 10.1007/s11606-014-2878-x
   Craig RT, 2020, GROUNDED PRACTICAL THEORY: INVESTIGATING COMMUNICATION PROBLEMS, V0, P0, DOI DOI 10.1002/9781118611463.WBIELSI146
   Craig RT, 2006, COMMUNICATION AS ...: PERSPECTIVES ON THEORY, V0, PP38, DOI 10.4135/9781483329055.n5
   Craig RT, 2018, J COMMUN, V68, P289, DOI 10.1093/joc/jqx013
   Craig RT, 2005, CONTROVERSIES, V2, P11
   Denvir P, 2014, COMMUNITY MED, V11, P263, DOI 10.1558/cam.v11i3.17876
   Dimock A, 2010, ARGUMENTATION, V24, P423, DOI 10.1007/s10503-009-9175-6
   Esmail Laura, 2015, J COMP EFF RES, V4, P133, DOI 10.2217/cer.14.79
   Fitch KristineL, 2005, HANDBOOK OF LANGUAGE AND SOCIAL INTERACTION, V0, P0
   Forsythe LP, 2016, J GEN INTERN MED, V31, P13, DOI 10.1007/s11606-015-3450-z
   Frank L, 2015, QUAL LIFE RES, V24, P1033, DOI 10.1007/s11136-014-0893-3
   Goldsmith DJ, 1997, HUM COMMUN RES, V23, P454, DOI 10.1111/j.1468-2958.1997.tb00406.x
   Mirivel JC, 2005, RES LANG SOC INTERAC, V38, P1, DOI 10.1207/s15327973rlsi3801_1
   Mirivel JC, 2007, DISCOURSE COMMUN, V1, P309, DOI 10.1177/1750481307079203
   Mirivel JC, 2008, HEALTH COMMUN, V23, P153, DOI 10.1080/10410230801968203
   Muller HL, 2014, J APPL COMMUN RES, V42, P325, DOI 10.1080/00909882.2014.911941
   Oldfield BJ, 2019, J GEN INTERN MED, V34, P1292, DOI 10.1007/s11606-018-4565-9
   Robles JS, 2012, DISCOURSE STUD, V14, P753, DOI 10.1177/1461445612457490
   Sharma AE, 2016, J AM BOARD FAM MED, V29, P775, DOI 10.3122/jabfm.2016.06.150380
   Sheridan S, 2017, ANN FAM MED, V15, P165, DOI 10.1370/afm.2042
   Sprain L, 2017, COMMUN MONOGR, V84, P241, DOI 10.1080/03637751.2016.1257141
   Tracy K, 2010, RHETOR DEMOCR DELIB, V0, P1
   Tracy K, 2005, LEA COMMUN SER, V0, P301
   TRACY K, 1995, J LANG SOC PSYCHOL, V14, P195, DOI 10.1177/0261927X95141011
   Tracy K, 1999, DISCOURSE STUDIES, V1, P201, DOI 10.1177/1461445699001002004
   Tracy K, 2010, PRAG BEYOND NEW SER, V196, P145
NR 31
TC 1
Z9 1
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD APR 15
PY 2022
VL 37
IS SUPPL 1
BP 99
EP 104
DI 10.1007/s11606-021-07062-3
EA SEP 2021
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 0L3EW
UT WOS:000702178800002
PM 34591265
DA 2026-01-16
ER

PT J
AU Han, G
   Lee, YS
   Jang, HJ
   Kim, SY
   Lee, YJ
   Ha, IH
AF Han, Gajin
   Lee, Ye-Seul
   Jang, Hee Jae
   Kim, Song-Yi
   Lee, Yoon Jae
   Ha, In-Hyuk
TI Symptom Management and Quality of Life of Breast Cancer Patients Using
SO Cancers
LA English
DT Journal Article
DE acupuncture; anticancer treatment; breast cancer; herbal medicine; scoping review; side effects
AB The side effects associated with breast cancer treatments often reduce the  patients' quality of life. The effectiveness of acupuncture-related therapies and  herbal medicine in managing the side effect is not fully understood. The study  included clinical studies published in the 10 years since 2011 and analyzed the  effectiveness of the therapies for managing side effects of anticancer treatment.  The databases of MEDLINE via PubMed, CENTRAL, EMBASE, OASIS, and NSDL were  searched. Thirty studies, including 13 (43.3%) randomized controlled trials  (RCTs), 12 (40.0%) before-and-after studies, three (10.0%) case series, one  (3.3%) case report, and one (3.3%) non-RCT, were included in this review. The  main symptoms identified were aromatase inhibitors-induced arthralgia (AIA),  lymphedema, and chemotherapy-induced peripheral neuropathy (CIPN). The types of  acupuncture-related therapies applied included manual acupuncture,  electro-acupuncture, moxibustion, and electro-moxibustion. In ten studies, eight  herbal medications were administered. The Brief Pain Inventory-Short Form  (BPI-SF) and Functional Assessment of Cancer Therapy-General (FACT-G) and -Breast  (FACT-B) were frequently used to evaluate pain and QoL, respectively. Most  studies suggested beneficial effects of acupuncture and herbal medicine on  managing pain, daily function, and quality of life in patients going through AIA,  CIPN, and/or lymphedema, with mild side effects. The scoping review implies the  potential of CAM therapies as promising interventions for managing symptoms which  otherwise lack alternative management options, and for improving the quality of  life of breast cancer patients.
C1 JINRESEARCH, Namyangju 12113, Korea.
   Kyung Hee Sweet & Sunny Korean Medicine Clinic, Namyangju 12113, Korea.
   Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 06110, Korea.
   Kyung Hee Yakson Korean Medicine Clinic, Suwon 16393, Korea.
   Department of Anatomy and Acupoint, College of Korean Medicine, Gachon University, Seongnam 13120, Korea.
   Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 06110, Korea.
   Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul 06110, Korea.
NR 0
TC 0
SN 2072-669
EI 2072-669
J9 Cancers (Basel)
PD OCT 15
PY 2022
VL 14
IS 19
BP 
EP 
DI 10.3390/cancers14194683
PG 0
UT PubMed:36230606
PM 36230606
DA 2022-10-15
ER

PT J
AU Ben-Arye, E
   Zohar, S
   Keshet, Y
   Gressel, O
   Samuels, N
   Eden, A
   Vagedes, J
   Kassem, S
AF Ben-Arye, Eran
   Zohar, Shaked
   Keshet, Yael
   Gressel, Orit
   Samuels, Noah
   Eden, Arieh
   Vagedes, Jan
   Kassem, Sameer
TI Sensing the lightness: a narrative analysis of an integrative medicine program for healthcare providers in the COVID-19 department
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE COVID-19; Integrative medicine; Pain; Burnout; Palliative care; Narrative-based medicine
ID well-being mycaw; yourself concerns; burnout; professionals; anxiety; stress
AB Objectives The research addressing physical and emotional exhaustion among healthcare providers (HCPs) in COVID-19 departments is limited. We examined the impact of integrative medicine (IM) intervention for HCPs working in isolated COVID-19 in-patient departments, addressing concerns and well-being. Methods HCPs working in 3 isolated COVID-19 in-patient departments underwent 40-min IM treatment sessions (including acupuncture, manual movement, and/or mind-body modalities) provided by integrative oncology practitioners. The MYCAW (Measure Yourself Concerns and Well-being) questionnaire examined HCP concerns and free-text narratives following IM treatments. Data were qualitatively analyzed using ATLAS.Ti software for systematic coding. Results A total of 181 HCPs underwent 305 IM treatments. Narrative themes focused on physical symptoms (primarily pain and fatigue) and emotional concerns, including perceived communication barriers with patients, and reflections on well-being and insights following IM treatments. HCPs reported feeling a sense of "relief" which was likely related to the 3 main effects of the IM intervention: a sense of "being cared for" and treated; experiencing emotional, sometimes spiritual effects of the treatment; and the feeling of relaxation, combined with the relief of pain. Qualitative analysis identified clusters of emotional and spiritual-related keywords such as "calming," "release," "relaxation," and "disengagement" following the first IM session (119 of 181 narratives, 65.7%). Conclusions HCPs working in isolated COVID-19 departments reported improved well-being and the addressing of their concerns following IM treatment sessions provided during their work shift. Further research is needed to explore the impact of IM on HCP burnout and resilience in palliative care settings.
C1 [Ben-Arye, Eran; Gressel, Orit] Clalit Hlth Serv, Lin Carmel & Zebulun Med Ctr, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran; Zohar, Shaked; Gressel, Orit; Eden, Arieh; Kassem, Sameer] Technion Israel Inst Technol, Ruth & Bruch Rappaport Fac Med, Haifa, Israel.
   [Keshet, Yael] Western Galilee Acad Coll, Dept Sociol, Galilee, Israel.
   [Samuels, Noah] Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaarei Zedek Med Ctr, Jerusalem, Israel.
   [Eden, Arieh] Lady Davis Carmel Med Ctr, Dept Anesthesiol Crit Care & Pain Med, Haifa, Israel.
   [Vagedes, Jan] ARCIM Inst, Res Inst, Filderstadt, Germany.
   [Vagedes, Jan] Univ Tubingen, Univ Hosp Tuebingen, Dept Neonatol, Tubingen, Germany.
   [Kassem, Sameer] Lady Davis Carmel Med Ctr, Dept Internal Med, Haifa, Israel.
C3 Clalit Health Services; Technion Israel Institute of Technology; Western Galilee Academic College; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit Health Services; Carmel Medical Center; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Clalit Health Services; Carmel Medical Center
RP Ben-Arye, E (corresponding author), Clalit Hlth Serv, Lin Carmel & Zebulun Med Ctr, Integrat Oncol Program, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Technion Israel Inst Technol, Ruth & Bruch Rappaport Fac Med, Haifa, Israel.
EM eranben@netvision.net.il
CR Asghar MS, 2021, AM J TROP MED HYG, V104, P2185, DOI 10.4269/ajtmh.21-0141
   Ben-Arye E, 2021, J CANCER RES CLIN, V147, P2361, DOI 10.1007/s00432-020-03506-1
   Ben-Arye E, 2018, SUPPORT CARE CANCER, V26, P4039, DOI 10.1007/s00520-018-4271-5
   Buran F, 2021, LEGAL MED-TOKYO, V51, P0, DOI 10.1016/j.legalmed.2021.101881
   Damico Vincenzo, 2020, PROF INFERM, V73, P250, DOI 10.7429/pi.2020.734250
   Denning M, 2021, PLOS ONE, V16, P0, DOI 10.1371/journal.pone.0238666
   Dincer B, 2021, EXPLORE-NY, V17, P109, DOI 10.1016/j.explore.2020.11.012
   Georger F, 2020, ANN CARDIOL ANGEIOL (PARIS), V69, P227, DOI 10.1016/j.ancard.2020.09.005
   Gonzales Morgan, 2017, J ADV PRACT ONCOL, V8, P453, DOI 10.6004/jadpro.2017.8.5.1
   Ibar C, 2021, PSYCHONEUROENDOCRINO, V128, P0, DOI 10.1016/j.psyneuen.2021.105213
   Jalili M, 2021, INT ARCH OCC ENV HEA, V94, P1345, DOI 10.1007/s00420-021-01695-x
   Jolliffe R, 2015, INTEGR CANCER THER, V14, P26, DOI 10.1177/1534735414555809
   Keshet Y, 2015, PSYCHO-ONCOLOGY, V24, P169, DOI 10.1002/pon.3621
   Koh MYH, 2020, J PAIN SYMPTOM MANAG, V59, P105, DOI 10.1016/j.jpainsymman.2019.08.008
   Kok N, 2021, CRIT CARE MED, V49, P419, DOI 10.1097/CCM.0000000000004865
   Lou NM, 2021, EVAL HEALTH PROF, V44, P319, DOI 10.1177/01632787211012742
   Marton G, 2020, FRONT PSYCHOL, V11, P0, DOI 10.3389/fpsyg.2020.588762
   Naldi A, 2021, BJPSYCH OPEN, V7, P0, DOI 10.1192/bjo.2020.161
   Nawaz MW, 2020, PSYCHIAT DANUB, V32, P557, DOI 10.24869/psyd.2020.557
   Ng QX, 2020, ASIAN J PSYCHIATR, V54, P0, DOI 10.1016/j.ajp.2020.102258
   Norful AA, 2021, GEN HOSP PSYCHIAT, V69, P20, DOI 10.1016/j.genhosppsych.2021.01.001
   Norkiene I, 2021, INT J ENV RES PUB HE, V18, P0, DOI 10.3390/ijerph18052660
   Paterson C, 2007, COMPLEMENT THER MED, V15, P38, DOI 10.1016/j.ctim.2006.03.006
   Peeters R, 2023, MED CARE RES REV, V80, P266, DOI 10.1177/10775587221118156
   Ripp J, 2020, ACAD MED, V95, P1136, DOI 10.1097/ACM.0000000000003414
   Siddiqui I, 2021, CLIN MED, V21, P66, DOI 10.7861/clinmed.2020-0502
   Stewart NH, 2021, J MED INTERNET RES, V23, P0, DOI 10.2196/27331
   Thimmapuram J, 2021, HOSP PRACT, V49, P194, DOI 10.1080/21548331.2021.1896858
   Vajpeyee M, 2022, INT J SOC PSYCHIATR, V68, P798, DOI 10.1177/00207640211006742
   Zhang XD, 2021, INT ARCH OCC ENV HEA, V94, P1441, DOI 10.1007/s00420-021-01657-3
   Zhang XN, 2021, INT J MENT HEALTH NU, V30, P939, DOI 10.1111/inm.12847
NR 31
TC 6
Z9 7
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD FEB 15
PY 2022
VL 30
IS 2
BP 1419
EP 1426
DI 10.1007/s00520-021-06546-6
EA SEP 2021
PG 8
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA YB0VG
UT WOS:000696140100002
PM 34528124
DA 2026-01-16
ER

PT J
AU Tang, HY
   Chen, XQ
   Wang, H
   Chu, HR
   Zhu, CF
   Huang, S
   Zhang, MT
   Shen, GM
AF Tang, He-Yong
   Chen, Xi-Qiuyu
   Wang, Hao
   Chu, Hao-Ran
   Zhu, Cai-Feng
   Huang, Shun
   Zhang, Meng-Ting
   Shen, Guo-Ming
TI Acupuncture relieves the visceral pain of diarrhea-predominant irritable bowel
SO American journal of translational research
LA English
DT Journal Article
DE IBS-D rat; P2X4; acupuncture; visceral pain
AB OBJECTIVES: We researched the effect and mechanism of acupuncture treatment for  visceral pain in rats with diarrhea-predominant irritable bowel syndrome (IBS-D).  METHODS: We set up a rat model of IBS-D with chemical and chronic- and  acute-pressure stimulations. Then, the IBS-D rats were treated with acupuncture  or 5-BDBD, and the therapeutic efficacy of acupuncture in IBS-D rats was assessed  by means of the Bristol scale, diarrhea index, abdominal withdrawal reflex (AWR)  score, mast cell count and histologic staining. RESULTS: Acupuncture  significantly decreased clinical symptoms in IBS-D rats after a 14 day-treatment.  Furthermore, significant down-regulation of P2X4, OX42, BDNF (brain-derived  neurotrophic factor) and IRF-5 (interferon regulatory factor 5) expressions were  observed in the IBS-D rats, along with the decreased inflammatory factors  [interleukin 1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), and interleukin  6 (IL-6)], chemokines [monocyte chemoattractant protein-1 (MCP-1), regulated on  activation, normal T cell expressed and secreted (RANTES), and C-X-C motif  chemokine ligand 1 (CXCL1)], and neurotransmitters [substance P (SP),  5-hydroxytryptamine (5-HT), and calcitonin gene-related peptide (CGRP)]. 5-BDBD  treatment had a similar effect on IBS-D rats. CONCLUSIONS: Acupuncture can  effectively alleviate abdominal pain by decreasing visceral hypersensitivity and  controlling the expression of P2X4 and spinal microglial inflammation in IBS  rats.
C1 School of Integrated Traditional Chinese and Western Medicine, Anhui University of Traditional Chinese Medicine Hefei 230012, Anhui, China.
   School of Integrated Traditional Chinese and Western Medicine, Anhui University of Traditional Chinese Medicine Hefei 230012, Anhui, China.
   School of Integrated Traditional Chinese and Western Medicine, Anhui University of Traditional Chinese Medicine Hefei 230012, Anhui, China.
   The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine Hefei 230012, Anhui, China.
   The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine Hefei 230012, Anhui, China.
   School of Integrated Traditional Chinese and Western Medicine, Anhui University of Traditional Chinese Medicine Hefei 230012, Anhui, China.
   School of Integrated Traditional Chinese and Western Medicine, Anhui University of Traditional Chinese Medicine Hefei 230012, Anhui, China.
   School of Integrated Traditional Chinese and Western Medicine, Anhui University of Traditional Chinese Medicine Hefei 230012, Anhui, China.
NR 0
TC 0
SN 1943-814
EI 1943-814
J9 Am J Transl Res
PD SEP 16
PY 2022
VL 14
IS 8
BP 5563
EP 5573
DI 
PG 10
UT PubMed:36105029
PM 36105029
DA 2022-09-16
ER

PT J
AU Tang, J
   Sun, ZL
   Wang, Y
   Liu, J
   Wang, S
   Wang, XL
AF Tang, Jie
   Sun, Zhilu
   Wang, Yan
   Liu, Jing
   Wang, Shuai
   Wang, Xilian
TI Effect and Mechanism of Endothelin Receptor A Inhibitor BQ-123 Combined with Electroacupuncture on Tibia Cancer Pain in Rats
SO DISEASE MARKERS
LA English
DT Article
ID bone; model; pi3k/akt; eta
AB Objective. To research the impact and mechanism of endothelin receptor A inhibitor BQ-123 combined with electroacupuncture on tibia cancer pain in rats. Methods. Sprague-Dawley (SD) rats were randomly divided into sham group (SHAM group) and bone cancer pain model group (BCP group). The behavior of SD rats was measured. The histology of the right tibia was observed by hematoxylin-eosin (HE) staining. The remaining rats were randomly divided into model, BQ-123, electroacupuncture, and BQ123+ electroacupuncture group. Behavioral tests were performed, and mechanical pain threshold (MWT) and thermal pain threshold (TWL) were measured. The expressions of alpha-smooth muscle actin (alpha SMA), ETAR (endothelin A receptor), ETB (End of Transmission Block), P-Phosphatidylinositol 3-kinase (PI3K), and P-Protein kinase B (Akt) were detected by real-time fluorescence quantitative PCR and western blot. Results. In the BCP group, bone structure was severely damaged, local tissue swelling was obvious, bone trabecula was missing, and bone cortex was discontinuous. The optical density of Glial fibrillary acidic protein (GFAP) and CD11b immunoreactive signal in BCP group was significantly increased, and most of the ETAR of endothelin receptor was comapped with NeuN, and a small part of GFAP was comapped with CD11b, but no comapped with CD11b. The AS score of BQ-123+ electroacupuncture group was significantly lower than that of BQ-123 group and electroacupuncture group (P < 0.05), whereas the MWT and TWL values were significantly higher than that of the BQ-123 group and electroacupuncture group (P < 0.05). The mRNA expression of alpha-SMA and ETAR in BQ-123+ electroacupuncture group was lower than that in BQ-123 and electroacupuncture group, and the protein expression of P-PI3K and P-Akt in BQ123+ electroacupuncture group was lower as well. Conclusion. BQ-123 may inhibit the activation of PI3K/Akt signal path combined with electroacupuncture to alleviate the effects of tibia cancer pain in rats.
C1 [Tang, Jie; Wang, Xilian] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Pain, Hengyang 421001, Peoples R China.
   [Sun, Zhilu] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Emergency, Hengyang 421001, Peoples R China.
   [Wang, Yan] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Pathol, Hengyang 421001, Peoples R China.
   [Liu, Jing] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Rehabil, Hengyang 421001, Peoples R China.
   [Wang, Shuai] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Hand Foot Surg, Hengyang 421001, Peoples R China.
C3 University of South China; University of South China; University of South China; University of South China; University of South China
RP Wang, XL (corresponding author), Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Pain, Hengyang 421001, Peoples R China.
EM 84093678@qq.com; 18673413301m0@sina.cn; 1009427308@qq.com; liujing724@163.com; 469969060@qq.com; 2018011762@usc.edu.cn
FU Natural Science Youth Foundation of Hunan [2021JJ40500]; Project of Hunan Provincial Health Commission [20200410]; Project of Education Department of Hunan Province [20C1613]
CR Bao YJ, 2015, J MOL NEUROSCI, V55, P706, DOI 10.1007/s12031-014-0409-1
   Benigni A, 2004, EXPERT OPIN INV DRUG, V13, P1419, DOI 10.1517/13543784.13.11.1419
   Bian JH, 2016, SAUDI PHARM J, V24, P354, DOI 10.1016/j.jsps.2016.04.017
   BIGAUD M, 1992, BRIT J PHARMACOL, V107, P912, DOI 10.1111/j.1476-5381.1992.tb13385.x
   Chiou CS, 2012, PAIN, V153, P2097, DOI 10.1016/j.pain.2012.06.031
   DAntoni S, 2017, NEUROTOX RES, V32, P58, DOI 10.1007/s12640-017-9711-3
   Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479
   Forner S, 2016, NEUROSCI LETT, V617, P14, DOI 10.1016/j.neulet.2016.02.005
   Goblirsch M, 2005, RADIAT RES, V164, P400, DOI 10.1667/RR3439.1
   Guedon JMG, 2016, PAIN, V157, P1239, DOI 10.1097/j.pain.0000000000000514
   Hang LH, 2016, NEUROCHEM RES, V41, P1200, DOI 10.1007/s11064-015-1815-7
   He XT, 2020, J NEUROINFLAMM, V17, P0, DOI 10.1186/s12974-020-01740-5
   Jiang B, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735421995237
   KAWAKAMI M, 1994, SPINE, V19, P1780, DOI 10.1097/00007632-199408150-00001
   Ke CB, 2017, MOL NEUROBIOL, V54, P295, DOI 10.1007/s12035-015-9564-9
   Liu Y, 2014, HERALD MED, V22, P276
   Luger NM, 2002, PAIN, V99, P397, DOI 10.1016/S0304-3959(02)00102-1
   Lv BY, 2017, MOL NEUROBIOL, V54, P2380, DOI 10.1007/s12035-017-0464-z
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7
   Menéndez L, 2003, BRAIN RES, V969, P102, DOI 10.1016/S0006-8993(03)02284-4
   Mercadante S, 2016, ACTA ONCOL, V55, P129, DOI 10.3109/0284186X.2015.1073351
   Ozturk A, 2016, W INDIAN MED J, V31, P119
   Ozturk A, 2016, W INDIAN MED J, V11, P1239
   Wu DW, 2018, AM J CHINESE MED, V46, P1187, DOI 10.1142/S0192415X18500623
   Xiao WF, 2016, ONCOTARGET, V7, P52104, DOI 10.18632/oncotarget.10524
   Zhong WF, 2016, ONCOL LETT, V12, P2894, DOI 10.3892/ol.2016.4989
   Zhou YQ, 2018, REDOX BIOL, V14, P391, DOI 10.1016/j.redox.2017.10.011
NR 27
TC 2
Z9 4
U1 1
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0278-0240
EI 1875-8630
J9 DIS MARKERS
JI Dis. Markers
PD MAY 17
PY 2022
VL 2022
IS 
BP 
EP 
DI 10.1155/2022/8563202
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology
GA 3G2QD
UT WOS:000831199500002
PM 35620269
DA 2026-01-16
ER

PT J
AU Luna, AL
   González, JA
   Guardo, LL
   Castro, NP
AF Luna, Alma Luz
   Gonzalez, Jaime Andres
   Guardo, Linda Lucia
   Castro, Nerlis Pajaro
TI CyberKnife Radiosurgery for refractory bilateral trigeminal neuralgia. Case report
SO COLOMBIA MEDICA
LA English
DT Article
DE Radiosurgery; rhizotomy; microvascular decompression surgery; microsurgery; robotic surgical procedures; intractable pain; trigeminal neuralgia
ID microvascular decompression
AB Case description: A case of a 37-year-old female patient suffering from refractory bilateral trigeminal neuralgia is presented, who underwent various interventions such as acupuncture, block therapies and even microvascular decompression without effective pain relief.Clinical findings: Paresthesias and shooting-like twinges of pain intensity 10/10 in bilateral maxillary and mandibular branches of the trigeminal nerve, with nasal and intraoral triggers that made eating impossible, becoming increasingly severe since refractoriness to microvascular decompression and carbamazepine, triggering the twinges even during sleep, generating somnolence, depressive mood and social isolation.Treatment and results: The patient was evaluated by an interdisciplinary neuro-oncology team, where, in accordance with the analysis of the brain magnetic resonance imaging and the patient's history, it was indicated to perform Cyberknife (R) radiosurgery in monofraction on the left trigeminal and subsequently treat the contralateral trigeminal. When treated with Cyberknife (R) radiosurgery, the patient reported absolute improvement in her pain for 2 years.Clinical relevance: Radiosurgery by CyberKnife is not yet the first line of management in trigeminal neuralgia, however, it should be considered since several studies have managed to demonstrate an increase in the quality of life of patients and pain relief in refractory or severe cases. of said pathology.
C1 [Luna, Alma Luz; Gonzalez, Jaime Andres; Guardo, Linda Lucia; Castro, Nerlis Pajaro] Univ Sucre, Fac Ciencias Salud, Grp Ciencias Med & Farmaceut, Sincelejo, Colombia.
   [Luna, Alma Luz] Clin Las Penitas, Sincelejo, Colombia.
   [Gonzalez, Jaime Andres] Clin Santa Maria, Sincelejo, Colombia.
   [Guardo, Linda Lucia] Clin FOSCAL Int, Floridablanca, Colombia.
RP Castro, NP (corresponding author), Univ Sucre, Fac Ciencias Salud, Grp Ciencias Med & Farmaceut, Sincelejo, Colombia.
EM nerlis.pajaro@unisucre.edu.co
CR Alcantara Montero A, 2016, SEMERGEN, V42, P244, DOI 10.1016/j.semerg.2015.09.007
   Arnold M, 2018, CEPHALALGIA, V38, P1, DOI 10.1177/0333102417738202
   Berti A, 2018, CUREUS J MED SCIENCE, V10, P0, DOI 10.7759/cureus.2598
   Calcerrada N, 2005, EFECTIVIDAD SEGURID, V1st, P0
   Campero Alvaro, 2014, SURG NEUROL INT, V5, PS441, DOI 10.4103/2152-7806.142794
   Chumpitaz CV, 2014, ODONTOL SANMARQUINA, V16, P44, DOI 10.15381/os.v16i1.5379
   Fleetwood IG, 2001, J NEUROSURG, V95, P513, DOI 10.3171/jns.2001.95.3.0513
   Chaves JPG, 2021, ARQ NEURO-PSIQUIAT, V79, P51, DOI 10.1590/0004-282X-anp-2020-0115
   Green TH, 2019, J PAIN PALLIAT CARE, V33, P32, DOI 10.1080/15360288.2019.1624676
   Ho CC, 2020, NEURALGIA TRIGEMINA, V0, P0
   Lakshman Vijay Bhaskar, 2019, ASIAN J NEUROSURG, V14, P978, DOI 10.4103/ajns.ajns_53_18
   Li Y, 2019, J PAIN RES, V12, P1937, DOI 10.2147/JPR.S203141
   Liao JJ, 1997, SURG NEUROL, V47, P562, DOI 10.1016/S0090-3019(96)00250-9
   Merskey H, 1994, CLASSIFICATION CHRON, V2nd, P0
   Mora Díaz I, 2013, REV. SOC. ESP. DOLOR, V20, P161, DOI 10.4321/s1134-80462013000400003
   Romanelli P, 2019, CUREUS J MED SCIENCE, V11, P0, DOI 10.7759/cureus.6014
   Sanchez Arriaran Shery Lane, 2020, GAC MED BOL, V43, P67, DOI 10.47993/gmb.v43i1.21
   Serrano-Rubio AA, 2014, REV NEUROLOGIA, V59, P249, DOI 10.33588/rn.5906.2014177
   Tavakol S, 2020, OPER NEUROSURG, V18, P571, DOI 10.1093/ons/opz311
   Tian CL, 2020, NEUROSURGERY, V86, PE353, DOI 10.1093/neuros/nyz461
NR 20
TC 0
Z9 0
U1 0
U2 4
PU CORPORACION EDITORA MEDICA VALLE
PI CALI
PA UNIV VALLE, BLDG 118 FACULTY HEALTH, CALLE 4B 36-00, CALI, 00000, COLOMBIA
SN 1657-9534
EI 
J9 COLOMB MEDICA
JI Colomb. Medica
PD JUN 15
PY 2022
VL 53
IS 4
BP 
EP 
DI 10.25100/cm.v53i4.5283
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA G9ZM8
UT WOS:000992652100001
PM 37287585
DA 2026-01-16
ER

PT J
AU Kutcher, AM
   LeBaron, VT
AF Kutcher, Anna M.
   LeBaron, Virginia T.
TI Evaluating Acupuncture for the Treatment of Chemotherapy-induced Peripheral Neuropathy: An Integrative Review
SO WESTERN JOURNAL OF NURSING RESEARCH
LA English
DT Review
DE acupuncture; electro-acupuncture; chemotherapy-induced peripheral neuropathy; integrative oncology; cancer; integrative review
ID electroacupuncture; cancer; prevention; management; survivors; efficacy; oncology; trial; risk
AB The purpose of this integrative review of the literature is to synthesize the current evidence and identify gaps in knowledge regarding the effectiveness of acupuncture to treat chemotherapy-induced peripheral neuropathy (CIPN). PubMed, CINAHL, Web of Science, and Cochrane Review databases were searched using inclusion criteria: keywords acupuncture, cancer, and peripheral neuropathy, published in English, between 2009 and 2019. Sixteen articles met the inclusion criteria. The literature indicates that acupuncture is generally well tolerated by patients with cancer, and a majority of patients with CIPN reported decreased pain and increased quality of life after receiving acupuncture treatment. A comprehensive understanding of the ability of acupuncture to treat CIPN is limited by variability of acupuncture techniques and inconsistency in measures of evaluation.
C1 [Kutcher, Anna M.; LeBaron, Virginia T.] Univ Virginia, Sch Nursing, 225 Jeanette Lancaster Way, Charlottesville, VA 22903 USA.
C3 University of Virginia
RP Kutcher, AM (corresponding author), Univ Virginia, Sch Nursing, 225 Jeanette Lancaster Way, Charlottesville, VA 22903 USA.
EM amn7r@virginia.edu
CR Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Baviera AF, 2019, REV LAT-AM ENFERM, V27, P0, DOI 10.1590/1518-8345.2959.3126
   Ben-Arye E, 2018, INT J GYNECOL CANCER, V28, P1045, DOI 10.1097/IGC.0000000000001246
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Franconi G, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/516916
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Hammond EA, 2019, NEUROREHAB NEURAL RE, V33, P792, DOI 10.1177/1545968319860486
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hopia H, 2016, SCAND J CARING SCI, V30, P662, DOI 10.1111/scs.12327
   Jeong YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5367014
   Kaptchuk TJ, 2010, CHIN J INTEGR MED, V16, P197, DOI 10.1007/s11655-010-0197-x
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Li A, 2011, SPINE, V36, P181, DOI 10.1097/BRS.0b013e3181e15ef8
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu ZX, 2017, J ALTERN COMPLEM MED, V23, P964, DOI 10.1089/acm.2017.0052
   Maeda Y, 2017, BRAIN, V140, P914, DOI 10.1093/brain/awx015
   Mandiroglu S, 2014, ACUPUNCT MED, V32, P194, DOI 10.1136/acupmed-2013-010491
   Molassiotis A, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5302-4
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Song SJ, 2017, SUPPORT CARE CANCER, V25, P2241, DOI 10.1007/s00520-017-3631-x
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Starobova H, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00174
   Tofthagen CS, 2020, CURR ONCOL REP, V22, P0, DOI 10.1007/s11912-020-00903-0
   Valentine-Davis B, 2015, MED ACUPUNCT, V27, P216, DOI 10.1089/acu.2015.1103
   Whittemore R, 2005, J ADV NURS, V52, P546, DOI 10.1111/j.1365-2648.2005.03621.x
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Xiong ZF, 2016, WORLD J ACUPUNCT-MOX, V26, P20, DOI 10.1016/S1003-5257(17)30005-3
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
   Zhi WI, 2018, INTEGR CANCER THER, V17, P1079, DOI 10.1177/1534735418788667
   Zhou W, 2014, J ACUPUNCT MERIDIAN, V7, P190
   Zhuang Y, 2013, INT REV NEUROBIOL, V111, P1, DOI 10.1016/B978-0-12-411545-3.00001-8
NR 42
TC 10
Z9 11
U1 2
U2 28
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0193-9459
EI 1552-8456
J9 WESTERN J NURS RES
JI West. J. Nurs. Res.
PD FEB 15
PY 2022
VL 44
IS 2
BP 169
EP 179
DI 10.1177/0193945921992538
EA FEB 2021
PG 11
WC Nursing
SC Nursing
GA YJ5CV
UT WOS:000626207200001
PM 33559535
DA 2026-01-16
ER

PT J
AU Wang, FQ
   Zhao, JN
   Li, YJ
   Yang, X
   Wu, D
   Yang, B
   Zhang, CK
   He, ZX
   Du, L
   Zhu, XD
   Ming, D
   Liu, Y
   Tang, DX
AF Wang, Feiqing
   Zhao, Jianing
   Li, Yanju
   Yang, Xu
   Wu, Dan
   Yang, Bo
   Zhang, Chike
   He, Zhixu
   Du, Liang
   Zhu, Xiaodong
   Ming, Dong
   Liu, Yang
   Tang, Dongxin
TI Acupuncture and acupressure with improved cancer-related depression of retrospective studies
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE acupuncture; acupressure; acupoints; cancer; tumor; oncology; depression
ID quality-of-life; clinical-trials; placebo; anxiety; instrument; mortality; nocebo; care; pain
AB IntroductionAcupuncture and acupressure are widely used for treating cancer pain and depression and recognized as safe and effective by the international medical community. In this study, we systematically evaluated the efficacy, safety, and clinical significance of acupuncture and acupressure in treating cancer-related depression. MethodsWe searched MEDLINE, PubMed, Science Direct, Google Scholar, Web of Science and Embase and Chinese-language databases for randomized clinical trials (RCTs). To assess efficacy, rating scales administered by clinicians or experts were preferred, including the Hamilton Depression Rating Scale (HAMD), Self-rating Depression Scale (SDS), Self-rating Anxiety Scale (SAS), and Quality of Life Questionnaire-Core 30 (QLQ-C30) and the total effective rate after treatment. In all, Sixteen RCTs involving 1019 cancer patients were included in the Meta-analysis. ResultsEleven (69%) of these studies reported the post-treatment total effective rate. Three hundred fifty-three patients received antidepressants; the total effective rate was 72.5%. Three hundred sixty-one patients underwent acupuncture and acupressure; the total effective rate was 90%. Meta-analysis results showed I-2 = 0%, no heterogeneity, (Z = 5.84, p < 0.00001); and combined OR = 3.55, (95% CI = 2.32 to 5.43). DiscussionThis study found that acupuncture and acupressure are as effective as medication in the treatment of cancer-related depression, provide a reliable basis for the clinical use of acupuncture to treat cancer-related depression, help promote nonpharmacological treatment for cancer-related complications. These approaches thus help reduce drug resistance and adverse reactions and improve patients' quality of life.
C1 [Wang, Feiqing; Zhao, Jianing; Yang, Xu; Wu, Dan; Yang, Bo; Liu, Yang; Tang, Dongxin] Guizhou Univ Tradit Chinese Med, Clin Med Res Ctr, Affiliated Hosp 1, Guiyang, Guizhou, Peoples R China.
   [Wang, Feiqing; Zhu, Xiaodong; Ming, Dong] Tianjin Univ, Acad Med Engn & Translat Med, Tianjin, Peoples R China.
   [Li, Yanju; Zhang, Chike; He, Zhixu] Guizhou Med Univ, Dept Hematol Oncol, Affiliated Hosp, Guiyang, Guizhou, Peoples R China.
   [He, Zhixu; Liu, Yang] Guizhou Med Univ, Chinese Acad Med Sci, Key Lab Adult Stem Cell Translat Res, Guiyang, Guizhou, Peoples R China.
   [Du, Liang] Sichuan Univ, West China Hosp, Chinese Evidence Based Med Ctr, Chengdu, Peoples R China.
   [Zhu, Xiaodong] Tianjin Med Univ, Gen Hosp, Neurol Inst, Tianjin, Peoples R China.
C3 Guizhou University of Traditional Chinese Medicine; Tianjin University; Guizhou Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Guizhou Medical University; Sichuan University; Tianjin Medical University
RP Liu, Y; Tang, DX (corresponding author), Guizhou Univ Tradit Chinese Med, Clin Med Res Ctr, Affiliated Hosp 1, Guiyang, Guizhou, Peoples R China.; Zhu, XD; Ming, D (corresponding author), Tianjin Univ, Acad Med Engn & Translat Med, Tianjin, Peoples R China.; Liu, Y (corresponding author), Guizhou Med Univ, Chinese Acad Med Sci, Key Lab Adult Stem Cell Translat Res, Guiyang, Guizhou, Peoples R China.; Zhu, XD (corresponding author), Tianjin Med Univ, Gen Hosp, Neurol Inst, Tianjin, Peoples R China.
EM zxdtju@163.com; mindtju@126.com; ly7878@163.com; tangdongxintcm@163.com
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Unknown -, 2002, WORLD HLTH ORGAN TEC, V912, P1
   Arrieta O, 2013, ANN SURG ONCOL, V20, P1941, DOI 10.1245/s10434-012-2793-5
   Astudillo O, 2012, LANCET ONCOL, V13, P976, DOI 10.1016/S1470-2045(12)70420-5
   Benedetti F, 2016, LANCET NEUROL, V15, P736, DOI 10.1016/S1474-4422(16)00066-1
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Chen J, 2018, ELECT J CLIN MED LIT, V5, P50, DOI 10.16281/j.cnki.jocml.2018.66.026
   Chua IS, 2019, JAMA ONCOL, V5, P734, DOI 10.1001/jamaoncol.2019.0042
   Clark SD, 2019, EXPLORE-NY, V15, P61, DOI 10.1016/j.explore.2018.07.006
   Colleoni M, 2000, LANCET, V356, P1326, DOI 10.1016/S0140-6736(00)02821-X
   Colloca L, 2020, NEW ENGL J MED, V382, P554, DOI 10.1056/NEJMra1907805
   Deng XY, 2018, ZHEJIANG ZHONG YI YA, V42, P748, DOI 10.16466/j.issn1005-5509.2018.09.018
   Deng XY, 2019, THESIS NANJING U NAN, V0, P0
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Fan L, 2016, J TRADIT CHIN MED, V36, P151
   Feng Y, 2011, J TRADIT CHIN MED, V31, P199, DOI 10.1016/S0254-6272(11)60042-3
   Fervaha G, 2019, UROL ONCOL-SEMIN ORI, V37, P282, DOI 10.1016/j.urolonc.2018.12.020
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Han JF, 2017, THESIS SHANDONG U JI, V0, P0
   HAN JS, 1982, ANNU REV PHARMACOL, V22, P193, DOI 10.1146/annurev.pa.22.040182.001205
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Jacobsen PB, 2008, CA-CANCER J CLIN, V58, P214, DOI 10.3322/CA.2008.0003
   Kim Y, 2010, PSYCHO-ONCOLOGY, V19, P431, DOI 10.1002/pon.1576
   Li WH, 2019, THESIS GUANGZHOU U G, V0, P0
   Liu G, 2016, ASIA PACIFIC TRADIT, V12, P112
   Liu YP, 2019, SHANGHAI J ACUPUNCT, V38, P417, DOI 10.13460/J.ISSN.1005-0957.2019.04.0417
   [吕晓皑 Lv Xiaoai], 2015, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V35, P447
   MacPherson H, 2001, ACUPUNCT MED, V19, P93
   MacPherson Hugh, 2005, ACUPUNCT MED, V23, P112
   Magovern PM, 1996, ACUPUNCT MED, V14, P51, DOI 10.1097/01.ajp.0000125265.40304.c5
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071
   Mitchell AJ, 2011, LANCET ONCOL, V12, P160, DOI 10.1016/S1470-2045(11)70002-X
   Mittleman E, 2000, J AM VET MED ASSOC, V217, P1201, DOI 10.2460/javma.2000.217.1201
   Ostuzzi G, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011006.pub3
   Paley CA, 2020, MEDICINA-LITHUANIA, V56, P0, DOI 10.3390/medicina56010006
   Pei Y, 2010, CHIN J INF TRADIT CH, V17, P62
   Pinquart M, 2010, PSYCHOL MED, V40, P1797, DOI 10.1017/S0033291709992285
   Prieto JM, 2002, J CLIN ONCOL, V20, P1907, DOI 10.1200/JCO.2002.07.101
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Satin JR, 2009, CANCER-AM CANCER SOC, V115, P5349, DOI 10.1002/cncr.24561
   Sharfstein JM, 2019, JAMA-J AM MED ASSOC, V322, P809, DOI 10.1001/jama.2019.9794
   Shim EJ, 2012, INT J PSYCHIAT MED, V43, P381, DOI 10.2190/PM.43.4.g
   Smith CA, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004046.pub4
   Stewart DE, 2016, NEW ENGL J MED, V375, P2177, DOI 10.1056/NEJMcp1607649
   Tick H, 2018, EXPLORE-NY, V14, P177, DOI 10.1016/j.explore.2018.02.001
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1
   Walker J, 2014, LANCET PSYCHIAT, V1, P343, DOI 10.1016/S2215-0366(14)70313-X
   Wang HJ, 2018, J PRA GYNECOL ENDOCR, V5, P134, DOI 10.16484/j.cnki.issn2095-8803.2018.36.091
   Wang YJ, 2017, CHIN NURS RES, V31, P731
   Wen CY, 1998, CANCER, V17, P237
   White A, 2004, RHEUMATOLOGY, V43, P662, DOI 10.1093/rheumatology/keg005
   World Health Organization, 2013, IMPL WHO TRAD MED ST, V0, P0
   Xia Q, 2017, J MOD NOCOL, V25, P3506
   Xiao Bin, 2014, ZHONGGUO ZHEN JIU, V34, P956
   Yan JX, 2019, DOCTOR, V4, P88
   Zeng XL, 2015, THESIS GUANGZHOU U G, V0, P0
   Zhu JF, 2018, HERALD MED, V37, P1198, DOI 10.3870/J.ISSN.1004-0781.2018.10.011
   ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 66
TC 7
Z9 12
U1 3
U2 26
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD DEC 12
PY 2022
VL 12
IS 
BP 
EP 
DI 10.3389/fonc.2022.1036634
PG 12
WC Oncology
SC Oncology
GA 7F5XT
UT WOS:000901920700001
PM 36578922
DA 2026-01-16
ER

PT J
AU Xu, Z
   Wang, X
   Wu, Y
   Wang, C
   Fang, X
AF Xu, Zhonghang
   Wang, Xingbo
   Wu, Yuanyu
   Wang, Chengbing
   Fang, Xuedong
TI The effectiveness and safety of acupuncture for chemotherapy-induced peripheral
SO Frontiers in neurology
LA English
DT Journal Article
DE acupuncture; chemotherapy-induced peripheral neuropathy; meta-analysis; physiotherapy; systematic review
AB OBJECTIVES: This systematic review and meta-analysis aimed to evaluate the  effectiveness and safety of acupuncture on chemotherapy-induced peripheral  neuropathy (CIPN). METHODS: We searched for relevant randomized controlled trials  (RCTs) in PubMed, Cochrane Library, and Embase databases from their inception to  1 April 2022. The Functional Assessment of Cancer Therapy/Gynecologic Oncology  Group-Neurotoxicity (FACT/GOG-Ntx), Brief Pain Inventory-Short Form (BPI-SF), the  European Organisation for Research and Treatment of Cancer Quality of Life  Questionnaire-Core30 (EORTC QLQ-C30), Numerical Rating Scale (NRS), and adverse  events were the outcome measures. All studies had at least one of these outcome  measures. Mean differences (MDs) with 95% confidence intervals (CIs) were  assessed in the meta-analysis using the RevMan 5.3 software. RESULTS: Five  studies were included in the analysis. The results showed that acupuncture and  placebo acupuncture were not significantly different in reducing  chemotherapy-induced neurotoxicity and functional disability (random-effects  estimates; MD: 4.30; 95% CI: -0.85~9.45; P = 0.10; I(2) = 74%). Acupuncture was  better than placebo acupuncture in reducing pain severity and pain interference  with patients' daily function (fixed-effect estimates; MD: -1.14; 95% CI: 1.87 to  -0.42; P = 0.002; I(2) = 13%). Acupuncture was not significantly different from  placebo acupuncture in relieving CIPN symptoms (MD: -0.81; 95% CI: -2.02 to 0.40,  P = 0.19). Acupuncture improved quality of life better than placebo acupuncture  (MD: 10.10; 95% CI: 12.34 to 17.86, P = 0.01). No severe adverse events were  recorded in all five studies. CONCLUSION: This meta-analysis suggests that  acupuncture may be more effective and safer in reducing pain severity and pain  interference with patients' daily function than placebo acupuncture.  Additionally, acupuncture may improve the quality of life of patients with CIPN.  However, large sample size studies are needed to confirm this conclusion.  SYSTEMATIC REVIEW REGISTRATION:  https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=324930,  identifier: CRD42022324930.
C1 China-Japan Union Hospital of Jilin University, Jilin University, Changchun, China.
   China-Japan Union Hospital of Jilin University, Jilin University, Changchun, China.
   China-Japan Union Hospital of Jilin University, Jilin University, Changchun, China.
   China-Japan Union Hospital of Jilin University, Jilin University, Changchun, China.
   China-Japan Union Hospital of Jilin University, Jilin University, Changchun, China.
NR 0
TC 0
SN 1664-229
EI 1664-229
J9 Front Neurol
PD OCT 21
PY 2022
VL 13
IS 
BP 963358
EP 963358
DI 10.3389/fneur.2022.963358
PG 0
UT PubMed:36262831
PM 36262831
DA 2022-10-21
ER

PT J
AU Chu, EC
   Trager, RJ
   Shum, JSF
   Lai, CR
AF Chu, Eric Chun-Pu
   Trager, Robert J
   Shum, John Sing Fai
   Lai, Colin Ritchie
TI Pancoast Tumor Presenting as Neck Pain in the Chiropractic Office: A Case Report
SO The American journal of case reports
LA English
DT Review
AB BACKGROUND Pancoast tumors, also called superior sulcus tumors, are a rare type  of cancer affecting the lung apex. These tumors can spread to the brachial plexus  and spine and present with symptoms that appear to be of musculoskeletal origin.  CASE REPORT A 59-year-old Asian man presented to a chiropractor in Hong Kong with  a 1-month history of neck and shoulder pain and numbness that had been treated  unsuccessfully with exercise, medications, and acupuncture. He had an active  history of tuberculosis, which was currently treated with antibiotics, and a  50-pack-year history of smoking. Cervical magnetic resonance imaging (MRI) was  performed urgently, revealing a small cervical disc herniation thought to  correspond with radicular symptoms. However, as the patient did not respond to a  brief trial of care, a thoracic MRI was urgently ordered, revealing a large  superior sulcus tumor invading the upper to mid-thoracic spine. The patient was  referred for medical care and received radiotherapy and chemotherapy with a  positive outcome. A literature review identified 6 previously published cases in  which a patient presented to a chiropractor with an undiagnosed Pancoast tumor.  All patients had shoulder, spine, and/or upper extremity pain. CONCLUSIONS  Patients with a previously undiagnosed Pancoast tumor can present to  chiropractors given that these tumors may invade the brachial plexus and spine,  causing shoulder, spine, and/or upper extremity pain. Chiropractors should be  aware of the clinical features and risk factors of Pancoast tumors to readily  identify them and refer such patients for medical care.
C1 New Chiropractic and Physiotherapy Centre, EC Healthcare, Hong Kong, Hong Kong.
   Connor Whole Health, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
   Hong Kong Advanced Imaging, EC Healthcare, Hong Kong, Hong Kong.
   New Chiropractic and Physiotherapy Centre, EC Healthcare, Hong Kong, Hong Kong.
NR 0
TC 0
SN 1941-592
EI 
J9 Am J Case Rep
PD JUL 8
PY 2022
VL 23
IS 
BP e937052
EP e937052
DI 10.12659/AJCR.937052
PG 1
WC Brachial Plexus; Chiropractic; Humans; Intervertebral Disc Displacement; Male; Middle Aged; Neck Pain; Pancoast Syndrome; diagnosis
UT PubMed:35797264
PM 35797264
DA 2022-07-08
ER

PT J
AU Yan, Z
   MuRong, Z
   Huo, B
   Zhong, H
   Yi, C
   Liu, M
   Liu, M
AF Yan, Zhaobo
   MuRong, Zhimiao
   Huo, Bixiu
   Zhong, Huan
   Yi, Chun
   Liu, Mailan
   Liu, Mi
TI Acupuncture as a Complementary Therapy for Cancer-Induced Bone Pain: A Systematic
SO Frontiers in pain research (Lausanne, Switzerland)
LA English
DT Journal Article
DE a systematic review; acupuncture; cancer pain; cancer-induced bone pain; meta-analysis
AB BACKGROUND: Cancer-induced bone pain (CIBP) is a special type of cancer pain and  lacks safe and effective treatments. Acupuncture is a potentially valuable  treatment for CIBP, studies evaluating the effect of acupuncture on CIBP have  increased significantly, but the safety and efficacy of acupuncture to control  CIBP remains controversial. OBJECTIVE: To provide the first meta-analysis to  evaluate the safety and efficacy of acupuncture in CIBP management. DATA SOURCES:  CNKI, CBM, Wanfang, VIP Database, PubMed, Embase, and Cochrane Library were  searched from their inception until 1 June 2022. STUDY SELECTION: RCTs with  primary bone tumor patients or other types of primary cancer companied by bone  metastases as the research subjects and to evaluate the efficacy of acupuncture  treatment alone or combined with the control treatment were included. Meanwhile,  RCTs should choose the pain score as the primary outcome and pain relief rate,  frequency of breakthrough pain, analgesic onset time, analgesia duration, quality  of life, and adverse events as reference outcomes. DATA COLLECTION AND ANALYSIS:  We designed a data-extraction form that was used to extract key information from  the articles. Data extraction study evaluation was conducted independently by two  reviewers, and a third reviewer would resolve any disagreements. The risk of bias  was assessed by the Cochrane Collaboration's tool for assessing the risk bias.  The quality of the evidence for main outcomes was evaluated by the GRADE system.  Mean differences (MD), relative risk (RR), and 95% confidence intervals (CIs)  were calculated. The forest plots were performed using the Review Manager  Software (5.3 version). Subgroup analysis was used to investigate the possible  sources of potential heterogeneity. Descriptive analysis was performed in case of  unacceptable clinical heterogeneity. RESULTS: Thirteen RCTs (with 1,069 patients)  were included, and all studies were at high risk of bias owing to lack of  blinding or other bias. Eleven studies evaluated the effectiveness of acupuncture  as a complementary therapy, and showed that acupuncture plus control treatment  (compared with control treatment) was connected with reduced pain intensity (MD =  -1.34, 95% CI -1.74 to -0.94; Q < 0.1; I (2) = 98%, P < 0.01). Subgroup analyses  based on acupoints type partly explain the potential heterogeneity. The results  also showed that acupuncture plus control treatment (compared with control  treatment) was connected with relieving pain intensity, increasing the pain  relief rate, reducing the frequency of breakthrough pain, shortening analgesic  onset time, extending the analgesic duration, and improving the quality of life.  We have no sufficient evidence to prove the effectiveness of acupuncture alone.  Four RCTs reported only adverse events related to opioids' side effects. Evidence  was qualified as "very low" because of low methodological quality, considerable  heterogeneity, or a low number of included studies. CONCLUSION: Acupuncture has a  certain effect as a complementary therapy on pain management of CIBP, which not  only mitigates the pain intensity but also improves the quality of life and  reduces the incidence of opioids' side effects, although the evidence level was  very low. In future, a larger sample size and rigorously designed RCTs are needed  to provide sufficient evidence to identify the efficacy and safety of acupuncture  as a treatment for CIBP.
C1 College of Acupuncture and Moxibustion, Hunan University of Chinese Medicine, Hunan, China.
   College of Acupuncture and Moxibustion, Hunan University of Chinese Medicine, Hunan, China.
   Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   College of Acupuncture and Moxibustion, Hunan University of Chinese Medicine, Hunan, China.
   Department of Pathology, Hunan University of Chinese Medicine, Hunan, China.
   College of Acupuncture and Moxibustion, Hunan University of Chinese Medicine, Hunan, China.
   College of Acupuncture and Moxibustion, Hunan University of Chinese Medicine, Hunan, China.
NR 0
TC 0
SN 2673-561
EI 2673-561
J9 Front Pain Res (Lausanne)
PD AUG 19
PY 2022
VL 3
IS 
BP 925013
EP 925013
DI 10.3389/fpain.2022.925013
PG 0
UT PubMed:35978992
PM 35978992
DA 2022-08-19
ER

PT J
AU He, Y
   Lu, LY
   Chen, MJ
   Wen, Q
   Li, N
AF He, Ying
   Lu, Ling-Yun
   Chen, Ming-Jin
   Wen, Qian
   Li, Ning
TI [Postoperative ileus after laparotomy for gastrointestinal cancer treated with
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE electroacupuncture; gastrointestinal cancer; gastrointestinal function; postoperative ileus; randomized controlled trial (RCT)
AB OBJECTIVE: To observe the effect of electroacupuncture (EA) on postoperative  ileus after laparotomy for gastrointestinal cancer. METHODS: A total of 90  patients with postoperative ileus after laparotomy for gastrointestinal cancer  were randomized into an EA group and a conventional treatment group, 45 cases in  each one. In the conventional treatment group, the postoperative fast track  surgical regimen was accepted. In the EA group, on the base of the treatment as  the conventional treatment group, acupuncture was applied to Zusanli (ST 36),  Shangjuxu (ST 37), Yinlingquan (SP 9) and Taichong (LR 3) and electric  stimulation was attached on Zusanli (ST 36) and Yinlingquan (SP 9), with  continuous wave, 2 Hz in frequency and 3-5 mA in intensity. Acupuncture was  provided once daily till the onset of postoperative exhaust and defecation. The  first postoperative exhaust time, the first postoperative defecation time, the  postoperative hospital stay and the wound pain under standing on the next morning  after entering group were compared in the patients between the two groups. The  impact of the EA expectation was analyzed on the first postoperative exhaust  time, the first postoperative defecation time and the postoperative hospital stay  separately. RESULTS: The first postoperative exhaust time and the first  postoperative defecation time in the EA group were earlier than the conventional  treatment group (P<0.05), the postoperative hospital stay was shorter than the  conventional treatment group (P<0.05), and the rate of wound pain in the  postoperative standing was lower than the conventional treatment group (P<0.05).  EA expectation had no obvious correlation with the clinical therapeutic effect  (P>0.05). CONCLUSION: EA can relieve postoperative ileus symptoms, alleviate pain  and shorten hospital stay in the patients after laparotomy for gastrointestinal  cancer.
C1 Department of Integrated Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
   Department of Integrated Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
   Department of Integrated Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
   Department of Integrated Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
   Department of Integrated Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JAN 14
PY 2022
VL 42
IS 1
BP 45
EP 8
DI 10.13703/j.0255-2930.20210125-0004
PG -37
WC Acupuncture Points; Electroacupuncture; Gastrointestinal Neoplasms; Humans; Ileus; etiology; Laparotomy; adverse effects
UT PubMed:35025157
PM 35025157
DA 2022-01-14
ER

PT J
AU Zou, X
   Yang, YC
   Wang, Y
   Pei, W
   Han, JG
   Lu, Y
   Zhang, MS
   Tu, JF
   Lin, LL
   Wang, LQ
   Shi, GX
   Yan, SY
   Yang, JW
   Liu, CZ
AF Zou, Xuan
   Yang, Ying-Chi
   Wang, Yu
   Pei, Wei
   Han, Jia-Gang
   Lu, Yun
   Zhang, Mao-Shen
   Tu, Jian Feng
   Lin, Lu Lu
   Wang, Li-Qiong
   Shi, Guangxia
   Yan, Shi-Yan
   Yang, Jing-Wen
   Liu, Cun-Zhi
TI Electroacupuncture versus sham electroacupuncture in the treatment of postoperative ileus after laparoscopic surgery for colorectal cancer: study protocol for a multicentre, randomised, sham-controlled trial
SO BMJ OPEN
LA English
DT Article
DE COMPLEMENTARY MEDICINE; Functional bowel disorders; Gastrointestinal tumours; Endoscopic surgery
ID postprandial distress syndrome; gastrointestinal motility; acupuncture; recovery; pathophysiology; complications; disorders
AB Introduction Postoperative ileus (POI) is an inevitable complication of almost all abdominal surgeries, which results in prolonged hospitalisation and increased healthcare costs. Various treatment strategies have been developed for POI but with limited success. Electroacupuncture (EA) might be a potential therapy for POI. However, evidence from rigorous trials that evaluated the effectiveness of EA for POI is limited. Thus, the aim of this study was to examine whether EA can safely reduce the time to the first defecation after laparoscopic surgery in patients with POI. Methods and analysis This multicentre randomised sham-controlled trial will be conducted in four hospitals in China. A total of 248 eligible participants with colorectal cancer who will undergo laparoscopic surgery will be randomly allocated to an EA group and a sham EA group in a 1:1 ratio. Treatment will be performed starting on postoperative day 1 and continued for four consecutive days, once per day. If the participant is discharged within 4 days after surgery, the treatment will cease on the day of discharge. The primary outcome will be the time to first defecation. The secondary outcome measures will include time to first flatus, tolerability of semiliquid and solid food, length of postoperative hospital stay, postoperative nausea and vomiting, abdominal distension, postoperative pain, postoperative analgesic, time to first ambulation, blinding assessment, credibility and expectancy and readmission rate. Ethics and dissemination Ethics approval was obtained from the Ethics Committee of Beijing University of Chinese Medicine (number 2020BZHYLL0116) and the institutional review board of each hospital. The results will be disseminated through peer-reviewed publications. This study protocol (V.3.0, 6 March 2020) involves human participants and was approved by the ethics committees of Beijing University of Chinese Medicine (number 2020BZHYLL0116), Beijing Friendship Hospital Affiliated to Capital Medical University (number 2020-P2-069-01), Beijing Chao-Yang Hospital Affiliated to Capital Medical University (number 2020-3-11-2), National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (number 20/163-2359), and the Affiliated Hospital of Qingdao University (number QYFYKYLL711311920). The participants gave informed consent to participate in the study before taking part.
C1 [Zou, Xuan; Wang, Yu; Tu, Jian Feng; Lin, Lu Lu; Wang, Li-Qiong; Shi, Guangxia; Yan, Shi-Yan; Yang, Jing-Wen; Liu, Cun-Zhi] Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Beijing, Peoples R China.
   [Zou, Xuan; Wang, Yu; Tu, Jian Feng; Lin, Lu Lu; Wang, Li-Qiong; Shi, Guangxia; Yan, Shi-Yan; Yang, Jing-Wen; Liu, Cun-Zhi] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
   [Yang, Ying-Chi] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China.
   [Pei, Wei] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China.
   [Han, Jia-Gang] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China.
   [Lu, Yun; Zhang, Mao-Shen] Qingdao Univ, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Capital Medical University; Qingdao University
RP Yan, SY; Yang, JW (corresponding author), Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Beijing, Peoples R China.; Yan, SY; Yang, JW (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
EM ysy20200927@163.com; yangjw0626@126.com
FU National Key R&D Program of China [2019YFC1712100]
CR AUN C, 1986, PAIN, V25, P215, DOI 10.1016/0304-3959(86)90095-3
   Bian ZX, 2011, ANN INTERN MED, V154, P290, DOI 10.7326/0003-4819-154-4-201102150-00016
   Brown SR, 2014, ANN SURG, V259, P916, DOI 10.1097/SLA.0000000000000407
   Chapman SJ, 2018, BRIT J SURG, V105, P797, DOI 10.1002/bjs.10781
   Chen JDZ, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13393
   Chen KB, 2019, INT J SURG, V70, P93, DOI 10.1016/j.ijsu.2019.08.034
   Chen L, 2018, CHINESE JOURNAL OF PRACTICAL SURGERY, V38, P1
   Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.17116/hirurgia2018090162
   Doorly MG, 2012, SURG CLIN N AM, V92, P259, DOI 10.1016/j.suc.2012.01.010
   Fang JF, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep39801
   Gkegkes ID, 2020, DIGEST SURG, V37, P22, DOI 10.1159/000496431
   Harnsberger CR, 2019, CLIN COLON RECT SURG, V32, P166, DOI 10.1055/s-0038-1677003
   Horowitz JA, 2018, WORLD NEUROSURG, V115, PE185, DOI 10.1016/j.wneu.2018.04.006
   Hou YQ, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3051-3
   Kim KH, 2016, ACUPUNCT MED, V34, P248, DOI 10.1136/acupmed-2015-010941
   Landrum Laurie, 2006, QUAL MANAG HEALTH CARE, V15, P83
   Li LDT, 2013, J AM GERIATR SOC, V61, P1175, DOI 10.1111/jgs.12307
   Li Y, 2012, CAN MED ASSOC J, V184, P401, DOI 10.1503/cmaj.110551
   Liu YH, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3178472
   Liu ZS, 2017, JAMA-J AM MED ASSOC, V317, P2493, DOI 10.1001/jama.2017.7220
   Ma TT, 2012, ALIMENT PHARM THER, V35, P552, DOI 10.1111/j.1365-2036.2011.04979.x
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Person B, 2006, CURR PROB SURG, V43, P6, DOI 10.1067/j.cpsurg.2005.10.003
   Peters EG, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13862
   Ravikumar R, 2017, BMJ-BRIT MED J, V357, P0, DOI 10.1136/bmj.j1455
   Rollins KE, 2019, ANN SURG, V270, P43, DOI 10.1097/SLA.0000000000003145
   Sen S, 2020, J ORAL REHABIL, V47, P783, DOI 10.1111/joor.12952
   Stakenborg N, 2017, HANDB EXP PHARMACOL, V239, P39, DOI 10.1007/164_2016_108
   Sultan S, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012111.pub2
   Sun DL, 2020, ANN TRANSL MED, V8, P0, DOI 10.21037/atm.2020.01.95
   Tevis SE, 2015, J GASTROINTEST SURG, V19, P1684, DOI 10.1007/s11605-015-2877-1
   van Bree SHW, 2014, ANN SURG, V259, P708, DOI 10.1097/SLA.0b013e318293ee55
   van Bree SHW, 2012, NAT REV GASTRO HEPAT, V9, P675, DOI 10.1038/nrgastro.2012.134
   Venara A, 2016, J VISC SURG, V153, P439, DOI 10.1016/j.jviscsurg.2016.08.010
   Wang HG, 2018, MED SCI MONITOR, V24, P7231, DOI 10.12659/MSM.910817
   Wong ELY, 2011, BMC HEALTH SERV RES, V11, P0, DOI 10.1186/1472-6963-11-149
   Wu ZQ, 2015, EUR SURG RES, V54, P127, DOI 10.1159/000369529
   Xu SB, 2013, CAN MED ASSOC J, V185, P473, DOI 10.1503/cmaj.121108
   Yang JW, 2020, ANN INTERN MED, V172, P777, DOI 10.7326/M19-2880
   Yang NN, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13808
   Yang Y, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep37826
   Yin JY, 2010, AUTON NEUROSCI-BASIC, V157, P31, DOI 10.1016/j.autneu.2010.03.007
   You XM, 2015, MEDICINE, V94, P0, DOI 10.1097/MD.0000000000001968
   Zhang X, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/860631
   Zhao L, 2019, JAMA INTERN MED, V179, P1388, DOI 10.1001/jamainternmed.2019.2407
   Zhou JZ, 2017, NEUROMODULATION, V20, P767, DOI 10.1111/ner.12602
NR 49
TC 4
Z9 6
U1 2
U2 21
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD APR 15
PY 2022
VL 12
IS 4
BP 
EP 
DI 10.1136/bmjopen-2021-050000
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 0O9KM
UT WOS:000783842400023
PM 35428615
DA 2026-01-16
ER

PT J
AU Efverman, A
AF Efverman, Anna
TI Implementation of Acupuncture in Routine Oncology Care: A Comparison of Physicians', Nurses', Physiotherapists' and Acupuncturists' Practice and Beliefs
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE integrative medicine; nursing; integrative oncology; acupuncture; evidence-based care; attitudes; expectations; physiotherapy
ID breast-cancer survivors; alternative medicine; placebo-acupuncture; induced nausea; hot flashes; complementary; chemotherapy; management; efficacy; electroacupuncture
AB Background:It is important to investigate beliefs in acupuncture in professionals because professionals' expectations may affect treatment outcomes. Aim:To document the type, number, and education of professionals practicing acupuncture. Further, to compare beliefs about the effectiveness of acupuncture for common cancer related symptoms in the different types of professionals. Methods:This cross-sectional study employed a questionnaire on practice and beliefs regarding acupuncture effects for symptoms that commonly occur in patients treated within oncology care settings. The respondents (n = 555) consisted of oncology professionals that is, physicians (n = 133), nurses (n = 172), and physiotherapists (n = 117). Additional respondents consisted of acupuncturists (n = 133), working outside approved health care. Results:Of the respondents, acupuncture was practiced by 4% of the physicians, 6% of the nurses, 58% of the physiotherapists, and 90% of the acupuncturists. The professionals believed acupuncture to be effective for pain (of the physicians, nurses, physiotherapists, and acupuncturists, 94%, 98%, 89%, and 99% respectively believed in the effectiveness), chemotherapy-induced nausea (corresponding figures: 74%, 89%, 89%, and 93%), and vasomotor symptoms (corresponding figures: 71%, 81%, 80%, and 97%). The physicians believed acupuncture to be effective in a mean of 5 symptoms, nurses in 6 symptoms, physiotherapists in 6 symptoms, and acupuncturists in 10 symptoms (P < .001). Conclusions:Since the professionals varied substantially regarding practice, education and beliefs in acupuncture, oncology clinics may consider delivering patient preferred acupuncture according to evidence-informed guidelines rather than on varying preferences among the professionals, since professionals' treatment expectations may modify treatment outcomes.
C1 [Efverman, Anna] Univ Gavle, Gavle, Sweden.
   [Efverman, Anna] Univ Gavle, Fac Hlth & Occupat Studies, Dept Caring Sci, S-80176 Gavle, Sweden.
C3 University of Gavle; University of Gavle
RP Efverman, A (corresponding author), Univ Gavle, Fac Hlth & Occupat Studies, Dept Caring Sci, S-80176 Gavle, Sweden.
EM anna.efverman@hig.se
CR Bauml Joshua, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP302, DOI 10.1093/jncimonographs/lgu029
   Birch S, 2020, J ALTERN COMPLEM MED, V26, P784, DOI 10.1089/acm.2020.0032
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Dai L, 2021, J PALLIAT MED, V24, P1078, DOI 10.1089/jpm.2020.0405
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Ebel MD, 2015, J CANCER RES CLIN, V141, P1449, DOI 10.1007/s00432-015-1940-3
   Efverman A, 2020, COMPLEMENT THER MED, V52, P0, DOI 10.1016/j.ctim.2020.102404
   Eippert F, 2009, NEURON, V63, P533, DOI 10.1016/j.neuron.2009.07.014
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Enblom A, 2017, ACUPUNCT MED, V35, P421, DOI 10.1136/acupmed-2016-011270
   Enblom A, 2017, ACUPUNCT MED, V35, P251, DOI 10.1136/acupmed-2015-011007
   Enblom A, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0014766
   Enblom A, 2009, SUPPORT CARE CANCER, V17, P23, DOI 10.1007/s00520-008-0445-x
   Garcia GT, 2021, MED ACUPUNCT, V33, P22, DOI 10.1089/acu.2020.1431
   Garland SN, 2018, SUPPORT CARE CANCER, V26, P2407, DOI 10.1007/s00520-018-4086-4
   Han G, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14194683
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Hou WZ, 2019, J OBSTET GYNAECOL RE, V45, P2307, DOI 10.1111/jog.14122
   Kelley JM, 2009, PSYCHOSOM MED, V71, P789, DOI 10.1097/PSY.0b013e3181acee12
   Kessel KA, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0165801
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Liu J, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/4243175
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Norheim AJ, 1998, SOC SCI MED, V47, P519, DOI 10.1016/S0277-9536(98)00152-X
   Peerdeman KJ, 2016, PAIN, V157, P1179, DOI 10.1097/j.pain.0000000000000540
   Puts MTE, 2015, CANCER TREAT REV, V41, P197, DOI 10.1016/j.ctrv.2014.12.010
   Quaschning K, 2013, PATIENT EDUC COUNS, V91, P167, DOI 10.1016/j.pec.2012.12.007
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Rossi E, 2015, SUPPORT CARE CANCER, V23, P1795, DOI 10.1007/s00520-014-2517-4
   Roter DL, 2016, PATIENT EDUC COUNS, V99, P1519, DOI 10.1016/j.pec.2016.06.002
   Ruhlmann CH, 2015, RADIOTHER ONCOL, V117, P333, DOI 10.1016/j.radonc.2015.09.014
   Scarton LA, 2018, J MED LIBR ASSOC, V106, P87, DOI 10.5195/jmla.2018.200
   Schofield PE, 2003, SUPPORT CARE CANCER, V11, P348, DOI 10.1007/s00520-002-0420-x
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Tuttle AH, 2015, PAIN, V156, P2616, DOI 10.1097/j.pain.0000000000000333
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Widgren Y, 2017, COMPLEMENT THER MED, V34, P16, DOI 10.1016/j.ctim.2017.07.003
   Witt CM, 2022, J CANCER EDUC, V37, P499, DOI 10.1007/s13187-020-01829-8
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Wode K, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2452-5
   Wu F, 2021, SOC SCI MED, V280, P0, DOI 10.1016/j.socscimed.2021.114050
   Ylva W, 2022, INTEGR CANCER THER, V21, P0, DOI 10.1177/15347354221077277
NR 45
TC 2
Z9 2
U1 1
U2 7
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2022
VL 21
IS 
BP 
EP 
DI 10.1177/15347354221132834
PG 10
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA 7K3MN
UT WOS:000905190300016
PM 36398874
DA 2026-01-16
ER

PT J
AU Chou, YH
   Yeh, ML
   Huang, ZS
   Hsu, HD
AF Chou, Ya-Hui
   Yeh, Mei-Ling
   Huang, Tzu-Shin
   Hsu, Hedi
TI Acupoint stimulation improves pain and quality of life in head and neck cancer patients with chemoradiotherapy: A randomized controlled trial
SO ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
DE Acupoint stimulation; Head and neck cancer; Chemoradiotherapy; Pain; Quality of life
ID acupuncture; radiotherapy; management; mucositis; symptoms; toxicity; distress; anxiety
AB Objective: This study aimed to evaluate the effect of acupoint stimulation on pain, negative moods, and quality of life for head and neck cancer (HNC) patients who underwent concurrent chemoradiotherapy (CCRT).Methods: This randomized controlled trial recruited participants from a medical center and randomly assigned using a permuted block randomization list with computer-generated random serial numbers into the AcuCare group (n = 46) receiving acupoint stimulation with transcutaneous acupoint electrical stimulation (TAES) and auricular acupressure (AA) or the control group (n = 46) without any acupoint stimulation. Outcomes were repeatedly assessed pain intensity using the visual analogue scale, negative moods using the hospital anxiety and depression scale, and quality of life (QoL) using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 35.Results: After adjusting varying mucositis grades and time-dependent growth effects, the generalized estimating equations showed a significantly increase in pain intensity at weeks 1, 2, 3, and 6 (P < 0.05), but not in negative moods (P > 0.05), compared to baseline and control group. Analysis of covariance showed a significant group difference in the senses problems of QoL (F = 7.33, P = 0.01) at Week 6.Conclusions: This study supports that acupoint stimulation could effectively reduce pain and improve senses problem of QoL for patients with HNC. Trial registration: This study was registered at https://clinicaltrials.gov/NCT03640195.
C1 [Chou, Ya-Hui] Natl Taipei Univ Nursing & Hlth Sci, Dept Nursing, Taoyuan Chang Gung Mem Hosp, Taoyuan, Taiwan.
   [Chou, Ya-Hui; Yeh, Mei-Ling; Hsu, Hedi] Natl Taipei Univ Nursing & Hlth Sci, Sch Nursing, Taoyuan, Taiwan.
   [Huang, Tzu-Shin] Taoyuan Chang Gung Mem Hosp, Dept Nursing, Taoyuan, Taiwan.
C3 National Taipei University of Nursing & Health Science (NTUNHS); Chang Gung Memorial Hospital; National Taipei University of Nursing & Health Science (NTUNHS); Chang Gung Memorial Hospital
RP Yeh, ML (corresponding author), Natl Taipei Univ Nursing & Hlth Sci, Sch Nursing, Taoyuan, Taiwan.
EM meiling@ntunhs.edu.tw
FU Chang Gung Memorial Hospital of Taiwan [CMRPG5F0131]
CR Akazawa K, 2018, J LARYNGOL OTOL, V132, P111, DOI 10.1017/S0022215118000014
   Allen-Ayodabo CO, 2019, ORAL ONCOL, V99, P0, DOI 10.1016/j.oraloncology.2019.09.026
   Unknown -, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Bjordal K, 1999, J CLIN ONCOL, V17, P1008, DOI 10.1200/JCO.1999.17.3.1008
   Bossi P, 2020, SUPPORT CARE CANCER, V28, P451, DOI 10.1007/s00520-019-05147-8
   Bottomley A, 2014, CANCER-AM CANCER SOC, V120, P390, DOI 10.1002/cncr.28392
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Chiou YF, 2020, REHABIL NURS, V45, P225, DOI 10.1097/RNJ.0000000000000198
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Colevas AD, 2018, J NATL COMPR CANC NE, V16, P479, DOI 10.6004/jnccn.2018.0026
   Cramer H, 2016, MEDICINE, V95, P2901
   Cramer JD, 2018, OTOLARYNG HEAD NECK, V159, P853, DOI 10.1177/0194599818783964
   Dymackova R, 2020, BIOMED PAP, V164, P454, DOI 10.5507/bp.2020.021
   Epstein JB, 2019, J NATL CANCER INST M, V53, P0
   Epstein JB, 2020, SUPPORT CARE CANCER, V28, P4305, DOI 10.1007/s00520-019-05232-y
   Gavronsky S, 2012, PAIN MANAG NURS, V13, P150, DOI 10.1016/j.pmn.2009.08.001
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Health Promotion Administration Ministry of Health and Welfare, 2017, CANCER REGISTRY ANNUAL REPORT, V0, P0
   Holländer-Mieritz C, 2019, ACTA ONCOL, V58, P603, DOI 10.1080/0284186X.2018.1563713
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Hu YQ, 2017, IRAN J PUBLIC HEALTH, V46, P1054
   Hura N, 2020, INT FORUM ALLERGY RH, V10, P1065, DOI 10.1002/alr.22624
   Iqbal MS, 2017, INT ARCH OTORHINOLAR, V21, P171
   Jacobs JM, 2019, J NATL COMPR CANC NE, V17, P221, DOI 10.6004/jnccn.2018.7098
   Jiang JR, 2019, J CLIN ONCOL, V37, P135, DOI 10.1200/JCO.18.00896
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Lopez-Vaquero D, 2017, MOL CLIN ONCOL, V6, P931, DOI 10.3892/mco.2017.1238
   Chien CHYLC, 2015, JOURNAL OF PAIN & RELIEF, V04, P0, DOI 10.4172/2167-0846.1000199
   Melo Andressa Lais Salvador de, 2014, FISIOTER. MOV., V27, P495, DOI 10.1590/0103-5150.027.004.AO01
   Michelson Michelle, 2018, EVID BASED DENT, V19, P60, DOI 10.1038/sj.ebd.6401312
   Mohammed N, 2018, J. COMPL. INTEGR. MED., V15, P0
   Muzumder S, 2018, INDIAN J PALLIAT CAR, V24, P176, DOI 10.4103/IJPC.IJPC_145_17
   Nayak SG, 2019, J CANCER RES THER, V15, P638, DOI 10.4103/jcrt.JCRT_1123_16
   Oh B, 2018, INTEGR CANCER THER, V17, P458, DOI 10.1177/1534735417734912
   Paley CA, 2015, COCHRANE DB SYST REV, V2015, P0
   Paley CA, 2017, PAIN MANAG, V7, P345, DOI 10.2217/pmt-2017-0018
   Polverini PJ, 2019, J DENT RES, V98, P489, DOI 10.1177/0022034519833645
   Romero-Reyes M, 2016, PATOLOG A ORAL CIRUG, V21, P665
   Rosenthal DI, 2014, CANCER-AM CANCER SOC, V120, P1975, DOI 10.1002/cncr.28672
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Sendlbeck M, 2015, RMD OPEN, V1, P0, DOI 10.1136/rmdopen-2015-000140
   Tao WW, 2015, ONCOTARGET, V6, P39725, DOI 10.18632/oncotarget.5388
   Vallim ETA, 2018, GLOB SURG, V4, P1
   van Beek FE, 2020, ORAL ONCOL, V102, P0, DOI 10.1016/j.oraloncology.2020.104576
   Villa A, 2015, CURR OPIN ONCOL, V27, P159, DOI 10.1097/CCO.0000000000000180
   Vodermaier A, 2009, JNCI-J NATL CANCER I, V101, P1464, DOI 10.1093/jnci/djp336
   Wang T, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/5645632
   WHO Regional Office for the Western Pacific, 2008, WHO STAND AC POINT L, V0, P0
   Yang DY, 2019, INT J NURS SCI, V6, P278, DOI 10.1016/j.ijnss.2019.05.006
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yeh CH, 2014, J PAIN RELIEF, V0, P0, DOI DOI 10.4172/2167-0846.1000139
   Yeh ML, 2018, CLIN NURS RES, V27, P450, DOI 10.1177/1054773816685745
   Yeh ML, 2010, ALTERN THER HEALTH M, V16, P10
   Yeh ML, 2004, CONTEMMPORARY MERIDI, V0, P0
   Yeh ML, 2020, TRADITIONAL CHINESE MEDICINE IN NURSING CARE, V3rd, P0
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   Zimmaro LA, 2018, CANCER-AM CANCER SOC, V124, P1053, DOI 10.1002/cncr.31109
NR 58
TC 6
Z9 6
U1 2
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2347-5625
EI 2349-6673
J9 ASIA-PAC J ONCOL NUR
JI Asia-Pac. J. Oncol. Nurs.
PD JAN 15
PY 2022
VL 9
IS 1
BP 61
EP 68
DI 10.1016/j.apjon.2021.11.002
PG 8
WC Nursing
SC Nursing
GA 1D0UW
UT WOS:000793526200011
PM 35528798
DA 2026-01-16
ER

PT J
AU Du, WQ
   Wang, LD
   Jia, M
   Liang, X
   Li, B
   Zhang, YL
   Liao, X
AF Du Wanqing
   Wang Liuding
   Jia Min
   Liang Xiao
   Li Bo
   Zhang Yunling
   Liao Xing
TI Mixed methods research in complementary and alternative medicine: a scoping review
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Review
DE complementary therapies; review; biomedical research; pilot projects; mixed methods
ID data-collection; health; integration; principles; systems; design
AB OBJECTIVE: To update the current characteristics about the scope and quality of mixed methods research (MMR) in complementary and alternative medicine (CAM) after nearly 10 years. METHODS: A 5-stage approach for conducting a scoping review was adopted. Articles published on the top 10 journals in CAM with the highest impact factor in 2020 were screened for MMR. Information of included articles were extracted, and then synthesized to illustrate the current state. Methodological quality was evaluated according to the Mixed Method Appraisal Tool (MMAT) 2018 version. mixed methods were retrieved, including 17 medical studies and 38 ethnobotanical studies. We performed an in-depth analysis on the 17 medical studies, which studied cancer, stress, pain, fatigue, exercises, mindfulness intervention, herbal medicine use, art and acupuncture. Thirteen pilot studies applied MMR to evaluate the feasibility of interventions or programs (13/17, 76%); phenomenology was inferred as the most common philosophical assumptions (13/17, 76%); the most applied type of MMR was convergent design (16/17, 94%); integration often took place at integration (12/17, 71%). Among the 16 eligible studies for quality appraisal, majority were rated as good (14/16, 88%), whereas two studies were rated as poorly described. Primarily, a poor rating was due to incomplete reporting of data analysis and citations in qualitative components; lack of confounder controlling and the sampling strategy in quantitative components; poor description of integration and justification for mixed methods. Comparing with the previous review, fewer MMR were published in 2020 in CAM, but the proportion of studies that clearly reported MMR has increased by 4 times (4%-> 15%). CONCLUSION: CAM researchers need to realize the benefits that MMR can have on conducting further health care research. Our findings highlight that applying MMR will be helpful to understand the complex dynamics and interdisciplinary nature of complex intervention. In addition, addressing a standardized reporting criteria for MMR is recommended. (c) 2022 JTCM. All rights reserved.
C1 [Du Wanqing; Wang Liuding; Jia Min; Liang Xiao; Zhang Yunling] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Neurol, Beijing 100091, Peoples R China.
   [Du Wanqing; Liao Xing] China Acad Chinese Med Sci, Ctr Evidence Based Chinese Med, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.
   [Du Wanqing] Beijing Univ Chinese Med, Xiyuan Sch Clin Med, Beijing 100029, Peoples R China.
   [Li Bo] Capital Med Univ, Beijing Tradit Chinese Med Hosp, Beijing Inst Tradit Chinese Med, Dept Clin Epidemiol, Beijing 100010, Peoples R China.
C3 Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences; China Academy of Chinese Medical Sciences; Institute of Basic Research In Clinical Medicine, CACMS; Beijing University of Chinese Medicine; Capital Medical University
RP Zhang, YL (corresponding author), China Acad Chinese Med Sci, Xiyuan Hosp, Dept Neurol, Beijing 100091, Peoples R China.; Liao, X (corresponding author), China Acad Chinese Med Sci, Ctr Evidence Based Chinese Med, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.
EM yunlingzhang2004@126.com; okfrom2008@hotmail.com
FU Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences: Design and Application of Mixed Method Research in Traditional Chinese Medicine [CI2021B003]; Special Project of China Center for Evidence Based Traditional Chinese Medicine: Integrated Innovation and Application of Traditional Trial and Real-World Study of Chinese Medicine in Integrated Chinese and Western Medicine Setting [2020YJSZX-3]; Fundamental Research Funds for the Central Public Welfare Research Institutes: the Optimal Subject Setting and Design of Evidence-Based Research Implementation in the Area of Brain Diseases of Traditional Chinese Medicine [ZZ13-024-3]
CR Abdusalam A, 2020, J ETHNOPHARMACOL, V260, P0, DOI 10.1016/j.jep.2020.113012
   Adam S, 2021, SUPPORT CARE CANCER, V29, P6259, DOI 10.1007/s00520-021-06132-w
   Ahn AC, 2010, J ALTERN COMPLEM MED, V16, P1015, DOI 10.1089/acm.2009.0593
   Ahoyo CC, 2021, J ETHNOPHARMACOL, V265, P0, DOI 10.1016/j.jep.2020.113417
   Alqethami A, 2020, J ETHNOPHARMACOL, V257, P0, DOI 10.1016/j.jep.2020.112899
   Unknown -, 2019, WHO, V0, P10
   Carabajal MPA, 2020, J ETHNOPHARMACOL, V247, P0, DOI 10.1016/j.jep.2019.112258
   Anywara G, 2020, J ETHNOPHARMACOL, V246, P0, DOI 10.1016/j.jep.2019.112205
   Arden-Close E, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420908341
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI 10.1080/1364557032000119616
   Arnold DM, 2009, CRIT CARE MED, V37, PS69, DOI 10.1097/CCM.0b013e3181920e33
   Ataba E, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-03008-0
   Attia M, 2017, OPEN REV EDUC RES, V4, P33, DOI 10.1080/23265507.2017.1300068
   Baldé MA, 2020, J ETHNOPHARMACOL, V263, P0, DOI 10.1016/j.jep.2020.113232
   Barbosa F, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-019-2809-9
   Bishop FL, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/187365
   Bloom-Foster J, 2020, J ALTERN COMPLEM MED, V26, P34, DOI 10.1089/acm.2019.0242
   Broom A, 2005, COMPLEMENT THER MED, V13, P65, DOI 10.1016/j.ctim.2005.01.001
   Campbell DJT, 2017, CIRC-CARDIOVASC QUAL, V10, P0, DOI 10.1161/CIRCOUTCOMES.116.003310
   Cargo M, 2018, MIXED METHODS APPRAI, V0, P0
   Chamorro MF, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-02952-1
   Clark VLP, 2010, QUAL INQ, V16, P428, DOI 10.1177/1077800410364609
   Conte E, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420983472
   Creswell JW, 2018, QUAL INQ, V4th, P30
   Creswell JW, 2017, DESIGNING CONDUCTING, V3rd, P34
   Curry LA, 2013, CIRC-CARDIOVASC QUAL, V6, P119, DOI 10.1161/CIRCOUTCOMES.112.967885
   Curry LA, 2009, CIRCULATION, V119, P1442, DOI 10.1161/CIRCULATIONAHA.107.742775
   Dassou GH, 2020, J ETHNOPHARMACOL, V261, P0, DOI 10.1016/j.jep.2020.113107
   De Allegri M, 2018, HEALTH POLICY PLANN, V33, P445, DOI 10.1093/heapol/czx182
   Dhakal P, 2020, J ETHNOPHARMACOL, V249, P0, DOI 10.1016/j.jep.2019.112386
   Dowding D, 2013, QUAL SOC WORK, V12, P541, DOI 10.1177/1473325013493540a
   Fàbregues S, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17113853
   Farquhar MC, 2011, PALLIATIVE MED, V25, P748, DOI 10.1177/0269216311417919
   Fetters MD, 2013, HEALTH SERV RES, V48, P2134, DOI 10.1111/1475-6773.12117
   Fielding NG, 2012, J MIX METHOD RES, V6, P124, DOI 10.1177/1558689812437101
   Gaglio B, 2020, BMJ-BRIT MED J, V371, P0, DOI 10.1136/bmj.m4435
   Hirschberg R, 2020, J ALTERN COMPLEM MED, V26, P198, DOI 10.1089/acm.2019.0368
   In J, 2017, KOREAN J ANESTHESIOL, V70, P601, DOI 10.4097/kjae.2017.70.6.601
   Irvine FE, 2020, J ADV NURS, V76, P2798, DOI 10.1111/jan.14479
   Kaimal G, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420912835
   Lewin S, 2009, BMJ-BRIT MED J, V339, P0, DOI 10.1136/bmj.b3496
   Low MY, 2020, J ALTERN COMPLEM MED, V26, P113, DOI 10.1089/acm.2019.0249
   Maudsley G, 2011, MED TEACH, V33, Pe92, DOI 10.3109/0142159X.2011.542523
   McDonnell KK, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420969829
   Mehl A, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420935618
   Nsibirwa S, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-02959-8
   Nunez-Smith M, 2014, MIXED METHODS HLTH S, V0, P0
   OCathain A, 2008, J HEALTH SERV RES PO, V13, P92, DOI 10.1258/jhsrp.2007.007074
   Osypiuk K, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735419893766
   Palinkas LA, 2019, ANNU REV PUBL HEALTH, V40, P423, DOI 10.1146/annurev-publhealth-040218-044215
   Peters BC, 2020, J ALTERN COMPLEM MED, V26, P743, DOI 10.1089/acm.2020.0039
   Pluye P, 2014, ANNU REV PUBL HEALTH, V35, P29, DOI 10.1146/annurev-publhealth-032013-182440
   Rahayu YYS, 2020, J ETHNOPHARMACOL, V260, P0, DOI 10.1016/j.jep.2020.112974
   ROSENFIELD PL, 1992, SOC SCI MED, V35, P1343, DOI 10.1016/0277-9536(92)90038-R
   Rothman JM, 2020, J ALTERN COMPLEM MED, V26, P636, DOI 10.1089/acm.2020.0063
   Sandelowski M, 2000, RES NURS HEALTH, V23, P246, DOI 10.1002/1098-240X(200006)23:3<246::AID-NUR9>3.0.CO;2-H
   Schultes RichardEvans, 1995, ETHNOBOTANY EVOLUTIO, V0, P0
   Sharma S, 2020, INT J NURS STUD, V110, P0, DOI 10.1016/j.ijnurstu.2020.103709
   Shewamene Z, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-2852-6
   Stritter W, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420928393
   Sylvia L, 2020, J INTEGR MED-JIM, V18, P169, DOI 10.1016/j.joim.2020.01.005
   Tariq Shema, 2013, JRSM SHORT REP, V4, P2042533313479197, DOI 10.1177/2042533313479197
   Tashakkori A, 1989, MIXED METHODOLOGY: COMBINING QUALITATIVE AND QUANTITATIVE APPROACHES, V0, P0
   Thangaraj P, 2016, PROG DRUG RES, V71, P1, DOI 10.1007/978-3-319-26811-8
   Veziari Y, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1660-0
   Wisdom JP, 2012, HEALTH SERV RES, V47, P721, DOI 10.1111/j.1475-6773.2011.01344.x
   Yan H, 2020, NEUROSURGERY, V86, P325, DOI 10.1093/neuros/nyz509
   Zhao Q, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420976579
   Zörgo S, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420910472
NR 70
TC 4
Z9 4
U1 1
U2 14
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD AUG 15
PY 2022
VL 42
IS 4
BP 652
EP 666
DI 10.19852/j.cnki.jtcm.20220602.002
PG 15
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 3D2EC
UT WOS:000829120500001
PM 35848983
DA 2026-01-16
ER

PT J
AU Pei, P
   Cui, SW
   Zhang, SS
   Hu, S
   Wang, LP
   Yang, WM
AF Pei, Pei
   Cui, Shengwei
   Zhang, Shuaishuai
   Hu, Sheng
   Wang, Linpeng
   Yang, Wenming
TI Effect of Electroacupuncture at Fengchi on Facial Allodynia, Microglial Activation, and Microglia-Neuron Interaction in a Rat Model of Migraine
SO BRAIN SCIENCES
LA English
DT Article
DE electroacupuncture; migraine; microglia; inflammatory cytokines
ID cutaneous allodynia; trigeminovascular pathway; pain; sensitization; pathophysiology; contribute; modulation; expression; headache; system
AB The purpose of the work was to investigate whether electroacupuncture (EA) could ameliorate migraine central sensitization by modulating microglial activation and the subsequent release of inflammatory cytokines in the trigeminal nucleus caudalis (TNC) in a rat model. Establishment of a rat model of recurrent migraine was achieved through repeated dural electrical stimulation (DES). After nine sessions of acupuncture treatment at Fengchi (GB20), facial mechanical thresholds were measured by electronic von Frey measurements. Microglial activation and cytokine receptors of TNC were evaluated by immunofluorescence staining. The expression of microglial biological marker Ibal-1, proinflammatory cytokines, and cytokine receptors in the TNC were evaluated by Western blot and/or real-time polymerase chain reaction. In addition, the effects of inhibition of microglial activation on facial thresholds and neuronal activation (i.e., expression of c-Fos in the TNC) induced by DES were observed. After consecutive EA-GB20 treatments, the facial withdrawal threshold was significantly higher than in the model group at different time points (p < 0.05). The hyperreactivity of microglia induced by DES was significantly inhibited, and the expressions of Ibal-1, interleukin-1 beta, tumor necrosis factor-alpha, and their receptors in the TNC were also significantly decreased (p < 0.05). Inhibition of microglia by minocycline demonstrated an acupuncture-like role, which was manifested by ameliorated mechanical hyperalgesia and decreased neuronal expression of c-Fos, Iba-1, and inflammatory factors. EA at GB20 could ameliorate migraine facial allodynia by inhibiting microglial activation and the subsequent release of inflammatory cytokines and their receptors in the TNC.
C1 [Pei, Pei; Yang, Wenming] Anhui Univ Chinese Med, Affiliated Hosp 1, Neurol Dept, Hefei 230031, Peoples R China.
   [Cui, Shengwei; Zhang, Shuaishuai; Hu, Sheng] Anhui Univ Chinese Med, 350 Longzihu Rd, Hefei 230012, Peoples R China.
   [Wang, Linpeng] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Acupuncture & Moxibust Dept, Beijing 100010, Peoples R China.
C3 Anhui University of Chinese Medicine; Anhui University of Chinese Medicine; Capital Medical University
RP Yang, WM (corresponding author), Anhui Univ Chinese Med, Affiliated Hosp 1, Neurol Dept, Hefei 230031, Peoples R China.; Wang, LP (corresponding author), Capital Med Univ, Beijing Hosp Tradit Chinese Med, Acupuncture & Moxibust Dept, Beijing 100010, Peoples R China.
EM wanglinpeng@bjzhongyi.com; yangwm8810@126.com
FU National Natural Science Foundation of China [81973825]
CR Aczél T, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21082938
   Bernstein C, 2012, J CLIN NEUROL, V8, P89
   Boyer N, 2014, PAIN, V155, P1196, DOI 10.1016/j.pain.2014.03.001
   Burstein R, 2000, ANN NEUROL, V47, P614, DOI 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-N
   Burstein R, 2004, ANN NEUROL, V55, P19, DOI 10.1002/ana.10786
   Burstein R, 2015, J NEUROSCI, V35, P6619, DOI 10.1523/JNEUROSCI.0373-15.2015
   Conti P, 2019, EUR J PHARMACOL, V844, P87, DOI 10.1016/j.ejphar.2018.12.004
   Edelmayer RM, 2009, ANN NEUROL, V65, P184, DOI 10.1002/ana.21537
   Fried NT, 2018, CEPHALALGIA, V38, P674, DOI 10.1177/0333102417703764
   Güven H, 2013, NEUROL SCI, V34, P1397, DOI 10.1007/s10072-012-1249-9
   Gwak YS, 2017, NEURAL PLAST, V2017, P0, DOI 10.1155/2017/2480689
   Hazey Matthew A, 2009, W V MED J, V105, P15
   He W, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-019-1459-7
   Inoue K, 2018, NAT REV NEUROSCI, V19, P138, DOI 10.1038/nrn.2018.2
   Lai HC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6173412
   Ledeboer A, 2005, PAIN, V115, P71, DOI 10.1016/j.pain.2005.02.009
   Li YX, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/3825617
   Lipton RB, 2008, ANN NEUROL, V63, P148, DOI 10.1002/ana.21211
   Louter MA, 2013, BRAIN, V136, P3489, DOI 10.1093/brain/awt251
   Magni G, 2019, CEPHALALGIA, V39, P1809, DOI 10.1177/0333102419861710
   Mathew PG, 2016, J PAIN RES, V9, P101, DOI 10.2147/JPR.S103238
   Noseda R, 2013, PAIN, V154, PS44, DOI 10.1016/j.pain.2013.07.021
   Pei P, 2019, ACUPUNCT MED, V37, P47, DOI 10.1136/acupmed-2017-011410
   Pei P, 2016, ACUPUNCT MED, V34, P127, DOI 10.1136/acupmed-2015-010840
   Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407
   Rozen T, 2007, HEADACHE, V47, P1050, DOI 10.1111/j.1526-4610.2006.00722.x
   Sommer C, 2018, PAIN, V159, P595, DOI 10.1097/j.pain.0000000000001122
   Tozaki-Saitoh H, 2019, BIOCHEM PHARMACOL, V169, P0, DOI 10.1016/j.bcp.2019.08.016
   Tsuda M, 2019, BIOL PHARM BULL, V42, P1959, DOI 10.1248/bpb.b19-00715
   Tsuda M, 2018, ADV EXP MED BIOL, V1099, P77, DOI 10.1007/978-981-13-1756-9_7
   Wang LP, 2011, PAIN, V152, P1864, DOI 10.1016/j.pain.2011.04.006
   Wei F, 2008, J NEUROSCI, V28, P10482, DOI 10.1523/JNEUROSCI.3593-08.2008
   Wen Ya, 2018, ZHONGGUO ZHEN JIU, V38, P1183, DOI 10.13703/j.0255-2930.2018.11.013
   Wieseler J, 2017, BRAIN RES, V1664, P87, DOI 10.1016/j.brainres.2017.03.011
   Zhang NS, 2020, HEADACHE, V60, P309, DOI 10.1111/head.13723
   Zhao LP, 2017, NEURAL REGEN RES, V12, P804, DOI 10.4103/1673-5374.206652
NR 36
TC 10
Z9 12
U1 1
U2 20
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2076-3425
J9 BRAIN SCI
JI Brain Sci.
PD AUG 15
PY 2022
VL 12
IS 8
BP 
EP 
DI 10.3390/brainsci12081100
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 4C0TT
UT WOS:000846178200001
PM 36009163
DA 2026-01-16
ER

PT J
AU Zhong, X
   Zhang, Z
   Li, J
   Liu, D
   Ma, C
   Wang, G
AF Zhong, Xuelai
   Zhang, Zhaodi
   Li, Jiaying
   Liu, Dandan
   Ma, Chao
   Wang, Guonian
TI Effects of Electroacupuncture on Gastrointestinal Motility Function, Pain, and
SO Disease markers
LA English
DT Journal Article
AB BACKGROUND: Complications after colon surgery are a major obstacle to  postoperative recovery. The purpose of this study was to investigate the effect  of electroacupuncture (EA) at Zusanli (ST36) on gastrointestinal motility in rats  after colonic anastomosis and the mechanism of transient receptor potential  vanillin 1 (TRPV1) channel in regulating gastrointestinal motility, pain, and  inflammation. METHODS: The rats were randomly divided into six groups, including  the control, model, EA, sham-EA, capsaicin, and capsaicin+EA groups, with  preoperative capsaicin pretreatment and EA treatment at ST36 acupoint after  surgery. Rats were treated using EA at ST36 or sham acupoints after surgery for 5  days. Capsaicin was intraperitoneally injected into rats 3 hours before surgery.  Gastrointestinal motility was assessed by measuring the gastric residue, small  intestinal propulsion in vivo, contractile tension, and frequency of isolated  muscle strips in vitro. The mechanical withdrawal threshold (MWT) of abdominal  incision skin and spontaneous nociceptive scores were observed and recorded in  rats after colon anastomosis. The expressions of TRPV1, substance P (SP),  neurokinin 1 (NK1) receptor, nuclear factor kappa-B (NF-κB), interleukin- (IL-)  6, L-1β, and tumor necrosis factor- (TNF-) α were determined. RESULTS: Compared  with the model group, electroacupuncture at ST36 point could significantly reduce  the residual rate of stomach in rats after operation and increase the propulsive  force of the small intestine and the contraction tension of the isolated smooth  muscle. Electroacupuncture also increased postoperative day 3 MWT values and  decreased postoperative spontaneous nociception scores. In addition,  electroacupuncture treatment downregulated the expressions of IL-6, IL-1β, TNF-α,  TRPV1, NF-κB, SP, and NK1 receptors in the colon tissue of rats after colonic  anastomosis. CONCLUSIONS: Our study showed that electroacupuncture at ST36  acupoint could improve gastrointestinal motility in rats after colonic  anastomosis and relieve intestinal inflammation and pain. The mechanism may be to  inhibit the activation of NF-κB and SP/NK1 receptor signaling pathways by  inhibiting TRPV1.
C1 Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
   Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
   Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
   Department of Anesthesiology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
   Department of Anesthesiology, The Fourth Hospital of Harbin Medical University, Harbin 150081, China.
   Department of Anesthesiology, The Fourth Hospital of Harbin Medical University
   Pain Research Institute of Heilongjiang Academy of Medical Science, 150 HapingRd, Nangang District, Harbin 150081, China.
NR 0
TC 0
SN 1875-863
EI 0278-024
J9 Dis Markers
PD JUL 19
PY 2022
VL 2022
IS 
BP 5113473
EP 5113473
DI 10.1155/2022/5113473
PG 0
WC Animals; Capsaicin; pharmacology; Electroacupuncture; Gastrointestinal Motility; Inflammation; therapy; NF-kappa B; metabolism; Pain; Rats; Tumor Necrosis Factor-alpha; metabolism
UT PubMed:35845135
PM 35845135
DA 2022-07-19
ER

PT J
AU Cope, DG
AF Cope, Diane G.
TI Clinical Updates in Nausea and Vomiting
SO SEMINARS IN ONCOLOGY NURSING
LA English
DT Article
DE Chemotherapy-induced nausea and vomiting; Nausea; Vomiting; Antiemetics; Drug therapy; Quality of life
ID chemotherapy-induced nausea; cancer; acupuncture; prevention; guidelines; efficacy; emesis
AB Objective: To review recent updated antiemetic guidelines from national cancer organizations and its impact on chemotherapy-induced nausea and vomiting (CINV) in the prevention and delayed phase of therapy. This article will also describe assessment and nursing strategies for individualized care and timely side effect management.Data Sources: Data sources include peer-reviewed articles sourced in electronic databases. Conclusion: CINV is a persistent problem for a large percentage of patients undergoing chemotherapy treatment despite advances in antiemetic therapy and increased use of targeted therapies. CINV management should be based on patient-focused assessment and adherence to national antiemetic guidelines. Ongoing assessment and follow-up are critical to ensure optimum management of side effects to optimized quality of life.Implications for Nursing Practice: Awareness of national antiemetic guidelines is important in caring for patients undergoing chemotherapy. CINV can have a significant impact on patients, causing physical effects, treatment delays, and diminished quality of life. Oncology nurses play a key role in assessment of patient related risk factors, education of patients and caregivers regarding pain medications, side effects, and oral adherence and continued follow-up for early recognition and intervention for uncontrolled CINV.(c) 2022 Elsevier Inc. All rights reserved.
C1 [Cope, Diane G.] Florida Canc Specialists & Res Inst, Nursing, Ft Myers, FL 33919 USA.
C3 Florida Cancer Specialists
RP Cope, DG (corresponding author), Florida Canc Specialists & Res Inst, 605 Astarias Circle, Ft Myers, FL 33919 USA.
EM dgcope@comcast.net
CR Cheng PY, 2020, INT J CLIN EXP MED, V13, P7965
   Clark-Snow R, 2018, SUPPORT CARE CANCER, V26, P557, DOI 10.1007/s00520-017-3866-6
   Crichton M, 2019, J ACAD NUTR DIET, V119, P2055, DOI 10.1016/j.jand.2019.06.009
   Das S, 2019, J IMMUNOTHER CANCER, V7, P0, DOI 10.1186/s40425-019-0805-8
   Dranitsaris G, 2017, ANN ONCOL, V28, P1260, DOI 10.1093/annonc/mdx100
   Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Gupta Kush, 2021, CANCER TREAT RES COMMUN, V26, P100278, DOI 10.1016/j.ctarc.2020.100278
   Hesketh PJ, 2020, J CLIN ONCOL, V38, P2782, DOI 10.1200/JCO.20.01296
   Ilyas AB, 2020, CUREUS J MED SCIENCE, V12, P0, DOI 10.7759/cureus.12038
   Janowitz T, 2021, ONCOLOGIST, V26, P269, DOI 10.1002/onco.13680
   Kapogiannis A, 2018, EXPLORE-NY, V14, P137, DOI 10.1016/j.explore.2017.10.008
   Li QW, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-00333-x
   Mahidin EIB, 2019, ANN ONCOL, V30, P128, DOI 10.1093/annonc/mdz343.046
   Marx WM, 2013, NUTR REV, V71, P245, DOI 10.1111/nure.12016
   Mosa AM, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.00329
   Navari RM, 2016, NEW ENGL J MED, V374, P1356, DOI 10.1056/NEJMra1515442
   Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865
   Raghavendra RM, 2007, EUR J CANCER CARE, V16, P462, DOI 10.1111/j.1365-2354.2006.00739.x
   Rapoport BL, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00019
   Roila F, 2006, ANN ONCOL, V17, P20, DOI 10.1093/annonc/mdj078
   Roila F, 2016, ANN ONCOL, V27, Pv119, DOI 10.1093/annonc/mdw270
   Shankar Abhishek, 2015, ASIAN PAC J CANCER PREV, V16, P6207, DOI 10.7314/apjcp.2015.16.15.6207
   Singh P, 2016, THER ADV GASTROENTER, V9, P98, DOI 10.1177/1756283X15618131
   Smith C, 2020, CANCER NURS, V43, PE217, DOI 10.1097/NCC.0000000000000694
   Sommariva S, 2016, CRIT REV ONCOL HEMAT, V99, P13, DOI 10.1016/j.critrevonc.2015.12.001
   Totmaj AS, 2019, PHYTOTHER RES, V33, P1957, DOI 10.1002/ptr.6377
   Underhill ML, 2015, CLIN J ONCOL NURS, V19, P38, DOI 10.1188/15.CJON.38-40
   Wei TT, 2020, SUPPORT CARE CANCER, V28, P4031, DOI 10.1007/s00520-020-05409-w
NR 31
TC 12
Z9 16
U1 1
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0749-2081
EI 1878-3449
J9 SEMIN ONCOL NURS
JI Semin. Oncol. Nurs.
PD FEB 15
PY 2022
VL 38
IS 1
BP 
EP 
DI 10.1016/j.soncn.2022.151249
PG 5
WC Oncology; Nursing
SC Oncology; Nursing
GA 1C1UC
UT WOS:000792911800007
PM 35219568
DA 2026-01-16
ER

PT J
AU Jiao, L
   He, X
   Zhang, J
   Liu, Y
   Luo, Y
   Wei, H
AF Jiao, Liangbo
   He, Xiaoxia
   Zhang, Jihong
   Liu, Yali
   Luo, Yanan
   Wei, Hu
TI Effects of Acupuncture on Cancer Pain in Animal Intervention Studies: A
SO Integrative cancer therapies
LA English
DT Journal Article
DE ARRIVE; SYRCLE; acupuncture; cancer pain; methodological and reporting quality
AB BACKGROUND: Preclinical studies often provide the evidence base for clinical  studies. However, the design and reporting of preclinical trial results are  inadequate, resulting in poor reproducibility and clinical translatability. We  aimed to systematically evaluate the methodology and reporting quality of animal  studies of acupuncture for cancer pain. METHODS: About 7 databases were searched  for animal research articles on acupuncture for cancer pain from the beginning of  the database to January 31, 2022. ARRIVE guidelines, STRICTA, and SYRCLE risk of  bias tools were used to assess the reporting quality and risk of bias of the  selected studies. RESULTS: A total of 18 studies were evaluated. Of the 22 items  on the SYRCLE tool, only 6 items had a positive reporting rate of more than 50%.  Of the 39 items in the ARRIVE guidelines, 14 were rated excellent, and the least  frequently reported checklist items were 7. Out of the 17 STRICTA checklist items  analyzed, 10 were considered appropriately reported in more than 80% of the  studies, while 4 were correctly reported in less than 20%. CONCLUSIONS: Some  crucial points in the design, implementation, and reporting of the experiments  included in the study were not well developed, which could significantly affect  the clarity, reproducibility, and translatability of the experiments. There is a  need to fully implement scientific tool guidelines for future experimental  studies in order to improve the quality of preclinical studies and facilitate  effective translation of their results to the clinic.
C1 The Second People's Hospital of China Three Gorges University, Yichang, Hubei, China.
   Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, Medical College of China ThreeGorges University, Yichang, Hubei, China.
   The Second People's Hospital of China Three Gorges University, Yichang, Hubei, China.
   Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, Medical College of China ThreeGorges University, Yichang, Hubei, China.
   Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, Medical College of China ThreeGorges University, Yichang, Hubei, China.
   Third-Grade Pharmacological Laboratory on Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, Medical College of China ThreeGorges University, Yichang, Hubei, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD NOV 1
PY 2022
VL 21
IS 
BP 15347354221123788
EP 15347354221123788
DI 10.1177/15347354221123788
PG 1
WC Animals; Cancer Pain; Reproducibility of Results; Acupuncture; Acupuncture Therapy; methods; Neoplasms; therapy
UT PubMed:36314416
PM 36314416
DA 2022-11-01
ER

PT J
AU Shah, S
   Godhardt, L
   Spofford, C
AF Shah, Shivani
   Godhardt, Lisa
   Spofford, Christina
TI Acupuncture and Postoperative Pain Reduction
SO CURRENT PAIN AND HEADACHE REPORTS
LA English
DT Review
DE Perioperative pain; Perioperative analgesia; Perioperative acupuncture; Electroacupuncture; Transcutaneous electric acupoint stimulation; Moxibustion; Acupressure
ID gastric-cancer; electroacupuncture; stimulation; acupressure; analgesia; surgery
AB Purpose of Review Acupuncture is an analgesic technique that has long been utilized in Eastern medicine. In recent times, various acupuncture techniques have been used in integrated pain management approaches in Western medicine. It has even been adopted as an analgesic method in surgical patients. Currently, no review exists regarding various acupuncture techniques used in perioperative pain management and data describing the utility of these techniques. This paper synthesizes the latest literature regarding the role of acupuncture in perioperative pain management. The authors sought to describe various acupuncture modalities used to help manage surgical pain and synthesize the current body of literature to help readers make informed judgements on the topic. Recent Findings Patients undergoing abdominal, spine/neuro, and gynecologic pelvic surgery generally benefit from acupuncture. Out of the various acupuncture techniques, electroacupuncture, transcutaneous electric acupoint stimulation, and traditional total body acupuncture seem to be most promising as adjuncts to multimodal perioperative analgesia. Benefits include improved analgesia and/or reduced narcotic requirements, decrease in PONV, and shorter time to return of bowel function. Acupuncture is a low-risk method that has the potential to enhance perioperative analgesia, decrease opioid requirement, and reduce unwanted side effects of anesthesia, surgery, and opioid administration such as nausea/vomiting. Given the variety of patient populations, various acupuncture techniques, and small patient populations for most current studies; it remains difficult to determine which acupuncture method would most benefit specific patients. Future studies with more robust sample sizes and prospective comparison on acupuncture technique would help better characterize acupuncture's role in perioperative pain management.
C1 [Shah, Shivani; Godhardt, Lisa; Spofford, Christina] Med Coll Wisconsin, Dept Anesthesiol, 9200 W Wisconsin Ave,P347, Milwaukee, WI 53226 USA.
C3 Medical College of Wisconsin
RP Spofford, C (corresponding author), Med Coll Wisconsin, Dept Anesthesiol, 9200 W Wisconsin Ave,P347, Milwaukee, WI 53226 USA.
EM lgodhardt@mcw.edu; cspofford@mcw.edu
CR ANDERSSON SA, 1973, BRAIN RES, V63, P393, DOI 10.1016/0006-8993(73)90111-X
   Unknown -, 1997, NIH CONSENS STATEMENT, V15, P1
   Unknown -, 2003, NATIONAL ACADEMY OF SCIENCES OF UKRAINE, V0, P0, DOI DOI 10.1007/978-3-642-18988-3_2
   Bache Franklin, 1826, NORTH AMERICAN MEDICAL AND SURGICAL JOURNAL, V1, P311
   CASSEDY JH, 1974, B NEW YORK ACAD MED, V50, P892
   Chang LH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/528452
   Chen Da, 2018, ZHEN CI YAN JIU, V43, P616, DOI 10.13702/j.1000-0607.180404
   Chen TY, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/2126416
   Cho YH, 2015, PAIN PRACT, V15, P279, DOI 10.1111/papr.12208
   Cui J, 2013, J ACUPUNCT TUINA SCI, V11, P46, DOI 10.1007/s11726-013-0654-9
   DAATC, 2017, TYP AC, V0, P0
   Deng HY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/379291
   HA H, 1981, EXP NEUROL, V73, P298, DOI 10.1016/0014-4886(81)90063-7
   Hah JM, 2017, ANESTH ANALG, V125, P1733, DOI 10.1213/ANE.0000000000002458
   Helms, 2020, OVERVIEW MED ACUPUNC, V0, P0
   Hsiung WT, 2015, COMPLEMENT THER MED, V23, P339, DOI 10.1016/j.ctim.2015.03.010
   Ismail SA, 2021, J PAIN RES, V14, P273, DOI 10.2147/JPR.S285322
   Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015
   Liu, 2012, FOCUS ALTERN COMPLEM, V17, P50, DOI 10.1111/j.2042-7166.2011.01138_4.x
   Lu DP, 2013, MED ACUPUNCT, V25, P311, DOI 10.1089/acu.2012.0921
   Lv J, 2023, ENVIRON TECHNOL, V44, P1145, DOI 10.1080/09593330.2021.1996466
   MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5
   Qin D, 2020, EUR J INTEGR MED, V37, P0, DOI 10.1016/j.eujim.2020.101112
   Sahmeddini MA, 2010, J ALTERN COMPLEM MED, V16, P53, DOI 10.1089/acm.2009.0288
   Sakurai M, 2003, ANESTH ANALG, V96, P493, DOI 10.1097/00000539-200302000-00036
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Szmit M, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10010146
   Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6
   White A, 2004, RHEUMATOLOGY, V43, P662, DOI 10.1093/rheumatology/keg005
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Xiong J, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000010014
   Yao YS, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/324360
   Yeh Mei-Ling, 2010, ACTA ANAESTHESIOL TAIWAN, V48, P80, DOI 10.1016/S1875-4597(10)60018-5
   Yoshimoto K, 2001, ALCOHOL CLIN EXP RES, V25, P0
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
   Zhu J, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2583-8
NR 37
TC 44
Z9 52
U1 4
U2 40
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1531-3433
EI 1534-3081
J9 CURR PAIN HEADACHE R
JI Curr. Pain Headache Rep.
PD JUN 15
PY 2022
VL 26
IS 6
BP 453
EP 458
DI 10.1007/s11916-022-01048-4
EA APR 2022
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 1M1NV
UT WOS:000788410900001
PM 35482244
DA 2026-01-16
ER

PT J
AU Halámková, J
   Dymáčková, R
   Adámková, Krákorová D
AF Halámková, J
   Dymáčková, R
   Adámková Krákorová, D
TI Acupuncture from the perspective of evidence-based medicine - options of clinical
SO Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
LA English
DT Review
DE Acupuncture; Arthralgia; Fatigue; Myalgia; Pain; Vomiting; guidelines; pain; vasomotor symptoms
AB BACKGROUND: Acupuncture is one of the oldest therapeutic methods. The traditional  view of acupuncture is represented by influencing energy pathways through  stimulation of specific points. The original meridian theory, which works with  the assumption of normalization of the flowing energy Qi in the organism is, with  increasing evidence, supplemented with information about the bio-logical impact  of the use of acupuncture from the perspective of Western medicine. Specific  stimulation of particular points on the body leads to the activation of  hypothalamus and pituitary gland through neurotransmitters, resulting in a wide  range of systemic effects. Stimulation of nerves in the muscle, which then  trans-mits a signal to the spinal cord, midbrain, and hypothalamic-pituitary  system, releases neurotransmitters, endogenous opioid peptides, or hormones.  Stimulation of acupuncture points changes the levels of proinflammatory  cytokines, including IL-1-beta, IL-6, IL-17, and TNF-alpha. Currently, according  to the National Comprehensive Cancer Network (NCCN) guidelines, the following  symptoms are indicated for acupuncture treatment: pain including neuropathic  pain, arthralgia, and myalgia, especially in the aromatase inhibitors therapy,  nausea, and vomiting, fatigue, vasomotor symptoms in women and vasomotor symptoms  in men caused by androgen deprivation therapy. Acupuncture seems to be an  effective and safe treatment method for many of the cancer symptoms or the side  effects of cancer treatment, but, like any other treatment method, it has its  indications and contraindications. PURPOSE: This work aims to provide a  comprehensive overview of the use of acupuncture in defined indications,  according to current international guidelines. Thus, the therapeutic  possibilities of symptomatic treatment of cancer and therapy of adverse events of  oncological treatment can be extended.
NR 0
TC 0
SN 1802-530
EI 
J9 Klin Onkol
PD APR 24
PY 2022
VL 35
IS 2
BP 94
EP 99
DI 10.48095/ccko202294
PG 5
WC Acupuncture Therapy; adverse effects; Androgen Antagonists; Evidence-Based Medicine; Humans; Male; Neurotransmitter Agents; Prostatic Neoplasms
UT PubMed:35459333
PM 35459333
DA 2022-04-24
ER

PT J
AU Cho, E
   Park, CH
   Cho, SY
AF Cho, Eunae
   Park, Chang-Hwan
   Cho, Seo Yeon
TI Single balloon enteroscopy-guided endoscopic retrograde pancreatography for the
SO Medicine
LA English
DT Journal Article
AB RATIONALE: Endoscopic treatment of a pancreatic pseudocyst complicated by  pancreaticojejunostomy (PJ) stricture is challenging. PATIENT CONCERNS: A  76-year-old woman presented with worsening abdominal pain and dyspepsia. She had  been receiving adjuvant chemotherapy (capecitabine and cisplatin) for 4 months  after pylorus-preserving pancreaticoduodenectomy (PPPD) for the treatment of  extrahepatic cholangiocarcinoma. DIAGNOSES: Laboratory findings included elevated  serum amylase (145 U/L) and lipase (437 U/L) levels. Abdominal computed  tomography (CT) showed a pancreatic pseudocyst of approximately 3 cm in size and  pancreatic duct dilatation in the remnant pancreas. According to the Response  Evaluation Criteria in Solid Tumors, cholangiocarcinoma is a stable disease.  INTERVENTIONS AND OUTCOMES: Endoscopic drainage of the pancreatic pseudocyst was  planned. Single-balloon enteroscopy (SBE)-guided endoscopic retrograde  pancreatography (ERP) with endoscopic ultrasonography (EUS) using a mini probe  demonstrated a membranous PJ stricture and a pancreatic pseudocyst. Endoscopic  pseudocyst drainage using a 7-Fr plastic stent was successfully performed after  needle-knife incision of the PJ stricture. Follow-up abdominal CT after 3 weeks  showed complete resolution of the pseudocyst. Chemotherapy was resumed. LESSONS:  SBE-guided ERP with EUS using a mini probe may be an effective and safe treatment  in a patient with a pancreatic pseudocyst complicated by membranous PJ stricture  after PPPD.
C1 Division of Gastroenterology, Department of Internal Medicine, Chonnam National University School of Medicine, Gwangju, South Korea.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD NOV 2
PY 2022
VL 101
IS 43
BP e31293
EP e31293
DI 10.1097/MD.0000000000031293
PG 1
WC Female; Humans; Aged; Pancreatic Pseudocyst; complications; Pancreaticojejunostomy; adverse effects; Single-Balloon Enteroscopy; Constriction, Pathologic; surgery; Pancreas; Endosonography; adverse effects; Drainage; methods; Treatment Outcome
UT PubMed:36316922
PM 36316922
DA 2022-11-02
ER

PT J
AU Viel, E
   Truong, D
   Rambach, L
   Guinet, F
   Vanoli, A
   Schipman, B
   Harami, D
AF Viel, Erika
   Truong, David
   Rambach, Laurie
   Guinet, François
   Vanoli, André
   Schipman, Benjamin
   Harami, Djamel
TI Efficacy of Auricular Acupuncture in Chemotherapy-Induced Peripheral Neuropathy:
SO Medical acupuncture
LA English
DT Journal Article
DE auricular acupuncture; auriculotherapy; cancer; chemotherapy-induced peripheral neuropathy; neuropathy
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) can adversely  affect completion of systemic anticancer treatment and cause long-term morbidity.  To date, its physiopathology remains unclear, and treatments are rare and poorly  performed. Auricular acupuncture has already offered interesting results in  several symptoms. Objective: This study (AACIPN2020) assessed the efficacy of  auriculotherapy in CIPN. Design: We used patients' systematically collected data  of 2014-2016 in a medical oncology practice. The treatment was made according to  guidelines of the interuniversity diploma and the cartography of the World Health  Organization. Pain assessment according to the Common Terminology Criteria for  Adverse Event scale was orally collected. Results: Seventy-three cancer patients  were treated for CIPN. They had finished chemotherapy 24 weeks prior on average.  They received on average 23 punctures at each appointment. Sixty-five percent of  patients met satisfaction, with 31% with a real impact on their daily life.  Efficacy appeared after one or two treatments for 96% of cases. Some patients  continued treatment to maximize benefits. Conclusions: Auricular acupuncture is a  safe and inexpensive method of CIPN treatment. It may be applied earlier in  chemotherapy administration, and in a large variety of other symptoms. Clinical  trial registration number: COS RGDS 2019 09 001.
C1 Medical Oncology, Ramsay Générale de Santé, Hopital Privé Sainte Marie, Chalon-sur-Saône, France.
   Centre Georges-François Leclerc, Dijon, France.
   Toussus-Le-Noble, France.
   Medical Oncology, Centre Hospitalier William Morey, Chalon-sur-Saône, France.
   Medical Oncology, Centre Hospitalier Galuzot, Montceau Les Mines, France.
   Medical Oncology, Ramsay Générale de Santé, Hopital Privé Sainte Marie, Chalon-sur-Saône, France.
   Radiotherapy, Institut de Cancérologie de Bourgogne, Chalon-sur-Saône, France.
   Oncology Department, Chalon-sur-Saône, France.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD JAN 11
PY 2022
VL 33
IS 3
BP 212
EP 218
DI 10.1089/acu.2020.1506
PG 6
UT PubMed:35003493
PM 35003493
DA 2022-01-11
ER

PT J
AU Escobar, Y
   Margarit, C
   Pérez-Hernández, C
   Quintanar, T
   Virizuela, JA
AF Escobar, Yolanda
   Margarit, Cesar
   Perez-Hernandez, Concepcion
   Quintanar, Teresa
   Virizuela, Juan A.
TI Good practice recommendations to better coordinate the management of oncological pain: a Delphi survey
SO SCIENTIFIC REPORTS
LA English
DT Article
ID cancer-related pain; palliative care; prevalence; barriers; continuity
AB Treatment of oncological pain is complex and requires a multidisciplinary management approach between oncology services and pain units. Although significant improvements have been achieved in the treatment and overall survival of cancer patients, the management of oncological pain has not followed the same directions. Many patients are not referred to pain units even though they could benefit from it. The purpose of this Delphi survey was to map the current situation in the management of cancer pain, identify barriers and propose recommendations to improve its management by emphasizing the importance of collaboration and coordination between oncology services and pain units. A survey among members with recognized experience in the management of oncology patients and oncological pain was held based on the Delphi method principles. The experts were asked to vote preselected statements on cancer pain management in two rounds and conclusions and recommendations were formulated based on the consensus reached for each statement. Barriers and areas for improvement were identified: need of multidisciplinary management approach, effective communication between oncology services and pain units, timely referral of cancer patients to pain units, training of health care professionals dealing with cancer aspects and identification of those patients that could benefit from a multidisciplinary management of their oncological disease. The experts issued recommendations targeting the identified barriers and areas for improvement by defining the service requirements of hospital and units treating cancer pain patients, establishing referral pathways necessities and adopted measures to improve the care of cancer patients.
C1 [Escobar, Yolanda] Univ Gen Hosp Gregorio Maranon, Med Oncol Serv, Spanish Med Oncol Soc, Madrid, Spain.
   [Margarit, Cesar] Univ Gen Hosp Alicante, Pain Unit, Spanish Pain Soc, Alicante, Spain.
   [Perez-Hernandez, Concepcion] Univ Hosp La Princesa, Pain Unit, Spanish Pain Soc, Madrid, Spain.
   [Quintanar, Teresa] Univ Gen Hosp Elche, Med Oncol Serv, Spanish Med Oncol Soc, Alicante, Spain.
   [Virizuela, Juan A.] Univ Hosp Virgen Macarena, Med Oncol Serv, Spanish Med Oncol Soc, Seville, Spain.
C3 General University Gregorio Maranon Hospital; General University Hospital of Alicante; Virgen del Rocio University Hospital; University of Sevilla; Hospital Universitario Virgen Macarena
RP Escobar, Y (corresponding author), Univ Gen Hosp Gregorio Maranon, Med Oncol Serv, Spanish Med Oncol Soc, Madrid, Spain.
EM yolandaesco@yahoo.es
CR Bakitas MA, 2015, J CLIN ONCOL, V33, P1438, DOI 10.1200/JCO.2014.58.6362
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Breuer B, 2011, J CLIN ONCOL, V29, P4769, DOI 10.1200/JCO.2011.35.0561
   Butt S, 2013, JPMI, V27, P387
   Callaway M, 2007, J PAIN SYMPTOM MANAG, V33, P483, DOI 10.1016/j.jpainsymman.2007.02.030
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Dekel BGS, 2014, CLIN MANAG ISSUES, V8, P83, DOI 10.7175/cmi.v8i3.930
   Diamond IR, 2014, J CLIN EPIDEMIOL, V67, P401, DOI 10.1016/j.jclinepi.2013.12.002
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fennell Mary L, 2010, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP72, DOI 10.1093/jncimonographs/lgq010
   Gallagher R, 2004, PAIN RES MANAG, V9, P188
   Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574
   Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761
   Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219
   Hong SH, 2011, J PAIN SYMPTOM MANAG, V41, P93, DOI 10.1016/j.jpainsymman.2010.03.025
   Hui D, 2016, NAT REV CLIN ONCOL, V13, P159, DOI 10.1038/nrclinonc.2015.201
   Jerant A, 2011, PATIENT PREFER ADHER, V5, P23, DOI 10.2147/PPA.S16236
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Palanca Sanchez I, 2011, UNIDAD TRATAMIENTO D, V0, P0
   Pargeon KL, 1999, J PAIN SYMPTOM MANAG, V18, P358, DOI 10.1016/S0885-3924(99)00097-4
   Pérez C, 2015, EUR J PAIN, V19, P752, DOI 10.1002/ejp.598
   Pérez C, 2021, J PERS MED, V11, P0, DOI 10.3390/jpm11020102
   Perez J, 2016, PAIN RES MANAG, V2016, P0, DOI 10.1155/2016/2157950
   Pérez-Hernández C, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-019-54195-x
   Porta-Sales J, 2015, J PALLIAT MED, V18, P923, DOI 10.1089/jpm.2015.29002.jps
   González-Escalada JR, 2011, MED PALIATIVA, V18, P63
   Sayed D, 2013, TECHNIQUES IN REGIONAL ANESTHESIA AND PAIN MANAGEMENT, V17, P163, DOI 10.1053/j.trap.2014.07.003
   Schenker Y, 2014, J ONCOL PRACT, V10, PE37, DOI 10.1200/JOP.2013.001130
   Silvoniemi M, 2012, SUPPORT CARE CANCER, V20, P2747, DOI 10.1007/s00520-012-1396-9
   Smith T, 2002, J CLIN ONCOL, V20, P7
   Stjernswärd J, 2007, J PAIN SYMPTOM MANAG, V33, P486, DOI 10.1016/j.jpainsymman.2007.02.016
   Turk DC, 2010, INTERDISCIPLINARY PA, V0, P0
   Wang HL, 2012, PSYCHOSOM MED, V74, P642, DOI 10.1097/PSY.0b013e3182590904
   WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L
NR 34
TC 5
Z9 5
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
EI 
J9 SCI REP-UK
JI Sci Rep
PD DEC 28
PY 2022
VL 12
IS 1
BP 
EP 
DI 10.1038/s41598-022-26753-3
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 7L1VX
UT WOS:000905762900013
PM 36577791
DA 2026-01-16
ER

PT J
AU Sheng, GY
   Yang, J
   Rong, P
   Yang, XY
AF Sheng, Guanyun
   Yang, Jing
   Rong, Peng
   Yang, Xueyi
TI RETRACTED: Effects of Warm Needle Acupuncture plus Xitong Waixi Lotion in Patients with Knee Osteoarthritis: A Randomized Controlled Trial (Retracted Article)
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article; Retracted Publication
AB Objective. To evaluate the effect of warm needle acupuncture plus Xitong Waixi lotion on the levels of IL-1, TNF-alpha, and MMP-3 in patients with knee osteoarthritis. Methods. Eighty patients with knee osteoarthritis admitted to our hospital from October 2019 to June 2021 were recruited and assigned via the random number table method at a ratio of 1:1 to receive either Xitong Waixi lotion (conventional group) or warm needle acupuncture plus Xitong Waixi lotion (combined group). Outcome measures included clinical efficacy, inflammatory cytokine level, Western Ontario and McMaster Universities Arthritis Index (WOMAC) score, visual analogue scale (VAS) score, Hospital for Special Surgery (HSS) knee score, and adverse reactions. Results. Warm needle acupuncture plus Xitong Waixi lotion was associated with a significantly higher clinical efficacy versus Xitong Waixi lotion alone (P = 0.006). Patients in the combined group had significantly lower levels of interleukin (IL)-1, tumor necrosis factor-alpha (TNF-alpha), and matrix metalloproteinase-3 (MMP-3) than those in the conventional group (P = 0.020). Warm needle acupuncture plus Xitong Waixi lotion resulted in significantly lower WOMAC scores and VAS scores and higher HSS scores for the patients versus Xitong Waixi lotion (P = 0.012). The two groups had a similar incidence of adverse events (P = 0.068). Conclusion. Warm needle acupuncture plus Xitong Waixi lotion effectively alleviates the inflammatory response and knee pain in patients with knee osteoarthritis, with significant clinical effects and a high safety profile.
C1 [Sheng, Guanyun; Yang, Xueyi] Guangxi Univ Chinese Med, Liuzhou Tradit Chinese Med Hosp, Dept Orthopaed, Liuzhou 545001, Peoples R China.
   [Yang, Jing] Guangxi Univ Chinese Med, Liuzhou Tradit Chinese Med Hosp, Intens Care Unit, Liuzhou 545001, Peoples R China.
   [Rong, Peng] Guangxi Univ Chinese Med, Grad Sch, Nanning 530000, Peoples R China.
C3 Guangxi University of Chinese Medicine; Guangxi University of Chinese Medicine; Guangxi University of Chinese Medicine
RP Yang, XY (corresponding author), Guangxi Univ Chinese Med, Liuzhou Tradit Chinese Med Hosp, Dept Orthopaed, Liuzhou 545001, Peoples R China.
EM leiyixie6132476816@163.com
FU Guangxi Natural Science Foundation Program;  [2018GXNSFAA050103]
CR Adly AS, 2021, J TELEMED TELECARE, V27, P298, DOI 10.1177/1357633X211009861
   Aljasir B, 2010, EVID-BASED COMPL ALT, V7, P399, DOI 10.1093/ecam/nen027
   Barnard A, 2020, J HAND SURG-EUR VOL, V45, P488, DOI 10.1177/1753193420911326
   Chen RX, 2010, BMC COMPLEM ALTERN M, V10, P0, DOI 10.1186/1472-6882-10-32
   Chen WJ, 2021, FRONT MED-LAUSANNE, V8, P0, DOI 10.3389/fmed.2021.752556
   Chen WJ, 2021, FRONT MED-LAUSANNE, V7, P0, DOI 10.3389/fmed.2020.601606
   Chi XS, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0297-y
   da Costa BR, 2021, BMJ-BRIT MED J, V375, P0, DOI 10.1136/bmj.n2321
   Davidson Patricia, 2003, EUR J CARDIOVASC NURS, V2, P171, DOI 10.1016/S1474-5151(03)00057-4
   Guo Yao-Guang, 2021, ZHEN CI YAN JIU, V46, P145, DOI 10.13702/j.1000-0607.200181
   Hashemi MS, 2019, EUR J INTEGR MED, V29, P0, DOI 10.1016/j.eujim.2019.100929
   Jorge Liliana L, 2010, J PAIN RES, V4, P11, DOI 10.2147/JPR.S9492
   Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI 10.1002/art.41142
   Lee G, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023527
   Li J, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000016301
   Liang H, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/8161731
   Liu Jing, 2020, ZHEN CI YAN JIU, V45, P914, DOI 10.13702/j.1000-0607.190848
   Luo HF, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05514-z
   Luo HF, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05416-0
   Lv Shan-Guang, 2021, ZHONGGUO ZHEN JIU, V41, P999, DOI 10.13703/j.0255-2930.20200721-k0008
   Ma YF, 2019, JOURNAL OF INTEGRATIVE NURSING, V1, P73, DOI 10.35437/intnur.issn.2663-4481.2019.01.02.02
   Marchetti G, 2020, ACUPUNCT MED, V38, P440, DOI 10.1177/0964528420920281
   Morgan MM, 2011, BRIT J PHARMACOL, V164, P1322, DOI 10.1111/j.1476-5381.2011.01335.x
   Nayebi Neda, 2019, J COMPLEMENT INTEGR MED, V16, P0, DOI 10.1515/jcim-2018-0088
   Qu Xiao-Dong, 2019, ZHONGGUO GU SHANG, V32, P493, DOI 10.3969/j.issn.1003-0034.2019.06.002
   Ren SJ, 2021, J NANOBIOTECHNOL, V19, P0, DOI 10.1186/s12951-021-01157-z
   Riddle DL, 2020, OSTEOARTHR CARTILAGE, V28, P0
   Shang JW, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000026859
   Shang JW, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021857
   Shen D, 2021, PURINERG SIGNAL, V17, P411, DOI 10.1007/s11302-021-09777-8
   Smolen JS, 2019, LANCET, V393, P2303, DOI 10.1016/S0140-6736(19)30419-2
   Suarez-Almazor ME, 2010, JCR-J CLIN RHEUMATOL, V16, P158, DOI 10.1097/RHU.0b013e3181df4de4
   Tong J, 2022, PAIN RES MANAG, V2022, P0, DOI 10.1155/2022/9939891
   Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584
   Uckay Ilker, 2019, FOOT ANKLE INT, V40, P3S, DOI 10.1177/1071100719857082
   Zheng YW, 2021, LIFE-BASEL, V11, P0, DOI 10.3390/life11060513
NR 36
TC 0
Z9 1
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD AUG 5
PY 2022
VL 2022
IS 
BP 
EP 
DI 10.1155/2022/5467712
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 3Z7XB
UT WOS:000844628800008
PM 35966733
DA 2026-01-16
ER

PT J
AU Zou, X
   Yang, YC
   Wang, Y
   Pei, W
   Han, JG
   Lu, Y
   Zhang, MS
   Tu, JF
   Lin, LL
   Wang, LQ
   Shi, G
   Yan, SY
   Yang, JW
   Liu, CZ
AF Zou, Xuan
   Yang, Ying-Chi
   Wang, Yu
   Pei, Wei
   Han, Jia-Gang
   Lu, Yun
   Zhang, Mao-Shen
   Tu, Jian Feng
   Lin, Lu Lu
   Wang, Li-Qiong
   Shi, Guangxia
   Yan, Shi-Yan
   Yang, Jing-Wen
   Liu, Cun-Zhi
TI Electroacupuncture versus sham electroacupuncture in the treatment of
SO BMJ open
LA English
DT Journal Article
DE COMPLEMENTARY MEDICINE; Endoscopic surgery; Functional bowel disorders; Gastrointestinal tumours
AB INTRODUCTION: Postoperative ileus (POI) is an inevitable complication of almost  all abdominal surgeries, which results in prolonged hospitalisation and increased  healthcare costs. Various treatment strategies have been developed for POI but  with limited success. Electroacupuncture (EA) might be a potential therapy for  POI. However, evidence from rigorous trials that evaluated the effectiveness of  EA for POI is limited. Thus, the aim of this study was to examine whether EA can  safely reduce the time to the first defecation after laparoscopic surgery in  patients with POI. METHODS AND ANALYSIS: This multicentre randomised  sham-controlled trial will be conducted in four hospitals in China. A total of  248 eligible participants with colorectal cancer who will undergo laparoscopic  surgery will be randomly allocated to an EA group and a sham EA group in a 1:1  ratio. Treatment will be performed starting on postoperative day 1 and continued  for four consecutive days, once per day. If the participant is discharged within  4 days after surgery, the treatment will cease on the day of discharge. The  primary outcome will be the time to first defecation. The secondary outcome  measures will include time to first flatus, tolerability of semiliquid and solid  food, length of postoperative hospital stay, postoperative nausea and vomiting,  abdominal distension, postoperative pain, postoperative analgesic, time to first  ambulation, blinding assessment, credibility and expectancy and readmission rate.  ETHICS AND DISSEMINATION: Ethics approval was obtained from the Ethics Committee  of Beijing University of Chinese Medicine (number 2020BZHYLL0116) and the  institutional review board of each hospital. The results will be disseminated  through peer-reviewed publications. This study protocol (V.3.0, 6 March 2020)  involves human participants and was approved by the ethics committees of Beijing  University of Chinese Medicine (number 2020BZHYLL0116), Beijing Friendship  Hospital Affiliated to Capital Medical University (number 2020-P2-069-01),  Beijing Chao-Yang Hospital Affiliated to Capital Medical University (number  2020-3-11-2), National Cancer Center/National Clinical Research Center for  Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union  Medical College (number 20/163-2359), and the Affiliated Hospital of Qingdao  University (number QYFYKYLL711311920). The participants gave informed consent to  participate in the study before taking part. TRIAL REGISTRATION NUMBER:  ChiCTR2000038444.
C1 International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing, China.
   Beijing Chao-Yang Hospital Affiliated to Capital Medical University, Beijing, China.
   The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
   The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China ysy20200927@163.comyangjw0626@126.com.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China ysy20200927@163.comyangjw0626@126.com.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD APR 17
PY 2022
VL 12
IS 4
BP e050000
EP e050000
DI 10.1136/bmjopen-2021-050000
PG 1
WC Colorectal Neoplasms; complications; Electroacupuncture; methods; Humans; Ileus; etiology; Laparoscopy; adverse effects; Multicenter Studies as Topic; Postoperative Complications; therapy; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:35428615
PM 35428615
DA 2022-04-17
ER

PT J
AU Ylva, W
   Per, F
   Anna, E
AF Ylva, Widgren
   Per, Fransson
   Anna, Efverman
TI Acupuncture in Patients Undergoing Cancer Therapy: Their Interest and Belief in Acupuncture is High, But Few are Using It
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture therapy; attitudes; cancer survivors; complementary and alternative medicine; expectations; oncology nursing
ID alternative medicine; complementary; expectations; survivors; outcm; health
AB Objectives: Since pre-existing expectations, that is, beliefs, in a treatment may modify outcomes, and acupuncture studies often fail to measure expectations, we wanted to investigate the use of acupuncture, interest, and belief in acupuncture effects among patients undergoing cancer therapy. Method: A cross-sectional design, where the participants answered a study-specific questionnaire with questions regarding their use of, interest and belief in acupuncture treatment. Results: A total of 457 patients with cancer (48% men, mean age 65 years) answered the questionnaire. Acupuncture was used by 4 (1%) patients during their cancer therapy, and 368 (83%) expressed an interest in receiving acupuncture. Of the 457 patients, 289 (63%) believed acupuncture to be effective for at least 1 of 17 requested symptoms, most commonly pain (56% of the patients) and muscle tension (40%). They believed acupuncture to be effective for a mean value 3 of the 17 requested symptoms. Women (P < .001), and patients 41 to 65 years (P < .001), expressed a stronger belief in acupuncture effects than others. Conclusions: Men and older patients expressed weaker beliefs in acupuncture effects than other patients, indicating the importance of collecting expectancy data in future randomized sham-controlled acupuncture studies to be able to treat expectancy as an effect-modifier. The high interest and beliefs in acupuncture effects found also indicate that acupuncture should be available for patients with cancer, for side effects where acupuncture has shown to be effective. In a clinical setting, older men might need more encouragement regarding positive expected outcomes of the acupuncture treatment than younger women.
C1 [Ylva, Widgren; Anna, Efverman] Univ Gavle, Gavle, Sweden.
   [Ylva, Widgren] Region Hosp Sundsvall Harnosand, Cty Council Vasternorrland, Vasternorrland, Sweden.
   [Per, Fransson] Umea Univ, Umea, Sweden.
   [Per, Fransson] Umea Univ Hosp, Umea, Sweden.
C3 University of Gavle; Umea University; Umea University; Umea University Hospital
RP Ylva, W (corresponding author), Univ Gavle, Fac Hlth & Occupat Studies, Dept Caring Sci, S-80176 Gavle, Sweden.
EM ylva.widgren@hig.se
CR Bauml Joshua, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP302, DOI 10.1093/jncimonographs/lgu029
   Bausewein C, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005623.pub2
   Buettner C, 2006, BREAST CANCER RES TR, V100, P219, DOI 10.1007/s10549-006-9239-3
   Carmady B, 2011, CHIN MED-UK, V6, P0, DOI 10.1186/1749-8546-6-22
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   Colagiuri B, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/857804
   Colloca L, 2009, PAIN, V144, P28, DOI 10.1016/j.pain.2009.01.033
   Dai L, 2021, J PALLIAT MED, V24, P1078, DOI 10.1089/jpm.2020.0405
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   Efverman A, 2020, COMPLEMENT THER MED, V52, P0, DOI 10.1016/j.ctim.2020.102404
   Enblom A, 2017, ACUPUNCT MED, V35, P251, DOI 10.1136/acupmed-2015-011007
   Enblom A, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0014766
   Enblom A, 2009, SUPPORT CARE CANCER, V17, P23, DOI 10.1007/s00520-008-0445-x
   Fava GA, 2012, INT J CLIN PRACT, V66, P11, DOI 10.1111/j.1742-1241.2011.02825.x
   Forde JC, 2016, INT UROGYNECOL J, V27, P1645, DOI 10.1007/s00192-015-2935-y
   Garcia GT, 2021, MED ACUPUNCT, V33, P22, DOI 10.1089/acu.2020.1431
   Garcia MK, 2015, CANCER-AM CANCER SOC, V121, P3948, DOI 10.1002/cncr.29630
   Gras M, 2019, ONCOLOGY-BASEL, V97, P18, DOI 10.1159/000499629
   Haddad NE, 2014, INTEGR CANCER THER, V13, P371, DOI 10.1177/1534735413520181
   Hanssen B, 2005, SCAND J PRIM HEALTH, V23, P57, DOI 10.1080/02813430510018419
   Hunter T, 2014, EUR J PAIN, V18, P914, DOI 10.1002/j.1532-2149.2013.00436.x
   Jang S, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021820
   Kaptchuk TJ, 2020, BMJ-BRIT MED J, V370, P0, DOI 10.1136/bmj.m1668
   Kelley JM, 2009, PSYCHOSOM MED, V71, P789, DOI 10.1097/PSY.0b013e3181acee12
   Kessel KA, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0165801
   Lee I, 2017, ACUPUNCT MED, V35, P0, DOI 10.1136/acupmed-2016-011056
   Lettner S, 2017, STRAHLENTHER ONKOL, V193, P419, DOI 10.1007/s00066-017-1101-5
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Loquai C, 2017, EUR J CANCER, V71, P70, DOI 10.1016/j.ejca.2016.10.029
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Mitchell C, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002088.pub3
   Ni XX, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420980825
   Nissen N, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-388
   Prady SL, 2015, COMPLEMENT THER MED, V23, P185, DOI 10.1016/j.ctim.2015.01.007
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Rossi E, 2015, SUPPORT CARE CANCER, V23, P1795, DOI 10.1007/s00520-014-2517-4
   Sharp Debbie, 2018, BJGP OPEN, V2, Pbjgpopen18X101614, DOI 10.3399/bjgpopen18x101614
   Shay LA, 2015, MED DECIS MAKING, V35, P114, DOI 10.1177/0272989X14551638
   Steineck G, 2002, ACTA ONCOL, V41, P244, DOI 10.1080/02841860260088782
   Steineck G, 2002, NEW ENGL J MED, V347, P790, DOI 10.1056/NEJMoa021483
   Stub T, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2106-z
   Widgren Y, 2021, IMPORTANCE STR UNPUB, V0, P0
   Witt CM, 2017, J NATL CANC I MONOGR, V2017, P0
   Wode K, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2452-5
   Xu MM, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003317.pub3
NR 47
TC 10
Z9 10
U1 1
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD FEB 15
PY 2022
VL 21
IS 
BP 
EP 
DI 10.1177/15347354221077277
PG 11
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA ZO7AW
UT WOS:000765880900001
PM 35212241
DA 2026-01-16
ER

PT J
AU Choi, TY
   Ang, L
   Jun, JH
   Alraek, T
   Birch, S
   Lu, WD
   Lee, MS
AF Choi, Tae-Young
   Ang, Lin
   Jun, Ji Hee
   Alraek, Terje
   Birch, Stephen
   Lu, Weidong
   Lee, Myeong Soo
TI Acupuncture for Managing Cancer-Related Fatigue in Breast Cancer Patients: A Systematic Review and Meta-Analysis
SO CANCERS
LA English
DT Review
DE acupuncture; cancer; breast; fatigue; systematic review; meta-analysis
ID inhibitor-related arthralgia; double-blind; therapy; moxibustion; safety; women
AB Simple Summary Acupuncture (AT) itself is not used to treat cancer. AT is used to help manage various side effects (pain, hot flashes, and fatigue) that occur in cancer treatment. However, the mechanism of action and efficacy of AT are uncertain. The purpose of this systematic review and meta-analysis was to explore the benefits of acupuncture in patients with breast cancer-related fatigue (CRF). Breast cancer (BC) is the most common cancer in women and is a serious threat to women's health. Cancer-related fatigue (CRF) is a distressing symptom in BC patients during and after chemotherapy or radiation therapy that severely affects quality of life (QoL). AT is widely used for fatigue management. However, the effect of AT on CRF is still uncertain. This study aimed to evaluate the efficacy and safety of AT in the management of CRF in patients with BC. Eleven databases were searched through June 2022. Two researchers independently performed the database search, study selection, data extraction, and risk of bias assessment. Study selection was performed based on predefined Participants, Intervention, Comparators, Outcomes, Study design (PICOS) criteria, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed when reporting the results. A meta-analysis was performed according to the Cochrane systematic review method using RevMan 5.3. A total of 12 studies including a total of 1084 participants were included. The results showed that AT had a beneficial effect compared with sham AT (n = 256, SMD = -0.26, 95% CI [-0.51, -0.01], p = 0.04, I-2 = 0%) and a long-term effect on fatigue score (n = 209, MD = -0.32, 95% CI [-0.59, -0.04], p = 0.02, I-2 = 0%). Meta-analysis showed that AT had a beneficial effect compared with usual care (UC) on fatigue scores (n = 238, SMD = -0.39, 95% CI [-0.66 to -0.12], p = 0.005, I-2 = 0%). Of the 12 articles, 3 articles were judged as having a low risk of bias in all domains and hence were of high quality. No serious adverse effects were identified. AT is an effective and safe treatment for CRF, and AT is more effective than sham AT or UC or wait-list control (WLC). Nevertheless, the methodological quality of most of these studies was low, and the included studies/sample sizes were small, so the ability to derive decisive implications was limited. Further research is needed to confirm these findings.
C1 [Choi, Tae-Young; Ang, Lin; Jun, Ji Hee; Lee, Myeong Soo] Korea Inst Oriental Med, KM Sci Res Div, Daejeon 34054, South Korea.
   [Alraek, Terje; Birch, Stephen] Kristiania Univ Coll, Sch Hlth Sci, N-0107 Oslo, Norway.
   [Alraek, Terje] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Community Med, Natl Res Ctr Complementary & Alternat Med NAFKAM, N-9037 Tromso, Norway.
   [Lu, Weidong] Harvard Med Sch USA, Dana Farber Canc Inst, Boston, MA 02115 USA.
C3 Korea Institute of Oriental Medicine (KIOM); Kristiania University College; UiT The Arctic University of Tromso; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute
RP Lee, MS (corresponding author), Korea Inst Oriental Med, KM Sci Res Div, Daejeon 34054, South Korea.
EM drmslee@gmail.com
FU Korea Institute of Oriental Medicine, Korea [KSN2022210]; Pink Ribbon [207697-2019]
CR Unknown -, 2009, BMJ-BRIT MED J, V6, Pe1000097, DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1371/JOURNAL.PMED.1000097
   Arring NM, 2019, CANCER J, V25, P349, DOI 10.1097/PPO.0000000000000396
   Berger AM, 2015, J NATL COMPR CANC NE, V13, P1012, DOI 10.6004/jnccn.2015.0122
   Birch S, 2022, INTEGR MED RES, V11, P0, DOI 10.1016/j.imr.2022.100834
   Birch S, 2022, INTEGR MED RES, V11, P0, DOI 10.1016/j.imr.2021.100725
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Brinkhaus B, 2019, BREAST CANCER RES TR, V178, P617, DOI 10.1007/s10549-019-05431-5
   Chen J, 2016, JIANGSU J TRADIT CHI, V48, P56
   Chen YP, 2016, J CANCER RES THER, V12, P535, DOI 10.4103/0973-1482.172716
   Cheng CS, 2017, SUPPORT CARE CANCER, V25, P3807, DOI 10.1007/s00520-017-3812-7
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Chien TJ, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180918
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14102347
   Cybularz PA, 2015, MED ACUPUNCT, V27, P224, DOI 10.1089/acu.2015.1099
   Ebede CC, 2017, MED CLIN N AM, V101, P1085, DOI 10.1016/j.mcna.2017.06.007
   Fabi A, 2020, ANN ONCOL, V31, P713, DOI 10.1016/j.annonc.2020.02.016
   Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
   Halamkova J, 2022, KLIN ONKOL, V35, P94, DOI 10.48095/ccko202294
   Hou WZ, 2019, J OBSTET GYNAECOL RE, V45, P2307, DOI 10.1111/jog.14122
   Höxtermann MD, 2022, CANCER-AM CANCER SOC, V128, P2159, DOI 10.1002/cncr.34165
   Johnston MF, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-49
   Juvet LK, 2017, BREAST, V33, P166, DOI 10.1016/j.breast.2017.04.003
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee IS, 2021, INTEGR MED RES, V10, P0, DOI 10.1016/j.imr.2021.100754
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li YF, 2020, ONCOTARGETS THER, V13, P11743, DOI 10.2147/OTT.S272747
   Liu JP, 2022, INTEGR MED RES, V11, P0, DOI 10.1016/j.imr.2022.100836
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   Maass SWMC, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13061301
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mao HJ, 2016, CANCER-AM CANCER SOC, V122, P3667, DOI 10.1002/cncr.30189
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Minton O, 2008, BREAST CANCER RES TR, V112, P5, DOI 10.1007/s10549-007-9831-1
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Noal S, 2011, INT J RADIAT ONCOL, V81, P795, DOI 10.1016/j.ijrobp.2010.06.037
   Pan YQ, 2018, INTEGR CANCER THER, V17, P602, DOI 10.1177/1534735418786801
   Pudkasam S, 2021, MATURITAS, V152, P32, DOI 10.1016/j.maturitas.2021.06.008
   Roldán-Jiménez C, 2022, SUPPORT CARE CANCER, V30, P1243, DOI 10.1007/s00520-021-06470-9
   Saligan LN, 2015, SUPPORT CARE CANCER, V23, P2461, DOI 10.1007/s00520-015-2763-0
   Shih YW, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211063884
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Tan JY, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.866284
   Wang XS, 2015, GYNECOL ONCOL, V136, P446, DOI 10.1016/j.ygyno.2014.10.013
   Witt CM, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-148
   Yu M, 2017, CHINA MED HERALD, V14, P89
   Pan YQ, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420940394
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   [张玉 Zhang Yu], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P509
   Zhang YZ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.646315
   Zhou C, 2018, ACTA CHIN MED, V33, P950, DOI 10.16368/j.issn.1674-8999.2018.06.227
   Zhu DL, 2016, SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION SHANG HAI ZHEN JIU ZA ZHI, V35, P964, DOI 10.13460/j.issn.1005-0957.2016.08.0964
NR 53
TC 27
Z9 31
U1 3
U2 20
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6694
J9 CANCERS
JI Cancers
PD SEP 15
PY 2022
VL 14
IS 18
BP 
EP 
DI 10.3390/cancers14184419
PG 14
WC Oncology
SC Oncology
GA 4S8UM
UT WOS:000857708700001
PM 36139579
DA 2026-01-16
ER

PT J
AU Wang, F
   Zhao, J
   Li, Y
   Yang, X
   Wu, D
   Yang, B
   Zhang, C
   He, Z
   Du, L
   Zhu, X
   Ming, D
   Liu, Y
   Tang, D
AF Wang, Feiqing
   Zhao, Jianing
   Li, Yanju
   Yang, Xu
   Wu, Dan
   Yang, Bo
   Zhang, Chike
   He, Zhixu
   Du, Liang
   Zhu, Xiaodong
   Ming, Dong
   Liu, Yang
   Tang, Dongxin
TI Acupuncture and acupressure with improved cancer-related depression of
SO Frontiers in oncology
LA English
DT Journal Article
DE acupoints; acupressure; acupuncture; cancer/tumor/oncology; depression
AB INTRODUCTION: Acupuncture and acupressure are widely used for treating cancer  pain and depression and recognized as safe and effective by the international  medical community. In this study, we systematically evaluated the efficacy,  safety, and clinical significance of acupuncture and acupressure in treating  cancer-related depression. METHODS: We searched MEDLINE, PubMed, Science Direct,  Google Scholar, Web of Science and Embase and Chinese-language databases for  randomized clinical trials (RCTs). To assess efficacy, rating scales administered  by clinicians or experts were preferred, including the Hamilton Depression Rating  Scale (HAMD), Self-rating Depression Scale (SDS), Self-rating Anxiety Scale  (SAS), and Quality of Life Questionnaire-Core 30 (QLQ-C30) and the total  effective rate after treatment. In all, Sixteen RCTs involving 1019 cancer  patients were included in the Meta-analysis. RESULTS: Eleven (69%) of these  studies reported the post-treatment total effective rate. Three hundred  fifty-three patients received antidepressants; the total effective rate was  72.5%. Three hundred sixty-one patients underwent acupuncture and acupressure;  the total effective rate was 90%. Meta-analysis results showed I(2) = 0%, no  heterogeneity, (Z = 5.84, p < 0.00001); and combined OR = 3.55, (95% CI = 2.32 to  5.43). DISCUSSION: This study found that acupuncture and acupressure are as  effective as medication in the treatment of cancer-related depression, provide a  reliable basis for the clinical use of acupuncture to treat cancer-related  depression, help promote nonpharmacological treatment for cancer-related  complications. These approaches thus help reduce drug resistance and adverse  reactions and improve patients' quality of life.
C1 Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
   Academy of Medical Engineering and Translational Medicine, Tianjin University, 
   Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
   Department of Hematology Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
   Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
   Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
   Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
   Department of Hematology Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
   Department of Hematology Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
   Key Laboratory of Adult Stem Cell Translational Research, Chinese Academy of 
   Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
   Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.
   Neurological Institute, Tianjin Medical University General Hospital, Tianjin, 
   Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.
   Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
   Key Laboratory of Adult Stem Cell Translational Research, Chinese Academy of 
   Clinical Medical Research Center, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD DEC 30
PY 2022
VL 12
IS 
BP 1036634
EP 1036634
DI 10.3389/fonc.2022.1036634
PG 0
UT PubMed:36578922
PM 36578922
DA 2022-12-30
ER

PT J
AU Huemer, M
   Jahn-Kuch, D
   Hofmann, G
   Pichler, M
AF Huemer, Matthias
   Jahn-Kuch, Daniela
   Hofmann, Guenter
   Pichler, Martin
TI A case report of immediate effects of acupuncture on neuropathic cancer
SO Complementary therapies in clinical practice
LA English
DT Journal Article
DE Acupuncture; Cancer pain; Complementary & alternative medicine (CAM); Neuropathic pain; Pain management; Palliative care
AB INTRODUCTION: Acupuncture is a promising treatment for visceral cancer pain, but  to date, evidence for immediate effects on neuropathic pain is limited. CASE  PRESENTATION: This report presents a case of immediate pain relief by  single-needle acupuncture on opioid-refractory neuropathic breakthrough pain in a  78-year-old female breast cancer patient with cervical bone metastases.  Acupuncture was applied at a single point neuroanatomically correlating to the  pain affected spinal segment. DISCUSSION: Immediately after acupuncture, the  patient reported a complete pain relief lasting for one day. In the following  days, neuropathic breakthrough pain was better manageable with reduced dosages of  opioids. Acupuncture is possibly effective in providing immediate and safe pain  relief in neuropathic cancer pain through neuromodulating effects on the spinal  and central nervous level. Randomized controlled studies with individualized  acupuncture point protocols are needed to establish efficacy and safety.
C1 Department of Internal Medicine, Division of Oncology, Palliative Care Unit, Medical University of Graz, Graz, Austria.
   Department of Internal Medicine, Division of Oncology, Palliative Care Unit, Medical University of Graz, Graz, Austria.
   Department of Internal Medicine, Division of Oncology, Palliative Care Unit, Medical University of Graz, Graz, Austria.
   Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria.
EM martin.pichler@medunigraz.at
NR 0
TC 0
SN 1873-694
EI 
J9 Complement Ther Clin Pract
PD MAY 19
PY 2022
VL 48
IS 
BP 101599
EP 101599
DI 10.1016/j.ctcp.2022.101599
PG 0
WC Acupuncture Therapy; adverse effects; Aged; Analgesics, Opioid; Breakthrough Pain; complications; Cancer Pain; therapy; Female; Humans; Neoplasms; Neuralgia; therapy
UT PubMed:35584602
PM 35584602
DA 2022-05-19
ER

PT J
AU Tian, SX
   Xu, T
   Shi, RY
   Cai, YQ
   Wu, MH
   Zhen, SJ
   Wang, W
   Zhou, Y
   Du, JY
   Fang, JF
   Shao, XM
   Liu, BY
   Jiang, YL
   He, XF
   Fang, JQ
   Liang, Y
AF Tian, Shu-Xin
   Xu, Ting
   Shi, Ren-Yi
   Cai, Yang-Qian
   Wu, Ming-Hui
   Zhen, Si-Jia
   Wang, Wen
   Zhou, You
   Du, Jun-Ying
   Fang, Jun-Fan
   Shao, Xiao-Mei
   Liu, Bo-Yi
   Jiang, Yong-Liang
   He, Xiao-Fen
   Fang, Jian-Qiao
   Liang, Yi
TI Analgesic effect of electroacupuncture on bone cancer pain in rat model: the role
SO Purinergic signalling
LA English
DT Journal Article
DE Bone cancer-induced pain; DRG; Electroacupuncture; P2X3 receptor
AB Upregulation of P2X3 receptor (P2X3R) has been strongly implicated in nociceptive  signaling including bone cancer pain (BCP). The present study, using rat bone  cancer model, aimed to explore the role of P2X3R in regulating rat pain behavior  under the intervention of electroacupuncture (EA). The BCP model was successfully  established by injection with MRMT-1 breast cancer cell into the medullary cavity  of left tibia for 3 × 10(4) cells/3 μL PBS in rats as revealed by obvious bone  destruction, decreased paw withdrawal thresholds (PWTs), and reduced paw  withdrawal latencies (PWLs). Western blot analyses showed that P2X3R expression  was significantly upregulated in ipsilateral lumbar 4-6 (L4-6) dorsal root  ganglia (DRG), but the difference not seen in spinal cord dorsal horn (SCDH).  With the in-depth study of P2X3R activation, we observed that intrathecal  injection of P2X3R agonist α,β-meATP aggravated MRMT-1 induced BCP, while  injection of P2X3R inhibitor A-317491 alleviated pain. Subsequently, we  demonstrated that BCP induced mechanical allodynia and thermal hyperalgesia were  attenuated after EA treatment. Under EA treatment, total P2X3R protein expression  in ipsilateral DRGs was decreased, and it is worth mentioning that decreased  expression of P2X3R membrane protein, which indicated that both the expression  and membrane trafficking of P2X3R were inhibited by EA. The immunofluorescence  assay showed that EA stimulation exerted functions by reducing the expression of  P2X3R-positive cells in ipsilateral DRGs of BCP rats. Ca(2+) imaging analysis  revealed that the EA stimulation decreased the percentage of α,β-meATP responsive  neurons in DRGs and inhibited calcium influx. Notably, the inhibitory effect of  EA on mechanical allodynia and nociceptive flinches was abolished by intrathecal  injection of α,β-meATP. These findings demonstrated EA stimulation ameliorated  mechanical allodynia and thermal hyperalgesia in rat model of MRMT-1-induced BCP.  EA exerts analgesic effect on BCP by reducing the overexpression and functional  activity of P2X3R in ipsilateral DRGs of BCP rats. Our work first demonstrates  the critical and overall role of P2X3R in EA's analgesia against peripheral  sensitization of MRMT-1-induced BCP and further supports EA as a potential  therapeutic option for cancer pain in clinic.
C1 Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Acupuncture and Moxibustion, Sanya Traditional Chinese Medicine Hospital, Sanya, 572000, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of 
   Department of Neurobiology and Acupuncture Research, The Third School of Clinical Medicine, Key Laboratory of Acupuncture and Neurology of Zhejiang Province,Zhejiang Chinese Medical University, 548 Binwen Road, Binjiang District,Hangzhou, 310053, Zhejiang Province, China. liangyiwww@126.com.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of
NR 0
TC 0
SN 1573-954
EI 1573-953
J9 Purinergic Signal
PD APR 29
PY 2022
VL 19
IS 1
BP 13
EP 27
DI 10.1007/s11302-022-09861-7
PG 14
WC Rats; Animals; Hyperalgesia; metabolism; Cancer Pain; metabolism; Receptors, Purinergic P2X3; metabolism; Rats, Sprague-Dawley; Electroacupuncture; methods; Pain; metabolism; Bone Neoplasms; metabolism; Analgesics; Ganglia, Spinal; metabolism
UT PubMed:35478452
PM 35478452
DA 2022-04-29
ER

PT J
AU Dev, R
   Bruera, E
AF Dev, Rony
   Bruera, Eduardo
TI Treatment options for persistent pain and numbness in cancer survivors
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Editorial Material; Early Access
DE Pain; numbness; cancer survivors; exercise; alternative medicine
ID induced peripheral neuropathy; breast-cancer; musculoskeletal symptoms; aromatase inhibitors; american society; controlled-trial; acupuncture; prevention; arthralgia; management
C1 [Dev, Rony; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Symptom Control & Palliat Med, Houston, TX USA.
   [Dev, Rony] Univ Texas MD Anderson Canc Ctr, Symptom Control & Palliat Med, 1515 Holcombe Blvd Unit 1212, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center
RP Dev, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Symptom Control & Palliat Med, 1515 Holcombe Blvd Unit 1212, Houston, TX 77030 USA.
EM rdev@mdanderson.org
CR Abe H, 2022, ANN PALLIAT MED, V0, P0, DOI DOI 10.21037/apm-22-420
   Aziz NM, 2003, SEMIN RADIAT ONCOL, V13, P248, DOI 10.1016/S1053-4296(03)00024-9
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Brier MJ, 2018, EUR J CANCER, V91, P145, DOI 10.1016/j.ejca.2017.12.006
   Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559
   Fenton JJ, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.16726
   Galantino ML, 2012, INTEGR CANCER THER, V11, P313, DOI 10.1177/1534735411413270
   Glare P, 2022, DRUGS, V82, P275, DOI 10.1007/s40265-022-01675-6
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Jairam V, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.13605
   Kuehn BM, 2022, JAMA-J AM MED ASSOC, V327, P2387, DOI 10.1001/jama.2022.10100
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Maihöfner C, 2021, SUPPORT CARE CANCER, V29, P4223, DOI 10.1007/s00520-021-06042-x
   Mols F, 2014, SUPPORT CARE CANCER, V22, P2261, DOI 10.1007/s00520-014-2255-7
   Ng AH, 2021, JCO ONCOL PRACT, V17, P440, DOI 10.1200/OP.20.00625
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Pergolizzi JV, 2021, FRONT PAIN RES, V2, P0, DOI 10.3389/fpain.2021.691720
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Tait RC, 2018, J PAIN, V19, P1367, DOI 10.1016/j.jpain.2018.06.002
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Yuksel SS, 2022, JPRAS OPEN, V31, P32, DOI 10.1016/j.jpra.2021.10.009
NR 25
TC 0
Z9 0
U1 1
U2 3
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD DEC 19
PY 2022
VL 0
IS 
BP 
EP 
DI 10.21037/apm-22-1392
EA DEC 2022
PG 4
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 7M5SZ
UT WOS:000906718200001
PM 36627856
DA 2026-01-16
ER

PT J
AU Katta, MR
   Valisekka, SS
   Agarwal, P
   Hameed, M
   Shivam, S
   Kaur, J
   Prasad, S
   Bethineedi, LD
   Lavu, DV
   Katamreddy, Y
AF Katta, Maanya Rajasree
   Valisekka, Sai Sudha
   Agarwal, Pahel
   Hameed, Maha
   Shivam, Swadha
   Kaur, Jasneet
   Prasad, Sakshi
   Bethineedi, Lakshmi Deepak
   Lavu, Diti Vinuthna
   Katamreddy, Yamini
TI Non-pharmacological integrative therapies for chronic cancer pain
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Review
DE Chronic cancer pain; non-pharmacological; patient education; physical therapy; psychosocial therapy
ID quality-of-life; palliative care; patient education; stress reduction; physical-therapy; management; interventions; acupuncture; mindfulness; complementary
AB Objective Chronic pain is one of the most detrimental symptoms exhibited by cancer patients, being an indication for opioid therapy in up to half of the patients' receiving chemotherapy and in 90% of advanced cases. Various successful non-pharmacological integrative therapy options have been explored and implemented to improve the quality of life in these patients. This review aims to highlight the mechanisms implicated; assessment tools used for cancer pain and summarize current evidence on non-pharmacological approaches in the treatment of chronic cancer pain. Data sources A review of the literature was conducted using a combination of MeSH keywords including "Chronic cancer pain," "Assessment," "Non-pharmacological management," and "Integrative therapy." Data summary Data on the approach and assessment of chronic cancer pain as well as non-pharmacological integrative options have been displayed with the help of figures and tables. Of note, non-pharmacological integrative management was divided into three subcategories; physical therapy (involving exercise, acupuncture, massage, and transcutaneous electric nerve stimulation), psychosocial therapy (e.g. mindful practices, supportive therapy), and herbal supplementation. Conclusions The use of non-pharmacological integrative therapy in the management of chronic cancer pain has been grossly underestimated and must be considered before or as an adjuvant of other treatment regimens to ensure appropriate care.
C1 [Katta, Maanya Rajasree] Gandhi Med Coll, Hyderabad, Telangana, India.
   [Valisekka, Sai Sudha] Sri Venkateshwara Med Coll, Tirupati, Andhra Pradesh, India.
   [Agarwal, Pahel; Shivam, Swadha] Bhaskar Med Coll, Hyderabad, Telangana, India.
   [Hameed, Maha] AlFaisal Univ, Coll Med, Takhassusi St,Al Zahrawi St, Riyadh 11533, Saudi Arabia.
   [Kaur, Jasneet] Govt Med Coll, Amritsar, Punjab, India.
   [Prasad, Sakshi] Natl Pirogov Mem Med Univ, Fac Med, Vinnytsya, Ukraine.
   [Bethineedi, Lakshmi Deepak] Andhra Med Coll, Visakhapatnam, Andhra Pradesh, India.
   [Lavu, Diti Vinuthna] Siddhartha Med Coll, Vijayawada, AP, India.
   [Katamreddy, Yamini] West Anaheim Med Ctr, Anaheim, CA USA.
C3 Gandhi Medical College & Hospital, Hyderabad; National Pirogov Memorial Medical University Vinnytsya; Andhra Medical College
RP Hameed, M (corresponding author), AlFaisal Univ, Coll Med, Takhassusi St,Al Zahrawi St, Riyadh 11533, Saudi Arabia.
EM mwhameed2016@gmail.com
CR Adam R, 2015, PATIENT EDUC COUNS, V98, P269, DOI 10.1016/j.pec.2014.11.003
   Bennett MI, 2009, PAIN, V143, P192, DOI 10.1016/j.pain.2009.01.016
   Benyamin R, 2008, PAIN PHYSICIAN, V11, P0
   Birdsall SM, 2016, CURR ONCOL REP, V18, P0, DOI 10.1007/s11912-016-0530-0
   Brant JM, 2017, CLIN J ONCOL NURS, V21, P31, DOI 10.1188/17.CJON.S3.31-53
   Bruera E, 2010, J CLIN ONCOL, V28, P4013, DOI 10.1200/JCO.2010.29.5618
   Chan HK, 2014, ASIAN PAC J CANCER P, V15, P5305, DOI 10.7314/APJCP.2014.15.13.5305
   Chu LF, 2008, CLIN J PAIN, V24, P479, DOI 10.1097/AJP.0b013e31816b2f43
   Chwistek M, 2017, F1000 RES, V6, P0
   Davis MP, 2016, J NATL COMPR CANC NE, V14, P915, DOI 10.6004/jnccn.2016.0094
   Davis MP, 2012, PAIN RES TREAT, V2012, P0, DOI 10.1155/2012/265605
   de Sante, 2008, M DECINE MALADIES M, V2, P193
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Engel LW, 2002, NAT REV DRUG DISCOV, V1, P229, DOI 10.1038/nrd750
   Fink RM, 2019, SEMIN ONCOL NURS, V35, P229, DOI 10.1016/j.soncn.2019.04.003
   Forsythe LP, 2013, BREAST CANCER RES TR, V137, P617, DOI 10.1007/s10549-012-2335-7
   García-Galicia A, 2021, CIR CIR, V89, P212, DOI 10.24875/CIRU.20000094
   Gélinas C, 2014, NURS CRIT CARE, V19, P272, DOI 10.1111/nicc.12084
   Gibson W, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011976.pub2
   Glynn BA, 2020, MINDFULNESS, V11, P1666, DOI 10.1007/s12671-020-01380-z
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Greco MT, 2014, J CLIN ONCOL, V32, P4149, DOI 10.1200/JCO.2014.56.0383
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Hadjistavropoulos T, 2007, CLIN J PAIN, V23, PS1, DOI 10.1097/AJP.0b013e31802be869
   Herr K, 2011, PAIN MANAG NURS, V12, P230, DOI 10.1016/j.pmn.2011.10.002
   Higginson IJ, 2011, PALLIATIVE MED, V25, P741, DOI 10.1177/0269216311421835
   Hurlow A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub3
   Javid FA, 2016, EUR J PHARMACOL, V775, P1, DOI 10.1016/j.ejphar.2016.02.010
   Jo HG, 2022, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.800571
   Kang YJ, 2018, INT J OLDER PEOPLE N, V13, P0, DOI 10.1111/opn.12170
   Knobf MT, 2014, CANCER NURS, V37, PE43, DOI 10.1097/NCC.0b013e318288d40e
   Kotfis K, 2017, ANAESTH INTENSIVE TH, V49, P66, DOI 10.5603/AIT.2017.0010
   Kroenke K, 2010, J PAIN SYMPTOM MANAG, V40, P327, DOI 10.1016/j.jpainsymman.2009.12.023
   Kumar SP, 2011, INDIAN J PALLIAT CAR, V17, P116, DOI 10.4103/0973-1075.84532
   Kumar SP, 2010, INDIAN J PALLIAT CAR, V16, P138, DOI 10.4103/0973-1075.73670
   Lawson SL, 2021, PEDIATR EMERG CARE, V37, PE950, DOI 10.1097/PEC.0000000000001837
   Lee CE, 2017, HOLIST NURS PRACT, V31, P260, DOI 10.1097/HNP.0000000000000220
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   Liu WYC, 2017, CURR ONCOL REP, V19, P0, DOI 10.1007/s11912-017-0570-0
   Lorusso D, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12618
   Lovell MR, 2014, J CLIN ONCOL, V32, P1712, DOI 10.1200/JCO.2013.52.4850
   Lukas A, 2019, PAIN, V160, P742, DOI 10.1097/j.pain.0000000000001430
   Mancuso P, 2016, IMMUNOTARGETS THER, V5, P47, DOI 10.2147/ITT.S73223
   Marie N, 2013, SUPPORT CARE CANCER, V21, P3529, DOI 10.1007/s00520-013-1995-0
   Matis J, 2020, J MED INTERNET RES, V22, P0, DOI 10.2196/20709
   McGuire DB, 2011, J PALLIAT MED, V14, P287, DOI 10.1089/jpm.2010.0302
   Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721
   Montgomery GH, 2013, CA-CANCER J CLIN, V63, P31, DOI 10.3322/caac.21165
   Murnion BP, 2018, AUST PRESCR, V41, P60, DOI 10.18773/austprescr.2018.022
   Mustafa M, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004253.pub4
   Ngamkham S, 2021, ASIA-PAC J ONCOL NUR, V8, P58, DOI 10.4103/apjon.apjon_43_20
   Otti A, 2012, FORSCH KOMPLEMENTMED, V19, P197, DOI 10.1159/000341928
   Paice JA, 2017, J PAIN, V18, P233, DOI 10.1016/j.jpain.2016.10.020
   Paley CA, 2011, BMJ SUPPORT PALLIAT, V1, P51, DOI 10.1136/bmjspcare-2011-000022
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq020
   Pathak P, 2013, INT J ADV NURSING ST, V2, P58, DOI 10.14419/IJANS.V2I2.715
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Rajotte EJ, 2012, J CANCER SURVIV, V6, P219, DOI 10.1007/s11764-011-0213-7
   Raphael J, 2010, PAIN MED, V11, P742, DOI 10.1111/j.1526-4637.2010.00840.x
   Rodin G, 2020, SUPPORT CARE CANCER, V28, P163, DOI 10.1007/s00520-019-04723-2
   Russo MM, 2019, SEMIN ONCOL NURS, V35, P223, DOI 10.1016/j.soncn.2019.04.002
   Sanford NN, 2019, JAMA ONCOL, V5, P735, DOI 10.1001/jamaoncol.2019.0349
   Sawynok J, 2016, NEUROSCIENCE, V338, P1, DOI 10.1016/j.neuroscience.2015.10.031
   Skosnik PD, 2016, BIOL PSYCHIAT, V79, P568, DOI 10.1016/j.biopsych.2015.12.011
   Smith TJ, 2015, MAYO CLIN PROC, V90, P1428, DOI 10.1016/j.mayocp.2015.08.009
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Syrjala KL, 2014, J CLIN ONCOL, V32, P1703, DOI 10.1200/JCO.2013.54.4825
   Teunissen SCCM, 2007, J PAIN SYMPTOM MANAG, V34, P94, DOI 10.1016/j.jpainsymman.2006.10.015
   Tuggey EM, 2014, ANN PALLIAT MED, V3, P139, DOI 10.3978/j.issn.2224-5820.2014.07.02
   van den Hurk DGM, 2015, PALLIATIVE MED, V29, P652, DOI 10.1177/0269216315572720
   Voepel-Lewis T, 2010, AM J CRIT CARE, V19, P55, DOI 10.4037/ajcc2010624
   Ware LJ, 2006, PAIN MANAG NURS, V7, P117, DOI 10.1016/j.pmn.2006.06.005
   West H, 2018, JAMA ONCOL, V4, P139, DOI 10.1001/jamaoncol.2017.3120
   Yoon SY, 2018, KOREAN J INTERN MED, V33, P1058, DOI 10.3904/kjim.2018.162
NR 75
TC 10
Z9 14
U1 1
U2 19
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD DEC 15
PY 2022
VL 28
IS 8
BP 1859
EP 1868
DI 10.1177/10781552221098437
EA MAY 2022
PG 10
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA 5U4HK
UT WOS:000797677600001
PM 35532081
DA 2026-01-16
ER

PT J
AU Abe, H
   Inoue, R
   Tsuchida, R
   Ando, M
   Saita, K
   Konishi, M
   Edamura, T
   Ogawa, A
   Matsuoka, Y
   Sumitani, M
AF Abe, Hiroaki
   Inoue, Reo
   Tsuchida, Rikuhei
   Ando, Masae
   Saita, Kosuke
   Konishi, Mitsuru
   Edamura, Tatsuma
   Ogawa, Asao
   Matsuoka, Yutaka
   Sumitani, Masahiko
TI Efficacy of treatments for pain and numbness in cancer survivors: a systematic
SO Annals of palliative medicine
LA English
DT Journal Article
DE Meta-analysis; cancer survivors; numbness; pain; treatment
AB BACKGROUND: Pain and numbness in cancer survivors frequently have negative  impacts on quality of life (QoL). This meta-analysis aimed to identify the  current treatment options for pain and numbness in cancer survivors and to  evaluate their effects. METHODS: Cancer survivors were defined as patients  diagnosed with cancer who had completed active cancer treatment, whose conditions  were stable, and who had no evidence of recurrent or progressive disease. A  systematic search through the PubMed, MEDLINE, Embase, Cochrane Central Register  of Controlled Trials, Web of Science, PsycInfo, and CINAHL databases was  conducted, which targeted randomized controlled trials (RCTs) published until  April 2022 that evaluated any type of treatment for pain or numbness in cancer  survivors. A meta-analysis was conducted using the random-effects model to obtain  the effect sizes of 7 types of treatments: opioid therapy, nonopioid  pharmacotherapy, interventional therapy, acupuncture, education/cognitive  behavioral therapy (CBT), physical exercise, and alternative medicine. RESULTS: A  total of 36 studies involving 2,870 cancer survivors were included. Among them,  35 (n=2,813) were included in the meta-analysis for pain. The analysis suggested  that physical exercise [n=761; 13 studies; standardized mean difference (SMD)  -0.84; 95% confidence interval (CI): -1.14 to -0.55], acupuncture (n=409; 3  studies; SMD -0.80; 95% CI: -1.04 to -0.56), and alternative medicine (n=206; 6  studies; SMD -0.44; 95% CI: -0.71 to -0.16) could significantly reduce pain.  Nonopioid pharmacotherapy and education/CBT did not demonstrate significant  effects. No studies were identified that investigated the effects of opioid  therapy or interventional therapy on pain. Regarding numbness, 5 studies (n=566)  were included in the meta-analysis. Acupuncture (n=99; 2 studies) did not  demonstrate significant effects on numbness, and the effects of nonopioid  pharmacotherapy, education/CBT, and physical exercise could not be determined due  to the small number of included studies. No studies were identified that  investigated the effects of opioid therapy, interventional therapy, or  alternative medicine on numbness. CONCLUSIONS: This meta-analysis suggested that  physical exercise, acupuncture, and alternative medicine may reduce pain in  cancer survivors, with a very small to moderate amount of evidence. The effect of  treatments for numbness could not be determined due to the limited number of  included studies. Further studies are needed, particularly on widely used  pharmacotherapy.
C1 Department of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan.
   Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan.
   Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan.
   Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan.
   Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan.
   Department of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan.
   Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan.
   Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Tokyo, Japan.
   Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
   Department of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan.
NR 0
TC 0
SN 2224-583
EI 
J9 Ann Palliat Med
PD NOV 22
PY 2022
VL 11
IS 12
BP 3674
EP 3696
DI 10.21037/apm-22-420
PG 22
WC Humans; Cancer Survivors; Analgesics, Opioid; Pain; Cognitive Behavioral Therapy; Quality of Life; Neoplasms; therapy
UT PubMed:36408559
PM 36408559
DA 2022-11-22
ER

PT J
AU Xi, ZQ
   Wei, XQ
   Ye, Z
   Wang, K
   Zhou, J
AF Xi, Ziqi
   Wei, Xuqiang
   Ye, Zi
   Wang, Ke
   Zhou, Jia
TI Acupuncture for adult lung cancer of patient-reported outcomes: A systematic review and meta-analysis
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE acupuncture; lung cancer; PROs = patient-reported outcomes; systematic review; meta-analysis
ID quality-of-life; chemotherapy-induced nausea; psychometric assessment; sleep quality; double-blind; fatigue; pain; instrument; surgery; scale
AB Purpose: This systematic review and meta-analysis aims to assess the effects of acupuncture on patient-reported outcomes (PROs) in adults with lung cancer. Methods: Electronic databases including PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CQVIP), Wanfang Data, SinoMed, and gray literatures were retrieved from inception to 1 July 2022 for randomized controlled trials (RCTs). Acupuncture was defined as an experimental intervention, and the patients of the control groups included either treatment including conventional therapy (usual care, sham/placebo acupuncture, pharmacotherapy including Western medicine and Chinese traditional medicine). PROs for this study were measured by seven scales of primary outcomes including the Karnofsky Performance Status (KPS), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Functional Assessment of Cancer Therapy-Lung, Functional Assessment of Cancer Therapy Lung Cancer Subscale, Leicester Cough Questionnaire (LCQ score), the Medical Outcomes Study (MOS) item short form health survey (SF-36), and the St George's Respiratory Questionnaire, and 12 scales of secondary outcomes. Cochrane Collaboration's tool was used to assess the risks of bias. Data were combined and analyzed with RevMan 5.4 and Stata/SE 16.0. Results: We retrieved 3,002 lung cancer patients from 33 trials. KPS included with 1,000 patients showed that acupuncture could significantly improve the quality of life (QOL) compared with the control group regardless of different tumor-node-metastasis stages or the different stages of disease. The study showed that acupuncture significantly improved lung cancer-related symptoms in the QOL, pain, nausea and vomiting, insomnia, anxiety and depression, fatigue, and constipation compared with the control group. Eight RCTs reported the occurrence of adverse events, whereas four reported none and four RCTs reported that the events in the observation group were significantly less than those in the control group. Conclusion: Acupuncture proved to be a promising intervention, both postoperatively and after chemotherapy, and should be recommended as a beneficial alternative strategy to promote PROs in lung cancer patients at all stages of application. Considering the low quality, we suggest more rigorous clinical trials of acupuncture for lung cancer in the future and more emphasis on the effect of acupuncture in patients with lung cancer on their PROs, mainly in the aspect of the QOL.Systematic review registration, identifier [CRD42021274122].
C1 [Xi, Ziqi; Wei, Xuqiang; Ye, Zi; Wang, Ke; Zhou, Jia] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Acupuncture Anesthesia Clin Res Inst, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine
RP Wang, K; Zhou, J (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Acupuncture Anesthesia Clin Res Inst, Shanghai, Peoples R China.
EM wangke8430@163.com; pdzhoujia@163.com
FU Project BEBPC-TCM [2019XZZX-ZJ0011]; Shanghai Clinical Research Center for Acupuncture and Moxibustion Accelerating [20MC1920500]; Clinical Key Specialty Construction Foundation of Shanghai [shslczdzk04701]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3
   Unknown -, 2010, CONSORT 2010 CHECKL, V0, P0
   Bai Y, 2021, CHIN NATUROPATH, V29, P32, DOI 10.19621/j.cnki.11-3555/r.2021.2412
   Basch E, 2016, J CLIN ONCOL, V34, P557, DOI 10.1200/JCO.2015.63.0830
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Chai QY, 2015, INTEGR MED RES, V4, P19, DOI 10.1016/j.imr.2015.04.333
   Chen DY, 2018, SUPPORT CARE CANCER, V26, P405, DOI 10.1007/s00520-017-3927-x
   Chen HB, 2016, CLIN LUNG CANCER, V17, PE141, DOI 10.1016/j.cllc.2015.12.009
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Cheng CS, 2017, SUPPORT CARE CANCER, V25, P3807, DOI 10.1007/s00520-017-3812-7
   Cheng PY, 2020, INT J CLIN EXP MED, V13, P7965
   Chien Tsai-Ju, 2013, J TRADIT COMPLEMENT MED, V3, P234, DOI 10.4103/2225-4110.119733
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Dean GE, 2015, CANCER NURS, V38, P60, DOI 10.1097/NCC.0000000000000128
   Deng W, 2019, CHIN MEDCINE MODERN, V17, P69, DOI 10.3969/j.issn.1672-2779.2019.04.029
   Dogan Nurhan, 2020, ALTERN THER HEALTH MED, V26, P49
   Fan AY, 2017, J INTEGR MED-JIM, V15, P411, DOI 10.1016/S2095-4964(17)60378-9
   Fan LY, 2017, HEBEI J TRADITIONAL CHINESE MED., V29, P36, DOI 10.3969/j.issn.1672-0369.2017.11.017
   Feng QX, 2017, ZHEJIANG ZHONGYIYAO DAXUE XUEBAO, V52, P544, DOI 10.13633/j.cnki.zjtcm.2017.07.053
   Fernando HC, 2015, J THORAC CARDIOV SUR, V149, P718, DOI 10.1016/j.jtcvs.2014.11.003
   Guo X, 2019, TIANJIN NURSING, V27, P352, DOI 10.3969/j.issn.1006-9143.2019.03.035
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hjermstad MJ, 2008, PALLIATIVE MED, V22, P895, DOI 10.1177/0269216308095701
   Hou LL, 2017, J THORAC DIS, V9, P1959, DOI 10.21037/jtd.2017.06.05
   Huang LC, 2006, AURICULAR THERAPY, V0, P0
   JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6
   Kenny PM, 2008, J CLIN ONCOL, V26, P233, DOI 10.1200/JCO.2006.07.7230
   Khullar OV, 2021, ANN THORAC SURG, V112, P415, DOI 10.1016/j.athoracsur.2020.09.016
   Li SC, 2014, J N CHIN MEDCINE, V46, P170, DOI 10.13457/j.cnki.jncm.2014.05.066
   Li WWL, 2002, CHEST, V122, P584, DOI 10.1378/chest.122.2.584
   Lin CH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/1399258
   Liu CY, 2021, ONCOL PROG, V19, P570
   Liu FY, 2020, CHIN MOD DOCT, V58, P129
   Liu XH, 2018, BEIJING J TRADIT CHI, V37, P954, DOI 10.16025/j.1674-1307.2018.10.012
   Liu XP, 2016, WORLD CHIN MED, V11, P1244
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lu Y, 2017, SHANGHAI NURS, V17, P41, DOI 10.3969/j.issn.1009-8399.2017.01.017
   Luo J, 2022, CHINA MODERN DOCTOR, V60, P127
   Ma HX, 2019, WORLD J INTEGRATED T, V14, P978, DOI 10.13935/j.cnki.sjzx.190723
   Ma Y, 2021, SLEEP MED REV, V55, P0, DOI 10.1016/j.smrv.2020.101376
   MACKWORTH N, 1992, J NEURO-ONCOL, V14, P243
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Moradian S, 2014, EUR J CANCER CARE, V23, P811, DOI 10.1111/ecc.12147
   Nasser Mona, 2020, AM J PUBLIC HEALTH, V110, P753, DOI 10.2105/AJPH.2020.305609
   Nipp RD, 2019, ANN ONCOL, V30, P274, DOI 10.1093/annonc/mdy488
   ORegan D, 2010, AUTON NEUROSCI-BASIC, V157, P96, DOI 10.1016/j.autneu.2010.05.001
   Ou W, 2016, J CLIN ACUPUNCTURE M, V32, P23, DOI 10.3969/j.issn.1005-0779.2016.12.008
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Pei Wenya, 2017, ZHONGGUO ZHEN JIU, V37, P1191, DOI 10.13703/j.0255-2930.2017.11.014
   Piper B F, 1998, ONCOL NURS FORUM, V25, P677
   Poquet N, 2016, J PHYSIOTHER, V62, P52, DOI 10.1016/j.jphys.2015.07.001
   SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Shen L, 2016, J MED RES, V45, P87
   Soldatos CR, 2000, J PSYCHOSOM RES, V48, P555, DOI 10.1016/S0022-3999(00)00095-7
   Sun Yue, 2020, ZHONGGUO ZHEN JIU, V40, P1304, DOI 10.13703/j.0255-2930.20191204-k0007
   Tan JY, 2016, SUPPORT CARE CANCER, V24, P3729, DOI 10.1007/s00520-016-3181-7
   Tashjian RZ, 2009, J SHOULDER ELB SURG, V18, P927, DOI 10.1016/j.jse.2009.03.021
   Thai AA, 2021, LANCET, V398, P535, DOI 10.1016/S0140-6736(21)00312-3
   U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, 2006, HEALTH QUAL LIFE OUTCOMES, V4, P79
   Wang LQ, 2017, CHINA MODERN MED, V24, P62, DOI 10.3969/j.issn.1674-4721.2017.29.021
   Wang X, 2020, J SICHUAN TRADIT CHIN MED, V38, P191
   Wang XS, 2015, GYNECOL ONCOL, V136, P446, DOI 10.1016/j.ygyno.2014.10.013
   Wang Ya-Ling, 2019, ZHONGGUO ZHEN JIU, V39, P1269, DOI 10.13703/j.0255-2930.2019.12.004
   Ward N, 2016, J PHYSIOTHER, V62, P53, DOI 10.1016/j.jphys.2015.05.011
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Wei YG, 2016, J PREVENTIVE MED CHI, V34, P297, DOI 10.13704/j.cnki.jyyx
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Wu HY, 2016, J CLIN ACUPUNCT MOXI, V32, P52
   Xu YL, 2021, J SICHUAN TRADIT CHIN MED, V39, P176
   Xue GW, 2021, REFLEXOLOGY REHABIL, V2, P43
   Yang H, 2021, CHIN NURS RES, V35, P892, DOI 10.12102/J.ISSN.1009-6493.2021.03.001
   Yin YF, 2019, MED INF, V32, P82, DOI 10.3969/j.issn.1006-1959.2019.23.022
   Yu LT, 2020, J N CHIN MED, V52, P187, DOI 10.13457/j.cnki.jncm.2020.12.056
   Yue T, 2020, DERMATOLOGY, V236, P170, DOI 10.1159/000498848
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   Zhang YL, 2020, J N CHIN MED, V52, P153, DOI 10.13457/j.cnki.jncm.2020.05.046
   Zhou XQ, 2019, MODERN NURSE, V26, P93
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 83
TC 11
Z9 12
U1 0
U2 76
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 2
PY 2022
VL 12
IS 
BP 
EP 
DI 10.3389/fonc.2022.921151
PG 18
WC Oncology
SC Oncology
GA 4P2TK
UT WOS:000855249700001
PM 36119472
DA 2026-01-16
ER

PT J
AU Mora, DC
   Kristoffersen, AE
   Overvåg, G
   Jong, MC
   Mentink, M
   Liu, J
   Stub, T
AF Mora, Dana C
   Kristoffersen, Agnete E
   Overvåg, Grete
   Jong, Miek C
   Mentink, Marit
   Liu, Jianping
   Stub, Trine
TI Safety of Complementary and Alternative Medicine (CAM) treatment among children
SO Integrative cancer therapies
LA English
DT Journal Article
DE complementary and alternative medicine; observational studies; patient safety; qualitative studies; risk; systematic review
AB BACKGROUND: Complementary and Alternative Medicine (CAM) is widely used around  the world to treat adverse effects derived from cancer treatment among children  and young adults. Parents often seek CAM to restore and maintain the child's  physical and emotional condition during and after cancer treatment. OBJECTIVES:  The objectives of this review were (i) to identify literature that investigates  CAM use for treating adverse effects of conventional cancer treatment, (ii) to  investigate the safety of the included CAM modalities, and (iii) to evaluate the  quality of included studies. METHODS: Five scientific research databases were  used to identify observational, quasi-experimental, and qualitative studies from  January 1990 to May 2021. Included studies investigated the use of CAM to treat  adverse effects of cancer treatment in childhood cancer. RESULTS: Fifteen studies  were included in this review. Ten quasi-experimental, 3 observational studies  (longitudinal/prospective), 2 qualitative studies, and 1 study with a  quasi-experimental and qualitative arm were identified. Less than half (n = 6;  40%) of the studies included reported adverse effects for the CAM modality being  studied. Among the studies that reported adverse effects, they were mostly  considered as direct risk, as 13% reported mainly bleeding and bruising upon  acupuncture treatment, and dizziness with yoga treatment. All adverse effects  were assessed as minor and transient. CAM modalities identified for treating  adverse effects of cancer treatment were alternative medical systems,  manipulative and body-based therapies, biologically-based therapies, and  mind-body therapies. CAM modalities were used to alleviate anxiety, pain,  toxicity, prevent trauma, and improve health-related quality of life, functional  mobility, and physical activity levels. All studies assessed scored 70% or above  according to the Joanna Briggs Institute critical appraisal for study quality  checklists. CONCLUSION: Most of the studies (58.3%) included in this review did  not report adverse effects from CAM modalities used to treat adverse effects of  cancer treatment in children and young adults. This lack of safety information is  of concern because parents need to know whether the modality represents an extra  burden or harm to the child. To improve awareness about safety in the field, a  universal and uniform reporting system for adverse effects in CAM research is  needed.
C1 UiT The Arctic University of Norway, Tromsø, Norway.
   UiT The Arctic University of Norway, Tromsø, Norway.
   UiT The Arctic University of Norway, Tromsø, Norway.
   UiT The Arctic University of Norway, Tromsø, Norway.
   Netherlands Institute for Health Services Research, Utrecht, The Netherlands.
   Beijing University of Chinese Medicine and Pharmacology, Beijing, China.
   UiT The Arctic University of Norway, Tromsø, Norway.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD JUN 22
PY 2022
VL 21
IS 
BP 15347354221105563
EP 15347354221105563
DI 10.1177/15347354221105563
PG 1
WC Child; Complementary Therapies; adverse effects; Drug-Related Side Effects and Adverse Reactions; etiology; Humans; Mind-Body Therapies; Neoplasms; therapy; Prospective Studies; Quality of Life; Young Adult
UT PubMed:35726681
PM 35726681
DA 2022-06-22
ER

PT J
AU Mai, QL
   Li, XJ
   Yang, D
   Zhang, XY
   Peng, K
   Hao, YF
AF Mai, Qiulu
   Li, Xuejing
   Yang, Dan
   Zhang, Xiaoyan
   Peng, Ke
   Hao, Yufang
TI Effects of acupressure on cancer-related pain management: A systematic review and meta-analysis of randomized controlled trials
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Cancer pain; Acupressure; Pain intensity; Pain remission rate; Systematic review; Meta-analysis
ID medicine
AB Introduction: Acupressure is a non-invasive complementary treatment method that can positively affect the relief of cancer pain symptoms. The results from clinical trials have revealed that the effects of acupressure (including auricular acupressure) on cancer pain management are inconsistent. Our objective was to systematically evaluate the effect of acupressure on cancer pain.& nbsp;Methods: Seven databases (CNKI, VIP, Wanfang Database, SinoMed, Pubmed, Embase, and The Cochrane Library) were searched from their inception to November 2021 for randomized controlled trials (RCTs) of acupressure used for cancer pain. All analyses were conducted by RevMan5.3. The Cochrane RoB tool and GRADE were used to assess the risk bias and quality of evidence, respectively.& nbsp;Results: Twenty-eight RCTs involving 2630 patients were included. Combined results showed the acupressure group had better outcomes in pain remission rate [RR 1.20, 95%CI (1.10, 1.30), P < 0.0001, I-2= 61%], pain intensity [SMD-1.78, 95% CI, (-2.21,-1.35), P < 0.00001, I-2= 94%], quality of life [SMD 0.62, 95%CI (0.35, 0.89), P < 0.00001, I-2=61%], patient satisfaction with analgesia [RR 1.14, 95%CI (1.05, 1.23), P = 0.001, I-2=43%] compared with a control group. Two studies mentioned that acupressure as an adjunctive treatment could reduce the dose of analgesics. The bias of most studies was unclear because of irregular reporting according to the ROB tool, and meanwhile, most studies had high risk with no blinding. The GRADE evidence level was rated as moderate to very low. No studies measured adverse reactions.& nbsp;Conclusion: Acupressure (including auricular acupressure) group seemed to be more effective than the control group for cancer pain. However, the results were inconclusive due to weak evidence, and robust methodological RCTs with appropriate blinding are still needed to reconfirm the findings of our review.
C1 [Mai, Qiulu; Li, Xuejing; Yang, Dan; Zhang, Xiaoyan; Peng, Ke; Hao, Yufang] Beijing Univ Chinese Med, Sch Nursing, 11 Beisanhuandonglu, Beijing, Peoples R China.
   [Mai, Qiulu; Li, Xuejing; Yang, Dan; Zhang, Xiaoyan; Peng, Ke; Hao, Yufang] Beijing Univ Chinese Med, Collaborating Ctr, Joanna Briggs Inst, 11 Beisanhuandonglu, Beijing, Peoples R China.
   [Mai, Qiulu; Li, Xuejing; Yang, Dan; Zhang, Xiaoyan; Peng, Ke; Hao, Yufang] Beijing Univ Chinese Med, Best Practice Spotlight Org, 11 Beisanhuandonglu, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Hao, YF (corresponding author), Beijing Univ Chinese Med, Sch Nursing, 11 Beisanhuandonglu, Beijing, Peoples R China.; Hao, YF (corresponding author), Beijing Univ Chinese Med, Collaborating Ctr, Joanna Briggs Inst, 11 Beisanhuandonglu, Beijing, Peoples R China.; Hao, YF (corresponding author), Beijing Univ Chinese Med, Best Practice Spotlight Org, 11 Beisanhuandonglu, Beijing, Peoples R China.
EM bucmnursing@163.com
FU Major special funding of Bei-jing University of Traditional Chinese Medicine [2020-JYB-ZDGG-075]
CR Alimoradi Z, 2020, COMPLEMENT THER MED, V51, P0, DOI 10.1016/j.ctim.2020.102413
   刘洁, 2014, 中国中西医结合杂志 CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE, V34, P1392
   Behzadmehr R, 2020, COMPLEMENT THER MED, V49, P0, DOI 10.1016/j.ctim.2020.102318
   Chai L, 2019, CONSTRUCTION EFFECTI, V0, P0
   Chen JX, 2019, ELECT J PRACTIC CLIN, V4, P27
   Chen LX, 2020, J ACUPUNCT TUINA SCI, V18, P276, DOI 10.1007/s11726-020-1188-6
   Chen YM, 2021, MOD J INTEGR TRADIT, V30, P286, DOI 10.3969/j.issn.1008-8849.2021.03.013
   Chen YW, 2017, NURS RES, V31, P471
   Cheung DST, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13314
   Cunningham AB, 2019, J ETHNOPHARMACOL, V229, P288, DOI 10.1016/j.jep.2018.10.006
   Dai HP, 2018, J CLIN MED PRACTICE, V22, P81, DOI 10.7619/jcmp.201812024
   Fu XY, 2021, HEILONGJIANG MED J, V36, P2249, DOI 10.3969/j.issn.1003-8914.2021.13.055
   Giannitrapani KF, 2021, JCO ONCOL PRACT, V17, P447, DOI 10.1200/OP.20.00679
   Gu LL, 2017, CHIN GEN PRACTICE, V20, P2249
   Haltia O, 2018, PALLIATIVE MED, V32, P493, DOI 10.1177/0269216317729789
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Henschke N, 2015, MAYO CLIN PROC, V90, P139, DOI 10.1016/j.mayocp.2014.09.010
   Higgins J, 2011, COCHRANE COLLABORATI, V0, P0
   Huang ZF, 2019, CHIN J ETHNOMED ETHN, V28, P92
   [金艾香 Jin Aixiang], 2021, 中国护理管理 CHINESE NURSING MANAGEMENT, V21, P1510
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Lee WQ, 2019, J INTEGR MED-JIM, V17, P396, DOI 10.1016/j.joim.2019.09.001
   Lei J, 2017, NEUROSCIENCE, V358, P325, DOI 10.1016/j.neuroscience.2017.06.051
   Li LJ, 2020, CHIN MOD DOCT, V58, P92
   Liu Changhua, 2011, FRONT MED, V5, P212, DOI 10.1007/s11684-011-0142-x
   Liu FY, 2020, CHIN MOD DOCT, V58, P129
   Liu XZ, 2018, QILU J NURS, V24, P36, DOI 10.3969/j.issn.1006-7256.2018.20.013
   Lu YQ, 2019, ELECTRONIC JOURNAL OF PRACTICAL CLINICAL NURSING SCIENCE, V4, P95
   Luo Y, 2019, AM J CHINESE MED, V47, P1223, DOI 10.1142/S0192415X19500629
   Ma XH, 2019, CHIN J CLIN ONCOL RE, V26, P1189, DOI 10.13455/j.cnki.cjcor.2019.10.09
   Maindet C, 2019, SUPPORT CARE CANCER, V27, P3119, DOI 10.1007/s00520-019-04829-7
   Marieke HJVD, 2016, J PAIN SYMPTOM MANAG, V51, P0
   Mehta Piyush, 2017, J TRADIT COMPLEMENT MED, V7, P251, DOI 10.1016/j.jtcme.2016.06.004
   Michael V, 2020, ANESTHESIOLOGY, V0, P133
   Mitchell AJ, 2011, LANCET ONCOL, V12, P160, DOI 10.1016/S1470-2045(11)70002-X
   Moher D, 2009, PHYS THER, V89, P873
   Nia HS, 2017, INT J NURS PRACT, V23, P0, DOI 10.1111/ijn.12513
   Porter LS, 2011, CURR PAIN HEADACHE R, V15, P263, DOI 10.1007/s11916-011-0190-6
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Schreijenberg M, 2019, EXPERT REV CLIN PHAR, V12, P145, DOI 10.1080/17512433.2019.1565992
   Shangguan XF, 2020, CURR MED SCI, V40, P249, DOI 10.1007/s11596-020-2167-3
   Sutradhar R, 2017, CANCER-AM CANCER SOC, V123, P4286, DOI 10.1002/cncr.30839
   Estévez FV, 2020, CURR MED RES OPIN, V36, P1383, DOI 10.1080/03007995.2020.1775073
   Wang CX, 2017, CHIN GEN PRACT NURS, V15, P1194, DOI 10.3969/J.ISSN.1674-4748.2017.10.015
   Wang J, 2015, YUNNAN J TRADIT CHIN MED, V36, P43, DOI 10.16254/j.cnki.53-1120/r.2015.02.027
   Wang QQ, 2016, J CHIN MED EXTERN TREAT, V25, P18
   Wang Qi, 2012, FRONT MED, V6, P1, DOI 10.1007/s11684-012-0173-y
   Wang YQ, 2018, CHIN GEN PRACTICE NU, V16, P4165, DOI 10.12104/j/issn.1674-4748.2018.33.025
   Wu SJ, 2018, J CLIN MED, V5, P99, DOI 10.16281/j.cnki.jocml.2018.68.058
   Xiong XY, 2015, MEDICAL INNOVATION OF CHINA, V12, P85, DOI 10.3969/j.issn.1674-4985.2015.24.031
   Xu L, 2018, NA MOD DOCTOR, V56, P98
   Yan JL, 2021, STUDY ON THE EFFECT OF ACUPOINT MASSAGE ON MILD TO MODERATE PAIN IN CANCER PATIENTS BASED ON HOLOGRAPHIC THEORY IN CHINESE, V0, P0
   Zhang JY, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/9679213
   Zhang W, 2015, INN MONG TRADITIONAL, V34, P72
   Zhang XQ, 2016, ACTA CHIN MED BALTIM, V31, P482
   Zheng WR, 2020, BIOETHICS, V34, P166, DOI 10.1111/bioe.12456
   Zhou AQ, 2019, J PRACTICAL TRADIT C, V33, P78, DOI 10.13729/j.issn.1671-7813.Z20190306
   朱利楠, 2013, 中华物理医学与康复杂志 CHINESE JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, V35, P579
NR 58
TC 7
Z9 8
U1 1
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD APR 15
PY 2022
VL 51
IS 
BP 
EP 
DI 10.1016/j.eujim.2022.102120
EA APR 2022
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 1C0PA
UT WOS:000792829700002
DA 2026-01-16
ER

PT J
AU Chen, L
   Shen, Y
   Liu, SM
   Cao, YY
AF Chen, Liang
   Shen, Yang
   Liu, Shuangmei
   Cao, Yanyan
TI Transcutaneous Electrical Acupoint Stimulation Improved Preoperative Blood Pressure in Gynecological Malignant Tumor Patients With Hypertension: A Randomized, Controlled Trial
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE malignant tumor; hypertension; preoperative; electrical stimulation; acupoint; complementary therapy
ID nerve-stimulation; high-frequency; acupuncture; electroacupuncture; pain; anesthesia; recovery; release; stress; model
AB ObjectiveGynecological malignant tumor patients with hypertension, even if blood pressure is well controlled, are prone to hypertension before surgery. We plan to verify the effect of transcutaneous electrical acupoint stimulation (TEAS) on stabilizing blood pressure before operation. MethodsWe enrolled 91 patients and randomly divided them into TEAS group (n=46) and control group (n=45). Patients in TEAS group received TEAS at acupoints Hegu and Neiguan. Patients in control group received transcutaneous electrical stimulation at the nonacupoint position of the upper limbs. After entering the operating room, the blood pressure before and after induction was measured. The main results were the occurrence of preinduction hypertension and postinduction hypotension. ResultsThere was no difference in the general information of the two groups. There were four cases (9%) of preinduction hypertension in TEAS group and 13 cases (29%) in control group. The incidence in TEAS group was significantly lower (P=0.013). There were five cases (11%) of postinduction hypotension in TEAS group and eight cases (18%) in control group. There was no significant difference between the two groups (P=0.346). The systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean blood pressure (MBP) of the highest blood pressure before induction in TEAS group were lower than those in control group (P=0.002, 0.002, and 0.001). There was no difference in SBP, DBP, or MBP between the two groups on the day before the operation. There was no difference in the lowest blood pressure before operation between the two groups after induction ConclusionTEAS can prevent preinduction hypertension in patients with gynecological malignant tumors.
C1 [Chen, Liang; Liu, Shuangmei; Cao, Yanyan] China Med Univ, Dept Anesthesiol, Shengjing Hosp, Shenyang, Peoples R China.
   [Shen, Yang] China Med Univ, Dept Emergency Med, Shengjing Hosp, Shenyang, Peoples R China.
C3 China Medical University; China Medical University
RP Shen, Y (corresponding author), China Med Univ, Dept Emergency Med, Shengjing Hosp, Shenyang, Peoples R China.
EM cmushy@163.com
CR Abdi H, 2017, COMPLEMENT THER MED, V31, P20, DOI 10.1016/j.ctim.2017.01.003
   Bai WY, 2018, J NEUROSURG ANESTH, V30, P337, DOI 10.1097/ANA.0000000000000460
   Bang SK, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-33402-1
   Chen L, 2009, J PAIN, V10, P732, DOI 10.1016/j.jpain.2008.12.012
   Chen YD, 2015, ACUPUNCT MED, V33, P103, DOI 10.1136/acupmed-2014-010594
   Frey UH, 2009, BRIT J ANAESTH, V102, P620, DOI 10.1093/bja/aep014
   HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   Jiang Y, 2012, BRAIN RES, V1457, P13, DOI 10.1016/j.brainres.2012.03.063
   Li P, 2015, MED ACUPUNCT, V27, P253, DOI 10.1089/acu.2015.1106
   Liu JY, 2014, 2014 11TH WORLD CONGRESS ON INTELLIGENT CONTROL AND AUTOMATION (WCICA), V0, PP215, DOI 10.1109/WCICA.2014.7052715
   Liu X, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1008-1
   Liu X, 2015, ACUPUNCT MED, V33, P270, DOI 10.1136/acupmed-2014-010749
   Sartori SD, 2018, CURR HYPERTENS REV, V14, P66, DOI 10.2174/1573402114666180416155528
   Somers DL, 2006, PHYS THER, V86, P698, DOI 10.1093/ptj/86.5.698
   Su TF, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-98
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Szmit M, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10010146
   Tu JF, 2021, HYPERTENS RES, V44, P1300, DOI 10.1038/s41440-021-00702-5
   Wang BG, 1997, ANESTH ANALG, V85, P406, DOI 10.1097/00000539-199708000-00029
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wang XR, 2018, HYPERTENSION, V71, P356, DOI 10.1161/HYPERTENSIONAHA.117.09759
   Wang Y, 2005, EXP NEUROL, V192, P156, DOI 10.1016/j.expneurol.2004.11.003
   Yang L, 2010, ANAT REC, V293, P1207, DOI 10.1002/ar.21157
   Yin C, 2007, NEUROL RES, V29, PS98, DOI 10.1179/016164107X172220
   Yin CP, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000013814
   Yoo YC, 2011, YONSEI MED J, V52, P1016, DOI 10.3349/ymj.2011.52.6.1016
   Zhang H, 2007, J NEUROSCI, V27, P12067, DOI 10.1523/JNEUROSCI.0496-07.2007
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
NR 30
TC 7
Z9 9
U1 1
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD JUN 1
PY 2022
VL 12
IS 
BP 
EP 
DI 10.3389/fonc.2022.906528
PG 7
WC Oncology
SC Oncology
GA 2D9WP
UT WOS:000811888200001
PM 35720011
DA 2026-01-16
ER

PT J
AU Oberoi, D
   Reed, EN
   Piedalue, KA
   Landmann, J
   Carlson, LE
AF Oberoi, Devesh
   Reed, Erica N
   Piedalue, Katherine-Ann
   Landmann, Jessa
   Carlson, Linda E
TI Exploring patient experiences and acceptability of group vs. individual
SO BMC complementary medicine and therapies
LA English
DT Journal Article
DE Acupuncture; Group acupuncture; Individual acupuncture; Oncology; Patient experience; Patient privacy; Qualitative; Social support
AB BACKGROUND: Individual acupuncture (AP) is a safe and effective treatment for  cancer-related pain and other symptoms in cancer survivors. However, access to  individual AP is limited, and costs can be prohibitive. Group AP could be a more  cost-effective alternative as it is less expensive and non-inferior to individual  AP for pain relief. Despite growing evidence in favour of group AP, patient  acceptability and experience of group AP in cancer patients is relatively  unknown. This exploratory study sought to compare patient experiences and  acceptability of group versus individual AP in cancer patients. METHODS:  Semi-structured, open-ended, in-depth interviews were conducted in a subset of 11  cancer patients enrolled in a randomized non-inferiority trial of group vs.  individual AP for cancer pain. Participants for this study were recruited via  purposive sampling, aiming for diversity in age, sex, education, employment,  cancer types, and treatment arms. Data was analyzed using inductive thematic  analysis. RESULTS: Two major themes were identified: a) overall experience of AP  treatment b) value of AP. Participants across both treatment arms acknowledged  improvement in pain, quality of sleep, mood and fatigue. Participants in the  group AP arm reported a significant increase in perceived social support, while  participants in the individual arm valued privacy and one-on-one interaction with  the acupuncturist. Although some participants in the group arm had  privacy-related concerns before the commencement of the program, these concerns  waned after a few AP sessions. Participants across both the treatment arms  reported cordial clinician-patient relationship with the acupuncturist.  Willingness to pursue AP treatment in the future was comparable across both the  treatment arms and was limited by out-of-pocket costs. CONCLUSION: Patient  acceptability and experience of treatment in group AP was on par with individual  AP. Group AP may further augment perceived social support among patients and  privacy concerns, if any, subside after a few sessions. TRIAL REGISTRATION:  ClinicalTrials.gov ( NCT03641222 ). Registered 10 July 2018 - Retrospectively  registered.
C1 Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
   Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
   Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
   Vive Integrative Health Group, 1889 - 45 Street NW, Calgary, AB, Canada.
   Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. lcarlso@ucalgary.ca.
   Department of Psychosocial Oncology, Cancer Control Alberta, Tom Baker Cancer
NR 0
TC 0
SN 2662-767
EI 
J9 BMC Complement Med Ther
PD JUN 14
PY 2022
VL 22
IS 1
BP 155
EP 155
DI 10.1186/s12906-022-03600-6
PG 0
WC Acupuncture Therapy; Cancer Pain; therapy; Humans; Neoplasms; complications; Pain; Pain Management; Patient Outcome Assessment
UT PubMed:35698124
PM 35698124
DA 2022-06-14
ER

PT J
AU Lee, YS
   Wie, C
   Pew, S
   Kling, JM
AF Lee, Yeonsoo Sara
   Wie, Christopher
   Pew, Scott
   Kling, Juliana M.
TI Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application
SO CLEVELAND CLINIC JOURNAL OF MEDICINE
LA English
DT Review
ID breast-cancer survivors; regional pain syndrome; hot flashes; treatment options; unifying theory; management; menopausal; acupuncture; duration; flushes
AB Vasomotor symptoms, also called hot flashes, hot flushes, and night sweats, are common during the menopause transition. Severe symptoms can substantially decrease quality of life. The authors first review current hormonal and nonhormonal therapies, then review evidence supporting the potential use of stellate ganglion block for managing vasomotor symptoms in perimenopausal and women.
C1 [Lee, Yeonsoo Sara; Kling, Juliana M.] Mayo Clin, Alix Sch Med, Scottsdale, AZ 85260 USA.
   [Wie, Christopher; Pew, Scott] Mayo Clin, Dept Anesthesiol & Perioperat Med, Anesthesiol, Phoenix, AZ USA.
   [Kling, Juliana M.] Mayo Clin, Div Womens Hlth Internal Med, 13737 North 92nd St, Scottsdale, AZ 85260 USA.
   [Kling, Juliana M.] Mayo Clin, Dept Med, Equ Inclus & Divers, Scottsdale, AZ 85260 USA.
C3 Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix
RP Kling, JM (corresponding author), Mayo Clin, Div Womens Hlth Internal Med, 13737 North 92nd St, Scottsdale, AZ 85260 USA.
EM kling.juliana@mayo.edu
CR Academic Committee of the Korean Society of Menopause, 2020, J MENOPAUSAL MED, V26, P69, DOI 10.6118/jmm.20000
   Alino J, 2011, MED HYPOTHESES, V77, P465, DOI 10.1016/j.mehy.2011.06.038
   Assaf AR, 2017, AM HEALTH DRUG BENEF, V10, P311
   Avis NE, 2008, MENOPAUSE, V15, P1070, DOI 10.1097/gme.0b013e31816d5b03
   Avis NE, 2015, JAMA INTERN MED, V175, P531, DOI 10.1001/jamainternmed.2014.8063
   Blümel JE, 2011, MENOPAUSE, V18, P778, DOI 10.1097/gme.0b013e318207851d
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Carpenter J, 2015, MENOPAUSE, V22, P1155, DOI 10.1097/GME.0000000000000546
   Daley A, 2007, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006108.pub2
   Dampier C, 2019, CHICAGO TRIBUNE, V0, P0
   David PS, 2018, MENOPAUSE, V25, P1105, DOI 10.1097/GME.0000000000001126
   El Khoudary SR, 2019, MENOPAUSE, V26, P1213, DOI 10.1097/GME.0000000000001424
   Ferrillo MG, 2016, CLIN CASE REP, V4, P861, DOI 10.1002/ccr3.614
   Freeman EW, 2014, MENOPAUSE, V21, P924, DOI 10.1097/gme.0000000000000196
   Guttuso T, 2013, MATURITAS, V76, P221, DOI 10.1016/j.maturitas.2013.08.001
   Haest K, 2012, ANN ONCOL, V23, P1449, DOI 10.1093/annonc/mdr478
   Leon-Ferre RA, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkz088
   Lipov E, 2005, J WOMENS HEALTH, V14, P737, DOI 10.1089/jwh.2005.14.737
   Lipov EG, 2008, LANCET ONCOL, V9, P523, DOI 10.1016/S1470-2045(08)70131-1
   Lipov EG, 2012, MIL MED, V177, P125, DOI 10.7205/MILMED-D-11-00328
   Lipov EG, 2009, MED HYPOTHESES, V72, P657, DOI 10.1016/j.mehy.2009.01.009
   Maclennan A H, 2004, COCHRANE DATABASE SYST REV, V0, PPCD002978, DOI 10.1002/14651858.CD002978.pub2
   Munakomi S, 2021, STATPEARLS, V0, P0
   North Amer Menopause Soc, 2018, MENOPAUSE, V25, P1362, DOI 10.1097/GME.0000000000001241
   Othman AH, 2014, PAIN MED, V15, P410, DOI 10.1111/pme.12331
   Pachman DR, 2011, SUPPORT CARE CANCER, V19, P941, DOI 10.1007/s00520-010-0907-9
   Pachman DR, 2010, INT J WOMENS HEALTH, V2, P123
   Pandya KJ, 2005, LANCET, V366, P818, DOI 10.1016/S0140-6736(05)67215-7
   Pandya KJ, 2000, ANN INTERN MED, V132, P788, DOI 10.7326/0003-4819-132-10-200005160-00004
   Peterson K, 2017, VA EVIDENCE SYNTHESI, V0, P0
   Prague JK, 2018, MENOPAUSE, V25, P862, DOI 10.1097/GME.0000000000001090
   Rahimzadeh P, 2018, CANCER MANAG RES, V10, P4831, DOI 10.2147/CMAR.S173511
   Sarrel P, 2015, MENOPAUSE, V22, P260, DOI 10.1097/gme.0000000000000320
   Sloan JA, 2001, J CLIN ONCOL, V19, P4280, DOI 10.1200/JCO.2001.19.23.4280
   Stubbs Chris, 2017, J OKLA STATE MED ASSOC, V110, P272
   Thacker HL, 2011, J WOMENS HEALTH, V20, P1007, DOI 10.1089/jwh.2010.2403
   Thurston RC, 2011, OBSTET GYN CLIN N AM, V38, P489, DOI 10.1016/j.ogc.2011.05.006
   Uchida K, 2002, MED HYPOTHESES, V59, P446, DOI 10.1016/S0306-9877(02)00158-5
   Umland EM, 2012, INT J WOMENS HEALTH, V4, P305, DOI 10.2147/IJWH.S24614
   van Gastel P, 2013, CLIMACTERIC, V16, P41, DOI 10.3109/13697137.2012.709889
   Walega DR, 2014, MENOPAUSE, V21, P807, DOI 10.1097/gme.0000000000000194
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Westerhaus MJ, 2001, BRAIN RES, V903, P117, DOI 10.1016/S0006-8993(01)02453-2
NR 44
TC 22
Z9 24
U1 1
U2 15
PU CLEVELAND CLINIC
PI CLEVELAND
PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA
SN 0891-1150
EI 1939-2869
J9 CLEV CLIN J MED
JI Clevel. Clin. J. Med.
PD MAR 15
PY 2022
VL 89
IS 3
BP 147
EP 153
DI 10.3949/ccjm.89a.21032
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 0O8CW
UT WOS:000783752300006
PM 35232827
DA 2026-01-16
ER

PT J
AU Wang, YY
   Li, XY
   Ji, XP
   Wu, J
   Li, JX
   Zheng, W
   Wu, CQ
   Huang, L
   Geng, ZH
   Zhou, J
AF Wang, Yuyan
   Li, Xinyu
   Ji, Xiaopeng
   Wu, Jing
   Li, Junxin
   Zheng, Wei
   Wu, Caiqin
   Huang, Lan
   Geng, Zhaohui
   Zhou, Jie
TI Adaptive Auricular Point Acupressure for Sleep Disturbance in Women with Breast Cancer: A Randomized Controlled Trial
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID quality-of-life; single-blind; acupuncture; insomnia; pain; chemotherapy; actigraphy; symptoms; therapy; fatigue
AB Objectives. The study aimed to evaluate the preliminary effect and efficacy of auricular point acupressure (APA) on the quality of sleep in women with breast cancer who were undergoing chemotherapy. Sample & Setting. We conducted a randomized controlled trial on 68 patients with breast cancer who reported poor sleep quality based on the Pittsburgh Sleep Quality Index (PSQI) scores (>7). Methods & Variables. Participants were randomly assigned to an APA treatment group or a control group. Patients in the APA group had magnetic pellets attached to selected auricular points and were instructed to apply pressure to these points 4x/day for three consecutive weeks. We objectively measured sleep quality using the Actiwatch Spectrum and the PSQI at the baseline and postintervention. Statistical analyses of changes in sleep data were performed using the t-test, a rank-sum test, and analyses of covariance. Results. In patients treated with APA, the PSQI total score and sleep onset latency had significantly decreased, while the total sleep time and sleep efficiency had significantly increased. Although the total PSQI score differed between groups at the baseline, ANCOVA results showed that the APA group had a significantly lower total PSQI score. Conclusion. APA could be an inexpensive and effective approach to improving sleep quality and reducing sleep disturbance in patients with breast cancer. Further research needs a larger sample size to verify our findings.
C1 [Wang, Yuyan; Li, Xinyu; Wu, Jing; Wu, Caiqin; Huang, Lan; Geng, Zhaohui; Zhou, Jie] Shanghai Univ Tradit Chinese Med, Sch Nursing, Shanghai, Peoples R China.
   [Ji, Xiaopeng] Univ Delaware, Sch Nursing, Newark, DE USA.
   [Li, Junxin] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA.
   [Zheng, Wei] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; University of Delaware; Johns Hopkins University; Shanghai University of Traditional Chinese Medicine
RP Geng, ZH; Zhou, J (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Nursing, Shanghai, Peoples R China.
EM gengzh200890@163.com; zhoujieshutcmpaper@163.com
FU Humanities and Social Science Research Project of Ministry of Education; National Natural Science Foundation of China; Shanghai Science and Technology Innovation Action Plan Sailing Project;  [21YJCZH032];  [72104145];  [21YF1447700]
CR Aasm AAOS, 2014, INT CLASSIFICATION S, V3, P0
   Afrasiabian F, 2019, PHYTOTHER RES, V33, P350, DOI 10.1002/ptr.6228
   Unknown -, 2011, JOURNAL OF ACUPUNCTURE AND TUINA SCIENCE, V0, P0, DOI DOI 10.1007/S11726-011-0557-6
   Unknown -, 2005, AURICULAR MEDICINE: A COMPLETE MANUAL OF AURICULAR DIAGNOSIS AND TREATMENT, V0, P0
   Barsevick A, 2010, J PAIN SYMPTOM MANAG, V40, P200, DOI 10.1016/j.jpainsymman.2009.12.020
   Bower JE, 2012, CANCER-AM CANCER SOC, V118, P3766, DOI 10.1002/cncr.26702
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Chaoul A, 2018, CANCER-AM CANCER SOC, V124, P36, DOI 10.1002/cncr.30938
   Chueh KH, 2018, J NURS RES, V26, P10, DOI 10.1097/JNR.0000000000000209
   Costa AR, 2014, BREAST, V23, P697, DOI 10.1016/j.breast.2014.09.003
   Feng CX, 1994, CHINESE AURICULAR THERAPY, V0, P0
   Garner BK, 2018, MED ACUPUNCT, V30, P262, DOI 10.1089/acu.2018.1294
   Gori L, 2007, EVID-BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106
   Harding C, 2009, BJU INT, V103, P186, DOI 10.1111/j.1464-410X.2008.07884.x
   Innominato PF, 2015, SLEEP MED, V16, P391, DOI 10.1016/j.sleep.2014.10.022
   Ko YL, 2016, J CLIN NURS, V25, P332, DOI 10.1111/jocn.13053
   Kuo HC, 2018, RES NURS HEALTH, V41, P469, DOI 10.1002/nur.21885
   Lan Y, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0606-7
   Lee MS, 2008, INT J CLIN PRACT, V62, P1744, DOI 10.1111/j.1742-1241.2008.01876.x
   Lees J, 2011, LANCET ONCOL, V12, P1249, DOI 10.1016/S1470-2045(11)70040-7
   Li MK, 2014, COMPLEMENT THER MED, V22, P266, DOI 10.1016/j.ctim.2014.01.010
   Lin WC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/103570
   Liu XC, 1996, CHIN. J. PSYCHIATRY, V29, P103
   Lo C, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/530438
   Lua PL, 2013, ALTERN THER HEALTH M, V19, P28
   Macciò A, 2012, CYTOKINE, V58, P133, DOI 10.1016/j.cyto.2012.01.015
   Matthews EE, 2013, SLEEP MED REV, V17, P453, DOI 10.1016/j.smrv.2013.01.001
   Ng JY, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-021-03223-3
   Nogier P, 1981, HDB AURICULOTHERAPY, V0, P0
   Oleson T, 2013, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Palesh O, 2017, QUAL LIFE RES, V26, P2783, DOI 10.1007/s11136-017-1617-2
   Palesh O, 2013, J NATL COMPR CANC NE, V11, P1523, DOI 10.6004/jnccn.2013.0179
   Prisco MK, 2013, MED ACUPUNCT, V25, P407, DOI 10.1089/acu.2013.0989
   Qaseem A, 2016, ANN INTERN MED, V165, P125, DOI 10.7326/M15-2175
   Qz Z, 1986, SHANXI J TRADITIONAL, V2, P38
   Rahmani A, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/2753294
   Rusch HL, 2019, ANN NY ACAD SCI, V1445, P5, DOI 10.1111/nyas.13996
   Sadeh A, 2011, SLEEP MED REV, V15, P259, DOI 10.1016/j.smrv.2010.10.001
   Sadler P, 2018, SLEEP, V41, P0, DOI 10.1093/sleep/zsy104
   Savard J, 2012, PSYCHO-ONCOLOGY, V21, P37
   Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19
   Suen L K, 2001, COMPLEMENT THER NURS MIDWIFERY, V7, P132, DOI 10.1054/ctnm.2001.0565
   Tan JY, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/506758
   Usichenko TI, 2007, CAN MED ASSOC J, V176, P179, DOI 10.1503/cmaj.060875
   Vas J, 2014, ACUPUNCT MED, V32, P227, DOI 10.1136/acupmed-2013-010507
   Wan C, 1991, CHINESE MENTAL HLTH, V05, P0
   Wan XP, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/1334255
   Wang SM, 2001, ANESTH ANALG, V93, P1178, DOI 10.1097/00000539-200111000-00024
   WASHBURN AM, 1993, J SUBST ABUSE TREAT, V10, P345, DOI 10.1016/0740-5472(93)90019-X
   Yeh CH, 2014, J PAIN RELIEF, V0, P0, DOI DOI 10.4172/2167-0846.1000139
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeung WF, 2012, SLEEP MED, V13, P971, DOI 10.1016/j.sleep.2012.06.003
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Yuanyuan Y, 2015, J NURSING SCI, V5, P0
   Zou C, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0122724
NR 55
TC 18
Z9 19
U1 2
U2 31
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD OCT 31
PY 2022
VL 2022
IS 
BP 
EP 
DI 10.1155/2022/8637386
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 6G8IV
UT WOS:000884994700001
PM 36353150
DA 2026-01-16
ER

PT J
AU Ge, L
   Wang, Q
   He, YH
   Wu, DR
   Zhou, Q
   Xu, NG
   Yang, KH
   Chen, YL
   Zhang, AL
   Hua, HQ
   Huang, JC
   Hui, KK
   Liang, FR
   Wang, LP
   Xu, B
   Yang, YF
   Zhang, WM
   Zhao, BX
   Zhu, B
   Guo, XF
   Xue, CC
   Zhang, HB
   Xue, CC
   Xue, CC
   Zhang, HB
   Guo, XF
   Wu, DR
   Yang, KH
   Chen, YL
   Ge, L
   He, RN
   Hua, HQ
   Huang, JC
   Hui, KK
   Liang, FR
   Pan, ZD
   Wang, LP
   Xu, B
   Xu, NG
   Yang, YF
   Zhang, AL
   Zhang, WM
   Zhao, BX
   Zhu, B
   Wang, Q
   He, YH
   Zhou, Q
   Yang, LH
   Liu, SN
   Li, JY
   Hou, LY
   Zhang, Q
   Lai, HH
   Chen, XL
   Deng, XY
   Kang, FQ
AF Ge, Long
   Wang, Qi
   He, Yihan
   Wu, Darong
   Zhou, Qi
   Xu, Nenggui
   Yang, Kehu
   Chen, Yaolong
   Zhang, Anthony Lin
   Hua, Haiqing
   Huang, Jinchang
   Hui, Ka-Kit
   Liang, Fanrong
   Wang, Linpeng
   Xu, Bin
   Yang, Yufei
   Zhang, Weimin
   Zhao, Baixiao
   Zhu, Bing
   Guo, Xinfeng
   Xue, Charlie Changli
   Zhang, Haibo
   Xue, Charlie Changli
   Xue, Charlie Changli
   Zhang, Haibo
   Guo, Xinfeng
   Wu, Darong
   Yang, Kehu
   Chen, Yaolong
   Ge, Long
   He, Runsen
   Hua, Haiqing
   Huang, Jinchang
   Hui, Ka-Kit
   Liang, Fanrong
   Pan, Zuodi
   Wang, Linpeng
   Xu, Bin
   Xu, Nenggui
   Yang, Yufei
   Zhang, Anthony Lin
   Zhang, Weimin
   Zhao, Baixiao
   Zhu, Bing
   Wang, Qi
   He, Yihan
   Zhou, Qi
   Yang, Lihong
   Liu, Shaonan
   Li, Jieyun
   Hou, Liangying
   Zhang, Qian
   Lai, Honghao
   Chen, Xueling
   Deng, Xueyi
   Kang, Fuqin
TI Acupuncture for cancer pain: an evidence-based clinical practice guideline
SO CHINESE MEDICINE
LA English
DT Review
DE Acupuncture; Cancer pain; Practice guideline; Evidence-based practice
ID breast-cancer; integrative oncology; health-care; management; electroacupuncture; complementary; trial; women
AB Background: This study aims to develop an evidence-based clinical practice guideline of acupuncture in the treatment of patients with moderate and severe cancer pain. Methods: The development of this guideline was triggered by a systematic review published in JAMA Oncology in 2020. We searched databases and websites for evidence on patient preferences and values, and other resources of using acupuncture for treatment of cancer pain. Recommendations were developed through a Delphi consensus of an international multidisciplinary panel including 13 western medicine oncologists, Chinese medicine/acupuncture clinical practitioners, and two patient representatives. The certainty of evidence, patient preferences and values, resources, and other factors were fully considered in formulating the recommendations. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was employed to rate the certainty of evidence and the strength of recommendations. Results: The guideline proposed three recommendations: (1) a strong recommendation for the treatment of acupuncture rather than no treatment to relieve pain in patients with moderate to severe cancer pain; (2) a weak recommendation for the combination treatments with acupuncture/acupressure to reduce pain intensity, decrease the opioid dose, and alleviate opioid-related side effects in moderate to severe cancer pain patients who are using analgesics; and (3) a strong recommendation for acupuncture in breast cancer patients to relieve their aromatase inhibitor-induced arthralgia. Conclusion: This proposed guideline provides recommendations for the management of patients with cancer pain. The small sample sizes of evidence limit the strength of the recommendations and highlights the need for additional research.
C1 [Ge, Long; Wang, Qi] Lanzhou Univ, Sch Publ Hlth, Dept Social Med & Hlth Management, Lanzhou, Peoples R China.
   [Ge, Long; Wang, Qi; Yang, Kehu] Lanzhou Univ, Sch Publ Hlth, Evidence Based Social Sci Res Ctr, Lanzhou, Peoples R China.
   [Ge, Long; Yang, Kehu; Chen, Yaolong] WHO, Collaborating Ctr Guideline Implementat & Knowled, Lanzhou, Peoples R China.
   [Yang, Kehu] Lanzhou Univ, Chinese GRADE Ctr, Lanzhou, Peoples R China.
   [He, Yihan; Wu, Darong; Xue, Charlie Changli; Zhang, Haibo; Guo, Xinfeng] Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China.
   [He, Yihan; Wu, Darong; Guo, Xinfeng; Xue, Charlie Changli; Zhang, Haibo] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [He, Yihan; Wu, Darong; Guo, Xinfeng; Xue, Charlie Changli; Zhang, Haibo] Guangdong Prov Acad Chinese Med Sci, Guangzhou, Peoples R China.
   [Zhou, Qi; Chen, Yaolong] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou, Peoples R China.
   [Xu, Nenggui] Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Guangzhou, Peoples R China.
   [Yang, Kehu; Chen, Yaolong] Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou, Peoples R China.
   [Zhang, Anthony Lin; Xue, Charlie Changli] RMIT Univ, Sch Hlth & Biomed Sci, China Australia Int Res Ctr Chinese Med, Melbourne, Vic, Australia.
   [Hua, Haiqing] Nanjing Univ Chinese Med, Bayi Hosp, Dept Oncol, Nanjing, Peoples R China.
   [Huang, Jinchang] Beijing Univ Chinese Med, Affiliated Hosp 3, Beijing, Peoples R China.
   [Hui, Ka-Kit] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Ctr East West Med, Los Angeles, CA USA.
   [Liang, Fanrong] Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China.
   [Wang, Linpeng] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Beijing, Peoples R China.
   [Xu, Bin] Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, Nanjing, Peoples R China.
   [Yang, Yufei] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Oncol, Beijing, Peoples R China.
   [Zhang, Weimin] Southern Theater Command Gen Hosp PLA, Dept Oncol, Guangzhou, Peoples R China.
   [Zhao, Baixiao] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing, Peoples R China.
   [Zhu, Bing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Beijing, Peoples R China.
C3 Lanzhou University; Lanzhou University; World Health Organization; Lanzhou University; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Lanzhou University; Guangzhou University of Chinese Medicine; Royal Melbourne Institute of Technology (RMIT); Nanjing University of Chinese Medicine; Beijing University of Chinese Medicine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Chengdu University of Traditional Chinese Medicine; Capital Medical University; Nanjing University of Chinese Medicine; Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences; Beijing University of Chinese Medicine; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS
RP Guo, XF; Xue, CC; Zhang, HB (corresponding author), Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China.; Xue, CC (corresponding author), RMIT Univ, Sch Hlth & Biomed Sci, China Australia Int Res Ctr Chinese Med, Melbourne, Vic, Australia.
EM guoxinfeng@gzucm.edu; charlie.xue@rmit.edu.au; haibozh@gzucm.edu.cn
FU National Key R&D Program, China National Centre for Biotechnology Development [2019YFC1709805]
CR AAMA, 2017, AM AC MED AC, V0, P0
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Ambrósio EMM, 2012, COMPLEMENT THER MED, V20, P364, DOI 10.1016/j.ctim.2012.05.002
   Unknown -, 2017, ZHEJIANG J TRADIT CH, V0, P0
   Australian Government Department of Health, 2014, MEDICARE BENEFITS SC, V0, P11
   Badgut, 2013, AC REG COV CAN, V0, P0
   Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Beijing Youth Daily, 2013, WOMENS LIFE, V1, P32
   Ben-Arye E, 2021, J CANCER RES CLIN, V147, P2361, DOI 10.1007/s00432-020-03506-1
   Black N, 1999, J HEALTH SERV RES POLICY, V4, P236
   Brouwers MC, 2010, J CLIN EPIDEMIOL, V63, P1308, DOI 10.1016/j.jclinepi.2010.07.001
   Carreira H, 2021, J CANCER SURVIV, V15, P564, DOI 10.1007/s11764-020-00950-3
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen YL, 2017, ANN INTERN MED, V166, P128, DOI 10.7326/M16-1565
   Chinese Medicine Board Ahpra, 2020, 2019 20 ANN SUMM, V0, P0
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Critical Appraisal Skills Programme, 2019, CASP QUALITATIVE CHECKLIST, V0, P0
   David Geffen School of Medicine at UCLA 10833 Le Conte Ave Los Angeles CA 90095 USA, 2020, OBM INTEGRATIVE AND COMPLEMENTARY MEDICINE, V5, P1, DOI 10.21926/obm.icm.2001011
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019
   Enblom A, 2017, ACUPUNCT MED, V35, P251, DOI 10.1136/acupmed-2015-011007
   Fan AY, 2019, J INTEGR MED-JIM, V17, P315, DOI 10.1016/j.joim.2019.06.003
   Fan AY, 2017, J INTEGR MED-JIM, V15, P411, DOI 10.1016/S2095-4964(17)60378-9
   Fan AY, 2014, J INTEGR MED-JIM, V12, P390, DOI 10.1016/S2095-4964(14)60035-2
   Filshie J, 2001, ACUPUNCT MED, V19, P117
   Filshie J, 1984, ACUPUNCT MED, V2, P12
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Frankel E, 2014, EUR J INTEGR MED, V6, P532, DOI 10.1016/j.eujim.2014.06.007
   Garcia MK, 2014, INTEGR CANCER THER, V13, P133, DOI 10.1177/1534735413510558
   Guo Z, 2015, INT J TRAD CHIN MED, V37, P371
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   He Yi-Han, 2021, ZHONGGUO ZHEN JIU, V41, P1161, DOI 10.13703/j.0255-2930.20200831-k0002
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hsu C-C, 2007, PRACTICAL ASSESSMENT RESEARCH EVALUATION, V12, P0, DOI 10.7275/PDZ9-TH90
   Institute of Medicine. National Academy of Sciences, 2019, PRACTICE GUIDELINES, V0, P0
   Jiang KR, 2011, THESIS GUANGZHOU U, V0, P0
   Jiang YG, 2015, CHIN J TRADIT CHIN M, V3, P0
   Johnstone PAS, 2002, PALLIATIVE MED, V16, P235, DOI 10.1191/0269216302pm540oa
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Laird B, 2008, EUR J CANCER, V44, P1078, DOI 10.1016/j.ejca.2008.03.022
   Lao LX, 2003, ALTERN THER HEALTH M, V9, P72
   Li Dan, 2020, ZHONGGUO ZHEN JIU, V40, P257, DOI 10.13703/j.0255-2930.20190311-k0001
   [李石良 Li Shiliang], 2004, 中国针灸 CHINESE ACUPUNCTURE AND MOXIBUSTION, V24, P283
   Liou KT, 2021, SUPPORT CARE CANCER, V29, P427, DOI 10.1007/s00520-020-05504-y
   Liou KT, 2020, J ALTERN COMPLEM MED, V26, P85, DOI 10.1089/acm.2020.0022
   Lopez G, 2019, CANCER J, V25, P311, DOI 10.1097/PPO.0000000000000401
   Lopez G, 2017, MED CLIN N AM, V101, P977, DOI 10.1016/j.mcna.2017.04.011
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Ma BY, 2019, J CLIN ACUPUNCT MOX, V35, P83
   Mallory MJ, 2015, AM J CHINESE MED, V43, P45, DOI 10.1142/S0192415X15500032
   Mao JJ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-7
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Schunemann H, 2013, HDB GRADING QUALITY, V0, P0
   Sharfstein JM, 2019, JAMA-J AM MED ASSOC, V322, P809, DOI 10.1001/jama.2019.9794
   Shen L, 2016, J MED RES, V45, P87
   Swarm RA, 2021, J NATL COMPR CANC NE, V19, P329
   Vernooij RWM, 2017, PLOS MED, V14, P0, DOI 10.1371/journal.pmed.1002207
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang J, 2015, YUNNAN J TRADIT CHIN, V2, P43
   Weidenhammer W, 2007, COMPLEMENT THER MED, V15, P238, DOI 10.1016/j.ctim.2006.09.005
   Wengström Y, 2014, EUR J ONCOL NURS, V18, P127, DOI 10.1016/j.ejon.2013.11.009
   WHO, 2018, CANC, V0, P0
   World Health Organization, 2019, WHO GUIDELINES FOR THE PHARMACOLOGICAL AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS, V0, P0
   World Health Organization, 2014, GUIDELINE, V2nd, P0
   Zhang Y, 2019, J CLIN EPIDEMIOL, V111, P94, DOI 10.1016/j.jclinepi.2018.01.013
   朱利楠, 2013, 中华物理医学与康复杂志 CHINESE JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, V35, P579
NR 74
TC 46
Z9 57
U1 7
U2 76
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
EI 
J9 CHIN MED-UK
JI Chin. Med.
PD JAN 5
PY 2022
VL 17
IS 1
BP 
EP 
DI 10.1186/s13020-021-00558-4
PG 12
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA YB0AG
UT WOS:000738685000003
PM 34983587
DA 2026-01-16
ER

PT J
AU Shenouda, M
   Copley, R
   Pacioles, T
   Lebowicz, Y
   Jamil, M
   Akpanudo, S
   Tirona, MT
AF Shenouda, Mina
   Copley, Renee
   Pacioles, Toni
   Lebowicz, Yehuda
   Jamil, Muhammad
   Akpanudo, Sutoidem
   Tirona, Maria Tria
TI Effect of Tart Cherry on Aromatase Inhibitor-Induced Arthralgia (AIA) in Nonmetastatic Hormone-Positive Breast Cancer Patients: A Randomized Double-Blind Placebo-Controlled Trial
SO CLINICAL BREAST CANCER
LA English
DT Article
DE Aromatase inhibitor arthralgia; Aromatase inhibitor adherence; Musculoskeletal syndrome; Tart cherry; Pain
ID musculoskeletal syndrome; juice blend; symptoms; pain; consumption; women; risk; acupuncture; survivors; estrogen
AB Aromatase Inhibitor induced Arthralgia (AIA) can cause noncompliance leading to decreased breast-cancer survival. Effective interventions for AIA are limited. Tart cherry (TC) showed beneficial effect on musculoskeletal pain. 48 patients (Pts) randomized to TC versus placebo over 6 weeks, TC (23pts) had 34.7% mean pain decrease versus 1.4% in Placebo (25pts). TC can improve AIA in non-metastatic breast-cancer patients. Background: Aromatase Inhibitor induced Arthralgia (AIA) can cause noncompliance leading to decreased breastcancer survival. Effective interventions for AIA are limited. Tart cherry (TC) showed beneficial effect on musculoskeletal pain. 48 patients (Pts) randomized to TC versus placebo over 6 weeks, TC (23pts) had 34.7% mean pain decrease versus 1.4% in Placebo (25pts). TC can improve AIA in nonmetastatic breast-cancer patients. Methods: Randomized, placebo-controlled, double-blind trial. Eligible patients with NMHPBC on AI for at least 4 weeks were randomized to TC concentrate [50 tart cherries] vs. placebo (P) [syrup] in 1:1 model. Patients instructed to consume 1 Oz of concentrate in 8 Oz water daily for 6 weeks, and document their pain intensity at baseline, weekly and at study completion in a diary using Visual Analog Scale (VAS), with 0 mm indicating no pain, and 100 mm indicating highest pain. Results: Sixty patients were enrolled. Two patients did not complete the study due to diarrhea, and 10 patients were noncompliant. Forty-eight patients were included in the final analysis. TC group (23 pts) had 34.7% mean decrease in pain compared to 1.4% in P group (25 pts). This difference was statistically significant (Mann-Whitney U Test, P =.034). Conclusions: Tart cherry can significantly improve AIA in nonmetastatic breast cancer patient. (C) 2021 The Authors. Published by Elsevier Inc.
C1 [Shenouda, Mina; Copley, Renee; Pacioles, Toni; Lebowicz, Yehuda; Jamil, Muhammad; Tirona, Maria Tria] Marshall Univ, Joan C Edwards Sch Med, Edwards Comprehens Canc Ctr, Hematol Oncol Dept, Huntington, WV 25701 USA.
   [Lebowicz, Yehuda] Univ Pittsburgh, Hillman Canc Ctr, Pittsburgh, PA USA.
   [Akpanudo, Sutoidem] Marshall Univ, Joan C Edwards Sch Med, Internal Med Dept, Huntington, WV 25701 USA.
   [Akpanudo, Sutoidem] Duke Univ, Internal Med Dept, Durham, NC USA.
C3 Marshall University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Marshall University; Duke University
RP Shenouda, M (corresponding author), Marshall Univ, Joan C Edwards Sch Med, Hematol Oncol Dept, 1400 Hal Greer Blvd, Huntington, WV 25701 USA.
EM mshenouda11@gmail.com
FU Cherry Marketing Institute, Dewitt, Michigan; 2019 Conquer Cancer Foundation ASCO Merit Award
CR Alba CMA, 2019, CRIT REV FOOD SCI, V59, P626, DOI 10.1080/10408398.2017.1384918
   Baglia ML, 2019, CANCER-AM CANCER SOC, V125, P2262, DOI 10.1002/cncr.32051
   Bauml J, 2015, BREAST CANCER RES, V17, P0, DOI 10.1186/s13058-015-0599-7
   Bell PG, 2014, SCAND J MED SCI SPOR, V24, P477, DOI 10.1111/sms.12085
   Bell PG, 2016, NUTRIENTS, V8, P0, DOI 10.3390/nu8070441
   Bell PG, 2014, NUTRIENTS, V6, P829, DOI 10.3390/nu6020829
   Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x
   Bowtell JL, 2011, MED SCI SPORT EXER, V43, P1544, DOI 10.1249/MSS.0b013e31820e5adc
   Briot K, 2010, BREAST CANCER RES TR, V120, P127, DOI 10.1007/s10549-009-0692-7
   Chai SC, 2019, NUTRIENTS, V11, P0, DOI 10.3390/nu11020228
   Chirgwin JH, 2016, J CLIN ONCOL, V34, P2452, DOI 10.1200/JCO.2015.63.8619
   Coates AS, 2007, J CLIN ONCOL, V25, P486, DOI 10.1200/JCO.2006.08.8617
   Connolly DAJ, 2006, BRIT J SPORT MED, V40, P679, DOI 10.1136/bjsm.2005.025429
   Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140-6736(07)60200-1
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dimitriou L, 2015, J INT SOC SPORT NUTR, V12, P0, DOI 10.1186/s12970-015-0085-8
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Felson DT, 2005, ARTHRITIS RHEUM-US, V52, P2594, DOI 10.1002/art.21364
   Galantino ML, 2012, INTEGR CANCER THER, V11, P313, DOI 10.1177/1534735411413270
   Gallagher EJ, 2001, ANN EMERG MED, V38, P633, DOI 10.1067/mem.2001.118863
   Gupta A, 2020, JCO ONCOL PRACT, V16, P733, DOI 10.1200/OP.20.00113
   Halvorsen BL, 2006, AM J CLIN NUTR, V84, P95, DOI 10.1093/ajcn/84.1.95
   Henry NL, 2010, BRIT J CANCER, V103, P291, DOI 10.1038/sj.bjc.6605768
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Howatson G, 2010, SCAND J MED SCI SPOR, V20, P843, DOI 10.1111/j.1600-0838.2009.01005.x
   Jacob RA, 2003, J NUTR, V133, P1826, DOI 10.1093/jn/133.6.1826
   Johnsen SP, 2005, ARCH INTERN MED, V165, P978, DOI 10.1001/archinte.165.9.978
   Kelley DS, 2006, J NUTR, V136, P981, DOI 10.1093/jn/136.4.981
   Kent K, 2017, EUR J NUTR, V56, P333, DOI 10.1007/s00394-015-1083-y
   Kim TH, 2018, MATURITAS, V118, P29, DOI 10.1016/j.maturitas.2018.09.005
   Kuehl KS, 2010, J INT SOC SPORT NUTR, V7, P0, DOI 10.1186/1550-2783-7-17
   Lachin T, 2014, RECENT PATENTS ENDOC, V8, P67, DOI 10.2174/1872214808666140121151334
   Levers K, 2016, J INT SOC SPORT NUTR, V13, P0, DOI 10.1186/s12970-016-0133-z
   Lintermans A, 2014, EUR J CANCER, V50, P2925, DOI 10.1016/j.ejca.2014.08.012
   Lombard JM, 2016, SUPPORT CARE CANCER, V24, P2139, DOI 10.1007/s00520-015-3001-5
   Magliano M, 2010, MATURITAS, V67, P29, DOI 10.1016/j.maturitas.2010.04.009
   Mao JJ, 2009, CANCER, V115, P3631, DOI 10.1002/cncr.24419
   McCormick R, 2016, J INT SOC SPORT NUTR, V13, P0, DOI 10.1186/s12970-016-0151-x
   McCune LM, 2011, CRIT REV FOOD SCI, V51, P1, DOI 10.1080/10408390903001719
   Nahm Nicole, 2018, ASIA PAC J CLIN ONCOL, V14, P374, DOI 10.1111/ajco.12845
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Ou BX, 2012, J FOOD SCI, V77, PH105, DOI 10.1111/j.1750-3841.2012.02681.x
   Pfeilschifter J, 2002, ENDOCR REV, V23, P90, DOI 10.1210/er.23.1.90
   Presant CA, 2007, CLIN BREAST CANCER, V7, P775, DOI 10.3816/CBC.2007.n.038
   Richette P, 2003, JOINT BONE SPINE, V70, P257, DOI 10.1016/S1297-319X(03)00067-8
   Santos RS, 2017, BIOL SEX DIFFER, V8, P0, DOI 10.1186/s13293-017-0151-9
   Schumacher HR, 2013, OSTEOARTHR CARTILAGE, V21, P1035, DOI 10.1016/j.joca.2013.05.009
   Seeram NP, 2001, PHYTOMEDICINE, V8, P362, DOI 10.1078/0944-7113-00053
   Shen S, 2018, BREAST CANCER RES TR, V172, P603, DOI 10.1007/s10549-018-4946-0
   Tan AL, 2008, LANCET ONCOL, V9, P817, DOI 10.1016/S1470-2045(08)70217-1
   Vargas AJ, 2014, NUTR CANCER, V66, P1144, DOI 10.1080/01635581.2014.949801
   Zhang YQ, 2012, ARTHRITIS RHEUM-US, V64, P4004, DOI 10.1002/art.34677
NR 54
TC 7
Z9 8
U1 0
U2 5
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1526-8209
EI 1938-0666
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD JAN 15
PY 2022
VL 22
IS 1
BP E30
EP E36
DI 10.1016/j.clbc.2021.06.007
EA JAN 2022
PG 7
WC Oncology
SC Oncology
GA YE1RO
UT WOS:000740907700008
PM 34275765
DA 2026-01-16
ER

PT J
AU Wang, M
   Pei, ZW
   Molassiotis, A
AF Wang, Mian
   Pei, Ziwen
   Molassiotis, Alex
TI Recent advances in managing chemotherapy-induced peripheral neuropathy: A systematic review
SO EUROPEAN JOURNAL OF ONCOLOGY NURSING
LA English
DT Review
DE Cancer; Chemotherapy-induced peripheral neuropathy; Pain; Symptom management; Systematic review
ID induced sensory neuropathy; quality-of-life; breast-cancer; randomized-trial; therapy; duloxetine; prevalence; prevention; pregabalin; management
AB Purpose: The aim in this review was to explore recent advances in chemotherapy-induced peripheral neuropathy (CIPN) management interventions and to identify the implications for practice and future research.Methods: A comprehensive search through seven electronic databases (AMED, CINAHL, Cochrane Library, EMBASE, PEDro, PubMed, and Web of Science) was conducted for studies published between January 1, 2013 and August 3, 2019. An updated search for subsequently published studies was made through PubMed on February 15, 2022. Randomized controlled trials (RCTs) involving either pharmacological or non pharmacological interventions were considered eligible. The Cochrane Risk of Bias tool version 2.0 (RoB 2.0) was used to appraise the methodological risk of bias. Data extracted from the included RCTs were synthesized in a narrative approach.Results: Forty-two RCTs involving a total of 3393 participants were included. Overall, a high risk of bias was found in most of the included RCTs. The results further confirmed the analgesic effect of duloxetine on pain related to CIPN. Exercise-based interventions, acupuncture, and several non-invasive neuromodulation techniques showed promise for managing CIPN.Conclusions: The effects of most pharmacological and non-pharmacological interventions on CIPN are inconclusive due to methodological issues. Duloxetine remains the only pharmacological intervention recommended for managing pain related to CIPN. Although definitive recommendations cannot be made based on current research evidence, non-pharmacological interventions, especially non-invasive neuromodulation techniques, warrant future research.
C1 [Wang, Mian; Molassiotis, Alex] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Peoples R China.
   [Pei, Ziwen] Wuhan Hosp Tradit Chinese & Western Med, Dept Rehabil Med, Wuhan, Hubei, Peoples R China.
C3 Hong Kong Polytechnic University
RP Molassiotis, A (corresponding author), Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Peoples R China.
EM alex.molasiotis@polyu.edu.hk
CR Akyuz G, 2014, AM J PHYS MED REHAB, V93, P253, DOI 10.1097/PHM.0000000000000037
   Al Onazi MM, 2021, J PAIN SYMPTOM MANAG, V61, P1127, DOI 10.1016/j.jpainsymman.2020.10.028
   Argenta PA, 2017, GYNECOL ONCOL, V144, P159, DOI 10.1016/j.ygyno.2016.11.013
   Argyriou AA, 2020, EXPERT REV NEUROTHER, V20, P1005, DOI 10.1080/14737175.2020.1796639
   Avan R, 2018, J RES MED SCI, V23, P0, DOI 10.4103/jrms.JRMS_1068_17
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkaa048
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Bonhof CS, 2021, J CANCER SURVIV, V15, P190, DOI 10.1007/s11764-020-00923-6
   Bozorgi H, 2021, J ETHNOPHARMACOL, V281, P0, DOI 10.1016/j.jep.2021.114511
   Childs DS, 2021, J PAIN SYMPTOM MANAG, V61, P1247, DOI 10.1016/j.jpainsymman.2020.11.025
   Chu SH, 2015, SUPPORT CARE CANCER, V23, P513, DOI 10.1007/s00520-014-2408-8
   Chung KH, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14051224
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Dhawan S, 2020, CANCER NURS, V43, P269, DOI 10.1097/NCC.0000000000000693
   Dorsey SG, 2019, JNCI-J NATL CANCER I, V111, P531, DOI 10.1093/jnci/djz011
   Drossman DA, 2018, GASTROENTEROLOGY, V154, P1140, DOI 10.1053/j.gastro.2017.11.279
   Emine KE, 2021, IN PRESS, V0, P0, DOI DOI 10.1016/j.explore.2021.07.002.S1550-8307(21)00144-0
   Farshchian N, 2018, CANCER CHEMOTH PHARM, V82, P787, DOI 10.1007/s00280-018-3664-y
   Forstenpointner J, 2018, PAIN, V159, P569, DOI 10.1097/j.pain.0000000000001088
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hershman DL, 2018, JNCI-J NATL CANCER I, V110, P669, DOI 10.1093/jnci/djx259
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hincker A, 2019, PAIN, V160, P1835, DOI 10.1097/j.pain.0000000000001577
   Hirayama Y, 2015, INT J CLIN ONCOL, V20, P866, DOI 10.1007/s10147-015-0810-y
   Hou S, 2018, PAIN PHYSICIAN, V21, P571, DOI 10.36076/ppj.2018.6.571
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Husebo AML, 2015, J CLIN NURS, V24, P500, DOI 10.1111/jocn.12633
   Iravani S, 2020, PAIN, V0, P0
   Izgu N, 2019, CANCER NURS, V42, P139, DOI 10.1097/NCC.0000000000000577
   Jones KF, 2022, J PALLIAT MED, V25, P964, DOI 10.1089/jpm.2021.0512
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Kneis S, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5522-7
   Knoerl R, 2022, J CANCER SURVIV, V16, P882, DOI 10.1007/s11764-021-01081-z
   Knoerl R, 2018, J PAIN, V19, P382, DOI 10.1016/j.jpain.2017.11.009
   Knotkova H, 2021, LANCET, V397, P2111, DOI 10.1016/S0140-6736(21)00794-7
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Kurt S, 2018, EUR J ONCOL NURS, V32, P12, DOI 10.1016/j.ejon.2017.11.001
   Leen AJ, 2022, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.763229
   Lin WL, 2021, SUPPORT CARE CANCER, V29, P5303, DOI 10.1007/s00520-021-06082-3
   Lindblad K, 2016, SUPPORT CARE CANCER, V24, P2523, DOI 10.1007/s00520-015-3060-7
   Loprinzi C, 2020, SUPPORT CARE CANCER, V28, P1183, DOI 10.1007/s00520-019-04881-3
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lynch ME, 2014, J PAIN SYMPTOM MANAG, V47, P166, DOI 10.1016/j.jpainsymman.2013.02.018
   Mariano TY, 2021, J TELEMED TELECARE, V27, P195, DOI 10.1177/1357633X19871746
   McGuinness LA, 2021, RES SYNTH METHODS, V12, P55, DOI 10.1002/jrsm.1411
   Molassiotis A, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5302-4
   Noh GO, 2019, EUR J ONCOL NURS, V42, P82, DOI 10.1016/j.ejon.2019.08.007
   Noh H, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/6194184
   Prinsloo S, 2018, J PAIN SYMPTOM MANAG, V55, P1276, DOI 10.1016/j.jpainsymman.2018.01.010
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Rick O, 2017, BIOELECTROMAGNETICS, V38, P85, DOI 10.1002/bem.22005
   Rostami N, 2019, PHYTOTHER RES, V33, P2685, DOI 10.1002/ptr.6442
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Salehifar E, 2020, CLIN DRUG INVEST, V40, P249, DOI 10.1007/s40261-019-00882-6
   Schloss JM, 2013, CLIN NUTR, V32, P888, DOI 10.1016/j.clnu.2013.04.007
   Schönsteiner SS, 2017, EXP HEMATOL ONCOL, V5, P0, DOI 10.1186/s40164-017-0065-6
   Schwenk M, 2016, GERONTOLOGY, V62, P553, DOI 10.1159/000442253
   Selvy M, 2020, J CLIN MED, V9, P0, DOI 10.3390/jcm9082400
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Simon NB, 2017, QUAL LIFE RES, V26, P2763, DOI 10.1007/s11136-017-1635-0
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Song SY, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420925519
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, P0, DOI 10.1136/bmj.l4898
   Streckmann F, 2019, SUPPORT CARE CANCER, V27, P2471, DOI 10.1007/s00520-018-4531-4
   Sun YJ, 2016, EXP THER MED, V12, P4017, DOI 10.3892/etm.2016.3871
   Tamburin S, 2022, CRIT REV ONCOL HEMAT, V171, P0, DOI 10.1016/j.critrevonc.2021.103575
   Tonezzer Tania, 2017, J PHYS THER SCI, V29, P685, DOI 10.1589/jpts.29.685
   Xiong ZF, 2016, WORLD J ACUPUNCT-MOX, V26, P20, DOI 10.1016/S1003-5257(17)30005-3
   Zhi WI, 2021, CANCER MED-US, V10, P5456, DOI 10.1002/cam4.4098
   Zhou LK, 2021, ECLINICALMEDICINE, V41, P0, DOI 10.1016/j.eclinm.2021.101157
NR 78
TC 9
Z9 12
U1 1
U2 18
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1462-3889
EI 1532-2122
J9 EUR J ONCOL NURS
JI Eur. J. Oncol. Nurs.
PD JUN 15
PY 2022
VL 58
IS 
BP 
EP 
DI 10.1016/j.ejon.2022.102134
EA APR 2022
PG 23
WC Oncology; Nursing
SC Oncology; Nursing
GA 1G2WH
UT WOS:000795712900002
PM 35421796
DA 2026-01-16
ER

PT J
AU Pan, ZQ
   Chen, M
   Jia, YP
AF Pan, Zhi-Qiang
   Chen, Ming
   Jia, Yun-Peng
TI [Clinical study of type Ⅲ prostatitis treated with "warming and promoting
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Extracorporeal shock wave; Type Ⅲ prostatitis; “Warming and promoting technique” of acupuncture
AB OBJECTIVE: To observe the clinical curative effect of wentongzhenfa (warming and  promoting technique of acupuncture) combined with extracorporeal shock wave in  treatment of type Ⅲ prostatitis. METHODS: A total of 96 patients with type Ⅲ  prostatitis were randomly divided into an observation group (48 cases) and a  control group (48 cases). In the control group, the extracorporeal shock wave was  combined with even-needling technique of acupuncture at Guanyuan (CV4), Mingmen  (GV4), Zhongji (CV3), Zusanli (ST36), etc. In the observation group, the  extracorporeal shock wave was combined with "warming and promoting technique" of  acupuncture at the same acupoints as the control group. The treatment lasted 30  min each time, once daily in either group. There were 2 days of interval after  consecutive treatment for 5 days. Totally, the duration of treatment was 1 month  in two groups. The clinical curative effect was assessed after treatment. Before  and after treatment, the changes in the concentrations of tumor nerosis factor-α  (TNF-α), interleukin-1β(IL-1β) and IL-6 in prostatic fluid were determined; and  the symptoms were scored, i.e. frequent, urgent and burning painful urine,  difficulty in urination, dribbling urine, distending pain in perineum, bitter  taste and dry mouth, and scrotal dampness. The changes in the scores of National  Institute of Health chronic prostatitis symptom index (NIH-CPSI), international  index of erectile function (IIEF), visual analogue scale (VAS) were evaluated  befroe and after treatment. Successively, before treatment, after treatment, as  well as 1 and 3 months after treatment, the quality of life was evaluated by  Karnofsky in the patients of two groups. RESULTS: After treatment, the total  effective rate was 89.6% (43/48) in the observation group, higher than 70.8%  (34/48) in the control group (P<0.05). Compared with those before treatment, the  concentrations of TNF-α and IL-1β in the prostatic fluid were all decreased  (P<0.05) and the concentration of IL-6 was increased (P<0.05), the scores of  symptoms, NIH-CPSI, IIEF and VAS were all reduced (P<0.05) in two groups. The  changes of the above indexes were more obvious in the observation group than  those in the control group (P<0.05). After treatment and 1 and 3 months after  treatment, Karnofsky scores all increased (P<0.05) in two groups，and the  increases were more significant in the observation group (P<0.05). CONCLUSION:  "Warming and promoting technique" of acupuncture combined with extracorporeal  shock wave promotes the elimination of local inflammatory factors, relieves  clinical symptoms, improves the quality of life, as well as has a satisfactory  short-term and medium-term curative effect on type Ⅲ prostatitis.
C1 Department of Urinary Surgery, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China.
   Department of Urinary Surgery, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China.
   Department of Urinary Surgery, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD APR 30
PY 2022
VL 47
IS 4
BP 343
EP 8
DI 10.13702/j.1000-0607.20210278
PG -335
WC Acupuncture Therapy; methods; Chronic Disease; Humans; Interleukin-6; Male; Pain; Prostatitis; therapy; Quality of Life; Tumor Necrosis Factor-alpha
UT PubMed:35486014
PM 35486014
DA 2022-04-30
ER

PT J
AU Wang, WM
   Wang, XL
   Liu, Y
   Sun, YJ
   Liu, XX
   Yan, Y
   Liu, ZS
AF Wang, Weiming
   Wang, Xinlu
   Liu, Yan
   Sun, Yuanjie
   Liu, Xiaoxu
   Yan, Yan
   Liu, Zhishun
TI Effects of Electroacupuncture on Opioid-Induced Constipation in Patients With Cancer: Study Protocol for a Multicenter Randomized Controlled Trial
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE opioid-induced constipation; acupuncture; cancer patients; randomized controlled trial; spontaneous bowel movements
ID bowel dysfunction; management; efficacy; impact; pain; recommendations; prucalopride; acupuncture; diagnosis; events
AB Background: Opioid-induced constipation (OIC) is one of the most prevalent adverse events associated with cancer patients who receive opioid analgesics for moderate to severe pain. Acupuncture may be an effective treatment for OIC. We designed this trial to assess the efficacy and safety of electroacupuncture for OIC in cancer patients. Methods: This is a multicenter, sham-controlled, parallel-group, subject- and assessor-blinded randomized trial. A total of 100 cancer patients with OIC will be randomly assigned to either the electroacupuncture group or the sham electroacupuncture group at a ratio of 1:1. Patients in each group will receive a total of 24-session treatment over 8 weeks, three sessions a week and 30 min each session. Thereafter, patients will be followed up for another 8 weeks. The primary outcome will be the proportion of responders, defined as a patient who has >= 3 spontaneous bowel movements (SBMs)/wk and >= increase of 1 SBM from baseline simultaneously for at least 6 out of 8 weeks of the treatment period. The secondary outcomes will include the mean weekly SBMs and complete spontaneous bowel movements, the mean Bristol Stool Form Scale score for stool consistency, the mean score for straining of SBM, the total and subscale scores of Patient Assessment of Constipation-Symptom questionnaires, and the total and subscale scores of Patient Assessment of Constipation-Quality of Life questionnaire. Patients' global assessment of treatment effectiveness, patients' expectation toward the effectiveness of acupuncture and safety of acupuncture will also be assessed. All efficacy analyses will be performed in the intention-to-treat population. Discussion: To improve the adherence to intervention protocols, the majority of the participants will be recruited from an inpatient setting. The results will help to determine the clinical effects and safety of electroacupuncture for the treatment of OIC among patients with cancer.
EM zhishunjournal@163.com
FU 2019 National Administration of Traditional Chinese Medicine Project of building evidence-based practice capacity for TCM-Project BEBPC-TCM [2019XZZX-ZJ]
CR Alame Amer M, 2012, CLIN COLON RECTAL SURG, V25, P5, DOI 10.1055/s-0032-1301753
   Unknown -, 1996, CANC PAIN REL GUID O, V0, P0
   Bell TJ, 2009, PAIN MED, V10, P35, DOI 10.1111/j.1526-4637.2008.00495.x
   Camilleri M, 2008, NEW ENGL J MED, V358, P2344, DOI 10.1056/NEJMoa0800670
   Camilleri M, 2011, AM J GASTROENTEROL, V106, P835, DOI 10.1038/ajg.2011.30
   Caraceni A, 2012, LANCET ONCOL, V13, PE58, DOI 10.1016/S1470-2045(12)70040-2
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Cherny NI, 2001, EUR J CANCER, V37, P0
   Drewes AM, 2016, SCAND J PAIN, V11, P111, DOI 10.1016/j.sjpain.2015.12.005
   Farmer AD, 2018, LANCET GASTROENTEROL, V3, P203, DOI 10.1016/S2468-1253(18)30008-6
   Jin X, 2011, WORLD CHINESE J DIGE, V19, P209, DOI 10.11569/WCJD.V19.I2.209
   Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019
   Katakami N, 2017, J CLIN ONCOL, V35, P1921, DOI 10.1200/JCO.2016.70.8453
   Kessler ER, 2013, PHARMACOTHERAPY, V33, P383, DOI 10.1002/phar.1223
   Lacy BE, 2016, GASTROENTEROLOGY, V150, P1393, DOI 10.1053/j.gastro.2016.02.031
   Lazzari M, 2015, DRUG DES DEV THER, V9, P5863, DOI 10.2147/DDDT.S92998
   Lewis SJ, 1997, SCAND J GASTROENTERO, V32, P920, DOI 10.3109/00365529709011203
   Liu BY, 2021, AM J GASTROENTEROL, V116, P1024, DOI 10.14309/ajg.0000000000001050
   Liu BY, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-260
   Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118
   Luo M, 2011, EUR J GASTROEN HEPAT, V23, P1250, DOI 10.1097/MEG.0b013e32834d1938
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Marquis P, 2005, SCAND J GASTROENTERO, V40, P540, DOI 10.1080/00365520510012208
   Mercadante S, 2010, LANCET ONCOL, V11, P484, DOI 10.1016/S1470-2045(09)70350-X
   Morlion B, 2015, CLIN DRUG INVEST, V35, P1, DOI 10.1007/s40261-014-0254-6
   Müller-Lissner S, 2017, PAIN MED, V18, P1837, DOI 10.1093/pm/pnw255
   Nee J, 2018, CLIN GASTROENTEROL H, V16, P1569, DOI 10.1016/j.cgh.2018.01.021
   Oderda GM, 2007, ANN PHARMACOTHER, V41, P400, DOI 10.1345/aph.1H386
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Poulsen JL, 2015, THER ADV GASTROENTER, V8, P360, DOI 10.1177/1756283X15589526
   Preston CC, 2000, ACTA PSYCHOL, V104, P1, DOI 10.1016/S0001-6918(99)00050-5
   Rauck R, 2017, PAIN PRACT, V17, P820, DOI 10.1111/papr.12535
   Slatkin Neal, 2009, J SUPPORT ONCOL, V7, P39
   Song Y, 2012, J NURS SCI, V27, P73, DOI 10.3870/hlxzz.2012.07.073
   Standardization Administration of the Peoples Republic of China, 2006, GBT123462006, V0, P0
   Sykes NP, 1998, PALLIATIVE MED, V12, P375, DOI 10.1191/026921698674125048
   Takahashi T, 2011, NEUROMODULATION, V14, P8, DOI 10.1111/j.1525-1403.2010.00295.x
   Yiannakou Y, 2017, ALIMENT PHARM THER, V46, P1103, DOI 10.1111/apt.14349
   Zhang T, 2013, AM J CHINESE MED, V41, P717, DOI 10.1142/S0192415X13500493
   Zhou KH, 2011, J ALTERN COMPLEM MED, V17, P1007, DOI 10.1089/acm.2010.0652
   Zhou SL, 2017, ACUPUNCT MED, V35, P324, DOI 10.1136/acupmed-2016-011127
NR 41
TC 3
Z9 3
U1 4
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD APR 13
PY 2022
VL 9
IS 
BP 
EP 
DI 10.3389/fmed.2022.818258
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 1Y3NQ
UT WOS:000808050500001
PM 35492306
DA 2026-01-16
ER

PT J
AU Qiu, ML
   Sun, KL
   Zhong, JW
   Sun, LQ
   Zhou, LQ
   Wu, Q
   Song, ZY
   Pan, YY
   Lou, Y
   Yuan, X
   Li, J
AF Qiu, Man-Li
   Sun, Kai-Long
   Zhong, Jun-Wu
   Sun, Li-Qin
   Zhou, Ling-Qin
   Wu, Qi
   Song, Zhe-Yu
   Pan, Yuan-Yuan
   Lou, Ying
   Yuan, Xu
   Li, Jing
TI [Short needling for knee osteoarthritis with blood stasis obstruction and its
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture; knee osteoarthritis; randomized controlled trial (RCT); short needling
AB OBJECTIVE: To compare the clinical efficacy and its effect on serum levels of  tumor necrosis factor α(TNF-α), interleukin 1β(IL-1β), interleukin 6 (IL-6) and  prostaglandin E(2) (PGE(2)) between short needling (close-to-bone needling) and  conventional acupuncture for knee osteoarthritis (KOA) with blood stasis  obstruction. METHODS: A total of 68 KOA patients with blood stasis obstruction  were randomized into a short needling group (34 cases, 3 cases dropped off) and a  conventional acupuncture group (34 cases, 3 cases dropped off). The same  acupoints (Dubi [ST 35], Neixiyan [EX-LE 4], Binzhong [Extra], Liangqiu [ST 34],  etc. on the affected side) were selected in the two groups. In the short needling  group, short needling technique was adopted, the needles were slowly inserted and  the needle bodies were shaken, thus gradually penetrated to the bone. In the  conventional acupuncture group, conventional acupuncture was adopted, the needles  were penetrated to the muscle. After qi-arrival, Dubi (ST 35) and Neixiyan (EX-LE  4), Zusanli (ST 36) and Liangqiu (ST 34) were connected with CMNS6-1 electronic  acupuncture instrument, with disperse-dense wave, 2 Hz/10 Hz in frequency, the  current intensity was based on patients' feeling, the needles were retained for  30 min, at the same time, the knee joint was irradiated for 30 min with a special  electromagnetic wave apparatus in the two groups. Once every other day, 3 times a  week for 4 weeks. Before and after treatment, the Western Ontario and McMaster  Universities osteoarthritis index (WOMAC) score, knee joint pain visual analogue  scale (VAS) score, inflammatory response related indexes (serum TNF-a, IL-1β,  IL-6 and PGE(2)) and knee joint ultrasound were observed，and the clinical effect  was evaluated in the two groups. RESULTS: After treatment，the pain, stiffness,  function scores and total scores of WOMAC were decreased as compared with those  before treatment in the two groups (P<0.05), except for the pain score, the  changes of above scores in the short needling group were greater than the  conventional acupuncture group (P<0.05). After treatment, the VAS scores, serum  levels of TNF-a, IL-1β, IL-6, PGE(2) and knee joint synovium thickness,  intra-articular effusion were decreased as compared with those before treatment  in the two groups (P<0.05), the levels of TNF-a, IL-1β, IL-6 in the short  needling group were lower than the conventional acupuncture group (P<0.05). The  total effective rate in the short needling group was 87.1% (27/31), which was  superior to 83.9% (26/31) in the conventional acupuncture group (P<0.05).  CONCLUSION: Short needling could improve the knee joint function, relieve the  pain and inflammatory response, improve the knee joint synovium inflammatory  response, reduce the knee joint intra-articular effusion for KOA patients, its  effect is better than conventional acupuncture.
C1 Department of Acupuncture and Moxibustion, Shanghai Putuo Hospital of TCM, Shanghai 200062, China.
   Department of Acupuncture and Moxibustion, Shanghai Putuo Hospital of TCM, Shanghai 200062, China.
   Department of Acupuncture and Moxibustion, Shanghai Putuo Hospital of TCM, Shanghai 200062, China.
   Department of Acupuncture and Moxibustion, Shanghai Putuo Hospital of TCM, Shanghai 200062, China.
   Department of Acupuncture and Moxibustion, Shanghai Putuo Hospital of TCM, Shanghai 200062, China.
   Department of Acupuncture and Moxibustion, Shanghai Putuo Hospital of TCM, Shanghai 200062, China.
   Department of Acupuncture and Moxibustion, Shanghai Putuo Hospital of TCM, Shanghai 200062, China.
   Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai200437.
   Department of Acupuncture and Moxibustion, Shanghai Putuo Hospital of TCM, Shanghai 200062, China.
   Department of TCM, Shanghai Putuo Central Hospital.
   Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai200437.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUL 7
PY 2022
VL 42
IS 7
BP 733
EP 8
DI 10.13703/j.0255-2930.20210901-k0008
PG -725
WC Acupuncture Points; Humans; Inflammation; Interleukin-6; Osteoarthritis, Knee; therapy; Pain; Prostaglandins E
UT PubMed:35793881
PM 35793881
DA 2022-07-07
ER

PT J
AU Ashby, J
   Toveg, M
   Ye, H
   Rubin, LH
   Reddy, S
   Chao, MT
AF Ashby, Jennifer
   Toveg, Miria
   Ye, Helen
   Rubin, Lee Hullender
   Reddy, Sanjay
   Chao, Maria T
TI The Assessment and Treatment of Inpatient Cancer-Related Pain with Acupuncture:
SO Medical acupuncture
LA English
DT Journal Article
DE Traditional Chinese Medicine; acupuncture; complementary and alternative medicine; inpatient; oncology; pain management
AB Background and Objective: Pain is a highly prevalent and distressing experience  of hospitalized patients with cancer, and undertreatment is a challenging issue.  Adding nonpharmacologic treatments such as acupuncture to conventional pain  management may help address a patient's total pain experience. A dearth of  acupuncture treatment guidelines exists, leaving individual practitioners to  develop treatments themselves. The aim of the work described in this report was  to develop a standardized clinical reference manual for East Asian Medicine (EAM)  assessment, diagnosis, and acupuncture treatment of cancer-related pain in  hospitalized patients with cancer. Design: The acupuncture manual was developed  based on: (1) a narrative review of existing literature on acupuncture and cancer  pain; (2) a review of acupuncture charting notes of more than 200 treatments  provided in an inpatient setting; and (3) meetings of an expert panel of senior  acupuncturists to reach consensus on a manual protocol. Results: The resulting  manual described diagnosis of patients based on EAM constitution, symptoms and  signs, and channel location of the cancer-related pain symptoms. The resulting  point selections for acupuncture treatment enables adaptability, reproducibility,  and individualized acupuncture treatment of cancer-related pain in hospitalized  patients with cancer. Conclusions: The manual fills a vital gap in the current  literature, and supports community- and hospital-based acupuncturists as a  standardized clinical reference. The manual provides guidance for cancer-related  pain management, using EAM acupuncture in hospitalized patients.
C1 Osher Center for Integrative Medicine, University of California-San Francisco, San Francisco, CA, USA.
   Osher Center for Integrative Medicine, University of California-San Francisco, San Francisco, CA, USA.
   Osher Center for Integrative Medicine, University of California-San Francisco, San Francisco, CA, USA.
   Osher Center for Integrative Medicine, University of California-San Francisco, San Francisco, CA, USA.
   Osher Center for Integrative Medicine, University of California-San Francisco, San Francisco, CA, USA.
   Division of Hospital Medicine, University of California-San Francisco, San 
   Osher Center for Integrative Medicine, University of California-San Francisco, San Francisco, CA, USA.
   Division of General Internal Medicine, University of California-San Francisco,
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD MAR 8
PY 2022
VL 34
IS 1
BP 15
EP 23
DI 10.1089/acu.2021.0035
PG 8
UT PubMed:35251434
PM 35251434
DA 2022-03-08
ER

PT J
AU Radeva, S
   Zaralieva, A
   Tonev, D
AF Radeva, Stoika
   Zaralieva, Aycha
   Tonev, Dimitar
TI Predetermined physical factors and alternative factors in the treatment of
SO Reumatologia
LA English
DT Journal Article
DE chronic pain; discogenic lumbosacral radiculitis; predetermined physical factors
AB OBJECTIVES: Evolution of acute pain in discogenic lumbosacral radiculopathy to  subacute and chronic pain reflects pharmacotherapeutic issues and even  helplessness in some cases. It has social significance since 80% of people in  working age have faced it at least once in their working lifetime. Most of the  acute and subacute (> 6 weeks) episodes resolve within 3 months while in 10-15%  of patients their condition does not resolve and they develop chronic (> 3  months) lumbosacral syndrome. MATERIAL AND METHODS: We present our experience in  non-pharmaceutical treatment of chronic pain in discogenic lumbosacral  radiculopathy after comparison of different predetermined and alternative  therapies that have been given to patients who were selected by highly  informative assessment indicators for the extent of spinal root lesion. Sixty  patients were enrolled in this study and were divided into two groups of 30  patients each. The first group was treated with classic acupuncture, and the  second group with two predetermined factors from conventional physiotherapy. The  effect of the two treatments applied was followed up after each procedure in the  therapeutic course, and also a month later. RESULTS: As a result of the obtained  statistical data, we present a variant of non-invasive treatment of chronic pain  that would be useful in clinical practice. CONCLUSIONS: In cases of chronic pain  in this particular disease, a recommendation should be given for the combination  of two physical factors - paravertebral application of ultrasound in impulse mode  with an appropriate anti-inflammatory medicament as a mediator in the area of the  lumbosacral spine segment, by a labile method, combined with low frequency  impulse magnet field in the low back area and the affected leg. Also, acupuncture  could be used in fighting against pain, especially in patients contraindicated  for predetermined factors (those with a pacemaker, or an oncological process in  the small pelvis area).
C1 Department of Physiotherapy, Tsaritsa Yoanna-ISUL University Hospital, Sofia, Bulgaria.
   Department of Physical Medicine and Rehabilitation, Medical University Sofia, Bulgaria.
   Department of Anesthesiology and Intensive Care, Tsaritsa Yoanna-ISUL University Hospital, Sofia, Bulgaria.
NR 0
TC 0
SN 2084-983
EI 0034-623
J9 Reumatologia
PD JUL 6
PY 2022
VL 60
IS 2
BP 110
EP 115
DI 10.5114/reum.2022.116143
PG 5
UT PubMed:35782025
PM 35782025
DA 2022-07-06
ER

PT J
AU Huemer, M
   Jahn-Kuch, D
   Hofmann, G
   Pichler, M
AF Huemer, Matthias
   Jahn-Kuch, Daniela
   Hofmann, Guenter
   Pichler, Martin
TI A case report of immediate effects of acupuncture on neuropathic cancer breakthrough pain
SO COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE
LA English
DT Article
DE Palliative care; Pain management; Acupuncture; Complementary &amp; alternative medicine (CAM); Neuropathic pain; Cancer pain
AB Introduction: Acupuncture is a promising treatment for visceral cancer pain, but to date, evidence for immediate effects on neuropathic pain is limited. Case presentation: This report presents a case of immediate pain relief by single-needle acupuncture on opioidrefractory neuropathic breakthrough pain in a 78-year-old female breast cancer patient with cervical bone metastases. Acupuncture was applied at a single point neuroanatomically correlating to the pain affected spinal segment. Discussion: Immediately after acupuncture, the patient reported a complete pain relief lasting for one day. In the following days, neuropathic breakthrough pain was better manageable with reduced dosages of opioids. Acupuncture is possibly effective in providing immediate and safe pain relief in neuropathic cancer pain through neuromodulating effects on the spinal and central nervous level. Randomized controlled studies with individualized acupuncture point protocols are needed to establish efficacy and safety.
C1 [Huemer, Matthias; Jahn-Kuch, Daniela; Hofmann, Guenter] Med Univ Graz, Dept Internal Med, Div Oncol, Palliat Care Unit, Graz, Austria.
   [Pichler, Martin] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria.
C3 Medical University of Graz; Medical University of Graz
RP Pichler, M (corresponding author), Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria.
EM martin.pichler@medunigraz.at
CR Baeumler PI, 2015, PAIN, V156, P2245, DOI 10.1097/j.pain.0000000000000283
   Caraceni A, 2004, J CLIN ONCOL, V22, P2909, DOI 10.1200/jco.2004.08.141
   Fallon MT, 2013, BRIT J ANAESTH, V111, P105, DOI 10.1093/bja/aet208
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Ju ZY, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012057.pub2
   Maeda Y, 2017, BRAIN, V140, P914, DOI 10.1093/brain/awx015
   Ots T, 2020, ACUPUNCT MED, V38, P211, DOI 10.1177/0964528419889636
   Su CF, 2018, J INTEGR MED-JIM, V16, P208, DOI 10.1016/j.joim.2018.04.003
   Xiang AF, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/3837194
   Yang XY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/319734
   Zhang CP, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0289-y
NR 11
TC 3
Z9 4
U1 0
U2 15
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1744-3881
EI 1873-6947
J9 COMPLEMENT THER CLIN
JI Complement. Ther. Clin. Pract.
PD AUG 15
PY 2022
VL 48
IS 
BP 
EP 
DI 10.1016/j.ctcp.2022.101599
EA MAY 2022
PG 3
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 1T8GW
UT WOS:000804965400007
PM 35584602
DA 2026-01-16
ER

PT J
AU Zhang, XW
   Hou, WB
   Pu, FL
   Wang, XF
   Wang, YR
   Yang, M
   Cheng, K
   Wang, Y
   Robinson, N
   Liu, JP
AF Zhang, Xiao-Wen
   Hou, Wen-Bin
   Pu, Feng-Lan
   Wang, Xue-Feng
   Wang, Yi-Ran
   Yang, Ming
   Cheng, Ke
   Wang, Yuyi
   Robinson, Nicola
   Liu, Jian-Ping
TI Acupuncture for cancer-related conditions: An overview of systematic reviews.
SO Phytomedicine : international journal of phytotherapy and phytopharmacology
LA English
DT Review
DE Acupuncture; Cancer-related conditions; Overview; Randomized controlled trials; Systematic reviews
AB BACKGROUND: Acupuncture is commonly used for cancer-related conditions worldwide,  and evidence is increasing year on year. There is a need to summarize the  evidence of acupuncture for cancer-related conditions comprehensively and  critically. OBJECTIVE: To evaluate and summarize the systematic reviews (SRs)  that assess the effects and safety of acupuncture for cancer-related conditions,  and to inform clinical practice and future studies. METHODS: A comprehensive  search was conducted on Pubmed, Embase, the Cochrane Library, Web of Science,  CNKI, VIP, Sinomed, and Wanfang from their inception to October 16, 2021. SRs of  randomized controlled trials (RCTs) on acupuncture for cancer-related conditions  were to be included. Two reviewers screened the eligible articles, and four  reviewers in pair extracted data and assessed the methodological quality/risk of  bias of all included reviews by AMSTAR 2 and ROBIS tools. The overlap of primary  studies was measured by calculating corrected covered areas. Data from the  included reviews were synthesized with a summary of meta-analysis or narrative  description. RESULTS: Fifty-one SRs of RCTs on acupuncture for cancer-related  conditions were included and synthesized. The methodological quality of SRs  included 1 "high", 5 "low" and 45 "very low" by AMSTAR 2. Sixteen SRs assessed as  low risk of bias (31.37%), and 35 SRs had high risk of bias (68.63%) by ROBIS.  Acupuncture showed effective on systemic conditions in relation to different  cancers, including cancer-related pain (17 SRs, 80 RCTs), fatigue (7 SRs, 18  RCTs), insomnia (4 SRs, 10 RCTs), quality of life (2 SRs, 15 RCTs); conditions in  relation to chemo-radiotherapy, including nausea and vomiting (3 SRs, 36 RCTs)  and bone marrow suppression (2 SRs, 21 RCTs); and conditions in relation to  specific cancers, including breast cancer-related menopause (3 SRs, 6 RCTs), hot  flashes (12 SRs, 13 RCTs), arthralgia (5 SRs, 10 RCTs), and nasopharyngeal  cancer-related dysphagia (1 SRs, 7 RCTs). Acupuncture appeared to have benefit  for patients with lymphoedema (3 SRs, 3 RCTs), gastrointestinal function (5 SRs,  27 RCTs), and xerostomia (4 SRs, 7 RCTs). Limited evidence showed inconsistent  results on acupuncture for chemotherapy-induced peripheral neuropathy (3 SRs, 6  RCTs), depression and anxiety (3 SRs, 9 RCTs). Acupuncture was regarded as a safe  therapy for cancer patients as no severe adverse events related were reported.  CONCLUSION: Evidence from SRs showed that acupuncture is beneficial to cancer  survivors with cancer-related pain, fatigue, insomnia, improved quality of life,  nausea and vomiting, bone marrow suppression, menopausal symptoms, arthralgia,  and dysphagia, and may also be potential for lymphoedema, gastrointestinal  function, and xerostomia. For neuropathy, depression and anxiety, acupuncture  should be used as an option based on individual conditions. Acupuncture is  relatively safe without serious adverse events. More well-designed clinical  trials of acupuncture are recommended on cancer-related depression and anxiety,  arthralgia, xerostomia, gastrointestinal dysfunction and dysphagia.
C1 Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
   Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
   Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
   School of Humanities, Beijing University of Chinese Medicine, Beijing 100029, China.
   School of Humanities, Beijing University of Chinese Medicine, Beijing 100029, China.
   The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing 100029, China.
   School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
   Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400011, China.
   Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
   Institute of Health and Social Care, LondonSouth Bank University, London, UK.
   Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
   The National Research Center in Complementaryand Alternative Medicine (NAFKAM), Department of Community Medicine, Faculty ofHealth Science, UiT The Arctic University of Tromsø, Tromsø 9037, Norway.
EM Liujp@bucm.edu.cn
NR 0
TC 0
SN 1618-095
EI 
J9 Phytomedicine
PD SEP 14
PY 2022
VL 106
IS 
BP 154430
EP 154430
DI 10.1016/j.phymed.2022.154430
PG 0
WC Acupuncture Therapy; methods; Antineoplastic Agents; Arthralgia; etiology; Cancer Pain; Deglutition Disorders; etiology; Fatigue; Female; Humans; Lymphedema; etiology; Nausea; etiology; Neoplasms; etiology; Sleep Initiation and Maintenance Disorders; Systematic Reviews as Topic; Vomiting; etiology; Xerostomia; etiology
UT PubMed:36099656
PM 36099656
DA 2022-09-14
ER

PT J
AU Yu, N
   Yang, F
   Zhao, X
   Guo, Y
   Xu, Y
   Pang, G
   Gong, Y
   Wang, S
   Liu, Y
   Fang, Y
   Yu, K
   Yao, L
   Wang, H
   Zhang, K
   Liu, B
   Wang, Z
   Guo, Y
   Xu, Z
AF Yu, Nannan
   Yang, Fuming
   Zhao, Xue
   Guo, Yongming
   Xu, Yuan
   Pang, Guangchang
   Gong, Yinan
   Wang, Shenjun
   Liu, Yangyang
   Fang, Yuxin
   Yu, Kun
   Yao, Lin
   Wang, Hui
   Zhang, Kuo
   Liu, Baohu
   Wang, Zhenguo
   Guo, Yi
   Xu, Zhifang
TI Manual acupuncture at ST36 attenuates rheumatoid arthritis by inhibiting M1
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE adjuvant-induced arthritis; macrophage polarization; manual acupuncture; regulatory T cells; transforming growth factor β1
AB OBJECTIVES: Acupuncture has been found to be effective at relieving many  inflammatory pain conditions, including rheumatoid arthritis (RA). We aimed to  assess the anti-inflammatory potential of manual acupuncture (MA) treatment of RA  using adjuvant-induced arthritic (AIA) rats and to explore the underlying  mechanisms. METHODS: The anti-inflammatory and analgesic actions of MA at ST36  (Zusanli) in AIA rats were assessed using paw withdrawal latency and swelling,  histological examination and cytokine detection by enzyme-linked immunoassay  (ELISA). The cell-cell communication (CCC) network was analyzed with a multiplex  immunoassay of 24 immune factors expressed in the inflamed joints, and the  macrophage and Treg populations and associated cytokines regulated by MA were  investigated using reverse-transcription quantitative polymerase chain reaction  (RT-qPCR), ELISA and flow cytometry. RESULTS: MA markedly decreased heat  hyperalgesia and paw swelling in AIA rats. MA-treated rats also exhibited  decreased levels of pro-inflammatory cytokines (tumor necrosis factor (TNF)-α,  interleukin (IL)-1β) coupled with increased anti-inflammatory cytokines (IL-10,  transforming growth factor (TGF)-β1) in the ankle joints at protein and mRNA  levels. CCC network analysis confirmed that macrophages are of critical  importance and are potential therapeutic targets in RA. Repeated treatment with  MA triggered a macrophage phenotypic switch in the paws, with fewer M1  macrophages. Prominent increases in the Treg cell population and TGF-β1 in the  popliteal lymph nodes demonstrated the immunomodulatory effects of MA.  Furthermore, a selective TGF-β1-receptor inhibitor, SB431542, attenuated the  anti-inflammatory effects of MA and MA-induced suppression of the levels of  M1-released cytokines. CONCLUSION: These findings provide novel evidence that the  anti-inflammatory and analgesic effects of MA on RA act through phenotypic  modulation involving the inhibition of M1 macrophage polarization and an increase  in the Treg cell population, highlighting the potential therapeutic advantages of  acupuncture in controlling pain and ameliorating inflammatory conditions.
C1 Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Department of Traditional Chinese Medicine, the First Affiliated Hospital, the 
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Tianjin Key Laboratory of Food Biotechnology, College of Biotechnology and Food Science, Tianjin University of Commerce, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Department of Rehabilitation, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing, P.R. China.
   Xi'an Encephalopathy Hospital of Traditional Chinese Medicine, Xi'an, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD MAY 20
PY 2022
VL 41
IS 2
BP 96
EP 109
DI 10.1177/09645284221085278
PG 13
WC Rats; Animals; T-Lymphocytes, Regulatory; metabolism; Transforming Growth Factor beta1; Cytokines; Arthritis, Rheumatoid; drug therapy; Acupuncture Therapy; Tumor Necrosis Factor-alpha; Macrophages; metabolism; Pain; drug therapy; Anti-Inflammatory Agents; adverse effects; Arthritis, Experimental; drug therapy
UT PubMed:35585798
PM 35585798
DA 2022-05-20
ER

PT J
AU Wang, Y
   Yan, TQ
   Mu, XJ
   Dong, H
   Su, JM
AF Wang, Yan
   Yan, Tingquan
   Mu, Xiaojing
   Dong, Hong
   Su, Jinman
TI RETRACTED: Effects of Moxibustion Combined with Ultrashort Wave on Pain and Oxidative Stress in Elderly Patients with Knee Osteoarthritis (Retracted Article)
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article; Retracted Publication
ID responsiveness; reliability; validity
AB Objective. To explore the effect of moxibustion instrument combined with ultrashort wave on pain and oxidative stress in elderly patients with knee osteoarthritis (KOA). Method. 84 elderly patients with knee osteoarthritis treated in our hospital from May 2020 to June 2021 were randomly divided into observation group (n=42) and control group (n=42). The observation group was treated with moxibustion instrument combined with ultrashort wave, while the control group was treated with moxibustion instrument. The clinical efficacy of the two groups was compared, and the pain of the two groups was evaluated by visual analogue scale (VAS). Lysholm knee joint score scale and osteoarthritis index (WOMAC) scale of Western Ontario and McMaster University were used to evaluate the knee joint function of the two groups, and the levels of interleukin-1 beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha), serum superoxide dismutase (SOD), serum malondialdehyde (MDA), serum miR-155, and NLRP3 were detected in the two groups, and the comprehensive quality of life assessment questionnaire-74 was used, and the adverse reactions were compared between the two groups. Results. The total effective rate of observation group (90.48%) was higher than that of control group (69.05%) (P < 0.05). After treatment, VAS, Lysholm knee joint, WOMAC, quality of life scores, IL-1 beta, TNF-alpha, SOD, MDA, miR-155, and NLRP3 in the observation group were better than those in the control group, and the differences were statistically significant (P < 0.05). There were no obvious adverse reactions in both groups. Conclusion. Moxibustion instrument combined with ultrashort wave can effectively improve knee joint pain, knee joint function, inflammatory reaction, oxidative stress reaction, and quality of life in elderly KOA patients, and the therapeutic effect is good.
C1 [Wang, Yan; Yan, Tingquan; Mu, Xiaojing; Dong, Hong] 971st Hosp, Outpatient Dept 1, Peoples Liberat Army Navy, Qingdao 266071, Shandong, Peoples R China.
   [Su, Jinman] Navy Qingdao Special Serv Convalescent Ctr, Ten Branches Recuperat, Qingdao 266071, Shandong, Peoples R China.
RP Yan, TQ (corresponding author), 971st Hosp, Outpatient Dept 1, Peoples Liberat Army Navy, Qingdao 266071, Shandong, Peoples R China.
EM 1203636806@qq.com; yantingquan0612@163.com; 108855689@qq.com; 838341399@qq.com; 125383730@qq.com
CR Unknown -, 2007, OSTE BRANCH CHINESE, V0, P0
   Bing S, 2012, J NEUROSURG, V28, P645
   Chen Yu, 2020, ZHONGGUO ZHEN JIU, V40, P913, DOI 10.13703/j.0255-2930.20200310-k0011
   Chen Yu, 2020, ZHEN CI YAN JIU, V45, P569, DOI 10.13702/j.1000-0607.191015
   Fu WJ, 2020, ADV MODERN BIOMEDICI, V20, P5
   Jian-Hui Sun, 2020, ZHONGGUO ZHONG YAO ZA ZHI, V45, P4065, DOI 10.19540/j.cnki.cjcmm.20200608.203
   Kan HS, 2019, HONG KONG MED J, V25, P0, DOI 10.12809/hkmj187600
   Kocher MS, 2004, J BONE JOINT SURG AM, V86A, P1139, DOI 10.2106/00004623-200406000-00004
   Li GS, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2020.9500
   Li SH, 2021, EUR REV MED PHARMACO, V25, P1185, DOI 10.26355/eurrev_202102_24821
   LiShumei WZ, 2020, CONT NURSE 1 ISSUE, V27, P3
   Liu CX, 2020, ORTHOP SURG, V12, P286, DOI 10.1111/os.12586
   LiXiaojuan T, 2011, LIAONING J TRADITION, V38, P2
   Roos EM, 1999, SCAND J RHEUMATOL, V28, P210
   Scanzello CR, 2017, CURR OPIN RHEUMATOL, V29, P79, DOI 10.1097/BOR.0000000000000353
   Shen W, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/8204522
   Wang X, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019974
   Xiao YC, 2021, MOL MED REP, V23, P0, DOI 10.3892/mmr.2020.11736
   Xu HF, 2018, TRIALS, V19, P0, DOI 10.1186/s13063-018-2794-1
   Yildiz K, 2021, ACTA ORTHOP TRAUMATO, V55, P235, DOI 10.5152/j.aott.2021.19249
   Zhao LR, 2018, MOL MED REP, V17, P5463, DOI 10.3892/mmr.2018.8520
NR 21
TC 3
Z9 5
U1 0
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD MAY 9
PY 2022
VL 2022
IS 
BP 
EP 
DI 10.1155/2022/3921021
PG 7
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 1T8IG
UT WOS:000804969000004
PM 35586674
DA 2026-01-16
ER

PT J
AU Pintas, S
   Zhang, AN
   James, KJ
   Lee, RM
   Shubov, A
AF Pintas, Stephanie
   Zhang, Annie
   James, Kevin J.
   Lee, Roger M.
   Shubov, Andrew
TI Effect of Inpatient Integrative Medicine Consultation on 30-Day Readmission Rates: A Retrospective Observational Study at a Major US Academic Hospital
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE acupuncture; cost effectiveness; East Asian Medicine; integrative medicine; pain management
ID low-back-pain; cost savings; acupuncture; care; oncology; efficacy; opioids; trials
AB Objectives: The prevalence of inpatient integrative medicine (IM) consult services is increasing among academic health care institutions. The diversity of services between institutions, as well as the novel nature of such interventions, makes it challenging for health care administrators to determine the cost/benefit of adding such a program to their institution. The main purpose of this study was to examine the performance of the new University of California, Los Angeles (UCLA) East-West (EW) consult service as measured by 30-day readmission rates and lengths of stay.Design: This is a retrospective observational case-control study with participants matched to themselves.Setting: UCLA Santa Monica Hospital, a 281-bed academic tertiary care hospital near Los Angeles, California.Subjects: Patients who had received an EW consultation during the inaugural 20 months of the program (2018-2020), and who had been hospitalized in the prior 2 years from the date of their first EW consult.Intervention: Inpatient East-West consultation, which may include counseling, acupuncture and/or trigger point injections depending on medical necessity.Outcome Measures: Thirty-day readmission rates and lengths of hospital admission were compared between the hospitalization that included an EW consult (which included the use of acupuncture and/or trigger point injections when appropriate) and any prior admissions during the 2 years before that EW consult. Secondary outcomes included quantitative analysis of average number of treatments and qualitative assessment of integrative treatment(s) received, conditions treated, and reasons that EW treatment may have been deferred during a consult.Results: One hundred sixty-five unique patients met the study criteria. The EW consultation was associated with clinically relevant, statistically significant decreased 30-day readmission rates (33.0% vs. 4.6%, p < 0.001, odds ratio [OR] 0.10, 95% confidence interval [CI] 0.06-0.17). This effect was similar when limiting the analysis to pain-related admissions (32.3% vs. 3.4%, p < 0.001, OR = 0.07, 95% CI 0.03-0.16). Hospital admissions with EW consults were found to have a statistically significant increased length of stay (7.03 days vs. 5.40 days, p < 0.001).Conclusion: The EW medicine, an example of IM, correlates with a reduced risk of 30-day readmission and with modestly increased lengths of stay.
C1 [Pintas, Stephanie; Zhang, Annie; James, Kevin J.; Lee, Roger M.; Shubov, Andrew] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
   [Zhang, Annie; Lee, Roger M.; Shubov, Andrew] UCLA Santa Mon Hosp, Dept Med, Santa Monica, CA USA.
   [Zhang, Annie; Shubov, Andrew] UCLA Ctr East West Med, Dept Med, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Shubov, A (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr East West Med, Dept Med, 200 Med Plaza,Suite 420, Los Angeles, CA 90095 USA.
EM ashubov@mednet.ucla.edu
CR Alvarez DJ, 2002, AM FAM PHYSICIAN, V65, P653
   Ballantyne JC, 2008, CLIN J PAIN, V24, P469, DOI 10.1097/AJP.0b013e31816b2f26
   Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Bron C, 2011, BMC MED, V9, P0, DOI 10.1186/1741-7015-9-8
   Cheong KB, 2014, COMPLEMENT THER MED, V22, P767, DOI 10.1016/j.ctim.2014.05.002
   Chien Tsai-Ju, 2013, J TRADIT COMPLEMENT MED, V3, P234, DOI 10.4103/2225-4110.119733
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Crespin DJ, 2015, PAIN MED, V16, P1195, DOI 10.1111/pme.12685
   Dagenais S, 2008, SPINE J, V8, P8, DOI 10.1016/j.spinee.2007.10.005
   Dorsher PT, 2009, J PAIN, V10, P723, DOI 10.1016/j.jpain.2008.12.010
   Dueñas M, 2016, J PAIN RES, V9, P457, DOI 10.2147/JPR.S105892
   Dusek JA, 2018, J ALTERN COMPLEM MED, V24, P557, DOI 10.1089/acm.2017.0203
   Dusek Jeffery A, 2010, J PATIENT SAF, V6, P48, DOI 10.1097/PTS.0b013e3181d10ad5
   Estores IM, 2018, EXPLORE-NY, V14, P212, DOI 10.1016/j.explore.2018.02.002
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   GARVEY TA, 1989, SPINE, V14, P962, DOI 10.1097/00007632-198909000-00008
   Gomes T, 2018, JAMA NETW OPEN, V1, P0, DOI 10.1001/jamanetworkopen.2018.0217
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Herman Patricia M, 2013, GLOB ADV HEALTH MED, V2, P56, DOI 10.7453/gahmj.2013.002
   Herman PM, 2012, BMJ OPEN, V2, P0, DOI 10.1136/bmjopen-2012-001046
   Herzig SJ, 2014, J HOSP MED, V9, P73, DOI 10.1002/jhm.2102
   Johnson JR, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-486
   Johnson Jill R, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP330, DOI 10.1093/jncimonographs/lgu030
   Kim SY, 2012, ACUPUNCT MED, V30, P273, DOI 10.1136/acupmed-2012-010178
   Kligler B, 2011, AM J MANAG CARE, V17, P779
   Lacy BE, 2018, J CLIN GASTROENTEROL, V52, P20, DOI 10.1097/MCG.0000000000000728
   Lee JH, 2013, CLIN J PAIN, V29, P172, DOI 10.1097/AJP.0b013e31824909f9
   Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4
   Madsen MV, 2009, BMJ-BRIT MED J, V338, P0, DOI 10.1136/bmj.a3115
   Maizes V, 2009, EXPLORE-NY, V5, P277, DOI 10.1016/j.explore.2009.06.008
   Manheimer E, 2012, AM J GASTROENTEROL, V107, P835, DOI 10.1038/ajg.2012.66
   Nate KC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/394040
   Osler W, 1892, PRINCIPLES PRACTICE, V0, P282
   Ratcliffe J, 2006, BRIT MED J, V333, P626, DOI 10.1136/bmj.38932.806134.7C
   Reinecke H, 2015, BRIT J PHARMACOL, V172, P324, DOI 10.1111/bph.12634
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wadhwa V, 2017, WORLD J GASTROENTERO, V23, P4428, DOI 10.3748/wjg.v23.i24.4428
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Yang MX, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-311
   Zhang AN, 2021, J ALTERN COMPLEM MED, V27, P803, DOI 10.1089/acm.2021.0087
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
NR 43
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD MAR 1
PY 2022
VL 28
IS 3
BP 241
EP 249
DI 10.1089/jicm.2021.0155
EA JAN 2022
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 8M4QR
UT WOS:000839254200001
PM 35294299
DA 2026-01-16
ER

PT J
AU Qi, QL
   Han, X
   Tang, C
AF Qi, Qing-Ling
   Han, Xue
   Tang, Cheng
TI Effects of Acupuncture on Breast Cancer Patients Taking Aromatase Inhibitors.
SO BioMed research international
LA English
DT Journal Article
AB Although acupuncture has been used in clinical practice for thousands of years,  it remains a controversial treatment option to help alleviate pain in cancer  patients. In this study, we analyzed published material on randomized trials of  acupuncture from MEDLINE published up until July 31, 2018, to assess its effects  on pain experienced by cancer patients. Revman 5.0 software was used to conduct  meta-analysis with pain score as the index. The results of nine randomized  controlled trials involving 592 patients were analyzed and showed that  acupuncture can relieve the pain caused by aromatase inhibitors. Weighted mean  difference of worst pain and pain severity was -3.03, 95% CI (-3.90,-2.16) and  -2.69, 95% CI (-4.08,-1.30), respectively (P < 0.01). This led us to conclude  that acupuncture has pain relieving effects against pain caused by aromatase  inhibitors.
C1 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture andMoxibustion, 300381 Tianjin, China.
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture andMoxibustion, 300381 Tianjin, China.
   School of Pharmacy, Tianjin Medical University, 300070 Tianjin, China.
NR 0
TC 0
SN 2314-614
EI 2314-613
J9 Biomed Res Int
PD SEP 23
PY 2022
VL 2022
IS 
BP 1164355
EP 1164355
DI 10.1155/2022/1164355
PG 0
WC Acupuncture; Acupuncture Therapy; methods; Aromatase Inhibitors; adverse effects; Breast Neoplasms; chemically induced; Female; Humans; Pain; drug therapy; Randomized Controlled Trials as Topic
UT PubMed:36132087
PM 36132087
DA 2022-09-23
ER

PT J
AU Wang, Y
   Fang, J
   Zhou, YL
   Lyu, Z
AF Wang, Yang
   Fang, Jie
   Zhou, Youlong
   Lyu, Zhifeng
TI Transcutaneous Electrical Acupoint Stimulation: Research Progress in Clinical Application (Review)
SO ACUPUNCTURE & ELECTRO-THERAPEUTICS RESEARCH
LA English
DT Review
DE Transcutaneous electrical acupoint stmulation (TEAS); Clinical application; Perioperative period
ID acupuncture point stimulation; elderly-patients; postoperative recovery; pain; prevention; disease; surgery; stress; cancer; teas
AB Transcutaneous electrical acupoint stimulation (TEAS) has become an important method for the treatment of diseases, which can be used alone or as a complementary mthod. TEAS combines the benefits of transcutaneous electrical Received: 4 July 2021/Accepted: 5 May 2022 nerve stimulation (TENS) and acupuncture, and it is welcomed by clinicians because Absr ct:Transc taneous el ctrical acupointimulatio(TEAS) habcome an of its safety and significant treatment effect . For instance, TEAS is helpful for importan mehod for t e treatmen of diseaes, which cabusd aone or s a sedation and analgesia, promotes gastrointestinal function re covery, reduces the occurrnce of postoperative cognitive dysfunction (POCD), postoperative nausea and complementary method. TEAS combines the benefits of transcutaneous elect ical vomiting (PONV), and other adverse reactios, enhances imune fucto, protects nerve stimulation (TENS) and acupuncture, and it is welcomed by clinicians because rgan funcion, accelerates he recovery of patients, improves the prognosis, and of its safety a d significant treatment effect. For i stance, TEAS is helpfu for enhnces patients' comfort degre. On this basis, more functions f TEAS need to bsedation and ana gesia, promote gastro ntestinal function recovery, reduces the occurnce of postopertive cognitive dysfunction (POCD), posto explored, and its clinical applications need to be further promoted.
C1 [Wang, Yang] Henan Univ Chinese Med, Clin Med Coll 1, Zhengzhou, Henan, Peoples R China.
   [Fang, Jie; Lyu, Zhifeng] Henan Univ Chinese Med, Dept Anesthesiol, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
   [Zhou, Youlong] Henan Univ Chinese Med, Dept Acupuncture & Pain, Affiliated Hosp 3, Zhengzhou, Henan, Peoples R China.
   [Lyu, Zhifeng] Henan Univ Chinese Med, Dept Anesthesiol, Affiliated Hosp 1, 19 Renmin Rd, Zhengzhou 450052, Henan, Peoples R China.
C3 Henan University of Traditional Chinese Medicine; Henan University of Traditional Chinese Medicine; Henan University of Traditional Chinese Medicine; Henan University of Traditional Chinese Medicine
RP Lyu, Z (corresponding author), Henan Univ Chinese Med, Dept Anesthesiol, Affiliated Hosp 1, 19 Renmin Rd, Zhengzhou 450052, Henan, Peoples R China.
EM mazui1846@126.com
CR Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Bai WY, 2018, J NEUROSURG ANESTH, V30, P337, DOI 10.1097/ANA.0000000000000460
   Chen YM, 2021, ACUPUNCT MED, V39, P292, DOI 10.1177/0964528420960479
   Chi YL, 2019, AM J CHINESE MED, V47, P1445, DOI 10.1142/S0192415X19500745
   Deng KF, 2021, J ACUPUNCT TUINA SCI, V19, P78, DOI 10.1007/s11726-021-1229-9
   Feng B, 2019, PSYCHIAT CLIN NEUROS, V73, P179, DOI 10.1111/pcn.12810
   Feng B, 2016, J PSYCHIATR RES, V80, P30, DOI 10.1016/j.jpsychires.2016.05.015
   Gao F, 2018, CLIN INTERV AGING, V13, P2127, DOI 10.2147/CIA.S183698
   Hadadian F, 2016, J CLIN DIAGN RES, V10, PYC1, DOI 10.7860/JCDR/2016/19516.8532
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hou LL, 2013, CANCER NURS, V36, P139, DOI 10.1097/NCC.0b013e3182483415
   Hou LL, 2017, J THORAC DIS, V9, P809, DOI 10.21037/jtd.2017.03.12
   Huang J, 2020, CHINA MEDICAL ABSTRA, V37, P141
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   Huang Wei, 2018, ZHEN CI YAN JIU, V43, P611, DOI 10.13702/j.1000-0607.180005
   Li HZ, 2019, CLIN INTERV AGING, V14, P1607, DOI 10.2147/CIA.S210751
   Liu XM, 2015, J ALTERN COMPLEM MED, V21, P610, DOI 10.1089/acm.2014.0284
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Miao Wei-Juan, 2020, ZHONGGUO ZHEN JIU, V40, P615, DOI 10.13703/j.0255-2930.20190824-0001
   Mo YC, 2017, MEDIAT INFLAMM, V2017, P0, DOI 10.1155/2017/8369737
   Ni XL, 2012, PEDIATR ANESTH, V22, P805, DOI 10.1111/j.1460-9592.2012.03822.x
   Qu F, 2017, EXPLORE-NY, V13, P306, DOI 10.1016/j.explore.2017.06.004
   Qu F, 2017, J ZHEJIANG UNIV-SC B, V18, P186, DOI 10.1631/jzus.B1600437
   Song BJ, 2020, NAT SCI SLEEP, V12, P809, DOI 10.2147/NSS.S270739
   Song Y, 2020, J INT MED RES, V48, P0, DOI 10.1177/0300060520910052
   Sun K, 2017, CLIN J PAIN, V33, P340, DOI 10.1097/AJP.0000000000000400
   Sun S L, 1989, SHENG LI XUE BAO, V41, P416
   Tu Q, 2018, TECHNOL CANCER RES T, V17, P0, DOI 10.1177/1533033818806477
   Tu Q, 2019, UROLITHIASIS, V47, P279, DOI 10.1007/s00240-018-1056-8
   Wu ZY, 2015, J TRADIT CHIN MED, V35, P134, DOI 10.1016/S0254-6272(15)30020-0
   Xie J, 2017, CHIN J CANCER, V36, P0, DOI 10.1186/s40880-016-0176-1
   Yang XY, 2015, BRIT J ANAESTH, V115, P883, DOI 10.1093/bja/aev352
   Yao YS, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/324360
   Yin CP, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000013814
   Yu XD, 2019, ACUPUNCT MED, V37, P312, DOI 10.1136/acupmed-2017-011536
   Zhang W, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5650413
   Zhao WL, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0116976
   Zhou DD, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/7341920
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
NR 39
TC 2
Z9 2
U1 8
U2 66
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0360-1293
EI 2167-9010
J9 ACUPUNCTURE ELECTRO
JI Acupunct. Electro-Ther. Res.
PD JUN 15
PY 2022
VL 47
IS 4
BP 379
EP 390
DI 10.3727/036012921X16341481788249
PG 12
WC Integrative & Complementary Medicine; Neurosciences
SC Integrative & Complementary Medicine; Neurosciences & Neurology
GA 6I1YR
UT WOS:000885927000001
DA 2026-01-16
ER

PT J
AU Mezzanotte, JN
   Grimm, M
   Shinde, N
   Nolan, T
   Worthen-Chaudhari, L
   Williams, NO
   Lustberg, MB
AF Mezzanotte, Jessica N.
   Grimm, Michael
   Shinde, Namrata, V
   Nolan, Timiya
   Worthen-Chaudhari, Lise
   Williams, Nicole O.
   Lustberg, Maryam B.
TI Updates in the Treatment of Chemotherapy-Induced Peripheral Neuropathy
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Review
DE Chemotherapy-induced peripheral neuropathy; Duloxetine; Acupuncture; Exercise therapy
ID placebo-controlled trial; cancer-patients; double-blind; topical amitriptyline; scrambler therapy; pain; prevention; paclitaxel; management; oxaliplatin
AB Opinion statement Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and other specific agents. The long-term consequences of this condition can result in decreased patient quality of life and can lead to reduced dose intensity, which can negatively impact disease outcomes. There are currently no evidence-based preventative strategies for CIPN and only limited options for treatment. However, there are several strategies that can be utilized to improve patient experience and outcomes as more data are gathered in the prevention and treatment setting. Before treatment, patient education on the potential side effects of chemotherapy is key, and although trials have been limited, recommending exercise and a healthy lifestyle before and while undergoing chemotherapy may provide some overall benefit. In patients who develop painful CIPN, our approach is to offer duloxetine and titrate up to 60 mg daily. Chemotherapy doses may also need to be reduced if intolerable symptoms develop during treatment. Some patients may also try acupuncture and physical therapy to help address their symptoms, although this can be limited by cost, time commitment, and patient motivation. Additionally, data on these modalities are currently limited, as studies are ongoing. Overall, approaching each patient on an individual level and tailoring treatment options for them based on overall physical condition, their disease burden, goals of care and co-morbid health conditions, and willingness to trial different approaches is necessary when addressing CIPN.
C1 [Mezzanotte, Jessica N.] Ohio State Univ, Wexner Med Ctr, Dept Internal Med, 395 W 12th Ave,Room 3348, Columbus, OH 43210 USA.
   [Grimm, Michael] Ohio State Univ, Comprehens Canc Ctr, 460 W 10th Ave, Columbus, OH 43210 USA.
   [Shinde, Namrata, V] Ohio State Univ, Wexner Med Ctr, Dept Radiol, 395 W 12th Ave, Columbus, OH 43210 USA.
   [Nolan, Timiya] Ohio State Univ, Coll Nursing, 1585 Neil Ave, Columbus, OH 43210 USA.
   [Worthen-Chaudhari, Lise] Ohio State Univ, Wexner Med Ctr, Dept Phys Med & Rehabil, 480 Med Ctr Dr,Dodd Hall,Suite 1060, Columbus, OH 43210 USA.
   [Williams, Nicole O.] Ohio State Univ, Wexner Med Ctr, Dept Med Oncol, 1800 Cannon Dr,1310K Lincoln Tower, Columbus, OH 43210 USA.
   [Lustberg, Maryam B.] Smilow Canc Hosp, Yale Canc Ctr, 35 Pk St, New Haven, CT 06519 USA.
C3 University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Yale University; Yale New Haven Hospital
RP Lustberg, MB (corresponding author), Smilow Canc Hosp, Yale Canc Ctr, 35 Pk St, New Haven, CT 06519 USA.
EM Maryam.lustberg@yale.edu
FU National Cancer Institute [R01CA238946] Funding Source: NIH RePORTER; National Institute on Aging [R21AG068831] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA238946] Funding Source: Medline; NIA NIH HHS [R21 AG068831] Funding Source: Medline
CR Alkislar I, 2021, BIOL PSYCHIAT-COGN N, V6, P479, DOI 10.1016/j.bpsc.2020.11.015
   Ambrosone CB, 2020, J CLIN ONCOL, V38, P804, DOI 10.1200/JCO.19.01203
   Aziz MT, 2014, ANN PHARMACOTHER, V48, P626, DOI 10.1177/1060028014525033
   Bao T, 2020, JNCI CANCER SPECT, V4, P0, DOI 10.1093/jncics/pkaa048
   Barton DL, 2011, SUPPORT CARE CANCER, V19, P833, DOI 10.1007/s00520-010-0911-0
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Besson M, 2015, PAIN, V156, P397, DOI 10.1097/01.j.pain.0000460331.33385.e8
   Bland KA, 2019, CLIN BREAST CANCER, V19, P411, DOI 10.1016/j.clbc.2019.05.013
   Bonhof CS, 2018, GYNECOL ONCOL, V149, P455, DOI 10.1016/j.ygyno.2018.03.052
   Brown TJ, 2019, JAMA ONCOL, V5, P750, DOI 10.1001/jamaoncol.2018.6771
   Caillaud M, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13010069
   Chen SC, 2020, EUR J ONCOL NURS, V49, P0, DOI 10.1016/j.ejon.2020.101834
   Clark PG, 2012, J EVID-BASED INTEGR, V17, P161, DOI 10.1177/2156587212450175
   Courneya KS, 2014, CANCER EPIDEM BIOMAR, V23, P857, DOI 10.1158/1055-9965.EPI-13-1163
   Coyne Patrick J, 2013, J PAIN PALLIAT CARE PHARMACOTHER, V27, P359, DOI 10.3109/15360288.2013.847519
   Desideri I, 2017, MED ONCOL, V34, P0, DOI 10.1007/s12032-017-0907-4
   Dhawan S, 2020, CANCER NURS, V43, P269, DOI 10.1097/NCC.0000000000000693
   Dorsey SG, 2019, JNCI-J NATL CANCER I, V111, P531, DOI 10.1093/jnci/djz011
   Duregon F, 2018, CRIT REV ONCOL HEMAT, V121, P90, DOI 10.1016/j.critrevonc.2017.11.002
   Fallon MT, 2015, SUPPORT CARE CANCER, V23, P2769, DOI 10.1007/s00520-015-2642-8
   Farshchian N, 2018, CANCER CHEMOTH PHARM, V82, P787, DOI 10.1007/s00280-018-3664-y
   Fradkin M, 2019, CURR MED CHEM, V26, P4698, DOI 10.2174/0929867326666190107163756
   Fujita S, 2019, J NEUROCHEM, V148, P373, DOI 10.1111/jnc.14607
   Galantino ML, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419850627
   Gamelin E, 2002, SEMIN ONCOL, V29, P21, DOI 10.1053/sonc.2002.35525
   Gerdts J, 2015, SCIENCE, V348, P453, DOI 10.1126/science.1258366
   Gewandter JS, 2013, SUPPORT CARE CANCER, V21, P2059, DOI 10.1007/s00520-013-1766-y
   Gewandter JS, 2018, NEUROLOGY, V91, P403, DOI 10.1212/WNL.0000000000006083
   Gewandter JS, 2014, SUPPORT CARE CANCER, V22, P1807, DOI 10.1007/s00520-014-2158-7
   Glimelius B, 2018, ACTA ONCOL, V57, P393, DOI 10.1080/0284186X.2017.1398836
   Hammack JE, 2002, PAIN, V98, P195, DOI 10.1016/S0304-3959(02)00047-7
   Hammond EA, 2020, NEUROREHAB NEURAL RE, V34, P235, DOI 10.1177/1545968319899918
   Hanai A, 2018, JNCI-J NATL CANCER I, V110, P0, DOI 10.1093/jnci/djx178
   Hartrick CT, 2012, EXPERT OPIN INV DRUG, V21, P1827, DOI 10.1517/13543784.2012.731393
   Hershman DL, 2013, J CLIN ONCOL, V31, P2627, DOI 10.1200/JCO.2012.44.8738
   Hoschneider DP, 2007, BRAIN RES, V1184, P96, DOI 10.1016/j.brainres.2007.09.081
   Hu SY, 2019, CLIN CANCER RES, V25, P6295, DOI 10.1158/1078-0432.CCR-18-2152
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Kanbayashi Y, 2020, BREAST, V49, P219, DOI 10.1016/j.breast.2019.12.011
   Kanzawa-Lee GA, 2020, CANCER NURS, V43, PE172, DOI 10.1097/NCC.0000000000000801
   Kautio AL, 2008, J PAIN SYMPTOM MANAG, V35, P31, DOI 10.1016/j.jpainsymman.2007.02.043
   Kelley MR, 2016, J PHARMACOL EXP THER, V359, P300, DOI 10.1124/jpet.116.235283
   Kelley MR, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0106485
   Kerr GW, 2001, EMERG MED J, V18, P236, DOI 10.1136/emj.18.4.236
   Kleckner IR, 2018, SUPPORT CARE CANCER, V26, P1019, DOI 10.1007/s00520-017-4013-0
   Kneis S, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5522-7
   Kroigård T, 2014, EUR J NEUROL, V21, P623, DOI 10.1111/ene.12353
   Kyte SL, 2018, J PHARMACOL EXP THER, V364, P110, DOI 10.1124/jpet.117.243972
   Leonard GD, 2005, BMC CANCER, V5, P0, DOI 10.1186/1471-2407-5-116
   Li Y, 2018, J NEUROSCI, V38, P1124, DOI 10.1523/JNEUROSCI.0899-17.2017
   Loprinzi C, 2020, SUPPORT CARE CANCER, V28, P1183, DOI 10.1007/s00520-019-04881-3
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Maihöfner C, 2021, SUPPORT CARE CANCER, V29, P4223, DOI 10.1007/s00520-021-06042-x
   Masocha W, 2018, PAIN RES MANAG, V2018, P0, DOI 10.1155/2018/5234943
   McCrary JM, 2019, SUPPORT CARE CANCER, V27, P3849, DOI 10.1007/s00520-019-04680-w
   Mercadante S, 2015, EXPERT REV NEUROTHER, V15, P1249, DOI 10.1586/14737175.2015.1101347
   Mishra S, 2012, AM J HOSP PALLIAT ME, V29, P177, DOI 10.1177/1049909111412539
   Mongiovi JM, 2018, BREAST CANCER RES, V20, P0, DOI 10.1186/s13058-018-1077-9
   Mustafa G, 2013, PAIN, V154, P2547, DOI 10.1016/j.pain.2013.07.041
   Nyrop KA, 2019, CANCER-AM CANCER SOC, V125, P2945, DOI 10.1002/cncr.32175
   Pachman DR, 2015, SUPPORT CARE CANCER, V23, P943, DOI 10.1007/s00520-014-2424-8
   Paice JA, 2019, J NATL COMPR CANC NE, V17, P595, DOI 10.6004/jnccn.2019.5010
   Paice JA, 2019, CURR TREAT OPTION ON, V20, P0, DOI 10.1007/s11864-019-0647-0
   Paice JA, 2017, J PAIN, V18, P233, DOI 10.1016/j.jpain.2016.10.020
   Pease-Raissi SE, 2017, NEURON, V96, P373, DOI 10.1016/j.neuron.2017.09.034
   Piccolo J, 2014, AM J HEALTH-SYST PH, V71, P19, DOI 10.2146/ajhp130126
   Prinsloo S, 2018, J PAIN SYMPTOM MANAG, V55, P1276, DOI 10.1016/j.jpainsymman.2018.01.010
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Privitera R, 2021, CURR OPIN SUPPORT PA, V15, P125, DOI 10.1097/SPC.0000000000000545
   Rao RD, 2008, CANCER, V112, P2802, DOI 10.1002/cncr.23482
   Rao RD, 2007, CANCER-AM CANCER SOC, V110, P2110, DOI 10.1002/cncr.23008
   Rosenbaek F, 2020, SUPPORT CARE CANCER, V28, P3763, DOI 10.1007/s00520-019-05196-z
   Saif MW, 2008, CANCER CHEMOTH PHARM, V61, P349, DOI 10.1007/s00280-007-0584-7
   Schneider BP, 2015, ADV EXP MED BIOL, V862, P77, DOI 10.1007/978-3-319-16366-6_6
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Schwenk M, 2016, GERONTOLOGY, V62, P553, DOI 10.1159/000442253
   Shah A, 2018, J NEUROL NEUROSUR PS, V89, P636, DOI 10.1136/jnnp-2017-317215
   Shi ZX, 2020, BREAST CANCER RES TR, V179, P229, DOI 10.1007/s10549-019-05457-9
   Shigematsu H, 2020, SUPPORT CARE CANCER, V28, P5005, DOI 10.1007/s00520-020-05345-9
   Shinde SS, 2016, SUPPORT CARE CANCER, V24, P547, DOI 10.1007/s00520-015-2807-5
   Siddiqui, 2021, CANCERS, V13, P0
   Smith EML, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12421
   Smith EML, 2018, CANCER CONTROL, V25, P0, DOI 10.1177/1073274818756608
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Speck R, 2012, SUPPORT CARE CANCER, V20, P2433, DOI 10.1007/s00520-011-1365-8
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Storey Dawn J, 2010, J PAIN SYMPTOM MANAGE, V39, Pe2, DOI 10.1016/j.jpainsymman.2010.02.004
   Streckmann F, 2019, SUPPORT CARE CANCER, V27, P2471, DOI 10.1007/s00520-018-4531-4
   Szepanowski F, 2016, J NEUROINFLAMM, V13, P0, DOI 10.1186/s12974-016-0612-9
   Tan AC, 2019, SUPPORT CARE CANCER, V27, P4771, DOI 10.1007/s00520-019-04781-6
   Ulker E, 2020, ONCOLOGIST, V25, P189, DOI 10.1634/theoncologist.2019-0540
   Waissengrin B, 2021, THER ADV MED ONCOL, V13, P0, DOI 10.1177/1758835921990203
   Ward SJ, 2014, BRIT J PHARMACOL, V171, P636, DOI 10.1111/bph.12439
   Wesselink E, 2018, NUTRIENTS, V10, P0, DOI 10.3390/nu10040398
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zhu J, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep28861
   Zhu YY, 2013, WORLD J SURG ONCOL, V11, P0, DOI 10.1186/1477-7819-11-19
   Zimmer P, 2018, SUPPORT CARE CANCER, V26, P615, DOI 10.1007/s00520-017-3875-5
   Zirpoli GR, 2017, JNCI-J NATL CANCER I, V109, P0, DOI 10.1093/jnci/djx098
NR 102
TC 50
Z9 57
U1 3
U2 25
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1527-2729
EI 1534-6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD JAN 15
PY 2022
VL 23
IS 1
BP 29
EP 42
DI 10.1007/s11864-021-00926-0
EA FEB 2022
PG 14
WC Oncology
SC Oncology
GA ZL0UR
UT WOS:000759028700004
PM 35167004
DA 2026-01-16
ER

PT J
AU Yeh, CH
   Lukkahatai, N
   Huang, X
   Wu, H
   Wang, H
   Zhang, J
   Sun, X
   Smith, TJ
AF Yeh, Chao Hsing
   Lukkahatai, Nada
   Huang, Xinran
   Wu, Hulin
   Wang, Hongyu
   Zhang, Jingyu
   Sun, Xinyi
   Smith, Thomas J
TI Biological Correlates of the Effects of Auricular Point Acupressure on Pain.
SO Pain management nursing : official journal of the American Society of Pain
LA English
DT Journal Article
DE Auricular point acupressure; Chemokines; Cytokines; Inflammatory biomarkers; Self-management
AB BACKGROUND: To identify candidate inflammatory biomarkers for the underlying  mechanism of auricular point acupressure (APA) on pain relief and examine the  correlations among pain intensity, interference, and inflammatory biomarkers.  DESIGN: This is a secondary data analysis. METHODS: Data on inflammatory  biomarkers collected via blood samples and patient self-reported pain intensity  and interference from three pilot studies (chronic low back pain, n = 61;  arthralgia related to aromatase inhibitors, n = 20; and chemotherapy-induced  neuropathy, n = 15) were integrated and analyzed. This paper reports the results  based on within-subject treatment effects (change in scores from pre- to post-APA  intervention) for each study group (chronic low back pain, cancer pain),  between-group differences (changes in scores from pre- to post-intervention  between targeted-point APA [T-APA] and non-targeted-point APA [NT-APA]), and  correlations among pain intensity, interference, and biomarkers. RESULTS:  Within-group analysis (the change score from pre- to post-APA) revealed  statistically significant changes in three biomarkers: TNF-α (cancer pain in the  APA group, p = .03), β-endorphin (back pain in the APA group, p = .04), and IL-2  (back pain in the NT-APA group, p = .002). Based on between-group analysis in  patients with chronic low back pain (T-APA vs NT-APA), IL-4 had the largest  effect size (0.35), followed by TNF-α (0.29). A strong positive monotonic  relationship between IL-1β and IL-2 was detected. CONCLUSIONS: The current  findings further support the potential role of inflammatory biomarkers in the  analgesic effects of APA. More work is needed to gain a comprehensive  understanding of the underlying mechanisms of APA on chronic pain. Because it is  simple, inexpensive, and has no negative side effects, APA can be widely  disseminated as an alternative to opioids.
C1 University of Texas Health Science Center at Houston Cizik School of Nursing. 
   Johns Hopkins University School of Nursing.
   University of Texas Health Science Center Houston School of Public Health.
   University of Texas Health Science Center Houston School of Public Health.
   University of Texas Health Science Center at Houston Cizik School of Nursing
   University of Texas Health Science Center at Houston, McGovern Medical School.
   Johns Hopkins University Krieger School of Arts and Sciences.
   Johns Hopkins University Krieger School of Arts and Sciences.
   Johns Hopkins University School of Medicine.
EM chao.hsing.yeh@uth.tmc.edu
NR 0
TC 0
SN 1532-863
EI 1524-904
J9 Pain Manag Nurs
PD DEC 22
PY 2022
VL 24
IS 1
BP 19
EP 26
DI 10.1016/j.pmn.2022.11.004
PG 7
WC Humans; Low Back Pain; therapy; Treatment Outcome; Cancer Pain; Acupressure; methods; Interleukin-2; Tumor Necrosis Factor-alpha
UT PubMed:36543665
PM 36543665
DA 2022-12-22
ER

PT J
AU Goel, AR
   Henderson, CR
   Reid, MC
AF Goel, Anurag Ratan
   Henderson, Charles R.
   Reid, Manney Carrington
TI Do Palliative Care Providers Use Complementary and Integrative Medicine? A Nationwide Survey
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Complementary; integrative; alternative; nationwide survey; usage patterns; recommendation rates
ID alternative medicine; advanced cancer; physicians attitudes; follow-up; therapy; prevalence; knowledge; patterns; management; hospice
AB Context. Given the high prevalence of burdensome symptoms in palliative care (PC) and increasing use of complementary and integrative medicine (CIM) therapies, research is needed to determine how often and what types of CIM therapies providers recommend to manage symptoms in PC. Objectives. To document recommendation rates of CIM for target symptoms and assess if, CIM use varies by provider characteristics. Methods. Nationwide survey's of physicians (MD and DO), physician assistants, and nurse practitioners in PC. Results. Participants (N = 404) were mostly female (71.3%), physicians (74.9%), and cared for adults (90.4%). Providers recommended CIM an average of 6.82 times per-month (95% CI: 6.04-7.60) and used an average of 5.13 (95% CI: 4.90-5.36) out of 10 CIM modalities. Respondents recommended mind-body medicines (e.g., meditation, biofeedback) most, followed by massage, and acupuncture and/or acupressure. The most targeted symptoms included pain; followed by anxiety, mood disturbance, and distress. Recommendation frequencies for specificmodality-for-symptomcombinations ranged fromlittle use (e.g., aromatherapy for constipation) to occasional use (e.g., mind-body interventions for psychiatric symptoms). Finally, recommendation rates increased as a function of pediatric practice, noninpatient practice setting, provider age, and proportion of effort spent delivering palliative care. Conclusion. To the best of our knowledge, this is the first national survey to characterize PC providers' CIM recommendation behaviors and assess specific therapies and common target symptoms. Providers recommended a broad range of CIM but do so less frequently than patients report using CIM. These findings should be of interest to any provider caring for patients with serious illness. (C) 2021 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Goel, Anurag Ratan] Brown Univ, Dept Med, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Goel, Anurag Ratan] Brown Univ, Dept Pediat, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Henderson, Charles R.] Cornell Univ, Dept Human Dev, Ithaca, NY USA.
   [Reid, Manney Carrington] Weill Cornell Med, Dept Med, New York, NY USA.
C3 Brown University; Brown University; Cornell University; Cornell University; Weill Cornell Medicine
RP Reid, MC (corresponding author), Weill Cornell Med, Div Geriatr & Palliat Med, 525 East 68th St Box 39, New York, NY 10065 USA.
EM mcr2004@med.cornell.edu
FU National Institute on Aging [K24AGO53462, P30AG022845]; National Institute on Aging [K24AG053462, P30AG022845, T32AG049666] Funding Source: NIH RePORTER
CR Unknown -, 1992, INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES AND RELATED HEALTH PROBLEMS, V0, P0
   Unknown -, 2013, NHPCOS FACTS AND FIGURES: HOSPICE CARE IN AMERICA, V0, P0
   Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
   Axtner J, 2016, BMC CANCER, V16, P0, DOI 10.1186/s12885-016-2594-5
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Bercovitz Anita, 2011, NATL HEALTH STAT REPORT, V0, P1
   Berman B M, 1998, J AM BOARD FAM PRACT, V11, P272
   Berman BM, 2002, ARCH INTERN MED, V162, P766, DOI 10.1001/archinte.162.7.766
   Bishop FL, 2010, PEDIATRICS, V125, P768, DOI 10.1542/peds.2009-1775
   Blinderman CD, 2015, NEW ENGL J MED, V373, P2549, DOI 10.1056/NEJMra1411746
   Bookbinder M, 2010, NURS CLIN N AM, V45, P271, DOI 10.1016/j.cnur.2010.04.002
   Chan Pon-Sang, 2004, HAWAII MED J, V63, P176
   Chiaramonte DR, 2020, J ALTERN COMPLEM MED, V26, P761, DOI 10.1089/acm.2020.0366
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Corbin LW, 2009, J PALLIAT MED, V12, P7, DOI 10.1089/jpm.2008.0198
   Cramer H, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010802.pub2
   Demmer Craig, 2004, J PALLIAT MED, V7, P510, DOI 10.1089/1096621041838335
   Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569
   Esplen MJ, 2020, SUPPORT CARE CANCER, V28, P381, DOI 10.1007/s00520-019-04812-2
   Frass M, 2012, OCHSNER J, V12, P45
   Gabbard J, 2019, AM J HOSP PALLIAT ME, V36, P273, DOI 10.1177/1049909118806664
   Glare P, 2011, CLIN INTERV AGING, V6, P243, DOI 10.2147/CIA.S13109
   Goel AR, 2022, AM J HOSP PALLIAT ME, V39, P370, DOI 10.1177/10499091211011708
   Goyal M, 2014, JAMA INTERN MED, V174, P357, DOI 10.1001/jamainternmed.2013.13018
   Greene Barry R, 2006, BMC COMPLEMENT ALTERN MED, V6, P5, DOI 10.1186/1472-6882-6-5
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Kemper KJ, 2004, AMBUL PEDIATR, V4, P482, DOI 10.1367/A04-050R.1
   Kent JB, 2020, ALTERN THER HEALTH M, V26, P28
   Klein E, 2017, ARCH GYNECOL OBSTET, V296, P295, DOI 10.1007/s00404-017-4420-y
   Korak LE, 2008, AM J HOSP PALLIAT ME, V25, P463, DOI 10.1177/1049909108322292
   Kundu A, 2011, CLIN PEDIATR, V50, P153, DOI 10.1177/0009922810384724
   Kurtz Margot E, 2003, JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, V103, P597
   Lee RT, 2014, J CLIN ONCOL, V32, P4095, DOI 10.1200/JCO.2014.55.8676
   Lin YC, 2017, ANESTH ANALG, V125, P2081, DOI 10.1213/ANE.0000000000002579
   Linde K, 2015, ANN FAM MED, V13, P69, DOI 10.1370/afm.1687
   Manek NJ, 2010, BMC COMPLEM ALTERN M, V10, P0, DOI 10.1186/1472-6882-10-5
   Maratos AS, 2008, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004517.pub2
   Mbizo J, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2342-2
   Mercadante S, 2017, SUPPORT CARE CANCER, V25, P1301, DOI 10.1007/s00520-016-3524-4
   Mitchell AJ, 2011, LANCET ONCOL, V12, P160, DOI 10.1016/S1470-2045(11)70002-X
   Moens K, 2014, J PAIN SYMPTOM MANAG, V48, P660, DOI 10.1016/j.jpainsymman.2013.11.009
   Muecke R, 2016, INTEGR CANCER THER, V15, P10, DOI 10.1177/1534735415596423
   Nahin Richard L, 2016, NATL HEALTH STAT REPORT, V0, P1
   Olotu BS, 2014, AM J HOSP PALLIAT ME, V31, P254, DOI 10.1177/1049909113486535
   Penney LS, 2017, BMC FAM PRACT, V17, P0, DOI 10.1186/s12875-016-0566-0
   Rhode JM, 2008, INT J GYNECOL OBSTET, V103, P111, DOI 10.1016/j.ijgo.2008.06.001
   Risberg T, 2004, EUR J CANCER, V40, P529, DOI 10.1016/j.ejca.2003.11.011
   Sarris J, 2011, EUR NEUROPSYCHOPHARM, V21, P841, DOI 10.1016/j.euroneuro.2011.04.002
   SAS Institute Inc, 2013, 9.4 STATEMENTS: REFERENCE, V0, P0
   Sawni Anju, 2007, BMC COMPLEMENT ALTERN MED, V7, P18, DOI 10.1186/1472-6882-7-18
   Sierpina V, 2007, EXPLORE-NY, V3, P129, DOI 10.1016/j.explore.2006.12.001
   Smith CA, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004046.pub4
   Stussman BJ, 2020, J ALTERN COMPLEM MED, V26, P25, DOI 10.1089/acm.2019.0303
   Thorne S, 2002, INT J NURS STUD, V39, P671, DOI 10.1016/S0020-7489(02)00005-6
   Tomlinson D, 2011, SUPPORT CARE CANCER, V19, P1857, DOI 10.1007/s00520-010-1029-0
   Valderas JM, 2009, BMC HEALTH SERV RES, V9, P0, DOI 10.1186/1472-6963-9-221
   Van Hyfte GJ, 2014, AM J HOSP PALLIAT ME, V31, P553, DOI 10.1177/1049909113500378
   Wahner-Roedler DL, 2014, COMPLEMENT THER CLIN, V20, P54, DOI 10.1016/j.ctcp.2013.09.003
   Weisel KK, 2019, NPJ DIGIT MED, V2, P0, DOI 10.1038/s41746-019-0188-8
NR 62
TC 7
Z9 8
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD APR 15
PY 2022
VL 63
IS 4
BP 599
EP 609
DI 10.1016/j.jpainsymman.2021.11.002
EA MAR 2022
PG 11
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA 2P7TK
UT WOS:000819938200028
PM 34788656
DA 2026-01-16
ER

PT J
AU Liedtke, W
AF Liedtke, Wolfgang
TI Long March Toward Safe and Effective Analgesia by Enhancing Gene Expression of Kcc2: First Steps Taken
SO FRONTIERS IN MOLECULAR NEUROSCIENCE
LA English
DT Review
DE pain; spinal cord dorsal horn; KCC2; Kcc2 gene expression enhancer; GSK3; delta-catenin; Kaiso
ID cation-chloride-cotransporters; nmda receptor-activity; neuropathic pain; developmental switch; synaptic inhibition; down-regulation; anion gradient; motor-neurons; up-regulation; nerve
AB Low intraneuronal chloride in spinal cord dorsal horn pain relay neurons is critical for physiologic transmission of primary pain afferents because low intraneuronal chloride dictates whether GABA-ergic and glycin-ergic neurotransmission is inhibitory. If the neuronal chloride elevates to pathologic levels, then spinal cord primary pain relay becomes leaky and exhibits the behavioral hallmarks of pathologic pain, namely hypersensitivity and allodynia. Low chloride in spinal cord dorsal horn neurons is maintained by proper gene expression of Kcc2 and sustained physiologic function of the KCC2 chloride extruding electroneutral transporter. Peripheral nerve injury and other forms of neural injury evoke greatly diminished Kcc2 gene expression and subsequent corruption of inhibitory neurotransmission in the spinal cord dorsal horn, thus causing derailment of the gate function for pain. Here I review key discoveries that have helped us understand these fundamentals, and focus on recent insights relating to the discovery of Kcc2 gene expression enhancing compounds via compound screens in neurons. One such study characterized the kinase inhibitor, kenpaullone, more in-depth, revealing its function as a robust and long-lasting analgesic in preclinical models of nerve injury and cancer bone pain, also elucidating its mechanism of action via GSK3 beta inhibition, diminishing delta-catenin phosphorylation, and facilitating its nuclear transfer and subsequent enhancement of Kcc2 gene expression by de-repressing Kaiso epigenetic transcriptional regulator. Future directions re Kcc2 gene expression enhancement are discussed, namely combination with other analgesics and analgesic methods, such as spinal cord stimulation and electroacupuncture, gene therapy, and leveraging Kcc2 gene expression-enhancing nanomaterials.
C1 [Liedtke, Wolfgang] Regeneron Pharmaceut, Global Dev Sci Council, Tarrytown, NY 10591 USA.
C3 Regeneron
RP Liedtke, W (corresponding author), Regeneron Pharmaceut, Global Dev Sci Council, Tarrytown, NY 10591 USA.
EM wolfgang.liedtke@regeneron.com
CR Austin TM, 2011, ANESTH ANALG, V113, P1509, DOI 10.1213/ANE.0b013e31822e0a5d
   Ben-Ari Y, 2012, NEUROSCIENTIST, V18, P467, DOI 10.1177/1073858412438697
   Berta T, 2017, EXPERT OPIN THER TAR, V21, P695, DOI 10.1080/14728222.2017.1328057
   Castro A, 2017, PAIN, V158, P1366, DOI 10.1097/j.pain.0000000000000926
   Chamessian A, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-25110-7
   Côme E, 2020, NEUROPHARMACOLOGY, V169, P0, DOI 10.1016/j.neuropharm.2019.03.014
   Cook C, 2018, ADV EMERG NURS J, V40, P148, DOI 10.1097/TME.0000000000000203
   Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223
   Coull JAM, 2003, NATURE, V424, P938, DOI 10.1038/nature01868
   Dai SD, 2011, CANCER SCI, V102, P95, DOI 10.1111/j.1349-7006.2010.01766.x
   Dedek A, 2019, BRAIN, V142, P1535, DOI 10.1093/brain/awz105
   Delpire E, 2000, NEWS PHYSIOL SCI, V15, P309, DOI 10.1152/physiologyonline.2000.15.6.309
   Diener HC, 1999, CURR OPIN NEUROL, V12, P261, DOI 10.1097/00019052-199906000-00004
   Doyon N, 2013, EXPERT REV NEUROTHER, V13, P469, DOI 10.1586/ERN.13.40
   Ferrini F, 2020, NAT COMMUN, V11, P0, DOI 10.1038/s41467-020-17824-y
   Fiumelli H, 2007, CURR OPIN NEUROBIOL, V17, P81, DOI 10.1016/j.conb.2007.01.002
   Friedman BW, 2017, NEUROLOGY, V89, P2075, DOI 10.1212/WNL.0000000000004642
   Gagnon M, 2013, NAT MED, V19, P1524, DOI 10.1038/nm.3356
   GAMSE R, 1981, N-S ARCH PHARMACOL, V316, P38, DOI 10.1007/BF00507224
   Ganguly K, 2001, CELL, V105, P521, DOI 10.1016/S0092-8674(01)00341-5
   Gutierrez-Mecinas M, 2017, PAIN, V158, P440, DOI 10.1097/j.pain.0000000000000778
   Hayek SM, 2015, NEUROMODULATION, V18, P603, DOI 10.1111/ner.12312
   Hochberg MC, 2015, OSTEOARTHR CARTILAGE, V23, PS18, DOI 10.1016/j.joca.2014.10.005
   Hozumi T, 2021, NEUROSCI LETT, V749, P0, DOI 10.1016/j.neulet.2021.135772
   Jaggi AS, 2015, CURR NEUROPHARMACOL, V13, P369, DOI 10.2174/1570159X13666150205130359
   Kahle KT, 2008, NAT CLIN PRACT NEURO, V4, P490, DOI 10.1038/ncpneuro0883
   Kahle KT, 2016, NEUROSCIENTIST, V22, P555, DOI 10.1177/1073858416645087
   Kahle KT, 2016, SCI SIGNAL, V9, P0, DOI 10.1126/scisignal.aad0163
   Kahle KT, 2014, EMBO REP, V15, P766, DOI 10.15252/embr.201438840
   Kahle KT, 2014, JAMA NEUROL, V71, P640, DOI 10.1001/jamaneurol.2014.21
   Kahle KT, 2013, TRENDS NEUROSCI, V36, P726, DOI 10.1016/j.tins.2013.08.006
   Kaplun D, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22147587
   Kelley MR, 2018, EBIOMEDICINE, V32, P62, DOI 10.1016/j.ebiom.2018.05.029
   King GF, 2014, ACS CHEM NEUROSCI, V5, P749, DOI 10.1021/cn500171p
   Kirmse K, 2015, NAT COMMUN, V6, P0, DOI 10.1038/ncomms8750
   Kontou G, 2021, J BIOL CHEM, V296, P0, DOI 10.1016/j.jbc.2021.100364
   Lagraize SC, 2010, NEUROSCIENCE, V171, P1341, DOI 10.1016/j.neuroscience.2010.09.040
   Lee HHC, 2011, NAT NEUROSCI, V14, P736, DOI 10.1038/nn.2806
   Lee HHC, 2010, MOL CELL NEUROSCI, V45, P173, DOI 10.1016/j.mcn.2010.06.008
   Li LY, 2016, CELL REP, V15, P1376, DOI 10.1016/j.celrep.2016.04.039
   Li SS, 2018, MOL MED REP, V17, P6961, DOI 10.3892/mmr.2018.8766
   Liabeuf S, 2017, J NEUROTRAUM, V34, P3397, DOI 10.1089/neu.2017.5152
   Liang LL, 2015, EPIGENOMICS-UK, V7, P235, DOI 10.2217/EPI.14.75
   Liedtke W, 2013, SMALL, V9, P1066, DOI 10.1002/smll.201201994
   Liu ML, 2016, CELL REP, V14, P115, DOI 10.1016/j.celrep.2015.12.018
   Lopes EC, 2008, CANCER RES, V68, P7258, DOI 10.1158/0008-5472.CAN-08-0344
   Lorenzo LE, 2020, NAT COMMUN, V11, P0, DOI 10.1038/s41467-019-14154-6
   Mantyh PW, 2004, TRENDS NEUROSCI, V27, P582, DOI 10.1016/j.tins.2004.07.007
   Mapplebeck JCS, 2019, CELL REP, V28, P590, DOI 10.1016/j.celrep.2019.06.059
   Medina I, 2014, FRONT CELL NEUROSCI, V8, P0, DOI 10.3389/fncel.2014.00027
   Mekhail N, 2022, JAMA NEUROL, V79, P251, DOI 10.1001/jamaneurol.2021.4998
   Miller RE, 2017, CURR OPIN RHEUMATOL, V29, P110, DOI 10.1097/BOR.0000000000000354
   Morrison D, 2021, MOL PAIN, V17, P0, DOI 10.1177/17448069211007289
   MORTON CR, 1989, BRAIN RES, V488, P89, DOI 10.1016/0006-8993(89)90696-3
   MOSKOWITZ MA, 1993, NEUROLOGY, V43, P16
   Mulcahy JV, 2019, J MED CHEM, V62, P8695, DOI 10.1021/acs.jmedchem.8b01906
   Munro G, 2013, EUR J PHARMACOL, V716, P17, DOI 10.1016/j.ejphar.2013.01.070
   Noorsal E, 2021, MICROMACHINES-BASEL, V12, P0, DOI 10.3390/mi12080968
   Okamoto K, 2001, EXP NEUROL, V169, P386, DOI 10.1006/exnr.2001.7677
   Otsu Y, 2020, J PHYSIOL-LONDON, V598, P1865, DOI 10.1113/JP279221
   Pilitsis JG, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.673998
   Pisella LI, 2019, SCI SIGNAL, V12, P0, DOI 10.1126/scisignal.aay0300
   Prescott SA, 2015, PROG MOL BIOL TRANSL, V131, P359, DOI 10.1016/bs.pmbts.2014.11.008
   Price TJ, 2005, CURR TOP MED CHEM, V5, P547, DOI 10.2174/1568026054367629
   Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501
   Rivat C, 2018, NAT COMMUN, V9, P0, DOI 10.1038/s41467-018-03496-2
   Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697
   Rodriguez E, 2017, NAT NEUROSCI, V20, P1734, DOI 10.1038/s41593-017-0012-1
   SANDKUHLER J, 1990, NEUROSCIENCE, V34, P565, DOI 10.1016/0306-4522(90)90165-Z
   Schulte JT, 2018, NEUROSCI BIOBEHAV R, V90, P260, DOI 10.1016/j.neubiorev.2018.05.001
   Shi TJS, 2014, MOL PAIN, V10, P0, DOI 10.1186/1744-8069-10-12
   Skardelly M, 2011, INT J DEV NEUROSCI, V29, P543, DOI 10.1016/j.ijdevneu.2011.03.010
   SMIRNE S, 1977, MED J AUSTRALIA, V1, P93, DOI 10.5694/j.1326-5377.1977.tb130531.x
   Strange K, 2000, AM J PHYSIOL-CELL PH, V279, PC860, DOI 10.1152/ajpcell.2000.279.3.C860
   Tang X, 2019, SCI TRANSL MED, V11, P0, DOI 10.1126/scitranslmed.aau0164
   Teitz T, 2018, J EXP MED, V215, P1187, DOI 10.1084/jem.20172246
   Uvarov P, 2006, J NEUROSCI, V26, P13463, DOI 10.1523/JNEUROSCI.4731-06.2006
   Wang H, 2002, NEUROSCIENCE, V114, P529, DOI 10.1016/S0306-4522(02)00341-X
   Watanabe M, 2019, SCI SIGNAL, V12, P0, DOI 10.1126/scisignal.aaw9315
   Wei B, 2013, NEUROSCIENCE, V228, P334, DOI 10.1016/j.neuroscience.2012.10.043
   Woo NS, 2002, HIPPOCAMPUS, V12, P258, DOI 10.1002/hipo.10014
   Woodin MA, 2003, NEURON, V39, P807, DOI 10.1016/S0896-6273(03)00507-5
   Wu LA, 2009, NEUROSCI LETT, V457, P36, DOI 10.1016/j.neulet.2009.03.107
   Xiao YC, 2010, MOL PHARMACOL, V78, P1124, DOI 10.1124/mol.110.066332
   Xu B, 2020, BRIT J PHARMACOL, V177, P93, DOI 10.1111/bph.14848
   Yang YM, 2013, CELL STEM CELL, V12, P713, DOI 10.1016/j.stem.2013.04.003
   Yeo M, 2020, NEURONAL CHLORIDE TR, V0, P0
   Yeo M, 2021, NAT COMMUN, V12, P0, DOI 10.1038/s41467-021-26270-3
   Yeo M, 2013, EPIGENETICS-US, V8, P1128, DOI 10.4161/epi.26406
   Yeo M, 2013, P NATL ACAD SCI USA, V110, P4315, DOI 10.1073/pnas.1300959110
   Yeo M, 2009, J NEUROSCI, V29, P14652, DOI 10.1523/JNEUROSCI.2934-09.2009
   YIN KJ, 1995, ANAT REC, V241, P579, DOI 10.1002/ar.1092410415
   Yuan XC, 2022, MOL PAIN, V18, P0, DOI 10.1177/17448069221087583
   Zeilhofer HU, 2012, PHYSIOL REV, V92, P193, DOI 10.1152/physrev.00043.2010
   Zhang P, 2017, INFLAMMATION, V40, P1102, DOI 10.1007/s10753-017-0552-2
   Zhu L, 2008, EPILEPSY RES, V79, P201, DOI 10.1016/j.eplepsyres.2008.02.005
NR 96
TC 5
Z9 5
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1662-5099
EI 
J9 FRONT MOL NEUROSCI
JI Front. Molec. Neurosci.
PD MAY 13
PY 2022
VL 15
IS 
BP 
EP 
DI 10.3389/fnmol.2022.865600
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 1R7XH
UT WOS:000803578200001
PM 35645734
DA 2026-01-16
ER

PT J
AU Jiao, LB
   He, XX
   Zhang, JH
   Liu, YL
   Luo, YA
   Wei, H
AF Jiao, Liangbo
   He, Xiaoxia
   Zhang, Jihong
   Liu, Yali
   Luo, Yanan
   Wei, Hu
TI Effects of Acupuncture on Cancer Pain in Animal Intervention Studies: A Systematic Review and Quality Assessment
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE acupuncture; methodological and reporting quality; cancer pain; SYRCLE; ARRIVE
ID electroacupuncture; expression
AB Background: Preclinical studies often provide the evidence base for clinical studies. However, the design and reporting of preclinical trial results are inadequate, resulting in poor reproducibility and clinical translatability. We aimed to systematically evaluate the methodology and reporting quality of animal studies of acupuncture for cancer pain. Methods: About 7 databases were searched for animal research articles on acupuncture for cancer pain from the beginning of the database to January 31, 2022. ARRIVE guidelines, STRICTA, and SYRCLE risk of bias tools were used to assess the reporting quality and risk of bias of the selected studies. Results: A total of 18 studies were evaluated. Of the 22 items on the SYRCLE tool, only 6 items had a positive reporting rate of more than 50%. Of the 39 items in the ARRIVE guidelines, 14 were rated excellent, and the least frequently reported checklist items were 7. Out of the 17 STRICTA checklist items analyzed, 10 were considered appropriately reported in more than 80% of the studies, while 4 were correctly reported in less than 20%. Conclusions: Some crucial points in the design, implementation, and reporting of the experiments included in the study were not well developed, which could significantly affect the clarity, reproducibility, and translatability of the experiments. There is a need to fully implement scientific tool guidelines for future experimental studies in order to improve the quality of preclinical studies and facilitate effective translation of their results to the clinic.
C1 [Jiao, Liangbo; Zhang, Jihong] China Three Gorges Univ, Peoples Hosp 2, Yichang, Hubei, Peoples R China.
   [He, Xiaoxia; Liu, Yali; Luo, Yanan; Wei, Hu] China Three Gorges Univ, Third Grade Pharmacol Lab Chinese Med, Med Coll, State Adm Tradit Chinese Med, Yichang, Hubei, Peoples R China.
C3 China Three Gorges University; China Three Gorges University
RP Luo, YA; Wei, H (corresponding author), China Three Gorges Univ, Med Coll, Third Grade Pharmacol Lab Chinese Med, 8 Univ Rd, Yichang 443002, Hubei, Peoples R China.
EM luoyanan@ctgu.edu.cn; huwei@ctgu.edu.cn
CR Abbas TO, 2021, FRONT PEDIATR, V9, P0, DOI 10.3389/fped.2021.718647
   Cai YG, 2019, CHIN J TRADIT CHIN M, V37, P137
   Chen YC, 2015, J ZHEJIANG CHIN MED, V39, P221
   Du Junying, 2015, ZHONGGUO ZHEN JIU, V35, P161
   du Sert NP, 2020, PLOS BIOL, V18, P0, DOI 10.1371/journal.pbio.3000411
   Emery J, 2022, LANCET, V399, P1537, DOI 10.1016/S0140-6736(22)00242-2
   García-González M, 2021, ANIMALS-BASEL, V11, P0, DOI 10.3390/ani11051233
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Grüter BE, 2020, TRANSL STROKE RES, V11, P1175, DOI 10.1007/s12975-020-00801-4
   Guan JF, 2015, CHIN J GERONTOL, V38, P4513
   Hackam DG, 2006, JAMA-J AM MED ASSOC, V296, P1731, DOI 10.1001/jama.296.14.1731
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, P0, DOI 10.1186/1471-2288-14-43
   Kuai Le, 2012, ZHONGGUO ZHEN JIU, V32, P331
   Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   [梁宜 Liang Yi], 2018, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V33, P4877
   Liang Y, 2018, INTEGR CANCER THER, V17, P401, DOI 10.1177/1534735417728335
   [陆琪赟 Lu Qiyun], 2015, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V30, P3329
   Lu QY, 2016, SHANGHAI J TRADIT CH, V50, P77
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mao-Ying Qi-liang, 2008, ZHONG XI YI JIE HE XUE BAO, V6, P830, DOI 10.3736/jcim20080812
   Qin SL, 2019, CHONGQING MED J, V48, P390
   Ritskes-Hoitinga M, 2019, ANIMALS-BASEL, V9, P0, DOI 10.3390/ani9121163
   Smith LN, 2022, FRONT BEHAV NEUROSCI, V16, P0, DOI 10.3389/fnbeh.2022.805661
   Syarifah-Noratiqah SB, 2020, FRONT VET SCI, V7, P0, DOI 10.3389/fvets.2020.00303
   van der Worp HB, 2011, J MOL CELL CARDIOL, V51, P449, DOI 10.1016/j.yjmcc.2011.04.008
   Xu M, 2021, ACS CHEM NEUROSCI, V12, P3323, DOI 10.1021/acschemneuro.1c00224
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Zhang CP, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0289-y
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang Z, 2011, J HARBIN MED U, V45, P567
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao W, 2013, J CLINI ACUPUNCT MED, V29, P69
NR 35
TC 0
Z9 0
U1 0
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD OCT 15
PY 2022
VL 21
IS 
BP 
EP 
DI 10.1177/15347354221123788
PG 10
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA 6L4ME
UT WOS:000888157400001
PM 36314416
DA 2026-01-16
ER

PT J
AU Ge, L
   Wang, Q
   He, Y
   Wu, D
   Zhou, Q
   Xu, N
   Yang, K
   Chen, Y
   Zhang, AL
   Hua, H
   Huang, J
   Hui, KK
   Liang, F
   Wang, L
   Xu, B
   Yang, Y
   Zhang, W
   Zhao, B
   Zhu, B
   Guo, X
   Xue, CC
   Zhang, H
AF Ge, Long
   Wang, Qi
   He, Yihan
   Wu, Darong
   Zhou, Qi
   Xu, Nenggui
   Yang, Kehu
   Chen, Yaolong
   Zhang, Anthony Lin
   Hua, Haiqing
   Huang, Jinchang
   Hui, Ka-Kit
   Liang, Fanrong
   Wang, Linpeng
   Xu, Bin
   Yang, Yufei
   Zhang, Weimin
   Zhao, Baixiao
   Zhu, Bing
   Guo, Xinfeng
   Xue, Charlie Changli
   Zhang, Haibo
TI Acupuncture for cancer pain: an evidence-based clinical practice guideline.
SO Chinese medicine
LA English
DT Review
DE Acupuncture; Cancer pain; Evidence-based practice; Practice guideline
AB BACKGROUND: This study aims to develop an evidence-based clinical practice  guideline of acupuncture in the treatment of patients with moderate and severe  cancer pain. METHODS: The development of this guideline was triggered by a  systematic review published in JAMA Oncology in 2020. We searched databases and  websites for evidence on patient preferences and values, and other resources of  using acupuncture for treatment of cancer pain. Recommendations were developed  through a Delphi consensus of an international multidisciplinary panel including  13 western medicine oncologists, Chinese medicine/acupuncture clinical  practitioners, and two patient representatives. The certainty of evidence,  patient preferences and values, resources, and other factors were fully  considered in formulating the recommendations. The Grading of Recommendations  Assessment, Development, and Evaluation (GRADE) approach was employed to rate the  certainty of evidence and the strength of recommendations. RESULTS: The guideline  proposed three recommendations: (1) a strong recommendation for the treatment of  acupuncture rather than no treatment to relieve pain in patients with moderate to  severe cancer pain; (2) a weak recommendation for the combination treatments with  acupuncture/acupressure to reduce pain intensity, decrease the opioid dose, and  alleviate opioid-related side effects in moderate to severe cancer pain patients  who are using analgesics; and (3) a strong recommendation for acupuncture in  breast cancer patients to relieve their aromatase inhibitor-induced arthralgia.  CONCLUSION: This proposed guideline provides recommendations for the management  of patients with cancer pain. The small sample sizes of evidence limit the  strength of the recommendations and highlights the need for additional research.
C1 Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China.
   Evidence Based Social Science Research Centre, School of Public Health, Lanzhou 
   WHO Collaborating Center for Guideline Implementation and Knowledge Translation, Lanzhou, China.
   Chinese GRADE Centre, Lanzhou University, Lanzhou, China.
   Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China.
   Evidence Based Social Science Research Centre, School of Public Health, Lanzhou 
   Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.
   Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.
   Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
   South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou,China.
   Evidence Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.
   WHO Collaborating Center for Guideline Implementation and Knowledge Translation, 
   Chinese GRADE Centre, Lanzhou University, Lanzhou, China.
   Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu 
   WHO Collaborating Center for Guideline Implementation and Knowledge Translation, Lanzhou, China.
   Chinese GRADE Centre, Lanzhou University, Lanzhou, China.
   Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
   Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu 
   China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.
   Oncology Department of Bayi Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
   The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Center for East-West Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Santa Monica, USA.
   Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing, China.
   Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
   Department of Oncology, Southern Theater Command General Hospital of PLA, Guangzhou, China.
   School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medicine Sciences, Beijing, China.
   Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China. guoxinfeng@gzucm.edu.
   The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China. guoxinfeng@gzucm.edu.
   Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China. charlie.xue@rmit.edu.au.
   The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China. charlie.xue@rmit.edu.au.
   China-Australia International Research Centre for Chinese Medicine, School of 
   Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China. haibozh@gzucm.edu.cn.
   The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, 
   Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China. haibozh@gzucm.edu.cn.
NR 0
TC 0
SN 1749-854
EI 1749-854
J9 Chin Med
PD JAN 6
PY 2022
VL 17
IS 1
BP 8
EP 8
DI 10.1186/s13020-021-00558-4
PG 0
UT PubMed:34983587
PM 34983587
DA 2022-01-06
ER

